{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "9Exi4PgwD-jo"
   },
   "source": [
    "# CS551J_Assessment 2_52097136\n",
    "\n",
    "## Student Information\n",
    "Student: ZHIXI TANG \\\n",
    "Student ID: 52097136\n",
    "\n",
    "## Abstract\n",
    "This is a project report to build up a knowledge graph about COVID-19 vaccines, and reprensting the knowledge graph, mapping the vacubulary on the known ontology, simulating answer questions by using SPARQL to query the graph."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "RgcdAnjvGIV_"
   },
   "source": [
    "## 1. Collect the data from websites\n",
    "\n",
    "As I don't have enough perception for NLP, I won't use crawler to collect the data from internet. I will use Requests and BeautifulSoup of Python to parse the contents of webpage. To keep the content data as clean as possible, I will manully choose some websites that the contents are related to COVID-19 vaccine. "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "FVlI_gUmLtV8"
   },
   "source": [
    "### Chosen websites\n",
    "The websites I manually chosen are:\n",
    "- wikipedia: https://en.wikipedia.org/wiki/COVID-19_vaccine\n",
    "- science: https://science.sciencemag.org/content/371/6532/916\n",
    "- CDC, introduction of COVID-19 vaccine:https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/how-they-work.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fvaccines%2Fabout-vaccines%2Fhow-they-work.html\n",
    "- NHS: https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/\n",
    "- Texas HHS: https://dshs.texas.gov/coronavirus/immunize/vaccine.aspx"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "OayZhQtYmQxO"
   },
   "source": [
    "### Collect the Data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "K6A-Qb1RPPB2",
    "outputId": "955c6e4f-7e8c-4b8e-a8e3-4b396bbfd2b6",
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/usr/local/lib/python3.7/dist-packages/urllib3/connectionpool.py:847: InsecureRequestWarning: Unverified HTTPS request is being made. Adding certificate verification is strongly advised. See: https://urllib3.readthedocs.io/en/latest/advanced-usage.html#ssl-warnings\n",
      "  InsecureRequestWarning)\n",
      "/usr/local/lib/python3.7/dist-packages/urllib3/connectionpool.py:847: InsecureRequestWarning: Unverified HTTPS request is being made. Adding certificate verification is strongly advised. See: https://urllib3.readthedocs.io/en/latest/advanced-usage.html#ssl-warnings\n",
      "  InsecureRequestWarning)\n",
      "/usr/local/lib/python3.7/dist-packages/urllib3/connectionpool.py:847: InsecureRequestWarning: Unverified HTTPS request is being made. Adding certificate verification is strongly advised. See: https://urllib3.readthedocs.io/en/latest/advanced-usage.html#ssl-warnings\n",
      "  InsecureRequestWarning)\n",
      "/usr/local/lib/python3.7/dist-packages/urllib3/connectionpool.py:847: InsecureRequestWarning: Unverified HTTPS request is being made. Adding certificate verification is strongly advised. See: https://urllib3.readthedocs.io/en/latest/advanced-usage.html#ssl-warnings\n",
      "  InsecureRequestWarning)\n",
      "/usr/local/lib/python3.7/dist-packages/urllib3/connectionpool.py:847: InsecureRequestWarning: Unverified HTTPS request is being made. Adding certificate verification is strongly advised. See: https://urllib3.readthedocs.io/en/latest/advanced-usage.html#ssl-warnings\n",
      "  InsecureRequestWarning)\n"
     ]
    }
   ],
   "source": [
    "# Using requests and bs4 to get the web contents from above websites\n",
    "import requests\n",
    "import bs4\n",
    "\n",
    "# Creating a list to save these website links\n",
    "webs = [\n",
    "        'https://en.wikipedia.org/wiki/COVID-19_vaccine',\n",
    "        'https://science.sciencemag.org/content/371/6532/916',\n",
    "        'https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/how-they-work.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fvaccines%2Fabout-vaccines%2Fhow-they-work.html',\n",
    "        'https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/',\n",
    "        'https://dshs.texas.gov/coronavirus/immunize/vaccine.aspx'\n",
    "]\n",
    "\n",
    "# Iterval these websites, get the information\n",
    "webContents = ''\n",
    "for web in webs:\n",
    "  url = web\n",
    "  res = requests.get(url, verify=False)  # Currently I am in home with the online course, to avoid SSL issues, set verify=Flase\n",
    "  html_page = res.content\n",
    "  soup = bs4.BeautifulSoup(html_page, 'html.parser')\n",
    "  webContents += soup.get_text()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "97SDXOHuRx-7"
   },
   "source": [
    "After this step we should have collected all the website texts and saved them to variable 'webContents', I will verify it."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "dHQ2qkisSBCj",
    "outputId": "f3dc31ee-e3db-42f1-edf5-81456bf3bc32"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "\n",
      "\n",
      "COVID-19 vaccine - Wikipedia\n",
      "document.documentElement.className=\"client-js\";RLCONF={\"wgBreakFrames\":!1,\"wgSeparatorTransformTable\":[\"\",\"\"],\"wgDigitTransformTable\":[\"\",\"\"],\"wgDefaultDateFormat\":\"dmy\",\"wgMonthNames\":[\"\",\"January\",\"February\",\"March\",\"April\",\"May\",\"June\",\"July\",\"August\",\"September\",\"October\",\"November\",\"December\"],\"wgRequestId\":\"YEIrsjRJ5mO4WxCjdHih7wAAAM4\",\"wgCSPNonce\":!1,\"wgCanonicalNamespace\":\"\",\"wgCanonicalSpecialPageName\":!1,\"wgNamespaceNumber\":0,\"wgPageName\":\"COVID-19_vaccine\",\"wgTitle\":\"COVID-19 vaccine\",\"wgCurRevisionId\":1010386361,\"wgRevisionId\":1010386361,\"wgArticleId\":63319438,\"wgIsArticle\":!0,\"wgIsRedirect\":!1,\"wgAction\":\"view\",\"wgUserName\":null,\"wgUserGroups\":[\"*\"],\"wgCategories\":[\"Pages with non-numeric formatnum arguments\",\"CS1 maint: uses authors parameter\",\"CS1 Spanish-language sources (es)\",\"CS1 German-language sources (de)\",\"CS1 Portuguese-language sources (pt)\",\"CS1 Danish-language sources (da)\",\"CS1 Icelandic-language sources (is)\",\n",
      "\"CS1 Norwegian Bokmål-language sources (nb)\",\"CS1 Serbian-language sources (sr)\",\"CS1 Russian-language sources (ru)\",\"Articles with short description\",\"Short description is different from Wikidata\",\"Wikipedia indefinitely semi-protected pages\",\"Use dmy dates from December 2020\",\"Articles containing potentially dated statements from February 2021\",\"All articles containing potentially dated statements\",\"Articles containing potentially dated statements from March 2021\",\"Articles with excerpts\",\"Articles containing potentially dated statements from January 2021\",\"All articles with unsourced statements\",\"Articles with unsourced statements from March 2021\",\"All articles lacking reliable references\",\"Articles lacking reliable references from March 2021\",\"Articles containing potentially dated statements from September 2020\",\"Articles with limited geographic scope from December 2020\",\"COVID-19 vaccines\",\"Medical research\",\"Medical responses to the COVID-19 pandemic\"],\"wgPageContentLanguage\":\n",
      "\"en\",\"wgPageContentModel\":\"wikitext\",\"wgRelevantPageName\":\"COVID-19_vaccine\",\"wgRelevantArticleId\":63319438,\"wgIsProbablyEditable\":!1,\"wgRelevantPageIsProbablyEditable\":!1,\"wgRestrictionEdit\":[\"autoconfirmed\"],\"wgRestrictionMove\":[],\"wgMediaViewerOnClick\":!0,\"wgMediaViewerEnabledByDefault\":!0,\"wgPopupsReferencePreviews\":!1,\"wgPopupsReferencePreviewsBeta\":!0,\"wgPopupsConflictsWithNavPopupGadget\":!1,\"wgPopupsConflictsWithRefTooltipsGadget\":!0,\"wgVisualEditor\":{\"pageLanguageCode\":\"en\",\"pageLanguageDir\":\"ltr\",\"pageVariantFallbacks\":\"en\"},\"wgMFDisplayWikibaseDescriptions\":{\"search\":!0,\"nearby\":!0,\"watchlist\":!0,\"tagline\":!1},\"wgWMESchemaEditAttemptStepOversample\":!1,\"wgULSCurrentAutonym\":\"English\",\"wgNoticeProject\":\"wikipedia\",\"wgCentralAuthMobileDomain\":!1,\"wgEditSubmitButtonLabelPublish\":!0,\"wgULSPosition\":\"interlanguage\",\"wgWikibaseItemId\":\"Q87719492\"};RLSTATE={\"ext.globalCssJs.user.styles\":\"ready\",\"site.styles\":\"ready\",\"noscript\":\"ready\",\n",
      "\"user.styles\":\"ready\",\"ext.globalCssJs.user\":\"ready\",\"user\":\"ready\",\"user.options\":\"loading\",\"ext.cite.styles\":\"ready\",\"mediawiki.page.gallery.styles\":\"ready\",\"skins.vector.styles.legacy\":\"ready\",\"jquery.tablesorter.styles\":\"ready\",\"jquery.makeCollapsible.styles\":\"ready\",\"ext.visualEditor.desktopArticleTarget.noscript\":\"ready\",\"ext.uls.interlanguage\":\"ready\",\"ext.wikimediaBadges\":\"ready\",\"wikibase.client.init\":\"ready\"};RLPAGEMODULES=[\"ext.cite.ux-enhancements\",\"ext.scribunto.logs\",\"site\",\"mediawiki.page.ready\",\"jquery.tablesorter\",\"jquery.makeCollapsible\",\"mediawiki.toc\",\"skins.vector.legacy.js\",\"ext.gadget.ReferenceTooltips\",\"ext.gadget.charinsert\",\"ext.gadget.extra-toolbar-buttons\",\"ext.gadget.refToolbar\",\"ext.gadget.switcher\",\"ext.centralauth.centralautologin\",\"mmv.head\",\"mmv.bootstrap.autostart\",\"ext.popups\",\"ext.visualEditor.desktopArticleTarget.init\",\"ext.visualEditor.targetLoader\",\"ext.eventLogging\",\"ext.wikimediaEvents\",\"ext.navigationTiming\",\"ext.uls.compactlinks\",\n",
      "\"ext.uls.interface\",\"ext.cx.eventlogging.campaigns\",\"ext.centralNotice.geoIP\",\"ext.centralNotice.startUp\"];\n",
      "(RLQ=window.RLQ||[]).push(function(){mw.loader.implement(\"user.options@1hzgi\",function($,jQuery,require,module){/*@nomin*/mw.user.tokens.set({\"patrolToken\":\"+\\\\\",\"watchToken\":\"+\\\\\",\"csrfToken\":\"+\\\\\"});\n",
      "});});\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "COVID-19 vaccine\n",
      "\n",
      "From Wikipedia, the free encyclopedia\n",
      "\n",
      "\n",
      "\n",
      "Jump to navigation\n",
      "Jump to search\n",
      "Vaccines to reduce the spread of COVID-19\n",
      "For vaccine development and distribution, see History of COVID-19 vaccine development and Deployment of COVID-19 vaccines.\n",
      "\n",
      "\n",
      " COVID-19 vaccination doses administered per 100 people, as of 1 March 2021\n",
      " Map of countries by approval status .mw-parser-output .legend{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .legend-color{display:inline-block;min-width:1.25em;height:1.25em;line-height:1.25;margin:1px 0;text-align:center;border:1px solid black;background-color:transparent;color:black}.mw-parser-output .legend-text{}  Approved for general use, mass vaccination underway   EUA (or equivalent) granted, mass vaccination underway   EUA granted, limited vaccination   Approved for general use, mass vaccination planned   EUA granted, mass vaccination planned   EUA pending\n",
      ".mw-parser-output .sidebar{width:22em;float:right;clear:right;margin:0.5em 0 1em 1em;background:#f8f9fa;border:1px solid #aaa;padding:0.2em;border-spacing:0.4em 0;text-align:center;line-height:1.4em;font-size:88%;display:table}body.skin-minerva .mw-parser-output .sidebar{display:table!important;float:right!important;margin:0.5em 0 1em 1em!important}.mw-parser-output .sidebar a{white-space:nowrap}.mw-parser-output .sidebar-wraplinks a{white-space:normal}.mw-parser-output .sidebar-subgroup{width:100%;margin:0;border-spacing:0}.mw-parser-output .sidebar-left{float:left;clear:left;margin:0.5em 1em 1em 0}.mw-parser-output .sidebar-none{float:none;clear:both;margin:0.5em 1em 1em 0}.mw-parser-output .sidebar-outer-title{padding-bottom:0.2em;font-size:125%;line-height:1.2em;font-weight:bold}.mw-parser-output .sidebar-top-image{padding:0.4em 0}.mw-parser-output .sidebar-top-caption,.mw-parser-output .sidebar-pretitle-with-top-image,.mw-parser-output .sidebar-caption{padding-top:0.2em;line-height:1.2em}.mw-parser-output .sidebar-pretitle{padding-top:0.4em;line-height:1.2em}.mw-parser-output .sidebar-title,.mw-parser-output .sidebar-title-with-pretitle{padding:0.2em 0.4em;font-size:145%;line-height:1.2em}.mw-parser-output .sidebar-title-with-pretitle{padding-top:0}.mw-parser-output .sidebar-image{padding:0.2em 0 0.4em}.mw-parser-output .sidebar-heading{padding:0.1em}.mw-parser-output .sidebar-content{padding:0 0.1em 0.4em}.mw-parser-output .sidebar-content-with-subgroup{padding:0.1em 0 0.2em}.mw-parser-output .sidebar-above,.mw-parser-output .sidebar-below{padding:0.3em 0.4em;font-weight:bold}.mw-parser-output .sidebar-collapse .sidebar-above,.mw-parser-output .sidebar-collapse .sidebar-below{border-top:1px solid #aaa;border-bottom:1px solid #aaa}.mw-parser-output .sidebar-navbar{text-align:right;font-size:115%}.mw-parser-output .sidebar-collapse .sidebar-navbar{padding-top:0.6em}.mw-parser-output .sidebar-collapse .mw-collapsible-toggle{margin-top:0.2em}.mw-parser-output .sidebar-list-title{text-align:left;font-weight:bold;line-height:1.6em;font-size:105%}@media(max-width:720px){body.mediawiki .mw-parser-output .sidebar{width:100%!important;clear:both;float:none!important;margin-left:0!important;margin-right:0!important}}Part of a series on theCOVID-19 pandemic\n",
      "\n",
      "SARS-CoV-2 (virus)\n",
      "COVID-19 (disease)\n",
      "\n",
      "Timeline2019\n",
      "2020\n",
      "\n",
      "\n",
      "January\n",
      "February\n",
      "responses\n",
      "March\n",
      "responses\n",
      "April\n",
      "responses\n",
      "May\n",
      "responses\n",
      "June\n",
      "responses\n",
      "July\n",
      "responses\n",
      "August\n",
      "responses\n",
      "September\n",
      "responses\n",
      "October\n",
      "responses\n",
      "November\n",
      "responses\n",
      "December\n",
      "responses\n",
      "2021\n",
      "\n",
      "January\n",
      "responses\n",
      "February\n",
      "responses\n",
      "March\n",
      "responses\n",
      "\n",
      "\n",
      "Locations\n",
      "By continent\n",
      "\n",
      "Africa\n",
      "Antarctica\n",
      "Asia\n",
      "Europe\n",
      "\n",
      "\n",
      "North America\n",
      "Oceania\n",
      "South America\n",
      "\n",
      "By conveyance\n",
      "\n",
      "Cruise ships\n",
      "Naval ships\n",
      "\n",
      "\n",
      "Cases\n",
      "Deaths\n",
      "\n",
      "\n",
      "International response\n",
      "European Union response\n",
      "Evacuations\n",
      "Face masks\n",
      "International aid\n",
      "Lockdowns\n",
      "National responses\n",
      "India\n",
      "New Zealand\n",
      "Philippines\n",
      "Russia\n",
      "Sweden\n",
      "U.K.\n",
      "U.S.\n",
      "Protests\n",
      "U.S.\n",
      "Travel restrictions\n",
      "United Nations\n",
      "World Health Organization\n",
      "\n",
      "Medical response\n",
      "Disease testing\n",
      "COVID-19 vaccines\n",
      "\n",
      "CanSino\n",
      "Gamaleya\n",
      "Johnson & Johnson\n",
      "Moderna\n",
      "Oxford–AstraZeneca\n",
      "Pfizer–BioNTech\n",
      "Sinopharm\n",
      "Sinovac\n",
      "Bharat Biotech\n",
      "Drug development\n",
      "Drug repurposing\n",
      "Variants of SARS-CoV-2\n",
      "\n",
      "Impact\n",
      "Socio-economic\n",
      "\n",
      "Crime\n",
      "Ireland\n",
      "Death rates by country\n",
      "Disability\n",
      "Domestic violence\n",
      "Economic\n",
      "Canada\n",
      "India\n",
      "Ireland\n",
      "New Zealand\n",
      "U.K.\n",
      "U.S.\n",
      "Recession\n",
      "Emergency evacuations\n",
      "Environment\n",
      "Fake treatments\n",
      "Financial markets\n",
      "Food security\n",
      "Hospitals\n",
      "Language\n",
      "Long-term care\n",
      "Migration\n",
      "Misinformation\n",
      "Governments\n",
      "United States\n",
      "China\n",
      "Military\n",
      "Other health issues\n",
      "Politics\n",
      "Ireland\n",
      "Pregnancy\n",
      "Prisons\n",
      "Religion\n",
      "Catholic Church\n",
      "Hajj\n",
      "Science and technology\n",
      "Social\n",
      "New Zealand\n",
      "Ireland\n",
      "U.K.\n",
      "U.S.\n",
      "Strikes\n",
      "Xenophobia and racism\n",
      "Notable deaths\n",
      "\n",
      "\n",
      "By industry\n",
      "\n",
      "\n",
      "Arts and culture\n",
      "Aviation\n",
      "Cannabis\n",
      "Cinema\n",
      "films\n",
      "Education\n",
      "Ireland\n",
      "United Kingdom\n",
      "Event cancellations\n",
      "Fashion\n",
      "Food\n",
      "Canada meat\n",
      "U.S. meat\n",
      "Journalism\n",
      "Music\n",
      "Performing arts\n",
      "Retail\n",
      "Sports\n",
      "Ireland\n",
      "Television\n",
      "U.S.\n",
      "Tourism\n",
      "Video games\n",
      "\n",
      "\n",
      " COVID-19 Portal.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:\"[ \"}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:\" ]\"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}.mw-parser-output .infobox .navbar{font-size:100%}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}vte\n",
      "A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus causing coronavirus disease 2019 (COVID‑19). Prior to the COVID‑19 pandemic, there was established body of knowledge about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), which enabled accelerated development of various vaccine technologies during early 2020.[1] On 10 January 2020, the SARS-CoV-2 genetic sequence data was shared through GISAID, and by 19 March, the global pharmaceutical industry announced a major commitment to address COVID-19.[2]\n",
      "As of February 2021[update], 66 vaccine candidates are in clinical research, including 17 in Phase I trials, 23 in Phase I–II trials, 6 in Phase II trials, and 20 in Phase III trials.[3] Trials for four other candidates were terminated.[3] In Phase III trials, several COVID‑19 vaccines demonstrate efficacy as high as 95% in preventing symptomatic COVID‑19 infections. As of February 2021[update], eleven vaccines are authorized by at least one national regulatory authority for public use: two RNA vaccines (the Pfizer–BioNTech vaccine and the Moderna vaccine), four conventional inactivated vaccines (BBIBP-CorV, Covaxin, CoronaVac, and CoviVac), four viral vector vaccines (Sputnik V, the Oxford–AstraZeneca vaccine, Convidicea, and the Johnson & Johnson vaccine), and one peptide vaccine (EpiVacCorona).[3]\n",
      "Many countries have implemented phased distribution plans that prioritize those at highest risk of complications, such as the elderly, and those at high risk of exposure and transmission, such as healthcare workers.[4] As of 3 March 2021[update], 275.84 million doses of COVID‑19 vaccine have been administered worldwide based on official reports from national health agencies.[5] AstraZeneca-Oxford anticipates producing 3 billion doses in 2021, Pfizer-BioNTech 1.3 billion doses, and Sputnik V, Sinopharm, Sinovac, and Johnson & Johnson 1 billion doses each. Moderna targets producing 600 million doses and Convidicea 500 million doses in 2021.[6][7] By December 2020, more than 10 billion vaccine doses had been preordered by countries,[8] with about half of the doses purchased by high-income countries comprising 14% of the world's population.[9]\n",
      "\n",
      "Contents\n",
      "\n",
      "1 Background\n",
      "2 Planning and development\n",
      "\n",
      "2.1 Organizations\n",
      "2.2 History\n",
      "\n",
      "\n",
      "3 Vaccine types\n",
      "\n",
      "3.1 RNA vaccines\n",
      "3.2 Adenovirus vector vaccines\n",
      "3.3 Inactivated virus vaccines\n",
      "3.4 Subunit vaccines\n",
      "3.5 Other types\n",
      "\n",
      "\n",
      "4 Trial and authorization status\n",
      "\n",
      "4.1 List of authorized and approved vaccines\n",
      "4.2 Vaccine candidates in human trials\n",
      "\n",
      "\n",
      "5 Efficacy\n",
      "\n",
      "5.1 Variants\n",
      "\n",
      "5.1.1 B.1.1.7 (United Kingdom) variant\n",
      "5.1.2 501.V2 (South Africa) variant\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "6 Formulation\n",
      "7 Deployment\n",
      "8 Liability\n",
      "9 Society and culture\n",
      "\n",
      "9.1 Access\n",
      "9.2 Misinformation\n",
      "9.3 Vaccine hesitancy\n",
      "\n",
      "\n",
      "10 See also\n",
      "11 References\n",
      "12 Further reading\n",
      "\n",
      "12.1 Vaccine protocols\n",
      "\n",
      "\n",
      "13 External links\n",
      "\n",
      "\n",
      "Background\n",
      " Fact sheet about COVID-19 vaccines\n",
      " A US airman receiving a COVID-19 vaccine.\n",
      "Prior to COVID‑19, a vaccine for an infectious disease had never been produced in less than several years—and no vaccine existed for preventing a coronavirus infection in humans.[10] However, vaccines have been produced against several animal diseases caused by coronaviruses, including (as of 2003) infectious bronchitis virus in birds, canine coronavirus, and feline coronavirus.[11] Previous projects to develop vaccines for viruses in the family Coronaviridae that affect humans have been aimed at severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Vaccines against SARS[12] and MERS[13] have been tested in non-human animals.\n",
      "According to studies published in 2005 and 2006, the identification and development of novel vaccines and medicines to treat SARS was a priority for governments and public health agencies around the world at that time.[14][15][16] As of 2020, there is no cure or protective vaccine proven to be safe and effective against SARS in humans.[17][18]  There is also no proven vaccine against MERS.[19] When MERS became prevalent, it was believed that existing SARS research may provide a useful template for developing vaccines and therapeutics against a MERS-CoV infection.[17][20] As of March 2020, there was one (DNA based) MERS vaccine which completed Phase I clinical trials in humans[21] and three others in progress, all being viral-vectored vaccines: two adenoviral-vectored (ChAdOx1-MERS, BVRS-GamVac) and one MVA-vectored (MVA-MERS-S).[22]\n",
      "The urgency to create a vaccine for COVID‑19, led to compressed schedules that shortened the standard vaccine development timeline, in some cases combining clinical trial steps over months, a process typically conducted sequentially over years.[23] Multiple steps along the entire development path are evaluated, including the level of acceptable toxicity of the vaccine (its safety), targeting vulnerable populations, the need for vaccine efficacy breakthroughs, the duration of vaccination protection, special delivery systems (such as oral or nasal, rather than by injection), dose regimen, stability and storage characteristics, emergency use authorization before formal licensing, optimal manufacturing for scaling to billions of doses, and dissemination of the licensed vaccine.[10][24] Timelines for conducting clinical research – normally a sequential process requiring years – are being compressed into safety, efficacy, and dosing trials running simultaneously over months, potentially compromising safety assurance.[23][25] As an example, Chinese vaccine developers and the government Chinese Center for Disease Control and Prevention began their efforts in January 2020,[26] and by March were pursuing numerous candidates on short timelines, with the goal to showcase Chinese technology strengths over those of the United States, and to reassure the Chinese people about the quality of vaccines produced in China.[23][27]\n",
      "\n",
      "Planning and development\n",
      "Since early 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments.[28] According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development puts North American entities having about 40% of the activity compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.[28][29]\n",
      "There have been several unique challenges with COVID-19 vaccine development.  The rapid development and urgency of producing a vaccine for the COVID‑19 pandemic may increase the risks and failure rate of delivering a safe, effective vaccine.[29][30][31]  Additionally, research at universities is obstructed by physical distancing and closing of laboratories.[32][33]\n",
      "Vaccines must progress through several phases of clinical trials to test for safety, immunogenicity, effectiveness, dose levels and adverse effects of the candidate vaccine.[34][35]  Vaccine developers have to invest resources internationally to find enough participants for Phase II–III clinical trials when the virus has proved to be a \"moving target\" of changing transmission rate across and within countries, forcing companies to compete for trial participants;[36] clinical trial organizers may encounter people unwilling to be vaccinated due to vaccine hesitancy[37] or disbelieving the science of the vaccine technology and its ability to prevent infection.[38]  Even as new vaccines are developed during the COVID‑19 pandemic, licensure of COVID‑19 vaccine candidates requires submission of a full dossier of information on development and manufacturing quality.[39][40][41]\n",
      "\n",
      "Organizations\n",
      "Internationally, the Access to COVID-19 Tools Accelerator is a G20 and World Health Organization (WHO) initiative announced in April 2020.[42][43] It is a cross-discipline support structure to enable partners to share resources and knowledge. It comprises four pillars, each managed by two to three collaborating partners: Vaccines (also called \"COVAX\"), Diagnostics, Therapeutics, and Health Systems Connector.[44]  The WHO's April 2020 \"R&D Blueprint (for the) novel Coronavirus\" documented a \"large, international, multi-site, individually randomized controlled clinical trial\" to allow \"the concurrent evaluation of the benefits and risks of each promising candidate vaccine within 3–6 months of it being made available for the trial.\"  The WHO vaccine coalition will prioritize which vaccines should go into Phase II and III clinical trials, and determine harmonized Phase III protocols for all vaccines achieving the pivotal trial stage.[45]\n",
      "National governments have also been involved in vaccine development. Canada announced funding for 96 research vaccine research projects at Canadian companies and universities, with plans to establish a \"vaccine bank\" that could be used if another coronavirus outbreak occurs,[46] and to support clinical trials and develop manufacturing and supply chains for vaccines.[47] China provided low-rate loans to a vaccine developer through its central bank and \"quickly made land available for the company\" to build production plants.[25]  Three Chinese vaccine companies and research institutes are supported by the government for financing research, conducting clinical trials, and manufacturing.[48]  Great Britain formed a COVID‑19 vaccine task force in April 2020 to stimulate local efforts for accelerated development of a vaccine through collaborations of industry, universities, and government agencies. It encompassed every phase of development from research to manufacturing.[49]  In the United States, the Biomedical Advanced Research and Development Authority (BARDA), a federal agency funding disease-fighting technology, announced investments to support American COVID‑19 vaccine development and manufacture of the most promising candidates.[25][50]  In May 2020, the government announced funding for a fast-track program called Operation Warp Speed.[51][52]\n",
      "Large pharmaceutical companies with experience in making vaccines at scale, including Johnson & Johnson, AstraZeneca, and GlaxoSmithKline (GSK), formed alliances with biotechnology companies, governments, and universities to accelerate progression to an effective vaccine.[25][23]\n",
      "\n",
      "History\n",
      ".mw-parser-output .excerpt .selflink{font-weight:normal}.mw-parser-output .excerpt-indicator{border-left:3px solid #c8ccd1;margin:1em 0;padding-left:1em}This section is an excerpt from History of COVID-19 vaccine development[edit]\n",
      " COVID‑19 vaccine research samples in NIAID lab freezer. (30 January 2020)\n",
      "After a coronavirus was isolated in December 2019,[53] its genetic sequence was published on 11 January 2020, triggering an urgent international response to prepare for an outbreak and hasten development of a preventive COVID-19 vaccine.[54][55][56] Since early 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments.[57] By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection.[55][58][59][60]  According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development puts North American entities having about 40% of the activity compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.[54][57]\n",
      "In February 2020, the WHO said it did not expect a vaccine against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the causative virus, to become available in less than 18 months.[61] The rapidly growing infection rate of COVID‑19 worldwide during early 2020 stimulated international alliances and government efforts to urgently organize resources to make multiple vaccines on shortened timelines,[62] with four vaccine candidates entering human evaluation in March (see the table of clinical trials started in 2020, below).[54][63]\n",
      "On 24 June 2020, China approved the CanSino vaccine for limited use in the military and two inactivated virus vaccines for emergency use in high-risk occupations.[64] On 11 August 2020, Russia announced the approval of its Sputnik V vaccine for emergency use, though one month later only small amounts of the vaccine had been distributed for use outside of the phase 3 trial.[65]\n",
      "\n",
      "The Pfizer-BioNTech partnership submitted an EUA request to the FDA for the mRNA vaccine BNT162b2 (active ingredient tozinameran) on 20 November 2020.[66][67] On 2 December 2020, the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) gave temporary regulatory approval for the Pfizer–BioNTech vaccine,[68][69] becoming the first country to approve this vaccine and the first country in the Western world to approve the use of any COVID‑19 vaccine.[70][71][72] As of 21 December, many countries and the European Union[73] have authorized or approved the Pfizer-BioNTech COVID‑19 vaccine. Bahrain and the United Arab Emirates granted emergency marketing authorization for BBIBP-CorV, manufactured by Sinopharm.[74][75] On 11 December 2020, the United States Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID‑19 vaccine.[76] A week later, they granted an EUA for mRNA-1273, the Moderna vaccine.[77][78][79]\n",
      "Vaccine types\n",
      " Conceptual diagram showing three vaccine types for forming SARS‑CoV‑2 proteins to prompt an immune response: (1) RNA vaccine, (2) subunit vaccine, (3) viral vector vaccine\n",
      "As of January 2021, nine different technology platforms – with the technology of numerous candidates remaining undefined – are under research and development to create an effective vaccine against COVID‑19.[3][80] Most of the platforms of vaccine candidates in clinical trials are focused on the coronavirus spike protein and its variants as the primary antigen of COVID‑19 infection.[80] Platforms being developed in 2020 involved nucleic acid technologies (nucleoside-modified messenger RNA and DNA), non-replicating viral vectors, peptides, recombinant proteins, live attenuated viruses, and inactivated viruses.[10][80][29][30]\n",
      "Many vaccine technologies being developed for COVID‑19 are not like vaccines already in use to prevent influenza, but rather are using \"next-generation\" strategies for precision on COVID‑19 infection mechanisms.[80][29][30] Vaccine platforms in development may improve flexibility for antigen manipulation and effectiveness for targeting mechanisms of COVID‑19 infection in susceptible population subgroups, such as healthcare workers, the elderly, children, pregnant women, and people with existing weakened immune systems.[80][29]\n",
      "\n",
      "RNA vaccines\n",
      " Diagram of the operation of an RNA vaccine.  Messenger RNA contained in the vaccine enters cells and is translated into foreign proteins, which trigger an immune response.\n",
      "An RNA vaccine contains RNA which, when introduced into a tissue, acts as messenger RNA (mRNA) to cause the cells to build the foreign protein and stimulate an adaptive immune response which teaches the body how to identify and destroy the corresponding pathogen or cancer cells.  RNA vaccines often, but not always, use nucleoside-modified messenger RNA.  The delivery of mRNA is achieved by a coformulation of the molecule into lipid nanoparticles which protect the RNA strands and help their absorption into the cells.[81][82][83][84]\n",
      "RNA vaccines were the first COVID-19 vaccines to be authorized in the United States and the European Union.[85][86] As of January 2021[update], authorized vaccines of this type are the Pfizer-BioNTech COVID‑19 vaccine[87][88][89] and the Moderna COVID-19 vaccine.[90][91] As of February 2021[update], the CVnCoV RNA vaccine from CureVac is awaiting authorization in the EU.[92]\n",
      "\n",
      "Adenovirus vector vaccines\n",
      "These vaccines are examples of non-replicating viral vectors, using an adenovirus shell containing DNA that encodes a SARS‑CoV‑2 protein.[93] The viral vector-based vaccines against COVID-19 are non-replicating, meaning that they do not make new virus particles, but rather produce only the antigen which elicits a systemic immune response.[93]\n",
      "As of January 2021, authorized vaccines of this type are the British Oxford–AstraZeneca COVID-19 vaccine,[94][95][96] Russian Sputnik V,[97] Chinese Convidicea, and the Johnson & Johnson COVID-19 vaccine.[98][99]\n",
      "Convidicia and Johnson & Johnson's vaccine's are both one-shot vaccines which offer less complicated logistics; and can be stored under ordinary refrigeration for several months.[100][101]\n",
      "\n",
      "Inactivated virus vaccines\n",
      "Inactivated vaccines consist of virus particles that have been grown in culture and then are killed using a method such as heat or formaldehyde to lose disease producing capacity, while still stimulating an immune response.[102]\n",
      "As of January 2021, authorized vaccines of this type are the Chinese CoronaVac[103][104][105] and BBIBP-CorV[106] as well as the Indian Covaxin.  Vaccines in clinical trials include the Valneva COVID-19 vaccine.[107][108]\n",
      "\n",
      "Subunit vaccines\n",
      "Subunit vaccines present one or more antigens without introducing whole pathogen particles. The antigens involved are often protein subunits, but can be any molecule that is a fragment of the pathogen.[109]\n",
      "As of January 2021, the only authorized vaccine of this type is the peptide vaccine EpiVacCorona.[110]  Vaccines in clinical trials include the Novavax COVID-19 vaccine[111] and RBD-Dimer.[3]  The V451 vaccine was previously in clinical trials, which were terminated because it was found that the vaccine may potentially cause incorrect results for subsequent HIV testing.[112][113]\n",
      "\n",
      "Other types\n",
      "Additional types of vaccines that are in clinical trials include multiple DNA plasmid vaccines,[114][115][116][117][118][119] at least two lentivirus vector vaccines,[120][121] a conjugate vaccine, and a vesicular stomatitis virus displaying the SARS‑CoV‑2 spike protein.[122]\n",
      "Scientists investigated whether existing vaccines for unrelated conditions could prime the immune system and lessen the severity of COVID‑19 infection.[123] There is experimental evidence that the BCG vaccine for tuberculosis has non-specific effects on the immune system, but no evidence that this vaccine is effective against COVID‑19.[124]\n",
      "\n",
      "Trial and authorization status\n",
      "Phase I trials test primarily for safety and preliminary dosing in a few dozen healthy subjects, while Phase II trials – following success in Phase I – evaluate immunogenicity, dose levels (efficacy based on biomarkers) and adverse effects of the candidate vaccine, typically in hundreds of people.[34][35] A Phase I–II trial consists of preliminary safety and immunogenicity testing, is typically randomized, placebo-controlled, while determining more precise, effective doses.[35] Phase III trials typically involve more participants at multiple sites, include a control group, and test effectiveness of the vaccine to prevent the disease (an \"interventional\" or \"pivotal\" trial), while monitoring for adverse effects at the optimal dose.[34][35] Definition of vaccine safety, efficacy, and clinical endpoints in a Phase III trial may vary between the trials of different companies, such as defining the degree of side effects, infection or amount of transmission, and whether the vaccine prevents moderate or severe COVID‑19 infection.[36][125][126]\n",
      "A clinical trial design in progress may be modified as an \"adaptive design\" if accumulating data in the trial provide early insights about positive or negative efficacy of the treatment.[127][128]  Adaptive designs within ongoing Phase II–III clinical trials on candidate vaccines may shorten trial durations and use fewer subjects, possibly expediting decisions for early termination or success, avoiding duplication of research efforts, and enhancing coordination of design changes for the Solidarity trial across its international locations.[127][129]\n",
      "\n",
      "List of authorized and approved vaccines\n",
      "National regulatory authorities have granted emergency use authorizations for eleven vaccines. Six of those have been approved for emergency or full use by at least one WHO-recognized stringent regulatory authorities.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "RNA vaccines  Pfizer–BioNTech  Moderna\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Adenovirus vector vaccines  Oxford–AstraZeneca  Sputnik V  Johnson & Johnson  Convidicea\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Inactivated virus vaccines  BBIBP-CorV  CoronaVac  CoviVac  Covaxin\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Vaccines authorized for emergency use or approved for full use\n",
      "\n",
      "\n",
      "Vaccine, developers/sponsors\n",
      "\n",
      "Country of origin\n",
      "\n",
      "Type (technology)\n",
      "\n",
      "Doses, interval\n",
      "\n",
      "Storage temperature\n",
      "\n",
      "Current phase (participants)\n",
      "\n",
      "Authorization\n",
      "\n",
      "\n",
      "Pfizer–BioNTech COVID-19 vaccine (Comirnaty)[87][88][89]BioNTech, Pfizer\n",
      "\n",
      "United States, Germany\n",
      "\n",
      "RNA (modRNA encapsulated in lipid nanoparticles)\n",
      "\n",
      "2 doses3–4 weeks\n",
      "\n",
      "-80 to -60 °C (ULT)\n",
      "\n",
      "Phase III (43,448)Randomized, placebo-controlled.Positive results from an interim analysis were announced on 18 November 2020[130] and published on 10 December 2020 reporting an overall efficacy of 95%.[131][132]Jul 2020 – Nov 2020,[133][134] Germany, United States\n",
      "\n",
      "\n",
      "Emergency (35)\n",
      " Albania[135]\n",
      " Andorra[136]\n",
      " Argentina[137]\n",
      " Aruba[138]\n",
      " Bahrain[139]\n",
      " Canada[87][140]\n",
      " Caribbean[141]\n",
      " Chile[142]\n",
      " Colombia[143]\n",
      " Costa Rica[144]\n",
      " Ecuador[145]\n",
      " Hong Kong[146]\n",
      " Iraq[147]\n",
      " Israel[148]\n",
      " Jordan[149]\n",
      " Kuwait[150]\n",
      " Liechtenstein[151]\n",
      " Mexico[152][153]\n",
      " Monaco[154]\n",
      " New Zealand[155]\n",
      " North Macedonia[156]\n",
      " Oman[157]\n",
      " Panama[158]\n",
      " Philippines[159]\n",
      " Qatar[160]\n",
      " Saint Vincent and the Grenadines[161]\n",
      " Singapore[162]\n",
      " Suriname[163]\n",
      " Switzerland[164][165]\n",
      " UAE[166]\n",
      " United Kingdom[167][168][169]\n",
      " Ukraine[170]\n",
      " United States[a][173][174]\n",
      " Vatican City[175][176]\n",
      " World Health Organization (WHO)[177][178]\n",
      "\n",
      "\n",
      "\n",
      "Full (12)\n",
      " Australia[179][180]\n",
      " Brazil[181]\n",
      " European Union[182][183][184]\n",
      " Faroe Islands[185]\n",
      " Greenland[185]\n",
      " Iceland[186]\n",
      " Japan[187]\n",
      " Malaysia[188]\n",
      " Norway[189]\n",
      " Saudi Arabia[190][191]\n",
      " Serbia[192][193]\n",
      " South Korea[194][195]\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Sputnik V COVID-19 vaccine  Gamaleya Research Institute of Epidemiology and Microbiology\n",
      "\n",
      "Russia\n",
      "\n",
      "Adenovirus vector (recombinant adenovirus type 5 and 26 vector)\n",
      "\n",
      "2 doses3 weeks\n",
      "\n",
      "-18 °C\n",
      "\n",
      "Phase III (40,000)Randomized double-blind, placebo-controlled to evaluate efficacy, immunogenicity, and safety.[196]Interim analysis from the trial was published in The Lancet, indicating 91.6% efficacy without unusual side effects.[197]Aug 2020 – May 2021, Russia, Belarus,[198] India,[199][200] Venezuela,[201][202] UAE[203]\n",
      "\n",
      "\n",
      "Emergency (35)\n",
      " Algeria[204]\n",
      " Argentina[205]\n",
      " Armenia[206]\n",
      " Bahrain[207]\n",
      " Belarus[208]\n",
      " Bolivia[209]\n",
      " Egypt[210]\n",
      " Gabon[211]\n",
      " Ghana[212]\n",
      " Guatemala[213]\n",
      " Guinea[214]\n",
      " Honduras[215]\n",
      " Iran[216]\n",
      " Kazakhstan[217]\n",
      " Laos[218]\n",
      " Lebanon[219]\n",
      " Mexico[220]\n",
      " Mongolia[221]\n",
      " Montenegro[222]\n",
      " Myanmar[223]\n",
      " Nicaragua[224]\n",
      " Pakistan[225]\n",
      " Palestine[226]\n",
      " Paraguay[227]\n",
      " Republika Srpska[228]\n",
      " Russia[229]\n",
      " Saint Vincent and the Grenadines[161]\n",
      " San Marino[230]\n",
      " Serbia[231]\n",
      " Slovakia[232]\n",
      " Tunisia[233]\n",
      " UAE[234]\n",
      " Uruguay[235]\n",
      " Venezuela[236]\n",
      " Vietnam[237]\n",
      "\n",
      "\n",
      "\n",
      "Full (8)\n",
      " Angola[238]\n",
      " Congo Republic[238]\n",
      " Djibouti[238]\n",
      " Hungary[239][228]\n",
      " Kyrgyzstan[240]\n",
      " Syria[241]\n",
      " Turkmenistan[242][228]\n",
      " Uzbekistan[243]\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Oxford–AstraZeneca COVID-19 vaccine (Covishield)[b][c][94][95][96]University of Oxford, AstraZeneca, CEPI\n",
      "\n",
      "United Kingdom\n",
      "\n",
      "Adenovirus vector (modified chimpanzee adenovirus vector, ChAdOx1)\n",
      "\n",
      "2 doses4–12 weeks\n",
      "\n",
      "2–8 °C\n",
      "\n",
      "Phase III (30,000)Interventional; randomized, placebo-controlled study for efficacy, safety, and immunogenicity.[247]Positive results from an interim analysis of four ongoing trials were announced on 23 November 2020, and published on 8 December 2020. Overall efficacy was 70%, ranging from 62% to 90% with different dosing regimens, with a peer-reviewed safety profile.[248]May 2020 – Aug 2021, Brazil (5,000),[249] United Kingdom, India[250]\n",
      "\n",
      "\n",
      "Emergency (30)\n",
      " Afghanistan[251][252]\n",
      " Argentina[253]\n",
      " Bahrain[254]\n",
      " Bangladesh[255][256]\n",
      " Brazil[257]\n",
      " Dominican Republic[258]\n",
      " Ecuador[259]\n",
      " Egypt[260]\n",
      " El Salvador[261]\n",
      " Guyana[262][263]\n",
      " India[264]\n",
      " Iraq[265]\n",
      " Maldives[266]\n",
      " Mauritius[267]\n",
      " Mexico[268]\n",
      " Myanmar[269]\n",
      " Nepal[270]\n",
      " Nigeria[271]\n",
      " Pakistan[272]\n",
      " Philippines[273]\n",
      " Rwanda [274]\n",
      " Saint Vincent and the Grenadines[161]\n",
      " Saudi Arabia[275]\n",
      " Sri Lanka[276]\n",
      " Suriname[277]\n",
      " Thailand[278]\n",
      " United Kingdom[279][280][281]\n",
      " Ukraine[170]\n",
      " Vietnam[282]\n",
      " World Health Organization (WHO)[177][283][284]\n",
      "\n",
      "\n",
      "\n",
      "Full (4)\n",
      " Australia[285][286]\n",
      " Canada[287][140]\n",
      " European Union[288][289][290]\n",
      " South Korea[291][292]\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "BBIBP-CorV[106]Sinopharm: Beijing Institute of Biological Products, Wuhan Institute of Biological Products\n",
      "\n",
      "China\n",
      "\n",
      "Inactivated SARS‑CoV‑2 (vero cells)\n",
      "\n",
      "2 doses3–4 weeks\n",
      "\n",
      "2–8 °C\n",
      "\n",
      "Phase III (48,000)Randomized, double-blind, parallel placebo-controlled, to evaluate safety and protective efficacy.Sinopharm's internal analysis indicated a 79% efficacy.[293]Jul 2020 – Jul 2021, United Arab Emirates, Bahrain, Jordan,[294] Argentina,[295] Morocco,[296] Peru[297]\n",
      "\n",
      "\n",
      "Emergency (19)\n",
      " Argentina[298]\n",
      " Bolivia[299]\n",
      " Cambodia[300]\n",
      " Egypt[301]\n",
      " Hungary[302]\n",
      " Iran[303]\n",
      " Iraq[265]\n",
      " Jordan[304]\n",
      " Laos[218]\n",
      " Lebanon[305]\n",
      " Macau[306]\n",
      " Morocco[307]\n",
      " Nepal[308]\n",
      " Pakistan[309]\n",
      " Peru[310]\n",
      " Senegal[311]\n",
      " Serbia[312]\n",
      " Venezuela[313]\n",
      " Zimbabwe[314]\n",
      "\n",
      "\n",
      "\n",
      "Full (4)\n",
      " Bahrain[315]\n",
      " China[316]\n",
      " Seychelles[317]\n",
      " United Arab Emirates (UAE)[318][319]\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "CoronaVac[103][104][105]Sinovac\n",
      "\n",
      "China\n",
      "\n",
      "Inactivated SARS‑CoV‑2\n",
      "\n",
      "2 doses2 weeks\n",
      "\n",
      "2–8 °C\n",
      "\n",
      "Phase III (33,620)Double-blind, randomized, placebo-controlled to evaluate efficacy and safety.Positive results from an interim analysis of a small sample were announced by Turkey on 24 December 2020, with an efficacy of 91%.[320] Additional results were announced by Indonesia on 11 January, with an overall efficacy of 65%.[321] The vaccine was 50% effective at preventing symptomatic infections in a Brazilian trial.[322]Jul 2020 – Oct 2021, Brazil (15,000);[323] Aug 2020 – January 2021, Indonesia (1,620); Chile (3,000);[324] Turkey (13,000)[325]\n",
      "\n",
      "\n",
      "Emergency (15)\n",
      " Azerbaijan[326]\n",
      " Bolivia[327]\n",
      " Brazil[257]\n",
      " Cambodia[328]\n",
      " Chile[329]\n",
      " Colombia[330]\n",
      " Ecuador[331]\n",
      " Hong Kong[332]\n",
      " Indonesia[321][333]\n",
      " Laos[334]\n",
      " Mexico[335]\n",
      " Philippines[336]\n",
      " Thailand[337]\n",
      " Turkey[338]\n",
      " Uruguay[334]\n",
      "\n",
      "\n",
      "\n",
      "Full (1)\n",
      " China[334]\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Moderna COVID-19 vaccine[90][91]Moderna, NIAID, BARDA, CEPI\n",
      "\n",
      "United States\n",
      "\n",
      "RNA (modRNA encapsulated in lipid nanoparticles)\n",
      "\n",
      "2 doses4 weeks\n",
      "\n",
      "-25 to -15 °C\n",
      "\n",
      "Phase III (30,000)Interventional; randomized, placebo-controlled study for efficacy, safety, and immunogenicity.Positive results from an interim analysis were announced on 15 November 2020[339] and published on 30 December 2020 reporting an overall efficacy of 94%.[340]Jul 2020 – Oct 2022, United States\n",
      "\n",
      "\n",
      "Emergency (9)\n",
      " Canada[341][140]\n",
      " Israel[342]\n",
      " Saint Vincent and the Grenadines[161]\n",
      " Saudi Arabia[275]\n",
      " Singapore[343]\n",
      " Switzerland[344]\n",
      " United Kingdom[345][346]\n",
      " United States[a][347][348]\n",
      " Vietnam[349]\n",
      "\n",
      "\n",
      "\n",
      "Full (5)\n",
      " European Union[350][351][352][353]\n",
      " Faroe Islands[354]\n",
      " Greenland[354]\n",
      " Iceland[355]\n",
      " Norway[356]\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Johnson & Johnson COVID-19 vaccine[98][99]Janssen Pharmaceutica (Johnson & Johnson), BIDMC\n",
      "\n",
      "United States, Netherlands\n",
      "\n",
      "Adenovirus vector (adenovirus serotype 26)\n",
      "\n",
      "1 dose\n",
      "\n",
      "2–8 °C\n",
      "\n",
      "Phase III (40,000)Randomized, double-blinded, placebo-controlledPositive results from an interim analysis were announced on 29 January 2021.[357]Jul 2020 – 2023, United States, Argentina, Brazil, Chile, Colombia, Mexico, Peru, the Philippines, South Africa, Ukraine\n",
      "\n",
      "\n",
      "Emergency (4)\n",
      " Bahrain[358][359]\n",
      " Saint Vincent and the Grenadines[161]\n",
      " South Africa[360]\n",
      " United States[361][362]\n",
      "\n",
      "\n",
      "\n",
      "Full (0)\n",
      " None\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Ad5-nCoV (Convidicea)CanSino Biologics, Beijing Institute of Biotechnology of the Academy of Military Medical Sciences\n",
      "\n",
      "China\n",
      "\n",
      "Adenovirus vector (recombinant adenovirus type 5 vector)\n",
      "\n",
      "1 dose\n",
      "\n",
      "2–8 °C\n",
      "\n",
      "Phase III (40,000)Global multi-center, randomized, double-blind, placebo-controlled to evaluate efficacy, safety and immunogenicity.In February 2021, interim analysis from global trials showed an efficacy of 65.7% against moderate cases of COVID-19 and 90.98% efficacy against severe cases.[363]Mar–Dec 2020, China; Sep 2020 – Dec 2021, Pakistan; Sep 2020 – Nov 2020, Russia,[364] China, Argentina, Chile;[365] Mexico;[366] Pakistan;[367] Saudi Arabia[368][369]\n",
      "\n",
      "\n",
      "Emergency (3)\n",
      " China[370][371]\n",
      " Mexico[335]\n",
      " Pakistan[372]\n",
      "\n",
      "\n",
      "\n",
      "Full (0)\n",
      " None\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "EpiVacCorona[110]Vector Institute\n",
      "\n",
      "Russia\n",
      "\n",
      "Subunit/Peptide[110]\n",
      "\n",
      "2 doses3–4 weeks\n",
      "\n",
      "2–8 °C\n",
      "\n",
      "Phase III (40,000)Randomized double-blind, placebo-controlled to evaluate efficacy, immunogenicity, and safetyNov 2020 – Dec 2021, Russia[373]\n",
      "\n",
      "\n",
      "Emergency (1)\n",
      " Russia[374][375]\n",
      "\n",
      "\n",
      "\n",
      "Full (1)\n",
      " Turkmenistan[376][377]\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "BBV152 (Covaxin)Bharat Biotech, Indian Council of Medical Research\n",
      "\n",
      "India\n",
      "\n",
      "Inactivated SARS‑CoV‑2\n",
      "\n",
      "2 doses4 weeks\n",
      "\n",
      "2–8 °C\n",
      "\n",
      "Phase III (25,800)Randomised, observer-blinded, placebo-controlled[378]The interim efficacy rate is 81% as per third phase trial.[379] All data from the second interim and final analyses is yet to be made available through peer-reviewed journal.[380]Nov 2020 – Mar 2021, India.\n",
      "\n",
      "\n",
      "Emergency (1)\n",
      " India (monitored)[264]\n",
      "\n",
      "\n",
      "\n",
      "Full (0)\n",
      " None\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "CoviVac[381]The Chumakov Centre at the Russian Academy of Sciences\n",
      "\n",
      "Russia\n",
      "\n",
      "Inactivated SARS‑CoV‑2\n",
      "\n",
      "2 doses2 weeks\n",
      "\n",
      "2–8 °C\n",
      "\n",
      "Phase III (3,000)Double-blind, randomized, placebo-controlled to evaluate efficacy and safety.\n",
      "\n",
      "\n",
      "Emergency (1)\n",
      " Russia[382]\n",
      "\n",
      "\n",
      "\n",
      "Full (0)\n",
      " None\n",
      "\n",
      "\n",
      "\n",
      "Vaccine candidates in human trials\n",
      "\n",
      "COVID‑19 candidate vaccines in Phase I–III trials[3][383][384]\n",
      "\n",
      "\n",
      "Vaccine candidates,developers, and sponsors\n",
      "\n",
      "Country of origin\n",
      "\n",
      "Type (technology)\n",
      "\n",
      "Current phase (participants)design\n",
      "\n",
      "Completed phase[d] (participants)Immune response\n",
      "\n",
      "Pending authorization\n",
      "\n",
      "\n",
      "Novavax COVID-19 vaccine[111]Novavax, CEPI\n",
      "\n",
      "United States\n",
      "\n",
      "Subunit[385][386][387]/virus-like particle[388][389]  (SARS‑CoV‑2 recombinant spike protein nanoparticle with adjuvant)\n",
      "\n",
      "Phase III (45,000)Randomised, observer-blinded, placebo-controlled trial[390]Sep 2020 – Jan 2021, UK (15,000); December 2020 – Mar 2021, US, Mexico, (30,000)[391]\n",
      "\n",
      "Phase I–II (131)IgG and neutralizing antibody response with adjuvant after booster dose.[392]\n",
      "\n",
      "\n",
      "Emergency (1)\n",
      " Ukraine[393][394]\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "ZF2001 (RBD-Dimer)[3]Anhui Zhifei Longcom Biopharmaceutical Co. Ltd.\n",
      "\n",
      "China\n",
      "\n",
      "Subunit (recombinant)\n",
      "\n",
      "Phase III (29,000)Randomized, double-blind, placebo-controlled[395]Dec 2020 – Apr 2022, China, Ecuador, Indonesia, Malaysia, Pakistan, Uzbekistan[396][397]\n",
      "\n",
      "Phase II (900)Interventional; randomized, double-blind, placebo-controlled[398]Jun 2020 – Sep 2021, Chongqing\n",
      "\n",
      "\n",
      "Emergency (1)\n",
      " Uzbekistan[399]\n",
      "\n",
      "\n",
      "\n",
      "CureVac COVID-19 vaccine (CVnCoV)CureVac, CEPI\n",
      "\n",
      "Germany\n",
      "\n",
      "RNA (unmodified RNA)[400]\n",
      "\n",
      "Phase III (36,500)[401]Phase 2b/3: Multicenter efficacy and safety trial in adultsNov 2020 – ?, Argentina, Belgium, Colombia, Dominican Republic, France, Germany, Mexico, Netherlands, Panama, Peru, Spain\n",
      "\n",
      "Phase I–II (944)[402][403]Phase I (284): Partially blind, controlled, dose-escalation to evaluate safety, reactogenicity and immunogenicity.Phase IIa (660):Partially observer-blind, multicenter, controlled, dose-confirmation.Jun 2020 – Oct 2021, Belgium (phase I), Germany (phase I), Panama (phase IIa), Peru (phase IIa)\n",
      "\n",
      "\n",
      "Emergency (1)\n",
      " EU[92]\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "QazCovid-in[404]Research Institute for Biological Safety Problems\n",
      "\n",
      "Kazakhstan\n",
      "\n",
      "Inactivated SARS‑CoV‑2\n",
      "\n",
      "Phase III (3,000)Randomised, blind, placebo-controlled trial[405]Dec 2020 – Jul 2021, Kazakhstan [405]\n",
      "\n",
      "Phase I–II (244[406])Sep 2020 – Nov 2020, Kazakhstan\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "ZyCoV-D[114]Cadila Healthcare\n",
      "\n",
      "India\n",
      "\n",
      "DNA (plasmid expressing SARS‑CoV‑2 S protein)\n",
      "\n",
      "Phase III (26,000)[407]Randomised, blind, placebo-controlled trial[408]Jan 2021 – ?, India[409]\n",
      "\n",
      "Phase I–II (1,000)Interventional; randomized, double-blind, placebo-controlled[410][408]Jul 2020 – Jan 2021, India\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "CoVLP[411]Medicago, GSK\n",
      "\n",
      "Canada, United Kingdom\n",
      "\n",
      "Virus-like particles[e] (recombinant, plant-based with AS03)\n",
      "\n",
      "Phase II–III (30,612)Event-driven, randomized, observer blinded, placebo-controlled[413]Nov 2020 – Apr 2022, Canada\n",
      "\n",
      "Phase I (180)Neutralizing antibodies at day 42 after the first injection (day 21 after the second injection) were at levels 10x that of COVID-19 survivors.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "IIBR-100 (Brilife)[122]The Israel Institute for Biological research\n",
      "\n",
      "Israel\n",
      "\n",
      "Vesicular stomatitis vector (recombinant)\n",
      "\n",
      "Phase II (1,000)[414]Dec 2020 – spring 2021, Israel\n",
      "\n",
      "Phase I (80)[122]Subjects (18–55 years old) randomly receiving a single administration of IIBR-100 at the low, mid, or high dose, or saline, or two administrations at a low dose, or saline, 28 days apart.Oct–Nov 2020, Israel\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "FINLAY-FR-2 (SOBERANA 02)Instituto Finlay de Vacunas\n",
      "\n",
      "Cuba\n",
      "\n",
      "Conjugate\n",
      "\n",
      "Phase II (910)[415]Allocation: Randomized controlled trial. Masking: Double Blind. Control group: Placebo. Study design: Parallel.Jan–Mar 2021, Cuba\n",
      "\n",
      "Phase I (40)[416]Allocation: Non-randomized controlled trial. Masking: Open. Control group: Uncontrolled. Study design: Adaptive, sequentialNov 2020 – Jan 2021, Cuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Nano Covax[417]Nanogen Pharmaceutical Biotechnology JSC\n",
      "\n",
      "Vietnam\n",
      "\n",
      "Subunit (SARS‑CoV‑2 recombinant spike protein with aluminum adjuvant)[418][419]\n",
      "\n",
      "Phase II (560)[420]Randomization, double-blind, multicenter, placebo-controlledFeb – May 2021, Vietnam\n",
      "\n",
      "Phase I (60)[417]Open label, dose escalationDec 2020 – Jan 2021, Vietnam\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "INO-4800[f][115][116]Inovio, CEPI, Korea National Institute of Health, International Vaccine Institute\n",
      "\n",
      "South Korea, United States\n",
      "\n",
      "DNA vaccine (plasmid delivered by electroporation)\n",
      "\n",
      "Phase I–II (40)Apr–Nov 2020, United States, South Korea\n",
      "\n",
      "PreclinicalPending Phase I report.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Unnamed[421]Chinese Academy of Medical Sciences\n",
      "\n",
      "China\n",
      "\n",
      "Inactivated SARS‑CoV‑2\n",
      "\n",
      "Phase I–II (942)Randomized, double-blinded, single-center, placebo-controlledJun 2020 – Sep 2021, Chengdu\n",
      "\n",
      "Preclinical\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "AG0301-COVID‑19[117]AnGes Inc.,[422] AMED\n",
      "\n",
      "Japan\n",
      "\n",
      "DNA vaccine (plasmid)\n",
      "\n",
      "Phase I–II (30)Non-randomized, single-center, two dosesJun 2020 – Jul 2021, Osaka\n",
      "\n",
      "Preclinical\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Lunar-COV19/ARCT-021[423][424]Arcturus Therapeutics, Duke–NUS Medical School\n",
      "\n",
      "United States, Singapore\n",
      "\n",
      "RNA\n",
      "\n",
      "Phase I–II (92)Randomized, double-blindedAug 2020 – ?, Singapore\n",
      "\n",
      "Preclinical\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "VLA2001[107][108]Valneva\n",
      "\n",
      "France\n",
      "\n",
      "Inactivated SARS‑CoV‑2\n",
      "\n",
      "Phase I–II (150)Randomized, multi-center, double-blindedDec 2020 – Feb 2021, United Kingdom\n",
      "\n",
      "Preclinical\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "COVID‑19/aAPC[120]Shenzhen Genoimmune Medical Institute[425]\n",
      "\n",
      "China\n",
      "\n",
      "Lentiviral vector (with minigene modifying aAPCs)\n",
      "\n",
      "Phase I (100)Mar 2020 – 2023, Shenzhen\n",
      "\n",
      "Preclinical\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "LV-SMENP-DC[121]Shenzhen Genoimmune Medical Institute[425]\n",
      "\n",
      "China\n",
      "\n",
      "Lentiviral vector (with minigene modifying DCs)\n",
      "\n",
      "Phase I (100)Mar 2020 – 2023, Shenzhen\n",
      "\n",
      "Preclinical\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "LNP-nCoVsaRNA[426]MRC clinical trials unit at Imperial College London\n",
      "\n",
      "United Kingdom\n",
      "\n",
      "RNA\n",
      "\n",
      "Phase I (105)Randomized trial, with dose escalation study (15) and expanded safety study (at least 200)Jun 2020 – Jul 2021, United Kingdom\n",
      "\n",
      "Preclinical\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "GRAd-COV2[427][428]ReiThera, Lazzaro Spallanzani National Institute for Infectious Diseases\n",
      "\n",
      "Italy\n",
      "\n",
      "Adenovirus vector (modified chimpanzee adenovirus vector, GRAd)\n",
      "\n",
      "Phase I (90)[429]Subjects (two groups: 18–55 and 65–85 years old) randomly receiving one of three escalating doses of GRAd-COV2 or a placebo, then monitored over a 24-week period. 93% of subjects who received GRAd-COV2 developed anti-bodies.Aug–Dec 2020, Rome\n",
      "\n",
      "Preclinical\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "GX-19[118][119]Genexine consortium,[430] International Vaccine Institute\n",
      "\n",
      "South Korea\n",
      "\n",
      "DNA vaccine\n",
      "\n",
      "Phase I (40)Jun 2020 – Jun 2022, Seoul\n",
      "\n",
      "Preclinical\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "SCB-2019[431][432]Clover Biopharmaceuticals,[433] GSK, CEPI\n",
      "\n",
      "China, United Kingdom\n",
      "\n",
      "Subunit (Spike protein trimeric subunit with AS03)\n",
      "\n",
      "Phase I (150)Jun 2020 – Mar 2021, Perth\n",
      "\n",
      "Preclinical\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "COVAX-19[434]Vaxine Pty Ltd[435]\n",
      "\n",
      "Australia\n",
      "\n",
      "Subunit (recombinant protein)\n",
      "\n",
      "Phase I (40)Jun 2020 – Jul 2021, Adelaide\n",
      "\n",
      "Preclinical\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Unnamed[436]PLA Academy of Military Science, Walvax Biotech[437]\n",
      "\n",
      "China\n",
      "\n",
      "RNA\n",
      "\n",
      "Phase I (168)Jun 2020 – Dec 2021, China\n",
      "\n",
      "Preclinical\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "HGC019[438]Gennova Biopharmaceuticals, HDT Biotech Corporation[439]\n",
      "\n",
      "India, United States\n",
      "\n",
      "RNA\n",
      "\n",
      "Phase I (120)[440]Jan 2021 – ?, India\n",
      "\n",
      "Preclinical\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Bangavax [441][442]Globe Biotech Ltd. of Bangladesh\n",
      "\n",
      "Bangladesh\n",
      "\n",
      "RNA\n",
      "\n",
      "Phase I (100)[441][443]Randomized, Parallel Group TrialFeb 2021 – Feb 2022,[444] Bangladesh\n",
      "\n",
      "Preclinical\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Unnamed[445]Biological E. Limited, Baylor College of Medicine[446]\n",
      "\n",
      "India, United States\n",
      "\n",
      "Inactivated SARS‑CoV‑2 (using an antigen)\n",
      "\n",
      "Phase I–II (360)[447]Randomized, Parallel Group TrialNov 2020 – Feb 2021, India\n",
      "\n",
      "Preclinical\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "PTX-COVID19-B[448]Providence Therapeutics\n",
      "\n",
      "Canada\n",
      "\n",
      "RNA\n",
      "\n",
      "Phase I (60)[448]Jan 2021 – May 2021, Canada\n",
      "\n",
      "Preclinical\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "COVAC-2[449]VIDO (University of Saskatchewan)\n",
      "\n",
      "Canada\n",
      "\n",
      "Subunit\n",
      "\n",
      "Phase I (108)[449]Feb 2021 – Jan 2022, Halifax\n",
      "\n",
      "Preclinical\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "SARS-CoV-2 Sclamp/V451[112][113]UQ, Syneos Health, CEPI, Seqirus\n",
      "\n",
      "Australia\n",
      "\n",
      "Subunit (molecular clamp stabilized spike protein with MF59)\n",
      "\n",
      "Terminated (120)Randomised, double-blind, placebo-controlled, dose-ranging.False positive HIV test found among participants.Jul–Oct 2020, Brisbane\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "V590[450] and V591/MV-SARS-CoV-2[451] Merck & Co. (Themis BIOscience), Institut Pasteur, University of Pittsburgh's Center for Vaccine Research (CVR), CEPI\n",
      "\n",
      "United States, France\n",
      "\n",
      "\n",
      "\n",
      "TerminatedIn phase I, immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines.[452]\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "^ a b US authorization also includes the three sovereign nations in the Compact of Free Association: Palau, the Marshall Islands, and Micronesia.[171][172]\n",
      "\n",
      "^ Serum Institute of India will be producing the ChAdOx1 nCoV-19 vaccine for India[244] and other low and middle income countries.[245]\n",
      "\n",
      "^ Oxford name: ChAdOx1 nCoV-19. Manufacturing in Brazil to be carried out by Oswaldo Cruz Foundation.[246]\n",
      "\n",
      "^ Latest Phase with published results.\n",
      "\n",
      "^ Virus-like particles grown in Nicotiana benthamiana[412]\n",
      "\n",
      "^ South Korean Phase I–II in parallel with Phase I in the US\n",
      "\n",
      "\n",
      "Efficacy\n",
      " Cumulative incidence curves for symptomatic COVID‑19 infections after the first dose of the Pfizer–BioNTech vaccine (tozinameran) or placebo in a double-blind clinical trial. (red: placebo; blue: tozinameran)[453]\n",
      "The effectiveness of a new vaccine is defined by its efficacy during clinical trials.[134] The efficacy is the risk of getting the disease by vaccinated participants in the trial compared with the risk of getting the disease by unvaccinated participants.[134] An efficacy of 0% means that the vaccine does not work (identical to placebo). An efficacy of 50% means that there are half as many cases of infection as in unvaccinated individuals.\n",
      "It is not straightforward to compare the efficacies of the different vaccines because the trials were run with different populations, geographies, and variants of the virus.[454] In the case of COVID‑19, a vaccine efficacy of 67% may be enough to slow the pandemic, but this assumes that the vaccine confers sterilizing immunity, which is necessary to prevent transmission. Vaccine efficacy reflects disease prevention, a poor indicator of transmissibility of SARS‑CoV‑2 since asymptomatic people can be highly infectious.[455] The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) set a cutoff of 50% as the efficacy required to approve a COVID‑19 vaccine.[456][457]\n",
      "In efficacy calculations, symptomatic COVID-19 is generally defined as having both a positive PCR test and at least one or two of a defined list of COVID-19 symptoms, although exact specifications varying between trials.  The trial location also affects the reported efficacy because different countries have different prevalences of SARS-CoV-2 variants.  Ranges below are 95% confidence intervals.  Authorized and approved vaccines have shown the following efficacies:\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Vaccine\n",
      "\n",
      "Efficacy against symptomatic COVID-19\n",
      "\n",
      "Efficacy against severe COVID-19\n",
      "\n",
      "Trial location\n",
      "\n",
      "Refs\n",
      "\n",
      "\n",
      "Moderna vaccine\n",
      "\n",
      "89–97%\n",
      "\n",
      "no cases\n",
      "\n",
      "United States\n",
      "\n",
      "[458]\n",
      "\n",
      "\n",
      "Pfizer–BioNTech vaccine\n",
      "\n",
      "90–97%\n",
      "\n",
      "not reported\n",
      "\n",
      "multinational\n",
      "\n",
      "[459]\n",
      "\n",
      "\n",
      "Sputnik V\n",
      "\n",
      "86–95%\n",
      "\n",
      "94–100%\n",
      "\n",
      "Russia\n",
      "\n",
      "[460]\n",
      "\n",
      "\n",
      "Oxford–AstraZeneca vaccine\n",
      "\n",
      "62–90%\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "[citation needed]\n",
      "\n",
      "\n",
      "Novavax vaccine\n",
      "\n",
      "75–95%\n",
      "\n",
      "no cases\n",
      "\n",
      "United Kingdom\n",
      "\n",
      "[461][462]\n",
      "\n",
      "\n",
      "20–80%\n",
      "\n",
      "no cases\n",
      "\n",
      "South Africa\n",
      "\n",
      "\n",
      "BBIBP-CorV\n",
      "\n",
      "~79%\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "[463][464]\n",
      "\n",
      "\n",
      "CoronaVac\n",
      "\n",
      "~78%\n",
      "\n",
      "~100%\n",
      "\n",
      "\n",
      "\n",
      "[465][466][unreliable medical source?]\n",
      "\n",
      "\n",
      "Johnson & Johnson vaccine\n",
      "\n",
      "55–75% (moderate cases)\n",
      "\n",
      "54–97%\n",
      "\n",
      "multinational\n",
      "\n",
      "[467][468]\n",
      "\n",
      "\n",
      "58–82% (moderate cases)\n",
      "\n",
      "-9–100%\n",
      "\n",
      "United States\n",
      "\n",
      "\n",
      "49–81% (moderate cases)\n",
      "\n",
      "8–100%\n",
      "\n",
      "Brazil\n",
      "\n",
      "\n",
      "41–79% (moderate cases)\n",
      "\n",
      "46–95%\n",
      "\n",
      "South Africa\n",
      "\n",
      "\n",
      "Covaxin\n",
      "\n",
      "~81%\n",
      "\n",
      "\n",
      "\n",
      "India\n",
      "\n",
      "[469][unreliable medical source?]\n",
      "\n",
      "At the University of Oxford, researchers have as of early February 2021 begun enrolling volunteers in an 820 person trial to evaluate the efficacy of combining two different vaccines, a mix and match approach, as opposed to using two doses of the same vaccine. The ultimate goal of the study will be find whether the mix and match method is just as or more effective than the currently used practice. The study will utilize the shot developed by Pfizer and BioNTech with the University of Oxford and AstraZeneca shot, two vaccines which rely on different methods to deliver information to the cells of the recipient. Ugur Sahin has voiced his opposition to the trial in December, stating that a study \"will use up doses that people who need them could profit from, I am not happy about this,\" though Pfizer and AstraZeneca have supported the trials.[470]\n",
      "\n",
      "Variants\n",
      "See also: Variants of SARS-CoV-2\n",
      "Further information: 501.V2 variant § Vaccine evasion\n",
      "A preliminary study by Pfizer, Inc. has indicated that there is, at most, only minor reduction of the company's mRNA vaccine effectiveness against different SARS-CoV-2 variants.[471]  According to the US CDC, most experts believe that, due to the nature of the virus, the emergence of variants that completely escape the immune response (both natural and vaccine induced) is considered unlikely.[99]\n",
      "T-cell immunity is under investigation as a potential solution to the problem of reduced effectiveness of vaccines against the relevant variants. This is because T-cells target multiple pieces of the virus.[472] As the majority of genetic variation is on the spike protein, T-cells that attack other parts of the virus should be able to recognise new variants. Viral vector and mRNA based vaccines are believed to elicit the strongest t-cell response.[473] This believed to be the reason why the vaccine developed for yellow fever, an RNA virus like SARS-CoV-2, has remained effective for so long; by targeting antigens within the virus that are unlikely to change, as opposed to those on the surface, it is unaffected by the majority of mutations. Companies including Emergex, Osivax and eTheRNA are targeting these internal antigens in the hope of creating a \"universal\" SARS-CoV-2 vaccine.[474] Biotechnology firm Gritstone is also experimenting to develop a vaccine aimed specifically at creating T-cell immunity.[475][476]\n",
      "On 29 January 2021, a deputy of the Moscow City Duma, Darya Besedina, turned to the Russian Minister of Health with a request to fund the study of new strains and conduct research on the effectiveness of Russian vaccines against these strains.[477] On 10 February 2021, the European Medicines Agency made a similar appeal to vaccine manufacturers.[478] On 15 February, Russian President Vladimir Putin instructed the government to deploy the sequencing of the genomes of Russian SARS-CoV-2 strains within a month, allocate funds for these studies, and also check whether Russian vaccines are effective against new strains.[479]\n",
      "\n",
      "B.1.1.7 (United Kingdom) variant\n",
      "In December 2020, a new SARS‑CoV‑2 variant, B.1.1.7, was identified in the UK.[480] Early results suggest that both the Pfizer and Moderna vaccines protect against the UK variant.[481][482] Another study of the effectiveness of the same Comirnaty vaccine against the B.1.1.7 variant confirmed this.[483] Preliminary results presented in biorxiv have shown Covaxin to be effective against neutralizing the strain.[484]\n",
      "\n",
      "501.V2 (South Africa) variant\n",
      "However they are less effective against the South Africa variant, with Moderna reporting that the current vaccine produced only one-sixth of the antibodies in response to the South African variant compared with the original virus. They have launched a trial of a new vaccine to tackle the South African 501.V2 variant (also known as B.1.351).[485] On 17 February 2021, Pfizer announced neutralization activity was reduced by two thirds for the 501.V2 variant, while stating no claims about the efficacy of the vaccine in preventing illness for this variant could yet be made.[486]\n",
      "In January, Johnson & Johnson, which held trials for its Ad26.COV2.S vaccine in South Africa, reported the level of protection against moderate to severe COVID-19 infection was 72% in the United States and 57% in South Africa.[487]\n",
      "On 6 February 2021, the Financial Times reported that provisional trial data from a study undertaken by South Africa's University of the Witwatersrand in conjunction with Oxford University demonstrated reduced efficacy of the Oxford–AstraZeneca COVID-19 vaccine against the 501.V2 variant.[488] The study found that in a sample size of 2,000 the AZD1222 vaccine afforded only \"minimal protection\" in all but the most severe cases of COVID-19.[489] On 7 February 2021, the Minister for Health for South Africa suspended the planned deployment of around 1 million doses of the vaccine whilst they examine the data and await advice on how to proceed.[490][491]\n",
      "\n",
      "Formulation\n",
      "As of September 2020[update], eleven of the vaccine candidates in clinical development use adjuvants to enhance immunogenicity.[80] An immunological adjuvant is a substance formulated with a vaccine to elevate the immune response to an antigen, such as the COVID‑19 virus or influenza virus.[492] Specifically, an adjuvant may be used in formulating a COVID‑19 vaccine candidate to boost its immunogenicity and efficacy to reduce or prevent COVID‑19 infection in vaccinated individuals.[492][493] Adjuvants used in COVID‑19 vaccine formulation may be particularly effective for technologies using the inactivated COVID‑19 virus and recombinant protein-based or vector-based vaccines.[493] Aluminum salts, known as \"alum\", were the first adjuvant used for licensed vaccines, and are the adjuvant of choice in some 80% of adjuvanted vaccines.[493] The alum adjuvant initiates diverse molecular and cellular mechanisms to enhance immunogenicity, including release of proinflammatory cytokines.[492][493]\n",
      "\n",
      "Deployment\n",
      ".mw-parser-output #covid19-container{box-sizing:border-box;float:right;max-width:100%;max-height:75vh;height:50.25em;overflow:auto;padding-right:18px}.mw-parser-output .covid-show-table{float:right;font-size:75%}.mw-parser-output .covid-collapse-table{font-size:75%;display:none}.mw-parser-output #covid19-container:target .covid-show-table{display:none}.mw-parser-output #covid19-container:target .covid-collapse-table{display:inline}.mw-parser-output #covid19-container:target{max-width:none;max-height:none;height:auto;overflow-y:visible;padding-right:0}.mw-parser-output div.covid19-container-wrapper:target div/**/#covid19-container .covid-show-table{display:none}.mw-parser-output div.covid19-container-wrapper:target div/**/#covid19-container .covid-collapse-table{display:inline}.mw-parser-output div.covid19-container-wrapper:target div/**/#covid19-container{max-width:none;max-height:none;height:auto;overflow-y:visible;padding-right:0}body .mw-parser-output th.covid-total-row{text-align:right!important;padding-right:16px}@media print{.mw-parser-output #covid19-container{max-width:none;max-height:none;height:auto;overflow-y:visible;padding-right:0}.mw-parser-output .covid-show-table{display:none}}@media screen{.mw-parser-output .covid-sticky th{height:2.1em;position:sticky;top:0;background-clip:padding-box;z-index:10}.mw-parser-output .covid-sticky th:after,.mw-parser-output .covid-sticky th:before{content:\"\";position:absolute;left:0;width:100%}.mw-parser-output .covid-sticky th:before{top:-1px;border-top:1px solid #a2a9b1}.mw-parser-output .covid-sticky th:after{bottom:-1px;border-bottom:1px solid #a2a9b1}.mw-parser-output .covid-sticky.covid-sticky-2 th{top:2.1em}}@media only screen and (max-width:650px){.mw-parser-output .covid-country-narrow-on-mobile{width:12ch}body .mw-parser-output th.covid-total-row{padding-right:3px}}@media only screen and (max-width:500px){.mw-parser-output #covid19-container{padding-right:0px;margin-top:10px}.mw-parser-output .covid-show-table{float:left}.mw-parser-output .plainlinks.hlist.navbar.mini{display:none}.mw-parser-output .plainlinks.hlist.navbar.mini+div{margin:0!important;float:left}.mw-parser-output .covid-country-narrow-on-mobile{text-align:left!important}.mw-parser-output .covid-total-row:first-of-type{text-align:left!important}.mw-parser-output #covid19-container table tbody>tr>:nth-child(2){text-align:left;padding-left:5px!important}.mw-parser-output #covid19-container table tbody>tr>:nth-child(2)>a{font-weight:500}}.mw-parser-output .pcs-collapse-table-container .covid-show-table{display:none}.mw-parser-output #covid19-container td{padding:0 2px}.mw-parser-output #covid19-container th[scope=row]:not(.covid-total-row){padding:0 2px 0 1px;border-left:none}.mw-parser-output #covid19-container th[scope=row]:first-child:not(.covid-total-row){padding:0 2px 1px;width:1px;border-right:none}.mw-parser-output #covid19-container .status-a{background:#ffd;text-align:center}.mw-parser-output #covid19-container .status-a:after{content:\"Admitted\"}.mw-parser-output #covid19-container .status-r{background:#bfb;text-align:center}.mw-parser-output #covid19-container .status-r:after{content:\"Recovered\"}.mw-parser-output #covid19-container .status-d{background:#fbb;text-align:center}.mw-parser-output #covid19-container .status-d:after{content:\"Died\"}.mw-parser-output #covid19-container .yes{background:#9f9;text-align:center}.mw-parser-output #covid19-container .yes:after{content:\"Yes\"}.mw-parser-output #covid19-container .no{background:#f99;text-align:center}.mw-parser-output #covid19-container .no:after{content:\"No\"}.mw-parser-output #covid19-container .tba{background:#ddf;color:#2c2c2c;text-align:center;font-size:85%}.mw-parser-output #covid19-container .tba:after{content:\"TBA\"}.mw-parser-output .covid19-countrynames tr>:first-child{text-align:left}\n",
      "\n",
      "\n",
      "\n",
      "[show all][collapse]vteCOVID-19 vaccine distribution by location(as of 4 March[a])[494]\n",
      "\n",
      "\n",
      "Location\n",
      "\n",
      "Vaccinated[b]\n",
      "\n",
      "% of pop.[c]\n",
      "\n",
      "\n",
      "   World[d]\n",
      "166,366,806\n",
      "2.1%\n",
      " United States\n",
      "54,035,670\n",
      "16.2%\n",
      " China[e]\n",
      "52,520,000\n",
      "--\n",
      " EU\n",
      "25,185,192\n",
      "5.7%\n",
      " United Kingdom\n",
      "20,982,571\n",
      "30.9%\n",
      " India\n",
      "14,796,835\n",
      "1.1%\n",
      " Brazil\n",
      "7,417,852\n",
      "3.5%\n",
      " Turkey\n",
      "7,353,536\n",
      "8.7%\n",
      " United Arab Emirates[e]\n",
      "6,204,004\n",
      "--\n",
      " Israel\n",
      "4,901,136\n",
      "56.6%\n",
      " Russia\n",
      "4,701,175\n",
      "3.2%\n",
      " Germany\n",
      "4,541,389\n",
      "5.4%\n",
      " Chile\n",
      "3,894,967\n",
      "20.4%\n",
      " Morocco\n",
      "3,820,097\n",
      "10.4%\n",
      " Bangladesh\n",
      "3,581,169\n",
      "2.2%\n",
      " Italy\n",
      "3,404,144\n",
      "5.6%\n",
      " France\n",
      "3,245,517\n",
      "4.8%\n",
      " Spain\n",
      "2,920,179\n",
      "6.3%\n",
      " Mexico[e]\n",
      "2,676,035\n",
      "--\n",
      " Poland\n",
      "2,338,137\n",
      "6.2%\n",
      " Indonesia\n",
      "2,286,123\n",
      "0.8%\n",
      " Canada\n",
      "1,610,535\n",
      "4.3%\n",
      " Saudi Arabia[e]\n",
      "1,093,468\n",
      "--\n",
      " Romania\n",
      "1,022,066\n",
      "5.3%\n",
      " Serbia\n",
      "1,013,061\n",
      "14.9%\n",
      " Netherlands\n",
      "1,004,757\n",
      "5.9%\n",
      " Argentina\n",
      "941,695\n",
      "2.1%\n",
      " Hungary\n",
      "862,953\n",
      "8.9%\n",
      " Austria[e]\n",
      "722,964\n",
      "--\n",
      " Greece\n",
      "669,152\n",
      "6.4%\n",
      " Portugal\n",
      "655,719\n",
      "6.4%\n",
      " Sweden\n",
      "568,031\n",
      "5.6%\n",
      " Sri Lanka[e]\n",
      "553,821\n",
      "--\n",
      " Switzerland\n",
      "546,228\n",
      "6.3%\n",
      " Belgium\n",
      "540,256\n",
      "4.7%\n",
      " Czech Republic\n",
      "515,743\n",
      "4.8%\n",
      " Denmark\n",
      "479,252\n",
      "8.3%\n",
      " Finland\n",
      "425,545\n",
      "7.7%\n",
      " Nepal[e]\n",
      "402,264\n",
      "--\n",
      " Norway\n",
      "361,565\n",
      "6.7%\n",
      " Singapore\n",
      "350,000\n",
      "6.0%\n",
      " Azerbaijan\n",
      "337,315\n",
      "3.3%\n",
      " Slovakia\n",
      "328,904\n",
      "6.0%\n",
      " Bahrain\n",
      "305,619\n",
      "18.0%\n",
      " Peru\n",
      "304,863\n",
      "0.9%\n",
      " Ireland\n",
      "303,550\n",
      "6.2%\n",
      " Dominican Republic\n",
      "227,719\n",
      "2.1%\n",
      " South Korea\n",
      "225,853\n",
      "0.4%\n",
      " Bulgaria\n",
      "221,832\n",
      "3.2%\n",
      " Colombia\n",
      "206,475\n",
      "0.4%\n",
      " Lithuania\n",
      "200,063\n",
      "7.4%\n",
      " Croatia\n",
      "182,000\n",
      "4.4%\n",
      " Panama[e]\n",
      "150,411\n",
      "--\n",
      " Jordan[e]\n",
      "150,000\n",
      "--\n",
      " Qatar[e]\n",
      "140,000\n",
      "--\n",
      " Maldives[e]\n",
      "137,124\n",
      "--\n",
      " Kuwait\n",
      "137,000\n",
      "3.2%\n",
      " Slovenia\n",
      "131,758\n",
      "6.3%\n",
      " Costa Rica\n",
      "103,695\n",
      "2.0%\n",
      " Myanmar\n",
      "103,142\n",
      "0.2%\n",
      " Estonia\n",
      "87,086\n",
      "6.6%\n",
      " Malaysia\n",
      "80,336\n",
      "0.3%\n",
      " Algeria[e]\n",
      "75,000\n",
      "--\n",
      " Pakistan\n",
      "72,882\n",
      "0.0%\n",
      " South Africa\n",
      "70,527\n",
      "0.1%\n",
      " Australia\n",
      "61,008\n",
      "0.2%\n",
      " Latvia\n",
      "58,146\n",
      "3.1%\n",
      " Lebanon[e]\n",
      "57,474\n",
      "--\n",
      " Malta\n",
      "56,525\n",
      "12.8%\n",
      " Seychelles\n",
      "56,261\n",
      "57.2%\n",
      " Uruguay[e]\n",
      "54,154\n",
      "--\n",
      " Cyprus\n",
      "53,617\n",
      "6.1%\n",
      " Hong Kong\n",
      "51,800\n",
      "0.7%\n",
      " Oman\n",
      "48,641\n",
      "1.0%\n",
      " Senegal\n",
      "45,638\n",
      "0.3%\n",
      " Barbados\n",
      "44,859\n",
      "15.6%\n",
      " Cambodia\n",
      "40,910\n",
      "0.2%\n",
      " Japan\n",
      "39,174\n",
      "0.0%\n",
      " Ecuador\n",
      "35,886\n",
      "0.2%\n",
      " Zimbabwe\n",
      "30,658\n",
      "0.2%\n",
      " Jersey\n",
      "30,191\n",
      "29.9%\n",
      " Luxembourg\n",
      "29,401\n",
      "4.7%\n",
      " Iceland\n",
      "26,489\n",
      "7.8%\n",
      " Gibraltar\n",
      "25,629\n",
      "76.1%\n",
      " Cayman Islands[e]\n",
      "24,008\n",
      "--\n",
      " Guernsey[e]\n",
      "22,040\n",
      "--\n",
      " Bermuda[e]\n",
      "21,387\n",
      "--\n",
      " Belarus\n",
      "20,944\n",
      "0.2%\n",
      " Kazakhstan\n",
      "20,157\n",
      "0.1%\n",
      " El Salvador\n",
      "16,000\n",
      "0.3%\n",
      " Albania[e]\n",
      "15,793\n",
      "--\n",
      " Isle of Man\n",
      "15,727\n",
      "18.5%\n",
      " Ukraine\n",
      "12,481\n",
      "0.0%\n",
      " Northern Cyprus[e]\n",
      "11,000\n",
      "--\n",
      " Bolivia\n",
      "10,325\n",
      "0.1%\n",
      " Iran\n",
      "10,000\n",
      "0.0%\n",
      " New Zealand\n",
      "9,431\n",
      "0.2%\n",
      " Thailand[e]\n",
      "7,262\n",
      "--\n",
      " Turks and Caicos Islands\n",
      "6,433\n",
      "16.6%\n",
      " Mongolia[e]\n",
      "4,926\n",
      "--\n",
      " Faroe Islands\n",
      "4,238\n",
      "8.7%\n",
      " Anguilla\n",
      "3,929\n",
      "26.2%\n",
      " Greenland\n",
      "3,927\n",
      "6.9%\n",
      " Mauritius\n",
      "3,843\n",
      "0.3%\n",
      " Philippines\n",
      "2,793\n",
      "0.0%\n",
      " Honduras\n",
      "2,684\n",
      "0.0%\n",
      " Liechtenstein[e]\n",
      "2,597\n",
      "--\n",
      " Andorra\n",
      "2,526\n",
      "3.3%\n",
      " Guatemala[e]\n",
      "2,427\n",
      "--\n",
      " Monaco[e]\n",
      "2,400\n",
      "--\n",
      " Macau[e]\n",
      "2,000\n",
      "--\n",
      " Montenegro\n",
      "1,927\n",
      "0.3%\n",
      " Guyana\n",
      "1,852\n",
      "0.2%\n",
      " Falkland Islands\n",
      "1,732\n",
      "49.7%\n",
      " Egypt[e]\n",
      "1,315\n",
      "--\n",
      " Paraguay\n",
      "1,000\n",
      "0.0%\n",
      " San Marino\n",
      "883\n",
      "2.6%\n",
      " Montserrat\n",
      "652\n",
      "13.0%\n",
      " Trinidad and Tobago\n",
      "440\n",
      "0.0%\n",
      " Venezuela\n",
      "157\n",
      "0.0%\n",
      " Saint Helena[e]\n",
      "107\n",
      "--\n",
      " F.S. Micronesia[495]\n",
      "10,928\n",
      "10.5%\n",
      " Marshall Islands[495]\n",
      "9,394\n",
      "16.1%\n",
      " Palau[495]\n",
      "5,145\n",
      "28.7%\n",
      "\n",
      "\n",
      "\n",
      "Sources\n",
      "\n",
      "List of sources by country.\n",
      "Notes\n",
      "\n",
      "\n",
      "\n",
      "^ Latest available data as of this date. Individual country reporting frequency varies.\n",
      "\n",
      "^ Number of unique individuals who have received at least one dose of a COVID-19 vaccine (unless noted otherwise).\n",
      "\n",
      "^ Percentage of population that has received at least one dose of a COVID-19 vaccine.\n",
      "\n",
      "^ Some countries are not yet reporting first-dose counts. Total dose counts for these countries are not included in the World total.\n",
      "\n",
      "^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa This country's data reflects total doses administered, not the first shot only.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "These paragraphs are an excerpt from Deployment of COVID-19 vaccines[edit]\n",
      "As of 3 March 2021, 275.84 million COVID‑19 vaccine doses had been administered worldwide based on official reports from national health agencies collated by Our World in Data.[496]\n",
      "During a pandemic on the rapid timeline and scale of COVID‑19 infections during 2020, international organizations like the WHO and CEPI, vaccine developers, governments, and industry are evaluating the distribution of the eventual vaccine(s).[497] Individual countries producing a vaccine may be persuaded to favor the highest bidder for manufacturing or provide first-service to their own country.[498][499][500][501] Experts emphasize that licensed vaccines should be available and affordable for people at the frontline of healthcare and having the greatest need.[498][499][501] In April, it was reported that the UK agreed to work with 20 other countries and global organizations including France, Germany and Italy to find a vaccine and to share the results and that UK citizens would not get preferential access to any new COVID‑19 vaccines developed by taxpayer-funded UK universities.[502] Several companies plan to initially manufacture a vaccine at artificially low pricing, then increase prices for profitability later if annual vaccinations are needed and as countries build stock for future needs.[501]\n",
      "\n",
      "An April 2020 CEPI report stated: \"Strong international coordination and cooperation between vaccine developers, regulators, policymakers, funders, public health bodies, and governments will be needed to ensure that promising late-stage vaccine candidates can be manufactured in sufficient quantities and equitably supplied to all affected areas, particularly low-resource regions.\"[503] The WHO and CEPI are developing financial resources and guidelines for global deployment of several safe, effective COVID‑19 vaccines, recognizing the need is different across countries and population segments.[497][504][505][506]  For example, successful COVID‑19 vaccines would likely be allocated first to healthcare personnel and populations at greatest risk of severe illness and death from COVID‑19 infection, such as the elderly or densely-populated impoverished people.[507][508] The WHO, CEPI, and GAVI have expressed concerns that affluent countries should not receive priority access to the global supply of eventual COVID‑19 vaccines, but rather protecting healthcare personnel and people at high risk of infection are needed to address public health concerns and reduce economic impact of the pandemic.[503][505][507]\n",
      "Liability\n",
      "The examples and perspective in this section may not represent a worldwide view of the subject. You may improve this section, discuss the issue on the talk page, or create a new section, as appropriate. (December 2020) (Learn how and when to remove this template message)\n",
      "On 4 February 2020, US Secretary of Health and Human Services Alex Azar published a notice of declaration under the Public Readiness and Emergency Preparedness Act for medical countermeasures against COVID‑19, covering \"any vaccine, used to treat, diagnose, cure, prevent, or mitigate COVID‑19, or the transmission of SARS-CoV-2 or a virus mutating therefrom\", and stating that the declaration precludes \"liability claims alleging negligence by a manufacturer in creating a vaccine, or negligence by a health care provider in prescribing the wrong dose, absent willful misconduct\".[509] The declaration is effective in the United States through 1 October 2024.[509]\n",
      "In the European Union, the COVID‑19 vaccines are licensed under a Conditional Marketing Authorisation which does not exempt manufacturers from civil and administrative liability claims.[510] While the purchasing contracts with vaccine manufacturers remain secret, they do not contain liability exemptions even for side-effects not known at the time of licensure.[511]\n",
      "\n",
      "Society and culture\n",
      "Access\n",
      "Nations pledged to buy doses of COVID-19 vaccine before the doses were available. Though high-income nations represent only 14% of the global population, as of 15 November 2020, they had contracted to buy 51% of all pre-sold doses. Some high-income nations bought more doses than would be necessary to vaccinate their entire populations.[512]\n",
      "On 18 January 2021, WHO Director-General Tedros Adhanom Ghebreyesus warned of problems with equitable distribution: \"More than 39 million doses of vaccine have now been administered in at least 49 higher-income countries. Just 25 doses have been given in one lowest-income country. Not 25 million; not 25 thousand; just 25.\"[513]\n",
      "The Chinese Sinopharm's COVID-19 vaccine was authorized for emergency use by Bahrain and the United Arab Emirates in December 2020.[514][515]\n",
      "Some nations involved in long-standing territorial disputes have reportedly had their access to vaccines blocked by competing nations; Palestine has accused Israel blocking vaccine delivery to Gaza, while Taiwan has suggested that China has hampered its efforts to procure vaccine doses.[516][517][518]\n",
      "A single dose of the COVID-19 vaccine by AstraZeneca would cost 47 Egyptian pounds (EGP) and the authorities are selling it between 100-200 EGP. A report by Carnegie Endowment for International Peace cited the current poverty rate in Egypt as around 29.7 percent, which constitutes approximately 30.5 million people, and claimed that about 15 million of the Egyptians would be unable to gain access to the luxury of vaccination. A human rights lawyer, Khaled Ali launched a lawsuit against the government, forcing them to provide vaccination free of cost to all members of the public.[519]\n",
      "According to the immunologist Anthony Fauci, mutant strains of virus and limited vaccine distribution pose continuing risks and he said: \"we have to get the entire world vaccinated, not just our own country.\"[520] Edward Bergmark and Arick Wierson are calling for an global vaccination effort and wrote that the wealthier nations' \"me-first\" mentality could ultimately backfire, because the spread of the virus in poorer countries would lead to more variants, against which current vaccines could be less effective.[521]\n",
      "\n",
      "Misinformation\n",
      "Main article: COVID-19 misinformation § Vaccines\n",
      "\n",
      "Anti-vaccination activists and other people spread a variety of rumors, including overblown claims about side effects, a story about COVID-19 being spread by childhood vaccines, misrepresentations about how the immune system works, and when and how COVID-19 vaccines are made.\n",
      "Vaccine hesitancy\n",
      "Some 10% of the public perceives vaccines as unsafe or unnecessary, refusing vaccination – a global health threat called vaccine hesitancy[522] – which increases the risk of further viral spread that could lead to COVID‑19 outbreaks.[37] In mid-2020, estimates from two surveys were that 67% or 80% of people in the U.S. would accept a new vaccination against COVID‑19, with wide disparity by education level, employment status, race, and geography.[523]\n",
      "A poll conducted by National Geographic and Morning Consult demonstrated a gender gap on willingness to take a COVID‑19 vaccine in the U.S., with 69% of men polled saying they would take the vaccine, compared to only 51% of women. The poll also showed a positive correlation between education level and willingness to take the vaccine.[524]\n",
      "In an effort to demonstrate the vaccine's safety, prominent politicians have received it on camera, with others pledging to do so.[525][526][527]\n",
      "\n",
      "See also\n",
      ".mw-parser-output .portal{border:solid #aaa 1px;padding:0}.mw-parser-output .portal.tleft{margin:0.5em 1em 0.5em 0}.mw-parser-output .portal.tright{margin:0.5em 0 0.5em 1em}.mw-parser-output .portal>ul{display:table;box-sizing:border-box;padding:0.1em;max-width:175px;background:#f9f9f9;font-size:85%;line-height:110%;font-style:italic;font-weight:bold}.mw-parser-output .portal>ul>li{display:table-row}.mw-parser-output .portal>ul>li>span:first-child{display:table-cell;padding:0.2em;vertical-align:middle;text-align:center}.mw-parser-output .portal>ul>li>span:last-child{display:table-cell;padding:0.2em 0.2em 0.2em 0.3em;vertical-align:middle}\n",
      "\n",
      "Coronavirus disease 2019 portal\n",
      "Medicine portal\n",
      "Modern history portal\n",
      "Viruses portal\n",
      "Current events portal\n",
      "2009 swine flu pandemic vaccine\n",
      "COVID‑19 drug development\n",
      "COVID‑19 drug repurposing research\n",
      "\n",
      "References\n",
      "\n",
      "\n",
      "^ .mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:\"\\\"\"\"\\\"\"\"'\"\"'\"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url(\"//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg\")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url(\"//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg\")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url(\"//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg\")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url(\"//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg\")right 0.1em center/12px no-repeat}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}Li YD, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC (December 2020). \"Coronavirus vaccine development: from SARS and MERS to COVID-19\". Journal of Biomedical Science. 27 (1): 104. doi:10.1186/s12929-020-00695-2. PMC 7749790. PMID 33341119.\n",
      "\n",
      "^ Padilla, Teodoro (24 February 2021). \"No one is safe unless everyone is safe\". BusinessWorld. Retrieved 24 February 2021.\n",
      "\n",
      "^ a b c d e f g \"COVID-19 vaccine development pipeline (Refresh URL to update)\". Vaccine Centre, London School of Hygiene and Tropical Medicine. 18 January 2021. Retrieved 18 January 2021.\n",
      "\n",
      "^ Beaumont, Peter (18 November 2020). \"Covid-19 vaccine: who are countries prioritising for first doses?\". The Guardian. ISSN 0261-3077. Retrieved 26 December 2020.\n",
      "\n",
      "^ \"Coronavirus (COVID-19) Vaccinations - Statistics and Research\". Our World in Data. Retrieved 7 February 2021.\n",
      "\n",
      "^ \"Which companies will likely produce the most COVID-19 vaccine in 2021?\". Pharmaceutical Processing World. 5 February 2021. Retrieved 1 March 2021.\n",
      "\n",
      "^ \"China can hit 500-mln-dose annual capacity of CanSinoBIO COVID-19 vaccine this year\". ca.sports.yahoo.com. Retrieved 1 March 2021.\n",
      "\n",
      "^ Mullard, Asher (30 November 2020). \"How COVID vaccines are being divvied up around the world Canada leads the pack in terms of doses secured per capita\". Nature. doi:10.1038/d41586-020-03370-6. PMID 33257891. S2CID 227246811. Retrieved 11 December 2020.\n",
      "\n",
      "^ So AD, Woo J (December 2020). \"Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis\". BMJ. 371: m4750. doi:10.1136/bmj.m4750. ISSN 1756-1833. PMC 7735431. PMID 33323376.\n",
      "\n",
      "^ a b c Gates B (30 April 2020). \"The vaccine race explained: What you need to know about the COVID-19 vaccine\". The Gates Notes. Archived from the original on 14 May 2020. Retrieved 2 May 2020.\n",
      "\n",
      "^ Cavanagh D (December 2003). \"Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus\". Avian Pathology. 32 (6): 567–82. doi:10.1080/03079450310001621198. PMC 7154303. PMID 14676007.\n",
      "\n",
      "^ Gao W, Tamin A, Soloff A, D'Aiuto L, Nwanegbo E, Robbins PD,  et al. (December 2003). \"Effects of a SARS-associated coronavirus vaccine in monkeys\". Lancet. 362 (9399): 1895–96. doi:10.1016/S0140-6736(03)14962-8. PMC 7112457. PMID 14667748.\n",
      "\n",
      "^ Kim E, Okada K, Kenniston T, Raj VS, AlHajri MM, Farag EA,  et al. (October 2014). \"Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice\". Vaccine. 32 (45): 5975–82. doi:10.1016/j.vaccine.2014.08.058. PMC 7115510. PMID 25192975.\n",
      "\n",
      "^ Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD, Coccia JA,  et al. (February 2005). \"Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice\". The Journal of Infectious Diseases. 191 (4): 507–14. doi:10.1086/427242. PMC 7110081. PMID 15655773.\n",
      "\n",
      "^ Tripp RA, Haynes LM, Moore D, Anderson B, Tamin A, Harcourt BH,  et al. (September 2005). \"Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins\". Journal of Virological Methods. 128 (1–2): 21–28. doi:10.1016/j.jviromet.2005.03.021. PMC 7112802. PMID 15885812.\n",
      "\n",
      "^ Roberts A, Thomas WD, Guarner J, Lamirande EW, Babcock GJ, Greenough TC,  et al. (March 2006). \"Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters\". The Journal of Infectious Diseases. 193 (5): 685–92. doi:10.1086/500143. PMC 7109703. PMID 16453264.\n",
      "\n",
      "^ a b Jiang S, Lu L, Du L (January 2013). \"Development of SARS vaccines and therapeutics is still needed\". Future Virology. 8 (1): 1–2. doi:10.2217/fvl.12.126. PMC 7079997. PMID 32201503.\n",
      "\n",
      "^ \"SARS (severe acute respiratory syndrome)\". National Health Service. 5 March 2020. Archived from the original on 9 March 2020. Retrieved 31 January 2020.\n",
      "\n",
      "^ Shehata MM, Gomaa MR, Ali MA, Kayali G (January 2016). \"Middle East respiratory syndrome coronavirus: a comprehensive review\". Frontiers of Medicine. 10 (2): 120–36. doi:10.1007/s11684-016-0430-6. PMC 7089261. PMID 26791756.\n",
      "\n",
      "^ Butler D (October 2012). \"SARS veterans tackle coronavirus\". Nature. 490 (7418): 20. Bibcode:2012Natur.490...20B. doi:10.1038/490020a. PMID 23038444.\n",
      "\n",
      "^ Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K,  et al. (September 2019). \"Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial\". The Lancet. Infectious Diseases. 19 (9): 1013–22. doi:10.1016/S1473-3099(19)30266-X. PMC 7185789. PMID 31351922.\n",
      "\n",
      "^ Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS (2019). \"Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus\". Frontiers in Microbiology. 10: 1781. doi:10.3389/fmicb.2019.01781. PMC 6688523. PMID 31428074.\n",
      "\n",
      "^ a b c d Sanger DE, Kirkpatrick DD, Zimmer C, Thomas K, Wee S (2 May 2020). \"With Pressure Growing, Global Race for a Vaccine Intensifies\". The New York Times. ISSN 0362-4331. Archived from the original on 11 May 2020. Retrieved 2 May 2020.\n",
      "\n",
      "^ Simpson S, Kaufmann MC, Glozman V, Chakrabarti A (May 2020). \"Disease X: accelerating the development of medical countermeasures for the next pandemic\". The Lancet. Infectious Diseases. 20 (5): e108–15. doi:10.1016/S1473-3099(20)30123-7. ISSN 1474-4457. PMC 7158580. PMID 32197097.\n",
      "\n",
      "^ a b c d Steenhuysen J, Eisler P, Martell A, Nebehay S (27 April 2020). \"Special Report: Countries, companies risk billions in race for coronavirus vaccine\". Reuters. Archived from the original on 15 May 2020. Retrieved 2 May 2020.\n",
      "\n",
      "^ Jeong-ho L, Zheng W, Zhou L (26 January 2020). \"Chinese scientists race to develop vaccine as coronavirus death toll jumps\". South China Morning Post. Archived from the original on 26 January 2020. Retrieved 28 January 2020.\n",
      "\n",
      "^ Wee S (4 May 2020). \"China's coronavirus vaccine drive empowers a troubled industry\". The New York Times. ISSN 0362-4331. Archived from the original on 4 May 2020. Retrieved 4 May 2020.\n",
      "\n",
      "^ a b Le TT, Cramer JP, Chen R, Mayhew S (4 September 2020). \"Evolution of the COVID-19 vaccine development landscape\". Nature Reviews Drug Discovery. 19 (10): 667–68. doi:10.1038/d41573-020-00151-8. ISSN 1474-1776. PMID 32887942. S2CID 221503034.\n",
      "\n",
      "^ a b c d e Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M,  et al. (9 April 2020). \"The COVID-19 vaccine development landscape\". Nature Reviews Drug Discovery. 19 (5): 305–06. doi:10.1038/d41573-020-00073-5. ISSN 1474-1776. PMID 32273591.\n",
      "\n",
      "^ a b c Diamond MS, Pierson TC (13 May 2020). \"The challenges of vaccine development against a new virus during a pandemic\". Cell Host and Microbe. 27 (5): 699–703. doi:10.1016/j.chom.2020.04.021. PMC 7219397. PMID 32407708.\n",
      "\n",
      "^ Thorp HH (27 March 2020). \"Underpromise, overdeliver\". Science. 367 (6485): 1405. Bibcode:2020Sci...367.1405T. doi:10.1126/science.abb8492. PMID 32205459.\n",
      "\n",
      "^ Blackwell T (20 April 2020). \"COVID-19 vaccine researchers say pandemic lockdown placing many serious obstacles to their work\". National Post. Archived from the original on 1 November 2020. Retrieved 3 May 2020.\n",
      "\n",
      "^ Chen J (4 May 2020). \"Covid-19 has shuttered labs. It could put a generation of researchers at risk\". Stat. Archived from the original on 6 May 2020. Retrieved 4 May 2020.\n",
      "\n",
      "^ a b c \"Vaccine Safety – Vaccines\". vaccines.gov. US Department of Health and Human Services. Archived from the original on 22 April 2020. Retrieved 13 April 2020.\n",
      "\n",
      "^ a b c d \"The drug development process\". U.S. Food and Drug Administration (FDA). 4 January 2018. Archived from the original on 22 February 2020. Retrieved 12 April 2020.\n",
      "\n",
      "^ a b Cohen J (19 June 2020). \"Pandemic vaccines are about to face the real test\". Science. 368 (6497): 1295–96. Bibcode:2020Sci...368.1295C. doi:10.1126/science.368.6497.1295. PMID 32554572.\n",
      "\n",
      "^ a b Dubé E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger J (1 August 2013). \"Vaccine hesitancy: an overview\". Human Vaccines and Immunotherapeutics. 9 (8): 1763–73. doi:10.4161/hv.24657. ISSN 2164-554X. PMC 3906279. PMID 23584253.\n",
      "\n",
      "^ Howard J, Stracqualursi V (18 June 2020). \"Fauci warns of 'anti-science bias' being a problem in US\". CNN. Archived from the original on 21 June 2020. Retrieved 21 June 2020.\n",
      "\n",
      "^ \"Vaccines: The Emergency Authorisation Procedure\". European Medicines Agency. 2020. Archived from the original on 24 September 2020. Retrieved 21 August 2020.\n",
      "\n",
      "^ Byrne, Jane (19 October 2020). \"Moderna COVID-19 vaccine under rolling review process in Canada, EU\". BioPharma-Reporter.com, William Reed Business Media Ltd. Retrieved 25 November 2020.\n",
      "\n",
      "^ Dangerfield, Katie (20 November 2020). \"Pfizer files for emergency use of coronavirus vaccine in U.S. – what about in Canada?\". Global News. Retrieved 25 November 2020.\n",
      "\n",
      "^ \"G20 launches initiative for health tools needed to combat the coronavirus\". 25 April 2020.\n",
      "\n",
      "^ \"Access to COVID-19 Tools (ACT) Accelerator\" (PDF). World Health Organization (WHO). 24 April 2020.\n",
      "\n",
      "^ \"The ACT-Accelerator: frequently asked questions (FAQ)\". World Health Organization (WHO). 2020. Retrieved 16 December 2020.\n",
      "\n",
      "^ \"Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine\". World Health Organization (WHO). 27 April 2020. Archived from the original on 30 April 2020. Retrieved 2 May 2020. It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. [The] WHO is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale.\n",
      "\n",
      "^ Abedi M (23 March 2020). \"Canada to spend $192M on developing COVID-19 vaccine\". Global News. Archived from the original on 9 April 2020. Retrieved 24 March 2020.\n",
      "\n",
      "^ \"Government of Canada's research response to COVID-19\". Government of Canada. 23 April 2020. Archived from the original on 13 May 2020. Retrieved 4 May 2020.\n",
      "\n",
      "^ Takada N, Satake M (2 May 2020). \"US and China unleash wallets in race for coronavirus vaccine\". Nikkei Asian Review. Archived from the original on 10 May 2020. Retrieved 3 May 2020.\n",
      "\n",
      "^ Morriss E (22 April 2020). \"Government launches coronavirus vaccine taskforce as human clinical trials start\". Pharmafield. Archived from the original on 17 June 2020. Retrieved 3 May 2020.\n",
      "\n",
      "^ Kuznia R, Polglase K, Mezzofiore G (1 May 2020). \"In quest for vaccine, US makes 'big bet' on company with unproven technology\". CNN. Archived from the original on 13 May 2020. Retrieved 2 May 2020.\n",
      "\n",
      "^ Cohen J (15 May 2020). \"U.S. 'Warp Speed' vaccine effort comes out of the shadows\". Science. 368 (6492): 692–93. Bibcode:2020Sci...368..692C. doi:10.1126/science.368.6492.692. ISSN 0036-8075. PMID 32409451.\n",
      "\n",
      "^ Justin Sink, Jordan Fabian, Riley Griffin (15 May 2020). \"Trump introduces 'Warp Speed' leaders to hasten COVID-19 vaccine\". Bloomberg. Archived from the original on 21 May 2020. Retrieved 15 May 2020.CS1 maint: uses authors parameter (link)\n",
      "\n",
      "^ \"World Health Organization timeline – COVID-19\". World Health Organization. 27 April 2020. Archived from the original on 29 April 2020. Retrieved 2 May 2020.\n",
      "\n",
      "^ a b c Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M,  et al. (9 April 2020). \"The COVID-19 vaccine development landscape\". Nature Reviews Drug Discovery. 19 (5): 305–06. doi:10.1038/d41573-020-00073-5. ISSN 1474-1776. PMID 32273591.\n",
      "\n",
      "^ a b Gates B (February 2020). \"Responding to Covid-19: A once-in-a-century pandemic?\". The New England Journal of Medicine. 382 (18): 1677–79. doi:10.1056/nejmp2003762. PMID 32109012.\n",
      "\n",
      "^ Fauci AS, Lane HC, Redfield RR (March 2020). \"Covid-19: Navigating the uncharted\". The New England Journal of Medicine. 382 (13): 1268–69. doi:10.1056/nejme2002387. PMC 7121221. PMID 32109011.\n",
      "\n",
      "^ a b Le TT, Cramer JP, Chen R, Mayhew S (4 September 2020). \"Evolution of the COVID-19 vaccine development landscape\". Nature Reviews Drug Discovery. 19 (10): 667–68. doi:10.1038/d41573-020-00151-8. ISSN 1474-1776. PMID 32887942. S2CID 221503034.\n",
      "\n",
      "^ Weintraub R, Yadav P, Berkley S (2 April 2020). \"A COVID-19 vaccine will need equitable, global distribution\". Harvard Business Review. ISSN 0017-8012. Archived from the original on 9 June 2020. Retrieved 9 June 2020.\n",
      "\n",
      "^ \"COVID-19 pandemic reveals the risks of relying on private sector for life-saving vaccines, says expert\". CBC Radio. 8 May 2020. Archived from the original on 13 May 2020. Retrieved 8 June 2020.\n",
      "\n",
      "^ Ahmed DD (4 June 2020). \"Oxford, AstraZeneca COVID-19 deal reinforces 'vaccine sovereignty'\". Stat. Archived from the original on 12 June 2020. Retrieved 8 June 2020.\n",
      "\n",
      "^ Grenfell R, Drew T (14 February 2020). \"Here's why the WHO says a coronavirus vaccine is 18 months away\". Business Insider. Retrieved 11 November 2020.\n",
      "\n",
      "^ \"Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine\". World Health Organization. 27 April 2020. Archived from the original on 30 April 2020. Retrieved 2 May 2020. It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. [The] WHO is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale.\n",
      "\n",
      "^ Yamey G, Schäferhoff M, Hatchett R, Pate M, Zhao F, McDade KK (May 2020). \"Ensuring global access to COVID‑19 vaccines\". Lancet. 395 (10234): 1405–06. doi:10.1016/S0140-6736(20)30763-7. PMC 7271264. PMID 32243778. CEPI estimates that developing up to three vaccines in the next 12–18 months will require an investment of at least US$2 billion. This estimate includes Phase 1 clinical trials of eight vaccine candidates, progression of up to six candidates through Phase 2 and 3 trials, completion of regulatory and quality requirements for at least three vaccines, and enhancing global manufacturing capacity for three vaccines.\n",
      "\n",
      "^ \"WHO 'backed China's emergency use' of experimental Covid-19 vaccines\". South China Morning Post. 25 September 2020. Archived from the original on 26 September 2020. Retrieved 26 September 2020.\n",
      "\n",
      "^ Kramer AE (19 September 2020). \"Russia Is Slow to Administer Virus Vaccine Despite Kremlin's Approval\". The New York Times. ISSN 0362-4331. Archived from the original on 27 September 2020. Retrieved 28 September 2020.\n",
      "\n",
      "^ \"Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine\". Pfizer (Press release). 20 November 2020. Retrieved 20 November 2020.\n",
      "\n",
      "^ Park A (20 November 2020). \"Exclusive: Pfizer CEO Discusses Submitting the First COVID-19 Vaccine Clearance Request to the FDA\". Time. Retrieved 20 November 2020.\n",
      "\n",
      "^ \"Information for Healthcare Professionals on Pfizer/BioNTech COVID-19 vaccine\". Medicines & Healthcare products Regulatory Agency (MHRA). 8 December 2020. Retrieved 13 December 2020.\n",
      "\n",
      "^ \"Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine\". Medicines and Healthcare products Regulatory Agency (MHRA). 3 December 2020. Retrieved 19 December 2020.\n",
      "\n",
      "^ \"UK medicines regulator gives approval for first UK COVID-19 vaccine\". Medicines and Healthcare Products Regulatory Agency, Government of the UK. 2 December 2020. Retrieved 2 December 2020.\n",
      "\n",
      "^ Mueller, Benjamin (2 December 2020). \"U.K. Approves Pfizer Coronavirus Vaccine, a First in the West\". The New York Times. Retrieved 2 December 2020.\n",
      "\n",
      "^ Roberts, Michelle (2 December 2020). \"Covid Pfizer vaccine approved for use next week in UK\". BBC. Retrieved 2 December 2020.\n",
      "\n",
      "^ \"Questions and Answers: COVID-19 vaccination in the EU\". European Commission. 21 December 2020. Retrieved 21 December 2020.\n",
      "\n",
      "^ \"Bahrain second in the world to approve the Pfizer/BioNTech Covid-19 vaccine\". Bahrain News Agency. 4 December 2020. Retrieved 9 December 2020.\n",
      "\n",
      "^ \"UAE: Ministry of Health announces 86 per cent vaccine efficacy\". Gulf News. Retrieved 9 December 2020.\n",
      "\n",
      "^ Thomas K, LaFraniere S, Weiland N, Goodnough A, Haberman M (12 December 2020). \"F.D.A. Clears Pfizer Vaccine, and Millions of Doses Will Be Shipped Right Away\". The New York Times. Retrieved 12 December 2020.\n",
      "\n",
      "^ \"FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine\". U.S. Food and Drug Administration (FDA) (Press release). Retrieved 18 December 2020.\n",
      "\n",
      "^ Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M,  et al. (December 2020). \"The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020\" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5152): 1653–1656. doi:10.15585/mmwr.mm695152e1. PMID 33382675. S2CID 229945697.\n",
      "\n",
      "^ Lovelace Jr B (19 December 2020). \"FDA approves second Covid vaccine for emergency use as it clears Moderna's for U.S. distribution\". CNBC. Retrieved 19 December 2020.\n",
      "\n",
      "^ a b c d e f Thanh Le T, Cramer JP, Chen R, Mayhew S (4 September 2020). \"Evolution of the COVID-19 vaccine development landscape\". Nature Reviews Drug Discovery. 19 (10): 667–68. doi:10.1038/d41573-020-00151-8. ISSN 1474-1776. PMID 32887942. S2CID 221503034.\n",
      "\n",
      "^ Krammer F (October 2020). \"SARS-CoV-2 vaccines in development\". Nature. 586 (7830): 516–27. Bibcode:2020Natur.586..516K. doi:10.1038/s41586-020-2798-3. PMID 32967006. S2CID 221887746.\n",
      "\n",
      "^ Park KS, Sun X, Aikins ME, Moon JJ (December 2020). \"Non-viral COVID-19 vaccine delivery systems\". Advanced Drug Delivery Reviews. 169: 137–51. doi:10.1016/j.addr.2020.12.008. PMC 7744276. PMID 33340620.\n",
      "\n",
      "^ Kowalski PS, Rudra A, Miao L, Anderson DG (April 2019). \"Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery\". Mol Ther. 27 (4): 710–28. doi:10.1016/j.ymthe.2019.02.012. PMC 6453548. PMID 30846391.\n",
      "\n",
      "^ Verbeke R, Lentacker I, De Smedt SC, Dewitte H (October 2019). \"Three decades of messenger RNA vaccine development\". Nano Today. 28: 100766. doi:10.1016/j.nantod.2019.100766.\n",
      "\n",
      "^ \"COVID-19 ACIP Vaccine Recommendations\". Centers for Disease Control and Prevention (CDC). Retrieved 18 February 2021.\n",
      "\n",
      "^ \"Safe COVID-19 vaccines for Europeans\". European Commission - European Commission. Retrieved 19 February 2021.\n",
      "\n",
      "^ a b c \"Regulatory Decision Summary – Pfizer-BioNTech COVID-19 Vaccine\". Health Canada, Government of Canada. 9 December 2020. Retrieved 9 December 2020.\n",
      "\n",
      "^ a b \"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults\". ClinicalTrials.gov. United States National Library of Medicine. 30 April 2020. NCT04368728. Archived from the original on 11 October 2020. Retrieved 14 July 2020.\n",
      "\n",
      "^ a b \"A Multi-site Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults\". EU Clinical Trials Register. European Union. 14 April 2020. EudraCT 2020-001038-36. Archived from the original on 22 April 2020. Retrieved 22 April 2020.\n",
      "\n",
      "^ a b \"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19\". ClinicalTrials.gov. United States National Library of Medicine. 14 July 2020. NCT04470427. Archived from the original on 11 October 2020. Retrieved 27 July 2020.\n",
      "\n",
      "^ a b Palca J (27 July 2020). \"COVID-19 vaccine candidate heads to widespread testing in U.S.\" NPR. Archived from the original on 11 October 2020. Retrieved 27 July 2020.\n",
      "\n",
      "^ a b \"EMA starts rolling review of CureVac's COVID-19 vaccine (CVnCoV)\". European Medicines Agency (EMA) (Press release). 1 December 2020. Retrieved 12 February 2021.\n",
      "\n",
      "^ a b \"What are viral vector-based vaccines and how could they be used against COVID-19?\". GAVI. 2020. Retrieved 26 January 2021.\n",
      "\n",
      "^ a b \"Investigating a Vaccine Against COVID-19\". ClinicalTrials.gov. United States National Library of Medicine. 26 May 2020. NCT04400838. Archived from the original on 11 October 2020. Retrieved 14 July 2020.\n",
      "\n",
      "^ a b \"A Phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19\". EU Clinical Trials Register. European Union. 21 April 2020. EudraCT 2020-001228-32. Archived from the original on 5 October 2020. Retrieved 3 August 2020.\n",
      "\n",
      "^ a b O'Reilly P (26 May 2020). \"A Phase III study to investigate a vaccine against COVID-19\". ISRCTN. doi:10.1186/ISRCTN89951424. ISRCTN89951424.\n",
      "\n",
      "^ Corum, Jonathan; Zimmer, Carl (8 January 2021). \"How Gamaleya's Vaccine Works\". The New York Times. Retrieved 27 January 2021.\n",
      "\n",
      "^ a b \"A Study of Ad26.COV2.S in Adults\". ClinicalTrials.gov. 4 August 2020. Archived from the original on 16 September 2020. Retrieved 23 August 2020.\n",
      "\n",
      "^ a b c \"A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants\". ClinicalTrials.gov. US National Library of Medicine. Archived from the original on 26 September 2020.\n",
      "\n",
      "^ Johnson, Carolyn; McGinley, Laura. \"Johnson & Johnson seeks emergency FDA authorization for single-shot coronavirus vaccine\". The Washington Post.\n",
      "\n",
      "^ \"It's not just Johnson & Johnson: China has a single-dose COVID-19 vaccine that's 65% effective\". Fortune. Retrieved 28 February 2021.\n",
      "\n",
      "^ Petrovsky, Nikolai; Aguilar, Julio César (28 September 2004). \"Vaccine adjuvants: Current state and future trends\". Immunology and Cell Biology. 82 (5): 488–96. doi:10.1111/j.0818-9641.2004.01272.x. ISSN 0818-9641. PMID 15479434. S2CID 154670.\n",
      "\n",
      "^ a b \"Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection (COVID-19) (Renqiu)\". ClinicalTrials.gov. United States National Library of Medicine. 12 May 2020. NCT04383574. Archived from the original on 11 October 2020. Retrieved 14 July 2020.\n",
      "\n",
      "^ a b \"Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV)\". ClinicalTrials.gov. United States National Library of Medicine. 2 July 2020. NCT04456595. Archived from the original on 11 October 2020. Retrieved 3 August 2020.\n",
      "\n",
      "^ a b PT. Bio Farma (10 August 2020). \"A Phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-COV-2 inactivated vaccine in healthy adults aged 18–59 years in Indonesia\". Registri Penyakit Indonesia. Retrieved 15 August 2020.\n",
      "\n",
      "^ a b Chen W, Al Kaabi N (18 July 2020). \"A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells)\". Chinese Clinical Trial Registry. Retrieved 15 August 2020.\n",
      "\n",
      "^ a b \"VLA2001 COVID-19 Vaccine\". Precision Vaccinations. 31 December 2020. Retrieved 11 January 2021.\n",
      "\n",
      "^ a b \"Dose Finding Study to Evaluate Safety, Tolerability and Immunogenicity of an Inactiviated Adjuvanted Sars-Cov-2 Virus Vaccine Candidate Against Covid-19 in Healthy Adults\". clinicaltrials.gov. U.S. National Library of Medicine. 30 December 2020. Retrieved 11 January 2021.\n",
      "\n",
      "^ \"Module 2 – Subunit vaccines\". WHO Vaccine Safety Basics.\n",
      "\n",
      "^ a b c \"Study of the Safety, Reactogenicity and Immunogenicity of \"EpiVacCorona\" Vaccine for the Prevention of COVID-19 (EpiVacCorona)\". ClinicalTrials.gov. United States National Library of Medicine. 22 September 2020. NCT04368988. Retrieved 16 November 2020.\n",
      "\n",
      "^ a b \"Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant\". ClinicalTrials.gov. United States National Library of Medicine. 30 April 2020. NCT04368988. Archived from the original on 14 July 2020. Retrieved 14 July 2020.\n",
      "\n",
      "^ a b \"A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults\". ClinicalTrials.gov. United States National Library of Medicine. 3 August 2020. NCT04495933. Archived from the original on 11 October 2020. Retrieved 4 August 2020.\n",
      "\n",
      "^ a b \"UQ-CSL V451 Vaccine\". precisionvaccinations.com. Retrieved 11 December 2020.\n",
      "\n",
      "^ a b \"A prospective, randomized, adaptive, phase I/II clinical study to evaluate the safety and immunogenicity of Novel Corona Virus −2019-nCov vaccine candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects\". ctri.nic.in. Clinical Trials Registry India. 15 December 2020. CTRI/2020/07/026352. Archived from the original on 22 November 2020.\n",
      "\n",
      "^ a b \"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers\". ClinicalTrials.gov. United States National Library of Medicine. 7 April 2020. NCT04336410. Archived from the original on 11 October 2020. Retrieved 14 July 2020.\n",
      "\n",
      "^ a b \"IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO's COVID-19 DNA vaccine in South Korea\". International Vaccine Institute. 16 April 2020. Retrieved 23 April 2020.\n",
      "\n",
      "^ a b \"Study of COVID-19 DNA Vaccine (AG0301-COVID19)\". ClinicalTrials.gov. United States National Library of Medicine. 9 July 2020. NCT04463472. Archived from the original on 11 October 2020. Retrieved 14 July 2020.\n",
      "\n",
      "^ a b \"Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults\". ClinicalTrials.gov. United States National Library of Medicine. 24 June 2020. NCT04445389. Archived from the original on 11 October 2020. Retrieved 14 July 2020.\n",
      "\n",
      "^ a b \"S. Korea's Genexine begins human trial of coronavirus vaccine\". Reuters. 19 June 2020. Archived from the original on 11 October 2020. Retrieved 25 June 2020.\n",
      "\n",
      "^ a b \"Safety and Immunity of Covid-19 aAPC Vaccine\". ClinicalTrials.gov. United States National Library of Medicine. 9 March 2020. NCT04299724. Archived from the original on 11 October 2020. Retrieved 14 July 2020.\n",
      "\n",
      "^ a b \"Immunity and Safety of Covid-19 Synthetic Minigene Vaccine\". ClinicalTrials.gov. United States National Library of Medicine. 19 February 2020. NCT04276896. Archived from the original on 11 October 2020. Retrieved 14 July 2020.\n",
      "\n",
      "^ a b c \"A Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults\". ClinicalTrials.gov. United States National Library of Medicine. 1 November 2020. NCT04608305.\n",
      "\n",
      "^ Johnson, Carolyn Y.; Mufson, Steven. \"Can old vaccines from science's medicine cabinet ward off coronavirus?\". The Washington Post. ISSN 0190-8286. Retrieved 31 December 2020.\n",
      "\n",
      "^ \"Bacille Calmette-Guérin (BCG) vaccination and COVID-19\". World Health Organization (WHO). 12 April 2020. Archived from the original on 30 April 2020. Retrieved 1 May 2020.\n",
      "\n",
      "^ \"How flu vaccine effectiveness and efficacy are measured\". Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, US Department of Health and Human Services. 29 January 2016. Archived from the original on 7 May 2020. Retrieved 6 May 2020.\n",
      "\n",
      "^ \"Principles of epidemiology, Section 8: Concepts of disease occurrence\". Centers for Disease Control and Prevention, Center for Surveillance, Epidemiology, and Laboratory Services, US Department of Health and Human Services. 18 May 2012. Archived from the original on 6 April 2020. Retrieved 6 May 2020.\n",
      "\n",
      "^ a b Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV,  et al. (February 2018). \"Adaptive designs in clinical trials: why use them, and how to run and report them\". BMC Medicine. 16 (1): 29. doi:10.1186/s12916-018-1017-7. PMC 5830330. PMID 29490655.\n",
      "\n",
      "^ \"Adaptive designs for clinical trials of drugs and biologics: Guidance for industry\" (PDF). U.S. Food and Drug Administration (FDA). 1 November 2019. Archived from the original on 13 December 2019. Retrieved 3 April 2020.\n",
      "\n",
      "^ \"An international randomised trial of candidate vaccines against COVID-19: Outline of Solidarity vaccine trial\" (PDF). World Health Organization (WHO). 9 April 2020. Archived (PDF) from the original on 12 May 2020. Retrieved 9 May 2020.\n",
      "\n",
      "^ \"Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints\". Pfizer. 18 November 2020.\n",
      "\n",
      "^ Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S,  et al. (December 2020). \"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine\". New England Journal of Medicine. 383 (27): 2603–15. doi:10.1056/NEJMoa2034577. PMC 7745181. PMID 33301246.\n",
      "\n",
      "^ FDA Review of Efficacy and Safety of Pfizer-BioNTech COVID-19 Vaccine Emergency Use Authorization Request (PDF). U.S. Food and Drug Administration (FDA) (Report). 10 December 2020. Retrieved 11 December 2020.  This article incorporates text from this source, which is in the public domain.\n",
      "\n",
      "^ Erman M (18 November 2020). \"Pfizer ends COVID-19 trial with 95% efficacy, to seek emergency-use authorization\". Reuters. Retrieved 18 November 2020.\n",
      "\n",
      "^ a b c Zimmer, Carl (20 November 2020). \"2 Companies Say Their Vaccines Are 95% Effective. What Does That Mean? You might assume that 95 out of every 100 people vaccinated will be protected from Covid-19. But that's not how the math works\". The New York Times. Retrieved 21 November 2020.\n",
      "\n",
      "^ \"Albania to start COVID-19 immunisation with Pfizer vaccine in January – report\". Seenews.\n",
      "\n",
      "^ \"ANDORRA COVID-19\". www.govern.ad. Retrieved 19 February 2021.\n",
      "\n",
      "^ \"Coronavirus en la Argentina: La ANMAT aprobo el uso de emergencia de la vacuna Pfizer\". La Nación (in Spanish). Retrieved 23 December 2020.\n",
      "\n",
      "^ Overheid, Aruba (7 January 2021). \"COVID-19 vaccine update\". www.government.aw. Retrieved 19 February 2021.\n",
      "\n",
      "^ \"Bahrain becomes second country to approve Pfizer COVID-19 vaccine\". Al Jazeera. Retrieved 5 December 2020.\n",
      "\n",
      "^ a b c \"Drug and vaccine authorizations for COVID-19: List of applications received\". Health Canada, Government of Canada. 9 December 2020. Retrieved 9 December 2020.\n",
      "\n",
      "^ \"Pfizer vaccine approved for region but Health Ministry wants more info\". Trinidad and Tobago Newsday. 6 January 2021. Retrieved 24 February 2021.\n",
      "\n",
      "^ \"Chile approves Pfizer-BioNTech Covid-19 vaccine for emergency use\". The Straits Times. 17 December 2020. Retrieved 17 December 2020.\n",
      "\n",
      "^ \"Colombia regulator approves Pfizer-BioNTech vaccine for emergency use\". Reuters. 6 January 2021. Retrieved 6 January 2021.\n",
      "\n",
      "^ \"Costa Rica authorizes Pfizer-BioNTech coronavirus vaccine\". The Tico Times. 16 December 2020. Retrieved 16 December 2020.\n",
      "\n",
      "^ \"Arcsa autoriza ingreso al país de vacuna Pfizer-BioNTech para el Covid-19 – Agencia Nacional de Regulación, Control y Vigilancia Sanitaria\" (in Spanish). Retrieved 17 December 2020.\n",
      "\n",
      "^ \"Use of vaccine approved\". news.gov.hk. 25 January 2021. Retrieved 15 February 2021.\n",
      "\n",
      "^ \"Iraq grants emergency approval for Pfizer COVID-19 vaccine\". MSN. Retrieved 27 December 2020.\n",
      "\n",
      "^ \"Israeli Health Minister 'pleased' as FDA approves Pfizer COVID-19 vaccine\". The Jerusalem Post. Retrieved 28 December 2020.\n",
      "\n",
      "^ \"Jordan approves Pfizer-BioNTech Covid vaccine\". France 24. 15 December 2020. Retrieved 15 December 2020.\n",
      "\n",
      "^ \"Kuwait authorizes emergency use of Pfizer-BioNTech COVID-19 vaccine\". Arab News. 13 December 2020. Retrieved 15 December 2020.\n",
      "\n",
      "^ \"Liechtenstein – COVID19 Vaccine Tracker\". covid19.trackvaccines.org. Retrieved 19 February 2021.\n",
      "\n",
      "^ \"Mexico Approves Pfizer Vaccine for Emergency Use as Covid Surges\". Bloomberg. 12 December 2020. Retrieved 12 December 2020.\n",
      "\n",
      "^ \"Mexico authorizes emergency use of Pfizer-BioNTech coronavirus vaccine\". The Economic Times. 12 December 2020. Retrieved 14 January 2021.\n",
      "\n",
      "^ \"FIRST VACCINES ARRIVE IN MONACO - COVID-19 vaccination campaign begins tomorrow / Actualités / Coronavirus (Covid-19) / Policy & Practice / Portail du Gouvernement - Monaco\". en.gouv.mc. Retrieved 19 February 2021.\n",
      "\n",
      "^ \"Robust assessment ahead of Medsafe approval of vaccine\". Ministry of Health. 3 February 2021. Retrieved 6 February 2021.\n",
      "\n",
      "^ \"North Macedonia Kicks Off COVID-19 Vaccinations As Serbia Looks To Highlight Regional Efforts\". RadioFreeEurope/RadioLiberty. Retrieved 19 February 2021.\n",
      "\n",
      "^ \"Oman issues licence to import Pfizer BioNTech Covid vaccine – TV\". Reuters. 15 December 2020. Retrieved 16 December 2020.\n",
      "\n",
      "^ \"Panama approves Pfizer's COVID-19 vaccine – health ministry\". Yahoo! Finance. Retrieved 16 December 2020.\n",
      "\n",
      "^ \"PH authorizes Pfizer's COVID-19 vaccine for emergency use\". CNN Philippines. 14 January 2021. Retrieved 14 January 2021.\n",
      "\n",
      "^ \"Qatar, Oman to receive Pfizer-BioNTech COVID-19 vaccine this week\". Reuters. Retrieved 24 December 2020.\n",
      "\n",
      "^ a b c d e \"Public Health (Emergency Authorisation of COVID-19 Vaccine) Rules, 2021\" (PDF). Government of Saint Vincent and the Grenadines. 11 February 2021. Retrieved 12 February 2021.\n",
      "\n",
      "^ \"Singapore approves use of Pfizer's COVID-19 vaccine\". AP NEWS. 14 December 2020. Retrieved 15 December 2020.\n",
      "\n",
      "^ Staff, Reuters (23 February 2021). \"Suriname begins coronavirus vaccination campaign with donated doses\". Reuters. Retrieved 28 February 2021.\n",
      "\n",
      "^ \"Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland\" (Press release). Swiss Agency for Therapeutic Products (Swissmedic). 19 December 2020. Retrieved 19 December 2020.\n",
      "\n",
      "^ \"Comirnaty Product information\" (in German). Retrieved 31 January 2021.  [Due to incomplete clinical data at the time of the assessment of the authorization application, the Comirnaty medicinal product is authorized for a limited period (Art. 9a Medicinal Products Act).]\n",
      "\n",
      "^ \"Dubai approves the Pfizer-BioNTech vaccine which will be free of charge\". Emirates Woman. 23 December 2020. Retrieved 28 December 2020.\n",
      "\n",
      "^ \"UK medicines regulator gives approval for first UK COVID-19 vaccine\". Medicines and Healthcare Products Regulatory Agency, Government of the UK. 2 December 2020. Retrieved 2 December 2020.\n",
      "\n",
      "^ \"Information for Healthcare Professionals on Pfizer/BioNTech COVID-19 vaccine\". Medicines & Healthcare products Regulatory Agency (MHRA). 8 December 2020. Retrieved 13 December 2020.\n",
      "\n",
      "^ \"Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine\". Medicines & Healthcare products Regulatory Agency (MHRA). 3 December 2020. Retrieved 13 December 2020.\n",
      "\n",
      "^ a b Гурлев, Игорь Валентинович (1 October 2019). \"Наказ царя Алексея Михайловича «О градском благочинии» 1649 г.\" Власть. 27 (5): 236. doi:10.31171/vlast.v27i5.6749. ISSN 2071-5358.\n",
      "\n",
      "^ \"Interior Applauds Inclusion of Insular Areas through Operation Warp Speed to Receive COVID-19 Vaccines\" (Press release). United States Department of the Interior (DOI). 12 December 2020. Retrieved 13 January 2021.  This article incorporates text from this source, which is in the public domain.\n",
      "\n",
      "^ Dorman B (6 January 2021). \"Asia Minute: Palau Administers Vaccines to Keep Country Free of COVID\". Hawaii Public Radio. Retrieved 13 January 2021.\n",
      "\n",
      "^ \"FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine\" (Press release). U.S. Food and Drug Administration (FDA). 11 December 2020. Retrieved 11 December 2020.  This article incorporates text from this source, which is in the public domain.\n",
      "\n",
      "^ \"Pfizer-BioNTech COVID-19 Vaccine EUA Fact Sheet for Healthcare Providers\" (PDF). Pfizer. 11 December 2020.\n",
      "\n",
      "^ McElwee, Joshua J. (11 December 2020). \"Vatican to offer coronavirus vaccine to residents and staff in early 2021\". National Catholic Reporter. Retrieved 9 February 2021.\n",
      "\n",
      "^ Menichetti, Massimiliano (11 December 2020). \"In Vaticano parte il piano vaccinale anticovid\". vatican.va (Press release). Retrieved 9 February 2021.\n",
      "\n",
      "^ a b \"Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process\" (PDF). World Health Organization (WHO).\n",
      "\n",
      "^ \"WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access\". World Health Organization (WHO) (Press release). 31 December 2020. Retrieved 6 January 2021.\n",
      "\n",
      "^ \"Comirnaty\". Therapeutic Goods Administration. 25 January 2021. Retrieved 25 January 2021.\n",
      "\n",
      "^ Australian Public Assessment Report for BNT162b2 (mRNA) (PDF) (Report). Therapeutic Goods Administration (TGA). Retrieved 25 January 2021.\n",
      "\n",
      "^ \"Vacina da Pfizer é a 1ª a obter registro definitivo no Brasil\" (in Portuguese). G1. 23 February 2021. Retrieved 23 February 2021.\n",
      "\n",
      "^ \"Comirnaty EPAR\". European Medicines Agency (EMA). Retrieved 23 December 2020.\n",
      "\n",
      "^ \"Questions and Answers: COVID-19 vaccination in the EU\". European Commission. 21 December 2020. Retrieved 21 December 2020.\n",
      "\n",
      "^ \"Comirnaty\". Union Register of medicinal products. Retrieved 8 January 2021.\n",
      "\n",
      "^ a b \"Første vaccine mod COVID19 godkendt i EU\". Lægemiddelstyrelsen (in Danish). Retrieved 26 December 2020.\n",
      "\n",
      "^ \"COVID-19: Bóluefninu Comirnaty frá BioNTech/Pfizer hefur verið veitt skilyrt íslenskt markaðsleyfi\". Lyfjastofnun (in Icelandic). Retrieved 26 December 2020.\n",
      "\n",
      "^ \"Japan approves Pfizer's COVID-19 vaccine, 1st for domestic use\". Nikkei Asia. 14 February 2021. Retrieved 14 February 2021.\n",
      "\n",
      "^ Lim I (8 January 2021). \"Khairy: Malaysia can use Pfizer's Covid-19 vaccine now as conditional registration granted\". Malay Mail. Retrieved 8 January 2021.\n",
      "\n",
      "^ \"Status på koronavaksiner under godkjenning per 21.12.20\". Statens legemiddelverk (in Norwegian Bokmål). Retrieved 26 December 2020.\n",
      "\n",
      "^ \"Coronavirus: Saudi Arabia approves Pfizer COVID-19 vaccine for use\". Al Arabiya English. 10 December 2020. Retrieved 10 December 2020.\n",
      "\n",
      "^ Zimmer C, Corum J, Wee S (10 June 2020). \"Coronavirus Vaccine Tracker\". The New York Times. Retrieved 12 December 2020.\n",
      "\n",
      "^ \"Serbia leads region in expecting COVID-19 vaccines within days\". BalkanInsight. 21 December 2020. Retrieved 26 December 2020.\n",
      "\n",
      "^ \"First shipment of Pfizer-BioNTech vaccine arrives in Serbia\". Serbian government website. 22 December 2020. Retrieved 26 December 2020.\n",
      "\n",
      "^ Lee, Kyung-eun (27 February 2021). \"S. Korea begins rolling out Pfizer vaccines on second day of national vaccination program\". Arirang News. Retrieved 28 February 2021.\n",
      "\n",
      "^ Kim, Han-joo (5 March 2021). \"S. Korea approves Pfizer's COVID-19 vaccine amid immunization push\". Yonhap News Agency. Retrieved 5 March 2021.\n",
      "\n",
      "^ \"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19\". ClinicalTrials.gov. Archived from the original on 12 September 2020. Retrieved 11 September 2020.\n",
      "\n",
      "^ Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS,  et al. (February 2021). \"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia\". The Lancet. 397 (10275): 671–681. doi:10.1016/S0140-6736(21)00234-8. ISSN 0140-6736. PMC 7852454. PMID 33545094.\n",
      "\n",
      "^ \"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus\". ClinicalTrials.gov. Health Ministry of the Russian Federation. 25 September 2020. Retrieved 18 January 2021.\n",
      "\n",
      "^ Kumar, Shivani (1 December 2020). \"Sputnik-V from Russia arrives in India for clinal trials\". Hindustan Times.\n",
      "\n",
      "^ \"Clinical trial: 17 volunteers given Russia's Sputnik V Covid-19 vaccine in Pune\". The Indian Express. 6 December 2020.\n",
      "\n",
      "^ \"Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Vaccine Against COVID-19 in Venezuela\". ClinicalTrials.gov. Health Ministry of the Russian Federation. 24 November 2020. Retrieved 18 January 2021.\n",
      "\n",
      "^ \"Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Vaccine Against COVID-19 in Venezuela\". ClinicalTrials.gov. Health Ministry of the Russian Federation. 24 November 2020. Retrieved 18 January 2021.\n",
      "\n",
      "^ \"UAE begins trials of Russia's Sputnik V Covid-19 vaccine\". Clinical Trials Arena. 8 January 2021.\n",
      "\n",
      "^ \"Covid19: National Pharmaceuticals Agency registers Sputnik V vaccine\". Algeria Press service. 10 January 2021.\n",
      "\n",
      "^ \"Argentina has registered the Sputnik V vaccine based on Russian clinical trial data\" (Press release). Gamaleya Center. Retrieved 1 January 2021.\n",
      "\n",
      "^ \"Armenia approves Russia's Sputnik V coronavirus vaccine -Russia's RDIF\". Reuters. 1 February 2021. Retrieved 1 February 2021.\n",
      "\n",
      "^ \"Bahrain authorises Sputnik V COVID-19 vaccine for emergency use - Bahrain TV\". 10 February 2021. Retrieved 19 February 2021 – via www.reuters.com.\n",
      "\n",
      "^ \"Belarus registers Sputnik V vaccine, in first outside Russia – RDIF\". Reuters. 21 December 2020. Retrieved 22 December 2020.\n",
      "\n",
      "^ \"Ministerio de Salud de Bolivia – Bolivia y Rusia firman contrato para adquirir 5,2 millones de dosis de la vacuna Sputnik-V contra la COVID-19\". www.minsalud.gob.bo. Retrieved 1 January 2021.\n",
      "\n",
      "^ \"COVID-19: Egypt authorises Sputnik V, AstraZeneca virus jabs\". Gulf News. Retrieved 24 February 2021.\n",
      "\n",
      "^ \"Sputnik V authorised in Gabon\" (Press release). Gamaleya Center. Retrieved 17 February 2021.\n",
      "\n",
      "^ \"Ghana approves Russia's Sputnik V vaccine for emergency use - RDIF\". Reuters. 20 February 2021.\n",
      "\n",
      "^ \"Guatemala to receive Russia's Sputnik vaccine in coming weeks\". Reuters. 24 February 2021.\n",
      "\n",
      "^ \"Guinea Begins Administering Russia's Sputnik V Covid-19 Vaccine\". africa news. 31 December 2020.\n",
      "\n",
      "^ \"Honduras approves use of Sputnik V vaccine against COVID-19\". Xinhuanet.com. 25 February 2021.\n",
      "\n",
      "^ \"Iran approves Russian coronavirus vaccine Sputnik V\". Reuters. 26 January 2021.\n",
      "\n",
      "^ \"Kazakhstan begins mass vaccination by Russian Sputnik V\". 1 February 2021. Retrieved 19 February 2021.\n",
      "\n",
      "^ a b \"Laos declares Covid-19 vaccinations safe, more to be inoculated next week | The Star\". www.thestar.com.my. Retrieved 19 February 2021.\n",
      "\n",
      "^ \"Lebanon authorises emergency use of Russia's Sputnik V vaccine\". Reuters. 5 February 2021.\n",
      "\n",
      "^ \"Mexico, Germany warm to Russia's Sputnik V virus vaccine\". The Jakarta Post. 3 February 2021.\n",
      "\n",
      "^ \"Mongolia Approves Russia's Sputnik V Coronavirus Vaccine - RDIF\". Urdu Point. 9 February 2021.\n",
      "\n",
      "^ \"Montenegro and St. Vincent approve Russia's Sputnik V vaccine - RDIF\". Reuters. 12 February 2021.\n",
      "\n",
      "^ \"Myanmar registers Russia's Sputnik V COVID-19 vaccine\". TASS. Retrieved 19 February 2021.\n",
      "\n",
      "^ \"Nicaragua approves Russian COVID-19 vaccine\". wsoctv. 3 February 2021.\n",
      "\n",
      "^ \"Govt okays Russian vaccine for 'emergency use'\". Dawn. 24 January 2021.\n",
      "\n",
      "^ \"Palestine has become the first country in the Middle East to register Sputnik V vaccine\". RFID. 11 January 2021.\n",
      "\n",
      "^ \"Paraguay approves Russia's Sputnik V vaccine: RDIF\". Reuters. 15 January 2021. Retrieved 15 January 2021.\n",
      "\n",
      "^ a b c \"Sputnik V vaccine registered in Bosnia and Herzegovina's Republika Srpska\". Tass. 5 February 2021. Retrieved 8 February 2021.\n",
      "\n",
      "^ Burki TK (November 2020). \"The Russian vaccine for COVID-19\". The Lancet. Respiratory Medicine. 8 (11): e85–e86. doi:10.1016/S2213-2600(20)30402-1. PMC 7837053. PMID 32896274.\n",
      "\n",
      "^ \"San Marino buys the Sputnik vaccine: \"First doses already in the next few days\"\". Unioneonline. 20 February 2021.\n",
      "\n",
      "^ \"Agencija odobrila uvoz ruske vakcine Sputnjik V u Srbiju\". N1 (in Serbian). 31 December 2020.\n",
      "\n",
      "^ \"Sputnik V approved for use in Slovakia\". rdif.ru. Retrieved 1 March 2021.\n",
      "\n",
      "^ \"Sputnik V vaccine authorized in Tunisia\" (Press release). Gamaleya Center. Retrieved 30 January 2021.\n",
      "\n",
      "^ \"UAE approves Russia's Sputnik vaccine for emergency use\". Khaleej Times. 21 January 2021. Retrieved 21 January 2021.\n",
      "\n",
      "^ \"Uruguay to start covid 19 Vaccination in April 2021\". India Blooms.\n",
      "\n",
      "^ \"Venezuela firma contrato para la adquisición de la vacuna rusa Sputnik V\" (in Spanish). Reuters. 29 December 2020.\n",
      "\n",
      "^ \"Vietnam approves US, Russia Covid-19 vaccines for emergency use\". VnExpress. Retrieved 26 February 2021.\n",
      "\n",
      "^ a b c \"Angola, Congo Republic and Djibouti approve Russia's Sputnik V vaccine\". Reuters. 3 March 2021.\n",
      "\n",
      "^ \"Hungarian drug regulator approves Sputnik V vaccine: website\". The Moscow Times. 7 February 2021.\n",
      "\n",
      "^ \"Sputnik V registered in Kyrgyzstan\". Gamaleya Center (Press release). 23 February 2021.\n",
      "\n",
      "^ \"Syria authorizes use of Sputnik-V\". Roya. 22 February 2021.\n",
      "\n",
      "^ \"Turkmenistan is the first in Central Asia to have registered \"Sputnik V\" vaccine\". Orient. 18 January 2021.\n",
      "\n",
      "^ \"Uzbekistan Certifies Russia's Sputnik Vaccine For Mass Use\". Agence France-Presse (Barron's). 17 February 2021.\n",
      "\n",
      "^ \"AstraZeneca & Serum Institute of India sign licensing deal for 1 million doses of Oxford vaccine\". The Economic Times. Retrieved 15 June 2020.\n",
      "\n",
      "^ \"Covid-19 vaccine: Serum Institute signs up for 100 million doses of vaccines for India, low and middle-income countries\". The Financial Express. 7 August 2020.\n",
      "\n",
      "^ Walsh N, Shelley J, Duwe E, Bonnett W (27 July 2020). \"The world's hopes for a coronavirus vaccine may run in these health care workers' veins\". São Paulo: CNN. Archived from the original on 3 August 2020. Retrieved 3 August 2020.\n",
      "\n",
      "^ \"A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19\". ClinicalTrials.gov. United States National Library of Medicine. 12 May 2020. NCT04383574. Archived from the original on 23 August 2020. Retrieved 26 August 2020.\n",
      "\n",
      "^ Voysey M, Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK,  et al. (January 2021). \"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK\". Lancet. 397 (10269): 99–111. doi:10.1016/S0140-6736(20)32661-1. PMC 7723445. PMID 33306989.\n",
      "\n",
      "^ \"Trial of Oxford COVID-19 vaccine starts in Brazil\". Jenner Institute. Archived from the original on 9 September 2020. Retrieved 26 August 2020.\n",
      "\n",
      "^ \"Oxford COVID-19 vaccine final trials will be held in these 17 hospitals in India\". mint. 19 August 2020.\n",
      "\n",
      "^ Sediqi, Abdul Qadir (7 February 2021). \"First doses of COVID-19 vaccine arrive in Afghanistan from India\". Reuters. Retrieved 24 February 2021.\n",
      "\n",
      "^ \"India donates 500,000 COVID vaccines to Afghanistan\". www.aljazeera.com. Retrieved 24 February 2021.\n",
      "\n",
      "^ \"Argentine regulator approves AstraZeneca/Oxford COVID-19 vaccine\". Reuters. 30 December 2020. Retrieved 30 December 2020.\n",
      "\n",
      "^ \"Bahrain approves Oxford/AstraZeneca coronavirus vaccine produced in India\". Saudigazette. 25 January 2021. Retrieved 30 January 2021.\n",
      "\n",
      "^ \"Oxford University-Astrazeneca vaccine: Bangladesh okays it for emergency use\". thedailystar.net. Retrieved 6 January 2021.\n",
      "\n",
      "^ \"Bangladesh approves Oxford-AstraZeneca COVID-19 vaccine\". aa.com.tr. Retrieved 6 January 2021.\n",
      "\n",
      "^ a b McGeever J, Fonseca P (17 January 2021). \"Brazil clears emergency use of Sinovac, AstraZeneca vaccines, shots begin\". Reuters. Retrieved 17 January 2021.\n",
      "\n",
      "^ \"La República Dominicana aprueba la vacuna de AstraZeneca contra la covid-19\". Agencia EFE (in Spanish). 31 December 2020.\n",
      "\n",
      "^ \"Ecuador approves use of AstraZeneca vaccine for COVID-19\". Reuters. 24 January 2021. Retrieved 30 January 2021.\n",
      "\n",
      "^ \"COVID-19: Egypt authorises Sputnik V, AstraZeneca virus jabs\". Gulf News. Retrieved 24 February 2021.\n",
      "\n",
      "^ \"El Salvador greenlights AstraZeneca, Oxford University COVID-19 vaccine\". Reuters. 30 December 2020.\n",
      "\n",
      "^ \"Guyana gets first batch of COVID-19 vaccines; CARICOM Secretariat to get 100 doses\". 10 February 2021. Retrieved 19 February 2021.\n",
      "\n",
      "^ \"Nurse administers first shot of AstraZeneca ( ChAdOx1 nCoV-19, ) vaccine to Brinnet Bernarai at Georgetown Public Hospital Corporation - PAHO/WHO | Pan American Health Organization\". www.paho.org. Retrieved 19 February 2021.\n",
      "\n",
      "^ a b Schmall E, Yasir S (3 January 2021). \"India Approves Oxford-AstraZeneca Covid-19 Vaccine and 1 Other\". The New York Times. Retrieved 3 January 2021.\n",
      "\n",
      "^ a b \"Iraq approves Sinopharm, AstraZeneca vaccines\". Big News Network.com. Retrieved 30 January 2021.\n",
      "\n",
      "^ \"Maldives starts training healthcare workers on COVID-19 vaccine distribution - Xinhua | English.news.cn\". www.xinhuanet.com. Retrieved 19 February 2021.\n",
      "\n",
      "^ AfricaNews (26 January 2021). \"Mauritius begins vaccinating frontline health workers against covid-19\". Africanews. Retrieved 24 February 2021.\n",
      "\n",
      "^ \"Mexico approves AstraZeneca COVID-19 vaccine, minister says\". Reuters. 5 January 2021. Retrieved 14 January 2021.\n",
      "\n",
      "^ \"Myanmar launches nationwide COVID-19 vaccination program\". Xinhua News. 27 January 2021.\n",
      "\n",
      "^ \"Nepal approves AstraZeneca COVID vaccine for emergency use – government statement\". Reuters. 15 January 2021.\n",
      "\n",
      "^ \"Wetin we sabi about NAFDAC approval of Oxford AstraZeneca vaccine use for Nigeria\". BBC News Pidgin. Retrieved 24 February 2021.\n",
      "\n",
      "^ \"Pakistan approves AstraZeneca COVID-19 vaccine for emergency use\". 16 January 2021.\n",
      "\n",
      "^ \"Philippine regulator approves emergency use of AstraZeneca vaccine\". Reuters. 28 January 2021. Retrieved 28 January 2021.\n",
      "\n",
      "^ https://www.afro.who.int/news/rwanda-receives-covid-19-vaccines-through-covax\n",
      "\n",
      "^ a b \"AstraZeneca and Moderna vaccines to be administered in Saudi Arabia\". gulfnews.com. Retrieved 19 January 2021.\n",
      "\n",
      "^ \"Sri Lanka approves vaccine amid warnings of virus spread\". AP NEWS. 22 January 2021. Retrieved 22 January 2021.\n",
      "\n",
      "^ Staff, Reuters (23 February 2021). \"Suriname begins coronavirus vaccination campaign with donated doses\". Reuters. Retrieved 28 February 2021.\n",
      "\n",
      "^ \"Thai Food and Drug registers COVID-19 vaccine developed by AstraZeneca\". Pattaya Mail. 23 January 2021.\n",
      "\n",
      "^ \"Information for Healthcare Professionals on COVID-19 Vaccine AstraZeneca\". Medicines and Healthcare products Regulatory Agency (MHRA). 30 December 2020. Retrieved 4 January 2021.\n",
      "\n",
      "^ \"Oxford University/AstraZeneca vaccine authorised by UK medicines regulator\" (Press release). Department of Health and Social Care. 30 December 2020. Retrieved 30 December 2020.\n",
      "\n",
      "^ \"Conditions of Authorisation for COVID-19 Vaccine AstraZeneca\". Medicines and Healthcare products Regulatory Agency (MHRA). 30 December 2020. Retrieved 4 January 2021.\n",
      "\n",
      "^ \"Vietnam approves AstraZeneca COVID-19 vaccine, cuts short Communist Party congress\". CNA. Retrieved 5 February 2021.\n",
      "\n",
      "^ \"Interim recommendations for use of the AZD1222 (ChAdOx1-S (recombinant)) vaccine against COVID-19 developed by Oxford University and AstraZeneca\". World Health Organization (WHO). Retrieved 27 February 2021.\n",
      "\n",
      "^ \"AstraZeneca/Oxford Covid-19 Vaccine Gets Emergency Approval From WHO\". Forbes. Retrieved 16 February 2021.\n",
      "\n",
      "^ \"AstraZeneca coronavirus vaccine approved for use in Australia by TGA\". ABC News. 16 February 2021. Retrieved 16 February 2021.\n",
      "\n",
      "^ \"TGA provisionally approves AstraZeneca's COVID-19 vaccine\". Therapeutic Goods Administration (TGA). 16 February 2021. Retrieved 16 February 2021.\n",
      "\n",
      "^ \"Regulatory Decision Summary - AstraZeneca COVID-19 Vaccine\". Health Canada. 26 February 2021. Retrieved 26 February 2021.\n",
      "\n",
      "^ \"COVID-19 Vaccine AstraZeneca: Pending EC decision\". European Medicines Agency (EMA). 28 January 2021. Retrieved 29 January 2021.\n",
      "\n",
      "^ \"EMA recommends COVID-19 Vaccine AstraZeneca for authorisation in the EU\". European Medicines Agency (EMA) (Press release). 29 January 2021. Retrieved 29 January 2021.\n",
      "\n",
      "^ \"European Commission authorises third safe and effective vaccine against COVID-19\". European Commission (Press release). 29 January 2021. Retrieved 29 January 2021.\n",
      "\n",
      "^ Kim, Han-joo (10 February 2021). \"S. Korea approves AstraZeneca's COVID-19 vaccine for all adults\". Yonhap News Agency. Retrieved 10 February 2021.\n",
      "\n",
      "^ Maresca, Thomas (10 February 2021). \"South Korea approves AstraZeneca COVID-19 vaccine\". UPI. Retrieved 10 February 2021.\n",
      "\n",
      "^ Wee S, Qin A (30 December 2020). \"A Chinese Covid-19 Vaccine Has Proved Effective, Its Maker Says\". The New York Times. Retrieved 30 December 2020.\n",
      "\n",
      "^ Yang Y. \"A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above\". ClinicalTrials.gov. Archived from the original on 14 September 2020. Retrieved 15 September 2020.\n",
      "\n",
      "^ \"Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)\". ClinicalTrials.gov. Retrieved 28 September 2020.\n",
      "\n",
      "^ \"A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells)\". chictr.org.cn. Chinese Clinical Trial Register (ChiCTR). Retrieved 15 December 2020.\n",
      "\n",
      "^ \"Bahrain allows Sinopharm COVID-19 vaccine candidate use in frontline workers\". MSN. Reuters. Retrieved 3 November 2020.\n",
      "\n",
      "^ Biannchi, Walter (21 February 2021). \"Argentina approves Sinopharm COVID-19 vaccine for emergency use\". Reuters. Retrieved 23 February 2021.\n",
      "\n",
      "^ \"Bolivia begins inoculation with Sinopharm jabs | The Star\". www.thestar.com.my. Retrieved 28 February 2021.\n",
      "\n",
      "^ Rinith T (4 February 2021). \"Health Ministry grants Emergency Use Authorization to China's Sinopharm vaccine\". Khmer Times. Retrieved 4 February 2021.\n",
      "\n",
      "^ \"Egypt licenses China's Sinopharm COVID-19 vaccine for emergency use: health minister - Xinhua | English.news.cn\". xinhuanet.com.\n",
      "\n",
      "^ \"Hungary signs deal for Chinese Sinopharm's COVID-19 vaccine, first in EU\". National Post.\n",
      "\n",
      "^ \"Iran Launches Phase Two of Mass Inoculation Campaign\". Financial Tribune. 22 February 2021. Retrieved 23 February 2021.\n",
      "\n",
      "^ \"First batch of Chinese Sinopharm vaccine arrives in Jordan\". Roya News. Retrieved 9 January 2021.\n",
      "\n",
      "^ Crean, Rosabel. \"China donates 50,000 doses of Sinopharm vaccine to Lebanon | News , Lebanon News | THE DAILY STAR\". Daily Star. Retrieved 2 March 2021.\n",
      "\n",
      "^ \"Macau receives first batch of COVID-19 vaccines\". IAG. 7 February 2021. Retrieved 24 February 2021.\n",
      "\n",
      "^ \"Covid-19: Morocco authorizes use of the Sinopharm vaccine\". en.yabiladi.com.\n",
      "\n",
      "^ Poudel, Arjun. \"China's Shinopharm vaccine gets emergency use authorisation in Nepal\". Kathmandu Post. Retrieved 19 February 2021.\n",
      "\n",
      "^ Shahzad A (19 January 2021). \"Pakistan approves Chinese Sinopharm COVID-19 vaccine for emergency use\". Reuters.\n",
      "\n",
      "^ \"Peru grants 'exceptional' approval for Sinopharm COVID-19 vaccine - government sources\". Reuters. 27 January 2021.\n",
      "\n",
      "^ Asala, Kizzi. \"Senegal Kicks Off COVID-19 Vaccination Campaign with China's Sinopharm\". Africanews. Retrieved 23 February 2021.\n",
      "\n",
      "^ \"Serbia Becomes First European Nation To Use China's Sinopharm Vaccine\". RadioFreeEurope/RadioLiberty.\n",
      "\n",
      "^ Sequera, Vivian (1 March 2021). \"Venezuela approves use of China's Sinopharm coronavirus vaccine\". Reuters. Retrieved 2 March 2021.\n",
      "\n",
      "^ Mutsaka, Farai (18 February 2021). \"Zimbabwe starts administering China's Sinopharm vaccines\". The Star. Retrieved 20 February 2021.\n",
      "\n",
      "^ \"Bahrain approves China's Sinopharm coronavirus vaccine\". Arabian Business Industries. 13 December 2020.\n",
      "\n",
      "^ Kuo L. \"China approves Sinopharm coronavirus vaccine, the country's first for general use\". The Washington Post.\n",
      "\n",
      "^ \"President Ramkalawan and First Lady receives second dose SinoPharm Vaccine\". www.statehouse.gov.sc. Retrieved 5 February 2021.\n",
      "\n",
      "^ Wee S (9 December 2020). \"Chinese Covid-19 Vaccine Gets Key Push, but Doubts Swirl\". The New York Times. Retrieved 12 December 2020.\n",
      "\n",
      "^ \"Coronavirus: UAE authorises emergency use of vaccine for frontline workers\". The National. Retrieved 24 November 2020.\n",
      "\n",
      "^ \"Turkish official says CoronaVac vaccine 91.25% effective\". ABC News. Associated Press. Retrieved 28 December 2020.\n",
      "\n",
      "^ a b Soeriaatmadja W (11 January 2021). \"Indonesia grants emergency use approval to Sinovac's vaccine, local trials show 65% efficacy\". The Straits Times. Retrieved 11 January 2021.\n",
      "\n",
      "^ \"CoronaVac's Overall Efficacy in Brazil Measured at 50.4%\". Bloomberg. 12 January 2021. Retrieved 12 January 2021.\n",
      "\n",
      "^ \"Tests show coronavirus vaccine by China's Sinovac is safe, says Brazil's Butantan Institute\". Archived from the original on 29 October 2020. Retrieved 29 October 2020.\n",
      "\n",
      "^ \"Chile initiates clinical study for COVID-19 vaccine\". Archived from the original on 11 October 2020. Retrieved 29 October 2020.\n",
      "\n",
      "^ \"Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated\". ClinicalTrials.gov. 8 October 2020. Archived from the original on 20 October 2020. Retrieved 22 October 2020.\n",
      "\n",
      "^ Aliyev J. \"Azerbaijan kicks off COVID-19 vaccination\". Anadolu Agency. Retrieved 7 February 2021.\n",
      "\n",
      "^ \"Bolívia autoriza uso de vacinas Sputnik V e CoronaVac contra covid-19\". noticias.uol.com.br (in Portuguese). Retrieved 6 January 2021.\n",
      "\n",
      "^ Chanritheara, Torn. \"Cambodia Approves AstraZeneca and Sinovac Vaccines for COVID-19 Emergency Use\". Cambodianess. Retrieved 12 February 2021.\n",
      "\n",
      "^ \"Chile aprueba el uso de emergencia de la vacuna china de Sinovac contra covid-19\". France 24. 20 January 2021. Retrieved 30 January 2021.\n",
      "\n",
      "^ Aliyev J. \"Colombia approves emergency use of CoronaVac vaccine\". Anadolu Agency. Retrieved 7 February 2021.\n",
      "\n",
      "^ \"Ecuador signs agreement with Sinovac for 2 million COVID-19 vaccine: minister\". National Post. Retrieved 26 February 2021.\n",
      "\n",
      "^ \"Use of Sinovac vaccine authorised\". news.gov.hk. 18 February 2021. Retrieved 19 February 2021.\n",
      "\n",
      "^ \"BPOM Grants Emergency Use Authorization for Sinovac Vaccine\". Tempo. 11 January 2021. Retrieved 11 January 2021.\n",
      "\n",
      "^ a b c Liu R (6 February 2021). \"China approves Sinovac Biotech COVID-19 vaccine for general public use\". Reuters. Retrieved 7 February 2021.\n",
      "\n",
      "^ a b Barrera, Adriana (11 February 2021). \"Mexico approves China's CanSino and Sinovac COVID-19 vaccines\". Reuters. Retrieved 11 February 2021.\n",
      "\n",
      "^ \"Philippines approves Sinovac's COVID-19 vaccine for emergency use\". Reuters. 22 February 2021.\n",
      "\n",
      "^ Thepgumpanat, Panarat (22 February 2021). \"Thailand allows emergency use of Sinovac's COVID-19 vaccine\". Reuters. Retrieved 23 February 2021.\n",
      "\n",
      "^ \"Turkey to begin COVID-19 vaccine jabs by this weekend\". Anadolu. 11 January 2021. Retrieved 11 January 2021.\n",
      "\n",
      "^ \"Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine\". National Institutes of Health (NIH). 15 November 2020.\n",
      "\n",
      "^ Baden L, Essink B, Kotloff K, Frey S, Novak R, Diemert D,  et al. (December 2020). \"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine\". New England Journal of Medicine. 384 (5): 403–416. doi:10.1056/NEJMoa2035389. PMC 7787219. PMID 33378609.\n",
      "\n",
      "^ \"Regulatory Decision Summary – Moderna COVID-19 Vaccine\". Health Canada, Government of Canada. 23 December 2020. Retrieved 23 December 2020.\n",
      "\n",
      "^ \"Israeli Ministry of Health Authorizes COVID-19 Vaccine Moderna for Use in Israel\". modernatx.com. 4 January 2021. Retrieved 4 January 2021.\n",
      "\n",
      "^ \"Singapore becomes first in Asia to approve Moderna's COVID-19 vaccine\". Reuters. 3 February 2021. Retrieved 3 February 2021.\n",
      "\n",
      "^ \"Swissmedic grants authorisation for the COVID-19 vaccine from Moderna\" (Press release). Swiss Agency for Therapeutic Products (Swissmedic). 12 January 2020. Retrieved 12 January 2020.\n",
      "\n",
      "^ \"Information for Healthcare Professionals on COVID-19 Vaccine Moderna\". Medicines and Healthcare products Regulatory Agency (MHRA). 8 January 2021. Retrieved 8 January 2021.\n",
      "\n",
      "^ \"Conditions of Authorisation for COVID-19 Vaccine Moderna\". Medicines and Healthcare products Regulatory Agency (MHRA). 8 January 2021. Retrieved 9 January 2021.\n",
      "\n",
      "^ \"FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine\". U.S. Food and Drug Administration (FDA) (Press release). Retrieved 18 December 2020.\n",
      "\n",
      "^ Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M,  et al. (December 2020). \"The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine – United States, December 2020\" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5152): 1653–56. doi:10.15585/mmwr.mm695152e1. PMID 33382675. S2CID 229945697.\n",
      "\n",
      "^ \"Vietnam approves US, Russia Covid-19 vaccines for emergency use\". VnExpress. Retrieved 26 February 2021.\n",
      "\n",
      "^ \"COVID-19 Vaccine Moderna EPAR\". European Medicines Agency (EMA). Retrieved 20 January 2021.\n",
      "\n",
      "^ \"European Commission authorises second safe and effective vaccine against COVID-19\". European Commission (Press release). Retrieved 6 January 2021.\n",
      "\n",
      "^ \"EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU\" (Press release). European Medicines Agency. 6 January 2021. Retrieved 6 January 2021.\n",
      "\n",
      "^ \"COVID-19 Vaccine Moderna\". Union Register of medicinal products. Retrieved 14 January 2021.\n",
      "\n",
      "^ a b \"Endnu en vaccine mod COVID-19 er godkendt af EU-Kommissionen\". Lægemiddelstyrelsen (in Danish). Retrieved 7 January 2021.\n",
      "\n",
      "^ \"COVID-19: Bóluefninu COVID-19 Vaccine Moderna frá hefur verið veitt skilyrt íslenskt markaðsleyfi\". Lyfjastofnun (in Icelandic). Retrieved 7 January 2021.\n",
      "\n",
      "^ \"Status på koronavaksiner under godkjenning per 6. januar 2021\". Statens legemiddelverk (in Norwegian Bokmål). Retrieved 7 January 2021.\n",
      "\n",
      "^ \"Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial\" (Press release). Johnson & Johnson. 29 January 2021. Retrieved 29 January 2021.\n",
      "\n",
      "^ \"Bahrain first to approve Johnson & Johnson COVID-19 vaccine for emergency use\". Reuters. 25 February 2021. Retrieved 25 February 2021.\n",
      "\n",
      "^ \"Bahrain becomes 1st nation to grant J&J shot emergency use\". ABC News. 25 February 2021. Retrieved 25 February 2021.\n",
      "\n",
      "^ \"Coronavirus: South Africa rolls out vaccination programme\". BBC News Online. 17 February 2021. Retrieved 19 February 2021.\n",
      "\n",
      "^ \"FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine\". U.S. Food and Drug Administration (FDA) (Press release). 27 February 2021. Retrieved 27 February 2021.\n",
      "\n",
      "^ https://www.fda.gov/media/146303/download\n",
      "\n",
      "^ \"CanSinoBIO's COVID-19 vaccine 65.7% effective in global trials, Pakistan official says\". Reuters. 8 February 2021. Retrieved 8 February 2021.\n",
      "\n",
      "^ \"Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19\". ClinicalTrials.gov. United States National Library of Medicine. 13 November 2020. NCT04540419. Retrieved 17 November 2020.\n",
      "\n",
      "^ Lazcano P (15 November 2020). \"Así funcionan las cuatro vacunas que se probarán en Chile\". La Tercera. Retrieved 15 December 2020.\n",
      "\n",
      "^ Martinez AI (3 November 2020). \"CanSino Biologics delivers COVID-19 vaccine to Mexico for late-stage trial\". Reuters. Retrieved 4 November 2020.\n",
      "\n",
      "^ Ng E (28 October 2020). \"China's CanSino trials Covid-19 vaccine in 'high disease burden' nations\". South China Morning Post. Retrieved 4 November 2020.\n",
      "\n",
      "^ Nafisa E (9 August 2020). \"CanSino to start Phase III trial of COVID-19 vaccine in Saudi\". Reuters. Retrieved 4 November 2020.\n",
      "\n",
      "^ Gou J. \"Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above\". ClinicalTrials.gov. Archived from the original on 18 September 2020. Retrieved 17 September 2020.\n",
      "\n",
      "^ \"CanSino's COVID-19 vaccine approved for military use in China\". Nikkei Asia. Retrieved 24 December 2020.\n",
      "\n",
      "^ \"More Than 2.7 Million People Have Gotten Vaccines: Covid-19 Tracker\". Bloomberg L.P. Retrieved 24 December 2020.\n",
      "\n",
      "^ Shahzad, Asif (12 February 2021). \"Pakistan approves Chinese CanSinoBIO COVID vaccine for emergency use\". Reuters. Retrieved 12 February 2021.\n",
      "\n",
      "^ \"Russian EpiVacCorona Vaccine Has No Adverse Effects\". Oreanda News. 13 January 2021.\n",
      "\n",
      "^ \"О регистрации вакцины ФБУН ГНЦ ВБ \"Вектор\" Роспотребнадзора \"ЭпиВакКорона\"\". Rospotrebnadzor (in Russian). 14 October 2020.\n",
      "\n",
      "^ \"Russia's EpiVacCorona vaccine post-registration trials started\". The Pharma Letter. 18 November 2020.\n",
      "\n",
      "^ \"Turkmenistan registers vaccines for the prevention of infectious diseases\". Turkmenistan Today. 29 January 2021.\n",
      "\n",
      "^ \"Russian vaccine \"EpiVacCorona\" was registered in Turkmenistan\". EN24. 29 January 2021.\n",
      "\n",
      "^ \"An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers\". ClinicalTrials.gov. NCT04641481. Retrieved 26 November 2020.\n",
      "\n",
      "^ \"Bharat Biotech Recruits 23,000 Volunteers For Covaxin's Phase 3 Clinical Trial\". NDTV.com. 28 December 2020. Retrieved 3 January 2021.\n",
      "\n",
      "^ \"Covaxin showed 81% interim efficacy: Bharat Biotech on Phase 3 results\". Business Standard India. 3 March 2021.\n",
      "\n",
      "^ \"Briefing with Deputy Prime Minister Tatyana Golikova, Health Minister Mikhail Murashko and Head of Rospotrebnadzor Anna Popova\". Government of Russia. 18 January 2021. Retrieved 20 February 2021.\n",
      "\n",
      "^ \"Russia approves its third COVID-19 vaccine, CoviVac\". Reuters. 20 February 2021.\n",
      "\n",
      "^ \"COVID-19 vaccine tracker (Choose vaccines tab, apply filters to view select data)\". Milken Institute. 8 December 2020. Retrieved 11 December 2020. Lay summary.\n",
      "\n",
      "^ \"Draft landscape of COVID 19 candidate vaccines\". World Health Organization (WHO). 10 December 2020. Retrieved 11 December 2020.\n",
      "\n",
      "^ Wadman M (November 2020). \"The long shot\". Science. 370 (6517): 649–653. Bibcode:2020Sci...370..649W. doi:10.1126/science.370.6517.649. PMID 33154120.\n",
      "\n",
      "^ Wadman M (28 December 2020). \"Novavax launches pivotal U.S. trial of dark horse COVID-19 vaccine after manufacturing delays\". Science. doi:10.1126/science.abg3441.\n",
      "\n",
      "^ Parekh N (24 July 2020). \"Novavax: A SARS-CoV-2 Protein Factory to Beat COVID-19\". Archived from the original on 22 November 2020. Retrieved 24 July 2020.\n",
      "\n",
      "^ Chung YH, Beiss V, Fiering SN, Steinmetz NF (October 2020). \"COVID-19 Vaccine Frontrunners and Their Nanotechnology Design\". ACS Nano. 14 (10): 12522–12537. doi:10.1021/acsnano.0c07197. PMC 7553041. PMID 33034449.\n",
      "\n",
      "^ Medhi R, Srinoi P, Ngo N, Tran HV, Lee TR (25 September 2020). \"Nanoparticle-Based Strategies to Combat COVID-19\". ACS Applied Nano Materials. 3 (9): 8557–8580. doi:10.1021/acsanm.0c01978. PMC 7482545.\n",
      "\n",
      "^ \"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom\". ClinicalTrials.gov. Retrieved 22 November 2020.\n",
      "\n",
      "^ \"A Study Looking at the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults at Risk for SARS-CoV-2\". ClinicalTrials.gov. Retrieved 30 December 2020.\n",
      "\n",
      "^ Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S,  et al. (September 2020). \"Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine\". The New England Journal of Medicine. 383 (24): 2320–32. doi:10.1056/NEJMoa2026920. PMC 7494251. PMID 32877576.\n",
      "\n",
      "^ Staff, Reuters (5 February 2021). \"Ukraine secures 12 million AstraZeneca, Novavax COVID-19 vaccine doses\". Reuters. Retrieved 24 February 2021.\n",
      "\n",
      "^ \"COVID-19: Ukraine set to launch coronavirus vaccination programme\". euronews. 8 February 2021. Retrieved 24 February 2021.\n",
      "\n",
      "^ \"A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19\". ClinicalTrials.gov.\n",
      "\n",
      "^ Pinghui Z (20 November 2020). \"Fifth Chinese Covid-19 vaccine candidate ready to enter phase 3 trials\". South China Morning Post. Retrieved 26 December 2020.\n",
      "\n",
      "^ Ying TP (7 December 2020). \"MYEG to conduct phase 3 clinical trial for China's Covid-19 vaccine in Msia\". New Straits Times. Retrieved 28 December 2020.\n",
      "\n",
      "^ \"A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years\". ClinicalTrials.gov. United States National Library of Medicine. 10 July 2020. NCT04466085. Archived from the original on 28 July 2020. Retrieved 26 August 2020.\n",
      "\n",
      "^ Mamatkulov, Mukhammadsharif (1 March 2021). \"Uzbekistan approves Chinese-developed COVID-19 vaccine\". Reuters. Retrieved 2 March 2021.\n",
      "\n",
      "^ \"COVID-19\". CureVac. Retrieved 21 December 2020.\n",
      "\n",
      "^ \"COVID-19: A Phase 2b/3, Randomized, Observer-Blinded, Placebo Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older\". EU Clinical Trials Register. 19 November 2020. 2020-003998-22. Retrieved 19 December 2020.\n",
      "\n",
      "^ \"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults\". ClinicalTrials.gov. 26 June 2020. NCT04449276. Archived from the original on 11 October 2020. Retrieved 14 July 2020.\n",
      "\n",
      "^ \"A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults\". ClinicalTrials.gov. 17 August 2020. NCT04515147. Archived from the original on 23 August 2020. Retrieved 28 August 2020.\n",
      "\n",
      "^ Yergaliyeva, Aidana (20 December 2020). \"Kazakhstan Begins Vaccinating 3,000 Volunteers With Self-Made QazCovid-in\". The Astana Times. Retrieved 2 March 2021.\n",
      "\n",
      "^ a b \"Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine - Full Text View - ClinicalTrials.gov\". clinicaltrials.gov.\n",
      "\n",
      "^ \"Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine - Full Text View - ClinicalTrials.gov\". clinicaltrials.gov.\n",
      "\n",
      "^ \"Coronavirus | Zydus Cadila gets DCGI nod to initiate Phase-3 clinical trials for COVID-19 vaccine\". The Hindu. 3 January 2021.\n",
      "\n",
      "^ a b Thacker T. \"Zydus Cadila to test ZyCoV-D on 30,000 patients in Phase-3 trials\". The Economic Times. Retrieved 16 December 2020.\n",
      "\n",
      "^ \"DBT-BIRAC supported indigenously developed DNA Vaccine Candidate by Zydus Cadila, approved for Phase III clinical trials\" (Press release). Press Information Bureau. 3 January 2021.\n",
      "\n",
      "^ Rawat K, Kumari P, Saha L (February 2021). \"COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies\". European Journal of Pharmacology. 892: 173751. doi:10.1016/j.ejphar.2020.173751. ISSN 1879-0712. PMC 7685956. PMID 33245898.\n",
      "\n",
      "^ \"GSK, Medicago launch phase 2/3 clinical trials of plant-derived COVID-19 vaccine\". PMLive. 13 November 2020. Retrieved 16 November 2020.\n",
      "\n",
      "^ Chander V (14 July 2020). \"Canada's Medicago begins human trials of plant-based COVID-19 vaccine\". National Post. Reuters. Archived from the original on 1 November 2020. Retrieved 14 July 2020.\n",
      "\n",
      "^ Medicago (18 November 2020). \"Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years of Age or Older\". Clinical Trials. Retrieved 26 November 2020.\n",
      "\n",
      "^ \"As Israel goes vaccine-wild, will the homegrown version lose its shot?\". Times of Israel. 29 December 2020. Retrieved 1 January 2021.\n",
      "\n",
      "^ \"SOBERANA 02A\". Registro Público Cubano de Ensayos Clínicos. 17 December 2020. Retrieved 22 January 2021.\n",
      "\n",
      "^ \"SOBERANA 02\". Registro Público Cubano de Ensayos Clínicos. 27 October 2020. Retrieved 22 January 2021.\n",
      "\n",
      "^ a b \"VN starts injection of homegrown COVID-19 vaccine in first-stage human trial\". Viet Nam News. 17 December 2020.\n",
      "\n",
      "^ \"Draft landscape and tracker of COVID-19 candidate vaccines\". WHO. 26 February 2021.\n",
      "\n",
      "^ \"How much does first Made-in Vietnam COVID-19 vaccine cost?\". Voice of Vietnam. 11 December 2020.\n",
      "\n",
      "^ Chi Le, Anh Thu (26 February 2021). \"Vietnam enters second phase of Covid-19 vaccine trials\". VnExpress.\n",
      "\n",
      "^ \"Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19\". ClinicalTrials.gov. United States National Library of Medicine. 2 June 2020. NCT04412538. Archived from the original on 11 October 2020. Retrieved 14 July 2020.\n",
      "\n",
      "^ \"About AnGes – Introduction\". AnGes, Inc. Archived from the original on 11 October 2020. Retrieved 1 August 2020.\n",
      "\n",
      "^ \"CTI and Arcturus Therapeutics Announce Initiation of Dosing of COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study\". UK BioIndustry Association. 13 August 2020. Archived from the original on 11 October 2020. Retrieved 23 August 2020.\n",
      "\n",
      "^ \"Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects\". clinicaltrials.gov. Archived from the original on 11 October 2020. Retrieved 23 August 2020.\n",
      "\n",
      "^ a b \"About Us\". Shenzhen Genoimmune Medical Institute. Archived from the original on 11 October 2020. Retrieved 1 August 2020.\n",
      "\n",
      "^ Ward D, McCormack S (22 May 2020). \"Clinical trial to assess the safety of a coronavirus vaccine in healthy men and women\". ISRCTN. doi:10.1186/ISRCTN17072692. ISRCTN17072692.\n",
      "\n",
      "^ \"GRAd-COV2 Vaccine Against COVID-19\". ClinicalTrials.gov. United States National Library of Medicine. 7 January 2021. NCT04528641.\n",
      "\n",
      "^ \"ReiThera Announces its GRAd-COV2 COVID-19 Vaccine Candidate is Well Tolerated and Induces Clear Immune Responses in Healthy Subjects Aged 18–55 Years\". ReiThera Srl. Yahoo! Finance. 24 November 2020. Retrieved 12 January 2021.\n",
      "\n",
      "^ \"New ReiThera vaccine safe, response peak at 4 wks\". ANSA. 5 January 2021.\n",
      "\n",
      "^ \"Genexine consortium's Covid-19 vaccine acquires approval for clinical trails in Korea\". 11 June 2020. Retrieved 1 August 2020.\n",
      "\n",
      "^ \"SCB-2019 as COVID-19 Vaccine\". ClinicalTrials.gov. United States National Library of Medicine. 28 May 2020. NCT04405908. Archived from the original on 11 October 2020. Retrieved 14 July 2020.\n",
      "\n",
      "^ \"Clover Biopharmaceuticals starts Phase I Covid-19 vaccine trial\". Clinical Trials Arena. 20 June 2020. Archived from the original on 11 October 2020. Retrieved 25 June 2020.\n",
      "\n",
      "^ \"About Us\". Clover Biopharmaceuticals. Archived from the original on 11 October 2020. Retrieved 1 August 2020.\n",
      "\n",
      "^ \"Monovalent Recombinant COVID19 Vaccine (COVAX19)\". ClinicalTrials.gov. United States National Library of Medicine. 1 July 2020. NCT04453852. Archived from the original on 11 October 2020. Retrieved 14 July 2020.\n",
      "\n",
      "^ \"Vaxine\". Archived from the original on 11 October 2020. Retrieved 1 August 2020.\n",
      "\n",
      "^ \"A Phase I clinical trial to evaluate the safety, tolerance and preliminary immunogenicity of different doses of a SARS-CoV-2 mRNA vaccine in population aged 18–59 years and 60 years and above\". Chinese Clinical Trial Register. 24 June 2020. ChiCTR2000034112. Archived from the original on 11 October 2020. Retrieved 6 July 2020.\n",
      "\n",
      "^ \"Company introduction\". Walvax Biotechnology. Archived from the original on 11 October 2020. Retrieved 1 August 2020.\n",
      "\n",
      "^ \"Indigenous mRNA vaccine candidate supported by DBT gets Drug Controller nod to initiate Human clinical trials\" (Press release). Press Information Bureau. Retrieved 13 January 2021.\n",
      "\n",
      "^ \"mRNA Vaccines – HGC019\". Gennova Biopharmaceuticals Limited. Retrieved 13 January 2021.\n",
      "\n",
      "^ Raghavan P (15 December 2020). \"Pune-based Gennova to begin human trials of its Covid vaccine 'soon'\". The Indian Express.\n",
      "\n",
      "^ a b \"Bangavax Vaccine: Permission sought for clinical trial\". thedailystar.net. The Daily Star. 18 January 2021.\n",
      "\n",
      "^ \"Bangladesh joins global COVID-19 vaccine race with Bongavax set for clinical trial\". arabnews.com. Arab News. 8 January 2021.\n",
      "\n",
      "^ \"Globe Biotech applies for approval to run clinical trial of COVID vaccine\". bdnews24.com. Bdnews24.com. 17 January 2021.\n",
      "\n",
      "^ \"Globe Biotech seeks approval for vaccine trials\". newagebd.net. New Age. 17 January 2021.\n",
      "\n",
      "^ \"A prospective open label randomised phase-I seamlessly followed by phase-II study to assess the safety, reactogenicity and immunogenicity of Biological E's novel Covid-19 vaccine containing Receptor Binding Domain of SARS-CoV-2 for protection against Covid-19 disease when administered intramuscularly in a two dose schedule (0, 28D) to healthy volunteers\". ctri.nic.in. Clinical Trials Registry India. 13 January 2021. CTRI/2020/11/029032. Archived from the original on 12 November 2020.\n",
      "\n",
      "^ Chui M (16 November 2020). \"Biological E. Limited and Baylor COVID-19 vaccine begins clinical trial in India\". Baylor College of Medicine.\n",
      "\n",
      "^ Leo L (16 November 2020). \"Biological E initiates human trials of vaccine\". Mint.\n",
      "\n",
      "^ a b \"Made-in-Canada coronavirus vaccine starts human clinical trials\". CBC. 26 January 2021.\n",
      "\n",
      "^ a b \"VIDO COVID-19 vaccine moves to Phase 1 clinical testing\". globalnews.ca. 10 February 2021.\n",
      "\n",
      "^ \"Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)\". ClinicalTrials.gov. 30 September 2020. Retrieved 26 January 2021.\n",
      "\n",
      "^ \"A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)\". ClinicalTrials.gov. 4 August 2020. Retrieved 26 January 2021.\n",
      "\n",
      "^ \"Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates\". Merck (Press release). 25 January 2021. Retrieved 25 January 2021.\n",
      "\n",
      "^ \"FDA Briefing Document: Pfizer-BioNTech COVID-19 Vaccine\" (PDF). U.S. Food and Drug Administration. 10 December 2020. Retrieved 1 January 2021.\n",
      "\n",
      "^ Branswell, Helen (2 February 2021). \"Comparing three Covid-19 vaccines: Pfizer, Moderna, J&J\". Stat. Retrieved 28 February 2021.\n",
      "\n",
      "^ Randolph HE, Barreiro LB (May 2020). \"Herd Immunity: Understanding COVID-19\". Immunity. 52 (5): 737–41. doi:10.1016/j.immuni.2020.04.012. PMC 7236739. PMID 32433946.\n",
      "\n",
      "^ \"The FDA's cutoff for Covid-19 vaccine effectiveness is 50 percent. What does that mean?\". NBC News. Retrieved 8 January 2021.\n",
      "\n",
      "^ \"EMA sets 50% efficacy goal – with flexibility – for COVID vaccines\". www.raps.org. Retrieved 8 January 2021.\n",
      "\n",
      "^ \"Moderna COVID-19 Vaccine – cx-024414 injection, suspension\". DailyMed. U.S. National Institutes of Health. Retrieved 20 December 2020.\n",
      "\n",
      "^ \"Pfizer-BioNTech COVID-19 Vaccine – rna ingredient bnt-162b2 injection, suspension\". DailyMed. U.S. National Institutes of Health. Retrieved 14 December 2020.\n",
      "\n",
      "^ Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS,  et al. (February 2021). \"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia\". The Lancet. 397 (10275): 671–681. doi:10.1016/S0140-6736(21)00234-8. ISSN 0140-6736. PMC 7852454. PMID 33545094.\n",
      "\n",
      "^ Wadman M, Cohen J (28 January 2021). \"Novavax vaccine delivers 89% efficacy against COVID-19 in UK – but is less potent in South Africa\". Science. doi:10.1126/science.abg8101.\n",
      "\n",
      "^ \"Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial | Novavax Inc. - IR Site\". ir.novavax.com. Retrieved 3 March 2021.\n",
      "\n",
      "^ Wee S, Qin A (30 December 2020). \"A Chinese Covid-19 Vaccine Has Proved Effective, Its Maker Says\". The New York Times. Retrieved 30 December 2020.\n",
      "\n",
      "^ \"国药集团中国生物北京公司新冠病毒灭活疫苗Ⅲ期临床试验期中分析数据发布\". Sinopharm. Archived from the original on 9 February 2021. Retrieved 3 March 2021.\n",
      "\n",
      "^ Fonseca, Pedro. \"Brazil institute says CoronaVac efficacy above 50%, but delays full results\". Reuters. Retrieved December 25, 2020.\n",
      "\n",
      "^ \"Sinovac's Covid Shot Proves 78% Effective in Brazil Trial\". Bloomberg. 7 January 2021. Retrieved 7 January 2021.\n",
      "\n",
      "^ Sohn R (29 January 2021). \"J&J's Covid vaccine is 66% effective, a weapon but not a knockout punch\". Stat. Retrieved 29 January 2021.\n",
      "\n",
      "^ \"Emergency Use Authorization (EUA) of the Janssen COVID-19 Vaccine to prevent Coronavirus Disease 2019 (COVID-19)\" (PDF). Janssen Global Services. 27 February 2021. pp. 20–21. Retrieved 2 March 2021.\n",
      "\n",
      "^ \"Bharat Biotech's Covaxin found 81% effective in interim phase 3 trials\". mint. 3 March 2021.\n",
      "\n",
      "^ Douglas, Jason (4 February 2021). \"Scientists Test a New Covid-19 Vaccine Question: Mixing Different Doses\". The Wall Street Journal. ISSN 0099-9660. Retrieved 4 February 2021.\n",
      "\n",
      "^ Collier DA, Meng B, Ferreira, Gupta RK (2021). \"Neutralization of spike 69/70 deletion, E484K, and N501Y SARS-CoV-2 by BNT162b2 vaccine-elicited sera\" (PDF). bioRxiv : The Preprint Server for Biology. doi:10.1101/2021.01.27.427998. PMC 7852264. PMID 33532771 – via medRxiv.\n",
      "\n",
      "^ Tarke, Alison; Sidney, John; Kidd, Conner K.; Dan, Jennifer M.; Ramirez, Sydney I.; Yu, Esther Dawen; Mateus, Jose; Antunes, Ricardo da Silva; Moore, Erin; Rubiro, Paul; Methot, Nils (9 December 2020). \"Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases\". bioRxiv: 2020.12.08.416750. doi:10.1101/2020.12.08.416750.\n",
      "\n",
      "^ \"Vaccines Versus the Mutants\". The Scientist Magazine. Retrieved 25 January 2021.\n",
      "\n",
      "^ Smith, Jonathan (11 February 2021). \"Can Covid-19 Vaccines Keep up with an Evolving Virus?\". Labiotech.eu. Retrieved 25 January 2021.\n",
      "\n",
      "^ Ledford, Heidi (12 February 2021). \"How 'killer' T cells could boost COVID immunity in face of new variants\". www.nature.com. Retrieved 15 February 2021.\n",
      "\n",
      "^ Callaway, Ewen; Ledford, Heidi (29 January 2021). \"How to redesign COVID vaccines so they protect against variants\". Nature. 590 (7844): 15–16. doi:10.1038/d41586-021-00241-6.\n",
      "\n",
      "^ \"Эффективна ли российская вакцина против южноафриканского штамма ковида?\" [Is the Russian vaccine effective against the South African strain of covid?]. besedina.moscow. 26 January 2021. Retrieved 22 February 2021.\n",
      "\n",
      "^ \"EMA preparing guidance to tackle COVID-19 variants\". www.ema.europa.eu. 10 February 2021. Retrieved 22 February 2021.\n",
      "\n",
      "^ \"Перечень поручений по итогам совещания с членами Правительства\" [List of instructions following a meeting with members of the Government]. kremlin.ru. 12 February 2021. Retrieved 22 February 2021.\n",
      "\n",
      "^ \"Inside the B.1.1.7 Coronavirus Variant\". The New York Times. 18 January 2021. Retrieved 29 January 2021.\n",
      "\n",
      "^ \"Moderna vaccine appears to work against variants\". RNZ. 26 January 2021. Retrieved 30 January 2021.\n",
      "\n",
      "^ Muik, Alexander; Wallisch, Ann-Kathrin; Sänger, Bianca; Swanson, Kena A.; Mühl, Julia; Chen, Wei; Cai, Hui; Maurus, Daniel; Sarkar, Ritu; Türeci, Özlem; Dormitzer, Philip R. (29 January 2021). \"Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera\". Science: eabg6105. doi:10.1126/science.abg6105. ISSN 0036-8075. PMID 33514629.\n",
      "\n",
      "^ Muik, Alexander; Wallisch, Ann-Kathrin; Sänger, Bianca; Swanson, Kena A.; Mühl, Julia; Chen, Wei; Cai, Hui; Maurus, Daniel; Sarkar, Ritu; Türeci, Özlem; Dormitzer, Philip R. (29 January 2021). \"Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera\". Science: eabg6105. doi:10.1126/science.abg6105. ISSN 0036-8075. PMID 33514629.\n",
      "\n",
      "^ Sapkal, Gajanan N.; Yadav, Pragya D.; Ella, Raches; Deshpande, Gururaj R.; Sahay, Rima R.; Gupta, Nivedita; Mohan, V. Krishna; Abraham, Priya; Panda, Samiran; Bhargava, Balram (27 January 2021). \"Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum\". bioRxiv: 2021.01.26.426986. doi:10.1101/2021.01.26.426986.\n",
      "\n",
      "^ Kuchler, Hannah (25 January 2021). \"Moderna develops new vaccine to tackle mutant Covid strain\". Financial Times. Retrieved 30 January 2021.\n",
      "\n",
      "^ Liu, Yang; Liu, Jianying; Xia, Hongjie; Zhang, Xianwen; Fontes-Garfias, Camila R.; Swanson, Kena A.; Cai, Hui; Sarkar, Ritu; Chen, Wei; Cutler, Mark; Cooper, David; Weaver, Scott C.; Muik, Alexander; Sahin, Ugur; Jansen, Kathrin U.; Xie, Xuping; Dormitzer, Philip R.; Shi, Pei-Yong (17 February 2021). \"Neutralizing Activity of BNT162b2-Elicited Serum — Preliminary Report\". New England Journal of Medicine. doi:10.1056/nejmc2102017. Retrieved 25 February 2021.\n",
      "\n",
      "^ \"Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial\" (Press release). Johnson & Johnson. 29 January 2021. Retrieved 29 January 2021.\n",
      "\n",
      "^ Francis, Derek; Andy, Bruce (6 February 2021). \"Oxford/AstraZeneca COVID shot less effective against South African variant: study\". Reuters. Retrieved 8 February 2021.\n",
      "\n",
      "^ \"South Africa halts AstraZeneca jab over new strain\". BBC News. 7 February 2021. Retrieved 8 February 2021.\n",
      "\n",
      "^ Booth, William; Johnson, Carolyn Y. (7 February 2021). \"South Africa suspends Oxford-AstraZeneca vaccine rollout after researchers report 'minimal' protection against coronavirus variant\". The Washington Post. London. Retrieved 8 February 2021. South Africa will suspend use of the coronavirus vaccine being developed by Oxford University and AstraZeneca after researchers found it provided \"minimal protection\" against mild to moderate coronavirus infections caused by the new variant first detected in that country.\n",
      "\n",
      "^ \"Covid: South Africa halts AstraZeneca vaccine rollout over new variant\". BBC News Online. 8 February 2021. Retrieved 12 February 2021.\n",
      "\n",
      "^ a b c Tregoning JS, Russell RF, Kinnear E (25 January 2018). \"Adjuvanted influenza vaccines\". Human Vaccines and Immunotherapeutics. 14 (3): 550–64. doi:10.1080/21645515.2017.1415684. ISSN 2164-5515. PMC 5861793. PMID 29232151.\n",
      "\n",
      "^ a b c d Wang J, Peng Y, Xu H, Cui Z, Williams RO (5 August 2020). \"The COVID-19 vaccine race: Challenges and opportunities in vaccine formulation\". AAPS PharmSciTech. 21 (6): 225. doi:10.1208/s12249-020-01744-7. ISSN 1530-9932. PMC 7405756. PMID 32761294.\n",
      "\n",
      "^ \"Coronavirus (COVID-19) Vaccinations\". Our World in Data  Sourced from individual health agencies.\n",
      "\n",
      "^ a b c \"COVID Data Tracker\". Centers for Disease Control and Prevention.\n",
      "\n",
      "^ \"Coronavirus (COVID-19) Vaccinations - Statistics and Research\". Our World in Data.\n",
      "\n",
      "^ a b \"Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine\". World Health Organization. 27 April 2020. Archived from the original on 30 April 2020. Retrieved 2 May 2020. It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. [The] WHO is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale.\n",
      "\n",
      "^ a b Gates B (30 April 2020). \"The vaccine race explained: What you need to know about the COVID-19 vaccine\". The Gates Notes. Archived from the original on 14 May 2020. Retrieved 2 May 2020.\n",
      "\n",
      "^ a b Gates B (February 2020). \"Responding to Covid-19: A once-in-a-century pandemic?\". The New England Journal of Medicine. 382 (18): 1677–79. doi:10.1056/nejmp2003762. PMID 32109012.\n",
      "\n",
      "^ Weintraub R, Yadav P, Berkley S (2 April 2020). \"A COVID-19 vaccine will need equitable, global distribution\". Harvard Business Review. ISSN 0017-8012. Archived from the original on 9 June 2020. Retrieved 9 June 2020.\n",
      "\n",
      "^ a b c Steenhuysen J, Eisler P, Martell A, Nebehay S (27 April 2020). \"Special Report: Countries, companies risk billions in race for coronavirus vaccine\". Reuters. Archived from the original on 15 May 2020. Retrieved 2 May 2020.\n",
      "\n",
      "^ Gartner A, Roberts L (3 May 2020). \"How close are we to a coronavirus vaccine? Latest news on UK trials\". The Telegraph. ISSN 0307-1235. Archived from the original on 4 May 2020. Retrieved 3 May 2020.\n",
      "\n",
      "^ a b Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M,  et al. (9 April 2020). \"The COVID-19 vaccine development landscape\". Nature Reviews Drug Discovery. 19 (5): 305–06. doi:10.1038/d41573-020-00073-5. ISSN 1474-1776. PMID 32273591.\n",
      "\n",
      "^ Le TT, Cramer JP, Chen R, Mayhew S (4 September 2020). \"Evolution of the COVID-19 vaccine development landscape\". Nature Reviews Drug Discovery. 19 (10): 667–68. doi:10.1038/d41573-020-00151-8. ISSN 1474-1776. PMID 32887942. S2CID 221503034.\n",
      "\n",
      "^ a b Yamey G, Schäferhoff M, Hatchett R, Pate M, Zhao F, McDade KK (May 2020). \"Ensuring global access to COVID‑19 vaccines\". Lancet. 395 (10234): 1405–06. doi:10.1016/S0140-6736(20)30763-7. PMC 7271264. PMID 32243778. CEPI estimates that developing up to three vaccines in the next 12–18 months will require an investment of at least US$2 billion. This estimate includes Phase 1 clinical trials of eight vaccine candidates, progression of up to six candidates through Phase 2 and 3 trials, completion of regulatory and quality requirements for at least three vaccines, and enhancing global manufacturing capacity for three vaccines.\n",
      "\n",
      "^ \"An international randomised trial of candidate vaccines against COVID-19: Outline of Solidarity vaccine trial\" (PDF). World Health Organization. 9 April 2020. Archived (PDF) from the original on 12 May 2020. Retrieved 9 May 2020.\n",
      "\n",
      "^ a b \"COVAX: Ensuring global equitable access to COVID-19 vaccines\". GAVI. 2020. Archived from the original on 25 September 2020. Retrieved 28 August 2020.\n",
      "\n",
      "^ \"R&D Blueprint: A coordinated global research roadmap – 2019 novel coronavirus\" (PDF). World Health Organization. 1 March 2020. Archived (PDF) from the original on 15 May 2020. Retrieved 10 May 2020.\n",
      "\n",
      "^ a b Azar A (4 February 2020). \"Notice of Declaration under the Public Readiness and Emergency Preparedness Act for medical countermeasures against COVID-19\". Archived from the original on 25 April 2020. Retrieved 22 April 2020.\n",
      "\n",
      "^ \"Questions and Answers: Conditional Marketing Authorisation of COVID-19 Vaccines in the EU\". European Commission. 11 December 2020. Question: What is the difference in liability between EU Conditional Marketing Authorisation vs Emergency Use Authorisations?. Retrieved 29 December 2020.\n",
      "\n",
      "^ Haahr, Thomas (7 September 2020). \"COVID-19: MEPs want safe vaccines, full transparency and liability for companies\". European Parliament. Ms. Gallina stressed negotiations with companies had been difficult but underlined that those companies developing and manufacturing COVID-19 vaccines would indeed be liable according to current laws and if something goes wrong they could be taken to court. This also goes for compensation for hidden defects. Retrieved 29 December 2020.\n",
      "\n",
      "^ So AD, Woo J (December 2020). \"Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis\". BMJ. 371: m4750. doi:10.1136/bmj.m4750. ISSN 1756-1833. PMC 7735431. PMID 33323376.\n",
      "\n",
      "^ Adhanom Ghebreyesus, Tedros (18 January 2021). \"WHO Director-General's opening remarks at 148th session of the Executive Board\". www.who.int. Retrieved 25 January 2021.\n",
      "\n",
      "^ \"Bahrain approves Chinese COVID-19 vaccine for use\". ABC News. Retrieved 13 December 2020.\n",
      "\n",
      "^ \"UAE says Sinopharm vaccine has 86% efficacy against COVID-19\". Reuters. Retrieved 9 December 2020.\n",
      "\n",
      "^ Holmes, Oliver (16 February 2021). \"Israel blocked Covid vaccines from entering Gaza, say Palestinians\". The Guardian. Retrieved 17 February 2021.\n",
      "\n",
      "^ Rasgon, Adam (4 February 2021). \"Israel's Vaccine Success Unleashes a Debate on Palestinian Inequities\". The New York Times. Retrieved 17 February 2021.\n",
      "\n",
      "^ Horton, Chris (17 February 2021). \"Taiwan Concerned China May Have Blocked Vaccine Purchase\". Bloomberg. Retrieved 17 February 2021.\n",
      "\n",
      "^ \"Playing Politics with Poverty: Sisi's COVID-19 Vaccine Strategy\". Carnegie Endowment for International Peace. Retrieved 25 February 2021.\n",
      "\n",
      "^ Strazewski, Len (9 February 2021). \"Dr. Fauci: Variants reveal COVID-19 vaccination as global job\". American Medical Association. Retrieved 4 March 2021.\n",
      "\n",
      "^ Bergmark, Edward; Wierson, Arick (26 February 2021). \"Opinion: Without a global vaccine plan, coronavirus variants could lead to untold number of deaths\". CNN. Retrieved 4 March 2021.\n",
      "\n",
      "^ \"Ten health issues WHO will tackle this year\". World Health Organization (WHO). 2019. Archived from the original on 11 November 2019. Retrieved 26 May 2020.\n",
      "\n",
      "^ Malik AA, McFadden SM, Elharake J, Omer SB (2020). \"Determinants of COVID-19 vaccine acceptance in the US\". EClinicalMedicine, the Lancet. 26: 100495. doi:10.1016/j.eclinm.2020.100495. ISSN 2589-5370. PMC 7423333. PMID 32838242.\n",
      "\n",
      "^ Beard, David (3 December 2020). \"Poll shows 61 percent of Americans likely to take COVID-19 vaccine\". National Geographic. Retrieved 12 December 2020.\n",
      "\n",
      "^ Bekiempis, Victoria (21 December 2020). \"'I'm ready': Joe Biden receives coronavirus vaccine live on TV\". The Guardian. Retrieved 26 December 2020.\n",
      "\n",
      "^ Aratani, Lauren (18 December 2020). \"Mike Pence receives Covid-19 vaccine on live TV: 'I didn't feel a thing'\". The Guardian. Retrieved 26 December 2020.\n",
      "\n",
      "^ Gabbatt, Adam (3 December 2020). \"Obama, Clinton and Bush pledge to take Covid vaccine on TV to show its safety\". The Guardian. Retrieved 26 December 2020.\n",
      "\n",
      "\n",
      "Further reading\n",
      "Funk CD, Laferrière C, Ardakani A (2020). \"A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic\". Front Pharmacol. 11: 937. doi:10.3389/fphar.2020.00937. PMC 7317023. PMID 32636754.\n",
      "Development and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry (Report). U.S. Food and Drug Administration. June 2020.\n",
      "Ramsay M, ed. (2020). \"Chapter 14a: COVID-19\". Immunisation against infectious disease. Public Health England.\n",
      "Levine, Hallie (23 September 2020). \"The 5 Stages of COVID-19 Vaccine Development: What You Need to Know About How a Clinical Trial Works\". Johnson & Johnson.\n",
      "Zimmer C, Sheikh K, Weiland N (20 May 2020). \"A New Entry in the Race for a Coronavirus Vaccine: Hope\". The New York Times.\n",
      "Vaccine protocols\n",
      "\"Protocol mRNA-1273-P301\" (PDF). Moderna.\n",
      "\"Protocol C4591001 PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines)\" (PDF). Pfizer.\n",
      "\"Protocol AZD1222 – D8110C00001\" (PDF). AstraZeneca.\n",
      "\"Protocol VAC31518COV3001; Phase 3 (ENSEMBLE)\" (PDF). Janssen Vaccines & Prevention.\n",
      "\"Protocol VAC31518COV3009; Phase 3 (ENSEMBLE 2)\" (PDF). Janssen Vaccines & Prevention.\n",
      "External links\n",
      "\n",
      "\n",
      "\n",
      "Wikiquote has quotations related to: COVID-19 vaccine\n",
      "\n",
      "\"The COVID-19 candidate vaccine landscape\". World Health Organization (WHO).\n",
      "COVID‑19 Vaccine Tracker. Regulatory Focus\n",
      "\"STAT's Covid-19 Drugs and Vaccines Tracker\". Stat.\n",
      "\"COVID-19 vaccines: development, evaluation, approval and monitoring\". European Medicines Agency.\n",
      "\"Vaccine Development – 101\". U.S. Food and Drug Administration.\n",
      "\"Coronavirus Variants and Mutations\". The New York Times.\n",
      "M.I.T. Lecture 10: Kizzmekia Corbett, Vaccines\" on YouTube\n",
      "vteCOVID-19 pandemic\n",
      "SARS-CoV-2 (virus)\n",
      "COVID-19 (disease)\n",
      "Timeline\n",
      "Pre-pandemic\n",
      "Crimson Contagion\n",
      "Disease X\n",
      "Event 201\n",
      "Exercise Cygnus\n",
      "2019\n",
      "2020\n",
      "January\n",
      "February\n",
      "responses\n",
      "March\n",
      "responses\n",
      "April\n",
      "responses\n",
      "May\n",
      "responses\n",
      "June\n",
      "responses\n",
      "July\n",
      "responses\n",
      "August\n",
      "responses\n",
      "September\n",
      "responses\n",
      "October\n",
      "responses\n",
      "November\n",
      "responses\n",
      "December\n",
      "responses\n",
      "2021\n",
      "January\n",
      "responses\n",
      "February\n",
      "responses\n",
      "March\n",
      "responses\n",
      "LocationsAfricaNorthern\n",
      "Algeria\n",
      "Canary Islands\n",
      "Ceuta\n",
      "Egypt\n",
      "Libya\n",
      "Mauritania\n",
      "Melilla\n",
      "Morocco\n",
      "Sudan\n",
      "Tunisia\n",
      "Western Sahara\n",
      "Sahrawi Arab Democratic Republic\n",
      "Eastern\n",
      "Burundi\n",
      "Comoros\n",
      "Djibouti\n",
      "Eritrea\n",
      "Ethiopia\n",
      "Kenya\n",
      "Madagascar\n",
      "Mauritius\n",
      "Mayotte\n",
      "Réunion\n",
      "Rwanda\n",
      "Seychelles\n",
      "Somalia\n",
      "Puntland\n",
      "Somaliland\n",
      "South Sudan\n",
      "Tanzania\n",
      "Uganda\n",
      "Southern\n",
      "Angola\n",
      "Botswana\n",
      "Eswatini\n",
      "Lesotho\n",
      "Malawi\n",
      "Mozambique\n",
      "Namibia\n",
      "South Africa\n",
      "Zambia\n",
      "Zimbabwe\n",
      "Central\n",
      "Cameroon\n",
      "Central African Republic\n",
      "Chad\n",
      "Democratic Republic of the Congo\n",
      "Republic of the Congo\n",
      "Gabon\n",
      "São Tomé and Príncipe\n",
      "Western\n",
      "Benin\n",
      "Burkina Faso\n",
      "Cape Verde\n",
      "Equatorial Guinea\n",
      "Gambia\n",
      "Ghana\n",
      "timeline\n",
      "March–July 2020\n",
      "August–December 2020\n",
      "2021\n",
      "education impact\n",
      "Guinea\n",
      "Guinea-Bissau\n",
      "Ivory Coast\n",
      "Liberia\n",
      "Mali\n",
      "Niger\n",
      "Nigeria\n",
      "Senegal\n",
      "Sierra Leone\n",
      "Togo\n",
      "AsiaCentral / North\n",
      "Kazakhstan\n",
      "Kyrgyzstan\n",
      "Russia\n",
      "timeline\n",
      "Tajikistan\n",
      "Turkmenistan\n",
      "Uzbekistan\n",
      "East\n",
      "Hong Kong\n",
      "Japan\n",
      "timeline\n",
      "North Korea\n",
      "South Korea\n",
      "Macau\n",
      "Mongolia\n",
      "Taiwan\n",
      "Mainland China\n",
      "Beijing\n",
      "Heilongjiang\n",
      "Henan\n",
      "Hubei\n",
      "lockdown\n",
      "Inner Mongolia\n",
      "Liaoning\n",
      "Shanghai\n",
      "Sichuan\n",
      "Tibet\n",
      " Xinjiang\n",
      "\n",
      "South\n",
      "Afghanistan\n",
      "timeline\n",
      "Bangladesh\n",
      "timeline\n",
      "Bhutan\n",
      "Maldives\n",
      "Nepal\n",
      "timeline\n",
      "Pakistan\n",
      "timeline\n",
      "Sri Lanka\n",
      "India\n",
      "timeline\n",
      "January–May 2020\n",
      "June–December 2020\n",
      "economic impact\n",
      "evacuations\n",
      "lockdown\n",
      "migrant workers' crisis\n",
      "union government response\n",
      "Operation Namaste\n",
      "state government responses\n",
      "vaccination)\n",
      "Andaman and Nicobar Islands\n",
      "Andhra Pradesh\n",
      "Arunachal Pradesh\n",
      "Assam\n",
      "Bihar\n",
      "Chandigarh\n",
      "Chhattisgarh\n",
      "Dadra and Nagar Haveli and Daman and Diu\n",
      "Delhi\n",
      "Tablighi Jamaat hotspot\n",
      "Goa\n",
      "Gujarat\n",
      "Haryana\n",
      "Himachal Pradesh\n",
      "Jammu and Kashmir\n",
      "Jharkhand\n",
      "Karnataka\n",
      "Kerala\n",
      "timeline\n",
      "Ladakh\n",
      "Lakshadweep\n",
      "Madhya Pradesh\n",
      "Maharashtra\n",
      "Manipur\n",
      "Meghalaya\n",
      "Mizoram\n",
      "Nagaland\n",
      "Odisha\n",
      "Puducherry\n",
      "Punjab\n",
      "Rajasthan\n",
      "Sikkim\n",
      "Tamil Nadu\n",
      "Telangana\n",
      "Tripura\n",
      "Uttar Pradesh\n",
      "Uttarakhand\n",
      "West Bengal\n",
      "\n",
      "Southeast\n",
      "Brunei\n",
      "Cambodia\n",
      "East Timor\n",
      "Indonesia\n",
      "timeline\n",
      "social restrictions\n",
      "Laos\n",
      "Malaysia\n",
      "timeline\n",
      "movement control order\n",
      "Johor\n",
      "Kuala Lumpur\n",
      "Sabah\n",
      "Sarawak\n",
      "Selangor\n",
      "Myanmar\n",
      "Singapore\n",
      "timeline\n",
      "circuit breaker response\n",
      "Thailand\n",
      "timeline\n",
      "Vietnam\n",
      "timeline\n",
      "Philippines\n",
      "(timeline\n",
      "government response\n",
      "community quarantines\n",
      "Luzon\n",
      "evacuations\n",
      "testing controversy)\n",
      "Bangsamoro\n",
      "Bicol Region\n",
      "Cagayan Valley\n",
      "Calabarzon\n",
      "Caraga\n",
      "Central Luzon\n",
      "Central Visayas\n",
      "Cordillera\n",
      "Davao Region\n",
      "Eastern Visayas\n",
      "Ilocos Region\n",
      "Metro Manila\n",
      "Mimaropa\n",
      "Northern Mindanao\n",
      "Soccsksargen\n",
      "Western Visayas\n",
      "Zamboanga Peninsula\n",
      "Overseas Filipinos\n",
      "\n",
      "West\n",
      "Armenia\n",
      "Azerbaijan\n",
      "Artsakh\n",
      "Bahrain\n",
      "Georgia\n",
      "Abkhazia\n",
      "South Ossetia\n",
      "Iran\n",
      "Iraq\n",
      "Kurdistan\n",
      "Israel\n",
      "Jordan\n",
      "Kuwait\n",
      "Lebanon\n",
      "Oman\n",
      "Palestine\n",
      "Qatar\n",
      "Saudi Arabia\n",
      "Syria\n",
      "Turkey\n",
      "timeline\n",
      "United Arab Emirates\n",
      "Yemen\n",
      "EuropeUnited Kingdom\n",
      "\n",
      "timeline\n",
      "January–June 2020\n",
      "July–December 2020\n",
      "2021\n",
      "government response\n",
      "social impact\n",
      "economic impact\n",
      "education impact\n",
      "Operation Rescript\n",
      "England\n",
      "2020 timeline\n",
      "2021 timeline\n",
      "London\n",
      "Northern Ireland\n",
      "2020 timeline\n",
      "2021 timeline\n",
      "Scotland\n",
      "2020 timeline\n",
      "2021 timeline\n",
      "Wales\n",
      "2020 timeline\n",
      "2021 timeline\n",
      "Crown dependencies\n",
      "Isle of Man\n",
      "Jersey\n",
      "Guernsey\n",
      "Overseas territories\n",
      "Akrotiri and Dhekelia\n",
      "Gibraltar\n",
      "response\n",
      "\n",
      "Eastern\n",
      "Belarus\n",
      "Kazakhstan\n",
      "Moldova\n",
      "Gagauzia\n",
      "Transnistria\n",
      "Russia\n",
      "timeline\n",
      "government responses\n",
      "Crimea\n",
      "Sevastopol\n",
      "Ukraine\n",
      "Donetsk\n",
      "Luhansk\n",
      "Western Balkans\n",
      "Albania\n",
      "Bosnia and Herzegovina\n",
      "Kosovo\n",
      "Montenegro\n",
      "North Macedonia\n",
      "Serbia\n",
      "European Union\n",
      "Austria\n",
      "Belgium\n",
      "Bulgaria\n",
      "Croatia\n",
      "timeline\n",
      "Cyprus\n",
      "Northern Cyprus\n",
      "Czech Republic\n",
      "Denmark\n",
      "Faroe Islands\n",
      "Estonia\n",
      "Finland\n",
      "Åland Islands\n",
      "France\n",
      "Guadeloupe\n",
      "French Guiana\n",
      "Réunion\n",
      "Martinique\n",
      "Mayotte\n",
      "Saint Martin\n",
      "Germany\n",
      "North Rhine-Westphalia\n",
      "Greece\n",
      "Hungary\n",
      "Italy\n",
      "lockdown\n",
      "timeline\n",
      "Latvia\n",
      "Lithuania\n",
      "Luxembourg\n",
      "Malta\n",
      "Netherlands\n",
      "Poland\n",
      "Portugal\n",
      "Romania\n",
      "timeline\n",
      "Slovakia\n",
      "Slovenia\n",
      "Spain\n",
      "timeline\n",
      "Asturias\n",
      "Canary Islands\n",
      "Ceuta\n",
      "Community of Madrid\n",
      "Melilla\n",
      "Sweden\n",
      "timeline\n",
      "government response\n",
      "Ireland\n",
      "timeline\n",
      "January–June 2020\n",
      "July–December 2020\n",
      "2021\n",
      "economic impact\n",
      "social impact\n",
      "\n",
      "EFTA countries\n",
      "Iceland\n",
      "Liechtenstein\n",
      "Norway\n",
      "Switzerland\n",
      "Microstates\n",
      "Andorra\n",
      "Monaco\n",
      "San Marino\n",
      "Vatican City\n",
      "North AmericaMexico\n",
      "timeline\n",
      "Central America\n",
      "Belize\n",
      "Costa Rica\n",
      "El Salvador\n",
      "Guatemala\n",
      "Honduras\n",
      "Nicaragua\n",
      "Panama\n",
      "Canada\n",
      "timeline\n",
      "economic impact\n",
      "vaccination\n",
      "Alberta\n",
      "British Columbia\n",
      "Manitoba\n",
      "New Brunswick\n",
      "Newfoundland and Labrador\n",
      "Northwest Territories\n",
      "Nova Scotia\n",
      "Nunavut\n",
      "Ontario\n",
      "timeline\n",
      "Peel Region\n",
      "Toronto\n",
      "Prince Edward Island\n",
      "Quebec\n",
      "Montreal\n",
      "boroughs\n",
      "timeline\n",
      "Saskatchewan\n",
      "Yukon\n",
      "Caribbean\n",
      "Antigua and Barbuda\n",
      "Bahamas\n",
      "Barbados\n",
      "British Overseas Territories\n",
      "Anguilla\n",
      "British Virgin Islands\n",
      "Cayman Islands\n",
      "Montserrat\n",
      "Turks and Caicos Islands\n",
      "response\n",
      "Cuba\n",
      "Guantanamo Bay Naval Base\n",
      "Dominica\n",
      "Dominican Republic\n",
      "Dutch Caribbean\n",
      "Aruba\n",
      "Curaçao\n",
      "Sint Maarten\n",
      "Caribbean Netherlands\n",
      "Bonaire\n",
      "Saba\n",
      "Sint Eustatius\n",
      "French West Indies\n",
      "Guadeloupe\n",
      "Martinique\n",
      "Saint Barthélemy\n",
      "Saint Martin\n",
      "Grenada\n",
      "Haiti\n",
      "Jamaica\n",
      "Saint Kitts and Nevis\n",
      "Saint Lucia\n",
      "Saint Vincent and the Grenadines\n",
      "Trinidad and Tobago\n",
      "US insular areas\n",
      "Puerto Rico\n",
      "U.S. Virgin Islands\n",
      "United States\n",
      "timeline\n",
      "2020\n",
      "2021\n",
      "social impact\n",
      "economic impact\n",
      "federal government response\n",
      "state and local government responses\n",
      "Regional responses\n",
      "Eastern States Multi-state Council\n",
      "Midwest Governors Regional Pact\n",
      "Western States Pact\n",
      "Trump administration communication\n",
      "Alabama\n",
      "Alaska\n",
      "American Samoa\n",
      "Arizona\n",
      "Navajo Nation\n",
      "Arkansas\n",
      "California\n",
      "timeline\n",
      "S.F. Bay Area\n",
      "Colorado\n",
      "Connecticut\n",
      "Delaware\n",
      "Florida\n",
      "Georgia\n",
      "Guam\n",
      "Hawaii\n",
      "Idaho\n",
      "Illinois\n",
      "Indiana\n",
      "Iowa\n",
      "Kansas\n",
      "Kentucky\n",
      "Louisiana\n",
      "Maine\n",
      "Maryland\n",
      "Massachusetts\n",
      "timeline\n",
      "Boston\n",
      "timeline\n",
      "Michigan\n",
      "Minnesota\n",
      "Mississippi\n",
      "Missouri\n",
      "Montana\n",
      "Nebraska\n",
      "Nevada\n",
      "New Hampshire\n",
      "New Jersey\n",
      "New Mexico\n",
      "New York\n",
      "New York City\n",
      "North Carolina\n",
      "North Dakota\n",
      "Northern Mariana Islands\n",
      "Ohio\n",
      "impact\n",
      "Columbus\n",
      "Oklahoma\n",
      "Oregon\n",
      "Portland\n",
      "Pennsylvania\n",
      "Philadelphia\n",
      "Puerto Rico\n",
      "Rhode Island\n",
      "South Carolina\n",
      "South Dakota\n",
      "Tennessee\n",
      "Texas\n",
      "Austin\n",
      "timeline\n",
      "U.S. Virgin Islands\n",
      "Utah\n",
      "Vermont\n",
      "Virginia\n",
      "Washington\n",
      "Washington, D.C.\n",
      "White House\n",
      "West Virginia\n",
      "Wisconsin\n",
      "statistics\n",
      "Wyoming\n",
      "Atlantic\n",
      "Bermuda\n",
      "Greenland\n",
      "Saint Pierre and Miquelon\n",
      "Oceania\n",
      "American Samoa\n",
      "Australia\n",
      "Easter Island\n",
      "Federated States of Micronesia\n",
      "Fiji\n",
      "French Polynesia\n",
      "Guam\n",
      "Hawaii\n",
      "Marshall Islands\n",
      "New Caledonia\n",
      "New Zealand\n",
      "timeline\n",
      "government response\n",
      "Northern Mariana Islands\n",
      "Papua New Guinea\n",
      "Bougainville\n",
      "Samoa\n",
      "Solomon Islands\n",
      "Vanuatu\n",
      "Wallis and Futuna\n",
      "South America\n",
      "Argentina\n",
      "timeline\n",
      "statistics\n",
      "human rights\n",
      "Bolivia\n",
      "Brazil\n",
      "São Paulo\n",
      "Chile\n",
      "Easter Island\n",
      "Colombia\n",
      "Ecuador\n",
      "Falkland Islands\n",
      "French Guiana\n",
      "Guyana\n",
      "Paraguay\n",
      "Peru\n",
      "Suriname\n",
      "Uruguay\n",
      "timeline\n",
      "Venezuela\n",
      "Other\n",
      "Antarctica\n",
      "Cruise ships\n",
      "Diamond Princess\n",
      "Grand Princess\n",
      "Naval ships\n",
      "Charles de Gaulle\n",
      "USS Theodore Roosevelt\n",
      "ImpactsCulture andentertainment\n",
      "Arts and cultural heritage\n",
      "Cinema\n",
      "films affected\n",
      "Disney\n",
      "Education\n",
      "Ireland\n",
      "United Kingdom\n",
      "Events affected\n",
      "Fashion industry\n",
      "Music industry\n",
      "Performing arts\n",
      "Sports\n",
      "By country\n",
      "Ireland\n",
      "Philippines\n",
      "By sport\n",
      "association football\n",
      "cricket\n",
      "disc golf\n",
      "Gaelic games\n",
      "motorsport\n",
      "NBA\n",
      "rugby league\n",
      "Television\n",
      "U.S.\n",
      "programs affected\n",
      "Video games\n",
      "Society and rights\n",
      "Social\n",
      "social media\n",
      "stigma\n",
      "COVID-19 parties\n",
      "Children\n",
      "foster care in the United States\n",
      "Gender\n",
      "Healthcare workers\n",
      "Hospitals\n",
      "Human rights\n",
      "Legal\n",
      "abortion in the U.S.\n",
      "crime\n",
      "crime in Ireland\n",
      "domestic violence\n",
      "prisons\n",
      "U.S. immigration detention\n",
      "LGBT community\n",
      "Long-term care facilities\n",
      "Public transport\n",
      "Religion\n",
      "Catholic Church\n",
      "Hajj\n",
      "Strikes\n",
      "Xenophobia and racism\n",
      "Economic\n",
      "Aviation\n",
      "Airlines\n",
      "Cannabis industry\n",
      "Charitable activity\n",
      "Moldovan–Romanian collaboration\n",
      "COVID-19 recession\n",
      "Economic\n",
      "Canada\n",
      "India\n",
      "Ireland\n",
      "New Zealand\n",
      "U.K.\n",
      "U.S.\n",
      "Financial markets\n",
      "Food industry\n",
      "meat industry in Canada\n",
      "meat industry in the U.S.\n",
      "restaurant industry in the U.S.\n",
      "Global stock market crash\n",
      "Hospitals\n",
      "Mink farming\n",
      "Oil price war\n",
      "Retail\n",
      "Tourism\n",
      "Travel restrictions\n",
      "Information\n",
      "Journalism\n",
      "Media coverage\n",
      "Misinformation\n",
      "Governments\n",
      "China\n",
      "United States\n",
      "Plandemic\n",
      "Wikipedia's response\n",
      "Politics\n",
      "National responses\n",
      "Legislation\n",
      "Protests\n",
      "Italy\n",
      "Germany\n",
      "New Zealand\n",
      "Serbia\n",
      "United Kingdom\n",
      "United States\n",
      "International relations\n",
      "Italy\n",
      "Aid\n",
      "European Union\n",
      "Ireland\n",
      "Language\n",
      "Doomscrolling\n",
      "Flattening the curve\n",
      "Long-hauler\n",
      "Quarantini\n",
      "Social distancing\n",
      "Superspreader\n",
      "Zoom\n",
      "Others\n",
      "Anthropause\n",
      "Environment\n",
      "Military\n",
      "Science and technology\n",
      "Food security\n",
      "Health issuesMedical topics\n",
      "Transmission\n",
      "Symptoms\n",
      "Variants of SARS-CoV-2\n",
      "Cancer\n",
      "Skin manifestations\n",
      "Mental health\n",
      "Pregnancy\n",
      "Non-COVID-19-related health issues\n",
      "Shortages\n",
      "Raise the line\n",
      "Rehabilitation\n",
      "Unproven medical methods\n",
      "Testing andepidemiology\n",
      "Disease testing\n",
      "Breathalyzer\n",
      "Surveillance\n",
      "Death rates by country\n",
      "Datasets\n",
      "Coronavirus apps\n",
      "careFIJI\n",
      "COVID Alert\n",
      "COVIDSafe\n",
      "COVID Tracker Ireland\n",
      "Coronavirus Australia\n",
      "Aarogya Setu\n",
      "NZ COVID Tracer\n",
      "TraceTogether\n",
      "BlueTrace\n",
      "Decentralized Privacy-Preserving Proximity Tracing\n",
      "NHS COVID-19\n",
      "Nearby Spot\n",
      "SwissCovid\n",
      "TCN Protocol\n",
      "Exposure Notification\n",
      "Prevention\n",
      "Social distancing\n",
      "Face masks\n",
      "United States\n",
      "Flattening the curve\n",
      "Workplace hazard controls\n",
      "Lockdowns\n",
      "Evacuations\n",
      "Immunity passports\n",
      "International aid\n",
      "Safe Hands Challenge\n",
      "COVID fatigue\n",
      "Great Barrington Declaration\n",
      "Vaccines\n",
      "Ad5-nCoV\n",
      "BBIBP-CorV\n",
      "CoronaVac\n",
      "Covaxin\n",
      "Johnson & Johnson\n",
      "Moderna\n",
      "Oxford–AstraZeneca\n",
      "Pfizer–BioNTech\n",
      "RBD-Dimer\n",
      "Sputnik V\n",
      "V451\n",
      "Operation Warp Speed (U.S.)\n",
      "Vaccine development\n",
      "Vaccine deployment\n",
      "Albania\n",
      "Bulgaria\n",
      "Canada\n",
      "France\n",
      "India\n",
      "Ireland\n",
      "Israel\n",
      "Italy\n",
      "Philippines\n",
      "Romania\n",
      "Sweden\n",
      "United Kingdom\n",
      "Treatment\n",
      "Drug development\n",
      "Drug repurposing research\n",
      "Dexamethasone\n",
      "RECOVERY Trial (UK)\n",
      "Solidarity trial (WHO)\n",
      "Open-source ventilator\n",
      "Extracorporeal membrane oxygenation\n",
      "InstitutionsHospitals andrelated\n",
      "Hospital ships\n",
      "Central Hospital of Wuhan\n",
      "Dabie Mountain Regional Medical Centre\n",
      "Fangcang Hospitals\n",
      "Huoshenshan Hospital\n",
      "Wuhan Jinyintan Hospital\n",
      "Leishenshan Hospital\n",
      "Xinjia Express Hotel\n",
      "COVID-19 Hospital in Mumbai\n",
      "Kemayoran Athletes Village\n",
      "Malaysia Agro Exposition Park Serdang\n",
      "COVID-19 hospitals in the United Kingdom\n",
      "Canberra Coronavirus Field Hospital\n",
      "Hospital El Salvador\n",
      "Pyongyang General Hospital\n",
      "Sancaktepe Prof. Dr. Feriha Öz Emergency Hospital\n",
      "Yeşilköy Prof. Dr. Murat Dilmener Emergency Hospital\n",
      "We Heal As One Center\n",
      "Dragon's Heart Hospital\n",
      "NHS Nightingale Hospitals\n",
      "NHS Nightingale Hospital Birmingham\n",
      "NHS Nightingale Hospital London\n",
      "NHS Nightingale Hospital North East\n",
      "NHS Nightingale Hospital North West\n",
      "NHS Nightingale Hospital Yorkshire and the Humber\n",
      "NHS Louisa Jordan Hospital\n",
      "Kandakadu Treatment and Rehabilitation Centre\n",
      "Organizations\n",
      "Coalition for Epidemic Preparedness Innovations\n",
      "World Health Organization\n",
      "United Nations\n",
      "resolutions\n",
      "International Committee on Taxonomy of Viruses\n",
      "Wuhan Institute of Virology (China)\n",
      "Central Epidemic Command Center (Taiwan)\n",
      "Taiwan Centers for Disease Control (Taiwan)\n",
      "COVID-19 Response Acceleration Task Force (Indonesia)\n",
      "White House Coronavirus Task Force (United States)\n",
      "Great American Economic Revival Industry Groups (United States)\n",
      "Coronavirus Tech Handbook\n",
      "Inter-Agency Task Force on Emerging Infectious Diseases (Philippines)\n",
      "PM CARES Fund (India)\n",
      "Artist Relief (United States)\n",
      "Covid Watch\n",
      "SAARC COVID-19 Emergency Fund (India)\n",
      "Outbreak Management Team (Netherlands)\n",
      "COVID-19 Solidarity Response Fund\n",
      "MusiCares COVID-19 Relief Fund\n",
      "Imperial College COVID-19 Response Team (UK)\n",
      "SAGE (UK)\n",
      "Independent SAGE (UK)\n",
      "National Cabinet (Australia)\n",
      "National COVID-19 Coordination Commission (Australia)\n",
      "UN COVID-19 Supply Chain Task Force (WHO)\n",
      "COVID-19 Supply Council (Canada)\n",
      "PREPARE (European Union)\n",
      "National Public Health Emergency Team (Ireland)\n",
      "Africa Centres for Disease Control and Prevention (African Union)\n",
      "Ghana Infectious Disease Centre (Ghana)\n",
      "COVID-19 Immunity Task Force (Canada)\n",
      "Novel Coronavirus Expert Meeting (Japan)\n",
      "Coronavirus Scientific Advisory Board (Turkey)\n",
      "Crisis Preparedness and Response Centre (Malaysia)\n",
      "Korea Disease Control and Prevention Agency (Korea)\n",
      "PeopleMedical professionals\n",
      "Ai Fen\n",
      "Li Wenliang\n",
      "Liu Wen\n",
      "Corona Rintawan\n",
      "Xie Linka\n",
      "Zhang Wenhong\n",
      "Researchers\n",
      "Roberto Burioni\n",
      "Awang Bulgiba Awang Mahmud\n",
      "Chen Wei\n",
      "Andrea Crisanti\n",
      "Christian Drosten\n",
      "Neil Ferguson\n",
      "George F. Gao\n",
      "Azra Ghani\n",
      "Sarah Gilbert\n",
      "Guan Yi\n",
      "Kentaro Iwata\n",
      "Trudie Lang\n",
      "Li Lanjuan\n",
      "W. Ian Lipkin\n",
      "Ma Xiaowei\n",
      "Allison McGeer\n",
      "Luc Montagnier\n",
      "Shi Zhengli\n",
      "Moncef Slaoui\n",
      "John Todd\n",
      "Wang Chen\n",
      "Wang Guangfa\n",
      "Yuen Kwok-yung\n",
      "Zeng Guang\n",
      "Zhang Yongzhen\n",
      "Zhong Nanshan\n",
      "OfficialsWHO\n",
      "Tedros Adhanom (Director-General of the WHO)\n",
      "Bruce Aylward (Team lead of WHO-China COVID-19 mission)\n",
      "Maria Van Kerkhove (Technical Lead for COVID-19 response)\n",
      "Michael J. Ryan (Executive Director of the WHO Health Emergencies Programme)\n",
      "Countries\n",
      "Alma Möller (Iceland)\n",
      "Domenico Arcuri (Italy)\n",
      "Frank Atherton (Wales)\n",
      "Scott Atlas (United States)\n",
      "Deborah Birx (United States)\n",
      "Ashley Bloomfield (New Zealand)\n",
      "Angelo Borrelli (Italy)\n",
      "Catherine Calderwood (Scotland)\n",
      "Carmen Deseda (Puerto Rico)\n",
      "Jaap van Dissel (the Netherlands)\n",
      "Shan-chwen Chang (Taiwan)\n",
      "Chen Shih-chung (Taiwan)\n",
      "Chuang Yin-ching (Taiwan)\n",
      "Francisco Duque (Philippines)\n",
      "Anthony Fauci (United States)\n",
      "Graça Freitas (Portugal)\n",
      "Hamad Hasan (Lebanon)\n",
      "Tony Holohan (Ireland)\n",
      "Jeong Eun-kyeong (South Korea)\n",
      "Fahrettin Koca (Turkey)\n",
      "Li Keqiang (China)\n",
      "Michael McBride (Northern Ireland)\n",
      "Oriol Mitjà (Andorra)\n",
      "Doni Monardo (Indonesia)\n",
      "Noor Hisham Abdullah (Malaysia)\n",
      "Ali Pilli (Northern Cyprus)\n",
      "Jérôme Salomon (France)\n",
      "Fernando Simón (Spain)\n",
      "Gregor Smith (Scotland)\n",
      "Ih-Jen Su (Taiwan)\n",
      "Łukasz Szumowski (Poland)\n",
      "Theresa Tam (Canada)\n",
      "Anders Tegnell (Sweden)\n",
      "Sotiris Tsiodras (Greece)\n",
      "Víðir Reynisson (Iceland)\n",
      "Carla Vizzotti (Argentina)\n",
      "Vlad Voiculescu (Romania)\n",
      "Chris Whitty (United Kingdom)\n",
      "Lawrence Wong (Singapore)\n",
      "Þórólfur Guðnason (Iceland)\n",
      "Others\n",
      "Chen Qiushi\n",
      "Brett Crozier\n",
      "Fang Bin\n",
      "Fang Fang\n",
      "Li Zehua\n",
      "Qiu Menghuang\n",
      "Ren Zhiqiang\n",
      "Captain Tom\n",
      "DeathsListData (templates)Global\n",
      "Cases, deaths, recoveries by country\n",
      "Tests, cases, tests per capita, cases per capita by country\n",
      "Tests, cases, tests per capita, cases per capita by country subdivision\n",
      "WHO situation reports\n",
      "cases\n",
      "deaths\n",
      "World map by countries: confirmed per capita\n",
      "China\n",
      "Hospital beds by country\n",
      "Lockdowns\n",
      "Mainland China\n",
      "Africa\n",
      "Algeria\n",
      "chart\n",
      "Angola\n",
      "chart\n",
      "Burkina Faso\n",
      "chart\n",
      "Burundi\n",
      "chart\n",
      "Cameroon\n",
      "chart\n",
      "Egypt\n",
      "chart\n",
      "Eswatini\n",
      "chart\n",
      "Ethiopia\n",
      "chart\n",
      "Ghana\n",
      "chart\n",
      "Ivory Coast\n",
      "chart\n",
      "Kenya\n",
      "chart\n",
      "Libya\n",
      "chart\n",
      "Malawi\n",
      "chart\n",
      "Mali\n",
      "chart\n",
      "Mauritania\n",
      "chart\n",
      "Mauritius\n",
      "chart\n",
      "Morocco\n",
      "chart\n",
      "Nigeria\n",
      "chart\n",
      "Senegal\n",
      "chart\n",
      "Sierra Leone\n",
      "chart\n",
      "South Africa\n",
      "chart\n",
      "South Sudan\n",
      "chart\n",
      "Sudan\n",
      "chart\n",
      "Tanzania\n",
      "chart\n",
      "Togo\n",
      "chart\n",
      "Tunisia\n",
      "chart\n",
      "Americas\n",
      "Argentina\n",
      "chart\n",
      "Bolivia\n",
      "chart\n",
      "Brazil\n",
      "chart\n",
      "Canada\n",
      "by province\n",
      "chart\n",
      "Chile\n",
      "by commune\n",
      "chart\n",
      "Colombia\n",
      "chart\n",
      "Costa Rica\n",
      "chart\n",
      "Cuba\n",
      "chart\n",
      "Dominican Republic\n",
      "chart\n",
      "Ecuador\n",
      "chart\n",
      "El Salvador\n",
      "chart\n",
      "Guatemala\n",
      "chart\n",
      "Haiti\n",
      "chart\n",
      "Honduras\n",
      "chart\n",
      "Mexico\n",
      "chart\n",
      "Nicaragua\n",
      "chart\n",
      "Panama\n",
      "chart\n",
      "Paraguay\n",
      "chart\n",
      "Peru\n",
      "chart\n",
      "United States\n",
      "by state\n",
      "chart\n",
      "Uruguay\n",
      "chart\n",
      "Venezuela\n",
      "chart\n",
      "Asia\n",
      "Afghanistan\n",
      "chart\n",
      "Armenia\n",
      "chart\n",
      "Azerbaijan\n",
      "chart\n",
      "Bahrain\n",
      "chart\n",
      "Bangladesh\n",
      "chart\n",
      "Bhutan\n",
      "chart\n",
      "summary\n",
      "Brunei\n",
      "chart\n",
      "Cambodia\n",
      "chart\n",
      "summary\n",
      "Mainland China\n",
      "aggregate\n",
      "chart\n",
      "Georgia\n",
      "chart\n",
      "Hong Kong\n",
      "chart\n",
      "India\n",
      "chart\n",
      "summary\n",
      "Indonesia\n",
      "chart\n",
      "Iran\n",
      "chart\n",
      "Iraq\n",
      "chart\n",
      "Israel\n",
      "chart\n",
      "Japan\n",
      "chart\n",
      "Jordan\n",
      "chart\n",
      "Kazakhstan\n",
      "chart\n",
      "South Korea\n",
      "chart\n",
      "Kuwait\n",
      "graph\n",
      "chart\n",
      "Kyrgyzstan\n",
      "chart\n",
      "Laos\n",
      "chart\n",
      "Lebanon\n",
      "chart\n",
      "Malaysia\n",
      "chart\n",
      "Myanmar\n",
      "chart\n",
      "Nepal\n",
      "chart\n",
      "by district\n",
      "PCR tests\n",
      "Oman\n",
      "chart\n",
      "Pakistan\n",
      "chart\n",
      "Palestine\n",
      "chart\n",
      "Philippines\n",
      "chart\n",
      "areas of quarantine\n",
      "Qatar\n",
      "chart\n",
      "Russia/North Asia\n",
      "by federal subject\n",
      "chart\n",
      "Saudi Arabia\n",
      "chart\n",
      "Singapore\n",
      "chart\n",
      "Sri Lanka\n",
      "chart\n",
      "Syria\n",
      "chart\n",
      "Taiwan\n",
      "chart\n",
      "Tajikistan\n",
      "chart\n",
      "Thailand\n",
      "chart\n",
      "summary\n",
      "Turkey\n",
      "by province\n",
      "chart\n",
      "United Arab Emirates\n",
      "chart\n",
      "Uzbekistan\n",
      "chart\n",
      "Vietnam\n",
      "chart\n",
      "Yemen\n",
      "chart\n",
      "Europe(chart)\n",
      "Albania\n",
      "chart\n",
      "Austria\n",
      "chart\n",
      "Belarus\n",
      "chart\n",
      "Belgium\n",
      "chart\n",
      "Bosnia and Herzegovina\n",
      "chart\n",
      "Bulgaria\n",
      "chart\n",
      "Croatia\n",
      "chart\n",
      "Cyprus\n",
      "chart\n",
      "Czech Republic\n",
      "chart\n",
      "Denmark\n",
      "chart\n",
      "Estonia\n",
      "chart\n",
      "Faroe Islands\n",
      "chart\n",
      "Finland\n",
      "chart\n",
      "France\n",
      "chart\n",
      "Germany\n",
      "chart\n",
      "Greece\n",
      "chart\n",
      "Hungary\n",
      "chart\n",
      "Iceland\n",
      "chart\n",
      "Ireland\n",
      "chart\n",
      "Italy\n",
      "chart\n",
      "Kosovo\n",
      "chart\n",
      "Latvia\n",
      "chart\n",
      "Lithuania\n",
      "chart\n",
      "Luxembourg\n",
      "chart\n",
      "Malta\n",
      "chart\n",
      "Moldova\n",
      "chart\n",
      "Monaco\n",
      "chart\n",
      "Montenegro\n",
      "chart\n",
      "Netherlands\n",
      "chart\n",
      "North Macedonia\n",
      "chart\n",
      "Norway\n",
      "chart\n",
      "Poland\n",
      "chart\n",
      "Portugal\n",
      "chart\n",
      "Romania\n",
      "chart\n",
      "Russia\n",
      "by federal subject\n",
      "chart\n",
      "San Marino\n",
      "chart\n",
      "Serbia\n",
      "chart\n",
      "Slovakia\n",
      "by region\n",
      "chart\n",
      "Slovenia\n",
      "chart\n",
      "Spain\n",
      "chart\n",
      "Asturias\n",
      "Community of Madrid\n",
      "Sweden\n",
      "chart\n",
      "Switzerland\n",
      "chart\n",
      "Turkey\n",
      "by province\n",
      "chart\n",
      "Ukraine\n",
      "chart\n",
      "Donetsk People's Republic\n",
      "Luhansk People's Republic\n",
      "United Kingdom\n",
      "Scotland\n",
      "chart\n",
      "Vatican City\n",
      "chart\n",
      "Oceania\n",
      "Australia\n",
      "chart\n",
      "by state/territory\n",
      "Fiji\n",
      "chart\n",
      "French Polynesia\n",
      "chart\n",
      "New Caledonia\n",
      "chart\n",
      "New Zealand\n",
      "chart\n",
      "Papua New Guinea\n",
      "chart\n",
      "Solomon Islands\n",
      "Solomon Islands\n",
      "Others\n",
      "Cruise ships\n",
      "Diamond Princess\n",
      "\n",
      " Category\n",
      " Portal\n",
      "\n",
      "vteArtificial induction of immunity / Immunization: Vaccines, Vaccination, Infection, Inoculation (J07)Development\n",
      "Adjuvants\n",
      "List of vaccine ingredients\n",
      "Mathematical modelling\n",
      "Timeline\n",
      "Trials\n",
      "Classes\n",
      "Conjugate vaccine\n",
      "Inactivated vaccine\n",
      "Live vaccine\n",
      "Attenuated vaccine\n",
      "Heterologous vaccine\n",
      "Subunit/component / Peptide / Virus-like particle / Synthetic\n",
      "DNA / RNA\n",
      "Toxoid\n",
      "Administration\n",
      "Global:\n",
      "GAVI Alliance\n",
      "NITAG\n",
      "Policy\n",
      "Schedule\n",
      "Vaccine injury\n",
      "US:\n",
      "ACIP\n",
      "Vaccine court\n",
      "Vaccines for Children Program\n",
      "VAERS\n",
      "VSD\n",
      "VaccinesBacterial\n",
      "Anthrax\n",
      "Brucellosis\n",
      "Cholera#\n",
      "Diphtheria#\n",
      "Hib#\n",
      "Leptospirosis\n",
      "Lyme disease‡\n",
      "Meningococcus#\n",
      "MeNZB\n",
      "NmVac4-A/C/Y/W-135\n",
      "Pertussis#\n",
      "Plague\n",
      "Pneumococcal#\n",
      "PCV\n",
      "PPSV\n",
      "Q fever\n",
      "Tetanus#\n",
      "Tuberculosis\n",
      "BCG#\n",
      "Typhoid#\n",
      "Ty21a\n",
      "ViCPS\n",
      "Typhus\n",
      "combination:\n",
      "DPT/DTwP/DTaP\n",
      "Td/Tdap\n",
      "research:\n",
      "Clostridioides difficile\n",
      "Group B streptococcal disease\n",
      "Shigellosis\n",
      "Viral\n",
      "Adenovirus\n",
      "Ebola\n",
      "Flu#\n",
      "H1N1 (Pandemrix)\n",
      "H5N1\n",
      "LAIV\n",
      "Hantavirus\n",
      "Hepatitis A#\n",
      "Hepatitis B#\n",
      "Hepatitis E\n",
      "HPV\n",
      "Cervarix\n",
      "Gardasil\n",
      "Japanese encephalitis#\n",
      "Measles#\n",
      "Mumps#\n",
      "Mumpsvax\n",
      "Polio#\n",
      "Sabin\n",
      "Salk\n",
      "Rabies#\n",
      "Rotavirus#\n",
      "Rubella#\n",
      "SARS-CoV-2\n",
      "BBIBP-CorV†\n",
      "Convidicea†\n",
      "CoronaVac†\n",
      "Covaxin†\n",
      "EpiVacCorona†\n",
      "Johnson & Johnson†\n",
      "Moderna†\n",
      "Oxford–AstraZeneca†\n",
      "Pfizer–BioNTech†\n",
      "Sputnik V†\n",
      "Smallpox\n",
      "Dryvax\n",
      "Tick-borne encephalitis\n",
      "Varicella zoster\n",
      "Chicken pox#\n",
      "Shingles\n",
      "Yellow fever#\n",
      "combination:\n",
      "Hepatitis A and B\n",
      "MMR\n",
      "MMRV\n",
      "research:\n",
      "Chikungunya\n",
      "Cytomegalovirus\n",
      "Dengue\n",
      "Ebola\n",
      "Epstein–Barr virus\n",
      "Hepatitis C\n",
      "Herpes simplex\n",
      "HIV\n",
      "Respiratory syncytial virus\n",
      "Zika\n",
      "Protozoan\n",
      "Malaria\n",
      "RTS,S\n",
      "research:\n",
      "Trypanosomiasis\n",
      "Helminthiasis\n",
      "research:\n",
      "Hookworm\n",
      "Schistosomiasis\n",
      "Other\n",
      "Androvax (androstenedione albumin)\n",
      "Cancer vaccines\n",
      "ALVAC-CEA\n",
      "BCG#\n",
      "Hepatitis B#\n",
      "HPV\n",
      "Cervarix\n",
      "Gardasil\n",
      "Prostvac\n",
      "NicVAX\n",
      "Ovandrotone albumin (Fecundin)\n",
      "TA-CD\n",
      "TA-NIC\n",
      "combination:\n",
      "DTaP-IPV/Hib\n",
      "DTaP-IPV-HepB\n",
      "Hexavalent vaccine\n",
      "Pentavalent vaccine\n",
      "Inventors/researchers\n",
      "Edward Jenner\n",
      "Louis Pasteur\n",
      "Hilary Koprowski\n",
      "Jonas Salk\n",
      "John Franklin Enders\n",
      "Maurice Hilleman\n",
      "Stanley Plotkin\n",
      "H. Fred Clark\n",
      "Paul Offit\n",
      "Anthony Fauci\n",
      "Controversy\n",
      "General\n",
      "MMR (Lancet MMR autism fraud)\n",
      "NCVIA\n",
      "Infection party\n",
      "Pox\n",
      "Flu\n",
      "CoV\n",
      "Thiomersal\n",
      "Vaccines and SIDS\n",
      "Cedillo v. Secretary of Health and Human Services\n",
      "Alternative vaccination schedule\n",
      "Related\n",
      "Epidemiology\n",
      "Eradication of infectious diseases\n",
      "Every Child by Two\n",
      "List of vaccine topics\n",
      "\n",
      "#WHO-EM\n",
      "‡Withdrawn from market\n",
      "Clinical trials:\n",
      "†Phase III\n",
      "§Never to phase III\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Retrieved from \"https://en.wikipedia.org/w/index.php?title=COVID-19_vaccine&oldid=1010386361\"\n",
      "Categories: COVID-19 vaccinesMedical researchMedical responses to the COVID-19 pandemicHidden categories: Pages with non-numeric formatnum argumentsCS1 maint: uses authors parameterCS1 Spanish-language sources (es)CS1 German-language sources (de)CS1 Portuguese-language sources (pt)CS1 Danish-language sources (da)CS1 Icelandic-language sources (is)CS1 Norwegian Bokmål-language sources (nb)CS1 Serbian-language sources (sr)CS1 Russian-language sources (ru)Articles with short descriptionShort description is different from WikidataWikipedia indefinitely semi-protected pagesUse dmy dates from December 2020Articles containing potentially dated statements from February 2021All articles containing potentially dated statementsArticles containing potentially dated statements from March 2021Articles with excerptsArticles containing potentially dated statements from January 2021All articles with unsourced statementsArticles with unsourced statements from March 2021All articles lacking reliable referencesArticles lacking reliable references from March 2021Articles containing potentially dated statements from September 2020Articles with limited geographic scope from December 2020\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Navigation menu\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Personal tools\n",
      "\n",
      "\n",
      "Not logged inTalkContributionsCreate accountLog in\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Namespaces\n",
      "\n",
      "\n",
      "ArticleTalk\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Variants\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Views\n",
      "\n",
      "\n",
      "ReadView sourceView history\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "More\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Search\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Navigation\n",
      "\n",
      "\n",
      "Main pageContentsCurrent eventsRandom articleAbout WikipediaContact usDonate\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Contribute\n",
      "\n",
      "\n",
      "HelpLearn to editCommunity portalRecent changesUpload file\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Tools\n",
      "\n",
      "\n",
      "What links hereRelated changesUpload fileSpecial pagesPermanent linkPage informationCite this pageWikidata item\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Print/export\n",
      "\n",
      "\n",
      "Download as PDFPrintable version\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "In other projects\n",
      "\n",
      "\n",
      "Wikimedia Commons\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Languages\n",
      "\n",
      "\n",
      "العربيةAzərbaycancaবাংলাBosanskiCatalàČeštinaDanskDeutschEestiΕλληνικάEspañolEuskaraفارسیFrançaisGalego한국어हिन्दीHrvatskiBahasa IndonesiaItalianoעבריתಕನ್ನಡLietuviųLumbaartMagyarമലയാളംمصرىဘာသာ မန်Bahasa MelayuNederlands日本語Norsk bokmålپنجابیPolskiPortuguêsRomânăРусскийShqipසිංහලSimple EnglishسنڌيSlovenčinaکوردیСрпски / srpskiSuomiSvenskaதமிழ்TaqbaylitไทยTürkçeУкраїнськаاردوئۇيغۇرچە / UyghurcheTiếng ViệtXitsonga粵語中文\n",
      "Edit links\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " This page was last edited on 5 March 2021, at 05:39 (UTC).\n",
      "Text is available under the Creative Commons Attribution-ShareAlike License;\n",
      "additional terms may apply.  By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.\n",
      "\n",
      "\n",
      "Privacy policy\n",
      "About Wikipedia\n",
      "Disclaimers\n",
      "Contact Wikipedia\n",
      "Mobile view\n",
      "Developers\n",
      "Statistics\n",
      "Cookie statement\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "(RLQ=window.RLQ||[]).push(function(){mw.config.set({\"wgPageParseReport\":{\"limitreport\":{\"cputime\":\"8.093\",\"walltime\":\"9.538\",\"ppvisitednodes\":{\"value\":61285,\"limit\":1000000},\"postexpandincludesize\":{\"value\":1748352,\"limit\":2097152},\"templateargumentsize\":{\"value\":68475,\"limit\":2097152},\"expansiondepth\":{\"value\":20,\"limit\":40},\"expensivefunctioncount\":{\"value\":147,\"limit\":500},\"unstrip-depth\":{\"value\":1,\"limit\":20},\"unstrip-size\":{\"value\":1825110,\"limit\":5000000},\"entityaccesscount\":{\"value\":0,\"limit\":400},\"timingprofile\":[\"100.00% 7990.676      1 -total\",\" 48.52% 3877.138      3 Template:Reflist\",\" 25.92% 2070.947      1 Template:COVID-19_vaccination_data\",\" 23.25% 1857.643    123 Template:Flag+link\",\" 19.53% 1560.344    290 Template:Cite_web\",\" 10.01%  799.730    150 Template:Cite_news\",\"  9.42%  752.955     71 Template:Cite_journal\",\"  4.94%  394.688     10 Template:Iso2country\",\"  4.37%  349.141     10 Template:Iso2country/article\",\"  4.26%  340.609     10 Template:ISO_3166_code\"]},\"scribunto\":{\"limitreport-timeusage\":{\"value\":\"4.480\",\"limit\":\"10.000\"},\"limitreport-memusage\":{\"value\":12325950,\"limit\":52428800},\"limitreport-logs\":\"table#1 {\\n  [\\\"size\\\"] = \\\"tiny\\\",\\n  [\\\"text\\\"] = \\\"COVID-19 Portal\\\",\\n}\\n\",\"limitreport-profile\":[[\"Scribunto_LuaSandboxCallback::getAllExpandedArguments\",\"540\",\"10.8\"],[\"Scribunto_LuaSandboxCallback::gsub\",\"520\",\"10.4\"],[\"dataWrapper \\u003Cmw.lua:661\\u003E\",\"500\",\"10.0\"],[\"Scribunto_LuaSandboxCallback::expandTemplate\",\"480\",\"9.6\"],[\"Scribunto_LuaSandboxCallback::match\",\"320\",\"6.4\"],[\"?\",\"280\",\"5.6\"],[\"Scribunto_LuaSandboxCallback::callParserFunction\",\"260\",\"5.2\"],[\"Scribunto_LuaSandboxCallback::find\",\"220\",\"4.4\"],[\"Scribunto_LuaSandboxCallback::plain\",\"180\",\"3.6\"],[\"recursiveClone \\u003CmwInit.lua:41\\u003E\",\"180\",\"3.6\"],[\"[others]\",\"1540\",\"30.7\"]]},\"cachereport\":{\"origin\":\"mw1371\",\"timestamp\":\"20210305123346\",\"ttl\":2592000,\"transientcontent\":false}}});});\n",
      "{\"@context\":\"https:\\/\\/schema.org\",\"@type\":\"Article\",\"name\":\"COVID-19 vaccine\",\"url\":\"https:\\/\\/en.wikipedia.org\\/wiki\\/COVID-19_vaccine\",\"sameAs\":\"http:\\/\\/www.wikidata.org\\/entity\\/Q87719492\",\"mainEntity\":\"http:\\/\\/www.wikidata.org\\/entity\\/Q87719492\",\"author\":{\"@type\":\"Organization\",\"name\":\"Contributors to Wikimedia projects\"},\"publisher\":{\"@type\":\"Organization\",\"name\":\"Wikimedia Foundation, Inc.\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\/\\/www.wikimedia.org\\/static\\/images\\/wmf-hor-googpub.png\"}},\"datePublished\":\"2020-03-08T17:51:40Z\",\"dateModified\":\"2021-03-05T05:39:40Z\",\"image\":\"https:\\/\\/upload.wikimedia.org\\/wikipedia\\/commons\\/7\\/72\\/World_map_of_COVID-19_vaccination_doses_administered_per_100_people_by_country_or_territory.png\",\"headline\":\"vaccine against SARS-CoV-2 coronavirus\"}\n",
      "(RLQ=window.RLQ||[]).push(function(){mw.config.set({\"wgBackendResponseTime\":225,\"wgHostname\":\"mw1352\"});});\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "/* <![CDATA[ */\n",
      ".panels-flexible-region{padding:0}.panels-flexible-region-inside{padding-right:.5em;padding-left:.5em}.panels-flexible-region-inside-first{padding-left:0}.panels-flexible-region-inside-last{padding-right:0}.panels-flexible-column{padding:0}.panels-flexible-column-inside{padding-right:.5em;padding-left:.5em}.panels-flexible-column-inside-first{padding-left:0}.panels-flexible-column-inside-last{padding-right:0}.panels-flexible-row{padding:0 0 .5em 0;margin:0}.panels-flexible-row-last{padding-bottom:0}.panels-flexible-column-new-main{float:left;width:99.0000%}.panels-flexible-new-inside{padding-right:0}.panels-flexible-new{width:auto}.panels-flexible-region-new-center{float:left;width:99.0000%}.panels-flexible-row-new-main-row-inside{padding-right:0}\n",
      "/* ]]> */\n",
      "\n",
      "\n",
      "\n",
      "/* <![CDATA[ */\n",
      ".panels-flexible-region{padding:0}.panels-flexible-region-inside{padding-right:.5em;padding-left:.5em}.panels-flexible-region-inside-first{padding-left:0}.panels-flexible-region-inside-last{padding-right:0}.panels-flexible-column{padding:0}.panels-flexible-column-inside{padding-right:.5em;padding-left:.5em}.panels-flexible-column-inside-first{padding-left:0}.panels-flexible-column-inside-last{padding-right:0}.panels-flexible-row{padding:0 0 .5em 0;margin:0}.panels-flexible-row-last{padding-bottom:0}.panels-flexible-column-new-main{float:left;width:99.0000%}.panels-flexible-new-inside{padding-right:0}.panels-flexible-new{width:auto}.panels-flexible-region-new-center{float:left;width:99.0000%}.panels-flexible-row-new-main-row-inside{padding-right:0}\n",
      "/* ]]> */\n",
      "\n",
      "\n",
      "Model-informed COVID-19 vaccine prioritization strategies by age and serostatus | Science\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "<!--//--><![CDATA[//><!--\n",
      "AAASdataLayer = {\"page\":{\"pageInfo\":{\"pageTitle\":\"Model-informed COVID-19 vaccine prioritization strategies by age and serostatus\",\"pageURL\":\"science.sciencemag.org/content/371/6532/916\",\"pagePath\":\"916\",\"pageType\":\"journal page\",\"issueDate\":\"2021-02-26\",\"pubDate\":\"2021-02-25 10:41:01\",\"nlmArticleType\":\"research-article\",\"DOI\":\"10.1126/science.abe6959\",\"author\":\"Kate M. Bubar|Kyle Reinholt|Stephen M. Kissler|Marc Lipsitch|Sarah Cobey|Yonatan H. Grad|Daniel B. Larremore\",\"firstRelease\":\"no\",\"issnOnline\":\"1095-9203\",\"issnPrint\":\"0036-8075\",\"volume\":\"371\",\"issue\":\"6532\",\"articleType\":\"Research Article\",\"tabView\":\"main_tab\",\"viewType\":\"full\"},\"attributes\":{\"accessType\":\"Free\",\"openAccess\":\"yes\",\"freeAccess\":\"yes\",\"subject\":\"\",\"fieldCode\":\"EPIDEMIOLOGY\",\"OAS_subject\":\"subject=EPIDEMIOLOGY;\"}},\"user\":{\"memberID\":\"\",\"institutionID\":\"\",\"institution\":\"\",\"accessMethod\":\"guest\",\"registeredUser\":\"no\",\"authenticated\":\"no\",\"access\":\"yes\",\"entitled\":\"no\"}}\n",
      "//--><!]]>\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "      /*! loadCSS. [c]2017 Filament Group, Inc. MIT License */\n",
      "      !function(a){\"use strict\";var b=function(b,c,d){function e(a){return h.body?a():void setTimeout(function(){e(a)})}function f(){i.addEventListener&&i.removeEventListener(\"load\",f),i.media=d||\"all\"}var g,h=a.document,i=h.createElement(\"link\");if(c)g=c;else{var j=(h.body||h.getElementsByTagName(\"head\")[0]).childNodes;g=j[j.length-1]}var k=h.styleSheets;i.rel=\"stylesheet\",i.href=b,i.media=\"only x\",e(function(){g.parentNode.insertBefore(i,c?g:g.nextSibling)});var l=function(a){for(var b=i.href,c=k.length;c--;)if(k[c].href===b)return a();setTimeout(function(){l(a)})};return i.addEventListener&&i.addEventListener(\"load\",f),i.onloadcssdefined=l,l(f),i};\"undefined\"!=typeof exports?exports.loadCSS=b:a.loadCSS=b}(\"undefined\"!=typeof global?global:this);\n",
      "/*! loadCSS rel=preload polyfill. [c]2017 Filament Group, Inc. MIT License */\n",
      "!function(a){if(a.loadCSS){var b=loadCSS.relpreload={};if(b.support=function(){try{return a.document.createElement(\"link\").relList.supports(\"preload\")}catch(b){return!1}},b.poly=function(){for(var b=a.document.getElementsByTagName(\"link\"),c=0;c<b.length;c++){var d=b[c];\"preload\"===d.rel&&\"style\"===d.getAttribute(\"as\")&&(a.loadCSS(d.href,d,d.getAttribute(\"media\")),d.rel=null)}},!b.support()){b.poly();var c=a.setInterval(b.poly,300);a.addEventListener&&a.addEventListener(\"load\",function(){b.poly(),a.clearInterval(c)}),a.attachEvent&&a.attachEvent(\"onload\",function(){a.clearInterval(c)})}}}(this);\n",
      "    \n",
      "\n",
      "      /*! CSS rel=preload polyfill. Depends on loadCSS function. [c]2016 @scottjehl, Filament Group, Inc. Licensed MIT  */\n",
      "(function( w ){\n",
      "  // rel=preload support test\n",
      "  if( !w.loadCSS ){\n",
      "    return;\n",
      "  }\n",
      "  var rp = loadCSS.relpreload = {};\n",
      "  rp.support = function(){\n",
      "    try {\n",
      "      return w.document.createElement( \"link\" ).relList.supports( \"preload\" );\n",
      "    } catch (e) {\n",
      "      return false;\n",
      "    }\n",
      "  };\n",
      "\n",
      "  // loop preload links and fetch using loadCSS\n",
      "  rp.poly = function(){\n",
      "    var links = w.document.getElementsByTagName( \"link\" );\n",
      "    for( var i = 0; i < links.length; i++ ){\n",
      "      var link = links[ i ];\n",
      "      if( link.rel === \"preload\" && link.getAttribute( \"as\" ) === \"style\" ){\n",
      "        w.loadCSS( link.href, link );\n",
      "        link.rel = null;\n",
      "      }\n",
      "    }\n",
      "  };\n",
      "\n",
      "  // if link[rel=preload] is not supported, we must fetch the CSS manually using loadCSS\n",
      "  if( !rp.support() ){\n",
      "    rp.poly();\n",
      "    var run = w.setInterval( rp.poly, 300 );\n",
      "    if( w.addEventListener ){\n",
      "      w.addEventListener( \"load\", function(){\n",
      "        w.clearInterval( run );\n",
      "      } );\n",
      "    }\n",
      "    if( w.attachEvent ){\n",
      "      w.attachEvent( \"onload\", function(){\n",
      "        w.clearInterval( run );\n",
      "      } )\n",
      "    }\n",
      "  }\n",
      "}( this ));\n",
      "    \n",
      "\n",
      "\n",
      "Skip to main content\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "AAAS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "ScienceMag.org\n",
      "\n",
      "\n",
      "\n",
      "Search\n",
      "\n",
      "\n",
      "Search\n",
      "\n",
      "\n",
      "X\n",
      "\n",
      "\n",
      "\n",
      "Advanced Search\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Science\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Contents\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "News\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Careers\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Journals\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Menu\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Read our COVID-19 research and news.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "          share        \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Research Article\n",
      "Model-informed COVID-19 vaccine prioritization strategies by age and serostatus\n",
      "\n",
      "View ORCID ProfileKate M. Bubar1,2,*, Kyle Reinholt3, Stephen M. Kissler4, View ORCID ProfileMarc Lipsitch4,5, View ORCID ProfileSarah Cobey6, View ORCID ProfileYonatan H. Grad4, View ORCID ProfileDaniel B. Larremore3,7,*1Department of Applied Mathematics, University of Colorado Boulder, Boulder, CO 80309, USA.2IQ Biology Program, University of Colorado Boulder, Boulder, CO 80303, USA.3Department of Computer Science, University of Colorado Boulder, Boulder, CO 80309, USA.4Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.5Center for Communicable Disease Dynamics, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.6Department of Ecology and Evolution, University of Chicago, Chicago, IL 60637, USA.7BioFrontiers Institute, University of Colorado Boulder, Boulder, CO 80303, USA.↵*Correspondng author. E-mail: kate.bubar{at}colorado.edu (K.M.B.); daniel.larremore{at}colorado.edu (D.B.L.)\n",
      "\n",
      "\n",
      "\n",
      " See allHide authors and affiliations\n",
      "\n",
      "\n",
      "\n",
      "Science  26 Feb 2021:Vol. 371, Issue 6532, pp. 916-921DOI: 10.1126/science.abe6959      \n",
      "\n",
      "Kate M. Bubar 1Department of Applied Mathematics, University of Colorado Boulder, Boulder, CO 80309, USA.2IQ Biology Program, University of Colorado Boulder, Boulder, CO 80303, USA.Find this author on Google Scholar\n",
      "Find this author on PubMed\n",
      "Search for this author on this site\n",
      "ORCID record for Kate M. Bubar \n",
      "For correspondence: \n",
      "kate.bubar@colorado.edu\n",
      "daniel.larremore@colorado.edu\n",
      "Kyle Reinholt 3Department of Computer Science, University of Colorado Boulder, Boulder, CO 80309, USA.Find this author on Google Scholar\n",
      "Find this author on PubMed\n",
      "Search for this author on this site\n",
      "Stephen M. Kissler 4Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.Find this author on Google Scholar\n",
      "Find this author on PubMed\n",
      "Search for this author on this site\n",
      "Marc Lipsitch 4Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.5Center for Communicable Disease Dynamics, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.Find this author on Google Scholar\n",
      "Find this author on PubMed\n",
      "Search for this author on this site\n",
      "ORCID record for Marc Lipsitch \n",
      "Sarah Cobey 6Department of Ecology and Evolution, University of Chicago, Chicago, IL 60637, USA.Find this author on Google Scholar\n",
      "Find this author on PubMed\n",
      "Search for this author on this site\n",
      "ORCID record for Sarah Cobey \n",
      "Yonatan H. Grad 4Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.Find this author on Google Scholar\n",
      "Find this author on PubMed\n",
      "Search for this author on this site\n",
      "ORCID record for Yonatan H. Grad \n",
      "Daniel B. Larremore 3Department of Computer Science, University of Colorado Boulder, Boulder, CO 80309, USA.7BioFrontiers Institute, University of Colorado Boulder, Boulder, CO 80303, USA.Find this author on Google Scholar\n",
      "Find this author on PubMed\n",
      "Search for this author on this site\n",
      "ORCID record for Daniel B. Larremore \n",
      "For correspondence: \n",
      "kate.bubar@colorado.edu\n",
      "daniel.larremore@colorado.edu\n",
      " \n",
      "\n",
      "\n",
      "Article\n",
      "Figures & Data\n",
      "Info & Metrics\n",
      "eLetters\n",
      " PDF\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Vaccine prioritizationThere is likely to be high demand for the limited supplies of vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), so how should vaccine distribution be prioritized? Bubar et al. modeled across countries how uncertainty about a vaccine's characteristics affects prioritization strategies for reducing deaths and transmission (see the Perspective by Fitzpatrick and Galvani). In the model, vaccine efficacy and its ability to reduce disease and/or block transmission was accounted for in relation to age-related variations in susceptibility, fatality rates, and immune decline. In almost all circumstances, reducing fatalities required distributing the vaccine to those who are most at risk of death, usually persons over 60 years of age and those with comorbidities. If a vaccine is leaky or poorly efficacious in older adults, then priority could be given to younger age groups. To increase the available doses, further priority should be given to seronegative individuals.Science, this issue p. 916; see also p. 890AbstractLimited initial supply of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine raises the question of how to prioritize available doses. We used a mathematical model to compare five age-stratified prioritization strategies. A highly effective transmission-blocking vaccine prioritized to adults ages 20 to 49 years minimized cumulative incidence, but mortality and years of life lost were minimized in most scenarios when the vaccine was prioritized to adults greater than 60 years old. Use of individual-level serological tests to redirect doses to seronegative individuals improved the marginal impact of each dose while potentially reducing existing inequities in COVID-19 impact. Although maximum impact prioritization strategies were broadly consistent across countries, transmission rates, vaccination rollout speeds, and estimates of naturally acquired immunity, this framework can be used to compare impacts of prioritization strategies across contexts.Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a public health and economic crisis worldwide. As of January 2021, there have been more than 85 million cases and 1.8 million deaths reported (1). To combat this crisis, a variety of nonpharmaceutical interventions have been implemented, including shelter-in-place orders, limited travel, and remote schooling. Although these efforts are essential to slowing transmission in the short term, long-term solutions—such as vaccines that protect from SARS-CoV-2 infection—remain urgently needed. The benefits of an effective vaccine for individuals and their communities have resulted in widespread demand, so it is critical that decision-making on vaccine distribution is well motivated, particularly in the initial phases when vaccine availability is limited (2).We used a model-informed approach to quantify the impact of COVID-19 vaccine prioritization strategies on cumulative incidence, mortality, and years of life lost. Our approach explicitly addresses variation in three areas that can influence the outcome of vaccine distribution decisions. First, we considered variation in the performance of the vaccine, including its overall efficacy, a hypothetical decrease in efficacy by age, and the vaccine’s ability to block transmission. Second, we considered variation in both susceptibility to infection and the infection fatality rate by age. Third, we considered variation in the population and policy—including the age distribution, age-stratified contact rates, and initial fraction of seropositive individuals by age—and the speed and timing of the vaccine’s rollout relative to transmission. Although the earliest doses of vaccines will be given to front-line health care workers under plans such as those from the COVAX initiative and the U.S. National Academies of Sciences, Engineering, and Medicine (NASEM) recommendations (3), our work is focused on informing the prioritization of the doses that follow. On the basis of regulatory approvals and initial vaccine rollout speeds of early 2021, our investigation focuses generally on scenarios with a partially mitigated pandemic [reproduction number (R) between 1.1 and 2.0], vaccines with protective efficacy of 90%, and rollout speeds of 0.2% of the population per day.There are two main approaches to vaccine prioritization: (i) directly vaccinate those at highest risk for severe outcomes and (ii) protect them indirectly by vaccinating those who do the most transmitting. Model-based investigations of the trade-offs between these strategies for influenza vaccination have led to recommendations that children be vaccinated because of their critical role in transmission (4, 5) and have shown that direct protection is superior when reproduction numbers are high but indirect protection is superior when transmission is low (6). Similar modeling for COVID-19 vaccination has found that the optimal balance between direct and indirect protection depends on both vaccine efficacy and supply, recommending direct vaccination of older adults for low-efficacy vaccines and for high-efficacy but supply-limited vaccines (7). Rather than comparing prioritization strategies, others have compared hypothetical vaccines, showing that even those with lower efficacy for direct protection may be more valuable if they also provide better indirect protection by blocking transmission (8). Prioritization of transmission-blocking vaccines can also be dynamically updated on the basis of the current state of the epidemic, shifting prioritization to avoid decreasing marginal returns (9). These efforts to prioritize and optimize doses complement other work showing that under different vaccine efficacy and durability of immunity, the economic and health benefits of COVID-19 vaccines will be large in the short and medium terms (10). The problem of vaccine prioritization also parallels the more general problem of optimal resource allocation to reduce transmission, such as with masks (11).Evaluation of vaccine prioritization strategiesWe evaluated the impact of vaccine prioritization strategies using an age-stratified SEIR model (susceptible, exposed, infectious, recovered) because age has been shown to be an important correlate of susceptibility (12–14), seroprevalence (12, 15), severity (16–18), and mortality (19, 20). This model includes an age-dependent contact matrix, susceptibility to infection, and infection fatality rate (IFR), allowing us to estimate cumulative incidence of SARS-CoV-2 infections, mortality due to infection, and years of life lost (YLL) (supplementary materials, materials and methods) by means of forward simulations of 1 year of disease dynamics. Cumulative incidence, mortality, and YLL were then used as outcomes by which to compare vaccine prioritization strategies. These comparisons may be explored by using accompanying open-source and interactive calculation tools that accompany this study (21).We first examined the impact of five vaccine prioritization strategies for a hypothetical infection- and transmission-blocking vaccine of varying efficacy. The strategies prioritized vaccines to (i) children and teenagers, (ii) adults between ages 20 and 49 years, (iii) adults 20 years or older, (iv) adults 60 years or older, and (v) all individuals (Fig. 1A). In all strategies, once the prioritized population was vaccinated, vaccines were allocated irrespective of age—that is, in proportion to their numbers in the population. To incorporate vaccine hesitancy, at most 70% of any age group was eligible to be vaccinated (22).\n",
      "\n",
      " \n",
      " Download high-res image\n",
      " Open in new tab\n",
      " Download Powerpoint\n",
      " \n",
      "\n",
      "\n",
      "Fig. 1 Impacts of vaccine prioritization strategies on mortality and infections.(A) Distribution of vaccines for five prioritization strategies: under 20 years, adults 20 to 49 years, adults 20+ years, adults 60+ years, and all ages. (B, C, F, and G) Example simulation curves show [(B) and (C)] percentage of the total population infected over time and [(F) and (G)] cumulative mortality for no vaccines (gray dashed lines) and for five different prioritization strategies [colored lines matching (A)], with [(B) and (F)] 10% and [(C) and (G)] 30% vaccine supply. (D, E, H, and I) Summary curves show percent reductions in [(D) and (E)] infections and [(H) and (I)] deaths in comparison to an unmitigated outbreak for vaccine supplies between 1 and 50% after 365 days of simulation. Squares and diamonds show how the outputs from single simulations [(F) and (G)] correspond to points in summary curves (H). Gray shading indicates the period during which vaccine is being rolled out at 0.2% of total population per day. Black dots indicate break points at which prioritized demographic groups have been 70% vaccinated, after which vaccines are distributed without prioritization. These simulations assume contact patterns and demographics of the United States (38, 53) and an all-or-nothing, transmission-blocking vaccine with 90% vaccine efficacy and R0 = 1.5 (scenario 2) and R0 = 1.15 (scenario 1). \n",
      "We measured reductions in cumulative incidence, mortality, and YLL achieved by each strategy, varying the vaccine supply between 1 and 50% of the total population, under two scenarios. In scenario 1, vaccines were administered to 0.2% of the population per day until supply was exhausted, with basic reproduction number (R0) = 1.15, representing highly mitigated spread during vaccine rollout. In scenario 2, vaccines were administered to 0.2% of the population per day until supply was exhausted, but with R0 = 1.5, representing substantial viral growth during vaccine rollout (example model outputs are provided in Fig. 1). Results for additional scenarios in which vaccines were administered before transmission began are described in the supplementary materials, supplementary text, corresponding to countries without ongoing community spread such as South Korea and New Zealand. We considered two ways in which vaccine efficacy (ve) could be below 100%: an all-or-nothing vaccine, in which the vaccine provides perfect protection to a fraction ve of individuals who receive it, or as a leaky vaccine, in which all vaccinated individuals have reduced probability ve of infection after vaccination (supplementary materials, materials and methods).Of the five strategies, direct vaccination of adults older than 60 years of age (60+) always reduced mortality and YLL more than the alternative strategies when transmission was high [R0 = 1.5, scenario 2, 90% efficacy (Fig. 1); 30 to 100% efficacy (fig. S5)]. For lower transmission (R0 = 1.15, scenario 1), vaccination of adults aged 20 to 49 years reduced mortality and YLL more than the alternative strategies, but differences between prioritization of adults aged 20 to 49 years, 20+ years, and 60+ years were small for vaccine supplies above 25% (Fig. 1 and fig. S5). Prioritizing adults aged 20 to 49 years minimized cumulative incidence in both scenarios for all vaccine efficacies (Fig. 1 and fig. S5). Prioritizing adults aged 20 to 49 years also minimized cumulative incidence in both scenarios under alternative rollout speeds (0.05 to 1% vaccinated per day) (fig. S6). When rollout speeds were at least 0.3% per day and vaccine supply covered at least 25% of the population, the mortality-minimizing strategy shifted from prioritization of ages 20 to 49 years to adults aged 20+ or 60+ years for scenario 1; when rollout speeds were at least 0.75% per day and covered at least 24% of the population, the mortality-minimizing strategy shifted from prioritization of adults aged 60+ years to adults aged 20+ or 20 to 49 years for scenario 2 (fig. S6). Findings for mortality and YLL were only slightly changed by modeling vaccine efficacy as all or nothing (fig. S5) or leaky (fig. S7).Impact of transmission rates, age demographics, and contact structureTo evaluate the impact of transmission rates on the strategy that most reduced mortality, we varied the basic reproductive number R0 from 1.1 to 2.0 when considering a hypothetical infection- and transmission-blocking vaccine with 90% vaccine efficacy. We found that prioritizing adults aged 60+ years remained the best way to reduce mortality and YLL for R0 ≥ 1.3, but prioritizing adults aged 20 to 49 years was superior for R0 ≤ 1.2 (Fig. 2, A and B, and fig. S8). Prioritizing adults aged 20 to 49 years minimized infections for all values of R0 investigated (fig. S8).To evaluate the impact of transmission rates on the strategy that most reduced mortality, we varied the basic reproductive number R0 from 1.1 to 2.0 when considering a hypothetical infection- and transmission-blocking vaccine with 90% vaccine efficacy. We found that prioritizing adults aged 60+ years remained the best way to reduce mortality and YLL for R0 ≥ 1.3, but prioritizing adults aged 20 to 49 years was superior for R0 ≤ 1.2 (Fig. 2, A and B, and fig. S8). Prioritizing adults aged 20 to 49 years minimized infections for all values of R0 investigated (fig. S8).To evaluate the impact of transmission rates on the strategy that most reduced mortality, we varied the basic reproductive number R0 from 1.1 to 2.0 when considering a hypothetical infection- and transmission-blocking vaccine with 90% vaccine efficacy. We found that prioritizing adults aged 60+ years remained the best way to reduce mortality and YLL for R0 ≥ 1.3, but prioritizing adults aged 20 to 49 years was superior for R0 ≤ 1.2 (Fig. 2, A and B, and fig. S8). Prioritizing adults aged 20 to 49 years minimized infections for all values of R0 investigated (fig. S8).\n",
      "\n",
      " \n",
      " Download high-res image\n",
      " Open in new tab\n",
      " Download Powerpoint\n",
      " \n",
      "\n",
      "\n",
      "Fig. 2 Mortality-minimizing vaccine prioritization strategies across reproductive numbers R0 and countries.(A to E) Heatmaps show the prioritization strategies that result in maximum reduction of mortality for varying values of [(A) and (B)] the basic reproductive number R0 and [(C), (D), and (E)] across nine countries, for vaccine supplies between 1 and 50% of the total population, for an all-or-nothing and transmission-blocking vaccine, 90% vaccine efficacy. [(A) and (B)] Contact patterns and demographics of the United States (38, 53). [(C), (D), and (E)] Contact patterns and demographics of POL, Poland; ZAF, South Africa; CHN, China; BRA, Brazil; ZWE, Zimbabwe; ESP, Spain; IND, India; USA, United States of America; and BEL, Belgium, with R0 and rollout speeds as indicated. \n",
      "To determine whether our findings were robust across countries, we analyzed the ranking of prioritization strategies for populations with the age distributions and modeled contact structures of the United States, Belgium, Brazil, China, India, Poland, South Africa, and Spain. Across these countries, direct vaccination of adults aged 60+ years minimized mortality for all levels of vaccine supply when transmission was high (R0 = 1.5, scenario 2) (Fig. 2E) but in only some cases when transmission was lower (R0 = 1.15, rollout 0.2% per day, scenario 1) (Fig. 2D). Decreasing rollout speed from 0.2% to 0.1% per day caused prioritization of adults aged 60+ years to be favored in additional scenarios (Fig. 2C). Across countries, vaccination of adults aged 20 to 49 years nearly always minimized infections, and vaccination of adults aged 60+ years nearly always minimized YLL for scenario 2, but no clear ranking of strategies emerged consistently to minimize YLL in scenario 1 (fig. S9).Vaccines with imperfect transmission-blocking effectsWe also considered whether the rankings of prioritization strategies to minimize mortality would change if a vaccine were to block COVID-19 symptoms and mortality with 90% efficacy but with variable impact on SARS-CoV-2 infection and transmission. We found that direct vaccination of adults aged 60+ years minimized mortality for all vaccine supplies and transmission-blocking effects under scenario 2 and for all vaccine supplies when up to 50% of transmission was blocked in scenario 1 (supplementary text and fig. S10).Variation in vaccine efficacy by ageCOVID-19 vaccines may not be equally effective across age groups in preventing infection or disease, a phenomenon known to affect influenza vaccines (23–26). To understand the impact of age-dependent COVID-19 vaccine efficacy, we incorporated a hypothetical linear decrease from a baseline efficacy of 90% for those younger than 60 years to 50% in those 80 years and older (Fig. 3). As expected, this diminished the benefits of any prioritization strategy that included older adults. For example, strategies that prioritize adults aged 20 to 49 years were unaffected by decreased efficacy among adults aged 60+ years, whereas strategies prioritizing adults aged 60+ years were markedly diminished (Fig. 3). Despite these effects, prioritization of adults aged 60+ years remained superior to the alternative strategies to minimize mortality in scenario 2.\n",
      "\n",
      " \n",
      " Download high-res image\n",
      " Open in new tab\n",
      " Download Powerpoint\n",
      " \n",
      "\n",
      "\n",
      "Fig. 3 Effects of age-dependent vaccine efficacy on the impacts of prioritization strategies.(A) Diagram of hypothetical age-dependent vaccine efficacy shows decrease from 90% baseline efficacy to 50% efficacy among individuals aged 80+ years, beginning at age 60 (dashed line). (B and C) Percent reduction in deaths in comparison with an unmitigated outbreak for transmission-blocking all-or-nothing vaccines with either constant 90% efficacy for all age groups (solid lines) or age-dependent efficacy shown in (A) (dashed lines), covering scenario 1 [0.2% rollout per day, R0 = 1.15; (B)] and scenario 2 [0.2% rollout per day, R0 = 1.5 (C)]. Black dots indicate break points at which prioritized demographic groups have been 70% vaccinated, after which vaccines are distributed without prioritization. Shown are contact patterns and demographics of the United States (38, 53); all-or-nothing and transmission-blocking vaccine. \n",
      "To test whether more substantial age-dependent vaccine effects would change which strategy minimized mortality in scenario 2, we varied the onset age of age-dependent decreases in efficacy, the extent to which it decreased, and the baseline efficacy from which it decreased. We found that as long as the age at which efficacy began to decrease was 70 years or older and vaccine efficacy among adults aged 80+ years was at least 25%, prioritizing adults aged 60+ years remained superior in the majority of parameter combinations. This finding was robust to whether the vaccine was modeled as leaky versus all or nothing, but we observed considerable variation from country to country (fig. S11).Incorporation of population seroprevalence and individual serological testingBecause of early indications that naturally acquired antibodies correlate with protection from reinfection (27), seroprevalence will affect vaccine prioritization in two ways. First, depending on the magnitude and age distribution of seroprevalence at the time of vaccine distribution, the ranking of strategies could change. Second, distributing vaccines to seropositive individuals would reduce the marginal benefit of vaccination per dose.To investigate the impact of vaccinating midepidemic while using serology to target the vaccine to seronegative individuals, we included age-stratified seroprevalence estimates in our model by moving the data-specified proportion of seropositive individuals from susceptible to recovered status. We then simulated two approaches to vaccine distribution. In the first, vaccines were distributed according to the five prioritization strategies introduced above, regardless of any individual’s serostatus. In the second, vaccines were distributed with a serological test, so that individuals with a positive serological test would not be vaccinated, allowing their dose to be given to someone else in their age group.We included age-stratified seroprevalence estimates from New York City [August 2020; overall seroprevalence 26.9% (28)] and demographics and age-contact structure from the United States in evaluations of the previous five prioritization strategies. For this analysis, we focused on scenario 2 (0.2% rollout per day, R0 = 1.5 inclusive of seropositives) and found that the ranking of strategies to minimize incidence, mortality, and YLL remained unchanged: Prioritizing adults aged 60+ years most reduced mortality, and prioritizing adults aged 20 to 49 years most reduced incidence, regardless of whether vaccination was limited to seronegative individuals (Fig. 4). These rankings were unchanged when we used lower or higher age-stratified seroprevalence estimates to test the consistency of results [Connecticut, July 2020, overall seroprevalence 3.4% (29) and synthetic, overall seroprevalence 39.5%] (figs. S12 and S13). Despite lowered sensitivity to detect past exposure due to seroreversion (30, 31), preferentially vaccinating seronegative individuals yielded large additional reductions in cumulative incidence and mortality in locations with higher seroprevalence (Fig. 4 and fig. S13) and modest reductions in locations with low seroprevalence (fig. S12). These results remained unchanged when statistical uncertainty, because of sample size and imperfect test sensitivity and specificity, was incorporated into the model (32).\n",
      "\n",
      " \n",
      " Download high-res image\n",
      " Open in new tab\n",
      " Download Powerpoint\n",
      " \n",
      "\n",
      "\n",
      "Fig. 4 Effects of existing seropositivity on the impacts of prioritization strategies.(A to C) Percent reductions in (A) infections, (B) deaths, and (C) years of life lost (YLL) for prioritization strategies when existing age-stratified seroprevalence is incorporated [August 2020 estimates for New York City; mean seroprevalence 26.9% (28)]. Plots show reductions for scenario 2 (0.2% rollout per day, R0 = 1.5) when vaccines are given to all individuals (solid lines) or to only seronegatives (dashed lines), inclusive of 96% serotest sensitivity, 99% specificity (54), and approximately 3 months of seroreversion (supplementary materials, materials and methods) (29). Shown are U.S. contact patterns and demographics (38, 53), all-or-nothing and transmission-blocking vaccine with 90% vaccine efficacy. Lower and higher seroprevalence examples are provided in figs. S12 and S13, respectively. \n",
      "DiscussionThis study demonstrated the use of an age-stratified modeling approach to evaluate and compare vaccine prioritization strategies for SARS-CoV-2. After accounting for country-specific age structure, age-contact structure, infection fatality rates, and seroprevalence, as well as the age-varying efficacy of a hypothetical vaccine, we found that across countries, those aged 60 years and older should be prioritized to minimize deaths, assuming a return to high contact rates and prepandemic behavior during or after vaccine rollout. This recommendation is robust because of the dramatic differences in IFR by age. Our model identified three general regimes in which prioritizing adults aged 20 to 49 years would provide greater mortality benefits than would prioritizing older adults. One such regime was in the presence of substantial transmission-mitigating interventions (R0 = 1.15) and a vaccine with 80% or higher transmission-blocking effects. A second regime was characterized by substantial transmission-mitigating interventions (R0 = 1.15) and either rollout speeds of at most 0.2% per day or vaccine supplies of at most 25% of the population. The third regime was characterized by vaccines with very low efficacy in older adults, very high efficacy in younger adults, and declines in efficacy starting at age 59 or 69 years. The advantage of prioritizing all adults or adults aged 20 to 49 versus 60+ years was small under these conditions. Thus, we conclude that for mortality reduction, prioritization of older adults is a robust strategy that will be optimal or close to optimal to minimize mortality for virtually all plausible vaccine characteristics.By contrast, the ranking of infection-minimizing strategies for midepidemic vaccination led to consistent recommendations to prioritize adults aged 20 to 49 years across efficacy values and countries. For pretransmission vaccination, prioritization shifted toward children and teenagers for leaky vaccine efficacies 50% and below, which is in line with prior work (7), as well as for vaccines with weak transmission-blocking properties. Because a vaccine is likely to have properties of both leaky and all-or-nothing models, empirical data on vaccine performance could help resolve this difference in model recommendations, although data are difficult to obtain in practice [for example, (33, 34)].It is not yet clear whether the first generation of COVID-19 vaccines will be approved everywhere for the elderly or those under 18 years of age (35–37). Although our conclusions assumed that the vaccine would be approved for all age groups, the evaluation approaches introduced here can be tailored to evaluate a subset of approaches restricted to those within the age groups for which a vaccine is licensed, by using open-source tools such as those that accompany this study. Furthermore, although we considered three possible goals of vaccination—minimizing cumulative incidence, mortality, or YLL—our framework can be adapted to consider goals such as minimizing hospitalizations, intensive care unit occupancy (7), or economic costs (10).We demonstrated that there is value in pairing individual-level serological tests with vaccination, even when accounting for the uncertainties in seroprevalence estimates (32) and seroreversion (30). The marginal gain in effective vaccine supply, relative to no serological testing, must be weighed against the challenges of serological testing before vaccination. Serostatus itself is an imperfect indicator of protection, and the relationship of prior infection, serostatus, and protection may change over time (10, 27, 30, 31). Delays in serological test results would impair vaccine distribution, but partial seronegative-targeting effects might be realized if those with past polymerase chain reaction (PCR)–confirmed infections voluntarily deprioritized their own vaccinations.The best-performing strategies depend on assumptions about the extent of a population’s interactions. We used prepandemic contact matrices (38), reflecting the goal of a return to prepandemic routines once a vaccine is available, but more recent estimates of age-stratified contact rates could be valuable in modeling midpandemic scenarios (39, 40). Whether prepandemic or midpandemic contact estimates are representative of contact patterns during vaccine rollout remains unknown and may vary on the basis of numerous social, political, and other factors. The scenarios modeled here did not incorporate explicit nonpharmaceutical interventions, which might persist if vaccination coverage is incomplete, but are implicitly represented in scenario 1 (R0 = 1.15).Our study relies on estimates of other epidemiological parameters. In local contexts, these include age-structured seroprevalence and IFR, which vary by population (19, 20, 41). Globally, key parameters include the degree to which antibodies protect against reinfection or severity of disease and relative infectiousness by age. From vaccine trials, we also need evidence of efficacy in groups vulnerable to severe outcomes, including the elderly. Additionally, it will be critical to measure whether a vaccine that protects against symptomatic disease also blocks infection and transmission of SARS-CoV-2 (42).The role of children during this pandemic has been unclear. Under our assumptions about susceptibility by age, children are not the major drivers of transmission in communities, which is consistent with emerging evidence (12). Thus, our results differ from the optimal distribution for influenza vaccines, which prioritize school-age children and adults aged 30 to 39 years (5). However, the relative susceptibility and infectiousness of SARS-CoV-2 by age remain uncertain. Although it is unlikely that susceptibility to infection conditional on exposure is constant across age groups (12), we ran our model to test the sensitivity of this parameter. Under the scenario of constant susceptibility by age, vaccinating those under 20 years of age has a greater impact on reducing cumulative cases than vaccinating those aged 20 to 49 years (figs. S14 and 15).Our study is subject to a number of limitations. First, our evaluation strategy focuses on a single country at a time, rather than on between-population allocation (43). Second, we only consider variation in disease severity by age. However, other factors correlate with disease outcomes, such as treatment and health care access and comorbidities, which may correlate with factors such as rural versus urban location, socioeconomic status, sex (44, 45), and race and ethnicity (46), which are not accounted for in this study. Inclusion of these factors in a model would be possible, but only with statistically sound measurements of their stratified infection risk, contact rates, and disease outcomes. Even in the case of age stratification, contact surveys have typically not surveyed those 80 years and older, yet it is this population that suffers dramatically more severe COVID-19 disease and higher infection fatality rates. We extrapolated contact matrices to those older than 80, but direct measurements would be superior. Last, our study focused on guiding strategy rather than providing more detailed forecasting or estimates (10). As such, we have not made detailed parameter fits to time series of cases or deaths but rather have used epidemiologic models to identify robust strategies across a range of transmission scenarios.Our study also considers variation in disease risk only by age, through age-structured contact matrices and age-specific susceptibility, whereas many discussions around COVID-19 vaccine distribution have thus far focused on prioritizing health care or essential workers (47, 48). Contact rates, and thus infection potential, vary greatly not only by occupation and age but also by living arrangement (such as congregate settings or dormitories), neighborhood and mobility (49–52), and whether the population has a coordinated and fundamentally effective policy to control the virus. With a better understanding of population structure during the pandemic, and risk factors of COVID-19, these limitations could be addressed. Meanwhile, the robust findings in favor of prioritizing those age groups with the highest IFR to minimize mortality could potentially be extended to prioritize those with comorbidities that predispose them to a high IFR because the strategy of prioritizing the older age groups depends on direct rather than indirect protection.Vaccine prioritization is not solely a question of science but a question of ethics as well. Hallmarks of the COVID-19 pandemic, as with other global diseases, are inequalities and disparities. Although these modeling efforts focus on age and minimizing incidence and death within a simply structured population, other considerations are crucial, from equity in allocation between countries to disparities in access to health care, including vaccination, that vary by neighborhood. Thus, the model’s simplistic representation of vulnerability (age) should be augmented by better information on the correlates of infection risk and severity. Fair vaccine prioritization should avoid further harming disadvantaged populations. We suggest that after distribution, pairing serological testing with vaccination in the hardest-hit populations is one possible equitable way to extend the benefits of vaccination in settings where vaccination might otherwise not be deemed cost effective.Supplementary Materialsscience.sciencemag.org/content/371/6532/916/suppl/DC1Materials and MethodsSupplementary TextFigs. S1 to S15Tables S1 and S2References (55–57)MDAR Reproducibility Checklisthttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.References and Notes↵Johns Hopkins University Coronavirus Research Center, COVID-19 Dashboard by the Center for Systems Science and Engineering at Johns Hopkins University (2020); https://coronavirus.jhu.edu/map.html.↵ R. Khamsi, \n",
      "If a coronavirus vaccine arrives, can the world make enough? Nature\n",
      "580, \n",
      "578–580 (2020). doi:10.1038/d41586-020-01063-8pmid:32273621OpenUrlCrossRefPubMed↵National Academies of Sciences, Engineering, and Medicine, Framework for Equitable Allocation of COVID-19 Vaccine (National Academies Press, 2020); https://doi.org/10.17226/25917.doi:10.17226/25917↵ D. Weycker,  J. Edelsberg,  M. E. Halloran,  I. M. Longini Jr..,  A. Nizam,  V. Ciuryla,  G. Oster, \n",
      "Population-wide benefits of routine vaccination of children against influenza. Vaccine\n",
      "23, \n",
      "1284–1293 (2005). doi:10.1016/j.vaccine.2004.08.044pmid:15652671OpenUrlCrossRefPubMedWeb of Science↵ J. Medlock,  A. P. Galvani, \n",
      "Optimizing influenza vaccine distribution. Science\n",
      "325, \n",
      "1705–1708 (2009). doi:10.1126/science.1175570pmid:19696313OpenUrlAbstract/FREE Full Text↵ S. Bansal,  B. Pourbohloul,  L. A. Meyers, \n",
      "A comparative analysis of influenza vaccination programs. PLOS Med.\n",
      "3, \n",
      "e387 (2006). doi:10.1371/journal.pmed.0030387pmid:17020406OpenUrlCrossRefPubMed↵L. Matrajt, J. Eaton, T. Leung, E. R. Brown, Vaccine optimization for COVID-19: who to vaccinate first? medRxiv 20175257 [Preprint]. 15 December 2020. https://doi.org/10.1101/2020.08.14.20175257.doi:10.1101/2020.08.14.20175257OpenUrlAbstract/FREE Full Text↵M. E. Gallagher et al., Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates. medRxiv 20170456 [Preprint]. 11 August 2020. https://doi.org/10.1101/2020.08.07.20170456.doi:10.1101/2020.08.07.20170456OpenUrlAbstract/FREE Full Text↵J. H. Buckner, G. Chowell, M. R. Springborn, Dynamic prioritization of COVID-19 vaccines when social distancing is limited for essential workers. medRxiv 20199174 [Preprint] 6 October 2020. https://doi.org/10.1101/2020.09.22.20199174.doi:10.1101/2020.09.22.20199174OpenUrlAbstract/FREE Full Text↵F. Sandmann et al., The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: transmission model-based future scenario analysis and economic evaluation. medRxiv 20200857 [Preprint] 25 September 2020. https://doi.org/10.1101/2020.09.24.20200857.doi:10.1101/2020.09.24.20200857OpenUrlAbstract/FREE Full Text↵ C. J. Worby,  H.-H. Chang, \n",
      "Face mask use in the general population and optimal resource allocation during the COVID-19 pandemic. Nat. Commun.\n",
      "11, \n",
      "4049 (2020). doi:10.1038/s41467-020-17922-xpmid:32792562OpenUrlCrossRefPubMed↵ E. Goldstein,  M. Lipsitch,  M. Cevik, \n",
      "On the effect of age on the transmission of SARS-CoV-2 in households, schools and the community. J. Infect. Dis.\n",
      "2020, \n",
      "jiaa691 (2020). doi:10.1093/infdis/jiaa691pmid:33119738OpenUrlCrossRefPubMed N. G. Davies,  P. Klepac,  Y. Liu,  K. Prem,  M. Jit,  R. M. Eggo; CMMID COVID-19 working group, \n",
      "Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat. Med.\n",
      "26, \n",
      "1205–1211 (2020). doi:10.1038/s41591-020-0962-9pmid:32546824OpenUrlCrossRefPubMed↵ J. Zhang,  M. Litvinova,  Y. Liang,  Y. Wang,  W. Wang,  S. Zhao,  Q. Wu,  S. Merler,  C. Viboud,  A. Vespignani,  M. Ajelli,  H. Yu, \n",
      "Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China. Science\n",
      "368, \n",
      "1481–1486 (2020). doi:10.1126/science.abb8001pmid:32350060OpenUrlAbstract/FREE Full Text↵S. Herzog et al., Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium – a serial prospective cross-sectional nationwide study of residual samples. medRxiv 20125179 [Preprint] (2020). https://doi.org/10.1101/2020.06.08.20125179.doi:10.1101/2020.06.08.20125179OpenUrlAbstract/FREE Full Text↵ A. L. Mueller,  M. S. McNamara,  D. A. Sinclair, \n",
      "Why does COVID-19 disproportionately affect older people? Aging (Albany NY)\n",
      "12, \n",
      "9959–9981 (2020). doi:10.18632/aging.103344pmid:32470948OpenUrlCrossRefPubMed Y. Liu,  B. Mao,  S. Liang,  J. W. Yang,  H. W. Lu,  Y. H. Chai,  L. Wang,  L. Zhang,  Q. H. Li,  L. Zhao,  Y. He,  X. L. Gu,  X. B. Ji,  L. Li,  Z. J. Jie,  Q. Li,  X. Y. Li,  H. Z. Lu,  W. H. Zhang,  Y. L. Song,  J. M. Qu,  J. F. Xu, Shanghai Clinical Treatment Experts Group for COVID-19, \n",
      "Association between ages and clinical characteristics and outcomes of coronavirus disease 2019. Eur. Respir. J.\n",
      "55, \n",
      "2001112 (2020). doi:10.1183/13993003.01112-2020pmid:32312864OpenUrlAbstract/FREE Full Text↵ J. Westmeier,  K. Paniskaki,  Z. Karaköse,  T. Werner,  K. Sutter,  S. Dolff,  M. Overbeck,  A. Limmer,  J. Liu,  X. Zheng,  T. Brenner,  M. M. Berger,  O. Witzke,  M. Trilling,  M. Lu,  D. Yang,  N. Babel,  T. Westhoff,  U. Dittmer,  G. Zelinskyy, \n",
      "Impaired Cytotoxic CD8+ T Cell Response in Elderly COVID-19 Patients. mBio\n",
      "11, \n",
      "e02243–e20 (2020). pmid:32948688OpenUrlPubMed↵ A. T. Levin,  W. P. Hanage,  N. Owusu-Boaitey,  K. B. Cochran,  S. P. Walsh,  G. Meyerowitz-Katz, \n",
      "Assessing the age specificity of infection fatality rates for COVID-19: Systematic review, meta-analysis, and public policy implications. Eur. J. Epidemiol.\n",
      "35, \n",
      "1123–1138 (2020). doi:10.1007/s10654-020-00698-1pmid:33289900OpenUrlCrossRefPubMed↵ H. Salje,  C. Tran Kiem,  N. Lefrancq,  N. Courtejoie,  P. Bosetti,  J. Paireau,  A. Andronico,  N. Hozé,  J. Richet,  C.-L. Dubost,  Y. Le Strat,  J. Lessler,  D. Levy-Bruhl,  A. Fontanet,  L. Opatowski,  P.-Y. Boelle,  S. Cauchemez, \n",
      "Estimating the burden of SARS-CoV-2 in France. Science\n",
      "369, \n",
      "208–211 (2020). doi:10.1126/science.abc3517pmid:32404476OpenUrlAbstract/FREE Full Text↵K. M. Bubar et al., kbubar/vaccine_prioritization: Updated code for published paper. Zenodo (2020).doi:10.5281/zenodo.4308794↵M. Brenan, Willingness to Get COVID-19 Vaccine Ticks Up to 63% in U.S., Online (8 December 2020); https://news.gallup.com/poll/327425/willingness-covid-vaccine-ticks.aspx.↵ P. A. Gross,  A. W. Hermogenes,  H. S. Sacks,  J. Lau,  R. A. Levandowski, \n",
      "The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann. Intern. Med.\n",
      "123, \n",
      "518–527 (1995). doi:10.7326/0003-4819-123-7-199510010-00008pmid:7661497OpenUrlCrossRefPubMedWeb of Science J. K. H. Lee,  G. K. L. Lam,  T. Shin,  J. Kim,  A. Krishnan,  D. P. Greenberg,  A. Chit, \n",
      "Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: A systematic review and meta-analysis. Expert Rev. Vaccines\n",
      "17, \n",
      "435–443 (2018). doi:10.1080/14760584.2018.1471989pmid:29715054OpenUrlCrossRefPubMed T. M. E. Govaert,  C. T. Thijs,  N. Masurel,  M. J. Sprenger,  G. J. Dinant,  J. A. Knottnerus, \n",
      "The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA\n",
      "272, \n",
      "1661–1665 (1994). doi:10.1001/jama.1994.03520210045030pmid:7966893OpenUrlCrossRefPubMedWeb of Science↵ J. A. Lewnard,  S. Cobey, \n",
      "Immune History and Influenza Vaccine Effectiveness. Vaccines\n",
      "6, \n",
      "28 (2018). doi:10.3390/vaccines6020028pmid:29883414OpenUrlCrossRefPubMed↵ S. F. Lumley et al., N. Engl. J. Med. 10.1056/NEJMoa2034545 (2020).↵City of New York, COVID-19 data (2020); www1.nyc.gov/site/doh/covid/covid-19-data-testing.page.↵ K. L. Bajema et al., JAMA Intern. Med. 10.1001/jamainternmed.2020.7976 (2020).↵H. Ward et al., Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults. medRxiv 20219725 [Preprint] 27 October 2020. https://doi.org/10.1101/2020.10.26.20219725.doi:10.1101/2020.10.26.20219725OpenUrlAbstract/FREE Full Text↵J. M. Dan et al., Immunological memory to SARS-CoV-2 assessed for up to eight months after infection. bioRxiv 383323 [Preprint] 18 December 2020. https://doi.org/10.1101/2020.11.15.383323.doi:10.1101/2020.11.15.383323OpenUrlAbstract/FREE Full Text↵D. B. Larremore et al., Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys. medRxiv 20067066 [Preprint] 22 June 2020. https://doi.org/10.1101/2020.04.15.20067066.doi:10.1101/2020.04.15.20067066OpenUrlAbstract/FREE Full Text↵ D. Ellenberger,  R. A. Otten,  B. Li,  M. Aidoo,  I. V. Rodriguez,  C. A. Sariol,  M. Martinez,  M. Monsour,  L. Wyatt,  M. G. Hudgens,  E. Kraiselburd,  B. Moss,  H. Robinson,  T. Folks,  S. Butera, \n",
      "HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. Virology\n",
      "352, \n",
      "216–225 (2006). doi:10.1016/j.virol.2006.04.005pmid:16725169OpenUrlCrossRefPubMedWeb of Science↵ K. E. Langwig,  A. R. Wargo,  D. R. Jones,  J. R. Viss,  B. J. Rutan,  N. A. Egan,  P. Sá-Guimarães,  M. S. Kim,  G. Kurath,  M. G. M. Gomes,  M. Lipsitch, \n",
      "Vaccine effects on heterogeneity in susceptibility and implications for population health management. mBio\n",
      "8, \n",
      "e00796-17 (2017). doi:10.1128/mBio.00796-17pmid:29162706OpenUrlAbstract/FREE Full Text↵P. Span, “Older adults may be left out of some COVID-19 trials,” The New York Times 19 June 2020; https://www.nytimes.com/2020/06/19/health/vaccine-trials-elderly.html. H. R. Sharpe,  C. Gilbride,  E. Allen,  S. Belij-Rammerstorfer,  C. Bissett,  K. Ewer,  T. Lambe, \n",
      "The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world. Immunology\n",
      "160, \n",
      "223–232 (2020). doi:10.1111/imm.13222pmid:32460358OpenUrlCrossRefPubMed↵M. Kornfield, “When will children get a coronavirus vaccine? Not in time for the new school year, experts fear,” The Washington Post 2 December 2020; www.washingtonpost.com/health/2020/12/02/kids-vaccine-delay.↵K. Prem et al., Projecting contact matrices in 177 geographical regions: an update and comparison with empirical data for the COVID-19 era. medRxiv 20159772 [Preprint] (2020); https://doi.org/10.1101/2020.07.22.20159772.doi:10.1101/2020.07.22.20159772OpenUrlAbstract/FREE Full Text↵ C. I. Jarvis,  K. Van Zandvoort,  A. Gimma,  K. Prem,  P. Klepac,  G. J. Rubin,  W. J. Edmunds; CMMID COVID-19 working group, \n",
      "Quantifying the impact of physical distance measures on the transmission of COVID-19 in the UK. BMC Med.\n",
      "18, \n",
      "124 (2020). doi:10.1186/s12916-020-01597-8pmid:32375776OpenUrlCrossRefPubMed↵J. A. Backer et al., The impact of physical distancing measures against COVID-19 transmission on contacts and mixing patterns in the Netherlands: repeated cross-sectional surveys in 2016/2017, April 2020 and June 2020. medRxiv 20101501 [Preprint] 16 October 2020. https://doi.org/10.1101/2020.05.18.20101501.doi:10.1101/2020.05.18.20101501OpenUrlAbstract/FREE Full Text↵S. Ghisolfi et al., “Predicted COVID-19 fatality rates based on age, sex, comorbidities, and health system capacity,” working paper (Center for Global Development, 2020).↵ M. Lipsitch,  N. E. Dean, \n",
      "Understanding COVID-19 vaccine efficacy. Science\n",
      "370, \n",
      "763–765 (2020). doi:10.1126/science.abe5938pmid:33087460OpenUrlAbstract/FREE Full Text↵ L. E. Duijzer,  W. L. van Jaarsveld,  J. Wallinga,  R. Dekker, \n",
      "Dose-Optimal Vaccine Allocation over Multiple Populations. Prod. Oper. Manag.\n",
      "27, \n",
      "143–159 (2018). doi:10.1111/poms.12788pmid:32327917OpenUrlCrossRefPubMed↵ T. Takahashi,  M. K. Ellingson,  P. Wong,  B. Israelow,  C. Lucas,  J. Klein,  J. Silva,  T. Mao,  J. E. Oh,  M. Tokuyama,  P. Lu,  A. Venkataraman,  A. Park,  F. Liu,  A. Meir,  J. Sun,  E. Y. Wang,  A. Casanovas-Massana,  A. L. Wyllie,  C. B. F. Vogels,  R. Earnest,  S. Lapidus,  I. M. Ott,  A. J. Moore,  A. Shaw,  J. B. Fournier,  C. D. Odio,  S. Farhadian,  C. Dela Cruz,  N. D. Grubaugh,  W. L. Schulz,  A. M. Ring,  A. I. Ko,  S. B. Omer,  A. Iwasaki; Yale IMPACT Research Team, \n",
      "Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature\n",
      "588, \n",
      "315–320 (2020). doi:10.1038/s41586-020-2700-3pmid:32846427OpenUrlCrossRefPubMed↵ D. Chakravarty,  S. S. Nair,  N. Hammouda,  P. Ratnani,  Y. Gharib,  V. Wagaskar,  N. Mohamed,  D. Lundon,  Z. Dovey,  N. Kyprianou,  A. K. Tewari, \n",
      "Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer. Commun. Biol.\n",
      "3, \n",
      "374 (2020). doi:10.1038/s42003-020-1088-9pmid:32641750OpenUrlCrossRefPubMed↵ M. Webb Hooper,  A. M. Nápoles,  E. J. Pérez-Stable, \n",
      "COVID-19 and racial/ethnic disparities. JAMA\n",
      "323, \n",
      "2466–2467 (2020). doi:10.1001/jama.2020.8598pmid:32391864OpenUrlCrossRefPubMed↵M. Jenco, “CDC vaccine committee may prioritize health care workers for COVID-19 vaccines,”AAP News 27 August 2020; https://www.aappublications.org/news/2020/08/27/covid19vaccinepriorities082620.↵ J. Cohen, \n",
      "The line starts to form for a coronavirus vaccine. Science\n",
      "369, \n",
      "15–16 (2020). doi:10.1126/science.369.6499.15pmid:32631874OpenUrlAbstract/FREE Full Text↵ S. Mishra,  J. C. Kwong,  A. K. Chan,  S. D. Baral, \n",
      "Understanding heterogeneity to inform the public health response to COVID-19 in Canada. CMAJ\n",
      "192, \n",
      "E684–E685 (2020). doi:10.1503/cmaj.201112pmid:32493741OpenUrlFREE Full Text L. Hawks,  S. Woolhandler,  D. McCormick, \n",
      "COVID-19 in Prisons and Jails in the United States. JAMA Intern. Med.\n",
      "180, \n",
      "1041–1042 (2020). doi:10.1001/jamainternmed.2020.1856pmid:32343355OpenUrlCrossRefPubMed H. S. Badr et al., Lancet Infect. Dis. 10.1016/S1473-3099(20)30861-6 (2020).↵J. Ducharme, “These maps show how drastically COVID-19 risk varies by neighborhood,” Time 22 July 2020; https://time.com/5870041/COVID-19-neighborhood-risk.↵United Nations Department of Economic and Social Affairs Population Division, World population prospects (2019); https://population.un.org/wpp.↵ C. H. GeurtsvanKessel,  N. M. A. Okba,  Z. Igloi,  S. Bogers,  C. W. E. Embregts,  B. M. Laksono,  L. Leijten,  C. Rokx,  B. Rijnders,  J. Rahamat-Langendoen,  J. P. C. van den Akker,  J. J. A. van Kampen,  A. A. van der Eijk,  R. S. van Binnendijk,  B. Haagmans,  M. Koopmans, \n",
      "An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nat. Commun.\n",
      "11, \n",
      "3436 (2020). doi:10.1038/s41467-020-17317-ypmid:32632160OpenUrlCrossRefPubMed↵R Core Team, R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2019).K. E. Atkinson, An Introduction to Numerical Analysis (Wiley, 1989), chap. 2, pp. 56–58, second edn.↵Global Health Observatory, Life tables by country (2016); https://apps.who.int/gho/data/view.main.LT62160?lang=en.Acknowledgments: The authors thank S. Herzog, M. Jit, J. Wallinga, and H. Johnson for their feedback. Funding: K.M.B. was supported in part by the Interdisciplinary Quantitative Biology (IQ Biology) Ph.D. program at the BioFrontiers Institute, University of Colorado Boulder. K.M.B. and D.B.L. were supported in part through the MIDAS Coordination Center (MIDASNI2020-2) by a grant from the National Institute of General Medical Science (3U24GM132013-02S2). M.L., S.M.K., and Y.H.G. were supported in part by the Morris-Singer Fund for the Center for Communicable Disease Dynamics at the Harvard T. H. Chan School of Public Health. M.L. and D.B.L. were supported in part by the SeroNet program of the National Cancer Institute (1U01CA261277-01). Author contributions: K.M.B., S.M.K., M.L., S.C., Y.H.G., and D.B.L. conceived of the study. K.M.B. and D.B.L. performed the analyses. K.M.B. and K.R. generated all figures. K.R. created interactive visualization tools. All authors wrote and revised the manuscript. Competing interests: M.L. discloses honoraria from and consulting for Merck, Affinivax, Sanofi-Pasteur, Bristol Myers Squibb, and Antigen Discovery; research funding (institutional) from Pfizer; and unpaid scientific advice to Janssen, Astra-Zeneca, and Covaxx (United Biomedical); M.L. is an honorary faculty member, Wellcome Sanger Institute, and an associate member, Broad Institute. Y.H.G. discloses consulting for Merck and GlaxoSmithKline, and research funding from Pfizer not related to this project or topic. D.B.L. is a member of the scientific advisory board of Darwin BioSciences. Data and materials availability: Reproduction code is open source and provided by the authors (21). This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material. \n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Science\n",
      "Vol 371, Issue 653226 February 2021 \n",
      "Table of Contents \n",
      "Print Table of Contents \n",
      "Advertising (PDF)\n",
      "Classified (PDF)\n",
      "Masthead (PDF)\n",
      " \n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "          Article Tools        \n",
      "\n",
      "\n",
      " Email\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Thank you for your interest in spreading the word about Science.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.\n",
      "\n",
      "\n",
      "Your Email\n",
      "\n",
      "\n",
      "\n",
      "Your Name\n",
      "\n",
      "\n",
      "\n",
      "Send To\n",
      "\n",
      "Enter multiple addresses on separate lines or separate them with commas.\n",
      "\n",
      "\n",
      "You are going to email the following\n",
      "Model-informed COVID-19 vaccine prioritization strategies by age and serostatus\n",
      "\n",
      "\n",
      "Message Subject\n",
      " (Your Name) has forwarded a page to you from Science\n",
      "\n",
      "\n",
      "Message Body\n",
      " (Your Name) thought you would like to see this page from the Science web site.\n",
      "\n",
      "\n",
      "Your Personal Message\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "CAPTCHAThis question is for testing whether or not you are a human visitor and to prevent automated spam submissions.\n",
      "\n",
      "\n",
      "\n",
      "Send Message \n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      " Download Powerpoint \n",
      "\n",
      "\n",
      "\n",
      "\n",
      " Print \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      " Alerts \n",
      "\n",
      "Please log in to add an alert for this article. \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Log In with your AAAS ID\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Sign In to Email Alerts with your Email Address\n",
      "Email\n",
      "\n",
      "\n",
      "Log in\n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      " Citation tools \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Model-informed COVID-19 vaccine prioritization strategies by age and serostatus\n",
      "By Kate M. Bubar, Kyle Reinholt, Stephen M. Kissler, Marc Lipsitch, Sarah Cobey, Yonatan H. Grad, Daniel B. Larremore\n",
      "Science26 Feb 2021 : 916-921 \n",
      "\n",
      "To minimize mortality, vaccinate seronegative persons most at risk of death: those with comorbidities and those 60+ years of age. \n",
      "Supplementary Materials\n",
      " \n",
      " \n",
      "\n",
      "Citation Manager Formats\n",
      "\n",
      "BibTeX\n",
      "Bookends\n",
      "EasyBib\n",
      "EndNote (tagged)\n",
      "EndNote 8 (xml)\n",
      "Medlars\n",
      "Mendeley\n",
      "Papers\n",
      "RefWorks Tagged\n",
      "Ref Manager\n",
      "RIS\n",
      "Zotero\n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " Share \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Model-informed COVID-19 vaccine prioritization strategies by age and serostatus\n",
      "By Kate M. Bubar, Kyle Reinholt, Stephen M. Kissler, Marc Lipsitch, Sarah Cobey, Yonatan H. Grad, Daniel B. Larremore\n",
      "Science26 Feb 2021 : 916-921 \n",
      "\n",
      "To minimize mortality, vaccinate seronegative persons most at risk of death: those with comorbidities and those 60+ years of age. \n",
      "Supplementary Materials\n",
      " \n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Share This Article:\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Copy\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "         \n",
      "\n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "          My saved folders        \n",
      "\n",
      "\n",
      " Save to my folders\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Log In with your AAAS ID\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Stay Connected to Science\n",
      "\n",
      "Facebook\n",
      "Twitter\n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "          Related Content        \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "          Similar Articles in:        \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "          Citing Articles in:        \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "          Navigate This Article        \n",
      "ArticleVaccine prioritizationAbstractEvaluation of vaccine prioritization strategiesImpact of transmission rates, age demographics, and contact structureVaccines with imperfect transmission-blocking effectsVariation in vaccine efficacy by ageIncorporation of population seroprevalence and individual serological testingDiscussionSupplementary MaterialsReferences and NotesFigures & DataInfo & MetricseLetters PDF\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "\n",
      "\n",
      "Read the Latest Issue of Science\n",
      "\n",
      "5 March 2021\n",
      "Vol 371, Issue 6533\n",
      "Table of Contents\n",
      "\n",
      "\n",
      "Feature\n",
      "Nuclear medicine\n",
      "Research Ethics\n",
      "Human embryo research beyond the primitive streak\n",
      "Film\n",
      "Science at Sundance 2021\n",
      "SCI COMMUN\n",
      "News at a glance\n",
      "Hydrology\n",
      "Deforestation, forestation, and water supply\n",
      "Working Life\n",
      "Leadership challenges defused\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "  \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "About UsJournals\n",
      "News from Science\n",
      "Leadership\n",
      "Team Members\n",
      "Work at AAAS\n",
      "\n",
      "For AdvertisersAdvertising Kits\n",
      "Awards and Prizes\n",
      "Custom Publishing\n",
      "Webinars\n",
      "\n",
      "For AuthorsSubmit\n",
      "Information for Authors\n",
      "Editorial Policies\n",
      "\n",
      "For LibrariansManage Your Institutional Subscription\n",
      "Information for Librarians\n",
      "Request a Quote\n",
      "FAQs\n",
      "\n",
      "Related SitesAAAS.org\n",
      "EurekAlert!\n",
      "Science in the Classroom\n",
      "Science Magazine Japanese\n",
      "\n",
      "HelpAccess and Subscriptions\n",
      "Order a Single Issue\n",
      "Reprints and Permissions\n",
      "Contact Us\n",
      "Accessibility\n",
      "\n",
      "Stay Connected Facebook\n",
      " Twitter\n",
      " Instagram\n",
      " YouTube\n",
      " RSS Feeds\n",
      " WeChat\n",
      "\n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "© 2021 American Association for the Advancement of Science. All rights reserved. AAAS is a partner of HINARI, AGORA, OARE, CHORUS, CLOCKSS, CrossRef and COUNTER.\n",
      "Science ISSN 1095-9203.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Terms of Service\n",
      "Privacy Policy\n",
      "Contact AAAS\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "\n",
      "<!--//--><![CDATA[//><!--\n",
      "var _prum=[['id', '568d96eaabe53dc70c276890'], ['mark', 'firstbyte',\n",
      "      (new Date()).getTime()]]; (function() {\n",
      "      var s=document.getElementsByTagName('script')[0],\n",
      "      p=document.createElement('script');\n",
      "      p.async='async'; p.src='//rum-static.pingdom.net/prum.min.js';s.parentNode.insertBefore(p,s);})();\n",
      "//--><!]]>\n",
      "\n",
      "\n",
      "\n",
      "<!--//--><![CDATA[//><!--\n",
      "document.createElement( \"picture\" );\n",
      "//--><!]]>\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "<!--//--><![CDATA[//><!--\n",
      "if(typeof window.MathJax === \"undefined\") window.MathJax = { menuSettings: { zoom: \"Click\" } };\n",
      "//--><!]]>\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "<!--//--><![CDATA[//><!--\n",
      "(function(i,s,o,g,r,a,m){i[\"GoogleAnalyticsObject\"]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\"script\",\"//www.google-analytics.com/analytics.js\",\"ga\");ga(\"create\", \"UA-189672-10\", {\"cookieDomain\":\"auto\"});ga(\"set\", \"anonymizeIp\", true);ga(\"send\", \"pageview\");\n",
      "//--><!]]>\n",
      "\n",
      "\n",
      "\n",
      "<!--//--><![CDATA[//><!--\n",
      "var oas_tag = {};\n",
      "oas_tag.query = 'subject=EPIDEMIOLOGY';\n",
      "//--><!]]>\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "<!--//--><![CDATA[//><!--\n",
      "jQuery.extend(Drupal.settings,{\"basePath\":\"\\/\",\"pathPrefix\":\"\",\"ajaxPageState\":{\"theme\":\"science_jcore\",\"theme_token\":\"lA-TUN_YlTsOCecVIvIxw8x512x8EAH1jbUWrDUV9M8\",\"css\":{\"modules\\/system\\/system.base.css\":1,\"modules\\/system\\/system.menus.css\":1,\"modules\\/system\\/system.messages.css\":1,\"modules\\/system\\/system.theme.css\":1,\"misc\\/ui\\/jquery.ui.core.css\":1,\"misc\\/ui\\/jquery.ui.theme.css\":1,\"misc\\/ui\\/jquery.ui.button.css\":1,\"misc\\/ui\\/jquery.ui.resizable.css\":1,\"misc\\/ui\\/jquery.ui.dialog.css\":1,\"misc\\/ui\\/jquery.ui.tooltip.css\":1,\"sites\\/all\\/modules\\/contrib\\/date\\/date_api\\/date.css\":1,\"sites\\/all\\/modules\\/contrib\\/date\\/date_popup\\/themes\\/datepicker.1.7.css\":1,\"modules\\/field\\/theme\\/field.css\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/highwire_draw\\/css\\/highwire-draw.css\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/highwire_folders\\/highwire_folders.css\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/highwire_responsive\\/css\\/highwire-responsive.css\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/highwire_saved_searches\\/highwire_saved_searches.css\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/highwire_user\\/highwire_user.css\":1,\"sites\\/all\\/modules\\/shared\\/jnl_sci_styles\\/css\\/jnl_sci_styles.css\":1,\"modules\\/node\\/node.css\":1,\"sites\\/all\\/modules\\/contrib\\/picture\\/picture_wysiwyg.css\":1,\"modules\\/search\\/search.css\":1,\"modules\\/user\\/user.css\":1,\"sites\\/all\\/modules\\/contrib\\/views\\/css\\/views.css\":1,\"sites\\/all\\/modules\\/contrib\\/ckeditor\\/css\\/ckeditor.css\":1,\"sites\\/all\\/modules\\/contrib\\/colorbox\\/styles\\/default\\/colorbox_style.css\":1,\"sites\\/all\\/modules\\/contrib\\/ctools\\/css\\/ctools.css\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/highwire.style.highwire.css\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/css\\/nlm-elements.css\":1,\"sites\\/all\\/modules\\/contrib\\/panels\\/css\\/panels.css\":1,\"public:\\/\\/ctools\\/css\\/263bfdb18936424f0ade19d6bd885f37.css\":1,\"\\/\\/cdn.jsdelivr.net\\/qtip2\\/2.2.1\\/jquery.qtip.min.css\":1,\"sites\\/all\\/modules\\/contrib\\/panels_ajax_tab\\/css\\/panels_ajax_tab.css\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/highwire.style.markup.css\":1,\"sites\\/all\\/modules\\/contrib\\/panels\\/plugins\\/layouts\\/onecol\\/onecol.css\":1,\"sites\\/all\\/modules\\/contrib\\/forward\\/forward.css\":1,\"0\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/plugins\\/content_types\\/css\\/highwire_share_link.css\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/plugins\\/content_types\\/css\\/highwire_copy_permalink.css\":1,\"sites\\/all\\/modules\\/contrib\\/panels\\/plugins\\/layouts\\/flexible\\/flexible.css\":1,\"1\":1,\"sites\\/all\\/modules\\/contrib\\/ctools\\/css\\/collapsible-div.css\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/css\\/highwire.gtranslate.css\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/highwire_theme_tools\\/css\\/font-hwicons.css\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/highwire_theme_tools\\/css\\/font-hwicons-glyphs.css\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/plugins\\/content_types\\/css\\/highwire_corrections.css\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/library\\/css\\/critical-jcore.css\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/library\\/css\\/drupal-specific.css\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/css\\/global.css\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/css\\/temp.css\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/system.theme.css\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/system.base.css\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/system.menus.css\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/system.messages.css\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/field.css\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/date.css\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/datepicker.1.7.css\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/search_api_page.css\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/jquery.ui.theme.min.css\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/highwire_lens.css\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/highwire_issue_archive.css\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/highwire-article-citation-list.css\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/highwire_search.css\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/highwire_search_results_tool.css\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/highwire_user.css\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/highwire_folders.css\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/css\\/highwire-forms.css\":1},\"js\":{\"sites\\/all\\/libraries\\/enquire.js\\/enquire.min.js\":1,\"sites\\/all\\/modules\\/contrib\\/picture\\/picturefill2\\/picturefill.min.js\":1,\"sites\\/all\\/modules\\/contrib\\/picture\\/picture.min.js\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/plugins\\/content_types\\/js\\/highwire_panels_ajax_tab.js\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/plugins\\/highwire_markup_process\\/js\\/highwire_openurl.js\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/plugins\\/highwire_markup_process\\/js\\/highwire_google_scholar_sprinkle.js\":1,\"sites\\/all\\/libraries\\/lazysizes\\/lazysizes.min.js\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/plugins\\/highwire_markup_process\\/js\\/highwire_figures.js\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/plugins\\/content_types\\/js\\/highwire_article_trendmd.js\":1,\"sites\\/all\\/modules\\/shared\\/jnl_sci_styles\\/js\\/jnl_sci_cookie_domain.js\":1,\"sites\\/all\\/modules\\/contrib\\/jquery_update\\/replace\\/jquery\\/1.8\\/jquery.min.js\":1,\"misc\\/jquery-extend-3.4.0.js\":1,\"misc\\/jquery.once.js\":1,\"misc\\/drupal.js\":1,\"sites\\/all\\/modules\\/contrib\\/jquery_update\\/replace\\/ui\\/ui\\/minified\\/jquery.ui.core.min.js\":1,\"sites\\/all\\/modules\\/contrib\\/jquery_update\\/replace\\/ui\\/ui\\/minified\\/jquery.ui.widget.min.js\":1,\"sites\\/all\\/modules\\/contrib\\/jquery_update\\/replace\\/ui\\/ui\\/minified\\/jquery.ui.button.min.js\":1,\"sites\\/all\\/modules\\/contrib\\/jquery_update\\/replace\\/ui\\/ui\\/minified\\/jquery.ui.mouse.min.js\":1,\"sites\\/all\\/modules\\/contrib\\/jquery_update\\/replace\\/ui\\/ui\\/minified\\/jquery.ui.draggable.min.js\":1,\"sites\\/all\\/modules\\/contrib\\/jquery_update\\/replace\\/ui\\/ui\\/minified\\/jquery.ui.position.min.js\":1,\"sites\\/all\\/modules\\/contrib\\/jquery_update\\/replace\\/ui\\/ui\\/minified\\/jquery.ui.resizable.min.js\":1,\"sites\\/all\\/modules\\/contrib\\/jquery_update\\/replace\\/ui\\/ui\\/minified\\/jquery.ui.dialog.min.js\":1,\"sites\\/all\\/modules\\/contrib\\/jquery_update\\/replace\\/ui\\/ui\\/minified\\/jquery.ui.tooltip.min.js\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/js\\/highwire.equal-heights.js\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/js\\/highwire.panels-ajax-tab.js\":1,\"sites\\/all\\/modules\\/shared\\/jnl_sci_styles\\/js\\/jnl_sci_script.js\":1,\"sites\\/all\\/libraries\\/colorbox\\/jquery.colorbox-min.js\":1,\"sites\\/all\\/modules\\/contrib\\/colorbox\\/js\\/colorbox.js\":1,\"sites\\/all\\/modules\\/contrib\\/colorbox\\/styles\\/default\\/colorbox_style.js\":1,\"https:\\/\\/scholar.google.com\\/scholar_js\\/casa.js\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/highwire_log\\/highwire_log.js\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/highwire_user\\/js\\/highwire_user_meta.js\":1,\"sites\\/all\\/modules\\/contrib\\/panels\\/js\\/panels.js\":1,\"\\/\\/cdn.jsdelivr.net\\/qtip2\\/2.2.1\\/jquery.qtip.min.js\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/js\\/highwire.article-citation-author-tooltip.js\":1,\"sites\\/all\\/modules\\/contrib\\/panels_ajax_tab\\/js\\/panels_ajax_tab.js\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/plugins\\/highwire_markup_process\\/js\\/highwire_article_reference_popup.js\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/plugins\\/highwire_markup_process\\/js\\/highwire_article_glossary_popup.js\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/plugins\\/highwire_markup_process\\/js\\/highwire_at_symbol.js\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/library\\/js\\/swfobject.js\":1,\"sites\\/all\\/modules\\/contrib\\/captcha\\/captcha.js\":1,\"misc\\/textarea.js\":1,\"sites\\/all\\/modules\\/contrib\\/recaptcha\\/js\\/recaptcha.js\":1,\"https:\\/\\/www.google.com\\/recaptcha\\/api.js?hl=en\\u0026render=explicit\\u0026onload=drupalRecaptchaOnload\":1,\"sites\\/all\\/modules\\/contrib\\/panels_ajax_pane\\/panels_ajax_pane.js\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/highwire_citation\\/plugins\\/content_types\\/js\\/highwire_citation_export.js\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/plugins\\/content_types\\/js\\/highwire_share_dialog.js\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/plugins\\/content_types\\/js\\/clipboard.min.js\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/plugins\\/content_types\\/js\\/highwire_clipboard.js\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/plugins\\/content_types\\/js\\/minipanel_dialog_link.js\":1,\"sites\\/all\\/modules\\/contrib\\/ctools\\/js\\/collapsible-div.js\":1,\"sites\\/all\\/modules\\/shared\\/jnl_sci_styles\\/js\\/jnl_sci_social_icons.js\":1,\"sites\\/all\\/modules\\/contrib\\/google_analytics\\/googleanalytics.js\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/js\\/highwire.gtranslate.js\":1,\"sites\\/all\\/modules\\/shared\\/jnl_sci_data_layer\\/js\\/jnl_sci_user_data.js\":1,\"https:\\/\\/cdnjs.cloudflare.com\\/ajax\\/libs\\/ally.js\\/1.4.1\\/ally.min.js\":1,\"\\/\\/cdn.rawgit.com\\/ricmoo\\/aes-js\\/e27b99df\\/index.js\":1,\"\\/\\/assets.sciencemag.org\\/js\\/global-header-bundle.js\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/plugins\\/content_types\\/js\\/highwire_article_nav.js\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/library\\/js\\/fontfaceobserver.js\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/library\\/js\\/jquery.sticky.js\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/library\\/js\\/jquery.stickyHeader.js\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/library\\/js\\/jquery.switchPng.js\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/library\\/js\\/mediaelement-and-player.min.js\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/library\\/js\\/respondTable.js\":1,\"sites\\/all\\/themes\\/shared\\/science_jcore\\/js\\/script.js\":1,\"sites\\/all\\/modules\\/highwire\\/highwire\\/highwire_responsive\\/js\\/highwire-mediaqueries.js\":1}},\"colorbox\":{\"opacity\":\"0.85\",\"current\":\"{current} of {total}\",\"previous\":\"\\u00ab Prev\",\"next\":\"Next \\u00bb\",\"close\":\"Close\",\"maxWidth\":\"98%\",\"maxHeight\":\"98%\",\"fixed\":true,\"mobiledetect\":true,\"mobiledevicewidth\":\"480px\"},\"highwire\":{\"nid\":\"757409\",\"apath\":\"\\/sci\\/371\\/6532\\/916.atom\",\"pisa\":\"sci;371\\/6532\\/916\",\"markup\":[{\"requested\":\"short-text\",\"variant\":\"abstract\",\"view\":\"abstract\",\"pisa\":\"sci;371\\/6532\\/916\"},{\"requested\":\"long\",\"variant\":\"full-text\",\"view\":\"full\",\"pisa\":\"sci;371\\/6532\\/916\"},{\"requested\":\"precis-abstract\",\"variant\":\"precis-abstract\",\"view\":\"precis\",\"pisa\":\"sci;371\\/6532\\/916\"},{\"requested\":\"precis-abstract\",\"variant\":\"precis-abstract\",\"view\":\"precis\",\"pisa\":\"sci;371\\/6532\\/916\"},{\"requested\":\"full-text\",\"variant\":\"full-text\",\"view\":\"full\",\"pisa\":\"sci;371\\/6532\\/916\"}],\"ac\":{\"\\/sci\\/371\\/6532\\/916.atom\":{\"access\":{\"full\":true,\"abstract\":true,\"editor_summary\":true},\"pisa_id\":\"\",\"apath\":\"\\/sci\\/371\\/6532\\/916.atom\",\"jcode\":\"sci\"},\"sci;371\\/6532\\/916\":{\"access\":{\"full\":true},\"pisa_id\":\"sci;371\\/6532\\/916\",\"apath\":\"\",\"jcode\":\"sci\"}},\"processed\":[\"highwire_math\"],\"trendmd\":{\"trendmd-suggestions\":\"{\\u0022element\\u0022:\\u0022#trendmd-suggestions\\u0022,\\u0022track_id\\u0022:\\u0022null\\u0022}\"},\"modal_window_width\":\"560\",\"share_modal_width\":\"560\",\"share_modal_title\":\"Share this Article\",\"AAASdataLayer\":\"{\\u0022page\\u0022:{\\u0022pageInfo\\u0022:{\\u0022pageTitle\\u0022:\\u0022Model-informed COVID-19 vaccine prioritization strategies by age and serostatus\\u0022,\\u0022pageURL\\u0022:\\u0022science.sciencemag.org\\\\\\/content\\\\\\/371\\\\\\/6532\\\\\\/916\\u0022,\\u0022pagePath\\u0022:\\u0022916\\u0022,\\u0022pageType\\u0022:\\u0022journal page\\u0022,\\u0022issueDate\\u0022:\\u00222021-02-26\\u0022,\\u0022pubDate\\u0022:\\u00222021-02-25 10:41:01\\u0022,\\u0022nlmArticleType\\u0022:\\u0022research-article\\u0022,\\u0022DOI\\u0022:\\u002210.1126\\\\\\/science.abe6959\\u0022,\\u0022author\\u0022:\\u0022Kate M. Bubar|Kyle Reinholt|Stephen M. Kissler|Marc Lipsitch|Sarah Cobey|Yonatan H. Grad|Daniel B. Larremore\\u0022,\\u0022firstRelease\\u0022:\\u0022no\\u0022,\\u0022issnOnline\\u0022:\\u00221095-9203\\u0022,\\u0022issnPrint\\u0022:\\u00220036-8075\\u0022,\\u0022volume\\u0022:\\u0022371\\u0022,\\u0022issue\\u0022:\\u00226532\\u0022,\\u0022articleType\\u0022:\\u0022Research Article\\u0022,\\u0022tabView\\u0022:\\u0022main_tab\\u0022,\\u0022viewType\\u0022:\\u0022full\\u0022},\\u0022attributes\\u0022:{\\u0022accessType\\u0022:\\u0022Free\\u0022,\\u0022openAccess\\u0022:\\u0022yes\\u0022,\\u0022freeAccess\\u0022:\\u0022yes\\u0022,\\u0022subject\\u0022:\\u0022\\u0022,\\u0022fieldCode\\u0022:\\u0022EPIDEMIOLOGY\\u0022,\\u0022OAS_subject\\u0022:\\u0022subject=EPIDEMIOLOGY;\\u0022}},\\u0022user\\u0022:{\\u0022memberID\\u0022:\\u0022\\u0022,\\u0022institutionID\\u0022:\\u0022\\u0022,\\u0022institution\\u0022:\\u0022\\u0022,\\u0022accessMethod\\u0022:\\u0022guest\\u0022,\\u0022registeredUser\\u0022:\\u0022no\\u0022,\\u0022authenticated\\u0022:\\u0022no\\u0022,\\u0022access\\u0022:\\u0022yes\\u0022,\\u0022entitled\\u0022:\\u0022no\\u0022}}\"},\"jcarousel\":{\"ajaxPath\":\"\\/jcarousel\\/ajax\\/views\"},\"panels_ajax_pane\":{\"new-26\":\"{\\u0022encrypted\\u0022:\\u0022{\\\\\\u0022encrypted\\\\\\u0022:\\\\\\u0022ZfwNSM\\\\\\\\\\\\\\/vTtYg6xBh4UcDHkG7MiR3otR+vLBMqR20JXSeusE3xkXhp7mVeahCtoeUhNCxxVfktkBJjIibah3qFm\\\\\\\\\\\\\\/WAOwvATy8BtWA5HnY5rJ\\\\\\\\\\\\\\/n\\\\\\\\\\\\\\/QZfWVcVrx5yq0b8IgFs3zG+v5tSBr\\\\\\\\\\\\\\/OMNuWwK1OA5HA5SBwlz2612SAy9fjOmPWhawjB+CiLzlGOdy7Le96FPaUt4BW9DMkMfZXQZvo\\\\\\\\\\\\\\/kLmiBOjrOGePrvSVCkbOw3Bgnix7O700qLRBwZTYepBS5dU7anXXoN\\\\\\\\\\\\\\/uFys\\\\\\\\\\\\\\/MpW8OqqaoG0edFBsTrC\\\\\\\\\\\\\\/wZvypR4R+846fE2JP85g1j6yAiKW5n7cPP1es\\\\\\\\\\\\\\/WuSl9GSHBqed9fbR0VL5NR6HIdhNz2NPVR4LKVQWgDUyxnUZKX0+9fvouPh5dGzfT\\\\\\\\\\\\\\/lDnsxGI+zpCjMdj2uYLaZgZ3q5z9V+KNftsL4eC9n7QkECj4HD1oPjw424jKE1\\\\\\\\\\\\\\/cZw2TtImrO2n97EGPe2tN3rIBJkISIzXMWITHgUmVQTDnx3mRpRtcB42dUp8AZHSQvmKrO11\\\\\\\\\\\\\\/Gk6pu6VMicDHy3tP29OmmV149CEhPqZZq8FAvsohq5U6ZLQj1iBsVQnQrbVu1yZDDXanQST131kDag4cs0WV\\\\\\\\\\\\\\/xUvIqrVKiu+UVq9un+pEi1hRctZZVpLv\\\\\\\\\\\\\\/cnYgScpFeFqxkpIqPEP0oj2TMTk3jwnq94d+79cNMlN\\\\\\\\\\\\\\/Krm5NRN6YRvOW2iK7uziKwylb+xSF9eHX8xh8n1DL3AK\\\\\\\\\\\\\\/1zNarO4IH1iS8UdsAuttbeioiK85u075E1q3za9OFXTqPH79pXk6\\\\\\\\\\\\\\/FOzZyyZEGAQGmNz\\\\\\\\\\\\\\/\\\\\\\\\\\\\\/+SXIvBpX9OOaD17ybYogMBUnl84IKKiQq36KLJxbWF0gvA6v4phigdxKq0VWoJlVBwWcZQn9pcKi4n\\\\\\\\\\\\\\/Ltnzj94rfBrGF7B4A7Qe6IjeYrHVxWoyx9ZjSubYWX066sM9hXr9cbUEljmhoYNcv3WALNbeO3gs\\\\\\\\\\\\\\/Du+TivdG3ckxX5QJkefFlbAmrLtIHFIMcfAyseIb8KdhXVFt\\\\\\\\\\\\\\/R014cygPUzwA2F3D+a6Uiw9EsU7awYyoQabHetuIZKbs2g\\\\\\\\\\\\\\/zwd8G+rOeysKfcmwZ4kFxVDi6Q53GulG4EhQmczqL13fv5CYEHeaod7nb0I0WhxqrxZ2hdBUXKdLwN1\\\\\\\\\\\\\\/SPF\\\\\\\\\\\\\\/WLt\\\\\\\\\\\\\\/3\\\\\\\\\\\\\\/cgtYXcBfrBys9Dp9xSNRuGzqSodS1nP17hP1ockR21e6dE2f0IapGKt\\\\\\\\\\\\\\/2fSGw3s5\\\\\\\\\\\\\\/uI3BLjBilINdPejwHJR6K7MoeiRag9JMM8e4GIb1+do8G7iLkduAts\\\\\\\\\\\\\\/ZSCXrfejAysMSTM7+ADC33aNRvMg7I025sc3EcZ+QRBabDHOXNQtW0Z6wJpLCQTLbJTt+bWLMBa3YTgIHh9LuYONrYCEiw3Zqlx0edhM5mg8pjF2HspVeYi5bOQ4MVr2QAyK25PazxImtpA9cAWyymjksM7wYV8QLKdTllUzjQoBSWya+HkmcCHG1EZhjnc+gUsC5LlB3\\\\\\\\\\\\\\/MI7PgScCGHlrGw8wzLrmyzmrwo+gkZGULNJ1GzWC4neXBmM7EuD0tAnr31Yj+cK8OnDA8K9Y2Fht275Klg3WE3GedzonHbVUZ5jWnbD18d6Kl\\\\\\\\\\\\\\/22i1ocgsvm\\\\\\\\\\\\\\/ahYzbqUmdQSlu5ovykfaA+HmX\\\\\\\\\\\\\\/IFhU\\\\\\\\\\\\\\/2JABrcxx8qcuooLfcQF8YQZxos5dD0V51\\\\\\\\\\\\\\/dZ3p7KXBsqX\\\\\\\\\\\\\\/qvQLpYpkMKNMddFIr4KYbgDm1PAeTME6pd2gksjCxtGJXm5dQdkQBf+9fmZxkfYMWf6UT\\\\\\\\\\\\\\/K8tlDQCEHAnYMcWcXlpLBZFnC61B76\\\\\\\\\\\\\\/1PBPVct\\\\\\\\\\\\\\/isv56ck6fuv9\\\\\\\\\\\\\\/wGZmoDiZ+aj0IO6qXRXNEz2LiIy4D0qXGvmUQiUH0iOzxcH0+qCeVVEHqKq8hDt2du53e\\\\\\\\\\\\\\/WXc+C8tKtBwoQ\\\\\\\\\\\\\\/wmo7+SYfjtoYSLdgmW4kdpLj6N\\\\\\\\\\\\\\/4QFCF912iVyi0t5fnEGzRKQUdaizl9orYjiThfoiN9T7q0TXZB5nw1qwoaR0BX+hg4\\\\\\\\\\\\\\/+t7Hgwpulh9oMhqiAfpYQmHkLJgXmGMdui6hy8J1o89j+Vl80K+lZ6kbf4Gdb2r\\\\\\\\\\\\\\/D08Hnlb9Foyrtn4AwmcJlxqB8OJLR1OqQHsuOjCTa8Q2F4w17B4xuhyd+X1F72Xw7cLcLdtjB1l4yZGW1hGgW4qNGjv8JqAzHVph8htMSqcOkFy79tbpoQW4QG7pDp5sCoSgdCPjbWPAVb6Oxml+P55dvrBTn\\\\\\\\\\\\\\/lSW41DpKzLtce1S37sTKzx6L5irgC0Wm\\\\\\\\\\\\\\/knBJMpRIQmAJrE34dK7c0FAcBIEtchu\\\\\\\\\\\\\\/G2nEXXUzHShedwnBlyXy1gw2MDwA5MNxeRUNKA64lZcSczFHMdhutZj3GLCigyQbZlOcLMTR6\\\\\\\\\\\\\\/mkHxQgGaV8jCEwhZgSGMTpPT6ziCOSH0yKIqGPDwc4dDQTlSc27QGzZXqoOSLWdVhYq+kg8mebERAGvkLJ4HIi1fSmwQl5J8foOa+446tETK296LSZ7qha6kxrj4L2g9l+YdZaawKeqIF2gbz8mDiBs0c1yZzX2zetoJvChK1npBp3oTj8xWQijQdjzjyExAa4wYI2Pk178zox\\\\\\\\\\\\\\/+pU6nxcog1ilP3EyVsj7SJ0TTe\\\\\\\\\\\\\\/8GfW9J+mYktL0dsPgn0nncJPBO1AHKbM+fMimWxqw4R+9ckQcc+yw3nmN2PTMc1soYf8ydYNwU6y6HeENTqpMigxm8jG6q+zpWFSZAhchDg4GhV+TVdSBjVAWO\\\\\\\\\\\\\\/N4AcMNaW7r4vk3S0jpG1llilgE3EkkFvvsVuST9rB6daQXioydF9YqQij4mamhOw1pkhJjxO0jGvOR8FGLxX+6NCpozuwhqy4sMY51Tgjai80GR1mpvKnCnPXWrCuTNo9lLbDKAo0Ns7SHivNJ0H76miSMgnDeoEjT37IX8exzE8nyY5DsxZaYnJuIWHjQVwIu0eheer3LPGe0oV2NkU85oAzvvvrDSWRrvOM\\\\\\\\\\\\\\/0pkFuTMKv3AhNDW+JdpP3rAcnKJfc0dO9BkkpBKOq89LyM2lOUzG2AQ4Rj4KVayCL\\\\\\\\\\\\\\/GOqsE+vOcSaqwu93ln6kHgb9FLCWp9Wml+r1FW+qRg456Kewed2686EKUJVhjPVrMhGsQgn63qrlyyy6uhvxVG6HCbDRREbODhQcx9bFwMpGfpw7L8X\\\\\\\\\\\\\\/blRuzd5zCsp6KQCC\\\\\\\\\\\\\\/zTIj90CExowaTHLStEQEw7m0m7KG69w8+hKvgq85rHNhVE3G1A8F0EdtVFQsUv3rQ9TFJNgOGq3bt9j4J8nh5\\\\\\\\\\\\\\/HEiER5BfDOVTbP9gr2m\\\\\\\\\\\\\\/lVs9X99s6pBLgs0sYdm4\\\\\\\\\\\\\\/PL5JYcpT9XiWkP3usy1NDux+ifwl2qsgFsg1re+sg5CObhC8X9c3TAGBdVggGzf2S9oivmGDF4FH6M7ZT2W6HLKtSl3B83IMncgQn\\\\\\\\\\\\\\/razeTtp1lGevRMnfdmZ\\\\\\\\\\\\\\/LU4uunkni7U\\\\\\\\\\\\\\/wzeIirop14Xpjm94315WpREK+82\\\\\\\\\\\\\\/tSoDC6G\\\\\\\\\\\\\\/COuZah23Q\\\\\\\\\\\\\\/yF4BXRrCPhy7CzLhBXh4HyXT4oZspyabAnjHwYfBqbO35ccp3rBTyLGkn7p8zgv3Fhi7\\\\\\\\\\\\\\/4tYHo14kMv5TT7u7XMTr7QGZE2awBTgzgVLJlNieBTWkKkn6TINc8OZyK\\\\\\\\\\\\\\/N03CY1iRQWs4Boy\\\\\\\\\\\\\\/FMHEaFFcGogD0YTReZQftoL\\\\\\\\\\\\\\/TQYJKkQjbjZVAeTd5HU8gyO2FkLY5bh310ZW9jjB18GvkzGx52Pu6ejyqk9qicvqoDtiUy7q9FI8H0AeFR0QNDuInLiipjXqJTiGn6M0DZks8DjLTzQic1K7WfYpvUTD2Ptyjpq+w2wKlYxR3C+dm5qhxkx3qW7Ggj+kEi3K9N9MgsUO9p4hWD\\\\\\\\\\\\\\/eX5m+LimuLmy8VvKddAl21VuqSpeA0qkvo2xD+yMIrbkPyu25h2q7SmSvFo+3HCNg5zwMVAOIt5yV\\\\\\\\\\\\\\/IhUZZciVanNb2pm5R4J1+3Q\\\\\\\\\\\\\\/kpaB5ONykP8wanl5BKHtel88+1utdZaETrOFhXyxb7vYpMmBty\\\\\\\\\\\\\\/CciAYLzcH\\\\\\\\\\\\\\/kcI07ceTMNQKRC477rD31bEkWr9EC7FOXJ4m3WyfgBNJd63apsCxZJAhsilYbvXht8rq2DNiwsD30y1kx5r7Y\\\\\\\\\\\\\\/Ps74UW3xuM\\\\\\\\\\\\\\/b0PiVLEIaeqKY8CVyahNuBQiV8WNVv5gfIYh4xZlDC7oXbeIvPN2P1FGw1HecyNrpWI6nbqDr3oEzGaDNfHLBhmN84ia2icBuQQ0PoVsCnaLEBj6nxmpBHq\\\\\\\\\\\\\\/d3PzT\\\\\\\\\\\\\\/TDdD5d\\\\\\\\\\\\\\/I+EVkOPxcGaQMUIxZtopjhbfXELjU5ZgFmuED8ZLj33QyzT5wTcUpIqGXCkn002FSh+lfcnknn1ZR7LAoiR4TAqnUmK48jU7jYn9p8HF79vTROt+p8g8IvPkdsTi5znWR32jBMf2MR\\\\\\\\\\\\\\/jodpZn3qchtXB7LDAS2uQoEi6QPH38AfFgI7dlNWmSfUWTiVw7lU18oJlBlrpOazDn\\\\\\\\\\\\\\/LvYLXT17GLGNTnIC28xYSlevLovXTowvCZl0Yj3LQIzcvJdTN2eWQbzdVM+YvPArgej6cButkV2a7ivL91qD9wzX65bxTXWvgEi6DhzHYJFpRM17kp7SueiiB7OPPqzEBV+7WRA5lHyOq1ZWtncYqcy\\\\\\\\\\\\\\/T1v0hviqGJsbLEecCY9yPjI37qSSw4yleT84h4Cwm\\\\\\\\\\\\\\/ZIPzMRn5iVy3hmliSIBOFELcSibWQqpiBvRO5cTQm0MpW504OSl+FyjlDOg4BKasEja5NxbBhh195q\\\\\\\\\\\\\\/ZbDydTlzs9cQQYX3Qrhm1iTmEJNnxcWYR7Z2YoSvz7NkPgB2GfMtz\\\\\\\\\\\\\\/0i2x1xKMvaUCVCNeNBxBM+FRg4WpLCxAq3lD49KYBSStQZUQvmDd9T+N8qTwMWmIVdDjvY+nlMToprvQ3x3eNX2Drps7kxCtnXSG0VtvjL00lvrkEOAoS6HloT+FYw+0DgbLVQEjo1fP5be5Vr6nGgsbXITiKlZlvFmte5WHPBpro35CwY+Hn\\\\\\\\\\\\\\/OT8\\\\\\\\\\\\\\/q9cLco6D0aTc3CLsedoGYrPdOeCk+LPKa2WnfkD3pWEc65mj73EN\\\\\\\\\\\\\\/GU+tDeImsbuCmF2lZVJIdz+a5CsunPff42PNWt9GedEKfn5DhXtcYiubgVuUjwWEtGdAiT1nCWuBjAtQDTmILztvYWf86XFOwWPUrbnj8RfQLn\\\\\\\\\\\\\\/SUZnlW+1LnAnF\\\\\\\\\\\\\\/SuNDv35q5W4Vj1agSBVVCvMuVO1j36ShZY5oVBbBfi1LzYZWBDr\\\\\\\\\\\\\\/CfZ2CCrjszOLVdAKAqFbHilwOetHq3QjM7Bh4j4KhFr6aZlyxWlGgU8V6j8KNlAzhcWWaaB6Bp409gp6JY7h5++X4Lx15VSw6KJ8nSB4SV4XSaHgwqBjvVzYtdQwGWvc9Zjx7w\\\\\\\\\\\\\\/4TUdKHDsSz0hN1+7S1Zt6UwK8IWoEUzMRqor4izaKvZKTGspJ9F3dcGdz7CMRTcKq8AHLlnOyl9SHfAFyXOaO1XbMAw0L1tx\\\\\\\\\\\\\\/ja5WPbdJzrqHhcpnt32EAChBR9s5y8K8YXF5mi89w+z1yldNG8OuGh2Ap0C1GhzhK9O6rTG+xbbaDB+3iN0LYMVlpuOMPmQ1aJY98gizkc9Bzum8HFn6C4HIWJuzwXem7nt0AR5GRMqMm1EKOcJFss09Bpl302Ghmbh95Dct5xpp6XHZhw0R4oAIJoqEZiXJkqr\\\\\\\\\\\\\\/D1iFRKdgNdafMPHFrapyUVTKiQ4hMPTnToo8tv8wO5dytmdny7+G4tm9XMtothc+a+9zshuWNwClg+s3YpnHlxUx+eNCNIru6OdKWCfN0Csg7SUIsZKERK6taghZTSfSXMbfpcSKtYP8Gnafj1TewJvIKZRFb42nit2XDHv5WLu75Ia2n3+r1loMuWDfomDoyABTELCH8g9g3DMkCPmQu9M16CIsCUjxYAdx3i7MtSffSOiPvg14LctpCUVjXHNQ3kaT1lI7VqKYUsZnVUPw4o7Xh9Zvk46+5\\\\\\\\\\\\\\/DKe\\\\\\\\\\\\\\/T2yvJBLBQROFOiWCrI5K8rjo05IVl3NT1djyGsyOWKsneRV2ZDGEeT\\\\\\\\\\\\\\/hx2YzaYomgzA+5B9D1XGgQN1hdZt5KgJfT91cYCov0jG\\\\\\\\\\\\\\/jMWFnvizGhm4FU518PhgJf2jWO4O5vnitspAeMjS3hZYcVF4KXgrH7I\\\\\\\\\\\\\\/4nLI7JQqkDqxUZfkKMwQqXxkl04b2zbNsI3K8T\\\\\\\\\\\\\\/AWgP18XceK5dnIkzSpReYdpcC9huvz5XV2X90uRrJoX3J0J4YsyyH5SeoZSpaKO3\\\\\\\\\\\\\\/9Z+EtYDYGRAOBt5PvKfB5OBfewKZRwa+do+BkMU6hRq00aTIXvR2SkV+9l6wxgyq4trogHJpsWzi6gxZFF8ob4bk3qP9CxW+J87wOPEildNBKAeUs6W+xgAaFisdCBq0R+MYfmVdDk2JI1wULSV7xv4hjJtZjYEqHTkEqAge7B87N6JE6qxAXct+IjO10ymEw\\\\\\\\\\\\\\/\\\\\\\\\\\\\\/DS6JiLj1jSHvuXqAGQ2XmJzzKIypWcaf\\\\\\\\\\\\\\/IKu6pqJJUrXpAQBOsb0vS\\\\\\\\\\\\\\/QFG516TC6tPHFufhm5p4spj\\\\\\\\\\\\\\/GXkGNIVkwO\\\\\\\\\\\\\\/p\\\\\\\\\\\\\\/nlGak+YcdRlVGlsulsEYCQ4YbqNiMAREXVDtOgVtGEUc2NESbCl3o8K4bfK1tPWiZplKE831CbWkCqOiu83ePvCOOdBN1tKK0DwUcoj9zYrPFQNnN4E1vhfW7FtsMWw0xYvhH2Pi8t5HJC1biXejQYuxd3DnWJ\\\\\\\\\\\\\\/0ieiGqg64bnknbo8N\\\\\\\\\\\\\\/DiNu9L6g2d6nSOSd6ca8HicDOV5+v\\\\\\\\\\\\\\/AxixShmgMm38jTy\\\\\\\\\\\\\\/Z\\\\\\\\\\\\\\/hA+aKya\\\\\\\\\\\\\\/PWG0Cu\\\\\\\\\\\\\\/mUy2fqEdWcZb7OfGmGn0dMhS85kwjFupA+b5g9SGHyX1Fy3fHlN4SCSDgBhaR5zGgf4m2xsndWEJJuCWZiDJdh8IUG3cTgOVSCZwQrAfFWLIaTr\\\\\\\\\\\\\\/2Q4ikKQW9ROnFx8F4pBz0AxJPKG9sLiE6nf5+8i1Llt2UoTkeibrT0WVqvJmy4wWtCCXbq1yecLxuJL8CFue1XX7Nf0jsHSP7alToOx0K\\\\\\\\\\\\\\/UGnatuSsrgd8YIlf0OQire9ot6OpXAcdgMA9RGrEQ2qMJhbWR0Bp9Mp7CbW7tgv1CtpfYgCnMzG8gILl3Jq1xDGy4iaw4lWcgA0WzVj1mRJS5MHM50iMB+pAfRWQrDtxRycMTIYeNxiTyOSEFi690N2Fi2dRNJHmg68g4E7YZ+z0MfMCDJ3sV7qCmEa9N0SyK+TF396Jm\\\\\\\\\\\\\\/R3paEsOWe13mjnVLgJ4BX+jfX5SBJN04aBIBpm4R1fReTOT8Yq+UYobZhjm7+FdkwJtHzdIFneQe\\\\\\\\\\\\\\/SyizF4yE0yiLim0UG9wiU8v0UJfzqkB1pp2eq\\\\\\\\\\\\\\/hOiTAGJDF72GoOGrHOcHqmqEuDNK+f0EAKeudixfmTdxgp8PwzdLoBwDCzLuGhwZQUw+66ZfgNSYIeM2m2disXdOtfHnpeRJiaSP2E1nIDEUmcD8cDuOcK+nRi8VXyo9E\\\\\\\\\\\\\\/v5dLRHLw6fNSbQK\\\\\\\\\\\\\\/DaeHGtp8oFzGFzR+fz+ppkxNEe9aYQ8mELIlU6w7gmsJ394xl9eMG38xIQWYp2uYCETm\\\\\\\\\\\\\\/DSwJyape+JcexMONAdcl\\\\\\\\\\\\\\/oQZEcRxWPMBc8dUQmQn6lXg83ZX\\\\\\\\\\\\\\/cwiDuHngv5MFqaoEjJTFwAqbQqBLQv19uHkS83mEktE3GxzHeJOliEgBzv0jE1Nd7+cp\\\\\\\\\\\\\\/BYWgoyhDPaXjNuAz6mjxGdfU6\\\\\\\\\\\\\\/FdsUxRBr9KfIPq8b3j\\\\\\\\\\\\\\/r\\\\\\\\\\\\\\/Co+JTz8dH2t94F7pKRnO1Ehb3Kb61mAL5DqsWz712SmwZnmOYEvqQjXy1Uj7qbMQ3BN33YZfRbqV0xJA9MnsxMHmXHC1hr9zWQo0MZvoZ5UPh2Zs3bjZ+F8cozTt6QQfsoCLL3o\\\\\\\\\\\\\\/iTee6lvr7802cVtHRDKXRibh9w2U8KCLnmJRkbt024r7QGNO2+rMKvS7RE\\\\\\\\\\\\\\/nr2qzTQfla7XABZ0ydnvuyVB3x7B+wfd1SX7X2ycqavnufg3tstcEvidf3VFrauDj2lTT7BoIsjXXDwElwTZuLoEmnu6iAqU4+kj5LhI8JqP40rNYO+b1NI0tWAJrI8si75uEuUWdxmPb2wK+lFTbAlqQ6IJOwHnbeL\\\\\\\\\\\\\\/ttKPATq+vPAj7BgcC3djXxBeys314K93GqKfFDmF17tU7PkzoiiBaJwy5ADqfodNhxevxsKGEIvZdbi5NYb\\\\\\\\\\\\\\/LXNMUYZgt\\\\\\\\\\\\\\/VAl46IUG56a74Guj7CmD4Rk8HN5Hkazcu02OCx40nEqeHY0JOF2Sxa2rLhCFrSemFc7RKiruPoRoh9JNEPQaNFQaMKu6W6SMro4YjBUs77+ngLfhqy+pNsSHUoinjCQXKCUqnJ6pWXm+GjD\\\\\\\\\\\\\\/ZG99Vhr+CZm3dO8b5aolVD43KoD3d9x4ebcLH0ljCmKVRGRgD2wF4W4eNTefLCISs5jSp9pgVoFBnMqgpuNh3wpSMiGBaKFQVcZjPyRGP+ygoQcUXhd1BvpDrpR6DQRgyklxG9KyHo+6yrl705Dun3bYt3F+GjytYBeWBpXQXPyAyGOIo8jxip7cA0K95YuY9nHukbnItS7OrVCabutCRY6XVLsNw7WmV1ncatMAPAbD+pCvzygAaCf9s+EOcIGsFn1zeQ5Z0S9mVvWCaFBLxX202mUp+ja\\\\\\\\\\\\\\/N+55d0wmE6AH7lKNqIyoLKOAgn5yK1lm0t\\\\\\\\\\\\\\/620Pj1voTf+RWubVsDopZnwMXcAq3fi7JYeaEAuU04zNwRhzigAS5huyZiU+JyiY6x3Dgdgzrf9HdKIwz\\\\\\\\\\\\\\/4S7uO5GyUj5FBsJAkW+\\\\\\\\\\\\\\/bd2qzTzdxXMUbb6QfLLkeoVTHpbKMSW47rvCMi77KThKdmW9CR\\\\\\\\\\\\\\/b9Cni8GljgpYa2TVUTxNmtHX3aTZrbhxsoD95GM9Y2PJ2W8CNgji7PzOEvgycQX+BrchXQQ7KNpYuIJDjwDtew+5XL6NJToevDi3zPWnuabPm82zn14HA002GzZQXN9VyuTZ8QiNsTi\\\\\\\\\\\\\\/0JxWtK4cAGig6a0glywfY\\\\\\\\\\\\\\/OJlPbYTOPOC5lcqoSoI0ZdgA+9yfede+Cb7XlV7zdiivahE\\\\\\\\\\\\\\/h7GWxZZrZLEFFqv05hTZz2e1xal0yvSXPzARn1xurCAobQ+PtsraY40kWRitcG4noia9YsSOdv9PDc5RU5S5ClJ2eE1HjlMCEt8bWJfNr8UxSUC3V606zJafb75AVh9kNbNy0L7IHTQpuLz8hl0ANqqxmkmGLqAm3Pg9r\\\\\\\\\\\\\\/Sx1E1URCw90etv0IsVXfNzUDSCVIS2jyE5x\\\\\\\\\\\\\\/kwc+daNP\\\\\\\\\\\\\\/IDBv8pbLBsANb0QsrxKIEIkUPLMeGP2roLCVF4pU6mm9rZzUM0JE7IlhHzdx2oW83wJvApnrtDSg2OQm\\\\\\\\\\\\\\/m\\\\\\\\\\\\\\/AlHvvjiCgI7bo82ComoBrt9wNqg8s3IRRLE+vzdWr8xaEQK12tr8OO2YRr7PrO55K3SDqVW3RAUVHS51oMhb+bAzKKxpQz+kyYUVo2QevAHOoiSJp88vFKkvORvQdGZSD51NNYrB2VybPxE5FX9l4ppUbAI2OaEKr\\\\\\\\\\\\\\/mqpu219MZtvXUGXfIEWTm\\\\\\\\\\\\\\/Vyg4n2nSRR9knBBpB\\\\\\\\\\\\\\/4aexoUypU2uVMF\\\\\\\\\\\\\\/YP\\\\\\\\\\\\\\/S7hNe3csV2\\\\\\\\\\\\\\/3CCpbdlFvO\\\\\\\\\\\\\\/hwLRKXhChyvyLWJhHjjFDZegcKPaNnlK+26cg9Whc53lFkvC8Nxqq5E\\\\\\\\\\\\\\/am5G5uAJXSTCO3aIa8O3YS6YKmY+QteWaGWGUhHbzoNa9xwjcg3vJqfxazvkGR8Xdf5UXelH36i+pq7gm0ip+v+hCSCzMbIhTu2pSv2fBWtijIrLTvU3ixhOQe4l+GfX1PSLIseWAdjzvh7m4PUvhutym10dfxxLEs6phS9cNsiGLqLr3MuXA0IbE1jdXaxwk78zspFHIhEmTATBiGfuJ2OXABwQjevw46rN1p62MgPnZYKshr0AlXFjA6qK+hFcZ6KkE3kVZUjit+VDxO7AJqwmvCgYs\\\\\\\\\\\\\\/t4fyMWgnvY9c3XVqlsrPO\\\\\\\\\\\\\\/5sLkJQSqWcl9YHhs2INZqZtYDHnVDboce0OOzLWMdNiV3FVY+\\\\\\\\\\\\\\/0FrctQKqJ\\\\\\\\\\\\\\/gJZijCKHNpmzqi6rZ+YjmhZcquA0sf4kT+M\\\\\\\\\\\\\\/UWKhmptBLatCv2tutHvC6MNdUB2uoGbG455iwEyTraraJAPntF4hTIvRDynLHXVkaeBJXocI4pfxGnDtPwdCtyjNUh6l9bOHjMgPDncAT6Psna0TfQUFHB9YzpLEF8t3hJAzuPpP1tG\\\\\\\\\\\\\\/VnJA9OTiyyXiqV76rvfgb21lbRWMzqsAG\\\\\\\\\\\\\\/NS7HraaPOSFKBClWphB1Lk8uNhmqO56qVO5U+PO6MF0BptCjsHUEvQfBp9LO0ZtgzIZOdcWxcwRPpBElK52UWSbuj8CA4JAQ9YlydAcFVKUYJeUPPDjEMWRGQf27XXIK3vVai20iHM1\\\\\\\\\\\\\\/+JNA6tgVpqBapiTyXig6cCYDBpRd+zfbeDPFk6DXAHHUTGg61AbUYO3+mkPaN2vpNGJ9ZJmALXlWS9ESzMJt8V3jRxF5vCClminy2bXPXk5AAO4tnqQ3vIC4+u7CERbRYD46LRJ53qluQGKOEtpCormFDKMejJP1F4HT5HAkBRutDfimlIKQGs4\\\\\\\\\\\\\\/2VzcgaZ\\\\\\\\\\\\\\/327jB9hmSPvW7s9QzfphusS3j5\\\\\\\\\\\\\\/Ycm0oNKOfitI4DhVSQUHVRFii8oVaksQld2Xw511V8wWNLjEUQ9uK3I4gK\\\\\\\\\\\\\\/Kz+vRsz1hsypL2MM+Cx55YfEj2n6oo9mQXgWVTPVrWZSFbZ+jymGN4N+dcgvL00kZLY2pngPBuVm0DNIZ\\\\\\\\\\\\\\/fw4zruYWWCN9qt9ymSTh092E0SXuClS8URh\\\\\\\\\\\\\\/zy1TSy3C7v9vGLfnYikyI+xm98EuxTacDgPGuwSnHhksPh\\\\\\\\\\\\\\/AZzS0rvLsCc5HRxd+MkDMRLT2vrBeCrFyYLlUyZ6jygTCZ79cHwwiNwm7QlJ53jZ8Sr\\\\\\\\\\\\\\/TlaN\\\\\\\\\\\\\\/CG7c6aXcTqqcXy\\\\\\\\\\\\\\/RnmEj+u0MOLzoA9sTrrbfjdL7t8\\\\\\\\\\\\\\/Ms3wHpJngOLTGGBFLpwUxSLjI1dWLmIOJs3LmZiIfXa+8TIo1FPya1dq+xfYHdoHosdvbaz8wiy9vGN5q00RFmCIBTR1+0CnM5AU88YteOFiR1bPytso49CyHqWVvGXTvCUZQG9f4JkNAzvK\\\\\\\\\\\\\\/+kXa4WlFf0w+oNF2EFC295c2w4mJEs2TniQSWIv1vx95uF67NJs35SUxxdcj1d86O1OOE0IkZ7Dwnqo6z+\\\\\\\\\\\\\\/RcBfRC9yhcnsQ4n3QYgmJnSKufDv2AZ37U7TV0kFqX+vjDLNpKjA2DQ+OJ\\\\\\\\\\\\\\/xM8XwTYSGxtc+N9qdmt85gQtsFrP5lH\\\\\\\\\\\\\\/F0UTe6grnZY1Z1Xh0EIiXdPVrwZ\\\\\\\\\\\\\\/ricTf4xqDdWQC6lyf4ysvUgF4uriphk1Vn90iQ1\\\\\\\\\\\\\\/cK+Ece4123yHU9W35uvS5n5Hn2qnpyhOuFj\\\\\\\\\\\\\\/pW3rj2C2g6DedzD7P+6PVsQ8Iq8XS0EISMLoaqJ1vutm3Qu\\\\\\\\\\\\\\/u3tkVppPwpNiTnc0TE3pfLlY9inVN2Ch77GfK796ULsB3nSzySRd3O2pjhOL3CemdU81epGwPFFtaYq0UR8yqsQKVw\\\\\\\\\\\\\\/4diWBHIs+YiXU0cY0GukmrfgEHvvHhqtqVfFSR2OA+dsoqDeFXYhPu8SyimktqZuy704DmhGyVqjIegdLojifXUngq0IKVHGYk5H\\\\\\\\\\\\\\/CGNfxhOWS00qG6sgWrL5OAjpsdpSHpUFRildKE9W9SYJ+Je9feoBFD+fzeGAoiDIzJL6kvo1PoxUgrlLvr8711NOFT\\\\\\\\\\\\\\/BVxB0U1Nnj9HGT0GvtKMu+FEOp3HMg1URz6NYVAI3GC7o2ooWk0z6kRS0WJVltsUrp51FbN0sfQOltLgDewJYxV8ZkSmH5Fo5JAmhtMZ37wEjNlXgL5USX72sIAjv\\\\\\\\\\\\\\/bop1otUooNmI5eMxDAPLE4O7Hf0JprIZbDZk+TlY\\\\\\\\\\\\\\/x+9dAZm0J68KhF3X\\\\\\\\\\\\\\/1UMCvlMQq35zGJfdfVcqDcSyUoL6hLfHmOuDc736LyU6hSSlY19+ykFg\\\\\\\\\\\\\\/hAjKdKHt4l3FlY3wvyEs7okY3X7XIbaFzAhcPYqVRN00oGYNVeUgLG3x8IQS\\\\\\\\\\\\\\/JE2BdKwwB+NVUVfWgwfvIawpylXA3CJVjE\\\\\\\\\\\\\\/MXOepDcRSFcPk5XYi+g9qtFydzsvd5WnEtyDTFtOYePftym0NMYewiHShuEw6wbOJTPKKX25rG92ZxchyqCJ4uydv0UMc8qmx5YJpu5EfrFzf0ROFE9LKBC04ecOTmnxhU5eXG+kaEo8\\\\\\\\\\\\\\/Mnw\\\\\\\\\\\\\\/19GcQB3Shj5VolNP7QL0kEBV0lYvjV9bnT97dCBB9YPlNDpKN6yz\\\\\\\\\\\\\\/CkeVMmEDXPAe9iW3TBEBWb\\\\\\\\\\\\\\/v5X7BS71vKg+Exdpqcc7MQd9LlDpXm83xNr\\\\\\\\\\\\\\/g0eKOHj4ZF0bop\\\\\\\\\\\\\\/K4ayoXQ1DtLL6sH5YfoF6FGvsSP7+C9rELmzct31qIxrTphonIruZij9dtyiQjnsSEjqdX5TKdtNoGWtDsOOAv5Vbx6TngZuOTpjgFnIYya\\\\\\\\\\\\\\/W70HrAEJWyv7xLev1rPCIosILODETn56haB6iHPJjRdTAfUgGsU\\\\\\\\\\\\\\/SKhkAvdpz8gmmr40\\\\\\\\\\\\\\/WTkcgIhQTfy3wYt7+Z6FS6+m0dr5H+TK3d\\\\\\\\\\\\\\/CN3KY5HBuGELgyU\\\\\\\\\\\\\\/CIFKIuE2VvzuvhsOl1wEMPyQDxZ7jVQt3u6GiVeZuZHKvZIqRvJ7Nq7ke\\\\\\\\\\\\\\/F\\\\\\\\\\\\\\/w5XmtYyQkAEmrU+b6nkopKYrWzNQaD2dQ+hLpyixMO5ME+U8dMZXX\\\\\\\\\\\\\\/ol8MfuK304uOzQ7MiMS+E9rcKuogPODDqOLoIXszLwOIPmwCBZ2UUXcgExO+1X3EJ+1OdRZb7GdxGqGXTGBOFOIpiBfFdQa\\\\\\\\\\\\\\/Xyr2oEFQs7df+PP9GMZtls+2yPALh6xFvtyC\\\\\\\\\\\\\\/r9vDhH4OIm5KKrfeYDzBZdMnJUDZZziikz9n1ruVHMi3RAsB8ybJJruqBa5ed7bH5LD0UnnechfGnVvwrT25OsjSDw8B9OIoUrRvWUbY\\\\\\\\\\\\\\/9\\\\\\\\\\\\\\/xV1vIqOW0MzAtwHeKOxYn6Vh14QutDLo0PcEuHf2Ozu2lBAIjHZtb++tS3DlVNyABLd0cYBjYMGH44sv5DOM\\\\\\\\\\\\\\/DEP5QXrFsQU9lRbIn4qUddfOn1CnKmJoPt+Kb9YGzI+SoyYa60ShNjI27OzShc2pKmdIBLoSFbKcJKHA\\\\\\\\\\\\\\/eekjz+fxGIv8Z6k8vo2SbL0mYVj0ZY5uwaebPuDHPk8vKhV6BSf106VmfGmSyO55RYFXEY4U+fdKeCJQiOxIqb+kmaV6c6McY8pbqmY8475oZycGmGI3P7oVLCFOpsfVvA45wwVDoLtUWUHRu3ZH3K0VutMBvXyyqvzBhhBaGaAgquxKOeKseyQCJzrqu3cqERqLMvfxG8hqX0FukXmp6LZdNIaLVDLfyy8hu7UXUOId60Y1joeV2bIh8NVJ5nc9ISd7fCHpOQWHEY7htX3jZOhpuBbdIgFTNKPg8wzOTF+XN1jIxqNQGtqN+vKmw4Bvpv2J8LlbmCN4Axyl0sE\\\\\\\\\\\\\\/c8e296L3fS3QYNQ3BSkz9SxMWxA+XtHZsUam0LC2zRuOe0KdugeViINraDEM23q+8rEPu1EVJ\\\\\\\\\\\\\\/ResiDETu31BB8JGMvt0FRAL+jm3oZsVxSDqa5mBJPBxSA5arTN1y6YBTHIn5lFKLflyY5hEDlrKiQ1aTJrKoF3PeZ\\\\\\\\\\\\\\/RjEYdVINK6u4M9MT7wzYh4JocGLBeQ496szpBkAuHxRxj2lJMUZPJfewJScQX6YPk4iN\\\\\\\\\\\\\\/J1DEPrbG++t1FL+YMur+WVQFqCSshng\\\\\\\\\\\\\\/fNArNP6eLsvftnXjg4g1msbu+l3017Cjc3dLSzHvVG1O7UjgU8R5chjDAay1OpnOo2f3rQFeFhjsffeD5wdR6pbYPcQ9fc3X0DFM20KPOE3MHe6nrrR3w3x0BjgpbaaYJKSecF2j+JCAW6V9GVoiIgEGq\\\\\\\\\\\\\\/eSUI3E5REeCKUAZJ64cjqpwywnCly\\\\\\\\\\\\\\/N2zG1M5euX9e5jAyDaiQ2LN3m97Qywl7u+eeSZMsEG8R8LHvYyT8162ciyz9ePVJkvCv\\\\\\\\\\\\\\/w77Y3HhDp2EtAQHtwD7chWvlpay2NStMvaF\\\\\\\\\\\\\\/gV6BDVy7BQv7\\\\\\\\\\\\\\/A\\\\\\\\\\\\\\/GFdM6\\\\\\\\\\\\\\/wb0ekuDk3NYVWPPk2BOnWA\\\\\\\\\\\\\\/JmfATa7NBpbfvjC\\\\\\\\\\\\\\/+cbWC0qDv\\\\\\\\\\\\\\/AZlg3pQqQ2t0ZBIHNLQZ+nYqK1qy7sA1VzAKCy\\\\\\\\\\\\\\/uuo5DfWEbbtzgwpWylvKGa2bZ4u0MwONedIVOtyqvD46eb48St\\\\\\\\\\\\\\/ve\\\\\\\\\\\\\\/+PrqshUNcrQnInYdXWTmML5C\\\\\\\\\\\\\\/R4eETtg3t5f475b3mxPu0N6sVyAPzUadX0JcjhA9psroQGJ4dPSSD4JhXumbgdO7GQ9JsY3SJJoZAUUNMpW7sIOgk1FoM8BX0I9IYXfoEcsK3SQsS7vJwqWuQsmhZUsJo2IYY+DDMUuxLCyZF\\\\\\\\\\\\\\/nmNBC4sK\\\\\\\\\\\\\\/hEMCdB50jIPVkk6oi5tqDFpyMiurA7XJb2gJjLVmtk7T6ufDD0Mr0Mt4Mek2KtKtMMC4glTMufhtowAgOJu3Fsn66mAo2Y6TMlnJ49tvyYqVockER4BJJUq3QHobAJ0RihNTTV\\\\\\\\\\\\\\/EV1OMw4pNqB9r\\\\\\\\\\\\\\/HGzYUJBK1RmZ5Aa\\\\\\\\\\\\\\/3IHOWC1vPOGqB0zXytiqpIH9v4wzkj7DZcLYfRIUpoT2TH1pslEQZdFjL\\\\\\\\\\\\\\/9tORByhnYLquBydhGSrSQKnH5ySzdTdsqJ8BeQmHiaS\\\\\\\\\\\\\\/B9xhPjo89bjBRCglQR\\\\\\\\\\\\\\/XNYpaAcs8IxbRbBorgB7\\\\\\\\\\\\\\/wI5OmdmoLJrwX9vh\\\\\\\\\\\\\\/IxgVATqXUsQlOJZXUqPnXrfo0rgix4vm5xEDF3pw82vKiyIeYL8NihzhNZ5KuF4Zaue3bApYGRPeb3PByLNzxfapXuMMCpsQRkL8Kaxbg8gt6gKDq0z0tCOtAP8ehVOR5bWRHmKYo8zbgLQA7jN+hwY678QZE0OJZtilVLLRey7zrfxMdno15EPLASpbynLxIgcRIH8cOoo3m7KMJJK6ma1bNAnv2\\\\\\\\\\\\\\/UkB9J5YJF\\\\\\\\\\\\\\/2Hv1o95jlHW52Vwa90d+rvP41DDRAgG2r9bmnvuSMV3pHSo2YrDPrbZbovnN\\\\\\\\\\\\\\/qqH9T8JAg5DUpmlKrIhwV54J9R7aFafiT1z9WXZSvgvAJGc2B3T9gdEe7GWKIylj8cp6c5g08Gmvggabvt+L1ovSZuEcBlK+apVBJav\\\\\\\\\\\\\\/5vEMFuJGBAgtVH2exUgB\\\\\\\\\\\\\\/0T6NAegJtUCByaxO28TCeMJ0z8gXoqzqvHu3aTEnqrhMkjsimIGJMSgbFRN56YMxDdnNpEGc4X0kahH1YqsjjYJXMtZlOxpUY5vdzYt4voE2FhsaSVe5qaY3Tc8XfQe799Wg\\\\\\\\\\\\\\/oRwCzyNJvC44RiMlBd+tUSg\\\\\\\\\\\\\\/cw8ruMbsL0MziLnqS1leTxjZnURYXtPvYq6eWHB3chyq5qBegC4cceHoQLqyOr+R+Putwq9TPVyfjF\\\\\\\\\\\\\\/BehnCjpVZGJ7aTMMDS2KWylljMFT3xEdpr1IUQ5RUDhNN3gTTtXBF1DiklBbcD2ALTk1ca8ELNXoCBK9VnCdoiTIn5Ms7qOSZMZ33QjJpNJeRgNUhJhfFfvK4SP+zlEnws5JYDbA\\\\\\\\\\\\\\/X32H7EYIBmNABvSB\\\\\\\\\\\\\\/R5WqDn6\\\\\\\\\\\\\\/SQ67osWWA9m\\\\\\\\\\\\\\/YiwxwPyhw+6FhfLOWVhKXVUZz996YZpD5Cm44n2lt5Hz0\\\\\\\\\\\\\\/wp21I7lV1dDoK0XQuKq+7L4\\\\\\\\\\\\\\/+Fd0J8XrmZ3IE8kTs6QA0g2miS1WhxKfTepW2XYiSNbgSf5k8lAkgnRe2ctH5KsVe1BdSOM06mYeeqOlyiXQayRcONze+1WlD7ON92dYiF6BFXODETN8vWRujhZ7ESGLJ6S7DLBj2aBnj7X+aMIIxpFbgoAH8umexu\\\\\\\\\\\\\\/gfjLiyw27mDiJuQ460fZ8lQOe\\\\\\\\\\\\\\/Svw7ApgVNXhExy7NCMo2hDQSmGSjaAWiOl3B9MKncWWmP8usP26ZZiH8ys9Y1Ev5Ouo\\\\\\\\\\\\\\/f+uVqtfO6swCHaI4gjKLOfkgGMCPetPdtUhzGRYoksc4DGlDZghH7hs+SRRJuGAyEVRsxx7vcA7csWgo2vrBkTN4yYmK6Hmjg9lmjSMQL2OM9o96FfmCG37Gj+fNpX3OkskATRT3HPUnvnWzK8dwPKn18e+O1XUnrQKPz3q\\\\\\\\\\\\\\/CL64eoT0zpLzCd+lbBJ3YLXKfk6Ggix5Gi\\\\\\\\\\\\\\/lKCIy1wb91kjw9AGcyCIvTaTjCVxtQ9vYQPHUQO\\\\\\\\\\\\\\/zKOFCcgtdmon\\\\\\\\\\\\\\/VO\\\\\\\\\\\\\\/KQih2A8ua8wcLdOCy89rw4cldqeVrus\\\\\\\\\\\\\\/WuEZG2Ibb\\\\\\\\\\\\\\/Sm2AAE8TaM8wa9NYgT4fH4BvqzOm6ADyNltFSxdeXkekG3MxEJhYtPFqznuj5uBMCSH1X+E44UU6U\\\\\\\\\\\\\\/WVwAXm\\\\\\\\\\\\\\/ZHeFHd9MgIwLZO0JYcxEzjzT7K\\\\\\\\\\\\\\/ZR2fjJfcaFaLOf1AJVMfvZ462e1ZKoIaIomueNg+IjhiM+1I\\\\\\\\\\\\\\/SjIGzoNHV3CDocrQX29qpLvwBqYYrsMbonYNjL7n+66wV5WoOeAtOblqIEk3IrGDoaj0mBArT\\\\\\\\\\\\\\/LV+9B1Hk91+7RVFYygjLuucBZBvBMx3JJkh2N56mEYnwsYRx4OQdKPXj1GLbf7LI1OGPfitPUjt2VNmW1pZYLr4+BySWm0JoyCguwTGEMDLrO8wfvGfzkx8VybEbetWyJSR0wH1Rcig\\\\\\\\\\\\\\/US+Va+TAW1ffO0CbJKwZ9YHlo7DTsVxmxbKBAaUDtf\\\\\\\\\\\\\\/6Pu0TT0Rd7Pih4hA9K3zv+wdwbH+TWu\\\\\\\\\\\\\\/TAS\\\\\\\\\\\\\\/9YpyqzOUqs9iHBTla3W4W9xyn9VqEmZKacmO3U6aLQ6eRlZLiV4r\\\\\\\\\\\\\\/DH7TrEZ7cASajzUNa0azDNbMAiVdGO8a4\\\\\\\\\\\\\\/o9oWV5NW\\\\\\\\\\\\\\/pUPy4mc+y5UmXs6tT0EnYY+2r9DPsOzYcu+RvKVz4W9VVW5tj4mHuBXeAwPTffN91IKBxiI3Roc+HCn66JrcmywU7YLg9wuJeq8c4EtUFH20pQxPKnsTa7kHPHkjl5pr86kiTmhWYDXwZ85zePrj8E4tr\\\\\\\\\\\\\\/NW+dyjktMSg9LftlfUwLZ2kmyCtcWyUHWdLEfWW5m2b09LrmDNzbuJ6aLfCZVKJlAb1jzhBwKdq4aAgeBu3OOkWgqzfnGZhh3IKpHLhE3\\\\\\\\\\\\\\/EH6TxIyzc\\\\\\\\\\\\\\/kf7UCnLKtXF4Uxccda9dBXGtomxyJEfvcG8JwcXpH5Tdq0QVGJ69RNMDoTEGipxFLk0hUhMVmTJle\\\\\\\\\\\\\\/u3hxs9qSy31gxsasM\\\\\\\\\\\\\\/wkWeEpm5ElReSnvthu+J45V\\\\\\\\\\\\\\/rbBXSobTaAHlH04oEfDZsbjsoyr4lzuir7C9owiC00I\\\\\\\\\\\\\\/g7Y9GcGDjVDfz1xe2AE5A+vvH9vaz+NYl2wITB42t02BbIGBXDyFzhLxHhdnoRxty+YGcmFOo+dTVYM8zG30LoIRTjK9OlMrHcm+AOZuGEr2A9kLQtTNrbCGrALOkteFxkl+t2HijDINZDykm45jCWm2S1SwgG0fVUF+vn9vad9Ci4HuMUH2Fa9j+sLPGL+kAJFUIuwx3x2sFjTC0Ocfiofh6oxSKNiGT9TAzSDB7n3BPRz9dyVwoU8Hl5NjNkvsP31jmySGoyEktrR\\\\\\\\\\\\\\/8+rGz1uRlNZdCfr0kaPgLyK8jQLhmmFOT7Of5uFYsV5uiFzSn1WjlOZZJUv9YRgf5\\\\\\\\\\\\\\/OIcQFv55XNwu0HK1OtrdqX42haC5m9vqoxZJDW9xG8pPSiAWM1S+7d09+v7ubViT74MGaTOh1QmGyPlRD\\\\\\\\\\\\\\/ZaoZILpLkw4VZEk326DM6Y1JPogO1hVlheOrO9lQ1lwpCUdkiYQnhAteO7E9bpGYIRRQ+KfDqf1wJbTVljIte\\\\\\\\\\\\\\/FVGc3hu3QJ4K9o\\\\\\\\\\\\\\/cFTIdGchwbWESZ6G4x+bdP23zgmP4rAse1tS\\\\\\\\\\\\\\/gw13SouKLnH\\\\\\\\\\\\\\/bJIA2Yha2QPaV\\\\\\\\\\\\\\/W0Na0td5ehP2wscGrJpeYHumNzU0FWRkNs61ur68eckBlNTR39Uf1iQERRDQtpoTpONjZqK\\\\\\\\\\\\\\/DxE2TzxiYybQFtplXkIR+9Qicqma4QtqQaNoAICHo5f1ViAJ7KYHvVnQnscS0jmaQugODZD\\\\\\\\\\\\\\/jMD3bzqM6LCDFILKYgmI+a9EETXVRb8aWDmfucc2BD0BINl7i3jCYFdFMQ1zHB3SFVHV2qn3zdlydLu3tOWgDeWAs4h59ywz4pAjlCAnPO6HCc2\\\\\\\\\\\\\\/+8xcvFeZ0depOYAJSoaK55SOKuYmxcwIuOOaYkbm153cmMnVaI+RO1GBZFD7LYmkhvR5u67f81nuSFKk2Jv2FpUTGeW\\\\\\\\\\\\\\/lBnDmTYB6qEXjoFxD4QKeAGCiwbvQcMkk5msHO\\\\\\\\\\\\\\/g04j\\\\\\\\\\\\\\/xIonJT6VvaeJkehS3bHYiGWUvZdo1FAFavmRacwzMIWQpcwZZ1DFb9uNPJ19IksvATuD36qh+AMde+W9IMQiCTt87EmPRwyMP+4mq7H+12\\\\\\\\\\\\\\/3DwhRiw5IWKdfm\\\\\\\\\\\\\\/vRG03T9BXVrY3vWfhpSVukD1IzVcTszutUAL98LZtSPrrZkjDaxJ1E+r0g8ToUKApq2XKGGdmMNfQhhFfZnJkJDU69ytHh4cE9QP5jayNZBPBJ8sj0HhJUepfr+MgKkAUcMuRcC0UAlBLKJsIEza8gUUXRIx3PmYkWAvTsXZ0KRbS8PvIEaiudqDSzTLQiS8NlrFSsH7OUI8RmmvcQOuXv1ll0c\\\\\\\\\\\\\\/dkAjfIylJVqSiS0lmnCTeCWyAFZBVTybvzlMpAcWO978+ciY\\\\\\\\\\\\\\/mv5e9CacW3Jo7hz\\\\\\\\\\\\\\/wtzqUMSjGgamrWD+tdN9lImFNrp63rJhlvyWwZpw+SGCWcBxiGpnzNP3QDhgvN4D5HaI5YQz2EGaVFy\\\\\\\\\\\\\\/VDR4CUTRVL\\\\\\\\\\\\\\/lrVKUMleyksn+VjpLpyC1MHR0KcX6uFM7FpFoPPpxK0vDMCpojLbbDlDZRIcWLqqZsvrVOGvfNsI4zTLxkP8asjmRAcNcvVqyMtCqsBHOE8QEV14btPAPv6cW2vIIsknnj1CFGYixG8BXYeDXGUexjZ8Be7r6jvyT1PhYQ2UwFHvisnRXDlBpG1TVGRuW1hDJFdSGheTRON0HtV6ThA3qK+uNFi5eV1+OsBMSwhQGaFn9r+T8R1aXT9BwfxKV7RYGE\\\\\\\\\\\\\\/41EprN2iXvfY8yUL\\\\\\\\\\\\\\/\\\\\\\\\\\\\\/axlpDchJoh+XKBUY9mr4\\\\\\\\\\\\\\/1yKSc4RMbNTGDA19w8y\\\\\\\\\\\\\\/\\\\\\\\\\\\\\/FwxZ1ES8y5qvfE4sQb2pszKuBDs9Jbrj9ttaF9pCmH6bH4pbssVR8MosQo7K6mDIC9jAc3jot\\\\\\\\\\\\\\/8sSWp3TjEZUNyvL\\\\\\\\\\\\\\/Nmid6CIQshvA1jzLhrQ7jSk2GWi1VGMWZK8gz9RBTxqviA8uk114+a7yXq5\\\\\\\\\\\\\\/P8zEaJG0W9E3zkZGdwPjI5v7zKR2+tOvWh4LtoIwKQWF4dbrqb5ob7py+hvF8jFT741JykV+Jv+SBEGCxXLJe\\\\\\\\\\\\\\/RHQXsXyaQ3QammnryT5YIdwEoShH21Slb94XzctZP2zQkBCoDz8hDNJokYl3YxpteZxwvpvHaEi1siy5c+ITYHJRUIqcIKhGy1geePmFkyAeP6Hoh77LiO6W6xWFwy8SXxw\\\\\\\\\\\\\\/GiABdtWOSUs2x6BD0zH9MTSFSnCYPsiysoDE1b974YZ9J1CpRszkjIXqX\\\\\\\\\\\\\\/XbAL2hqitKMRTIqJVdwr8dIgXOwEsKXTecBKco9u9OGSCeY9PD4mKG\\\\\\\\\\\\\\/rmQ0ZAvrFx9qPzRLhF1x5oqBcEaFyQnINd9iEUOjeGu4IgaAXKMB3NUyNQXwT1cYwOx6q7NqxXTo383VMvwkc+NW8gppYUVtCnQnqJAQEOuC100EtNZp4rFWPFH51OIqt4JCOzpV68q12k\\\\\\\\\\\\\\/MU8Pl5n5L+9sduBZGGwFINJIQugRNF35bJl0KLtVs5M5hPr5t7zj+4hQbY8F+\\\\\\\\\\\\\\/yfU2NU9A3BPGZ\\\\\\\\\\\\\\/hBWss+Su+pMIJonGrWuZ+2FEa1pQtnT6IaQhMXKt7y03FONRnJQnkqkM0TGkH91w56KudhfyYvvAPmKD85sfGdgBseyUchUt3h6GCnH9dBZbPJn57ewNP4vzJ8zi6RdFa\\\\\\\\\\\\\\/WWXBfp7YwRGFOH5yu8\\\\\\\\\\\\\\/DeeCzPHzUAhrO3l5IBdJ0gt5r2pxtmVDq7ewFS7WHBapVaADXMT+MXfeNJd1SySosKv1CTVaKAXDb1Md0+n\\\\\\\\\\\\\\/IC8IgfUSbfLuqkwns1rN5NGkU35Rr1wwjbT3n+7RSn9jSE8TBLaO0CYN+kJ0s5FccSDUgpxBsQQW+hPxI82UThNxFG0mk00z8dajI92D\\\\\\\\\\\\\\/4V6W91J5mGt+dno2jZFLJFflOq6BceX2FfczqACYqMSCbgxtu3xbe9\\\\\\\\\\\\\\/b8w5XPxvb1dlxL93cqdzD0UmfWNTFZcuOph1tATz77mGKUzjrwyoS8miaELKnJSy9M8IWgBul\\\\\\\\\\\\\\/cB3GzN8ds7EPAKRSk2v57xMlM0pHzcCEGU2arK4jcwg2djDGgqtcRZa9cFADzlc\\\\\\\\\\\\\\/JlYrzZQAveQ5jlx7dC0Fhbm0J+ppxwvKnOnpo+BZ6G7iWxTLreqJt0EVvsG+NXAjbJMn2H3J2ZTrP3FILFLBRXXTZcAVNvBIdiAsPNGhvWg5yPAfoqLFsMbjMJ9cP2D2aY3f7ovX2MIukf\\\\\\\\\\\\\\/fPrff4\\\\\\\\\\\\\\/1SNZPglghhWahGE5EQhQfpEOxPowSHbOEYUcbauIxRdRl2f2P+4U7g6O9uhQWu3zzc1iZopTrt7tkWJs1n9\\\\\\\\\\\\\\/Wx48Exla4dl9aWRKCwKCGHrsO\\\\\\\\\\\\\\/Ijt5WFgvdNh8Ng16WrSePUOYgYrHpz0\\\\\\\\\\\\\\/ZqUnMSzxHps\\\\\\\\\\\\\\/w3VtgEVbDLiszn1dhaeTimz9ANahbGDTmR9SOCTJlTJyyAPQE6JDI90UJGXKNT6XSK1ZGCm\\\\\\\\\\\\\\/dUO8fA+bDwE2HdmAw2zTFm8hdPBcBMSe\\\\\\\\\\\\\\/lq72icdimchJJgpcv6uRKlULKJC7AQ46dJLu5P61DoFgCcHaYGAZmRs8O2JHN723oKZLKZKAAetOiqByYJZD2SB50J1HKsyfJKyicNqgBHWnJsRYEwqLf80nxfJFDW2PmI8DkCAWa\\\\\\\\\\\\\\/DoQAs\\\\\\\\\\\\\\/Ak0x+z5KRlG34k3M3ceAiDIV+vs5IEObh8Wdzj1U3HLJrQy7kYepbyJSMNLC6YHMJllasYreDa3TG3SJ20X9Ui\\\\\\\\\\\\\\/Ih4eq90u3Kc3bYqERDP\\\\\\\\\\\\\\/5iWXUgWucN+lnmIE9eGcxMiUS3vciMz6F2eHnZwBdXXIc8TPPmG7FNmzQuV7vSsviZlv6nl7xLVHvBh7P8nzLMG3HWECV91fTdQeWgPEsghH4pV7OuBNq8XdVQ0ANMdLF7awbB+npP5FywxIp9Y+TH1Sl8R1xLF+zX2HZ0\\\\\\\\\\\\\\/\\\\\\\\\\\\\\/S4nyhvRWPtvAf0nftAZWOQDEJETrkCnTzSzoIoHkTcD4gv\\\\\\\\\\\\\\/PEG+bRPYfla5zAaYzLqjtom9rskBwJV5SUB\\\\\\\\\\\\\\/1YtdMp12yq\\\\\\\\\\\\\\/FtDXwCrxrLRepQbfhaFMXHDURw6tnTLvX3qu9GBZeF2KrF3xlhRQAtHij0QfmktN0Cffu0j2r\\\\\\\\\\\\\\/tdrqElxqXPF3KDuviA7YlttDew76QsAuXs\\\\\\\\\\\\\\/soJ0oW9Es6Y2vN6ul9Ww6EkFQhQ3CKzPtlnubLVGIGsmu7nzjjUe2uexxrpTzLUuxs1sRupctKtFqlkgH9Ep\\\\\\\\\\\\\\/SfvOLNejVSCqyJi9yUHhpZroVXqsUizzgZIQELV8M9yHJmkLTwOk5yFxmgmJtaeTGj91lWmgIBxE7\\\\\\\\\\\\\\/oC67IHrag2gqI+KT0BLea8d56NCUs4xFltJatfN\\\\\\\\\\\\\\/tqDoCixeS5n4OrqHBjWMVkEuy\\\\\\\\\\\\\\/gJt3Q6vwrqubxQu+DOMCxy4LP2qWL9Vc8YH14ZJms2uGTJ3KZLaYVLV8UKJCdi7+WJfPtk4u44JIopRtbLebvIiFWdPNTgDcfuXHuSqI5y7hTMUuNMkWaCr+r1F+aak9pqA1Hk8cx6buSkzZ2TJfYz1zWA2tapy93CCr5KAM\\\\\\\\\\\\\\/WOvaAgEY5uGCrnbWPZfu7J1PbHgTc\\\\\\\\\\\\\\/3xSEpAx670J3+PxWPRlRLpvEqE8CQR13fyszmnWVtcvVBcJcyrVzN80+rxybR4z3o\\\\\\\\\\\\\\/R3sT9y9pZfRHdELICLl0AeRaNuSI01XaP99wQqK7ncKTu079i0whTMJoM4IE00CynFJHaekJPmifv2xvF16LQDUykjusZFhFj6jIbcJPABVebouVdt36cZMBFI0gP6IMOKXQ5Ali132P\\\\\\\\\\\\\\/gHFEGLabYBQoDBy4nO1sxhpCXk\\\\\\\\\\\\\\/iQMePuOxqpwDrvGt6w0MzfJJC3l8lkO\\\\\\\\\\\\\\/FBOQjneoVaYLnep1pvR4D30GMf74nDt6pRRzzSNElkcw38d3eor5ZphFd70U1YWaePzNmTqNyxeThNVbJo1igClNx5udG4vVCeSy1XHUVzzlUYo\\\\\\\\\\\\\\/YDwdG9rbnLXE06Tj+Qe9F5trW1dd9Fy9am5ZYLsOiak5SYWGz8XK8IQpscRZUFMXxAOU8eooPxVstiYkQS0jrhBSGwbNWdFycSfWJVNvsILa2rvZ+vY2ESMHTEgP2bJmdN8coFVek8gRaAeuT6HFpohbkiqrVG\\\\\\\\\\\\\\/XQloFf6RC+kh0s+U5keJbYkA1Hn4Z+tkN+SjCgyEVCtDV8Nketw7eLu5HRIQjCVZ4pE8QyZx0ktWoXcVftI4ab94FjRn3fZIU9ZZqv43SLzFjJRQzXLwud1C+UPd5oucbwmiThg4vZf4B\\\\\\\\\\\\\\/4MO9hGAIAf8OUlgT1NwtAKj5bcA+fYP1UK6zQ+kCJD7ED1zJQ8RdF0H6XU4Il4JBqfwgH4b8tbiuYvc5PBZy\\\\\\\\\\\\\\/PC4W1heju6ixe8oQvsTDQjnMhap9gVVc1\\\\\\\\\\\\\\/y0Oz+JFW3UES8jLmFgj1wMw3N8eJ1zpaJvIU\\\\\\\\\\\\\\/Nfr1JcHOcqhZUaaNXt7G\\\\\\\\\\\\\\/E0\\\\\\\\\\\\\\/kGjMzN9hUKgqgjkNRByi+WY7E7vo3ha+cAV0A6WZ6tw2eH4vMWki\\\\\\\\\\\\\\/sC58u2ifPr+hZ+5EWootOsZdYyWQxJmYef7Wgnw2Sc83PtB0+8Hmdzy\\\\\\\\\\\\\\/\\\\\\\\\\\\\\/u5kOOLjBwdVRcYU4AFGg8zNweR8zj+1xaTZBpoezXeCfDQ37Yu3WHhFuwhckRgVU58iG\\\\\\\\\\\\\\/tc17pzatYlYPepXYLxKmuITUwHI4gBG4dVPsuDNzAT+wtWxXxEBJMVHmVMDcCKqgXKVoJ9MCnNk4UQhSuB+dPZrJyxMkBZib1GeM9P2y+fpEprheA57Yx\\\\\\\\\\\\\\/MFKYKH79L3iEY5NGPCM4yo81U31DnkIvTuG6sOnYORTLCrKiktqhXWYuwFBUtTmyRHPN68ibzw0rOOrIeQOk5hDu\\\\\\\\\\\\\\/DHbgqXpbaPHmxNjc4AQrbuc8WbSbGrxdRUwg4qMYTdUpaew2H6IQUpsqCVRrWF91gbz0zJnZ8vsI7Lb3vEVUvyJ7T6UNwX4QQGWEduLnAEF9fMEf\\\\\\\\\\\\\\/sKrr9wEf1bpPJA\\\\\\\\\\\\\\/33hDFwD8ypcX26L2MOf4bISJWYVickPfefhfT\\\\\\\\\\\\\\/VuLF0DMparPeCdjNuXbNTxld5qllOamezvGk2D9r3OE8df4m6FvQzvjj4h+yJ4DQ7dogAb+AZFfsE8HgmQm50x2ySNmwK45BpTCBNEijL3Tm+lX7eWtdzyiUj0JlYIrT6owSb\\\\\\\\\\\\\\/0MtxKZTMN3iuCE3Y0\\\\\\\\\\\\\\/hv576uB4wlEI3geFz3GOyJuc9GbR79W4QHgqM+2JyDHQxKx7Qz8X2DImz5IA7PntrYaMjJ\\\\\\\\\\\\\\/0vdHVZW8o0siWfcKyLU0kkl\\\\\\\\\\\\\\/xVUVFlWazo74Lr4w3xh95I7rCvRdKj1Q\\\\\\\\\\\\\\/2GMBtzDw4GKHsBDDdQsPASXwqTucBlsKkXZMjtTAf\\\\\\\\\\\\\\/HZHMgXdz3l5C8hKwjguUcoIYRjme66TQ+AjaQE5LPFisdPJmqsHP55vVV2s6dusWrysENEFDkYqzrFegoSL3fZdGnrIqFKGPisMuAZK6ARO6ds2nd\\\\\\\\\\\\\\/KvQfeAk640FpiPkL7e4362M1Tq8FsGM58tEksmFc64+wiDpe4O7y3UP7auJUiWtsqTKhGhEsIxAOGKz3vbt392Epzwfdou7S4YZcRvFbq1Z17aU7zd2YsJJbYI9TN8M9MaqVObEgVmeeVT0mAzyjVlp2q1Hdg+GwTSEgnmdkD2gP1L7\\\\\\\\\\\\\\/7kotZlcsjO9d61mS+ToIcdPgsJFKgLPXhiWKDP8smHqamnC6h+gT5IIJnlkrq7s+iPcvlMw+eCnm1kbVcjGAh8o6q77F7e3iiiAaFglnK6XPUrsQSRRHoRD88orc2onM4tqV6mwBBH183eN7TTPRPQFH6TxEZHg9ZlAx40X78D1NmfBv9tL5lFGv46uDAGljfYOfwW13v9Nq1SJiQD9aKqqlNHi+RsaVbrwJCbkMXx2PGAWkf1LOcH\\\\\\\\\\\\\\/n0rwmmI\\\\\\\\\\\\\\/h1vkxqt01d4DPlehwty+MwbhssHtnHpLDIEv7CM3vnZxyBrIZr6bL2YVGYr2RTZiszmRqfUFW8R3pJA10pNzDbR3z7opkGn1gMydzqVMYKUmQu5fqM7AFjqOuwWL3FcyoFV6k7Pp0g5f5PNCXGHiAcYIoohQhOBQHoYOt8DY7UoFZJ3ORjjzSWdAjztwbifxTEvbP9fruqgp0EUFDh2DSa4W5Sv8hIjkXIXfO429gJMROPF1T8W2yzJGKNUw1pYluFhcTKYcHkbvzUZRm87qaq9l8fgBDc\\\\\\\\\\\\\\/\\\\\\\\\\\\\\/nfiwHClrfQF50cxpMNhECyAJgeiXwjukUvV0liInvj+XzysMNlLqLjwZoPnQugFP+d8RT2D+Dy7KGF7+865W2p\\\\\\\\\\\\\\/cM188QSc4G2lu1yFXGQIB1OeNeEWFIHjgXFhhm3IFLuuxUXovf36jqdDkxD8EhY5FzZYX3q49QciVF1PDDdp5B7l2bVfYhEMh67DgQbXRhLI0Zizd9kiwSgBGYk8jB5y+eU15XwrOiO+tTZzY+cOWkH3PjbMwx0nGOSLskucyWm1RIh7jj7SZ0YD8IQUkjFCR8X+5Z1Rc\\\\\\\\\\\\\\/NU8lw5MEFbbBahcIqdHyW0XwrSzUw5tVEBXnN1XUM5fLtx2RDHI33XG6E9+KxrAOOS8QIzA\\\\\\\\\\\\\\/pf0rvb3Vx5ifLgOLYENfnlMKlrb65bdwZnhvwC9jQgDwlD7\\\\\\\\\\\\\\/hnBCZS4OzuytPWjKNPTe6g0AQU61Q6OjeofW4A9CuKJYxPUUkhgs\\\\\\\\\\\\\\/e1\\\\\\\\\\\\\\/FKLl072efvFWO7qvNZl3MxdDmz7fjw1zdulWwDV85ye4GqiAoY6jsl6\\\\\\\\\\\\\\/vXtAX2M6wOHgDRujndDeY0wv6\\\\\\\\\\\\\\/gb3YYy\\\\\\\\\\\\\\/tn6MQDS\\\\\\\\\\\\\\/yzU9VkrJmpqR7wpFqhN6DMSSuupmGL7NUfxwYT116IdWTT1b1xg1PkTJ0B9YPd116Pcd17dxIFuooVzYjTxFJSO1bF0pvDaWqvRJ190X66ne8wLFcm3UtVP25z3fGeHXvBAwCiCIKrLY4IbrJpMpUX6E91S7PtQdJbYJcLIEMk5V508dIvnxlhFz4o+RelXGGqQrRvjWW2L\\\\\\\\\\\\\\/yN4pbDMNCTU7T4SZfla91RagtPKWc1k7Mmtrwak6aqJh0Vq2mHuwP+IDGvpg++4OxzgwesIB\\\\\\\\\\\\\\/43jROExq+YgOdnQipPhdfjIMs3I6Rhp6JmYTmSII8PZPAXfLeCteLu0G7NClDyN35clvLXJFqklxIRMi2uLKHPhor+J7a+cdX+VNJCDUOcLxbY80Fk6lL6CNrZdLEx705tx8szOX3gD5mpvzI2ZgmO6vlLmgfKaaTJJGxyJ8J3opid37IuC976UnZFvs2CphELdg5WQHg48x2lRuM1nQNfOjhEtonZS37Ty6QrD3OlIgHUWIR9NXfqs+8HWrQk5h3CvNROxr9OTxlj4BaikdC7bKzakNCpA10aoSeB1dP+\\\\\\\\\\\\\\/J\\\\\\\\\\\\\\/k1bU0ia876U4HIj5vYNFbp29x7cnY\\\\\\\\\\\\\\/\\\\\\\\\\\\\\/D\\\\\\\\\\\\\\/6lW7tyOZPDHkHhyaJyL1oQGas44AqIrJtBVNu6WerSHgPbnus90VqMDs16LIIfMTcB6WU+ed\\\\\\\\\\\\\\/u\\\\\\\\\\\\\\/5FZef3l8ju0df15qgt\\\\\\\\\\\\\\/2VGnYFOBit4fhMxc+OW\\\\\\\\\\\\\\/tU+ysyH\\\\\\\\\\\\\\/1JoQz08saz+alimCZzRnV2rlfULaX8XPns91gObLjjF2Q\\\\\\\\\\\\\\/4JaDj8pIgfNTnUVv8nBh0pm3H2\\\\\\\\\\\\\\/q5Ir03ajqfP5PRUWWC9NXN9a0Wf5s3T946xRm+b7zwZvx11gIWIaYwkJK58Tdx+vtSyEI1NVDYpLqrk2jh2hlYQ0EHehTt3CA2m7OZyL9L88z6dPXnU7hLhxIsN9lBh8tBBwRuabs1iZHMOzxG2VPaJR5yYtM0N7Fy+oihWo1sWMcFXnwwqGdFOiJwI+P3bExcr5TfFA1Z+1MTOLqic\\\\\\\\\\\\\\/sh8dbh+J6f4\\\\\\\\\\\\\\/LaXPoym3j74TulJxvX0FcrMTDliGd1TXlgR+h8o6HcTgTB\\\\\\\\\\\\\\/BvBXERFuSk7BWqGaJ3fMtcqiGP+IaChW\\\\\\\\\\\\\\/S4GrZF96KXCr4tk6jXIU5\\\\\\\\\\\\\\/9gSlm75+boozpKn4z4gJvCqr7Q6NGj7xhNVfQhvJM1A6zt1VhPnptbZJBhj6QGsnhD9AvpsIZXN+Ao+ZS362WhcJyuykZcolptws3Y2+daLtywItOnmLRfYEQOf8jXyV6rjtwwizfT1oIZSN9GMKtSCeq0HRZkhQZ9BcSgFSyqGU2b6HAN5GctrDd4vd9pmgAB0e7Hc53+tJJaBP8MqMsJZ6wtSVhdQlCWy7DqiL8pjyQkjW2h6rd1KjkYznZO1CTjOXS9yQKtaCsCZfKvF3D\\\\\\\\\\\\\\/sxNCgDET6u9aA9YPq45CPH3XUkNJAO5rZIaJtgtL03VM0S+wchpHIDNqgIC7Z8Af9Z7VHy7tvQnxpJDdGWEcHTFm8K\\\\\\\\\\\\\\/YgsDvuyr54ls5FtX\\\\\\\\\\\\\\/3TQYIXfH2GApTcQSh+ULPgpb7y9fzNU6vy3vVt+y8+oZ0zw9BYTQqOiaOeMdxqCAMHjqlUdNggjltqXvP00JUHEQFltMkVC33iZISbd+tdPXRjZfTCsIbbePVDGRhNv7QxjGl6YIxyIdfDJbYzu3uWIJ2KWiuToy88BRuHNqdmUwxDjHyc8ZNqUMIfKzC3NwWKcGGCCZdf25xdlN4junkfu2Phn92yhikVALUJWU6yLnuN0BK\\\\\\\\\\\\\\/+zfL2\\\\\\\\\\\\\\/l7X1UsYl+\\\\\\\\\\\\\\/lcQD7gkCrThMtTK5SI7nuPTmV8K9y99\\\\\\\\\\\\\\/E+G6odHoTo7CFYYh913NF0jP5plPEPE699NIUfBDWZUfWSTT4Wn8qJjfAyhu+E4SeWIrdtoh6MNo48JnpLEF1Ci5egGVej98fWpYMcygKrF+dtvIUnSyyuaaMq5+k73Y6RUU+HmbSHjapCVKldArB763ABQvIkmqxYtECMFRW7+aZz2QCpD2o3ysEjyIjPDWaTMiJd1iZ8tmvMeckJJDOQd1ZjRvVz625wSB3sKnS7rSNMO53dbkIQiD8kJFOt27dpkkrY2qO8zRZB\\\\\\u0022,\\\\\\u0022iv\\\\\\u0022:\\\\\\u0022CEQYdnAUqeO\\\\\\\\\\\\\\/GXfV3ylZkg==\\\\\\u0022,\\\\\\u0022salt\\\\\\u0022:\\\\\\u0022f4d040311b2fd2429a61a615cefc1b83\\\\\\u0022}\\u0022,\\u0022hmac\\u0022:\\u00229d75534928752a5ff2e05733230c34cc9d01007cd4efbe33dc9a94f000fb6de6\\u0022}\",\"new-28\":\"{\\u0022encrypted\\u0022:\\u0022{\\\\\\u0022encrypted\\\\\\u0022:\\\\\\u0022Sx1nAxu+nG6mAfi6evxd9YKZ6xE0zIjC07lr2EzxvnTr0gt5dzSUqvEpXn6eaVNaIzPncei\\\\\\\\\\\\\\/1oumCqYU+4Y9zMtJ6H+MKuNDNFZeEue0STonFZkGICncm7rvk\\\\\\\\\\\\\\/bXgSy8KT7fOadeeK7EuuH\\\\\\\\\\\\\\/sJpG0txMIQaMiDkyiRfAuFEeyrfKj\\\\\\\\\\\\\\/V3JUDCoQjuswTy+ePEQfKwws9G6SW0acEiLNxlmOGTPyz0KBGp9CCvuHTdzNscwRIXfD8uiC9iy5367Ve0OK9XtYnXkFoIXcZuBX7Y9TH1ZfnoZobf4fJFGcxdfkY7riX35+4VvB60MJ6Pe7cc2k6bcqO9CEALpXVHGW+10Xdz1ouq9ywYjdHuD9+3nm3Z6rOme9MOaRMzSV7a65ryZ\\\\\\\\\\\\\\/pN3gxPXSU\\\\\\\\\\\\\\/pTU539CWeHppmgQypwKUiqnjXHLRNR2h7U9IyylppwSpAUh5gKNiOSdItdRwoG2EwpiAzQzxU5hM0GY901SeDC4MufUnUC6peK5ak8FWqal3H4gvo2zR355qq4zPsWvSOR8yus3YKvjEvQm0UijwM4LFTreq8vNxzH39Dpo0Npev6qu7StEV7QxnNAOvymgm9y0Fe2g55UoVR05ba2O1c5mR7GysX3bP9b7oyiMoArargsQjUwZQk9INHjBXgDLbpuPhtbZSlUTp4ga8b5JUjP55U3Gl1Mi5ZYjLr+qJo4nVeCqDwA\\\\\\\\\\\\\\/0rM7QAue2ZryJ+F546B4eoZ5vbiC8dX4XgFwxh+GBf3r8Enex7vhzEEE4MDXugU+mZwY8c9cyahmUeXx7fjIShbxHimQAcasE3Yo3ZNjDogckIdXHLj2LqxsE41wzCG3qqpNAFUBgKSOuV032qhxdBpYfjKZwj4xJ2bYtmwmm5K0TWEw4Jh3jfEUuegkeKItmMHeTRgKjy5KqeqvvsCHbv2aDTKPCTsQwMZ1plG6WgbEhnWVt5lbOx7b97rhfSZvyRtmC3\\\\\\\\\\\\\\/uWS7Lm0fND92HFM0k9WvQzMsK+WGv3ijK2sQaW6S\\\\\\\\\\\\\\/0P6i65JeCCKrDLYPsTOjEawenNj3ch+ZRA\\\\\\\\\\\\\\/iLcvugl6dRCqrbmTQXcK\\\\\\\\\\\\\\/rKFTWhMHoiA0I\\\\\\\\\\\\\\/QTofYUG7w6TEbdV01Wr1k84BrYCTrUDw13OfyS23043l2D6PF33iOt\\\\\\\\\\\\\\/ulH1lyL\\\\\\\\\\\\\\/ST0gS6SYQh\\\\\\\\\\\\\\/oHzQcHhGBU\\\\\\\\\\\\\\/Nuq6Er7EkJOcYMQy9siecNan6UG7e+653a1phbVVspFPTJ9oZF5XMkgbRcFZgSlgNookwvaaSyncxbZvv8Gj4Hmre6s6D37C0\\\\\\\\\\\\\\/KuC+86\\\\\\\\\\\\\\/ZNV2GU1Tr61s0OTs8ey\\\\\\\\\\\\\\/jRNu3fcqksnB56IBBOD1ZaNwaXyzcqfjCV5CHOT95Du+Hw\\\\\\\\\\\\\\/r76QEBbE73driQpO7TacsUYzK48I+oG6g9b3jFTiP8aPqXbnpzQ0o\\\\\\\\\\\\\\/0X5slfsK9OCY9Tkxx0djdGmuG7NoviFw8HDpo8Ab643NmpoZVjkSz2ZV3Cgz\\\\\\\\\\\\\\/EJumx3lmGVGoD6O6ou5IXmwBJVCn9MRTFbGnPeSGl6gvWzgMSEuZQXyH8aJodBq9ywonafhdaQLrSRebQnQWsznEkPBm5pcKlg0KqBer\\\\\\\\\\\\\\/TAl6ijqthBPlvZIprYGNchLpkPFVAFuj1lYuCHMCAiNmCkr3h40meic1kIq1lTcvQmdCekgMbkKuL7SkosFSSCa1FEjDfIwle2TBY5fR34NwWP21sAbKjhC3tGICYMSjJ9R4QJMpl45CMKLLta\\\\\\\\\\\\\\/tKVOijGqFidmkU\\\\\\\\\\\\\\/cfnjBwFcvu08BIDwVGkeMLnAp52pVQkCUEeiUyL9jboakJEaDDtjhfZ1cZ4A829cYMcgjP0lu7nfcKlBTKHDDv+Caj+z1vm1pz1PeJSSMtYt71EK4mBAHTMN2QYVgBDkAuYvii6\\\\\\\\\\\\\\/ReAbNjygPPYYGeD0w3lhkopFru3gOutWGLowN5TWUKPQUjpfNmKvYdCG1sMLQtnJjyaFR79sB1p8yx56kgIKjzCGwpNIDicmc9CdJrpvVPrQN12UM4keJl\\\\\\\\\\\\\\/Z+aNA9JxzgAkTcb4KGosdEaKf\\\\\\\\\\\\\\/otLHMAbxR2Ew1hDFsKL1A+zmr+7VaSoEVJGBDiYQc0RWnXf4ewBxy8nhxjYMcO5LtBrdwVX1i3rUY55Y9Ey7N6kH3D3RtTohAuEtI6jYfTGuJUGQ1TeWeM6p\\\\\\\\\\\\\\/0JI4HOEK3su6F8FB1ifpnvC625rGkj\\\\\\\\\\\\\\/qOgGdYgM\\\\\\\\\\\\\\/F9pm95hRNvSQSweHS\\\\\\\\\\\\\\/brGYYL7MaVbjCaCx4uatlXGMGZTgnoKJwx8zJfhldctYq0Ml0nbMibk3398qUYwwcR5TTvOe06VNDz3vQfnWcC\\\\\\\\\\\\\\/K8PZreCJbtdfssYiJmQ0Ez6LYR2d3TAJFJ9vdqzo4dW62w4wBzzpWLJL8b1Jqv3Lw9ku3mPMoPbE\\\\\\\\\\\\\\/YtBJZy3ghw5P2U1Jc1BKwFbRnbc3F5IXJlcpOkxQztmL90WC7DAYHedT0ow\\\\\\\\\\\\\\/Yjoeta3T64v1WLNaLPUBqzH+OTgf5PuA\\\\\\\\\\\\\\/AkNv53MR7\\\\\\\\\\\\\\/ZCwNL09VgYj9vZ+vHatD4VL5YDTKmPWpwMDe36EvKfXJNWHWdWoqaGpX+Qeg2WWk6wR\\\\\\\\\\\\\\/Rld4flT9vmGe67wA52LgcksPe+8z0\\\\\\\\\\\\\\/cd7CSnEn38+3seSSpOz\\\\\\\\\\\\\\/mOIAyvC6IvPQ62CKdAGd+MMEpeVeCCgV4r7O6SC3fFXFSJIFDIuc6urUkbV88WaWUt7sJejLDPQzjjDRRWIbaAdygjS0Y178ZLBvtXRCbdwKW\\\\\\\\\\\\\\/szQJRJi3Xe56trp4qMyeQs01xm71+cbJC+KMMrT59PB\\\\\\\\\\\\\\/YrvTEo1\\\\\\\\\\\\\\/8Yx903IOXyE0IxYtdL8QTJC\\\\\\\\\\\\\\/96ShVbESFwQHwlnLtbUAco2D80K4xMXjP2CgGpKtggkqgAVzoQYOPsiGTEb8FUvn4BGN6B1u9RrVQ3DCN278Cf85GFdZrxh3Iu1RgnqDOd68LSRxqrF4fjEhgEZ97UqaeNWtisU5T6euEo8Pd6o31yCclO4vKlIHiAUIwvABvbZJ7h4whBViKNP8DSfmuySwKL3iUZFiDV+FPfnFor3Nj\\\\\\\\\\\\\\/UiJW9\\\\\\\\\\\\\\/HkyY3AMhv4IYHquxlYzT7Jx+amgSl\\\\\\\\\\\\\\/dlfsye7L9f5P0uCIYoBO0QXbTKkWC8elkQpg8\\\\\\\\\\\\\\/pVhn00UoXraGpvtaVZMQObByIZrG8Rk1yTG5IXEeiwkWoad4m\\\\\\\\\\\\\\/j4H8YmAxDRifZNAAd88rKPKz3tql+OrU6ktuHQzzb2AxyZ+I7ATAlJRw9LejVGBKRzjZJxHmFrc57JhHymkk6uPFb11\\\\\\\\\\\\\\/RyWUizTftq5JB9xYkeosPx+zGfEiMmHTh8\\\\\\\\\\\\\\/N2rz\\\\\\\\\\\\\\/Mr1\\\\\\\\\\\\\\/DYj9wFEHZuk82xmajGY9\\\\\\\\\\\\\\/ReapVm+8gjFY5XX0KtMiMYp+nro61ZKnEVG+SswRq6s+85Fwa\\\\\\\\\\\\\\/U7tUGuc0Xcl3ZvWAyG3xPlLcSY4PviAjmPCF8Ji4Qf9\\\\\\\\\\\\\\/eyUNkaIM9RgjFL14QhR+rDIPoMt2rf1rAr0bCwWMbl10nLjaKolxJ3trExTlvw5SObVH60zALXMKiEqq\\\\\\\\\\\\\\/3gbo1FhLnUGI006dVlMeXzzjrBkBJzy+4wxvX3fbce4aRiPdgZZ\\\\\\\\\\\\\\/LqEIQTwXG+ayDRpcVXLvSIGiU0Yu3bMBPXTX78OUSQyh2OPBL2P3KvDO7o29vFKvM8OKoA2gQzfMSAYfdT0mtsqR26XWOip0eYUkEPv07wVFvOV58mE666v3cQBgZ96soe4mX1M\\\\\\\\\\\\\\/Y8v1En4V847PlXHveSSO8mkDtfDKA+P2asm+H5uKuEDnrhpLxyqDJdOaP08I95NQpV\\\\\\\\\\\\\\/o0UBLec0u1RUbnBMw7vAS3yCQZl4poUjpfn+Dz0CYTVVIZxQ0q3jdbwriKYqnP5EH\\\\\\\\\\\\\\/Z0ZwyLAuiPYeafRyzfCUsfYcyWor1aET4dIgw5Bvr3v\\\\\\\\\\\\\\/IRPlNYsz7f79LsBgzuvqvs+TKH\\\\\\\\\\\\\\/BztnmxHFprXT+XPYprD+0aw2z2Z6\\\\\\\\\\\\\\/Vow\\\\\\\\\\\\\\/9IDNfAlBpILWSjZtreRHd1qwALocPG8gYjOC45pZV7Xp3g5fx\\\\\\\\\\\\\\/WjnQTlwfPIfZKo8Ze8QW1HFJDMdIwy19l7tXhlW2a3QG40heI2TBuZiiYiqmHSCwLhyK5VqZPo7Kt\\\\\\\\\\\\\\/Qv3wcn7kloaWQkkl4iw1QiKHymhv\\\\\\\\\\\\\\/WFiOUyYBrMByQIy3kfjc4vFecOhuFQ9Znb9cWrNnsTuueEw5WLTXA2fyrzc5Gk3r+HXpT9rNe2XcSSIyyTfUXQNZQEpjPehGJszRHXcSx4wSdXCeyPIaVHliPfJxa4gLMgQB7PGtWEPBD4e1R5RS\\\\\\\\\\\\\\/ui1mbrgE8bhYvQSEjgHVvQ+XU9pWU430mR39808l\\\\\\\\\\\\\\/\\\\\\\\\\\\\\/5CpyuAbOkWYdZZZgdTO4BWiWKiLxr6NgGfKoUZLhO+1gL2C7eUqIO5Z4e0o27SdsyHOV9ORZEQBdllopCp91K4+5Ad6i2oRhzxKBd6HmQhstyiy4AlW1DLfhD7p59TUBWWv0M553FAvwuyyxYVDAieE1oIm0TOzY5YxbgIUOrxK74nPcYoAvbdcQFwxtCSsvLtjIYhwenAvHkwNxJ5z2cU+azW10IoXHTOjcEMMCRP9hq2r7OhWygBqtVbfc9bkrF02b2B85gPep7JHZgmYPiXCFwNPNsL6KLtWJI3RIvhmDXXcAD5WnvjerzVlUCgoOWQelH82qHkDbZFptuC8OAEGlJJ6XPQL0bGFkTewwODlGEDI6bx6yg9weKPaG4yJXq3zNpaJKXbxv8pDD+LlQ5Tau9sLLdhNjLF21WLyGNwuUK+GIbSRkobhSsW7yAomfDy9XP\\\\\\\\\\\\\\/alj1p59JyWhnNGojdNQm\\\\\\\\\\\\\\/NG+6A2guKGibYUX0wxxrLdcWL5X52bY9bTooeDfIY0dI\\\\\\\\\\\\\\/iEinpjL4vx0JDEIu3GtOn\\\\\\\\\\\\\\/poA4r7tpIKRJtJPFyhZrdbHWV6W+7KkJnonq0wpT7ooCRFm27UJ2brtcj0HhRBUxUbP49TqKv8WZoFIJCqLPltHTHPW\\\\\\\\\\\\\\/whmvfT+BnNRxqz8dGqPQq2LBPHL6hndXLmqqSJUDwOdzow+M6w77VBTSSXBuEdtRymV1h5SvBLR2udZvlx1csOIjmBNUzZCTR8+q5C+W96cASVef8YQqWB\\\\\\\\\\\\\\/YkhwrvogIyF8wMIVqBZeCPIoZUZ\\\\\\\\\\\\\\/TJlSHHay5KsDq7erZk0uaFe38\\\\\\\\\\\\\\/LQn+jI0DpT4zKZ2m\\\\\\\\\\\\\\/13dRQg\\\\\\\\\\\\\\/ltUHoKcFlG\\\\\\\\\\\\\\/3vIfthifxe04ozksvTe1mRByzk954yV\\\\\\\\\\\\\\/xS3PB4Bk1sjk40qe9K4oPCq+4pGH6w00Nd4MDp0hUMUDSkSFAI0ReleMAKAXmrKE\\\\\\\\\\\\\\/I7K5dp1ASerlU65QnSLN2kNZb52iT9V450zWFGUt6uoms\\\\\\\\\\\\\\/Mtr8uJrF8YzIohBN04rx5zLv9pPAZxy7fk1bMTWSleOAgsZjspFVHGupqTRVJu7d0xuTA2NUI0nPCGH95xXThOsyrvJTOqtN\\\\\\\\\\\\\\/5EsZdIPa9vxQOuw4CpuOkn6AejXYx03tJEE6NcaFJlbhZpDfeCVqC81Q9niyaltI4Vd+pA6qu2\\\\\\\\\\\\\\/e\\\\\\\\\\\\\\/3dl9BxmhHgbXD5Yr2B6I3eFg6KiVuyF1re+WlZOwprGp4oInuezZ8vE2CLBPHOPZ24NyUhFo90qXgoKvKAOKwlc\\\\\\\\\\\\\\/ZobbKlhZjlPHsK\\\\\\\\\\\\\\/C1gWGEZq9fhPZTOr4c9OhE2p6yPW5ZQTm9BqqC9rxgQ8KjxP\\\\\\\\\\\\\\/wwBRpd+XxQIS5Vd0+XE87oayjhOAvOlwwifhDRUrS\\\\\\\\\\\\\\/4BnWtbjApaQ03Kf2+gRFzXg81P+wyNIuDL2lUPRFjvLEpiYvsKtVJiYhS64fTal7twYHl\\\\\\\\\\\\\\/LC6d20DbHUEsK4zyggv3G78Vr\\\\\\\\\\\\\\/Rqw4vqGvPyWaTeTu7puz\\\\\\\\\\\\\\/xTY0BQvBGTMqpdF+Guh\\\\\\\\\\\\\\/3Fi26z+426Pg+tvVMgZkn2\\\\\\\\\\\\\\/OYAOUgb\\\\\\\\\\\\\\/EJ6tP6bLfOX2E4abq45CePwp+Qj+SfeppUMQpLIjIYUKznHPAOuuwwQb9Jf6yeSIwFJqLbOOzQQ19pw5IxmGu2llA2cex3O0kmg3\\\\\\\\\\\\\\/yHklCxRQeXT\\\\\\\\\\\\\\/0gUAHAKcFWS8avTgAGzXV9ygnklt+0g1x9x5uYbpWutwZaT1zp28Syo93LbPyeWOM8LDcfBYFn+VBy1wjXK9xmbaIBYQJDaclv2E5W1HdwrfAccGpzPsOeApEyG0lz3m1\\\\\\\\\\\\\\/DGDiOkk1Q2cE9XU6ANYUxLg4ZuM7lamyU5D20n0RYMM1k1kVS29CjeyY3klkWnc9mV2GqaHQGAoy6stGzcF\\\\\\\\\\\\\\/kNKhxbFVNwOEXAInwcku4fvXzqWVRQRlCSwe1eWRepvV1fynl0cYyFSKa2tbzO5WLk+Kwqk8SLTaF89LShcPk+uweyTLX1+T2UkjbUNlflNR1yfNqkKAcEg1oMkNaVqTpEU8qNRLJeE7S6iK\\\\\\\\\\\\\\/kTCARLxXMJWyFRQPSJ8hq5izlfKE2WO1LK0BKNRWsqf39kV93Sw5nCwVdZ30ZvtPmjDa1+cDhCbKWaoDJLsOF1ImR\\\\\\\\\\\\\\/Hq525gcuMOMhvm4V0k97aSpaIPBZARDLOpUMPhA3LDln+tRIxpc2BHe\\\\\\\\\\\\\\/GE0qmzwmJ9hhCuHsorBvUc3OweXpKbFLutHgjXw2VslznSor1f6B4RgS8ONOU0xdkWRuXyxzRk796M5nB9tXA5BKevrytfGPVjj2cIyNVF91UoEo3s2rYTzNwjtAdWKJG5+Yo+NxHkVaXm9rjrQAjRebl8SP15eQWMwtDmrgBfcZaWPAS29AoMGI0ICO1jzt1j1EH6c9LPe5seF9rOZm7lxxE7fly6CYo3I4VEPw\\\\\\\\\\\\\\/eM8Wbu9wK2TIE17IaOWpSCWAVRiJHfiHmVBetzZ\\\\\\\\\\\\\\/i7I7cd+bYRiWlgVEvEx\\\\\\\\\\\\\\/vXI41xH7FFja4wknaTu2C5F6k9c1IY5B0f0PkWmLLa84vStP18hMJYOBf4tMZNX7ssFeLMNhph1SK5ymT4VpI4yyfm\\\\\\\\\\\\\\/rbw\\\\\\\\\\\\\\/9Nq2fjtzsiLN6GgxB6nPgHND2g7f8DjLSTA+QbfH\\\\\\\\\\\\\\/4mL2h0L8jWwljxRAskbskHKC24Z48zZYWdH\\\\\\\\\\\\\\/Acjhy47Bui54OzeYjsPUtk0PMDTOxMfEQZEe9fYT0D058oF03FA5oZQ6U5LUpc6t4CMieS7DK4Bnt7iO+\\\\\\\\\\\\\\/KpN03YycnWH5F5IanSb8ykENFUr6NEEyvJJMxxy\\\\\\\\\\\\\\/ZEz+fsU50TNrUhbsowDVsNXjdebJDzaArBHjYC4VbPACEJqPnfgpCJORA5lHXAycV+NyEZPoEToEswlB4vjVvc8705KLY2Pp7s+Lixesr8LnK+h8F4Nq0R9tOKzHtxLntggjsbBFgcnxUB0O01JMYPPu9d\\\\\\\\\\\\\\/deYCbjGNxdeohx7Bg9B5JGX1asWEbEZf3uvXbbEcAhUvV8rRaWWSwgMl236pEAY7T4ykyphslq59JWVKLQZrZqWaEl5dy3EzHqCIozrgMwo+V18a8pGNuzeiLGqIiRLoZb1F82vNPeKgkil0y7kbVAr1c1WopA25bPhbKnJwuYLVtGjWhXGeHMgXvJ4NG1SKaqtQ+AAkAJEtErn73IiK4vpEvERs5jY11bxktoLK1M08mcX9gfDzUrKDnPL07awVI9XM2JvQJsYSc0G2Wt68o5TKVxvZ8mpVM5eYgX337zz72RnUBCsPfaZn1vCzD6heQ1phMbsoVouokZ8dbo84NHi8AtXraLSFynbchKILCxV3RRyqQUQJZC3DYeVTQJMvWPj+gMvfAXM5h\\\\\\\\\\\\\\/7\\\\\\\\\\\\\\/CKJSIvqrEX4d+k7U11ztLkIuo3OzngueOlqoKK4BCZ0r7dJLUDUsgW\\\\\\\\\\\\\\/1IMCjEUzv\\\\\\\\\\\\\\/EKHZdmippXn7Ykt5rRm59u76GxngYiXs1rhAAiui6jvszUI9tr++NJscxuoi8j5r+AiJVDab86xs7RX4\\\\\\\\\\\\\\/qG8HI7qdRnlfzcI74Qyc5G+qP99huk2vPmZXJ+yGq5fhK5vJSArI7nqEyja1+MFZ\\\\\\\\\\\\\\/uhUm2MjHYA471XpJwGyN9qOpAIaimsc6vqY9SV3YttoJaBmTJpwEMq6syIoSMppIALPBZkAULkwFc3omvmsoIE2PyeXgA73GLa029AUPls1vshojOR+FxxEOdzcObBVjkyIpr6iWmZD+yUjpvOHZZPdD9zizaCoxoCrjZeeA0sSCSR8yjwafmTJCp9sQuSsGmwpOPDkUrh4vRbtHruaFfgD\\\\\\\\\\\\\\/tZroPx+WB4oH\\\\\\\\\\\\\\/k\\\\\\\\\\\\\\/dAn4DcJQUg9hq1PvzkfqJxsKrv8NDQ9rVxUBVeWKW\\\\\\\\\\\\\\/ObkGt2eAomX1fWZgFT9+4wh17mwe1ctAgDUHePICF9wYAZk88j2yBmKQ3dh+NfF53wTlx5YvcI+zung8K5Six+tHdew2Djt8J0z54ht8vARopxN+5BwIkDPvYAHKxMKL0qiT5jzuhPzrqsGNWA64agJj87dFX1RFc1JtLkYccjeK2G+hYsun8dqr8rOsZsKly3i8CDrMQBBa+vCKrYyQtFDtd0tKNjigyUFQ2yxD30Q0cUCYaF7IckA52pr2o52kZmNbNgEn5TODei8zCMEPeYrp+OhKtsppaCU7RF5fSPG5HtVbYL765lSuUWVizYEzQf+28A2RPY7qO9q3aHA64mgwEQjIjjUfl8u+\\\\\\\\\\\\\\/UvREG1JNbffvONFjnVjRcVTK8h0ShDxNFfBgUYv4R9inmhvteF9dLLDM+AJk7dLu8dOfWe6MOP8ABLlgam7xlHxM2FvAB9gHi33Agvlsa8rePTVCOqBogoHS1Y3qU3BjYZBIFub7D2RL3fYI80VTebxSG1FlbBFUz1OJR3Z+L3mj4KspwpxwtZ+QvcCSUvpswShhNB\\\\\\\\\\\\\\/lfRjO6QXt1JlhaGCqkpixGRibxQbzhuhqfyM1L4I043UhZwivUh3S9xnb40m+MPJ2q\\\\\\\\\\\\\\/7\\\\\\\\\\\\\\/ZSaXcqRInSVxu\\\\\\\\\\\\\\/Q+SEdiZQ1G3N4xElpKvElPGxoO7xHEE32PnaQotm\\\\\\\\\\\\\\/tDGh8Du9f6wHyzSEyTqNRViWsopWIF2R3z1QpbaGBIR9YP6K7\\\\\\\\\\\\\\/8lfbeG7occlGtfRu57x7hGHCBmbNPlQTBp+yj7jqWJvAJtomfcCK4YkCbQYs\\\\\\\\\\\\\\/TwEGvlHm7AJ7DnjZaUPgVV9JLuLhxwcMY4EOW0DC6cnfw2l7R5q\\\\\\\\\\\\\\/LHcCl6Nz8mcZgmYjrQ5ysYvcV42myTcQihOo\\\\\\\\\\\\\\/1MLRcYbvaoufKSao\\\\\\\\\\\\\\/rmnp2zHxjNxbNh1s0vFK3UU90iMWlVx1OXY9ITYIqgcvtOwdLfOG84FoFLlX0RHuohiYTOoBS2AVPk8etYabr+VKGVBb82sBAp0tv9HW2+nj\\\\\\\\\\\\\\/XaYhrVBEm\\\\\\\\\\\\\\/De5oAkIhOHbt5+NuKsI956Dfgymn7og4yOvlHInW\\\\\\\\\\\\\\/oXSIbJra7ZV\\\\\\\\\\\\\\/AQi78MXCeTaS2+c9xecQ41srg92oDEfXg2PPKg38\\\\\\\\\\\\\\/lFhV8eqft6IxmWEt9zCCLmYE6RpnAgT07rhRR80gInT3lMYOpWguTykUR8V9pWwCFBzcXMglSpQj6Utcqc\\\\\\\\\\\\\\/LqfYznp3bZfNgbZriDVmp32BdOaGScvEHAtUWRKFWiBLdUMUAtvEWHjaW+WHY2nTj4tCdE8hhiahJ0qiJ1fw6TSP8B5+WvCt3DDmOxTLT60xSxmNp1es7vK0mEVVgaXEtJPwy5QptGtbT7qy9MOHD9F8g8U7Qu7+TYCPW1h5ojqfMjolvOPSeWtZM2zNW\\\\\\\\\\\\\\/kLF+aVp\\\\\\\\\\\\\\/KX6JSUyX8Mc\\\\\\\\\\\\\\/HyH4hFOShfXJuA4Ed9+PU2qn2jMzDAlQ9vrc1BXdWTvpNhCXL9UARRbQtaOxEOZkXVu1x8CjF0l3WBdnvJHOn\\\\\\\\\\\\\\/WI77uIGkWcHk8jj+O4k4NNOahrtEuBjP9sVP1pMBJGf9Bu\\\\\\\\\\\\\\/cURSntO0DhNK1E2P4umEtdfa2jKyj4w6Co6hFlMDxBKCCVidchUD8Bvbk9GZTIOOXuCShX+J4Mz+B+7E9zixa7yw5PRUEMQ7h0yowW6ozcqax0YDjyqtBmrimmOad80vEW0\\\\\\\\\\\\\\/H1dcAZE5eBRmgZa8yGVqxbHZyGA3\\\\\\\\\\\\\\/1WWw7fvZhICefLaATO0kzNWEso7e1M3bXcs0UW42nx6yuy9g+iKKz6NyRMJ3Ujz5dBR6WJkkiJ7+joz5uFFLIJ1hGkknImtPYWXIDscMkKedkq\\\\\\\\\\\\\\/7TYbayWC7z7Q0Zn342eWqK6DbLme1lGDVJM0j8Jzy2qvqNnd4bF6npGtuZouxsXrgoBnXeWj3uPNkhikl+h\\\\\\\\\\\\\\/LyXhdLSQXqXnHBYrp0mC6TdwSrHz986Fc8f1IweyMzIKUgjOXTKAXTFXfoBBuLOahHjQBaQ0G8dPclkGF6a6jQmpGv8eQqKn7S9qCu7qnOw6Wfq3FSsJOrjdfFAdpuJ+tZXSzhwRZxr77VNoRYYCZrTZHNbOoZ1LdnrG5Sl+LltTZelhCxRSl0vjRBueNNDutllvR1+maRM3NQysPuRlyXHQ5ZS8Eq25Qwy8DnCl6oEJoC30onuUk9Vti9N6rnVpgGJY5jmxqdS\\\\\\\\\\\\\\/99K25q1Kmqnv59W1SdcXpfCOIkkD+mzOGpOEcaE884t6OtK7Zrfr8xW7VTJoX+bP1gGsrCWXM8OjZU7rbLtfa5Acif+LjTZdTjrVfblpSx0U8iX8TPXhUfeoWKNr+j9fJZ86\\\\\\\\\\\\\\/8cjK4XfVsR5x9j8QOkq5TX5zolYWHcW9v+7CCK6SWJI35vhQUCrFVYMo1GeGUQUGxGKXixM58WbILJEql8Oa8\\\\\\\\\\\\\\/k6ZJ5vinFXCeacmBX2LpcsoqdqL+5hDVtsd+W3tTDwRP1E2Bdobgcf3NseOomYd3vsLvnXAXaZ7N1GUunN0T8OVatijoPmr50XlHh5Nv4LluVrKG8YcTLIUOrFd2USAIEkFR+F1zul931zWCs\\\\\\\\\\\\\\/ddQTQqJkFqd6M\\\\\\\\\\\\\\/x0K4ecgwMZcdvASWTDlrEYL3Ozd54QLRVt\\\\\\\\\\\\\\/qwCrJ9LP6VKPH8rrFQsqLrzpt+3K8xv27H\\\\\\\\\\\\\\/TWHav\\\\\\\\\\\\\\/4CD9WHkP8lkqWs\\\\\\\\\\\\\\/SlSLgjC9SI8nvpiQRFCcNNswOZgRtO9K5b43iC3+zpVaHSJ5FPA5yABt+CWocpYyvmHm587KrLFPa\\\\\\\\\\\\\\/rY7NgI\\\\\\\\\\\\\\/\\\\\\\\\\\\\\/xcPAcI0x6dfAkwp6LfG2lzSLlj6lKtxZZUqnBUPpOFtlVxVAoB966PIB2L0efJRxgZrlamfmtrDJ1fHlKja4OaMBVMSau1uUOuUM8dbZul2MBxD8s9KhogVcQgidNwnKBIvLPzn68gBBo51WvRGjv\\\\\\\\\\\\\\/FDvZyiftw32ywHrXiTdQKpGjZvehpbUdxzA03quKOPAa\\\\\\\\\\\\\\/lLALC59XykbcDTGPR4\\\\\\\\\\\\\\/LrhUp4eND\\\\\\\\\\\\\\/skLn\\\\\\\\\\\\\\/yYFl1A17TIbsH\\\\\\\\\\\\\\/4M2Oqn6VbrBBDrN7L4HmRy7zuTtF\\\\\\\\\\\\\\/47VZxbwZfaN7inlLPy4bqZ2ehB3PjanZZUiApDL+OkAvRVLMCwX2ilyLF8AMRb55h7G5EsBNrsL1PfuwhD6KhfFL\\\\\\\\\\\\\\/V06r1P30+2pSm4Ed8vD5aQEai2jRmViO+PPUfXNi2p\\\\\\\\\\\\\\/C\\\\\\\\\\\\\\/6D736r5YI9wzrXKz8kzrRvKLfVAIETNx0gC6wG3uFK4g+nCs0tp1E2t\\\\\\\\\\\\\\/YtsiNpttdEfWKCKhBEfyCarGIqQCp\\\\\\\\\\\\\\/Gw1VHPUnN+TWlKQL+yw+Uh2K4FkW1GUdKPYYvpbiVN9TFd3\\\\\\\\\\\\\\/NzDcZWmrkymaaiZJ\\\\\\\\\\\\\\/PGGSDWnbWH0icOBL28564G1wV8gnsjBUvbHaniPfMYYHPu2J2wVzkN3V9dGHeZucUzC8odN2GRx5SwBz6rWaLihOcOQg3g2Jnik5OAEKVUeHlB15KkTXlatdgZHoSPW9uMezXxTdOuJsY3cGGDML43GfNh7pDc5fBM0lFN0zwwU7XvQ3G1WAjA6opjd0G2ODUpfn1QFptTOqlnYh0bg3jlldiGPnxhg5PFbNSzOpEJ03yxP+ALv+agt0P\\\\\\\\\\\\\\/7rNkq0O1XAi43o3pp4yiLyp33YQSBAir68I5NvXpwq4FLTZkt+4w0iQveVuXvVYLppZpDIfbXA3mas5ZRVstJzUKUpeGU71BmKXMqwgfYakr20GdjoL\\\\\\\\\\\\\\/CFFXJngeLgGPm33HK2phLChQA\\\\\\\\\\\\\\/YpEFhCjYyIfC2Vr4h7HVCwk4kdwkFgHz4fsC93Ah+2v9DLzpz5dvHMoYgvedYuSWmIgYQRJT86mvV032xNAETraTDduz24rVUoC\\\\\\\\\\\\\\/HrOwOYY1oJpRZN6G59qHAG\\\\\\\\\\\\\\/mV7ipIdL0wr6T5R962XA3LHWZcjPDC4IrOYXNd8ICEWN2iiwQ9I3tKsYEcggQPG0bbBBIMMfPjFdIRrDrh5G\\\\\\\\\\\\\\/CA05\\\\\\\\\\\\\\/cS2mNcT6y6SDkXLAR9wxi10Wko4vW2Icr8zbqc1Mk6yLHR3+x89\\\\\\\\\\\\\\/Y+5iUQ3cvb240TY84rjfLJ+OPB9mbPRk\\\\\\\\\\\\\\/ICjUFpRBIvnwA6W6d4zE5NoZidFXR26ROQhl0mWbkgiSck2xihtCpMkX1zA358kSWnAwaWVE1jniN4WrFzXijXQIDDhLqbZEFcLxKZKm2Bpyl1yNc0shV1KiAicYVYAm8fwRvovJIv8Q9oI5\\\\\\\\\\\\\\/NAI+UOhb78VWZiA\\\\\\\\\\\\\\/\\\\\\\\\\\\\\/gu0lrBaMx7ktiULbD\\\\\\\\\\\\\\/uynEezoV7\\\\\\\\\\\\\\/8YQRcuSgaqB9poCPbIcG9UpwgKcVDT0yLlChPva+lFPyjbNi3kGdyQOgzDs2ejheAy3pZ+pJ3leo25VtATl3Ts+ZwZ2OOyLyROjYmiT7p+UKado\\\\\\\\\\\\\\/t\\\\\\\\\\\\\\/pxqgAGL1eqZaBRAGHug6HdCaE3s7J\\\\\\\\\\\\\\/9G+UMosi+BLQ16PhiKBGWveUNE\\\\\\\\\\\\\\/qTxT43zy9nv8LmXbDO3xmydjFei+MSsWGXY1CtZKj94jmxVv4jhGFEvP9jyPDSgEypeZlrADqTBNvxIcYJ9dNARvDmHN2l369wDSxKG+Myfnq7WyBSgzs3YR474gDxX28o6R2tJXfge02R9If4OVF0rLBsdpgj5YsbCWKBiM7V3mJiLatLrH+25H\\\\\\\\\\\\\\/SiaqgQV0pTNOoe9ZEDLJ+jN3O\\\\\\\\\\\\\\/NDeA+5qn5NnwuCtzBea7z6NkHIO+lQrW3ltEEPNJnuYqizQA7OLZuUZw89Fs\\\\\\\\\\\\\\/PsPv1xU9PxRM1fRcU\\\\\\\\\\\\\\/B9Db8KanuAcAI95pNpFO1JdY3ep42M8kbvIed2\\\\\\\\\\\\\\/s5QyFlWF2ftilhcUuY2JNlxlLMZlrDl31MnJk2RhJ0Qkk9dLHfnpqwx6SIWv8I\\\\\\\\\\\\\\/F4QcYn1et1YpP7HZpFfY6RyE\\\\\\\\\\\\\\/f4q9lTd6bFDkpm\\\\\\\\\\\\\\/T3jWl5JnhmWfCBT3jkd\\\\\\\\\\\\\\/\\\\\\\\\\\\\\/M0mijVF9dp\\\\\\\\\\\\\\/0X3lLvJH1PSjYwRAzd3P4lF5K7531WRO9jHtLcS1PAVx51PNC6wHMpankwpMkanwSBGC9u91+rglcmCpVWvXG\\\\\\\\\\\\\\/ZBt5NepMLLrqC5R1DsMNZf4nLiO07BjtUZLNLsfK2p16klqln\\\\\\\\\\\\\\/0wybkivWWHHcn0fgIfj3nnQmCF3N8REHBitoFmZJ55k\\\\\\\\\\\\\\/0gmPauROmgh3tTrJ9tH53du3nGlUMBYMYfF7yivQuc9X+5KzASfUuatejRemBabEFY7ntSnJu0gfRR8zIF3wKRk7e1QaPOZh24eVWAo3++7zNQd\\\\\\\\\\\\\\/Ytcndh99PPyMnrs9iylytgTcMv6VUOf1XfKCNw0Mr1PzoWyoqzpZeWd2GG4\\\\\\\\\\\\\\/E1Da+fXyvSYZxrrcyNDOPbRhnFex5UgbucTI8L\\\\\\\\\\\\\\/w2fT8zyIK4BCuSifr9ypLyqa\\\\\\\\\\\\\\/dH51hgPykAU6e5RFBratUK2RBjioMjAyAR8vrEQjzLrADrJ0aCcvJ1HFVe6+\\\\\\\\\\\\\\/n1ttVFYMvOIdF893U+HMyRHz2wqVy4TBDfyd\\\\\\\\\\\\\\/mqM7LnTZcjxKuVY8QLkZhBnz9ZhZ5T2Bcagdy1BwXaXYjEvXpRBqeDlM9mvWKI8AfqWsoh5evNeXkbCtRg2KjCm+GkVLFW8zUl6Fublcfy5sVonXAijt6PDfTB3OaYO15r7Onmilvx8Fp09hO5L\\\\\\\\\\\\\\/+OMLpEdoLjSxK8N5XZu2trIPrzCfgY75xLnJ7QaTFZrpizwqsccY6KrpTNU8DLestTHtBvkx5RgL3QwAKTHF+Pvaq8hn\\\\\\\\\\\\\\/X0tWXUyzz4g5uX2QKlPWQZqoV5+VI4+Er0fJGtxbRnfqM0Arb9tCqckxvRFpwOfvWyy6ivCsG3oynNkEWTp3BaFkS5a9drCrLboeLjNsXF1tUPABXw1vjTvPvKSTjzxUxldbLGhJDOonvuCZiFdWL+CDwvvbSMI15VK+XegBfHgtH97iX7xuaj01ghH\\\\\\\\\\\\\\/5+AYEb7RGlFwd+kuqbLXkaVhc5D\\\\\\\\\\\\\\/iNW\\\\\\\\\\\\\\/1T6Fo9mNhhykHUexdPKECwqOIZ\\\\\\\\\\\\\\/qsaL722+dNES+RYVJu2RYAAi0V5Q1lKxnK\\\\\\\\\\\\\\/DwPXL49MwNPZyIZ9O+X1NxmJGXR1gf8MffPkLYHm\\\\\\\\\\\\\\/HtmgjGq+mpPBQVRJ4MQ1k0XkBAG+EKvUuxcvpHnrhrf9SCA5Go6LXgpimAps5M6b8R29zO\\\\\\\\\\\\\\/qHMgBJd21zx3blEn1yLMkdus6BDBF2\\\\\\\\\\\\\\/zb34AgfcB\\\\\\\\\\\\\\/wvnDCH+qNkRmXMu0B+fqrWyiu+ypXuZDmG1LfUKe\\\\\\\\\\\\\\/jzrbcTwsXgsP\\\\\\\\\\\\\\/Zt5YuJZDzPVE03GTkX2tGuwim+89EXwpLDxaK6OjCa69vnrIZgb9ZTtvW5FGVu5SLLBqsWEZIcrkPEUjn+s0yT+PAwIRoMCqCmkO\\\\\\\\\\\\\\/DWqD8tDAXa5xW5w+01+M1s9Dk4llQIs4FjRBz2v6354Hxg1K5daJmplka2sbOIwJ5zS26h\\\\\\\\\\\\\\/qVw1QZKUKm9NV9jCvNHq0TPJEl9X1H\\\\\\\\\\\\\\/s1PW3c\\\\\\\\\\\\\\/NQZKnI5KkVx\\\\\\\\\\\\\\/aM4M5TCtLxItbB98Cqy\\\\\\\\\\\\\\/a71bcYeBm49R\\\\\\\\\\\\\\/BoqYnki\\\\\\\\\\\\\\/6m1My0SctOTd8vMUIL0LusX\\\\\\\\\\\\\\/EUpbHh5zxPIQf2\\\\\\\\\\\\\\/O9jZHLDiwYOXRjRw3Ig\\\\\\\\\\\\\\/Wok3V81P2Y1jkHH+C17EqqmA+7TdYa3iPavX3ivrOrzh7B5Yn1Kbbr2GPwEpvFLLGuwz+wbaEGNQYIfdBCn0cUzg7F0Wy2pk4XOiHb3ZbHdxk6rCTpRHpwtwcAmuYM6d8ta7wbWlYswAHKTAi+X9GmTcf0Aci5TKX8P3MrLAaRJw5o7gZ8E9RkSsoDillX\\\\\\\\\\\\\\/RvVfLxXaDG7bcw1dsWRz0kixW6loW1ywjIDmYuTi6Y4XAYuvkES+a\\\\\\\\\\\\\\/uymffXSTnpK0WyuzSroq+DIFvY\\\\\\\\\\\\\\/us95dUmnHgloa4eKn5yLTgCF63TQDQdljbJipXdQxUtxv9utqY5Zo5TqG6UAFE2+Mmqd8Rxe3EWpLOkPOkKefbIBvDyHVlH0xezsbZy1jnE0Q\\\\\\\\\\\\\\/WL4t5lJfeUfCON8q7T3IVyLQAga6SkwuJzvxm12zNn7LzcHEvSw\\\\\\\\\\\\\\/\\\\\\\\\\\\\\/g+NPpCeptdUuuG217P866KlMwo7TPpEkNVe8RUdIMnwen3rTwd08DPCs2JnKGRtzEwe7uClwkqO\\\\\\\\\\\\\\/2vvAYVZY\\\\\\\\\\\\\\/caBNTU8t8m8g3erO1vn1sjdnBmlozvSz502Z4ncARLBfJDx0Kv6Eto52rD7Jpa6rvMqyNtdAoA8gmynf5qilFHFMss51VW1YkA5YnyXBgryhktDe1kncr0CX8P2brOh68Fkrx+bn959nfhpHoP6zwk6psVoY05k9DlizX5ikoq0c8Yx0DZhfAhq7RZ3L2nBI50vMISzoxjxUDfg6MLcWnWzh9OHzrcEIaTmaXj0p9kvbe8TfCzISFXOn4r1VDMasl4aW93iGQbI154YkbiwSSMW8JGmw5YpWR0cwRL0ugiZOimH0tQSDJeFDuiALX\\\\\\\\\\\\\\/EXMESxhwBq4KNP\\\\\\\\\\\\\\/DaeSDsIsN8Ffzan72DrFs\\\\\\\\\\\\\\/l6gF8xLNkevBZv8yxRI\\\\\\\\\\\\\\/vSVMiGRBX+mmVAdCRIAdNwvysbk4OD6iH15nqdfiAJjswOkgHzDHGtH5fubpmnYMDAzyKdrE7Uygq+8tVHRPAP+AR4zmZpRIaAWodIVZGoRIButajwhbP1IPx5Lc391EntsP9qtGOp58Avn0ZA2olxDhfSFMsEAJpsKVqUBmeTv3iphIPJ08UU2dLQmZ7hnlh\\\\\\\\\\\\\\/ceH7GK5rAnG1CKwU8iDdzPI+LwmbiBnbQ0Er5hEFO9WHlG1Ik9Y\\\\\\\\\\\\\\/s5DKbptCwP2FDcFbhUEYqHIu316QSlcPpwOhv+XhGkrcRzlqU+6+voBXD34ve8wFp8jkXdvC8\\\\\\\\\\\\\\/uqfVQHYCVIWt8s7tuyyAjPikAvIkTQrsNHqk73GACS7IDt5olqczuq7GDADHC08r1EoQFLpT0mB2AWGGUYbbcn70qL2HBn9365iLRT47ySgt5Z2e91\\\\\\\\\\\\\\/Sn89+bGWbEArpKXiMmmAPo8+VEmMc7Gf3U0uMMJvg+s144JTNk5CPKCiJugHL9JR7Ce3dDRI7E5hY4OuG3P9NFpgazw4fnKI7pmLsaGfift4WrkmNZYdTmqgP7NJ91ruSUpIfl6PohlLKlBtwCuX6JMJOZ2B9O7CsazEjoUIfVxRqtqKBT+4eaJnfrZRErqXlCFKYxTQHVlFKfqR6Qnj83l9rC6EaiDJKEJB4fGyb2PtW7J7j+yJOTZLi9rxC4JZpf5MiE+iCpy4mLtytQDFDhkUhUYQL9Sr0DxtgpBmkxlsFvSHIRLRpiAP\\\\\\\\\\\\\\/3qKyCybN4dn3rD9I15NvlPcuTV7tSBhN1MJa\\\\\\\\\\\\\\/GrXvxIosbS81Orqu4zg6cLD1AEmYDUZaAdaHK\\\\\\\\\\\\\\/XRRMwMcEEhayS0Roqx4NM8ZnyTaEG82LC7Z97wFOAvAYd2Vh37xEjbaA2v1Mn0u094h1XDcHwlfPN0zPe1pEXXdN3qaoZfOwN2ghtAUSpyeOQm4r5+Xyo186lIo4zAjb9BKmyMPGHk7qvrv1UHuIzTXKcY7zMNL2EKQdfwsfI+fBnPfIZ7GfTV9y78qAiiZU20+QlcgQQwvUpBh0D9KzA2OX2fFjIksLskOWDCLxLLwi5bk8pTKIrTd+QNQJoVvzy9zpTUgc3jY6bcWqaeBvn\\\\\\\\\\\\\\/ZCXQSOkt4BCOClhIr0eyFY\\\\\\\\\\\\\\/XBTbXd81J+nUfCJIAxqHVQYSuWKO6iajQIWwQKTwHag20JB35Gmwk+iRTcpqizgPNcvv5aP5Rqmwl5qIeMoHrG4kgNS81N1w+DXrchaE6p+DdQ+eIF3TfudoZ\\\\\\\\\\\\\\/3eJ00p6\\\\\\\\\\\\\\/hi0C777aSZjeHbIgWluiV3HNgfviAyFRYgpWSDEOpvZGaEmyn\\\\\\\\\\\\\\/gbOUJdOqlde9RO0j7HM6RF1Vpa3IuXsVQTX6ORZ7+dN2Ug3vhGrm8fFokseps+Ru76ZwlzL3Ik3vEt8yz3YmgaUTg7gGO+QTEHPSf54qS0ypvyx50atcLTyoepIuaP3jhbgBuNCwe6bRVewqqKPJ9ML3SHyKPYQRM8Zm82zoF\\\\\\\\\\\\\\/dvYn1ubBX1wTrg\\\\\\\\\\\\\\/JeCg3t1E+vGWDNReEbn5\\\\\\\\\\\\\\/eU6rngF+NCFVGWd\\\\\\\\\\\\\\/aWyiU3HGWmrSr2e2Zu2CHDT4MZLMrvlxjAGpH7zMrKRoKsDZii84NVdBUVnFW6j8g9NWppadXzt+3JxW0tk2lCcbnOyIArb7l+vNfMlUW0itNzQ\\\\\\\\\\\\\\/gispOBYuiliuh7S1js2s5PMxwHZxyytpekfcgBoFFvIpvCNEax4thTfBK03mq01fAE8Fu8ImZkHeh0woVX58sMOTIPFzv\\\\\\\\\\\\\\/74C9LorY+66KGvnO8N90FKjeKW0tW2GxERg3r9riDFQiVBoG9qhd8foW2kgfj4xfDZ8Ll+tQNSMwmuyRN3uF2nUpEfgwBdkQ8+4XDxMUZRquIZmuO\\\\\\\\\\\\\\/U4eV4VvceLb3s6NUr6er4sBLFmWvw3msIrOMuq+IjjYRtyu3eJS\\\\\\\\\\\\\\/PED3fqGbdpRtWODQjzTsgW3GT1EIhQgGvl9qnnyu1QLY\\\\\\\\\\\\\\/7P+o2fHKwcr4crCyi8l24PLfU60TBOgjRFC5BIwggJt21px8Bzdfv4rnSWY1SuLKJaFCgGCP0qGzj4uCNeX54rlFNrpQDPAQKI6gGeHCPywp4nzZfCQ2Suv3c29vPdHcNQPuZ9UGYn4TJuMknmBpRTx0TxEF\\\\\\\\\\\\\\/oX1+cVGvy0WLbMYLKFnkqNa6tfpQqkRsfg4\\\\\\\\\\\\\\/a9BMeoyfprK\\\\\\\\\\\\\\/orjFMCq3OAvGVjXHmpB3jZwq4+JwngKBVEhEvO1ToX2c+NJtidtdjE0dunvLnkmCoPt2wsZS0wyDYJcROeej3YtcUgW5Egb2aT8+Ancme1k6i5nvFa\\\\\\\\\\\\\\/xQQvcIoiJ4+7MqAm3uz5nPwmFph4T+waEr5QYRk8RTKHWK0ho97HgGZ2FxZHISHO971zogRUZ7Yko\\\\\\\\\\\\\\/f9wnF0QAMvm5ahhsmG3\\\\\\\\\\\\\\/KZlNC0parcrtOFwFalu6\\\\\\\\\\\\\\/N0H\\\\\\\\\\\\\\/FmvzldjE\\\\\\\\\\\\\\/hHlrSAfIyesBijQnvAnbgOYleJ3FFV1PRfH+PVbvamGji7+AXVZ14YTLFA9LnEC+SIGTvkusAPqj4v+n5F8AM4aTC2MTfQM18BJSZErUZLRd1rXnzAdqfH2x60leziy2gFoVNLtEyPmc6n7d54i+DXUk0fSYvDJocEZgKsB36rBJ\\\\\\\\\\\\\\/ZiIqCm2ukhmrbkDK7bTU74idwNubqmOZaYtRf3GPvUcqwOC5CHA4zCCbWeYSO+yyh3obFsnLT+lEK468LM0fhzyBrMb+mSVkPcGSYycvNcJR89hYBILHCeocets1q1w6hVDDlsnvUObnrAtyJvgWAg+ZMP21YTSTUzbDOawnCLdCdmr\\\\\\\\\\\\\\/3+TGzUuRf2g7Y1G8+7i85hsrdRm5Mz2yxkiY1wvXB3xjBSsY5QCQ0hnCzkAKUaMYnx\\\\\\\\\\\\\\/Da6XwJNgv9HfnH67MG+HIL0oRIOGzLKjOLECZz+Tghm1QLtG3XjEbTxa2hWKFsF9w3RaIORQSfGBAvZKzYABupmRx0iUWWn9WCagim7jzdd2tBTy7uQRaBkkuUyKCyeoCSCymAWSgvnEXPmOz2OMaBaU4jpnWCwdEfy\\\\\\\\\\\\\\/uNKzH13KgDt5t0toaougOzJ+NnVXy5+b3HkLPgikvKMHXfD25kzc6eGhQ8LNhO5Hmdyu6zBMJkmGBPAKHxmzldbaF6Y5l+0hofxyx01\\\\\\\\\\\\\\/MQsuGmaTJFXzqJ1AwR3dfhe0EaH9ZMS7Btw4MKj8EdwShplPDHSXmBFgBsh7oA\\\\\\\\\\\\\\/Ex9zuvPPp3ocHu1Mw\\\\\\\\\\\\\\/z25eX5v1bVGwvhU2D9LFHNl4Bs6lIEL\\\\\\\\\\\\\\/0QoWJjABwc1vtyX8T7MY1RxNfuZgfZBeaOlWqcElQQSzhnjiPI8i\\\\\\\\\\\\\\/y5cr7Bb3yXphPta8EsdxSWcvEKIPjCb+ai829HKhH64\\\\\\\\\\\\\\/Ln8broLItD4mMZBPxWArilqcxQJYDlbPCw3JQ7Ov1beqjXyyni35kv6zYXj\\\\\\\\\\\\\\/QsUaB7UCdLBurJLZRXOIpsWbZKgZ5ICCm196lBAc6EP2CnkmiRa0iakz9DzZEwHtinx9hArh32wqFWtHgZGISSQHvjaVLnWvvryALuronCG1crRYCeiyCBis4PXyVV6EUTyDf0eGU1zde+j\\\\\\\\\\\\\\/7OAHFExPd+Jpje3lm19bNlJ7pwCvMps6QrSh6QScETQVSEnb3H2iGmk3QlPus3slDe5hTw7wi6ub1no1KCa\\\\\\\\\\\\\\/2E95Ib9oo01NEbe9QXk52RJPslarxlZMbeLnmHWXfJ5idV4bZpsGWSg0hO8D9Pte6zbIxOkRVn9\\\\\\\\\\\\\\/4o\\\\\\\\\\\\\\/8nNGg+lrVLInH5MsMPo4gfLyL5d4rHbmiu+qv1dYcMjDW\\\\\\\\\\\\\\/UnIbPmjJVNQKSJXqgvSbqCyzYyKclB2KVpOxXVnIPMkMQNpt2k4qHzbfbciKeDC3v7Gjs5LOA6IRrwEOgyWn\\\\\\\\\\\\\\/dR3kP0GcZx0ln\\\\\\\\\\\\\\/QezTKoDAT4vk56EQOy1lNbtTVY4699yFMyWZemcEPuOk8oGBAJCtJuqayU2kXjj66yjGVA1uJTz6IkCXayyr82B84XSAGhahJ432Vmj1On6q6pRDFuwiCWuoes85YcLFtr7YS6HSZPr1Tlnv9bWTGY3P8VW+SmXKgqgRRaids4Rlo0iSUYl4TegSR1eSLjtY7+g5usrIqgBV+QGFLSyn9BdonnGWtkaiobEeWbaL5tafPvRkaTUfdLAn7N4xecJNS9RCCWS+AVEPaOEQ8LBrujiWt+GO\\\\\\\\\\\\\\/47wLNDS7KzQq4DEGJW\\\\\\\\\\\\\\/zIb9MH21ZBWe6D0FXp\\\\\\\\\\\\\\/epUQik81YXd8kxpcNb0iMUokRgaoXcMpQBgVmlWFuTYytPwayoa1cuYR6MtOLjeAS9y6aWA9k6YTouc+jIP6YtgztKuKG5lMlTi3I0ApTBBWi2L4ffWUWLGxlcwWFMmK0A9pCigmNEwsdPguYXgRoDbORBm8r1bGPmvYZ8O6uJy128ThZnRpqU7Oqf+ZP29SmRPenVGJQQYFO6AM1tQP49UUVmWv8dUjf9bJt6Xtb59fnovssIXN0XMArMmJagoK5hBs215T\\\\\\\\\\\\\\/SY2MUQy8ptSMPZ6qcko47lYpp4nvUKZox+Jwd+TmtqJwYrdZRbLHfAAjImUzHhXFKIj78K7j\\\\\\\\\\\\\\/0nroy8JuQ5\\\\\\\\\\\\\\/P5okBcGC9V79sdN95U2bofRs\\\\\\\\\\\\\\/\\\\\\\\\\\\\\/anbX51qjKMa4bHDLlhNwrWK7Hztm7L8+Ye080uinNSbbxEGRhMDNbOJ3gbqohw\\\\\\\\\\\\\\/V2tP1mzw5W8Nx8iUT+JijH0Vv\\\\\\\\\\\\\\/SQlt8pcMu0tdDibyp7jUZ4SJ6OGvSYHvZCrCdMqrrkgz3InjdS2CN2VV84hd7bL\\\\\\\\\\\\\\/moxK+gGEn9lqgoSBfTR3BCkmxdRQL1JCXXM5O7GdGb5Ps6esQt4y7Z75hS3rMBxX6n\\\\\\\\\\\\\\/\\\\\\\\\\\\\\/cZlCV74p83UmonTWMtxbeQ6IvO\\\\\\\\\\\\\\/JQBA0bieg8uXrAVAOC20WcksZj3J81hph+V6BKKTWELPmOq771aZ8xEd26w\\\\\\\\\\\\\\/kDhRe0fI5108T0Sasb9spKULk85scKb20Sliw5uNOVE100sErtTRXrJnLyJL0CmAWMq6w+mxFMB+KUrC+bJVmsArxhvjy\\\\\\\\\\\\\\/ifsK8gh1x3p6b5du6qJrC2M3ckt4uKHraBD8d9Oaw\\\\\\\\\\\\\\/rYQAqC4rL+E\\\\\\\\\\\\\\/TkzbOQJftO8DUw9TtDpx\\\\\\\\\\\\\\/jxfcLa2yrmCTWt34zqw2jF4ZfFzfImvZsB1ItQWvDxV1ruvbjBtIRXS2Viq7QFucQpWPRlJbaqqiywrJC49Y6RyZTVzmbheYMdcajACOSC\\\\\\\\\\\\\\/cwl8ZO6DFzKRHXo5uMa5FNB6bVAODSnQzEDvRb7D4ZLplMT18\\\\\\\\\\\\\\/kzJg9txqwLpvHHEiES0qHaJyphsAUsVyXPuU1NOqD4r3UHcaGo3n2Y7hWBmmoeAkOF4TBdKpxX9Hhsn4TzrXSHqonBz16ET4qgMQ2HNBnoAaPyUcjvGc9w6V5k+SXZ3l7jpjnk+BR5oCLdTK9+kBtZJMAPDM9dYJxe9Z8gzV5FicM\\\\\\\\\\\\\\/OcXGLWnRrvjhbbujYITwKDfbLrOF27j8rnWN3FWA0ymZXnCJXcClUM3Ilyj68yH30RvZGVbxDAA1usrJB4AJEON3KUzHS0ycFKH2BWcghKIHsfR18ujscDcFeaQyrAbEzxmNmBQrv0jVC57S12tzodVbHNrvKCxOM5avWxwxYs7+zupitKBumcxPIMlpIFjZnPfyfMESxOUvkogwvvgEqRu8g\\\\\\\\\\\\\\/2fjcWH\\\\\\\\\\\\\\/mNLv3eW82yblbO756kKrWVytKW9tjDoQ7DV+JptJMQVW7MfqRCB\\\\\\\\\\\\\\/iIY91KBJ8yxvWZxpLyWttC\\\\\\\\\\\\\\/thTEbzZefEmV2dp3xMxDg4uwBt6P7nfKStoN0\\\\\\\\\\\\\\/3sksZeRTlyQxxoqJ9YpJSMRZZrP4xYDABY2G4FOrEJyuUInQitmdh3RiPlLqXsz4h150TNSJj6CqN3LI52w\\\\\\\\\\\\\\/RWCPSuPHMPS+UkmU3gLuAs2EWfUdTPl8bpUSRinVvIGxx9rjcmlwuWArFpO+NiXslp2ktVfXTPsPSO+DRZTrqm1f5K4W4mliGexMZzcLN0FIrHdnT6YxX1ry38Zrg9chKr+daSjo2\\\\\\\\\\\\\\/GbZG6uTf9Z1gSSf5QcxEGkrK0nD5FS91TfRGjsoeqsy9qyangxEwTJIp9cWCrr5PkRy++wme5U5dgan7MkVgujDWP5uS\\\\\\\\\\\\\\/Z8yhdfpGr1PAhbnUPxzDFpSDZuUrGIR2Edi7y7IZmgpTsgXVTAcCsrYgk2i\\\\\\\\\\\\\\/BSVIAVzgMUtB+LeiMiYUY2HYJRzls+7Q8sz6gikgFudJoMAhjLMNxq1OpIPQZ4Jzo6lUWygllwNcQrnWkPCu076TZAV4b6C5aRWt7i9Fx8KzjNCqISZLLlyyKkPVhDX81S59WEFCit5LsuAstX+gl1Heh5fv4nZHMsEP\\\\\\\\\\\\\\/TRSRAAZESXL6udd4\\\\\\\\\\\\\\/I7ZwHzzwVX3TnB2iIYGi0TczQQvt0X2Qa3Bkf6Oprqgvg1nrWe+VV92FWLGuGhOK9fjBkxBoS1EXniswi\\\\\\\\\\\\\\/EHZswXbbsOs7vIN3+0k9wicr0b\\\\\\\\\\\\\\/fn0Ezj+GH5\\\\\\\\\\\\\\/fd3alWA\\\\\\\\\\\\\\/raLxk7x6I2+BfHl24GdbbZcSGtxW0q2QNdTHpbo\\\\\\\\\\\\\\/NNXUiVnEWaAeF0VaVpQUInLoxppXEwSX0toLoAiox87bVRFYjyi6PgvveBH3CYnXYLJ2a38paKB3b3ridE0YYnujFzXeU6ExE2Rac\\\\\\\\\\\\\\/GM4zhdoEISlSIQBxDYvL2w9F3uACQH9NFRn0ARjf7W+sss9VkrdxnqE2oV\\\\\\\\\\\\\\/bbASLDc8J0CbvPHB2DQcqBToKTeRk9zmhWaXiIxmTuuEMyZiJvTAXQDYElL12oCyGeEELaf45CtepWxepk94JUBIULpJkU\\\\\\\\\\\\\\/XzukXCnTHWKXutQQoZ9hC50nuzgWBanZEoEkqAq25R5q2W91dCppPxNkh1IcEB8wwcaEPoEro\\\\\\\\\\\\\\/HoQyJ8XZBn+kKRjioA1lJ1D6G\\\\\\\\\\\\\\/ceDZO3aHDd5laAWCit\\\\\\\\\\\\\\/7tfZSOkDYK5Y9fUHge69mb+85KxEzXsxPkzMHm5hPHjr\\\\\\\\\\\\\\/8zM+OwwaVjF4s55Ct3Zkv1lWXzIEaFUWByR3bL+9MaThSx0k+rJytFhNG6n6rl\\\\\\\\\\\\\\/bhz4nij\\\\\\\\\\\\\\/cZL2e5+V8VjBPLm\\\\\\\\\\\\\\/2yu5iGqQDMg4UBMC+FRG2x0JtDgdaiiXWrmpoPgN2juaFVuqYXGpABfy\\\\\\\\\\\\\\/TTK5cLBUDkVguBtI78\\\\\\\\\\\\\\/pH5HmBHn3k8K3gbBYqdzjQAU4hrfVihDO8PN58Zgrn+Snq28MyAm2W6LRfGT0VNB0skpATS9uC8\\\\\\\\\\\\\\/yfj8XyJY6VYxK3yYbTWyDaJbpq+PL9QvQoRdakKorHcTytB+MxnSSXoT\\\\\\\\\\\\\\/YduXIwUmKrQxPG3XVxBozJNPOqANo1rcxk8EbXXYuJWD+lTxLyL8dsn3r9qkiA3Mb1Fg\\\\\\\\\\\\\\/dqIwKVL44y1h9hk7lxCbXxR\\\\\\\\\\\\\\/BWDILvicVJ6uogVxFlXNdf6EwF65K3xLXC2IFYQ0e3YR5Ey7S7cxvQlio4JLFnWTzSgBivw5X3jvKr6nz9cTtKRq4u2lIEz7VhowHV21W+QNI8lbSsyNWTHDy1RPMWLFSe3MKW0gpRcT63eW6SSDhPHM0t6JOJT\\\\\\\\\\\\\\/v1Aog7HI6LC4VdsQJL9u6l9yqNu2uM86iEkN7qlp9kNNL49AZY4OCxxJebUxJcLjTxjnajcKvLg3QsPdawQpTfd95+Rhiket29KUBUTh\\\\\\\\\\\\\\/Id\\\\\\\\\\\\\\/wmmzH8prDMXDSGPrn2c8ewznkKscpgkEadlKJoI3odD7h184QyhF54GOVFpA\\\\\\\\\\\\\\/0M3u\\\\\\\\\\\\\\/9kjsnR+suR9WKfmcFvL1sGMpvgFqKhtvLndFk0hZhEDtlNPGRx4b7dwjrwa8jDc2ptfo0R+5h1CuFszMc8K4XMqnmbSJXyKCX\\\\\\\\\\\\\\/RW31pB\\\\\\\\\\\\\\/tZ6UI06gcRWPrOmBFB0CjEcbTFiq3HObpMJqs061qoIY\\\\\\\\\\\\\\/0ubQzr7Mz5lYMwtCPFIxOyzTOyXVcB9ONWlMnRzuadrQdxiYhR5d5G\\\\\\\\\\\\\\/mISW4A50Ylvng14lhv4H4RWgbeWF4kjCtC4qTSuu8Kz8ietc\\\\\\\\\\\\\\/7t1\\\\\\\\\\\\\\/KHvMfkivj+M2daZVoNcvJ+IeG8VW8ouz3XbbRI10ZH9aa\\\\\\\\\\\\\\/zX4wnhEdZPBtTN5V2cGMv7xw0VmswJ2V9VPh2JaCzncROuOgUZiWbjsE1lZ4CcWruj6eINZYoqbVPVjcE98qnNeMPXdfkxp5bQYe0a49Z8cNDFWP1z\\\\\\\\\\\\\\/JNoJ8GT2oDMm0a2NbDSBjOYyHYfajsIl3iAuwI4V9wmei\\\\\\\\\\\\\\/C9BLsulMqlNi4i03b5fjEzljGFVJnK7YEXOzMeCEq5swhuY6y4OYRzMScnOpoDqIutRc5cOey8Ps\\\\\\\\\\\\\\/CUcqAZjotRBuM\\\\\\\\\\\\\\/APlN\\\\\\\\\\\\\\/oxytDla4qCshv9qy9c28DIQqEL\\\\\\\\\\\\\\/UAgLdCv7rVloXez4GNGBr6a\\\\\\\\\\\\\\/k02qoFgcNx5Et2bRxxzhOpzV3gA1O4yxIt9xw9IZqzng3P6bOTkbBuoI4VmhnlmVNpcpsL1rCLNKsbe0eBDzGmp1Nh\\\\\\\\\\\\\\/gPkkEI4PlVUbZ3r5EWrJySlC9Mj9sxuk2z1ed4yJCRPqavY4UbS4hWbLCUJyk2LDPoWjQCL2olE757UtiUfL226ntHA\\\\\\\\\\\\\\/oM+5FKptW7aZOELam6JAMLwb3IXNtRDXlI8Ad\\\\\\\\\\\\\\/dWUht01S2DsRVuB1ExGoaySvtA6gD+4u7te5dNDaTIXldtaWpVWcDjz5OUzF\\\\\\\\\\\\\\/pgVEVwyuk\\\\\\\\\\\\\\/JOFXzS\\\\\\\\\\\\\\/CjPMsZnQULh+BBIO\\\\\\\\\\\\\\/dsaepQoUkNg2mkZYp5e4uU4ofdYwvRbZDq0t+TY6YsM2UQ8i+rzOWhn7B54sKcxOYVHY47OZZ7fbxWVdxq0NQZy9BvcbstcF2ANTGbGGCN035Ja0yWPLLnGxNVp4aa5O05sg0oqxMG6N5pmePpwWypPbUSZDPvBdxvbaww4QpSKGshTXqPFdqHu+5zyDIvnxfYozhQ4l+W57IcsgQwXt2QtCoJK9VwQQudT7QsV\\\\\\\\\\\\\\/4jmQmujzP1m2n4KrkoFO\\\\\\\\\\\\\\/kEiZ5J7O9JOhLRmFbIYOJPHqUotrTRprHt6GKJbuwpTcCKkxR2U2NvvjYOuY1PN0sGG\\\\\\\\\\\\\\/1f27sPDCdgHR+6e8DtUkU4XL9Z1wx9aIo7WDjo1eN6FjXzoZFGaGkzRvg1e\\\\\\\\\\\\\\/d9fvuqemBXgosdgxyPg+g97P0JagDl9F5FSDv048X\\\\\\\\\\\\\\/c40ADvC\\\\\\\\\\\\\\/VZJTulAkN3ufBLEU8FPqPMJTmZKoleU2zB6aKsfdhhJXND68exOM9aKcdzyn9R754fte+qjuba06Ng2fdVykaDZzbrkgokkEfHU0pKZExBl0z6IDZ05WbUmHSAssRaY5pJLd+ubQ0BDdBm\\\\\\\\\\\\\\/1RFwaKYcF6idaUkXeMdcUdqvfh5l+ZIIw3ZfOzZE4k90RbgEXzXi3Zo5LfnXu8D5SKh3OUN4qhtIpJLCRw\\\\\\\\\\\\\\/xoU+1YHoxdnPvPT\\\\\\\\\\\\\\/2zgyVW9PEtGSQKjDq+PgsfIpqGP7YQ8uwC0+jw85GGLwLw7ETYuB+vut9seDI0\\\\\\\\\\\\\\/Ve3RO+nsUaHJLwKFwaF4A5+iiLtPHNUfhO2+N0xou4\\\\\\\\\\\\\\/l7HxUNrKVRxwTzALA0SrGtAT\\\\\\\\\\\\\\/GqB5xyw2jp85qT4BqSacb2J4D7YBPAAqoxbPr9kahtCbbfGwMJMKwSxlJsDBInakjn++iGirOe1DF9rmd8Dq9UL8WqJUyA\\\\\\\\\\\\\\/YtpHvx6wxluwZvF+2KVEhoI+uEtI4wbxn9XvwKxSDHMEoMzodWdzIHP09aUX59UpLj4cCPM1Ps+kYY+rxbIaeh1zUSuSkZWK2SGyRCLoN3L1trgMAElpwqWeb7l9Oqfif37tGzYpiZn1H\\\\\\\\\\\\\\/JucMxSeUXV2PPE7DhPyt1BnWEd3inoyeFjAiOFH9vSUOs7M1wPzl67LGwvRxakmc12DT0vQ4nTYVG9LxYvhuMl604Ngn7bEVY0vREvcrfX9rPMeC9rCNSSyF+WFGXeTS2Q2umtwRzPyRwvspw65WgW9PxMHBfjLKqR4Y\\\\\\\\\\\\\\/v\\\\\\\\\\\\\\/BkumIs7SoeD1zwmF6x0Dp2gp\\\\\\\\\\\\\\/vKa3T7+XGfAa3YmV3XFkaRMgB6rLjMSSAbCAgrSA5gNWPnzNnGA8ZSguFOKgd0tEVj5e2dTAyWRtV2U5vySdPQRzKFGq\\\\\\\\\\\\\\/RJQVgTdJc8slGTBt6jc96CoBuYfSelLXSx+xCcmHyw\\\\\\\\\\\\\\/3wXn1Xr\\\\\\\\\\\\\\/fVyl0F10TAP1gggCrphOYggq+2NU5dL8O3KX9uOHThyhphlx2eRTj3BmtFjYdZd9+YJDCobi\\\\\\\\\\\\\\/1jSw8wTo\\\\\\\\\\\\\\/yS\\\\\\\\\\\\\\/gBpHNNe77fLYuHb5Ks8KN67KJcCWzxI9bBhc124R3s8BEf\\\\\\\\\\\\\\/sO6ExPdr\\\\\\\\\\\\\\/EkntuugnbPQlL\\\\\\\\\\\\\\/fZHmZdtskI63\\\\\\\\\\\\\\/rBcYhd15njRYcE\\\\\\\\\\\\\\/wGz7FLU1oN6f5685NHHh4znvAYAIbIoz3VTLDAZDtTv5xr1ouu7UEG7BYno+ndsHpStzyih+m9N0f8rcOVchag3dg7c+V1JCMnal\\\\\\\\\\\\\\/HD1eUBjXD0MynooQe0z4Y3V5jWU8g5gOP9EsqrEArtNyjYBGzhsN1sNmXfFaB7QTc1DsGZPKJWLzCB2sP7eIqzOmcITMK0+Bpqv6FDs+22GdxIhUrMyByl\\\\\\\\\\\\\\/tOqT+2Fa927aq0WSQ8xbh3\\\\\\\\\\\\\\/DPCk0O2lJDpHudz3kc1E2hOosBYT\\\\\\\\\\\\\\/bPotqpQNSvYAO7fWNkcphcxLEWfVKFVO+24g8dIgKgRJERNwEP+mDVPY1+NF6ZGcUAn0YkbXhFsVP\\\\\\\\\\\\\\/iJedBdYRF7wv8jrkWTT8cVLmKL1eZC5YBqnZpVTHYj5pOFFDZKxImXY8eJQ13J7DwyELWuG5HMVY2okcsoN6vqyEXNUTmz+1HJGEt3I8u22kykrTtdpwjW5++mFyK0V2cx1gEE4oeRBlIzBiHCCoM2AMt5DYiltwb9Jk5UMyG0ysWxn\\\\\\\\\\\\\\/s6543AL4+q4jvSQZPQ+8RmO5ClBcN64MlwVrcw8ZAXJuseWYxPkHKOgIKCOyBICVNk\\\\\\\\\\\\\\/TrnC9B4Q9+i0zSTjCmFx0RypLcSpsef4wdKAwsHfGZGiFgmaAqcQOjLVVc5o30eXTDYI3MKVYUX0WPQX8UUkwmFh8esmL9gyLfbLgDnMzjpG1PPnt2KhSCKvuQfSHPkpf9nHXXk2iWdNg4QcIuEdSc0Uy7C5GpoFHyi\\\\\\\\\\\\\\/xbt2+YnFX46lwj+aakvOzENLrMyPdHV9l8rG2BrcyEfjnoM0IAF8MPgW+ax4cQF0RKwoPCI2DcF35XFIyBpmSIe1p+CYzIgFrH88GuoLYXcNZJbvSTOXvGbIPGBEQmq7TiWeczlF1sxtzOkM5xEI3NxWDRXkLjnJpLqOVEKA+OTnTcfPjG5DBhOxuT5JJ2ZxGK1zYvFsiluI8MYDB6RbVMZxV1ZjKQ\\\\\\\\\\\\\\/PSDCVx4BJ6sztsl6yc2WSsbHxGlQEYVoG18KlGh30\\\\\\\\\\\\\\/GFB02UUai7Ww1Px2G5tO4FQNS+m2xpTod5FTntLWpRoL5lapf58pox3rIz2J1uxBvrEPVxBafWWh\\\\\\\\\\\\\\/utXHg197UX\\\\\\\\\\\\\\/5eh6GwaC52egQoqDGneadgAz9mRNW0K70L4vpCa+g8GGGavcmOttrams8QQOev7xQ++kLXwmdDNGtfG\\\\\\\\\\\\\\/GnSUnK2lXjqOp+Og\\\\\\\\\\\\\\/BL0S4ppk9tsQH33KVtWD6wTr9QcjbTnSonjtWt1ZutIpDKH12WkRu3k+FKJCKBge3YNQZxQWI5Sx5Dhu9Tl7pYZoc4zgZbbPxDSsIiBbOjkPYK1YqjKCZ7EauLjRwBs7J2xI70m5Q6uJgg8zXSSX\\\\\\u0022,\\\\\\u0022iv\\\\\\u0022:\\\\\\u00229Jm7EKDj6nSzKOXW1esBqA==\\\\\\u0022,\\\\\\u0022salt\\\\\\u0022:\\\\\\u0022f4d040311b2fd2429a61a615cefc1b83\\\\\\u0022}\\u0022,\\u0022hmac\\u0022:\\u002295bda9cbf8f4ad75b1e3ea9d659596cd53d18c2bf0c32c7f7c1db1781c05842f\\u0022}\",\"new-29\":\"{\\u0022encrypted\\u0022:\\u0022{\\\\\\u0022encrypted\\\\\\u0022:\\\\\\u0022ZBj0KAYuE6UNI2oBHtf6O8MG8Ffh6PWbIICKsQZ59ATx9ygrt8VFl1TGDlWy7M+vfG+hZtiGXLbI0wxXnTv6NhgvYFOOguPuYXy2zi1OOmXRi0BZSJUUlqNxq3IMofIj2Q5JrztTvlrma8cLoyxzxnpTQfkh2KuDGD9GoNmvuYwlqgu7wZWN2m8K29l924ieESxm+YvXytdyFtwTMetAm6nqi3BnWv1yIZxEUJ1rtQHzZdIh\\\\\\\\\\\\\\/c3Mum\\\\\\\\\\\\\\/6JWxgEAF33p+F\\\\\\\\\\\\\\/VYWYWMqm2OHBEmJPoj32fj0PHExfsRWnr\\\\\\\\\\\\\\/N5LwjY0rsPG2LPFaavHtdL5D2MuvxU7nnzSbMfDE6L\\\\\\\\\\\\\\/9+C3fxWt3BHEqcWhXg5Gp+bXyw8U41GbDwfwlKaIsVya2K5BnOy42tMYX2YPu46Ljx9Wh+PClwRDmWhfloCd7ELTvPk232ZXxW6t94b1rqKdBQPxo96dYtzWDX4sCtQljH15S\\\\\\\\\\\\\\/4O9LgPJGVRHYPzBIU1TbPRTBJghQl61XbDqhRI4xNtPxunxZz60WTAurbVPPrTVNAalviVpz4JhVeuwT3+kg5morjln3\\\\\\\\\\\\\\/FGGKsFJG2ZWSFPzVUvgcNTQJfDdk42P73Z1okqLQggAITUpEYEftq6SFZ2IBs0HDxKvCb3gQBeTEw3K7eG5\\\\\\\\\\\\\\/P3TcRMZRD75CXjWlOVOEY8c1lEeHDgTxxJ7QjjMvm1w6d8l3eXmmAgxEkXpGqbYXny1vXTdrpPmBeX0yiS8314pXwRVlt\\\\\\\\\\\\\\/dUt14wmfNeD3b1Lsyfmeix9HlZudOwjoz9hOHq7rGrY14nSPx0UjH+k0cBvXd05VgZYuSGajcCGvGLCmlAVLRtlFWZokNhX1y3yr5DzYe4V2Aq3zhXw9y6RU5krHdFKFt3Huauez0sQvaPSxn4IGpoPyMEj9Xp\\\\\\\\\\\\\\/+M1MCZUG552Ob6qIjWh0JYSr+AZcy3NI\\\\\\\\\\\\\\/hooLt74wnMEBt4DlcN4jwM93YRDmbVl8qlMAvS4kinG2bOTRzqab\\\\\\\\\\\\\\/dKshS6XhS5l0R4yYOC5ysACt8F4jZ6aJf0fuzYq4h3En7fg7jWVD\\\\\\\\\\\\\\/S8VsPIgYPVu3A\\\\\\\\\\\\\\/8KVp5Xn4WDwzNufGt2VVoGABfDiGRREMf6aL31OUtSP1YWdDwdEcryDUAGSAmlN8GxzgEmideBBa\\\\\\\\\\\\\\/AEvuclEzpPo3f+WukyxB3j\\\\\\\\\\\\\\/UtxjV\\\\\\\\\\\\\\/RQ9ihqIvyoNJwStr8Rs5YMoJN903osCjUqn94zf0O+bVl3JysKhdYi+WYPzobVLa\\\\\\\\\\\\\\/BOmy6Uq0qQFsmB08nRkEgV0hRB7ioeygYWide4DIfmwvtif2R9LnJ89pg4m+UpGdudgL6P3g1bW15eaIEglOg5b6\\\\\\\\\\\\\\/tR09qyq6cK6ObKutUUkxjLtddp\\\\\\\\\\\\\\/EzRzJ2rA4ET3FbW5DxqQdTPO\\\\\\\\\\\\\\/eGh669w+ayVGVKzcn6UDC66O+I\\\\\\\\\\\\\\/q5UYwfzNUEjs2hcIUSg1z9\\\\\\\\\\\\\\/5TvSrX9Pylcm7v8RkCn4x566OfmQFl50e5llQEkK5zCS86HnIrMAqvrf64FgsbwuFpUSAmRT+Zy4zUG\\\\\\\\\\\\\\/qkb6S82cFFj93CAeXWbCgW43TUQYNGXO4TV4QNERrfVp\\\\\\\\\\\\\\/mbf9xBZpJAWZDBLJhUN7eJoIOqVV0Zzwa82Vwan0SjzUfCUEmRtriEWpqyIeNPYKYJSepl0SGlW6yGKv\\\\\\\\\\\\\\/FwDhUonZ3nUBO\\\\\\\\\\\\\\/j9KfJ9OOuHJ9usaXmkxnHX7m8dWVd7743WOpeYwi8ZZUAJxd8K2Y5ABnKyKJc9cfc+Fm2iT3YWcIGmIQuYekYmJZN7V+v\\\\\\\\\\\\\\/1bpYSzEoJExpqFQ6OqxB67z94gqTbUyEjkxh+gf0INy\\\\\\\\\\\\\\/YEGB29xIXf9Fg7TIZPiPWPmlfz3LnSx6A8KUgL9avtCwiBShQL6mfRLTa6Ush2rFsFPGTCUpDQ60e\\\\\\\\\\\\\\/1neJf3Hmf0urzEIeFw3IZ51xmqKgLTPiRL90Mjy4pL2FIGTEibIVNjtJ7GwMPHyY6VP6GuHe3m5ervFyfAILwdvmjo4\\\\\\\\\\\\\\/WDFPXCn0RQKrIJihkyWiI+9UpHG89Y+B9VclsU8nRk5e\\\\\\\\\\\\\\/nYjuSkFFwOYweh2mVvyyQHFXqAWst1Z7XAy3OyedweXT2xDV2eZYLAPF9CWAz5E6uevMWIqwO0ZK2tUG0k5w\\\\\\\\\\\\\\/dloOJm\\\\\\\\\\\\\\/AQtKpkDctAZHOLGHs\\\\\\\\\\\\\\/J27Z4mF28cKiKi5zLlGjVUizqWgYl4EQDjaf5CjNk60XNB1CYUsSPITW6enbb\\\\\\\\\\\\\\/q6eIWihzFF7PEqDfiRkgiDJwCJ5gIVce9lj2imDiDMqWbDIH93Ne23QIK7nn8OFud5Jqn2e54S3rdDOde1jJo4xdxeg0f6UtWaok8x\\\\\\\\\\\\\\/JI87IG7tZcIjNKKn7YDHfMg57d9yaAoi6APYiFa\\\\\\u0022,\\\\\\u0022iv\\\\\\u0022:\\\\\\u0022V2C24i62cmxvDJKeEMNZtw==\\\\\\u0022,\\\\\\u0022salt\\\\\\u0022:\\\\\\u0022f4d040311b2fd2429a61a615cefc1b83\\\\\\u0022}\\u0022,\\u0022hmac\\u0022:\\u00225eceacd216e4eae67e8e71004f9518c3129690b62d7c544cf4192dae39829430\\u0022}\",\"new-30\":\"{\\u0022encrypted\\u0022:\\u0022{\\\\\\u0022encrypted\\\\\\u0022:\\\\\\u00227heW\\\\\\\\\\\\\\/w7GHf4ittIJju9navTtzeiTNpGrYiC1bCxuG\\\\\\\\\\\\\\/Z5xkJafb0inAv1ywG1r+sflDqkK4QunFLUNQ\\\\\\\\\\\\\\/rEuEj8q7CaHKvf+TimvPff\\\\\\\\\\\\\\/UydH62mpmbPRfRm08G7Rxc+lxYNrPkyh6tnXRAjkhLZ6ZpEjMItknAF0jVlHkigumC7WiNGvBCMb87qe4YSS+5jNDQJR20Q7aEqzIrQMGnBR9DXirMR9ccC0lYEPVMTwcSoG2NjQz4MMlBWaP6yY1uNWNfxFJUJxF9bqY3HOk22Jg\\\\\\\\\\\\\\/SrezLj+kIHl2xpk0Tsn6PFF4ML5BcbiJVh8zssqmNBmq9qGTHP2FelI8uOgsqJwl+3mJYSy4uN6SB3CMvTvReP6FSqAOusMxGwRGLhjZP4DUMynM+oG1hOmOu4AQERHhHCzAI\\\\\\\\\\\\\\/+eBfQ0qmoEq\\\\\\\\\\\\\\/tNZjfPZyx4\\\\\\\\\\\\\\/RhvedvUe4CiqpMqGqGMiik1z9tPo1Qwx0k2GiLEcDkaiFtf8QaWoJWy3I+lM1XGqs9zFpLrHSesYoFfiqhdUT9CtswJ+wmZz4M7a14H4Blpn1ag8PFTGpwLGgwBlGqz+smP51BL0QwVYHT+Rcxny83+0nu9+wOPpfbX4\\\\\\\\\\\\\\/Loo2eZI3AWj9qe\\\\\\\\\\\\\\/izQXq2YmNGPW3Na0IDGHjQGGclyBNvphaGko6rX\\\\\\\\\\\\\\/Q5pyu5+lRVKYbnQuwnNbZc9x55Lc7ZKlo0hTwhBOaZiT9N4m5VHP2Bky8a6A15iOpRGHZydxv+352XHiT9b23BoBAjGaUaTEqhZ1WalleyWA\\\\\\\\\\\\\\/iO\\\\\\\\\\\\\\/gFqJVhhsIPvKOD5WAAn56m2dZvqlyYwDE9QEVcy14y0zUkjsGXV3w5ZtKYG45j6T9tApmeMQu3o4+wo\\\\\\\\\\\\\\/yXy\\\\\\\\\\\\\\/K9VrIA49Q3eY2u4sz90juEfcfMxnVXCxBHN7sj9O4wCq7H5tUktPmA8FsdsrO5uDd2nZpuBTCW6J6RNWIj0Gj+VnkfytPyT0L\\\\\\\\\\\\\\/\\\\\\\\\\\\\\/YYHPnEyHAaG6a2AbbSX\\\\\\\\\\\\\\/HPxfv5rq5wx28dUOPrSgWp33ZpNKcZ\\\\\\\\\\\\\\/T+jiSaPvs4k5sd0pq2DOS6DbPDC0QZeZoQ\\\\\\\\\\\\\\/Du2rJRXTEuxzpurcbHgNxSoVES9PozNG1JE5P0WD4Wjp2dRzhMZXAXGE1d3hgy9k7QZw7vutPuGdvSfZkfT\\\\\\\\\\\\\\/rfACyeY6PKeoERzO2kbtGVa\\\\\\\\\\\\\\/4+LauYtt\\\\\\\\\\\\\\/IQgD0mHV69lDscuzRiAhva0IMOJUTb32ofD92q+nqBHBH5jdquXosJ8dJ1t7Ts6QVenoYKN71ZLcOoB98mpZ2ZL74jxp6dBKVGJdpb5KrwZK+ctJu59q3WNM0ENO+O+HI+y7jhM2eicc6gKbCOsf9KXhC5R0apa0sUM6yccayzKzt86nLxrplGXwj7xeyMOf8X7sYua7vMCt2rtL1YZ\\\\\\\\\\\\\\/JQRvCBw+VFQk\\\\\\\\\\\\\\/tvtVN1W372mPtWQQ8rqBlc+p\\\\\\\\\\\\\\/WUUDj6Ur6t9wYfGcCsxrU\\\\\\\\\\\\\\/b35exa8CIxCGNbGVGBGxLqLytpLhZwv3293Duh034WRgSCo8bTfdckxCNEdS946\\\\\\\\\\\\\\/PbjgjIeJceEefDIm6lroxO4mp60SdHqOpdlsjzwnvKi1Tfn6fnnCFpo1wKEj08e3NlW57Amj9dma1\\\\\\\\\\\\\\/09saSoolfJ8VGcpRY94hO5wxiUHfauuKZTs6IAlFicxYWJJ7Lt7hQ2T9rvoGUBDAtqtFvq\\\\\\\\\\\\\\/afI5vpUMEoK7AoLFhR2ZPALklz9zPBiCt8oR3JsJ9CwBMi\\\\\\\\\\\\\\/IrV2AgoOCSDQeySMjbAUY01oOauzUnbfO9YNlA4ERA1o7dI1AyHZBCByfjZyVU8OQN6JEFQPibfJEMF0lpvVOohLcyQGFWzj0SnRO1mgQMcP97K2XQdD72zhqBZcG6RhEda9QuWWgTIGbPuOaDAS72Qq7MaSOg+3gKVmZEGUoeztdQRt+FTsNGWGbxMpaINfPecUACPOaTX3Bsimz26GmaqlAo291tG2eqpPGg4HBZidVeoMl+yRvmh+X7lwerL8u5vkDNSrga+5bXsJOzCkZulisqteqM+P\\\\\\\\\\\\\\/44NGXWVeZR0\\\\\\\\\\\\\\/GFIxgvaA5t2U\\\\\\\\\\\\\\/JjT23F\\\\\\\\\\\\\\/nQjBmfsjebS0LSNevv80RZYO2LzdBwHsoKol\\\\\\\\\\\\\\/7xbJKLJ6E8SWIyyM\\\\\\\\\\\\\\/hbc77pfRjPGLnIdM2Vh69LaGLz1Y158Aj68Xc++swk9QwQm1Jj8E9ulVnWh2GFtZd1s9yGt+RvOvGrnEoPD4+IipbZfcVKEhcpEdyM1PftqjU1aYpIby2oLD15gvKc+zFdyuClZkXajBBWmrQJDUfLouxzAL\\\\\\\\\\\\\\/AQOLRAeyUz8J4Kw6hujPW2+ikIDNnqr0LKsEZ9f++qjWzfQFqebJJquiAXVeVXyI1Ze7XpDkO\\\\\\\\\\\\\\/Zc3MFL\\\\\\\\\\\\\\/kxcQ08ZPLpPU7yejYlGbs6T+19azN0mn7oqILiNiekEDRSnQF13joYQ3Z9GBTrmRqPu97Z\\\\\\\\\\\\\\/9Lu8deb3FMzhXQYmPppTjOBkEZW4c7AMTOXjhrPM5RLg=\\\\\\u0022,\\\\\\u0022iv\\\\\\u0022:\\\\\\u0022q08nw4z0IjWoA0mNCGZfBQ==\\\\\\u0022,\\\\\\u0022salt\\\\\\u0022:\\\\\\u0022f4d040311b2fd2429a61a615cefc1b83\\\\\\u0022}\\u0022,\\u0022hmac\\u0022:\\u0022dc6ca7faed64eb8c7c7fdce2fa046ff98ceb65564b17c9ac11ab7dcfea18b954\\u0022}\",\"new-43\":\"{\\u0022encrypted\\u0022:\\u0022{\\\\\\u0022encrypted\\\\\\u0022:\\\\\\u00221T95gzSX3lduDdgKX1P+CV42ih3nuerfAIBUfJqNpwVuP3AyW3+JzBA7LFGEgeJnphGm+eAGnNOg1r6K5KYpttOBGMx7QozSaSZApykcmwWuI4SgIfNHAdv2IwU3QgEifLJmVPoR6XoOxDsFx0rJWQSnpQFS2TeBjAI1Uq\\\\\\\\\\\\\\/RtCLaPJZkGd6EIxZ1Lc+3QhjicZZnQDqRRfkXqo8lriXyqm1KsA\\\\\\\\\\\\\\/KpWqQREDrmPe35UhT0X1RavjzidkhsEJPzD4CsIVmDPO1Gnt\\\\\\\\\\\\\\/RfC7cvuX+Nx08WewfodXz5khpwD3BIC\\\\\\\\\\\\\\/RJiIfqUNfqj1m1Y5UO+zciPvyb4fpTwa71xxbc1b\\\\\\\\\\\\\\/MHyXl6t5NsztSuhYyWxCP7GPgw\\\\\\\\\\\\\\/kfuke22sDjkdrmvktj5QlENtC+EeUnlvQQyzkWYhZ7HuQFR9HKJ65M7JJjbHq1byQhZeOrc8BGR2fRb3Y2EBSFoYSIXBdSh1l68a05lSt42SbWyF8pknuDMinn1K3zVtvSpF7kw7p7HQov8\\\\\\\\\\\\\\/gb6r7JtA8z6mnBDAiJqckkCqM42ETPR3u+aTC\\\\\\\\\\\\\\/YPOVNI5mBGGssVq1EyP92GaAd8F8pj49JJVV2n70zDNnAirBVFrWaxpMLlHN+1aMHdiUFzEkly1LV+l15pAUFVzhGgTJNC7wbAe3rLMjQQ28fOJtbSA2Ch4px23Pd5oMvjSOsSlswpNPG\\\\\\\\\\\\\\/6HdNjPSVjWE3isYa0JbNqp309J58vw5aXWhxmugI336aXkRaNSA5YVIWhtfPe6BI4dwy1LhFXmkDPTnCDBiR6HslUBDxlsjxvqWeSMyusLL1tBlOSgSb16oaAjDk7MnFA2VurOGoszUIMeIHWBaImPhrXXP+z4SY00XO9xZALkUzYUGeBQ47UYZYdTRyR2PdPJQb5N4aVsiMqfbvzgP9tpYZjQ+vkVvJlryz6YMvfiOKhlP9\\\\\\\\\\\\\\/0v8ZlNfwMZuPQTJv0X5MLdoManR92vwKUbheEvnXU2ALqrFVUO8IXKTcWWBAAE3qOFv9klZs3VKNxtazyxS+h\\\\\\\\\\\\\\/xSasJMA7kvMPTDBywLRx+ji5fGS3T2W2bRW6fQBY1nOK9EHCcPls\\\\\\\\\\\\\\/NpcLTLgO\\\\\\\\\\\\\\/NZIdzlLIZP3k+nawx1zhWZTq4iBJ5rlpXKbLw4A1bjckLJ7OkGBfVus0gpkNuQcDpo0rTDhR460GmmH6VBMMos1m5nKr5KaTDD7\\\\\\\\\\\\\\/MvqmfA6XGBQC7yHwITaCVkyvJZrJ25y\\\\\\\\\\\\\\/SscwW2Iw2uSsIXDaZTIsU0P1OXWEydGucIDo6hqAnMtNOYo5Cr5Ll+iCZHyPwYJ2QitC\\\\\\\\\\\\\\/y23q89jaBdC6eljN8ydjzlKbF64KUXE9JLz2G0uOvRN8ue3DMkvKJbZdPKMBFljD1qP+TLxceV5bx2GOXjd2ppDTkP12oJ+M8LNjlHfG9o+VeI4V5FuZh\\\\\\\\\\\\\\/060Lp4vMJ1cCOMpJlUE32u2jr+Qwz6n1p\\\\\\\\\\\\\\/WI37i\\\\\\\\\\\\\\/pwT3h6msGiQWasWv6pRZFEYt4ss2qormoHpD6CDRWM\\\\\\\\\\\\\\/SCoAtKyUHzaXk8wTqh6Xt+UPdSf5IIm+f7d70tO+ycG5Lk5Fp+CPhRzC2lIgTZRSQiEz7+XRVsZlfHe1CjGMIlRKqpe40ROikj6UOPuHMtZmWbKcb1\\\\\\\\\\\\\\/7AymYu8C5jPRuh7neZ+F0aPW\\\\\\\\\\\\\\/TCxM5VlIJcHFPI1KGSHJL0j3RvLZ\\\\\\\\\\\\\\/ppBLxXn53NPhGOm36JK1QClNqrv8fDrri84rXB7AIFeUgLfY7i66GNZiwynzQt5b84LRufDT8iReTvTrMNaFHYm2x8N4N\\\\\\\\\\\\\\/cgs6sHcrOMSAs2RT73E2RJ8XAS+N91kORIt\\\\\\\\\\\\\\/tiysaB9gusJiaauLWOrOSk+KfwZE3bDVaLtLR7E5HW0p1A4b98Xk0Cp+iMCTXUaEkfTcfqaEPtDPNww9e1XM5ne1nO62VEnxr9JLOdFxqnOoj1nCoU27hZt1WILyCxxrYeFBr+xIHSQ1Lg5TmcdAC+V8v+P9B9N6laaEGzk0cHurujzSDTomdvdZ3EEgYtDCAd6Z5WPKqI2w9phb5cvvuC9rGiMHmdMaCCHG+dxpLvRecs064UxXoV7X\\\\\\\\\\\\\\/+BFh3BeLfkzlGDxtg9w+avTl1RCjkgYIxLFYeCYRB2KXFObmm2yBZH7Sx9hzpTHvurI4CXvNb9CAedwvmlxRXSYpm6lgbIEVoJ1jZAYTLG00rstxij35R3Ip3MHU\\\\\\\\\\\\\\/dUttKSICa0Xbat\\\\\\\\\\\\\\/pF72Mpk84RuyQx79+vr614DT5mlOJ60TY94K0sTz1Bmoll7uxA4VmcJasWXimuhfk4DRlb9lJuTp5z+6qarU31APL4r\\\\\\\\\\\\\\/zxUZTDj8HwoxlI7EdzIluklLBNIO12c4OuzsomG4M3uMz4Y0uGWDa1R\\\\\\\\\\\\\\/VVf9UGaYCrdBWJ+LpfiLLnTesOJqfXvIUXNaSUr1+vEPgeN9GCRlolQidQHvDKxZI0bmn1KI\\\\\\\\\\\\\\/ObQ+vyNwcAvsrGZNgZ2khGjYIkPEyaamUnUIrNBZZZrj9CWgYRpEcTHtCXsgQYR8zYKMCcgpVyGrQNy0Z9AILnI2M3HiYgUIBx5XpMEovgnrpdEAygSWGE2457S6Zw==\\\\\\u0022,\\\\\\u0022iv\\\\\\u0022:\\\\\\u0022kEB0EFdRDVqMDH5ETy4i4g==\\\\\\u0022,\\\\\\u0022salt\\\\\\u0022:\\\\\\u0022f4d040311b2fd2429a61a615cefc1b83\\\\\\u0022}\\u0022,\\u0022hmac\\u0022:\\u0022e915ebbe8e8cd1019debda8643aa8adeab84eb63c70512416ad6fafaad5917c6\\u0022}\"},\"instances\":\"{\\u0022highwire_abstract_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:20,\\u0022height\\u0022:20,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-abstract-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-abstract-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022right center\\u0022,\\u0022my\\u0022:\\u0022left center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022shift\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter click \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_author_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-author-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-author-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022top center\\u0022,\\u0022my\\u0022:\\u0022bottom center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_reflinks_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022mimic\\u0022:\\u0022top center\\u0022,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-ref-link-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-ref-link-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022bottom left\\u0022,\\u0022my\\u0022:\\u0022top left\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022flip\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}}}\",\"qtipDebug\":\"{\\u0022leaveElement\\u0022:0}\",\"panel_ajax_tab\":{\"path\":\"sites\\/all\\/modules\\/contrib\\/panels_ajax_tab\"},\"urlIsAjaxTrusted\":{\"\\/content\\/371\\/6532\\/916\":true},\"highwireResponsive\":{\"enquire_enabled\":1,\"breakpoints_configured\":1,\"breakpoints\":{\"zero\":\"(min-width: 0px)\",\"small\":\"(min-width: 480px)\",\"med\":\"(min-width: 768px)\",\"med2\":\"(min-width: 900px)\",\"med3\":\"(min-width: 1025px)\",\"large\":\"(min-width: 1100px)\"}},\"googleanalytics\":{\"trackOutbound\":1,\"trackMailto\":1,\"trackDownload\":1,\"trackDownloadExtensions\":\"7z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\",\"trackColorbox\":1}});\n",
      "//--><!]]>\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "/* ForeSee Embed Script v2.01\n",
      "\t// DO NOT MODIFY BELOW THIS LINE *****************************************/\n",
      "\t;(function (g) {\n",
      "\t\tvar d = document, am = d.createElement(\"script\"), h = d.head || d.getElementsByTagName(\"head\")[0], fsr = \"fsReady\",\n",
      "\t\t\taex = {\n",
      "\t\t\t\t\"src\": \"https://www.cdc.gov/JScript/foresee/latest/gateway.min.js\",\n",
      "\t\t\t\t\"type\": \"text/javascript\",\n",
      "\t\t\t\t\"async\": \"true\",\n",
      "\t\t\t\t\"data-vendor\": \"fs\",\n",
      "\t\t\t\t\"data-mode\": \"selfhost\",\n",
      "\t\t\t\t\"data-environment\": \"production\",\n",
      "\t\t\t\t\"data-hasssl\": \"true\",\n",
      "\t\t\t\t\"data-client\": \"cdc\",\n",
      "\t\t\t\t\"data-codelocation\": \"https://www.cdc.gov/JScript/foresee/latest/foresee_assets/code/19.7.6/\",\n",
      "\t\t\t\t\"data-isselfhosted\": \"true\",\n",
      "\t\t\t\t\"data-product-assets\": \"https://www.cdc.gov/JScript/foresee/latest/foresee_assets/product_assets/\",\n",
      "\t\t\t\t\"data-role\": \"gateway\"\n",
      "\t\t\t};\n",
      "\t\tfor (var attr in aex){am.setAttribute(attr, aex[attr]);}h.appendChild(am); g[fsr] || (g[fsr] = function () {var aT = \"__\" + fsr + \"_stk__\";g[aT] = g[aT] || [];g[aT].push(arguments);});\n",
      "\t})(window);\n",
      "\t/* DO NOT MODIFY ABOVE THIS LINE *****************************************/\n",
      "\n",
      "Understanding How COVID-19 Vaccines Work  | CDC\n",
      "  \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      ".theme-cyan nav ul.tp-nav-main li.active.selected>a:first-child{color:#006c80;}\n",
      "  \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Skip directly to site content\n",
      "Skip directly to page options\n",
      "Skip directly to A-Z link\n",
      "\n",
      "\n",
      "\n",
      "var axel = Math.random() + \"\";\n",
      "var a = axel * 10000000000000;\n",
      "document.write('<iframe src=\"https://10322181.fls.doubleclick.net/activityi;src=10322181;type=ptnuh0;cat=2021_0;dc_lat=;dc_rdid=;tag_for_child_directed_treatment=;tfua=;npa=;gdpr=${GDPR};gdpr_consent=${GDPR_CONSENT_755};ord=1;num=' + a + '?\" width=\"1\" height=\"1\" frameborder=\"0\" style=\"display:none\">');\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Self-Checker\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Coronavirus Self-Checker\n",
      "\n",
      "×\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "       \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "×\n",
      "\n",
      "\n",
      "Submit\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "COVID-19\n",
      "\n",
      "\n",
      "COVID-19\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\tCoronavirus Home\t\t\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Home\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\tYour Health\t\t\t\t\t\t\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "About COVID-19 \n",
      "\n",
      "\n",
      "Symptoms\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Testing\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Variants\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\t\t\t\tVIEW MORE\r\n",
      "\t\t\t\t\t\t\t\t\t\t\n",
      "\n",
      "\n",
      "\n",
      "Masks \n",
      "\n",
      "\n",
      "Your Guide to Masks\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "How to Wear Masks\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Improve Your Masks\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\t\t\t\tVIEW MORE\r\n",
      "\t\t\t\t\t\t\t\t\t\t\n",
      "\n",
      "\n",
      "\n",
      "Daily Life \n",
      "\n",
      "\n",
      "If You Are Sick\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "People at Increased Risk\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Travel\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\t\t\t\tVIEW MORE\r\n",
      "\t\t\t\t\t\t\t\t\t\t\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\tVaccines\t\t\t\t\t\t\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Getting a Vaccine \n",
      "\n",
      "\n",
      "Information for Specific Groups \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Before Your Appointment\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "After the Vaccine\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\t\t\t\tVIEW MORE\r\n",
      "\t\t\t\t\t\t\t\t\t\t\n",
      "\n",
      "\n",
      "\n",
      "About the Vaccines \n",
      "\n",
      "\n",
      "Key Things to Know\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Different Vaccines \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Vaccine Safety\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\t\t\t\tVIEW MORE\r\n",
      "\t\t\t\t\t\t\t\t\t\t\n",
      "\n",
      "\n",
      "\n",
      "Resources \n",
      "\n",
      "\n",
      "Clinical Resources\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Questions & Answers\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Vaccine Rollout Recommendations \n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\t\t\t\tVIEW MORE\r\n",
      "\t\t\t\t\t\t\t\t\t\t\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\tCases & Data\t\t\t\t\t\t\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "COVID Data Tracker \n",
      "\n",
      "\n",
      "\n",
      "Cases in the Last 7 Days\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "County Level Cases\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Vaccinations in the US\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\t\t\t\tVIEW MORE\r\n",
      "\t\t\t\t\t\t\t\t\t\t\n",
      "\n",
      "\n",
      "\n",
      "Research & Surveillance \n",
      "\n",
      "\n",
      "Weekly Summary\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Special Populations Data\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Forecasts\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\t\t\t\tVIEW MORE\r\n",
      "\t\t\t\t\t\t\t\t\t\t\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\tWork & School\t\t\t\t\t\t\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Workplaces & Businesses \n",
      "\n",
      "\n",
      "Info by Industry\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Questions & Answers\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Disinfecting Your Facility\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\t\t\t\tVIEW MORE\r\n",
      "\t\t\t\t\t\t\t\t\t\t\n",
      "\n",
      "\n",
      "\n",
      "Schools & Child Care \n",
      "\n",
      "\n",
      "K-12 Operational Strategy\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Prevention in K-12 Schools\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Child Care Programs\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\t\t\t\tVIEW MORE\r\n",
      "\t\t\t\t\t\t\t\t\t\t\n",
      "\n",
      "\n",
      "\n",
      "Community \n",
      "\n",
      "\n",
      "Colleges & Universities\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Parks & Recreational Facilities\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Health Equity\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\t\t\t\tVIEW MORE\r\n",
      "\t\t\t\t\t\t\t\t\t\t\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\tHealthcare Workers\t\t\t\t\t\t\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Healthcare Workers \n",
      "\n",
      "\n",
      "Clinical Care\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Infection Control\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Exposure in Healthcare Settings\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\t\t\t\tVIEW MORE\r\n",
      "\t\t\t\t\t\t\t\t\t\t\n",
      "\n",
      "\n",
      "\n",
      "Laboratories \n",
      "\n",
      "\n",
      "Resources for Labs\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "CDC Lab Work\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Questions & Answers\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\t\t\t\tVIEW MORE\r\n",
      "\t\t\t\t\t\t\t\t\t\t\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\tHealth Depts\t\t\t\t\t\t\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Resources \n",
      "\n",
      "\n",
      "Key Resources\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Search Health Dept Resources\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Testing\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\t\t\t\tVIEW MORE\r\n",
      "\t\t\t\t\t\t\t\t\t\t\n",
      "\n",
      "\n",
      "\n",
      "Community Mitigation \n",
      "\n",
      "\n",
      "Community-Related Exposures\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Expanded Screening Testing\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Evaluating Strategies\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\t\t\t\tVIEW MORE\r\n",
      "\t\t\t\t\t\t\t\t\t\t\n",
      "\n",
      "\n",
      "\n",
      "Contact Tracing \n",
      "\n",
      "\n",
      "Resources\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Notification of Exposure\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Principles\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\t\t\t\tVIEW MORE\r\n",
      "\t\t\t\t\t\t\t\t\t\t\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\tMore\t\t\t\t\t\t\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "\n",
      "\n",
      "Science & Research \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Global COVID-19\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "CDC in Action\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Guidance for COVID-19\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Communication Resources\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\t\t\t\tVIEW MORE\r\n",
      "\t\t\t\t\t\t\t\t\t\t\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Section Navigation\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "CDC Home\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Understanding How COVID-19 Vaccines WorkUnderstanding How COVID-19 Vaccines Work \n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\t\t\tUpdated Jan. 13, 2021\t\t\t\t\t\t\t\t\n",
      "\n",
      "LanguagesEspañol简体中文Tiếng Việt한국어Other Languages \n",
      "\n",
      "Print\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Minus\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Related Pages\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "The Immune System—The Body’s Defense Against Infection\n",
      "To understand how COVID-19 vaccines work, it helps to first look at how our bodies fight illness. When germs, such as the virus that causes COVID-19, invade our bodies, they attack and multiply. This invasion, called an infection, is what causes illness. Our immune system uses several tools to fight infection. Blood contains red cells, which carry oxygen to tissues and organs, and white or immune cells, which fight infection. Different types of white blood cells fight infection in different ways:\n",
      "\n",
      "Macrophages are white blood cells that swallow up and digest germs and dead or dying cells. The macrophages leave behind parts of the invading germs called antigens. The body identifies antigens as dangerous and stimulates antibodies to attack them.\n",
      "B-lymphocytes are defensive white blood cells. They produce antibodies that attack the pieces of the virus left behind by the macrophages.\n",
      "T-lymphocytes are another type of defensive white blood cell. They attack cells in the body that have already been infected.\n",
      "\n",
      "The first time a person is infected with the virus that causes COVID-19, it can take several days or weeks for their body to make and use all the germ-fighting tools needed to get over the infection. After the infection, the person’s immune system remembers what it learned about how to protect the body against that disease.\n",
      "The body keeps a few T-lymphocytes, called memory cells, that go into action quickly if the body encounters the same virus again. When the familiar antigens are detected, B-lymphocytes produce antibodies to attack them. Experts are still learning how long these memory cells protect a person against the virus that causes COVID-19.\n",
      "How COVID-19 Vaccines Work\n",
      "COVID-19 vaccines help our bodies develop immunity to the virus that causes COVID-19 without us having to get the illness. Different types of vaccines work in different ways to offer protection, but with all types of vaccines, the body is left with a supply of “memory” T-lymphocytes as well as B-lymphocytes that will remember how to fight that virus in the future.\n",
      "It typically takes a few weeks for the body to produce T-lymphocytes and B-lymphocytes after vaccination. Therefore, it is possible that a person could be infected with the virus that causes COVID-19 just before or just after vaccination and then get sick because the vaccine did not have enough time to provide protection.\n",
      "Sometimes after vaccination, the process of building immunity can cause symptoms, such as fever. These symptoms are normal and are a sign that the body is building immunity.\n",
      "Types of Vaccines\n",
      "Currently, there are three main types of COVID-19 vaccines that are or soon will be undergoing large-scale (Phase 3) clinical trials in the United States. Below is a description of how each type of vaccine prompts our bodies to recognize and protect us from the virus that causes COVID-19. None of these vaccines can give you COVID-19.\n",
      "\n",
      "mRNA vaccines contain material from the virus that causes COVID-19 that gives our cells instructions for how to make a harmless protein that is unique to the virus. After our cells make copies of the protein, they destroy the genetic material from the vaccine. Our bodies recognize that the protein should not be there and build T-lymphocytes and B-lymphocytes that will remember how to fight the virus that causes COVID-19 if we are infected in the future.\n",
      "Protein subunit vaccines include harmless pieces (proteins) of the virus that cause COVID-19 instead of the entire germ. Once vaccinated, our immune system recognizes that the proteins don’t belong in the body and begins making T-lymphocytes and antibodies. If we are ever infected in the future, memory cells will recognize and fight the virus.\n",
      "Vector vaccines contain a weakened version of a live virus—a different virus than the one that causes COVID-19—that has genetic material from the virus that causes COVID-19 inserted in it (this is called a viral vector). Once the viral vector is inside our cells, the genetic material gives cells instructions to make a protein that is unique to the virus that causes COVID-19. Using these instructions, our cells make copies of the protein. This prompts our bodies to build T-lymphocytes and B-lymphocytes that will remember how to fight that virus if we are infected in the future.\n",
      "\n",
      "Most COVID-19 Vaccines Require More Than One Shot\n",
      "All but one of the COVID-19 vaccines that are currently in Phase 3 clinical trials in the United States use two shots. The first shot starts building protection. A second shot a few weeks later is needed to get the most protection the vaccine has to offer. One vaccine in Phase 3 clinical trials only needs one shot.\n",
      "The Bottom Line\n",
      "Getting vaccinated is one of many steps you can take to protect yourself and others from COVID-19.  Protection from COVID-19 is critically important because for some people, it can cause severe illness or death.\n",
      "Stopping a pandemic requires using all the tools available. Vaccines work with your immune system so your body will be ready to fight the virus if you are exposed. Other steps, like masks and social distancing, help reduce your chance of being exposed to the virus or spreading it to others. Together, COVID-19 vaccination and following CDC’s recommendations to protect yourself and others will offer the best protection from COVID-19.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Facebook\n",
      "Twitter\n",
      "LinkedIn\n",
      "Syndicate\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t\t\t\t\tLast Updated Jan. 13, 2021\t\t\t\t\t\t\tContent source: \tNational Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "homeVaccinesKey Things to Knowplus iconFrequently Asked Questions about VaccinationMyths & FactsInformation for Specific Groupsplus iconHealthcare PersonnelLong-term Care Facility ResidentsEssential Workersplus iconWorkplace Vaccination ProgramHow to Get VaccinatedOlder AdultsPeople with DisabilitiesPregnancy or BreastfeedingUnderlying Medical ConditionsPeople with AllergiesVaccine Rollout RecommendationsHow CDC is Making Vaccine RecommendationsWhat to Expect at Your Vaccine Appointmentplus iconAfter Getting the VaccineBenefits of Getting VaccinatedDifferent Vaccinesplus iconHow Vaccines WorkUnderstanding mRNA VaccinesPfizer-BioNTechModernaUnderstanding Viral Vector COVID-19 VaccinesJohnson & Johnson's JanssenEnsuring the Safety of Vaccinesplus iconV-safeV-safe Print ResourcesAllergic ReactionsSafety of COVID-19 VaccinesVaccine Reporting Systemsplus iconMonitoring Systems for Pregnant PeopleV-safe Pregnancy RegistryEnsuring Vaccines WorkHow Vaccines Get to Youplus iconPercent of Doses AdministeredCommunication Resourcesplus iconToolkitsplus iconFor Essential WorkersFor Community-Based Organizations \n",
      "\n",
      " email_03Get Email Updates  To receive email updates about COVID-19, enter your email address:     Email Address       What's this?   Submit       \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "// Print Button (pre 2020 theme)\r\n",
      "( function() {\r\n",
      "  var nTimer = setInterval( function() {\r\n",
      "    if ( window.jQuery && ! window.jQuery('html').hasClass('cdc-2020') ) {\r\n",
      "      clearInterval( nTimer );\r\n",
      "      var targetNodeForInsertion = jQuery( 'h1#content' );\r\n",
      "      if ( 0 === targetNodeForInsertion.length ) {\r\n",
      "        return;\r\n",
      "      }\r\n",
      "\r\n",
      "      if ( targetNodeForInsertion.parent().hasClass( 'syndicate' ) ) {\r\n",
      "        targetNodeForInsertion = targetNodeForInsertion.parent();\r\n",
      "      }\r\n",
      "\r\n",
      "      if ( targetNodeForInsertion.next().hasClass( 'dropdown' ) ) {\r\n",
      "        targetNodeForInsertion.next().append( '<button id=\"clickToPrint\" class=\"btn bg-white c-blue b-gray-l3 fs08 ml-2\" aria-label=\"Click to print page\" onclick=\"window.print()\">Print Page</button>' );\r\n",
      "      } else {\r\n",
      "        targetNodeForInsertion.after( '<div class=\"dropdown p-none\" style=\"margin-top:-5px; margin-bottom:33px;\"><button id=\"clickToPrint\" class=\"btn bg-white c-blue b-gray-l3 fs08\" aria-label=\"Click to print page\" onclick=\"window.print()\">Print Page</button></div>' );\r\n",
      "      }\r\n",
      "    }\r\n",
      "  }, 50 );\r\n",
      "})();\r\n",
      "\n",
      "\n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "HAVE QUESTIONS?\n",
      "\n",
      "\n",
      "\n",
      "Visit CDC-INFO\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Call 800-232-4636\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Email CDC-INFO\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Open 24/7\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "CDC INFORMATION\n",
      "\n",
      "About CDC\n",
      "Jobs\n",
      "Funding\n",
      "Policies\n",
      "File Viewers & Players\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Privacy\n",
      "FOIA\n",
      "No Fear Act\n",
      "OIG\n",
      "Nondiscrimination\n",
      "Accessibility\n",
      "\n",
      "\n",
      "\n",
      "CONNECT WITH CDC\n",
      "\n",
      "Facebook\n",
      "Twitter\n",
      "Instagram\n",
      "LinkedIn\n",
      "Snapchat\n",
      "\n",
      "\n",
      "Youtube\n",
      "Syndicate\n",
      "CDC TV\n",
      "RSS\n",
      "Email\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "U.S. Department of Health & Human Services\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "USA.gov\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "CDC Website Exit Disclaimer external icon\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "LANGUAGE ASSISTANCE\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Español\n",
      "\n",
      "\n",
      "繁體中文\n",
      "\n",
      "\n",
      "Tiếng Việt\n",
      "\n",
      "\n",
      "한국어\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Tagalog\n",
      "\n",
      "\n",
      "Русский\n",
      "\n",
      "\n",
      "العربية\n",
      "\n",
      "\n",
      "Kreyòl Ayisyen\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Français\n",
      "\n",
      "\n",
      "Polski\n",
      "\n",
      "\n",
      "Português\n",
      "\n",
      "\n",
      "Italiano\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Deutsch\n",
      "\n",
      "\n",
      "日本語\n",
      "\n",
      "\n",
      "فارسی\n",
      "\n",
      "\n",
      "English\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "CONTACT CDC\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Visit CDC-INFO\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Call 800-232-4636\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Email CDC-INFO\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Open 24/7\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "ABOUT CDC\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "About CDC\n",
      "\n",
      "\n",
      "Jobs\n",
      "\n",
      "\n",
      "Funding\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "POLICIES\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Policies\n",
      "\n",
      "\n",
      "File Viewers & Players\n",
      "\n",
      "\n",
      "Privacy\n",
      "\n",
      "\n",
      "FOIA\n",
      "\n",
      "\n",
      "No Fear Act\n",
      "\n",
      "\n",
      "OIG\n",
      "\n",
      "\n",
      "Nondiscrimination\n",
      "\n",
      "\n",
      "Accessibility\n",
      "\n",
      "\n",
      "CDC Website Exit Disclaimer external icon\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "LANGUAGE ASSISTANCE\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Español\n",
      "繁體中文\n",
      "Tiếng Việt\n",
      "한국어\n",
      "Tagalog\n",
      "Русский\n",
      "العربية\n",
      "Kreyòl Ayisyen\n",
      "Français\n",
      "Polski\n",
      "Português\n",
      "Italiano\n",
      "Deutsch\n",
      "日本語\n",
      "فارسی\n",
      "English\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Facebook\n",
      "\n",
      "\n",
      "Twitter\n",
      "\n",
      "\n",
      "Instagram\n",
      "\n",
      "\n",
      "LinkedIn\n",
      "\n",
      "\n",
      "Snapchat\n",
      "\n",
      "Youtube\n",
      "Syndicate\n",
      "CDC TV\n",
      "RSS\n",
      "Email\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "U.S. Department of Health & Human Services\n",
      "\n",
      "\n",
      "USA.gov\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "SAS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "stats\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t.st0 {\r\n",
      "\t\t\t\tfill: #FFFFFF;\r\n",
      "\t\t\t}\r\n",
      "\r\n",
      "\t\t\t.st1 {\r\n",
      "\t\t\t\tfill: none;\r\n",
      "\t\t\t\tstroke: #FFFFFF;\r\n",
      "\t\t\t\tstroke-width: 2.1206;\r\n",
      "\t\t\t}\r\n",
      "\r\n",
      "\t\t\t.st2 {\r\n",
      "\t\t\t\tfill: #005DA9;\r\n",
      "\t\t\t}\r\n",
      "\r\n",
      "\t\t\t.st3 {\r\n",
      "\t\t\t\tfill: none;\r\n",
      "\t\t\t\tstroke: #FFFFFF;\r\n",
      "\t\t\t\tstroke-width: 1.8943;\r\n",
      "\t\t\t}\r\n",
      "\r\n",
      "\t\t\t.st4 {\r\n",
      "\t\t\t\tfill: #607171;\r\n",
      "\t\t\t}\r\n",
      "\t\t\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t\t\t.st0 {\r\n",
      "\t\t\t\tfill: #FFFFFF;\r\n",
      "\t\t\t}\r\n",
      "\r\n",
      "\t\t\t.st1 {\r\n",
      "\t\t\t\tfill: none;\r\n",
      "\t\t\t\tstroke: #FFFFFF;\r\n",
      "\t\t\t\tstroke-width: 2.1206;\r\n",
      "\t\t\t}\r\n",
      "\r\n",
      "\t\t\t.st2 {\r\n",
      "\t\t\t\tfill: #005DA9;\r\n",
      "\t\t\t}\r\n",
      "\r\n",
      "\t\t\t.st3 {\r\n",
      "\t\t\t\tfill: none;\r\n",
      "\t\t\t\tstroke: #FFFFFF;\r\n",
      "\t\t\t\tstroke-width: 1.8943;\r\n",
      "\t\t\t}\r\n",
      "\r\n",
      "\t\t\t.st4 {\r\n",
      "\t\t\t\tfill: #607171;\r\n",
      "\t\t\t}\r\n",
      "\t\t\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "    \r\n",
      "    s.pageName=document.title;\r\n",
      "s.channel=\"Coronavirus\";\r\n",
      "siteCatalyst.setLevel1(\"ncird\");\r\n",
      "siteCatalyst.setLevel2(\"coronavirus\");\r\n",
      "siteCatalyst.setLevel3(\"multi\");\r\n",
      "siteCatalyst.setLevel4(\"dvd\");\r\n",
      "siteCatalyst.setLevel5(\"covid-vax\"); <!-- NEW LEVEL as of 12/16/2020 -->    \r\n",
      "    \n",
      "\r\n",
      "\twindow.shortTitle = \"Understanding How COVID-19 Vaccines Work\";\r\n",
      "\twindow.pageOptions = window.pageOptions || {};\r\n",
      "\twindow.pageOptions.navigation = window.pageOptions.navigation || { fourthLevelCollapsed: false, showFourthLevel: true\t}; \t\twindow.pageOptions.navigation.breadcrumbs = { mode: 'auto', showCurrentPage: false , prefix: [{\"text\":\"CDC\",\"href\":\"https:\\/\\/www.cdc.gov\\/\"}] }; \r\n",
      "\twindow.CDC.tp4.public.appInit( window.pageOptions );\r\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Exit Notification/Disclaimer Policy\n",
      "\n",
      "Close\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Links with this icon  indicate that you are leaving the CDC website.\n",
      "\n",
      "The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.\n",
      "Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.\n",
      "You will be subject to the destination website's privacy policy when you follow the link.\n",
      "CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.\n",
      "\r\n",
      "\r\n",
      "\t\t\tFor more information on CDC's web notification policies, see Website Disclaimers.\r\n",
      "\t\t\n",
      "\n",
      "\n",
      "Cancel\n",
      "Continue\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Coronavirus (COVID-19) vaccine - NHS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "{\"@context\": \"http://schema.org\", \"@type\": \"WebPage\", \"about\": {\"@type\": \"WebPage\", \"name\": \"Coronavirus (COVID-19) vaccine\"}, \"author\": {\"@type\": \"Organization\", \"email\": \"nhswebsite.servicedesk@nhs.net\", \"logo\": \"https://www.nhs.uk/nhscwebservices/documents/logo1.jpg\", \"name\": \"NHS website\", \"url\": \"https://www.nhs.uk\"}, \"breadcrumb\": {\"@context\": \"http://schema.org\", \"@type\": \"BreadcrumbList\", \"itemListElement\": [{\"@type\": \"ListItem\", \"item\": {\"@id\": \"https://www.nhs.uk/conditions/\", \"genre\": \"condition\", \"name\": \"Health A to Z\"}, \"position\": 0}, {\"@type\": \"ListItem\", \"item\": {\"@id\": \"https://www.nhs.uk/conditions/coronavirus-covid-19/\", \"genre\": \"hub\", \"name\": \"Coronavirus (COVID-19)\"}, \"position\": 1}, {\"@type\": \"ListItem\", \"item\": {\"@id\": \"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/\", \"genre\": \"hub\", \"name\": \"Coronavirus vaccination\"}, \"position\": 2}, {\"@type\": \"ListItem\", \"item\": {\"@id\": \"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/\", \"genre\": \"guide\", \"name\": \"Coronavirus (COVID-19) vaccine\"}, \"position\": 3}]}, \"copyrightHolder\": {\"@type\": \"Organization\", \"name\": \"Crown Copyright\"}, \"description\": \"NHS information about coronavirus vaccines, including vaccine safety and who can get the vaccine.\", \"genre\": \"guide\", \"hasPart\": [{\"@type\": \"WebPageElement\", \"description\": \"The coronavirus (COVID-19) vaccine is safe and effective. It gives you the best protection against coronavirus.\", \"name\": \"overview\", \"text\": \"\", \"title\": \"\", \"url\": \"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/#overview\"}, {\"@type\": \"WebPageElement\", \"description\": \"People most at risk from coronavirus (COVID-19) are being offered the COVID-19 vaccine first. It will be offered to more people over time.\", \"name\": \"SuitabilityHealthAspect\", \"text\": \"<p>The NHS is currently offering the COVID-19 vaccine to people most at risk from coronavirus.</p><p>In England, the vaccine is being\\u00a0offered in some hospitals and pharmacies, at local vaccination centres run by GPs and at larger vaccination centres. More centres are opening all the time.</p><p>It's being given to:</p><ul><li>people aged 60 and over</li><li>people at <a href=\\\"/conditions/coronavirus-covid-19/people-at-higher-risk/whos-at-higher-risk-from-coronavirus/\\\">high risk from coronavirus</a> (clinically extremely vulnerable)</li><li>people who live or work in care homes</li><li>health and social care workers</li><li>people with a condition that puts them at higher risk (clinically vulnerable)</li><li>people who are a main carer for someone at high risk from coronavirus</li></ul>\", \"title\": \"Who can get the COVID-19 vaccine\", \"url\": \"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/#suitability\"}, {\"@type\": \"WebPageElement\", \"description\": \"The coronavirus (COVID-19) vaccine is given as an injection. There are 2 doses given 3 to 12 weeks apart.\", \"name\": \"UsageOrScheduleHealthAspect\", \"text\": \"<p>The COVID-19 vaccine is given as an injection into your upper arm.</p><p>It's given as 2 doses. You will have the 2nd dose 3 to 12 weeks after having the 1st dose.</p>\", \"title\": \"How the COVID-19 vaccine is given\", \"url\": \"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/#dosage-and-administration\"}, {\"@type\": \"WebPageElement\", \"description\": \"If you\\u2019re eligible, you can book your coronavirus (COVID-19) vaccination appointments online at www.nhs.uk/covid-vaccination or by calling 119.\", \"name\": \"HowOrWhereHealthAspect\", \"text\": \"<p>You can book your vaccination appointments online if any of the following apply:</p><ul><li>you are aged 60 or over</li><li>you are at <a href=\\\"/conditions/coronavirus-covid-19/people-at-higher-risk/whos-at-higher-risk-from-coronavirus/\\\">high risk from coronavirus</a> (clinically extremely vulnerable)</li><li>you are an eligible frontline health or social care worker</li><li>you have a condition that puts you at higher risk (clinically vulnerable)</li><li>you are a main carer for someone at high risk from coronavirus</li></ul><p>You can book appointments at a larger vaccination centre or a pharmacy that provides COVID-19 vaccinations.</p><p>You do not need to wait to be contacted by the NHS.</p>\", \"title\": \"How to get the COVID-19 vaccine\", \"url\": \"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/#how-to-get-it\"}, {\"@type\": \"WebPageElement\", \"description\": \"Millions of people have had the coronavirus (COVID-19) vaccine and reports of serious problems, such as allergic reactions, have been very rare.\", \"name\": \"SafetyHealthAspect\", \"text\": \"<p>The vaccines approved for use in the UK have met strict standards of safety, quality and effectiveness set out by the independent Medicines and Healthcare products Regulatory Agency (MHRA).</p><p>Any coronavirus vaccine that is approved must go through all the clinical trials and safety checks all other licensed medicines go through. The MHRA follows international standards of safety.</p><p>Other vaccines are being developed. They will only be available on the NHS once they have been thoroughly tested to make sure they are safe and effective.</p><p>So far, millions of people have been given a COVID-19 vaccine and reports of serious side effects, such as allergic reactions, have been very rare. No long-term complications have been reported.</p>\", \"title\": \"How safe is the COVID-19 vaccine?\", \"url\": \"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/#safety\"}, {\"@type\": \"WebPageElement\", \"description\": \"Most people who have the coronavirus (COVID-19) vaccine will be protected from the virus. 2 doses are needed for longer lasting protection.\", \"name\": \"BenefitsHealthAspect\", \"text\": \"<p>The 1st dose of the COVID-19 vaccine should give you good protection from coronavirus. But you need to have the 2 doses of the vaccine to give you longer lasting protection.</p><p>There is a chance you might still get or spread coronavirus even if you have the vaccine.</p><p>This means it is important to:</p><ul><li>continue to follow <a href=\\\"/conditions/coronavirus-covid-19/social-distancing/what-you-need-to-do/\\\">social distancing guidance</a></li><li>if you can, wear something that covers your nose and mouth in places where it's hard to stay away from other people</li></ul>\", \"title\": \"How effective is the COVID-19 vaccine?\", \"url\": \"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/#effectiveness\"}, {\"@type\": \"WebPageElement\", \"description\": \"Some people who have the coronavirus (COVID-19) vaccine have mild side effects for a few days, such as a sore arm or tiredness.\", \"name\": \"SideEffectsHealthAspect\", \"text\": \"<p>Most side effects of the COVID-19 vaccine are mild and should not last longer than a week, such as:</p><ul><li>a sore arm where the needle went in</li><li>feeling tired</li><li>a headache</li><li>feeling achy</li><li>feeling or being sick</li></ul><p>You can take painkillers, such as paracetamol, if you need to.</p><p>If you have a high temperature you may have coronavirus or another infection.</p><p>If your symptoms get worse or you are worried, call 111.</p><h3>Allergic reactions</h3><p>Tell healthcare staff before you are vaccinated if you've ever had a serious allergic reaction.</p><p>You should not have the COVID-19 vaccine if you have ever had a serious allergic reaction (including anaphylaxis) to:</p><ul><li>a previous dose of the same vaccine</li><li>any of the ingredients in the vaccine</li></ul><p>Serious allergic reactions are rare. If you do have a reaction to the vaccine, it usually happens in minutes. Staff giving the vaccine are trained to deal with allergic reactions and treat them immediately.</p>\", \"title\": \"COVID-19 vaccine side effects\", \"url\": \"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/#side-effects\"}], \"lastReviewed\": [\"2021-02-26T08:10:00+00:00\", \"2021-03-12T18:10:00+00:00\"], \"license\": \"https://developer.api.nhs.uk/terms\", \"name\": \"Coronavirus (COVID-19) vaccine\", \"relatedLink\": [{\"@type\": \"LinkRole\", \"linkRelationship\": \"Navigation\", \"name\": \"Coronavirus vaccination\", \"position\": 0, \"url\": \"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/\"}, {\"@type\": \"LinkRole\", \"linkRelationship\": \"Navigation\", \"name\": \"Coronavirus (COVID-19) vaccine\", \"position\": 1, \"url\": \"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/\"}, {\"@type\": \"LinkRole\", \"linkRelationship\": \"Navigation\", \"name\": \"Who can get the coronavirus (COVID-19) vaccine\", \"position\": 2, \"url\": \"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/who-can-get-the-vaccine/\"}, {\"@type\": \"LinkRole\", \"linkRelationship\": \"Navigation\", \"name\": \"How you will be contacted for your coronavirus (COVID-19) vaccination\", \"position\": 3, \"url\": \"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/how-you-will-be-contacted/\"}, {\"@type\": \"LinkRole\", \"linkRelationship\": \"Navigation\", \"name\": \"Book or manage your coronavirus vaccination\", \"position\": 4, \"url\": \"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/book-coronavirus-vaccination/\"}, {\"@type\": \"LinkRole\", \"linkRelationship\": \"Navigation\", \"name\": \"What happens at your appointment\", \"position\": 5, \"url\": \"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/what-happens-at-your-appointment/\"}, {\"@type\": \"LinkRole\", \"linkRelationship\": \"Navigation\", \"name\": \"Health conditions and coronavirus (COVID-19) vaccination\", \"position\": 6, \"url\": \"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/health-conditions/\"}], \"schemaVersion\": [\"http://schema.org/version/3.9/\", \"g-20190515\"], \"url\": \"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/\"}\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "window.digitalData=\n",
      "            {\"page\": {\n",
      "                \"pageInfo\": {\n",
      "                    \"pageName\": \"nhs:web:conditions:coronavirus-covid-19:coronavirus-vaccination:coronavirus-vaccine\"\n",
      "               },\n",
      "                \"category\":\n",
      "                    {\n",
      "            \"primaryCategory\": \"conditions\",\n",
      "            \"subCategory1\":\"coronavirus-covid-19\",\n",
      "            \"subCategory2\":\"coronavirus-vaccination\",\n",
      "            \"subCategory3\":\"coronavirus-vaccine\"\n",
      "            }\n",
      "                },\n",
      "               };\n",
      "            \n",
      "\n",
      "\n",
      "        (function (h, o, t, j, a, r) {\n",
      "          h.hj = h.hj || function () {\n",
      "            (h.hj.q = h.hj.q || []).push(arguments)\n",
      "          };\n",
      "          h._hjSettings = {\n",
      "            hjid: 681718,\n",
      "            hjsv: 6,\n",
      "          };\n",
      "          a = o.getElementsByTagName('head')[0];\n",
      "          r = o.createElement('script');\n",
      "          r.async = 1;\n",
      "          r.src = t + h._hjSettings.hjid + j + h._hjSettings.hjsv;\n",
      "          a.appendChild(r);\n",
      "        })(window, document, '//static.hotjar.com/c/hotjar-', '.js?sv=');\n",
      "      \n",
      "\n",
      "      window.NHSUK_SETTINGS = {};\n",
      "      window.NHSUK_SETTINGS.BANNER_API_URL = \"//www.nhs.uk/externalservices/surveyfeedapi/api/bannerfeed\";\n",
      "      window.NHSUK_SETTINGS.BANNER_TEST_API_URL = \"//www.nhs.uk/externalservices/surveyfeedapi/api/testfeed\";\n",
      "      \n",
      "        window.NHSUK_SETTINGS.EMERGENCY_ALERT_DISABLED = true;\n",
      "      \n",
      "      window.NHSUK_SETTINGS.SUGGESTIONS_TEST_HOST = \"//api.nhs.uk/site-search/autocomplete\";\n",
      "      window.NHSUK_SETTINGS.SEARCH_TEST_HOST = \"//nhs.uk/search/results\";\n",
      "      window.NHSUK_SETTINGS.USER_FEEDBACK_STORE_ENDPOINT = \"https://nhsuk-user-feedback-func-prod-uks.azurewebsites.net/\";\n",
      "    \n",
      "\n",
      "\n",
      "Skip to main content\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Menu\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Search\n",
      "\n",
      "\n",
      "\n",
      "Search the NHS website\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Search\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Close search\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Menu\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Close menu\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "        Home\n",
      "        \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "    Health A-Z\n",
      "    \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "    Live Well\n",
      "    \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "    Care and support\n",
      "    \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "    Pregnancy\n",
      "    \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "    NHS services\n",
      "    \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Home\n",
      "\n",
      "\n",
      "Health A to Z\n",
      "\n",
      "\n",
      "Coronavirus (COVID-19)\n",
      "\n",
      "\n",
      "Coronavirus vaccination\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Back to \n",
      "            Coronavirus vaccination\n",
      "          \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Coronavirus (COVID-19) vaccine\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "The coronavirus (COVID-19) vaccine is safe and effective. It gives you the best protection against coronavirus.\n",
      "\n",
      "\n",
      "\n",
      "Who can get the COVID-19 vaccine\n",
      "The NHS is currently offering the COVID-19 vaccine to people most at risk from coronavirus.In England, the vaccine is being offered in some hospitals and pharmacies, at local vaccination centres run by GPs and at larger vaccination centres. More centres are opening all the time.It's being given to:people aged 60 and overpeople at high risk from coronavirus (clinically extremely vulnerable)people who live or work in care homeshealth and social care workerspeople with a condition that puts them at higher risk (clinically vulnerable)people who are a main carer for someone at high risk from coronavirus\n",
      "\n",
      "\n",
      "The order in which people will be offered the vaccine is based on advice from the Joint Committee on Vaccination and Immunisation (JCVI).Read the latest JCVI advice on priority groups for the COVID-19 vaccination on GOV.UK\n",
      "\n",
      "If you are not eligible yet\n",
      "Wait to be contacted. The NHS will let you know when it's your turn to have the vaccine. It's important not to contact the NHS for a vaccination before then.\n",
      "\n",
      "\n",
      "\n",
      "Advice if you're of childbearing age, pregnant or breastfeeding\n",
      "There's no evidence the COVID-19 vaccine is unsafe if you're pregnant. But more evidence is needed before you can routinely be offered it.The JCVI has updated its advice to recommend you may be able to have the vaccine if you're pregnant and:at high risk of getting coronavirus because of where you workhave a health condition that means you're at high risk of serious complications of coronavirusYou can have the COVID-19 vaccine if you're breastfeeding.Speak to a healthcare professional before you have the vaccination. They will discuss the benefits and risks with you.You do not need to avoid pregnancy after vaccination. The vaccine cannot give you or your baby COVID-19.Read the latest COVID-19 vaccine advice if you're pregnant, may get pregnant or are breastfeeding on GOV.UKRead the latest Royal College of Obstetricians and Gynaecologists and Royal College of Midwives statement on the COVID-19 vaccine and fertility\n",
      "\n",
      "\n",
      "\n",
      "How the COVID-19 vaccine is given\n",
      "The COVID-19 vaccine is given as an injection into your upper arm.It's given as 2 doses. You will have the 2nd dose 3 to 12 weeks after having the 1st dose.\n",
      "\n",
      "\n",
      "\n",
      "How to get the COVID-19 vaccine\n",
      "You can book your vaccination appointments online if any of the following apply:you are aged 60 or overyou are at high risk from coronavirus (clinically extremely vulnerable)you are an eligible frontline health or social care workeryou have a condition that puts you at higher risk (clinically vulnerable)you are a main carer for someone at high risk from coronavirusYou can book appointments at a larger vaccination centre or a pharmacy that provides COVID-19 vaccinations.You do not need to wait to be contacted by the NHS.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Book your COVID-19 vaccination appointments\n",
      "\n",
      "\n",
      "\n",
      "Information: \n",
      "If you are at moderate risk from coronavirus (clinically vulnerable) the NHS will contact you to arrange your vaccination appointments.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "How safe is the COVID-19 vaccine?\n",
      "The vaccines approved for use in the UK have met strict standards of safety, quality and effectiveness set out by the independent Medicines and Healthcare products Regulatory Agency (MHRA).Any coronavirus vaccine that is approved must go through all the clinical trials and safety checks all other licensed medicines go through. The MHRA follows international standards of safety.Other vaccines are being developed. They will only be available on the NHS once they have been thoroughly tested to make sure they are safe and effective.So far, millions of people have been given a COVID-19 vaccine and reports of serious side effects, such as allergic reactions, have been very rare. No long-term complications have been reported.\n",
      "\n",
      "\n",
      "To find out more about the vaccines approved in the UK, see:GOV.UK: Pfizer/BioNTech vaccine for COVID-19 approved by MHRAGOV.UK: Oxford/AstraZeneca vaccine for COVID-19 approved by MHRAGOV.UK: Moderna vaccine for COVID-19 approved by MHRA\n",
      "\n",
      "\n",
      "\n",
      "How effective is the COVID-19 vaccine?\n",
      "The 1st dose of the COVID-19 vaccine should give you good protection from coronavirus. But you need to have the 2 doses of the vaccine to give you longer lasting protection.There is a chance you might still get or spread coronavirus even if you have the vaccine.This means it is important to:continue to follow social distancing guidanceif you can, wear something that covers your nose and mouth in places where it's hard to stay away from other people\n",
      "\n",
      "\n",
      "\n",
      "Information: \n",
      "Read more about why vaccines are safe and important, including how they work and what they contain.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "COVID-19 vaccine side effects\n",
      "Most side effects of the COVID-19 vaccine are mild and should not last longer than a week, such as:a sore arm where the needle went infeeling tireda headachefeeling achyfeeling or being sickYou can take painkillers, such as paracetamol, if you need to.If you have a high temperature you may have coronavirus or another infection.If your symptoms get worse or you are worried, call 111.Allergic reactionsTell healthcare staff before you are vaccinated if you've ever had a serious allergic reaction.You should not have the COVID-19 vaccine if you have ever had a serious allergic reaction (including anaphylaxis) to:a previous dose of the same vaccineany of the ingredients in the vaccineSerious allergic reactions are rare. If you do have a reaction to the vaccine, it usually happens in minutes. Staff giving the vaccine are trained to deal with allergic reactions and treat them immediately.\n",
      "\n",
      "\n",
      "\n",
      "Information: \n",
      "You can report any suspected side effect using the Coronavirus Yellow Card safety scheme.Visit the Coronavirus Yellow Card to report a vaccine side effect\n",
      "\n",
      "\n",
      "\n",
      "COVID-19 vaccine ingredients\n",
      "The approved COVID-19 vaccines do not contain any animal products or egg.\n",
      "\n",
      "\n",
      "More information\n",
      "Sign up to be contacted for coronavirus vaccine researchGOV.UK: COVID-19 vaccination guide for older adultsGOV.UK: why you have to wait for your COVID-19 vaccineNHS Inform: coronavirus vaccination in ScotlandPublic Health Wales: coronavirus vaccination in WalesPublic Health Agency: coronavirus vaccination in Northern Ireland\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "          More in\n",
      "          \n",
      "            Coronavirus vaccination\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "                  Coronavirus (COVID-19) vaccine\n",
      "                \n",
      "\n",
      "\n",
      "                    Who can get the vaccine\n",
      "                  \n",
      "\n",
      "\n",
      "\n",
      "                    How you will be contacted\n",
      "                  \n",
      "\n",
      "\n",
      "\n",
      "                    What happens at your appointment\n",
      "                  \n",
      "\n",
      "\n",
      "\n",
      "                    Health conditions and coronavirus vaccination\n",
      "                  \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "      Page last reviewed: 26 February 2021\n",
      "      \n",
      "      Next review due: 12 March 2021\n",
      "    \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Support links\n",
      "\n",
      "NHS sites\n",
      "About us\n",
      "Contact us\n",
      "Profile editor login\n",
      "Site map\n",
      "Accessibility statement\n",
      "Our policies\n",
      "Cookies\n",
      "\n",
      "© Crown copyright\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "COVID-19 Vaccine Information\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "        // initialize plugins\r\n",
      "\t\t$ektron().ready(function(){\r\n",
      "\t\t\t$ektron('ul#mainNav').superfish();\r\n",
      "\t\t\t\t\t\t\r\n",
      "            $ektron(\".sort_color_off\").click(function(){        \r\n",
      "                $ektron(\"#srchloading\").show();\r\n",
      "            });            \r\n",
      "\t\t});\r\n",
      "    \n",
      "\n",
      "\r\n",
      "      /***********************************************\r\n",
      "      * Accordion Content script- (c) Dynamic Drive DHTML code library (www.dynamicdrive.com)\r\n",
      "      * Visit http://www.dynamicDrive.com for hundreds of DHTML scripts\r\n",
      "      * This notice must stay intact for legal use\r\n",
      "      ***********************************************/\r\n",
      "    \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){\r\n",
      "      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),\r\n",
      "      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)\r\n",
      "      })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');\r\n",
      "\r\n",
      "      ga('create', 'UA-76662241-1', 'auto');\r\n",
      "      ga('send', 'pageview');\r\n",
      "\r\n",
      "    \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "                Note: Javascript is disabled or is not supported by your browser. All \r\n",
      "            content is viewable but it will not display as intended.\r\n",
      "            \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Skip to global menu 5\n",
      "Skip to local menu 2\n",
      "Skip to content 3\n",
      "Skip to footer 6\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Advanced\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Topics:\n",
      "A\n",
      "B \n",
      "C \n",
      "D \n",
      "E \n",
      "F \n",
      "G \n",
      "H \n",
      "I \n",
      "J \n",
      "K \n",
      "L \n",
      "M \n",
      "N \n",
      "O \n",
      "P \n",
      "Q \n",
      "R \n",
      "S \n",
      "T \n",
      "U \n",
      "V \n",
      "W \n",
      "X \n",
      "Y \n",
      "Z \n",
      "All \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Mobile | \n",
      "Inicio en español\n",
      "\r\n",
      "                            Text Size:\r\n",
      "                        \r\n",
      "                    \r\n",
      "\n",
      "Font Larger\n",
      "Font Smaller\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "HomeCOVID-19About DSHSAdministrative ContactsAdvisory CommitteesContracts and BudgetsCustomer ServiceData and ReportsDoing Business with DSHSExecutive TeamHHS RulemakingHHSC Executive CouncilLegislative InformationOffice ClosuresOrganization ChartPublic Health CampaignsVisitor InformationVolunteer with DSHSNewsNews ReleasesHealth Alerts & AdvisoriesNews UpdatesI am a...CitizenContractorGrant WriterHealth ProfessionalIndividual or FamilyJournalistLicensee or BusinessParent/GuardianPublic ServantResearcherStudentTexas ResidentVolunteerMost PopularCoronavirus Disease 2019Birth CertificatesDeath CertificatesEMS Certification and LicensingFlu SurveillanceJobs at DSHSImmunizationsMarriage/Divorce VerificationOnline LicensesTxEVERAll Most Popular...ResourcesAdvisory CommitteesAudiovisual LibraryDisease ReportingDSHS Research ArticleseGrants SystemForms and PublicationsFunding Information CenterMedical and Research LibraryOpen MeetingsOpen Records RequestsPublic Health RegionsRelated WebsitesRules and RegulationsTexas Health LibraryOnline ServicesBirth CertificatesBusiness/Professional LicensesDeath CertificateseGrants SystemEMS Certification & LicensesFood Handler TrainingForms and PublicationsFunding OpportunitiesJob OpportunitiesMarriage/Divorce VerificationsTexas Immunization RegistryContact Us\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Skip to content 3\n",
      "\r\n",
      "        Ektron.PBSettings = { 'dontClose': false }\r\n",
      "    \n",
      "\n",
      "\n",
      "\r\n",
      "\r\n",
      "Ektron.ready(function(event, eventName){\r\n",
      "\r\n",
      "                $ektron(\".ux-app-siteApppageBuilder-setSizeTemplate .ui-dialog-buttonpane a\").button();\r\n",
      "                $ektron(\".ux-app-siteApppageBuilder-setSizeTemplate .framework\").accordion({\r\n",
      "                    heightStyle: \"content\",\r\n",
      "                    activate: function(event, ui){\r\n",
      "                        $ektron(ui).closest(\".ui-accordion\").accordion(\"refresh\");\r\n",
      "                    }\r\n",
      "                });\r\n",
      "                $ektron(\".ux-app-siteApppageBuilder-setSizeTemplate\").draggable({ handle: \"div.ui-dialog-titlebar \", containment: $ektron(\"body\") });\r\n",
      "            \r\n",
      "});\r\n",
      "\r\n",
      "\r\n",
      "\n",
      "\n",
      "\n",
      "COVID-19 Vaccine HomeFind VaccineHub ProvidersVaccine Availability MapAccessible List of Vaccine ProvidersCOVID-19 Vaccine FAQsInformation for Vaccination ProvidersInformation for ProvidersProvider EnrollmentVaccine ManagementProvider FAQsCOVID-19 Vaccine AllocationsExpert Vaccine Allocation PanelPublic Health Entity ForumsVaccine SafetyCOVID-19 Vaccine Communication Tools\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Home > COVID-19 > Immunizations > COVID-19 Vaccine > \n",
      "COVID-19 Vaccine Information\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "            COVID-19 Vaccine Information\r\n",
      "        \n",
      "\n",
      "\n",
      "\r\n",
      "span.red {\r\n",
      "    background: #AB2328;\r\n",
      "\tborder-radius: 0.8em;\r\n",
      "\t-moz-border-radius: 0.8em;\r\n",
      "\t-webkit-border-radius: 0.8em;\r\n",
      "\tcolor: #ffffff;\r\n",
      "\tdisplay: inline-block;\r\n",
      "\tfont-weight: bold;\r\n",
      "\tline-height: 1.6em;\r\n",
      "\tmargin-right: 15px;\r\n",
      "\ttext-align: center;\r\n",
      "\twidth: 1.6em;\r\n",
      "\tfloat: left;\r\n",
      "\tmargin-bottom: 60%;\r\n",
      "}\r\n",
      "div.fourThings, div.fourThings p {\r\n",
      "\toverflow: hidden;\r\n",
      "}\r\n",
      ".asideMenu a, .asideMenu a:visited {\r\n",
      "\tpadding: .5em .5em!important;\r\n",
      "}\r\n",
      "small {\r\n",
      "\tfont-size: 70%;\r\n",
      "}\r\n",
      "a.ctaButton {\r\n",
      "   margin: .25em 0; \r\n",
      "}\r\n",
      "div.contentTwoCols {\r\n",
      "    margin-top: .5em;\r\n",
      "}\r\n",
      "\n",
      "en españolFacebookInstagramTwitterYouTube\n",
      "\n",
      "\n",
      "More information\n",
      "\n",
      "Texas Vaccination Plan (PDF)\n",
      "Expert Vaccine Allocation Panel\n",
      "Vaccine Allocation Guiding Principles (PDF)\n",
      "Phase 1A: Who Is Eligible for Vaccine Now (PDF)\n",
      "Phase 1B: Who Is Eligible for Vaccine Now (PDF)\n",
      "COVID-19 Vaccine Allocations\n",
      "Vaccine FAQs\n",
      "V-safe Information Sheet (PDF)\n",
      "CDC Vaccine Information\n",
      "FDA Vaccine Information\n",
      "Texas Vaccine Data Dashboard\n",
      "Accessible Vaccine Data (XLS)\n",
      "\n",
      "\n",
      "\n",
      "Who's Eligible Now? Where to Get Vaccinated\n",
      "\n",
      "\n",
      "Important to Know TX Vaccine Timeline\n",
      "\n",
      "Who's Eligible to Get the Vaccine Now?\n",
      "\n",
      "School and Child Care Personnel Now Eligible To Be Vaccinated\n",
      "With the federal directive, the following education and child care personnel are now eligible to be vaccinated in Texas:\n",
      "\n",
      "Those who work in pre-primary, primary, and secondary schools;\n",
      "Head Start and Early Head Start programs (including teachers, staff, and bus drivers); and\n",
      "Those who work as or for licensed child care providers, including center-based and family care providers.\n",
      "\n",
      "\n",
      "Phase 1A: Front-line healthcare workers and residents at long-term care facilities\n",
      "Phase 1B: People 65+ or people 16+ with a health condition that increases risk of severe COVID‑19 illness, including but not limited to:\n",
      "\n",
      "Cancer\n",
      "Chronic kidney disease\n",
      "COPD (chronic obstructive pulmonary disease)\n",
      "Down Syndrome\n",
      "Heart conditions, such as heart failure, coronary artery disease, or cardiomyopathies\n",
      "Organ transplantation\n",
      "Obesity\n",
      "Pregnancy\n",
      "Sickle cell disease\n",
      "Type 2 diabetes\n",
      "\n",
      "If you have a medical condition not listed above, you may still qualify for the vaccine. Talk to your provider to confirm.\n",
      "Spring 2021 is the best estimate of when vaccines will be available for the general public. Availability will depend on vaccine supply. Check back here for updates.\n",
      "\n",
      "Where to Get Vaccinated\n",
      "If you’re eligible to get vaccinated now, you can check with a large vaccination hub and/or a local vaccine provider, like a nearby pharmacy or your doctor. \n",
      "Find Vaccine: \n",
      "Large Vaccination Hubs   Vaccine Availability Map   List of All Providers  \n",
      "When searching for a vaccination site, remember:\n",
      "\n",
      "Vaccine supply is limited. Not all local providers have vaccine each week and hubs may have long waiting lists.\n",
      "Do not show up at a hub or provider looking for a vaccine.\n",
      "Instead, check the provider’s website. Call only if the website doesn’t answer your questions.\n",
      "\n",
      "\n",
      "Do you know someone who is eligible for a vaccine but doesn’t have internet access? Please let them know they can call 2‑1‑1 for referral to a local vaccine provider.\n",
      "\n",
      "Vaccine supply is still limited in Texas, but more arrives each week.\n",
      "\n",
      "Important to Know\n",
      "\n",
      "Two Doses\n",
      "Moderna and Pfizer COVID-19 vaccines both require two doses. It’s best if you get your second dose from the same brand as your first dose. For example, if you got a Moderna first dose, it’s best to get Moderna for your second dose.\n",
      "The timing between your first and second dose depends on which vaccine you received:\n",
      "\n",
      "Moderna: 4 to 6 weeks after your first dose\n",
      "Pfizer: 3 to 6 weeks after your first dose\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Side Effects & Allergic Reactions\n",
      "Mild side effects are normal signs your body is building protection, and they usually go away after a few days. The chance of a severe reaction is less than 0.5%. To be safe, your provider will have you wait on-site for 15-30 minutes after your shot.\n",
      "V-safe: Register with CDC's V-safe After Vaccination Health Checker on your smartphone to report any side effects after getting the COVID-19 vaccine. You’ll also get reminders for your second vaccine dose.\n",
      "\n",
      "Texas Vaccine Rollout Timeline\n",
      "\n",
      "Texas continues to receive doses of the Pfizer and Moderna COVID-19 vaccines, and is distributing statewide to hospitals, pharmacies, local health departments, freestanding ERs, and other clinics.\n",
      "Spring 2021 is the best estimate of when vaccine will be available for the general public, but that may change. It depends on vaccine production and how quickly other vaccines become available. Please check this page regularly for updates.\n",
      " ▲ Top \n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "    $ektron('table.zebra tr:nth-child(even)')\r\n",
      "        .add('table.zebraBorder tr:nth-child(even)')\r\n",
      "        .addClass('zebraEven');\r\n",
      " \n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\r\n",
      "\t$ektron().ready(function(){\t\t\t\t\r\n",
      "\t\t $ektron('#navigation').accordion({\r\n",
      "\t\t\t    active: false,\r\n",
      "\t\t\t    header: '.head',\r\n",
      "\t\t\t    navigation: true,\r\n",
      "\t\t\t    event: 'mouseover',\r\n",
      "\t\t\t    fillSpace: true,\r\n",
      "\t\t\t    animated: 'slide'\r\n",
      "\t\t    });\r\n",
      "\t\t    $ektron('.navigation1').accordion({\r\n",
      "\t\t\t    active: false,\r\n",
      "\t\t\t    header: '.head',\r\n",
      "\t\t\t    navigation: true,\r\n",
      "\t\t\t    event: 'mouseover',\r\n",
      "\t\t\t    fillSpace: true,\r\n",
      "\t\t\t    animated: 'slide'\r\n",
      "\t\t    });\r\n",
      "\t});\t\r\n",
      "\t\n",
      "\r\n",
      "\t#navigation ul\r\n",
      "        {\r\n",
      "\t      height: auto !important;\t      \r\n",
      "        }\r\n",
      "\t\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Last updated  March 3, 2021\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Contact Us | Visitor Information | Compact with Texans | File Viewing Information | Site Policies | Texas HHS | Jobs at DSHSTexas Homeland Security | Statewide Search | Texas.gov | Texas Veterans Portal | Privacy Practices | Report Fraud, Waste, and Abuse\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(webContents)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "2wYLVmLuTM83"
   },
   "source": [
    "Then I will shortlist the web contents to sentences. I will use nltk module of python."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "bUdJ685PTf_V",
    "outputId": "d8fda525-7429-4e4f-dfb9-9849f3da8f1c",
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1;30;43m流式输出内容被截断，只能显示最后 5000 行内容。\u001b[0m\n",
      " 'chart\\n'\n",
      " 'Czech Republic\\n'\n",
      " 'chart\\n'\n",
      " 'Denmark\\n'\n",
      " 'chart\\n'\n",
      " 'Estonia\\n'\n",
      " 'chart\\n'\n",
      " 'Faroe Islands\\n'\n",
      " 'chart\\n'\n",
      " 'Finland\\n'\n",
      " 'chart\\n'\n",
      " 'France\\n'\n",
      " 'chart\\n'\n",
      " 'Germany\\n'\n",
      " 'chart\\n'\n",
      " 'Greece\\n'\n",
      " 'chart\\n'\n",
      " 'Hungary\\n'\n",
      " 'chart\\n'\n",
      " 'Iceland\\n'\n",
      " 'chart\\n'\n",
      " 'Ireland\\n'\n",
      " 'chart\\n'\n",
      " 'Italy\\n'\n",
      " 'chart\\n'\n",
      " 'Kosovo\\n'\n",
      " 'chart\\n'\n",
      " 'Latvia\\n'\n",
      " 'chart\\n'\n",
      " 'Lithuania\\n'\n",
      " 'chart\\n'\n",
      " 'Luxembourg\\n'\n",
      " 'chart\\n'\n",
      " 'Malta\\n'\n",
      " 'chart\\n'\n",
      " 'Moldova\\n'\n",
      " 'chart\\n'\n",
      " 'Monaco\\n'\n",
      " 'chart\\n'\n",
      " 'Montenegro\\n'\n",
      " 'chart\\n'\n",
      " 'Netherlands\\n'\n",
      " 'chart\\n'\n",
      " 'North Macedonia\\n'\n",
      " 'chart\\n'\n",
      " 'Norway\\n'\n",
      " 'chart\\n'\n",
      " 'Poland\\n'\n",
      " 'chart\\n'\n",
      " 'Portugal\\n'\n",
      " 'chart\\n'\n",
      " 'Romania\\n'\n",
      " 'chart\\n'\n",
      " 'Russia\\n'\n",
      " 'by federal subject\\n'\n",
      " 'chart\\n'\n",
      " 'San Marino\\n'\n",
      " 'chart\\n'\n",
      " 'Serbia\\n'\n",
      " 'chart\\n'\n",
      " 'Slovakia\\n'\n",
      " 'by region\\n'\n",
      " 'chart\\n'\n",
      " 'Slovenia\\n'\n",
      " 'chart\\n'\n",
      " 'Spain\\n'\n",
      " 'chart\\n'\n",
      " 'Asturias\\n'\n",
      " 'Community of Madrid\\n'\n",
      " 'Sweden\\n'\n",
      " 'chart\\n'\n",
      " 'Switzerland\\n'\n",
      " 'chart\\n'\n",
      " 'Turkey\\n'\n",
      " 'by province\\n'\n",
      " 'chart\\n'\n",
      " 'Ukraine\\n'\n",
      " 'chart\\n'\n",
      " \"Donetsk People's Republic\\n\"\n",
      " \"Luhansk People's Republic\\n\"\n",
      " 'United Kingdom\\n'\n",
      " 'Scotland\\n'\n",
      " 'chart\\n'\n",
      " 'Vatican City\\n'\n",
      " 'chart\\n'\n",
      " 'Oceania\\n'\n",
      " 'Australia\\n'\n",
      " 'chart\\n'\n",
      " 'by state/territory\\n'\n",
      " 'Fiji\\n'\n",
      " 'chart\\n'\n",
      " 'French Polynesia\\n'\n",
      " 'chart\\n'\n",
      " 'New Caledonia\\n'\n",
      " 'chart\\n'\n",
      " 'New Zealand\\n'\n",
      " 'chart\\n'\n",
      " 'Papua New Guinea\\n'\n",
      " 'chart\\n'\n",
      " 'Solomon Islands\\n'\n",
      " 'Solomon Islands\\n'\n",
      " 'Others\\n'\n",
      " 'Cruise ships\\n'\n",
      " 'Diamond Princess\\n'\n",
      " '\\n'\n",
      " ' Category\\n'\n",
      " ' Portal\\n'\n",
      " '\\n'\n",
      " 'vteArtificial induction of immunity / Immunization: Vaccines, Vaccination, '\n",
      " 'Infection, Inoculation (J07)Development\\n'\n",
      " 'Adjuvants\\n'\n",
      " 'List of vaccine ingredients\\n'\n",
      " 'Mathematical modelling\\n'\n",
      " 'Timeline\\n'\n",
      " 'Trials\\n'\n",
      " 'Classes\\n'\n",
      " 'Conjugate vaccine\\n'\n",
      " 'Inactivated vaccine\\n'\n",
      " 'Live vaccine\\n'\n",
      " 'Attenuated vaccine\\n'\n",
      " 'Heterologous vaccine\\n'\n",
      " 'Subunit/component / Peptide / Virus-like particle / Synthetic\\n'\n",
      " 'DNA / RNA\\n'\n",
      " 'Toxoid\\n'\n",
      " 'Administration\\n'\n",
      " 'Global:\\n'\n",
      " 'GAVI Alliance\\n'\n",
      " 'NITAG\\n'\n",
      " 'Policy\\n'\n",
      " 'Schedule\\n'\n",
      " 'Vaccine injury\\n'\n",
      " 'US:\\n'\n",
      " 'ACIP\\n'\n",
      " 'Vaccine court\\n'\n",
      " 'Vaccines for Children Program\\n'\n",
      " 'VAERS\\n'\n",
      " 'VSD\\n'\n",
      " 'VaccinesBacterial\\n'\n",
      " 'Anthrax\\n'\n",
      " 'Brucellosis\\n'\n",
      " 'Cholera#\\n'\n",
      " 'Diphtheria#\\n'\n",
      " 'Hib#\\n'\n",
      " 'Leptospirosis\\n'\n",
      " 'Lyme disease‡\\n'\n",
      " 'Meningococcus#\\n'\n",
      " 'MeNZB\\n'\n",
      " 'NmVac4-A/C/Y/W-135\\n'\n",
      " 'Pertussis#\\n'\n",
      " 'Plague\\n'\n",
      " 'Pneumococcal#\\n'\n",
      " 'PCV\\n'\n",
      " 'PPSV\\n'\n",
      " 'Q fever\\n'\n",
      " 'Tetanus#\\n'\n",
      " 'Tuberculosis\\n'\n",
      " 'BCG#\\n'\n",
      " 'Typhoid#\\n'\n",
      " 'Ty21a\\n'\n",
      " 'ViCPS\\n'\n",
      " 'Typhus\\n'\n",
      " 'combination:\\n'\n",
      " 'DPT/DTwP/DTaP\\n'\n",
      " 'Td/Tdap\\n'\n",
      " 'research:\\n'\n",
      " 'Clostridioides difficile\\n'\n",
      " 'Group B streptococcal disease\\n'\n",
      " 'Shigellosis\\n'\n",
      " 'Viral\\n'\n",
      " 'Adenovirus\\n'\n",
      " 'Ebola\\n'\n",
      " 'Flu#\\n'\n",
      " 'H1N1 (Pandemrix)\\n'\n",
      " 'H5N1\\n'\n",
      " 'LAIV\\n'\n",
      " 'Hantavirus\\n'\n",
      " 'Hepatitis A#\\n'\n",
      " 'Hepatitis B#\\n'\n",
      " 'Hepatitis E\\n'\n",
      " 'HPV\\n'\n",
      " 'Cervarix\\n'\n",
      " 'Gardasil\\n'\n",
      " 'Japanese encephalitis#\\n'\n",
      " 'Measles#\\n'\n",
      " 'Mumps#\\n'\n",
      " 'Mumpsvax\\n'\n",
      " 'Polio#\\n'\n",
      " 'Sabin\\n'\n",
      " 'Salk\\n'\n",
      " 'Rabies#\\n'\n",
      " 'Rotavirus#\\n'\n",
      " 'Rubella#\\n'\n",
      " 'SARS-CoV-2\\n'\n",
      " 'BBIBP-CorV†\\n'\n",
      " 'Convidicea†\\n'\n",
      " 'CoronaVac†\\n'\n",
      " 'Covaxin†\\n'\n",
      " 'EpiVacCorona†\\n'\n",
      " 'Johnson & Johnson†\\n'\n",
      " 'Moderna†\\n'\n",
      " 'Oxford–AstraZeneca†\\n'\n",
      " 'Pfizer–BioNTech†\\n'\n",
      " 'Sputnik V†\\n'\n",
      " 'Smallpox\\n'\n",
      " 'Dryvax\\n'\n",
      " 'Tick-borne encephalitis\\n'\n",
      " 'Varicella zoster\\n'\n",
      " 'Chicken pox#\\n'\n",
      " 'Shingles\\n'\n",
      " 'Yellow fever#\\n'\n",
      " 'combination:\\n'\n",
      " 'Hepatitis A and B\\n'\n",
      " 'MMR\\n'\n",
      " 'MMRV\\n'\n",
      " 'research:\\n'\n",
      " 'Chikungunya\\n'\n",
      " 'Cytomegalovirus\\n'\n",
      " 'Dengue\\n'\n",
      " 'Ebola\\n'\n",
      " 'Epstein–Barr virus\\n'\n",
      " 'Hepatitis C\\n'\n",
      " 'Herpes simplex\\n'\n",
      " 'HIV\\n'\n",
      " 'Respiratory syncytial virus\\n'\n",
      " 'Zika\\n'\n",
      " 'Protozoan\\n'\n",
      " 'Malaria\\n'\n",
      " 'RTS,S\\n'\n",
      " 'research:\\n'\n",
      " 'Trypanosomiasis\\n'\n",
      " 'Helminthiasis\\n'\n",
      " 'research:\\n'\n",
      " 'Hookworm\\n'\n",
      " 'Schistosomiasis\\n'\n",
      " 'Other\\n'\n",
      " 'Androvax (androstenedione albumin)\\n'\n",
      " 'Cancer vaccines\\n'\n",
      " 'ALVAC-CEA\\n'\n",
      " 'BCG#\\n'\n",
      " 'Hepatitis B#\\n'\n",
      " 'HPV\\n'\n",
      " 'Cervarix\\n'\n",
      " 'Gardasil\\n'\n",
      " 'Prostvac\\n'\n",
      " 'NicVAX\\n'\n",
      " 'Ovandrotone albumin (Fecundin)\\n'\n",
      " 'TA-CD\\n'\n",
      " 'TA-NIC\\n'\n",
      " 'combination:\\n'\n",
      " 'DTaP-IPV/Hib\\n'\n",
      " 'DTaP-IPV-HepB\\n'\n",
      " 'Hexavalent vaccine\\n'\n",
      " 'Pentavalent vaccine\\n'\n",
      " 'Inventors/researchers\\n'\n",
      " 'Edward Jenner\\n'\n",
      " 'Louis Pasteur\\n'\n",
      " 'Hilary Koprowski\\n'\n",
      " 'Jonas Salk\\n'\n",
      " 'John Franklin Enders\\n'\n",
      " 'Maurice Hilleman\\n'\n",
      " 'Stanley Plotkin\\n'\n",
      " 'H. Fred Clark\\n'\n",
      " 'Paul Offit\\n'\n",
      " 'Anthony Fauci\\n'\n",
      " 'Controversy\\n'\n",
      " 'General\\n'\n",
      " 'MMR (Lancet MMR autism fraud)\\n'\n",
      " 'NCVIA\\n'\n",
      " 'Infection party\\n'\n",
      " 'Pox\\n'\n",
      " 'Flu\\n'\n",
      " 'CoV\\n'\n",
      " 'Thiomersal\\n'\n",
      " 'Vaccines and SIDS\\n'\n",
      " 'Cedillo v. Secretary of Health and Human Services\\n'\n",
      " 'Alternative vaccination schedule\\n'\n",
      " 'Related\\n'\n",
      " 'Epidemiology\\n'\n",
      " 'Eradication of infectious diseases\\n'\n",
      " 'Every Child by Two\\n'\n",
      " 'List of vaccine topics\\n'\n",
      " '\\n'\n",
      " '#WHO-EM\\n'\n",
      " '‡Withdrawn from market\\n'\n",
      " 'Clinical trials:\\n'\n",
      " '†Phase III\\n'\n",
      " '§Never to phase III\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Retrieved from '\n",
      " '\"https://en.wikipedia.org/w/index.php?title=COVID-19_vaccine&oldid=1010386361\"\\n'\n",
      " 'Categories: COVID-19 vaccinesMedical researchMedical responses to the '\n",
      " 'COVID-19 pandemicHidden categories: Pages with non-numeric formatnum '\n",
      " 'argumentsCS1 maint: uses authors parameterCS1 Spanish-language sources '\n",
      " '(es)CS1 German-language sources (de)CS1 Portuguese-language sources (pt)CS1 '\n",
      " 'Danish-language sources (da)CS1 Icelandic-language sources (is)CS1 Norwegian '\n",
      " 'Bokmål-language sources (nb)CS1 Serbian-language sources (sr)CS1 '\n",
      " 'Russian-language sources (ru)Articles with short descriptionShort '\n",
      " 'description is different from WikidataWikipedia indefinitely semi-protected '\n",
      " 'pagesUse dmy dates from December 2020Articles containing potentially dated '\n",
      " 'statements from February 2021All articles containing potentially dated '\n",
      " 'statementsArticles containing potentially dated statements from March '\n",
      " '2021Articles with excerptsArticles containing potentially dated statements '\n",
      " 'from January 2021All articles with unsourced statementsArticles with '\n",
      " 'unsourced statements from March 2021All articles lacking reliable '\n",
      " 'referencesArticles lacking reliable references from March 2021Articles '\n",
      " 'containing potentially dated statements from September 2020Articles with '\n",
      " 'limited geographic scope from December 2020\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Navigation menu\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Personal tools\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Not logged inTalkContributionsCreate accountLog in\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Namespaces\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'ArticleTalk\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Variants\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Views\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'ReadView sourceView history\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'More\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Search\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Navigation\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Main pageContentsCurrent eventsRandom articleAbout WikipediaContact '\n",
      " 'usDonate\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Contribute\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'HelpLearn to editCommunity portalRecent changesUpload file\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Tools\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'What links hereRelated changesUpload fileSpecial pagesPermanent linkPage '\n",
      " 'informationCite this pageWikidata item\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Print/export\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Download as PDFPrintable version\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'In other projects\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Wikimedia Commons\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Languages\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'العربيةAzərbaycancaবাংলাBosanskiCatalàČeštinaDanskDeutschEestiΕλληνικάEspañolEuskaraفارسیFrançaisGalego한국어हिन्दीHrvatskiBahasa '\n",
      " 'IndonesiaItalianoעבריתಕನ್ನಡLietuviųLumbaartMagyarമലയാളംمصرىဘာသာ မန်Bahasa '\n",
      " 'MelayuNederlands日本語Norsk '\n",
      " 'bokmålپنجابیPolskiPortuguêsRomânăРусскийShqipසිංහලSimple '\n",
      " 'EnglishسنڌيSlovenčinaکوردیСрпски / '\n",
      " 'srpskiSuomiSvenskaதமிழ்TaqbaylitไทยTürkçeУкраїнськаاردوئۇيغۇرچە / '\n",
      " 'UyghurcheTiếng ViệtXitsonga粵語中文\\n'\n",
      " 'Edit links\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " ' This page was last edited on 5 March 2021, at 05:39\\xa0(UTC).',\n",
      " 'Text is available under the Creative Commons Attribution-ShareAlike '\n",
      " 'License;\\n'\n",
      " 'additional terms may apply.',\n",
      " 'By using this site, you agree to the Terms of Use and Privacy Policy.',\n",
      " 'Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a '\n",
      " 'non-profit organization.',\n",
      " 'Privacy policy\\n'\n",
      " 'About Wikipedia\\n'\n",
      " 'Disclaimers\\n'\n",
      " 'Contact Wikipedia\\n'\n",
      " 'Mobile view\\n'\n",
      " 'Developers\\n'\n",
      " 'Statistics\\n'\n",
      " 'Cookie statement\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '(RLQ=window.RLQ||[]).push(function(){mw.config.set({\"wgPageParseReport\":{\"limitreport\":{\"cputime\":\"8.093\",\"walltime\":\"9.538\",\"ppvisitednodes\":{\"value\":61285,\"limit\":1000000},\"postexpandincludesize\":{\"value\":1748352,\"limit\":2097152},\"templateargumentsize\":{\"value\":68475,\"limit\":2097152},\"expansiondepth\":{\"value\":20,\"limit\":40},\"expensivefunctioncount\":{\"value\":147,\"limit\":500},\"unstrip-depth\":{\"value\":1,\"limit\":20},\"unstrip-size\":{\"value\":1825110,\"limit\":5000000},\"entityaccesscount\":{\"value\":0,\"limit\":400},\"timingprofile\":[\"100.00% '\n",
      " '7990.676      1 -total\",\" 48.52% 3877.138      3 Template:Reflist\",\" 25.92% '\n",
      " '2070.947      1 Template:COVID-19_vaccination_data\",\" 23.25% 1857.643    123 '\n",
      " 'Template:Flag+link\",\" 19.53% 1560.344    290 Template:Cite_web\",\" 10.01%  '\n",
      " '799.730    150 Template:Cite_news\",\"  9.42%  752.955     71 '\n",
      " 'Template:Cite_journal\",\"  4.94%  394.688     10 Template:Iso2country\",\"  '\n",
      " '4.37%  349.141     10 Template:Iso2country/article\",\"  4.26%  340.609     10 '\n",
      " 'Template:ISO_3166_code\"]},\"scribunto\":{\"limitreport-timeusage\":{\"value\":\"4.480\",\"limit\":\"10.000\"},\"limitreport-memusage\":{\"value\":12325950,\"limit\":52428800},\"limitreport-logs\":\"table#1 '\n",
      " '{\\\\n  [\\\\\"size\\\\\"] = \\\\\"tiny\\\\\",\\\\n  [\\\\\"text\\\\\"] = \\\\\"COVID-19 '\n",
      " 'Portal\\\\\",\\\\n}\\\\n\",\"limitreport-profile\":[[\"Scribunto_LuaSandboxCallback::getAllExpandedArguments\",\"540\",\"10.8\"],[\"Scribunto_LuaSandboxCallback::gsub\",\"520\",\"10.4\"],[\"dataWrapper '\n",
      " '\\\\u003Cmw.lua:661\\\\u003E\",\"500\",\"10.0\"],[\"Scribunto_LuaSandboxCallback::expandTemplate\",\"480\",\"9.6\"],[\"Scribunto_LuaSandboxCallback::match\",\"320\",\"6.4\"],[\"?',\n",
      " '\",\"280\",\"5.6\"],[\"Scribunto_LuaSandboxCallback::callParserFunction\",\"260\",\"5.2\"],[\"Scribunto_LuaSandboxCallback::find\",\"220\",\"4.4\"],[\"Scribunto_LuaSandboxCallback::plain\",\"180\",\"3.6\"],[\"recursiveClone '\n",
      " '\\\\u003CmwInit.lua:41\\\\u003E\",\"180\",\"3.6\"],[\"[others]\",\"1540\",\"30.7\"]]},\"cachereport\":{\"origin\":\"mw1371\",\"timestamp\":\"20210305123346\",\"ttl\":2592000,\"transientcontent\":false}}});});\\n'\n",
      " '{\"@context\":\"https:\\\\/\\\\/schema.org\",\"@type\":\"Article\",\"name\":\"COVID-19 '\n",
      " 'vaccine\",\"url\":\"https:\\\\/\\\\/en.wikipedia.org\\\\/wiki\\\\/COVID-19_vaccine\",\"sameAs\":\"http:\\\\/\\\\/www.wikidata.org\\\\/entity\\\\/Q87719492\",\"mainEntity\":\"http:\\\\/\\\\/www.wikidata.org\\\\/entity\\\\/Q87719492\",\"author\":{\"@type\":\"Organization\",\"name\":\"Contributors '\n",
      " 'to Wikimedia '\n",
      " 'projects\"},\"publisher\":{\"@type\":\"Organization\",\"name\":\"Wikimedia Foundation, '\n",
      " 'Inc.\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\\/\\\\/www.wikimedia.org\\\\/static\\\\/images\\\\/wmf-hor-googpub.png\"}},\"datePublished\":\"2020-03-08T17:51:40Z\",\"dateModified\":\"2021-03-05T05:39:40Z\",\"image\":\"https:\\\\/\\\\/upload.wikimedia.org\\\\/wikipedia\\\\/commons\\\\/7\\\\/72\\\\/World_map_of_COVID-19_vaccination_doses_administered_per_100_people_by_country_or_territory.png\",\"headline\":\"vaccine '\n",
      " 'against SARS-CoV-2 coronavirus\"}\\n'\n",
      " '(RLQ=window.RLQ||[]).push(function(){mw.config.set({\"wgBackendResponseTime\":225,\"wgHostname\":\"mw1352\"});});\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '/* <!',\n",
      " '[CDATA[ */\\n'\n",
      " '.panels-flexible-region{padding:0}.panels-flexible-region-inside{padding-right:.5em;padding-left:.5em}.panels-flexible-region-inside-first{padding-left:0}.panels-flexible-region-inside-last{padding-right:0}.panels-flexible-column{padding:0}.panels-flexible-column-inside{padding-right:.5em;padding-left:.5em}.panels-flexible-column-inside-first{padding-left:0}.panels-flexible-column-inside-last{padding-right:0}.panels-flexible-row{padding:0 '\n",
      " '0 .5em '\n",
      " '0;margin:0}.panels-flexible-row-last{padding-bottom:0}.panels-flexible-column-new-main{float:left;width:99.0000%}.panels-flexible-new-inside{padding-right:0}.panels-flexible-new{width:auto}.panels-flexible-region-new-center{float:left;width:99.0000%}.panels-flexible-row-new-main-row-inside{padding-right:0}\\n'\n",
      " '/* ]]> */\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '/* <!',\n",
      " '[CDATA[ */\\n'\n",
      " '.panels-flexible-region{padding:0}.panels-flexible-region-inside{padding-right:.5em;padding-left:.5em}.panels-flexible-region-inside-first{padding-left:0}.panels-flexible-region-inside-last{padding-right:0}.panels-flexible-column{padding:0}.panels-flexible-column-inside{padding-right:.5em;padding-left:.5em}.panels-flexible-column-inside-first{padding-left:0}.panels-flexible-column-inside-last{padding-right:0}.panels-flexible-row{padding:0 '\n",
      " '0 .5em '\n",
      " '0;margin:0}.panels-flexible-row-last{padding-bottom:0}.panels-flexible-column-new-main{float:left;width:99.0000%}.panels-flexible-new-inside{padding-right:0}.panels-flexible-new{width:auto}.panels-flexible-region-new-center{float:left;width:99.0000%}.panels-flexible-row-new-main-row-inside{padding-right:0}\\n'\n",
      " '/* ]]> */\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Model-informed COVID-19 vaccine prioritization strategies by age and '\n",
      " 'serostatus | Science\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '<!--//--><!',\n",
      " '[CDATA[//><!--\\n'\n",
      " 'AAASdataLayer = {\"page\":{\"pageInfo\":{\"pageTitle\":\"Model-informed COVID-19 '\n",
      " 'vaccine prioritization strategies by age and '\n",
      " 'serostatus\",\"pageURL\":\"science.sciencemag.org/content/371/6532/916\",\"pagePath\":\"916\",\"pageType\":\"journal '\n",
      " 'page\",\"issueDate\":\"2021-02-26\",\"pubDate\":\"2021-02-25 '\n",
      " '10:41:01\",\"nlmArticleType\":\"research-article\",\"DOI\":\"10.1126/science.abe6959\",\"author\":\"Kate '\n",
      " 'M. Bubar|Kyle Reinholt|Stephen M. Kissler|Marc Lipsitch|Sarah Cobey|Yonatan '\n",
      " 'H. Grad|Daniel B. '\n",
      " 'Larremore\",\"firstRelease\":\"no\",\"issnOnline\":\"1095-9203\",\"issnPrint\":\"0036-8075\",\"volume\":\"371\",\"issue\":\"6532\",\"articleType\":\"Research '\n",
      " 'Article\",\"tabView\":\"main_tab\",\"viewType\":\"full\"},\"attributes\":{\"accessType\":\"Free\",\"openAccess\":\"yes\",\"freeAccess\":\"yes\",\"subject\":\"\",\"fieldCode\":\"EPIDEMIOLOGY\",\"OAS_subject\":\"subject=EPIDEMIOLOGY;\"}},\"user\":{\"memberID\":\"\",\"institutionID\":\"\",\"institution\":\"\",\"accessMethod\":\"guest\",\"registeredUser\":\"no\",\"authenticated\":\"no\",\"access\":\"yes\",\"entitled\":\"no\"}}\\n'\n",
      " '//--><!',\n",
      " ']]>\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '      /*!',\n",
      " 'loadCSS.',\n",
      " '[c]2017 Filament Group, Inc. MIT License */\\n'\n",
      " '      !function(a){\"use strict\";var b=function(b,c,d){function e(a){return '\n",
      " 'h.body?a():void setTimeout(function(){e(a)})}function '\n",
      " 'f(){i.addEventListener&&i.removeEventListener(\"load\",f),i.media=d||\"all\"}var '\n",
      " 'g,h=a.document,i=h.createElement(\"link\");if(c)g=c;else{var '\n",
      " 'j=(h.body||h.getElementsByTagName(\"head\")[0]).childNodes;g=j[j.length-1]}var '\n",
      " 'k=h.styleSheets;i.rel=\"stylesheet\",i.href=b,i.media=\"only '\n",
      " 'x\",e(function(){g.parentNode.insertBefore(i,c?g:g.nextSibling)});var '\n",
      " 'l=function(a){for(var b=i.href,c=k.length;c--;)if(k[c].href===b)return '\n",
      " 'a();setTimeout(function(){l(a)})};return '\n",
      " 'i.addEventListener&&i.addEventListener(\"load\",f),i.onloadcssdefined=l,l(f),i};\"undefined\"!=typeof '\n",
      " 'exports?exports.loadCSS=b:a.loadCSS=b}(\"undefined\"!=typeof '\n",
      " 'global?global:this);\\n'\n",
      " '/*!',\n",
      " 'loadCSS rel=preload polyfill.',\n",
      " '[c]2017 Filament Group, Inc. MIT License */\\n'\n",
      " '!function(a){if(a.loadCSS){var '\n",
      " 'b=loadCSS.relpreload={};if(b.support=function(){try{return '\n",
      " 'a.document.createElement(\"link\").relList.supports(\"preload\")}catch(b){return!1}},b.poly=function(){for(var '\n",
      " 'b=a.document.getElementsByTagName(\"link\"),c=0;c<b.length;c++){var '\n",
      " 'd=b[c];\"preload\"===d.rel&&\"style\"===d.getAttribute(\"as\")&&(a.loadCSS(d.href,d,d.getAttribute(\"media\")),d.rel=null)}},!b.support()){b.poly();var '\n",
      " 'c=a.setInterval(b.poly,300);a.addEventListener&&a.addEventListener(\"load\",function(){b.poly(),a.clearInterval(c)}),a.attachEvent&&a.attachEvent(\"onload\",function(){a.clearInterval(c)})}}}(this);\\n'\n",
      " '    \\n'\n",
      " '\\n'\n",
      " '      /*!',\n",
      " 'CSS rel=preload polyfill.',\n",
      " 'Depends on loadCSS function.',\n",
      " '[c]2016 @scottjehl, Filament Group, Inc.',\n",
      " 'Licensed MIT  */\\n'\n",
      " '(function( w ){\\n'\n",
      " '  // rel=preload support test\\n'\n",
      " '  if( !w.loadCSS ){\\n'\n",
      " '    return;\\n'\n",
      " '  }\\n'\n",
      " '  var rp = loadCSS.relpreload = {};\\n'\n",
      " '  rp.support = function(){\\n'\n",
      " '    try {\\n'\n",
      " '      return w.document.createElement( \"link\" ).relList.supports( \"preload\" '\n",
      " ');\\n'\n",
      " '    } catch (e) {\\n'\n",
      " '      return false;\\n'\n",
      " '    }\\n'\n",
      " '  };\\n'\n",
      " '\\n'\n",
      " '  // loop preload links and fetch using loadCSS\\n'\n",
      " '  rp.poly = function(){\\n'\n",
      " '    var links = w.document.getElementsByTagName( \"link\" );\\n'\n",
      " '    for( var i = 0; i < links.length; i++ ){\\n'\n",
      " '      var link = links[ i ];\\n'\n",
      " '      if( link.rel === \"preload\" && link.getAttribute( \"as\" ) === \"style\" '\n",
      " '){\\n'\n",
      " '        w.loadCSS( link.href, link );\\n'\n",
      " '        link.rel = null;\\n'\n",
      " '      }\\n'\n",
      " '    }\\n'\n",
      " '  };\\n'\n",
      " '\\n'\n",
      " '  // if link[rel=preload] is not supported, we must fetch the CSS manually '\n",
      " 'using loadCSS\\n'\n",
      " '  if( !rp.support() ){\\n'\n",
      " '    rp.poly();\\n'\n",
      " '    var run = w.setInterval( rp.poly, 300 );\\n'\n",
      " '    if( w.addEventListener ){\\n'\n",
      " '      w.addEventListener( \"load\", function(){\\n'\n",
      " '        w.clearInterval( run );\\n'\n",
      " '      } );\\n'\n",
      " '    }\\n'\n",
      " '    if( w.attachEvent ){\\n'\n",
      " '      w.attachEvent( \"onload\", function(){\\n'\n",
      " '        w.clearInterval( run );\\n'\n",
      " '      } )\\n'\n",
      " '    }\\n'\n",
      " '  }\\n'\n",
      " '}( this ));\\n'\n",
      " '    \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Skip to main content\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'AAAS\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'ScienceMag.org\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Search\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Search\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'X\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Advanced Search\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Science\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Contents\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'News\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Careers\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Journals\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Menu\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Read our COVID-19 research and news.',\n",
      " 'share        \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Research Article\\n'\n",
      " 'Model-informed COVID-19 vaccine prioritization strategies by age and '\n",
      " 'serostatus\\n'\n",
      " '\\n'\n",
      " 'View ORCID ProfileKate M. Bubar1,2,*, Kyle Reinholt3, Stephen M. Kissler4, '\n",
      " 'View ORCID ProfileMarc Lipsitch4,5, View ORCID ProfileSarah Cobey6, View '\n",
      " 'ORCID ProfileYonatan H. Grad4, View ORCID ProfileDaniel B. '\n",
      " 'Larremore3,7,*1Department of Applied Mathematics, University of Colorado '\n",
      " 'Boulder, Boulder, CO 80309, USA.2IQ Biology Program, University of Colorado '\n",
      " 'Boulder, Boulder, CO 80303, USA.3Department of Computer Science, University '\n",
      " 'of Colorado Boulder, Boulder, CO 80309, USA.4Department of Immunology and '\n",
      " 'Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA '\n",
      " '02115, USA.5Center for Communicable Disease Dynamics, Harvard T. H. Chan '\n",
      " 'School of Public Health, Boston, MA 02115, USA.6Department of Ecology and '\n",
      " 'Evolution, University of Chicago, Chicago, IL 60637, USA.7BioFrontiers '\n",
      " 'Institute, University of Colorado Boulder, Boulder, CO 80303, '\n",
      " 'USA.↵*Correspondng author.',\n",
      " 'E-mail: kate.bubar{at}colorado.edu (K.M.B.',\n",
      " '); daniel.larremore{at}colorado.edu (D.B.L.)',\n",
      " 'See allHide authors and affiliations\\n\\n\\n\\nScience\\xa0 26 Feb 2021:Vol.',\n",
      " '371, Issue 6532, pp.',\n",
      " '916-921DOI: 10.1126/science.abe6959      \\n'\n",
      " '\\n'\n",
      " 'Kate M. Bubar 1Department of Applied Mathematics, University of Colorado '\n",
      " 'Boulder, Boulder, CO 80309, USA.2IQ Biology Program, University of Colorado '\n",
      " 'Boulder, Boulder, CO 80303, USA.Find this author on Google Scholar\\n'\n",
      " 'Find this author on PubMed\\n'\n",
      " 'Search for this author on this site\\n'\n",
      " 'ORCID record for Kate M. Bubar \\n'\n",
      " 'For correspondence: \\n'\n",
      " 'kate.bubar@colorado.edu\\n'\n",
      " 'daniel.larremore@colorado.edu\\n'\n",
      " 'Kyle Reinholt 3Department of Computer Science, University of Colorado '\n",
      " 'Boulder, Boulder, CO 80309, USA.Find this author on Google Scholar\\n'\n",
      " 'Find this author on PubMed\\n'\n",
      " 'Search for this author on this site\\n'\n",
      " 'Stephen M. Kissler 4Department of Immunology and Infectious Diseases, '\n",
      " 'Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.Find this '\n",
      " 'author on Google Scholar\\n'\n",
      " 'Find this author on PubMed\\n'\n",
      " 'Search for this author on this site\\n'\n",
      " 'Marc Lipsitch 4Department of Immunology and Infectious Diseases, Harvard T. '\n",
      " 'H. Chan School of Public Health, Boston, MA 02115, USA.5Center for '\n",
      " 'Communicable Disease Dynamics, Harvard T. H. Chan School of Public Health, '\n",
      " 'Boston, MA 02115, USA.Find this author on Google Scholar\\n'\n",
      " 'Find this author on PubMed\\n'\n",
      " 'Search for this author on this site\\n'\n",
      " 'ORCID record for Marc Lipsitch \\n'\n",
      " 'Sarah Cobey 6Department of Ecology and Evolution, University of Chicago, '\n",
      " 'Chicago, IL 60637, USA.Find this author on Google Scholar\\n'\n",
      " 'Find this author on PubMed\\n'\n",
      " 'Search for this author on this site\\n'\n",
      " 'ORCID record for Sarah Cobey \\n'\n",
      " 'Yonatan H. Grad 4Department of Immunology and Infectious Diseases, Harvard '\n",
      " 'T. H. Chan School of Public Health, Boston, MA 02115, USA.Find this author '\n",
      " 'on Google Scholar\\n'\n",
      " 'Find this author on PubMed\\n'\n",
      " 'Search for this author on this site\\n'\n",
      " 'ORCID record for Yonatan H. Grad \\n'\n",
      " 'Daniel B. Larremore 3Department of Computer Science, University of Colorado '\n",
      " 'Boulder, Boulder, CO 80309, USA.7BioFrontiers Institute, University of '\n",
      " 'Colorado Boulder, Boulder, CO 80303, USA.Find this author on Google Scholar\\n'\n",
      " 'Find this author on PubMed\\n'\n",
      " 'Search for this author on this site\\n'\n",
      " 'ORCID record for Daniel B. Larremore \\n'\n",
      " 'For correspondence: \\n'\n",
      " 'kate.bubar@colorado.edu\\n'\n",
      " 'daniel.larremore@colorado.edu\\n'\n",
      " ' \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Article\\n'\n",
      " 'Figures & Data\\n'\n",
      " 'Info & Metrics\\n'\n",
      " 'eLetters\\n'\n",
      " ' PDF\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Vaccine prioritizationThere is likely to be high demand for the limited '\n",
      " 'supplies of vaccine against severe acute respiratory syndrome coronavirus 2 '\n",
      " '(SARS-CoV-2), so how should vaccine distribution be prioritized?',\n",
      " 'Bubar et al.',\n",
      " \"modeled across countries how uncertainty about a vaccine's characteristics \"\n",
      " 'affects prioritization strategies for reducing deaths and transmission (see '\n",
      " 'the Perspective by Fitzpatrick and Galvani).',\n",
      " 'In the model, vaccine efficacy and its ability to reduce disease and/or '\n",
      " 'block transmission was accounted for in relation to age-related variations '\n",
      " 'in susceptibility, fatality rates, and immune decline.',\n",
      " 'In almost all circumstances, reducing fatalities required distributing the '\n",
      " 'vaccine to those who are most at risk of death, usually persons over 60 '\n",
      " 'years of age and those with comorbidities.',\n",
      " 'If a vaccine is leaky or poorly efficacious in older adults, then priority '\n",
      " 'could be given to younger age groups.',\n",
      " 'To increase the available doses, further priority should be given to '\n",
      " 'seronegative individuals.Science, this issue p. 916; see also p. '\n",
      " '890AbstractLimited initial supply of severe acute respiratory syndrome '\n",
      " 'coronavirus 2 (SARS-CoV-2) vaccine raises the question of how to prioritize '\n",
      " 'available doses.',\n",
      " 'We used a mathematical model to compare five age-stratified prioritization '\n",
      " 'strategies.',\n",
      " 'A highly effective transmission-blocking vaccine prioritized to adults ages '\n",
      " '20 to 49 years minimized cumulative incidence, but mortality and years of '\n",
      " 'life lost were minimized in most scenarios when the vaccine was prioritized '\n",
      " 'to adults greater than 60 years old.',\n",
      " 'Use of individual-level serological tests to redirect doses to seronegative '\n",
      " 'individuals improved the marginal impact of each dose while potentially '\n",
      " 'reducing existing inequities in COVID-19 impact.',\n",
      " 'Although maximum impact prioritization strategies were broadly consistent '\n",
      " 'across countries, transmission rates, vaccination rollout speeds, and '\n",
      " 'estimates of naturally acquired immunity, this framework can be used to '\n",
      " 'compare impacts of prioritization strategies across contexts.Severe acute '\n",
      " 'respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a public health '\n",
      " 'and economic crisis worldwide.',\n",
      " 'As of January 2021, there have been more than 85 million cases and 1.8 '\n",
      " 'million deaths reported (1).',\n",
      " 'To combat this crisis, a variety of nonpharmaceutical interventions have '\n",
      " 'been implemented, including shelter-in-place orders, limited travel, and '\n",
      " 'remote schooling.',\n",
      " 'Although these efforts are essential to slowing transmission in the short '\n",
      " 'term, long-term solutions—such as vaccines that protect from SARS-CoV-2 '\n",
      " 'infection—remain urgently needed.',\n",
      " 'The benefits of an effective vaccine for individuals and their communities '\n",
      " 'have resulted in widespread demand, so it is critical that decision-making '\n",
      " 'on vaccine distribution is well motivated, particularly in the initial '\n",
      " 'phases when vaccine availability is limited (2).We used a model-informed '\n",
      " 'approach to quantify the impact of COVID-19 vaccine prioritization '\n",
      " 'strategies on cumulative incidence, mortality, and years of life lost.',\n",
      " 'Our approach explicitly addresses variation in three areas that can '\n",
      " 'influence the outcome of vaccine distribution decisions.',\n",
      " 'First, we considered variation in the performance of the vaccine, including '\n",
      " 'its overall efficacy, a hypothetical decrease in efficacy by age, and the '\n",
      " 'vaccine’s ability to block transmission.',\n",
      " 'Second, we considered variation in both susceptibility to infection and the '\n",
      " 'infection fatality rate by age.',\n",
      " 'Third, we considered variation in the population and policy—including the '\n",
      " 'age distribution, age-stratified contact rates, and initial fraction of '\n",
      " 'seropositive individuals by age—and the speed and timing of the vaccine’s '\n",
      " 'rollout relative to transmission.',\n",
      " 'Although the earliest doses of vaccines will be given to front-line health '\n",
      " 'care workers under plans such as those from the COVAX initiative and the '\n",
      " 'U.S. National Academies of Sciences, Engineering, and Medicine (NASEM) '\n",
      " 'recommendations (3), our work is focused on informing the prioritization of '\n",
      " 'the doses that follow.',\n",
      " 'On the basis of regulatory approvals and initial vaccine rollout speeds of '\n",
      " 'early 2021, our investigation focuses generally on scenarios with a '\n",
      " 'partially mitigated pandemic [reproduction number (R) between 1.1 and 2.0], '\n",
      " 'vaccines with protective efficacy of 90%, and rollout speeds of 0.2% of the '\n",
      " 'population per day.There are two main approaches to vaccine prioritization: '\n",
      " '(i) directly vaccinate those at highest risk for severe outcomes and (ii) '\n",
      " 'protect them indirectly by vaccinating those who do the most transmitting.',\n",
      " 'Model-based investigations of the trade-offs between these strategies for '\n",
      " 'influenza vaccination have led to recommendations that children be '\n",
      " 'vaccinated because of their critical role in transmission (4, 5) and have '\n",
      " 'shown that direct protection is superior when reproduction numbers are high '\n",
      " 'but indirect protection is superior when transmission is low (6).',\n",
      " 'Similar modeling for COVID-19 vaccination has found that the optimal balance '\n",
      " 'between direct and indirect protection depends on both vaccine efficacy and '\n",
      " 'supply, recommending direct vaccination of older adults for low-efficacy '\n",
      " 'vaccines and for high-efficacy but supply-limited vaccines (7).',\n",
      " 'Rather than comparing prioritization strategies, others have compared '\n",
      " 'hypothetical vaccines, showing that even those with lower efficacy for '\n",
      " 'direct protection may be more valuable if they also provide better indirect '\n",
      " 'protection by blocking transmission (8).',\n",
      " 'Prioritization of transmission-blocking vaccines can also be dynamically '\n",
      " 'updated on the basis of the current state of the epidemic, shifting '\n",
      " 'prioritization to avoid decreasing marginal returns (9).',\n",
      " 'These efforts to prioritize and optimize doses complement other work showing '\n",
      " 'that under different vaccine efficacy and durability of immunity, the '\n",
      " 'economic and health benefits of COVID-19 vaccines will be large in the short '\n",
      " 'and medium terms (10).',\n",
      " 'The problem of vaccine prioritization also parallels the more general '\n",
      " 'problem of optimal resource allocation to reduce transmission, such as with '\n",
      " 'masks (11).Evaluation of vaccine prioritization strategiesWe evaluated the '\n",
      " 'impact of vaccine prioritization strategies using an age-stratified SEIR '\n",
      " 'model (susceptible, exposed, infectious, recovered) because age has been '\n",
      " 'shown to be an important correlate of susceptibility (12–14), seroprevalence '\n",
      " '(12, 15), severity (16–18), and mortality (19, 20).',\n",
      " 'This model includes an age-dependent contact matrix, susceptibility to '\n",
      " 'infection, and infection fatality rate (IFR), allowing us to estimate '\n",
      " 'cumulative incidence of SARS-CoV-2 infections, mortality due to infection, '\n",
      " 'and years of life lost (YLL) (supplementary materials, materials and '\n",
      " 'methods) by means of forward simulations of 1 year of disease dynamics.',\n",
      " 'Cumulative incidence, mortality, and YLL were then used as outcomes by which '\n",
      " 'to compare vaccine prioritization strategies.',\n",
      " 'These comparisons may be explored by using accompanying open-source and '\n",
      " 'interactive calculation tools that accompany this study (21).We first '\n",
      " 'examined the impact of five vaccine prioritization strategies for a '\n",
      " 'hypothetical infection- and transmission-blocking vaccine of varying '\n",
      " 'efficacy.',\n",
      " 'The strategies prioritized vaccines to (i) children and teenagers, (ii) '\n",
      " 'adults between ages 20 and 49 years, (iii) adults 20 years or older, (iv) '\n",
      " 'adults 60 years or older, and (v) all individuals (Fig.',\n",
      " '1A).',\n",
      " 'In all strategies, once the prioritized population was vaccinated, vaccines '\n",
      " 'were allocated irrespective of age—that is, in proportion to their numbers '\n",
      " 'in the population.',\n",
      " 'To incorporate vaccine hesitancy, at most 70% of any age group was eligible '\n",
      " 'to be vaccinated (22).',\n",
      " 'Download high-res image\\n Open in new tab\\n Download Powerpoint\\n \\n\\n\\nFig.',\n",
      " '1 Impacts of vaccine prioritization strategies on mortality and infections.',\n",
      " '(A) Distribution of vaccines for five prioritization strategies: under 20 '\n",
      " 'years, adults 20 to 49 years, adults 20+ years, adults 60+ years, and all '\n",
      " 'ages.',\n",
      " '(B, C, F, and G) Example simulation curves show [(B) and (C)] percentage of '\n",
      " 'the total population infected over time and [(F) and (G)] cumulative '\n",
      " 'mortality for no vaccines (gray dashed lines) and for five different '\n",
      " 'prioritization strategies [colored lines matching (A)], with [(B) and (F)] '\n",
      " '10% and [(C) and (G)] 30% vaccine supply.',\n",
      " '(D, E, H, and I) Summary curves show percent reductions in [(D) and (E)] '\n",
      " 'infections and [(H) and (I)] deaths in comparison to an unmitigated outbreak '\n",
      " 'for vaccine supplies between 1 and 50% after 365 days of simulation.',\n",
      " 'Squares and diamonds show how the outputs from single simulations [(F) and '\n",
      " '(G)] correspond to points in summary curves (H).',\n",
      " 'Gray shading indicates the period during which vaccine is being rolled out '\n",
      " 'at 0.2% of total population per day.',\n",
      " 'Black dots indicate break points at which prioritized demographic groups '\n",
      " 'have been 70% vaccinated, after which vaccines are distributed without '\n",
      " 'prioritization.',\n",
      " 'These simulations assume contact patterns and demographics of the United '\n",
      " 'States (38, 53) and an all-or-nothing, transmission-blocking vaccine with '\n",
      " '90% vaccine efficacy and R0 = 1.5 (scenario 2) and R0 = 1.15 (scenario 1).',\n",
      " 'We measured reductions in cumulative incidence, mortality, and YLL achieved '\n",
      " 'by each strategy, varying the vaccine supply between 1 and 50% of the total '\n",
      " 'population, under two scenarios.',\n",
      " 'In scenario 1, vaccines were administered to 0.2% of the population per day '\n",
      " 'until supply was exhausted, with basic reproduction number (R0) = 1.15, '\n",
      " 'representing highly mitigated spread during vaccine rollout.',\n",
      " 'In scenario 2, vaccines were administered to 0.2% of the population per day '\n",
      " 'until supply was exhausted, but with R0 = 1.5, representing substantial '\n",
      " 'viral growth during vaccine rollout (example model outputs are provided in '\n",
      " 'Fig.',\n",
      " '1).',\n",
      " 'Results for additional scenarios in which vaccines were administered before '\n",
      " 'transmission began are described in the supplementary materials, '\n",
      " 'supplementary text, corresponding to countries without ongoing community '\n",
      " 'spread such as South Korea and New Zealand.',\n",
      " 'We considered two ways in which vaccine efficacy (ve) could be below 100%: '\n",
      " 'an all-or-nothing vaccine, in which the vaccine provides perfect protection '\n",
      " 'to a fraction ve of individuals who receive it, or as a leaky vaccine, in '\n",
      " 'which all vaccinated individuals have reduced probability ve of infection '\n",
      " 'after vaccination (supplementary materials, materials and methods).Of the '\n",
      " 'five strategies, direct vaccination of adults older than 60 years of age '\n",
      " '(60+) always reduced mortality and YLL more than the alternative strategies '\n",
      " 'when transmission was high [R0 = 1.5, scenario 2, 90% efficacy (Fig.',\n",
      " '1); 30 to 100% efficacy (fig.',\n",
      " 'S5)].',\n",
      " 'For lower transmission (R0 = 1.15, scenario 1), vaccination of adults aged '\n",
      " '20 to 49 years reduced mortality and YLL more than the alternative '\n",
      " 'strategies, but differences between prioritization of adults aged 20 to 49 '\n",
      " 'years, 20+ years, and 60+ years were small for vaccine supplies above 25% '\n",
      " '(Fig.',\n",
      " '1 and fig.',\n",
      " 'S5).',\n",
      " 'Prioritizing adults aged 20 to 49 years minimized cumulative incidence in '\n",
      " 'both scenarios for all vaccine efficacies (Fig.',\n",
      " '1 and fig.',\n",
      " 'S5).',\n",
      " 'Prioritizing adults aged 20 to 49 years also minimized cumulative incidence '\n",
      " 'in both scenarios under alternative rollout speeds (0.05 to 1% vaccinated '\n",
      " 'per day) (fig.',\n",
      " 'S6).',\n",
      " 'When rollout speeds were at least 0.3% per day and vaccine supply covered at '\n",
      " 'least 25% of the population, the mortality-minimizing strategy shifted from '\n",
      " 'prioritization of ages 20 to 49 years to adults aged 20+ or 60+ years for '\n",
      " 'scenario 1; when rollout speeds were at least 0.75% per day and covered at '\n",
      " 'least 24% of the population, the mortality-minimizing strategy shifted from '\n",
      " 'prioritization of adults aged 60+ years to adults aged 20+ or 20 to 49 years '\n",
      " 'for scenario 2 (fig.',\n",
      " 'S6).',\n",
      " 'Findings for mortality and YLL were only slightly changed by modeling '\n",
      " 'vaccine efficacy as all or nothing (fig.',\n",
      " 'S5) or leaky (fig.',\n",
      " 'S7).Impact of transmission rates, age demographics, and contact structureTo '\n",
      " 'evaluate the impact of transmission rates on the strategy that most reduced '\n",
      " 'mortality, we varied the basic reproductive number R0 from 1.1 to 2.0 when '\n",
      " 'considering a hypothetical infection- and transmission-blocking vaccine with '\n",
      " '90% vaccine efficacy.',\n",
      " 'We found that prioritizing adults aged 60+ years remained the best way to '\n",
      " 'reduce mortality and YLL for R0 ≥ 1.3, but prioritizing adults aged 20 to 49 '\n",
      " 'years was superior for R0 ≤ 1.2 (Fig.',\n",
      " '2, A and B, and fig.',\n",
      " 'S8).',\n",
      " 'Prioritizing adults aged 20 to 49 years minimized infections for all values '\n",
      " 'of R0 investigated (fig.',\n",
      " 'S8).To evaluate the impact of transmission rates on the strategy that most '\n",
      " 'reduced mortality, we varied the basic reproductive number R0 from 1.1 to '\n",
      " '2.0 when considering a hypothetical infection- and transmission-blocking '\n",
      " 'vaccine with 90% vaccine efficacy.',\n",
      " 'We found that prioritizing adults aged 60+ years remained the best way to '\n",
      " 'reduce mortality and YLL for R0 ≥ 1.3, but prioritizing adults aged 20 to 49 '\n",
      " 'years was superior for R0 ≤ 1.2 (Fig.',\n",
      " '2, A and B, and fig.',\n",
      " 'S8).',\n",
      " 'Prioritizing adults aged 20 to 49 years minimized infections for all values '\n",
      " 'of R0 investigated (fig.',\n",
      " 'S8).To evaluate the impact of transmission rates on the strategy that most '\n",
      " 'reduced mortality, we varied the basic reproductive number R0 from 1.1 to '\n",
      " '2.0 when considering a hypothetical infection- and transmission-blocking '\n",
      " 'vaccine with 90% vaccine efficacy.',\n",
      " 'We found that prioritizing adults aged 60+ years remained the best way to '\n",
      " 'reduce mortality and YLL for R0 ≥ 1.3, but prioritizing adults aged 20 to 49 '\n",
      " 'years was superior for R0 ≤ 1.2 (Fig.',\n",
      " '2, A and B, and fig.',\n",
      " 'S8).',\n",
      " 'Prioritizing adults aged 20 to 49 years minimized infections for all values '\n",
      " 'of R0 investigated (fig.',\n",
      " 'S8).',\n",
      " 'Download high-res image\\n Open in new tab\\n Download Powerpoint\\n \\n\\n\\nFig.',\n",
      " '2 Mortality-minimizing vaccine prioritization strategies across reproductive '\n",
      " 'numbers R0 and countries.',\n",
      " '(A to E) Heatmaps show the prioritization strategies that result in maximum '\n",
      " 'reduction of mortality for varying values of [(A) and (B)] the basic '\n",
      " 'reproductive number R0 and [(C), (D), and (E)] across nine countries, for '\n",
      " 'vaccine supplies between 1 and 50% of the total population, for an '\n",
      " 'all-or-nothing and transmission-blocking vaccine, 90% vaccine efficacy.',\n",
      " '[(A) and (B)] Contact patterns and demographics of the United States (38, '\n",
      " '53).',\n",
      " '[(C), (D), and (E)] Contact patterns and demographics of POL, Poland; ZAF, '\n",
      " 'South Africa; CHN, China; BRA, Brazil; ZWE, Zimbabwe; ESP, Spain; IND, '\n",
      " 'India; USA, United States of America; and BEL, Belgium, with R0 and rollout '\n",
      " 'speeds as indicated.',\n",
      " 'To determine whether our findings were robust across countries, we analyzed '\n",
      " 'the ranking of prioritization strategies for populations with the age '\n",
      " 'distributions and modeled contact structures of the United States, Belgium, '\n",
      " 'Brazil, China, India, Poland, South Africa, and Spain.',\n",
      " 'Across these countries, direct vaccination of adults aged 60+ years '\n",
      " 'minimized mortality for all levels of vaccine supply when transmission was '\n",
      " 'high (R0 = 1.5, scenario 2) (Fig.',\n",
      " '2E) but in only some cases when transmission was lower (R0 = 1.15, rollout '\n",
      " '0.2% per day, scenario 1) (Fig.',\n",
      " '2D).',\n",
      " 'Decreasing rollout speed from 0.2% to 0.1% per day caused prioritization of '\n",
      " 'adults aged 60+ years to be favored in additional scenarios (Fig.',\n",
      " '2C).',\n",
      " 'Across countries, vaccination of adults aged 20 to 49 years nearly always '\n",
      " 'minimized infections, and vaccination of adults aged 60+ years nearly always '\n",
      " 'minimized YLL for scenario 2, but no clear ranking of strategies emerged '\n",
      " 'consistently to minimize YLL in scenario 1 (fig.',\n",
      " 'S9).Vaccines with imperfect transmission-blocking effectsWe also considered '\n",
      " 'whether the rankings of prioritization strategies to minimize mortality '\n",
      " 'would change if a vaccine were to block COVID-19 symptoms and mortality with '\n",
      " '90% efficacy but with variable impact on SARS-CoV-2 infection and '\n",
      " 'transmission.',\n",
      " 'We found that direct vaccination of adults aged 60+ years minimized '\n",
      " 'mortality for all vaccine supplies and transmission-blocking effects under '\n",
      " 'scenario 2 and for all vaccine supplies when up to 50% of transmission was '\n",
      " 'blocked in scenario 1 (supplementary text and fig.',\n",
      " 'S10).Variation in vaccine efficacy by ageCOVID-19 vaccines may not be '\n",
      " 'equally effective across age groups in preventing infection or disease, a '\n",
      " 'phenomenon known to affect influenza vaccines (23–26).',\n",
      " 'To understand the impact of age-dependent COVID-19 vaccine efficacy, we '\n",
      " 'incorporated a hypothetical linear decrease from a baseline efficacy of 90% '\n",
      " 'for those younger than 60 years to 50% in those 80 years and older (Fig.',\n",
      " '3).',\n",
      " 'As expected, this diminished the benefits of any prioritization strategy '\n",
      " 'that included older adults.',\n",
      " 'For example, strategies that prioritize adults aged 20 to 49 years were '\n",
      " 'unaffected by decreased efficacy among adults aged 60+ years, whereas '\n",
      " 'strategies prioritizing adults aged 60+ years were markedly diminished (Fig.',\n",
      " '3).',\n",
      " 'Despite these effects, prioritization of adults aged 60+ years remained '\n",
      " 'superior to the alternative strategies to minimize mortality in scenario 2.',\n",
      " 'Download high-res image\\n Open in new tab\\n Download Powerpoint\\n \\n\\n\\nFig.',\n",
      " '3 Effects of age-dependent vaccine efficacy on the impacts of prioritization '\n",
      " 'strategies.',\n",
      " '(A) Diagram of hypothetical age-dependent vaccine efficacy shows decrease '\n",
      " 'from 90% baseline efficacy to 50% efficacy among individuals aged 80+ years, '\n",
      " 'beginning at age 60 (dashed line).',\n",
      " '(B and C) Percent reduction in deaths in comparison with an unmitigated '\n",
      " 'outbreak for transmission-blocking all-or-nothing vaccines with either '\n",
      " 'constant 90% efficacy for all age groups (solid lines) or age-dependent '\n",
      " 'efficacy shown in (A) (dashed lines), covering scenario 1 [0.2% rollout per '\n",
      " 'day, R0 = 1.15; (B)] and scenario 2 [0.2% rollout per day, R0 = 1.5 (C)].',\n",
      " 'Black dots indicate break points at which prioritized demographic groups '\n",
      " 'have been 70% vaccinated, after which vaccines are distributed without '\n",
      " 'prioritization.',\n",
      " 'Shown are contact patterns and demographics of the United States (38, 53); '\n",
      " 'all-or-nothing and transmission-blocking vaccine.',\n",
      " 'To test whether more substantial age-dependent vaccine effects would change '\n",
      " 'which strategy minimized mortality in scenario 2, we varied the onset age of '\n",
      " 'age-dependent decreases in efficacy, the extent to which it decreased, and '\n",
      " 'the baseline efficacy from which it decreased.',\n",
      " 'We found that as long as the age at which efficacy began to decrease was 70 '\n",
      " 'years or older and vaccine efficacy among adults aged 80+ years was at least '\n",
      " '25%, prioritizing adults aged 60+ years remained superior in the majority of '\n",
      " 'parameter combinations.',\n",
      " 'This finding was robust to whether the vaccine was modeled as leaky versus '\n",
      " 'all or nothing, but we observed considerable variation from country to '\n",
      " 'country (fig.',\n",
      " 'S11).Incorporation of population seroprevalence and individual serological '\n",
      " 'testingBecause of early indications that naturally acquired antibodies '\n",
      " 'correlate with protection from reinfection (27), seroprevalence will affect '\n",
      " 'vaccine prioritization in two ways.',\n",
      " 'First, depending on the magnitude and age distribution of seroprevalence at '\n",
      " 'the time of vaccine distribution, the ranking of strategies could change.',\n",
      " 'Second, distributing vaccines to seropositive individuals would reduce the '\n",
      " 'marginal benefit of vaccination per dose.To investigate the impact of '\n",
      " 'vaccinating midepidemic while using serology to target the vaccine to '\n",
      " 'seronegative individuals, we included age-stratified seroprevalence '\n",
      " 'estimates in our model by moving the data-specified proportion of '\n",
      " 'seropositive individuals from susceptible to recovered status.',\n",
      " 'We then simulated two approaches to vaccine distribution.',\n",
      " 'In the first, vaccines were distributed according to the five prioritization '\n",
      " 'strategies introduced above, regardless of any individual’s serostatus.',\n",
      " 'In the second, vaccines were distributed with a serological test, so that '\n",
      " 'individuals with a positive serological test would not be vaccinated, '\n",
      " 'allowing their dose to be given to someone else in their age group.We '\n",
      " 'included age-stratified seroprevalence estimates from New York City [August '\n",
      " '2020; overall seroprevalence 26.9% (28)] and demographics and age-contact '\n",
      " 'structure from the United States in evaluations of the previous five '\n",
      " 'prioritization strategies.',\n",
      " 'For this analysis, we focused on scenario 2 (0.2% rollout per day, R0 = 1.5 '\n",
      " 'inclusive of seropositives) and found that the ranking of strategies to '\n",
      " 'minimize incidence, mortality, and YLL remained unchanged: Prioritizing '\n",
      " 'adults aged 60+ years most reduced mortality, and prioritizing adults aged '\n",
      " '20 to 49 years most reduced incidence, regardless of whether vaccination was '\n",
      " 'limited to seronegative individuals (Fig.',\n",
      " '4).',\n",
      " 'These rankings were unchanged when we used lower or higher age-stratified '\n",
      " 'seroprevalence estimates to test the consistency of results [Connecticut, '\n",
      " 'July 2020, overall seroprevalence 3.4% (29) and synthetic, overall '\n",
      " 'seroprevalence 39.5%] (figs.',\n",
      " 'S12 and S13).',\n",
      " 'Despite lowered sensitivity to detect past exposure due to seroreversion '\n",
      " '(30, 31), preferentially vaccinating seronegative individuals yielded large '\n",
      " 'additional reductions in cumulative incidence and mortality in locations '\n",
      " 'with higher seroprevalence (Fig.',\n",
      " '4 and fig.',\n",
      " 'S13) and modest reductions in locations with low seroprevalence (fig.',\n",
      " 'S12).',\n",
      " 'These results remained unchanged when statistical uncertainty, because of '\n",
      " 'sample size and imperfect test sensitivity and specificity, was incorporated '\n",
      " 'into the model (32).',\n",
      " 'Download high-res image\\n Open in new tab\\n Download Powerpoint\\n \\n\\n\\nFig.',\n",
      " '4 Effects of existing seropositivity on the impacts of prioritization '\n",
      " 'strategies.',\n",
      " '(A to C) Percent reductions in (A) infections, (B) deaths, and (C) years of '\n",
      " 'life lost (YLL) for prioritization strategies when existing age-stratified '\n",
      " 'seroprevalence is incorporated [August 2020 estimates for New York City; '\n",
      " 'mean seroprevalence 26.9% (28)].',\n",
      " 'Plots show reductions for scenario 2 (0.2% rollout per day, R0 = 1.5) when '\n",
      " 'vaccines are given to all individuals (solid lines) or to only seronegatives '\n",
      " '(dashed lines), inclusive of 96% serotest sensitivity, 99% specificity (54), '\n",
      " 'and approximately 3 months of seroreversion (supplementary materials, '\n",
      " 'materials and methods) (29).',\n",
      " 'Shown are U.S. contact patterns and demographics (38, 53), all-or-nothing '\n",
      " 'and transmission-blocking vaccine with 90% vaccine efficacy.',\n",
      " 'Lower and higher seroprevalence examples are provided in figs.',\n",
      " 'S12 and S13, respectively.',\n",
      " 'DiscussionThis study demonstrated the use of an age-stratified modeling '\n",
      " 'approach to evaluate and compare vaccine prioritization strategies for '\n",
      " 'SARS-CoV-2.',\n",
      " 'After accounting for country-specific age structure, age-contact structure, '\n",
      " 'infection fatality rates, and seroprevalence, as well as the age-varying '\n",
      " 'efficacy of a hypothetical vaccine, we found that across countries, those '\n",
      " 'aged 60 years and older should be prioritized to minimize deaths, assuming a '\n",
      " 'return to high contact rates and prepandemic behavior during or after '\n",
      " 'vaccine rollout.',\n",
      " 'This recommendation is robust because of the dramatic differences in IFR by '\n",
      " 'age.',\n",
      " 'Our model identified three general regimes in which prioritizing adults aged '\n",
      " '20 to 49 years would provide greater mortality benefits than would '\n",
      " 'prioritizing older adults.',\n",
      " 'One such regime was in the presence of substantial transmission-mitigating '\n",
      " 'interventions (R0 = 1.15) and a vaccine with 80% or higher '\n",
      " 'transmission-blocking effects.',\n",
      " 'A second regime was characterized by substantial transmission-mitigating '\n",
      " 'interventions (R0 = 1.15) and either rollout speeds of at most 0.2% per day '\n",
      " 'or vaccine supplies of at most 25% of the population.',\n",
      " 'The third regime was characterized by vaccines with very low efficacy in '\n",
      " 'older adults, very high efficacy in younger adults, and declines in efficacy '\n",
      " 'starting at age 59 or 69 years.',\n",
      " 'The advantage of prioritizing all adults or adults aged 20 to 49 versus 60+ '\n",
      " 'years was small under these conditions.',\n",
      " 'Thus, we conclude that for mortality reduction, prioritization of older '\n",
      " 'adults is a robust strategy that will be optimal or close to optimal to '\n",
      " 'minimize mortality for virtually all plausible vaccine characteristics.By '\n",
      " 'contrast, the ranking of infection-minimizing strategies for midepidemic '\n",
      " 'vaccination led to consistent recommendations to prioritize adults aged 20 '\n",
      " 'to 49 years across efficacy values and countries.',\n",
      " 'For pretransmission vaccination, prioritization shifted toward children and '\n",
      " 'teenagers for leaky vaccine efficacies 50% and below, which is in line with '\n",
      " 'prior work (7), as well as for vaccines with weak transmission-blocking '\n",
      " 'properties.',\n",
      " 'Because a vaccine is likely to have properties of both leaky and '\n",
      " 'all-or-nothing models, empirical data on vaccine performance could help '\n",
      " 'resolve this difference in model recommendations, although data are '\n",
      " 'difficult to obtain in practice [for example, (33, 34)].It is not yet clear '\n",
      " 'whether the first generation of COVID-19 vaccines will be approved '\n",
      " 'everywhere for the elderly or those under 18 years of age (35–37).',\n",
      " 'Although our conclusions assumed that the vaccine would be approved for all '\n",
      " 'age groups, the evaluation approaches introduced here can be tailored to '\n",
      " 'evaluate a subset of approaches restricted to those within the age groups '\n",
      " 'for which a vaccine is licensed, by using open-source tools such as those '\n",
      " 'that accompany this study.',\n",
      " 'Furthermore, although we considered three possible goals of '\n",
      " 'vaccination—minimizing cumulative incidence, mortality, or YLL—our framework '\n",
      " 'can be adapted to consider goals such as minimizing hospitalizations, '\n",
      " 'intensive care unit occupancy (7), or economic costs (10).We demonstrated '\n",
      " 'that there is value in pairing individual-level serological tests with '\n",
      " 'vaccination, even when accounting for the uncertainties in seroprevalence '\n",
      " 'estimates (32) and seroreversion (30).',\n",
      " 'The marginal gain in effective vaccine supply, relative to no serological '\n",
      " 'testing, must be weighed against the challenges of serological testing '\n",
      " 'before vaccination.',\n",
      " 'Serostatus itself is an imperfect indicator of protection, and the '\n",
      " 'relationship of prior infection, serostatus, and protection may change over '\n",
      " 'time (10, 27, 30, 31).',\n",
      " 'Delays in serological test results would impair vaccine distribution, but '\n",
      " 'partial seronegative-targeting effects might be realized if those with past '\n",
      " 'polymerase chain reaction (PCR)–confirmed infections voluntarily '\n",
      " 'deprioritized their own vaccinations.The best-performing strategies depend '\n",
      " 'on assumptions about the extent of a population’s interactions.',\n",
      " 'We used prepandemic contact matrices (38), reflecting the goal of a return '\n",
      " 'to prepandemic routines once a vaccine is available, but more recent '\n",
      " 'estimates of age-stratified contact rates could be valuable in modeling '\n",
      " 'midpandemic scenarios (39, 40).',\n",
      " 'Whether prepandemic or midpandemic contact estimates are representative of '\n",
      " 'contact patterns during vaccine rollout remains unknown and may vary on the '\n",
      " 'basis of numerous social, political, and other factors.',\n",
      " 'The scenarios modeled here did not incorporate explicit nonpharmaceutical '\n",
      " 'interventions, which might persist if vaccination coverage is incomplete, '\n",
      " 'but are implicitly represented in scenario 1 (R0 = 1.15).Our study relies on '\n",
      " 'estimates of other epidemiological parameters.',\n",
      " 'In local contexts, these include age-structured seroprevalence and IFR, '\n",
      " 'which vary by population (19, 20, 41).',\n",
      " 'Globally, key parameters include the degree to which antibodies protect '\n",
      " 'against reinfection or severity of disease and relative infectiousness by '\n",
      " 'age.',\n",
      " 'From vaccine trials, we also need evidence of efficacy in groups vulnerable '\n",
      " 'to severe outcomes, including the elderly.',\n",
      " 'Additionally, it will be critical to measure whether a vaccine that protects '\n",
      " 'against symptomatic disease also blocks infection and transmission of '\n",
      " 'SARS-CoV-2 (42).The role of children during this pandemic has been unclear.',\n",
      " 'Under our assumptions about susceptibility by age, children are not the '\n",
      " 'major drivers of transmission in communities, which is consistent with '\n",
      " 'emerging evidence (12).',\n",
      " 'Thus, our results differ from the optimal distribution for influenza '\n",
      " 'vaccines, which prioritize school-age children and adults aged 30 to 39 '\n",
      " 'years (5).',\n",
      " 'However, the relative susceptibility and infectiousness of SARS-CoV-2 by age '\n",
      " 'remain uncertain.',\n",
      " 'Although it is unlikely that susceptibility to infection conditional on '\n",
      " 'exposure is constant across age groups (12), we ran our model to test the '\n",
      " 'sensitivity of this parameter.',\n",
      " 'Under the scenario of constant susceptibility by age, vaccinating those '\n",
      " 'under 20 years of age has a greater impact on reducing cumulative cases than '\n",
      " 'vaccinating those aged 20 to 49 years (figs.',\n",
      " 'S14 and 15).Our study is subject to a number of limitations.',\n",
      " 'First, our evaluation strategy focuses on a single country at a time, rather '\n",
      " 'than on between-population allocation (43).',\n",
      " 'Second, we only consider variation in disease severity by age.',\n",
      " 'However, other factors correlate with disease outcomes, such as treatment '\n",
      " 'and health care access and comorbidities, which may correlate with factors '\n",
      " 'such as rural versus urban location, socioeconomic status, sex (44, 45), and '\n",
      " 'race and ethnicity (46), which are not accounted for in this study.',\n",
      " 'Inclusion of these factors in a model would be possible, but only with '\n",
      " 'statistically sound measurements of their stratified infection risk, contact '\n",
      " 'rates, and disease outcomes.',\n",
      " 'Even in the case of age stratification, contact surveys have typically not '\n",
      " 'surveyed those 80 years and older, yet it is this population that suffers '\n",
      " 'dramatically more severe COVID-19 disease and higher infection fatality '\n",
      " 'rates.',\n",
      " 'We extrapolated contact matrices to those older than 80, but direct '\n",
      " 'measurements would be superior.',\n",
      " 'Last, our study focused on guiding strategy rather than providing more '\n",
      " 'detailed forecasting or estimates (10).',\n",
      " 'As such, we have not made detailed parameter fits to time series of cases or '\n",
      " 'deaths but rather have used epidemiologic models to identify robust '\n",
      " 'strategies across a range of transmission scenarios.Our study also considers '\n",
      " 'variation in disease risk only by age, through age-structured contact '\n",
      " 'matrices and age-specific susceptibility, whereas many discussions around '\n",
      " 'COVID-19 vaccine distribution have thus far focused on prioritizing health '\n",
      " 'care or essential workers (47, 48).',\n",
      " 'Contact rates, and thus infection potential, vary greatly not only by '\n",
      " 'occupation and age but also by living arrangement (such as congregate '\n",
      " 'settings or dormitories), neighborhood and mobility (49–52), and whether the '\n",
      " 'population has a coordinated and fundamentally effective policy to control '\n",
      " 'the virus.',\n",
      " 'With a better understanding of population structure during the pandemic, and '\n",
      " 'risk factors of COVID-19, these limitations could be addressed.',\n",
      " 'Meanwhile, the robust findings in favor of prioritizing those age groups '\n",
      " 'with the highest IFR to minimize mortality could potentially be extended to '\n",
      " 'prioritize those with comorbidities that predispose them to a high IFR '\n",
      " 'because the strategy of prioritizing the older age groups depends on direct '\n",
      " 'rather than indirect protection.Vaccine prioritization is not solely a '\n",
      " 'question of science but a question of ethics as well.',\n",
      " 'Hallmarks of the COVID-19 pandemic, as with other global diseases, are '\n",
      " 'inequalities and disparities.',\n",
      " 'Although these modeling efforts focus on age and minimizing incidence and '\n",
      " 'death within a simply structured population, other considerations are '\n",
      " 'crucial, from equity in allocation between countries to disparities in '\n",
      " 'access to health care, including vaccination, that vary by neighborhood.',\n",
      " 'Thus, the model’s simplistic representation of vulnerability (age) should be '\n",
      " 'augmented by better information on the correlates of infection risk and '\n",
      " 'severity.',\n",
      " 'Fair vaccine prioritization should avoid further harming disadvantaged '\n",
      " 'populations.',\n",
      " 'We suggest that after distribution, pairing serological testing with '\n",
      " 'vaccination in the hardest-hit populations is one possible equitable way to '\n",
      " 'extend the benefits of vaccination in settings where vaccination might '\n",
      " 'otherwise not be deemed cost effective.Supplementary '\n",
      " 'Materialsscience.sciencemag.org/content/371/6532/916/suppl/DC1Materials and '\n",
      " 'MethodsSupplementary TextFigs.',\n",
      " 'S1 to S15Tables S1 and S2References (55–57)MDAR Reproducibility '\n",
      " 'Checklisthttps://creativecommons.org/licenses/by/4.0/This is an open-access '\n",
      " 'article distributed under the terms of the Creative Commons Attribution '\n",
      " 'license, which permits unrestricted use, distribution, and reproduction in '\n",
      " 'any medium, provided the original work is properly cited.References and '\n",
      " 'Notes↵Johns Hopkins University Coronavirus Research Center, COVID-19 '\n",
      " 'Dashboard by the Center for Systems Science and Engineering at Johns Hopkins '\n",
      " 'University (2020); https://coronavirus.jhu.edu/map.html.↵ R. Khamsi, \\n'\n",
      " 'If a coronavirus vaccine arrives, can the world make enough?',\n",
      " 'Nature\\n580, \\n578–580 (2020).',\n",
      " 'doi:10.1038/d41586-020-01063-8pmid:32273621OpenUrlCrossRefPubMed↵National '\n",
      " 'Academies of Sciences, Engineering, and Medicine, Framework for Equitable '\n",
      " 'Allocation of COVID-19 Vaccine (National Academies Press, 2020); '\n",
      " 'https://doi.org/10.17226/25917.doi:10.17226/25917↵ D. Weycker,  J. '\n",
      " 'Edelsberg,  M. E. Halloran,  I. M. Longini Jr..,  A. Nizam,  V. Ciuryla,  G. '\n",
      " 'Oster, \\n'\n",
      " 'Population-wide benefits of routine vaccination of children against '\n",
      " 'influenza.',\n",
      " 'Vaccine\\n23, \\n1284–1293 (2005).',\n",
      " 'doi:10.1016/j.vaccine.2004.08.044pmid:15652671OpenUrlCrossRefPubMedWeb of '\n",
      " 'Science↵ J. Medlock,  A. P. Galvani, \\n'\n",
      " 'Optimizing influenza vaccine distribution.',\n",
      " 'Science\\n325, \\n1705–1708 (2009).',\n",
      " 'doi:10.1126/science.1175570pmid:19696313OpenUrlAbstract/FREE Full Text↵ S. '\n",
      " 'Bansal,  B. Pourbohloul,  L. A. Meyers, \\n'\n",
      " 'A comparative analysis of influenza vaccination programs.',\n",
      " 'PLOS Med.',\n",
      " '3, \\ne387 (2006).',\n",
      " 'doi:10.1371/journal.pmed.0030387pmid:17020406OpenUrlCrossRefPubMed↵L.',\n",
      " 'Matrajt, J. Eaton, T. Leung, E. R. Brown, Vaccine optimization for COVID-19: '\n",
      " 'who to vaccinate first?',\n",
      " 'medRxiv 20175257 [Preprint].',\n",
      " '15 December 2020. '\n",
      " 'https://doi.org/10.1101/2020.08.14.20175257.doi:10.1101/2020.08.14.20175257OpenUrlAbstract/FREE '\n",
      " 'Full Text↵M.',\n",
      " 'E. Gallagher et al., Considering indirect benefits is critical when '\n",
      " 'evaluating SARS-CoV-2 vaccine candidates.',\n",
      " 'medRxiv 20170456 [Preprint].',\n",
      " '11 August 2020. '\n",
      " 'https://doi.org/10.1101/2020.08.07.20170456.doi:10.1101/2020.08.07.20170456OpenUrlAbstract/FREE '\n",
      " 'Full Text↵J.',\n",
      " 'H. Buckner, G. Chowell, M. R. Springborn, Dynamic prioritization of COVID-19 '\n",
      " 'vaccines when social distancing is limited for essential workers.',\n",
      " 'medRxiv 20199174 [Preprint] 6 October 2020. '\n",
      " 'https://doi.org/10.1101/2020.09.22.20199174.doi:10.1101/2020.09.22.20199174OpenUrlAbstract/FREE '\n",
      " 'Full Text↵F.',\n",
      " 'Sandmann et al., The potential health and economic value of SARS-CoV-2 '\n",
      " 'vaccination alongside physical distancing in the UK: transmission '\n",
      " 'model-based future scenario analysis and economic evaluation.',\n",
      " 'medRxiv 20200857 [Preprint] 25 September 2020. '\n",
      " 'https://doi.org/10.1101/2020.09.24.20200857.doi:10.1101/2020.09.24.20200857OpenUrlAbstract/FREE '\n",
      " 'Full Text↵ C. J. Worby,  H.-H. Chang, \\n'\n",
      " 'Face mask use in the general population and optimal resource allocation '\n",
      " 'during the COVID-19 pandemic.',\n",
      " 'Nat.',\n",
      " 'Commun.',\n",
      " '11, \\n4049 (2020).',\n",
      " 'doi:10.1038/s41467-020-17922-xpmid:32792562OpenUrlCrossRefPubMed↵ E. '\n",
      " 'Goldstein,  M. Lipsitch,  M. Cevik, \\n'\n",
      " 'On the effect of age on the transmission of SARS-CoV-2 in households, '\n",
      " 'schools and the community.',\n",
      " 'J. Infect.',\n",
      " 'Dis.',\n",
      " '2020, \\njiaa691 (2020).',\n",
      " 'doi:10.1093/infdis/jiaa691pmid:33119738OpenUrlCrossRefPubMed N. G. Davies,  '\n",
      " 'P. Klepac,  Y. Liu,  K. Prem,  M. Jit,  R. M. Eggo; CMMID COVID-19 working '\n",
      " 'group, \\n'\n",
      " 'Age-dependent effects in the transmission and control of COVID-19 epidemics.',\n",
      " 'Nat.',\n",
      " 'Med.',\n",
      " '26, \\n1205–1211 (2020).',\n",
      " 'doi:10.1038/s41591-020-0962-9pmid:32546824OpenUrlCrossRefPubMed↵ J. Zhang,  '\n",
      " 'M. Litvinova,  Y. Liang,  Y. Wang,  W. Wang,  S. Zhao,  Q. Wu,  S. Merler,  '\n",
      " 'C. Viboud,  A. Vespignani,  M. Ajelli,  H. Yu, \\n'\n",
      " 'Changes in contact patterns shape the dynamics of the COVID-19 outbreak in '\n",
      " 'China.',\n",
      " 'Science\\n368, \\n1481–1486 (2020).',\n",
      " 'doi:10.1126/science.abb8001pmid:32350060OpenUrlAbstract/FREE Full Text↵S.',\n",
      " 'Herzog et al., Seroprevalence of IgG antibodies against SARS coronavirus 2 '\n",
      " 'in Belgium – a serial prospective cross-sectional nationwide study of '\n",
      " 'residual samples.',\n",
      " 'medRxiv 20125179 [Preprint] (2020).',\n",
      " 'https://doi.org/10.1101/2020.06.08.20125179.doi:10.1101/2020.06.08.20125179OpenUrlAbstract/FREE '\n",
      " 'Full Text↵ A. L. Mueller,  M. S. McNamara,  D. A. Sinclair, \\n'\n",
      " 'Why does COVID-19 disproportionately affect older people?',\n",
      " 'Aging (Albany NY)\\n12, \\n9959–9981 (2020).',\n",
      " 'doi:10.18632/aging.103344pmid:32470948OpenUrlCrossRefPubMed Y. Liu,  B. '\n",
      " 'Mao,  S. Liang,  J. W. Yang,  H. W. Lu,  Y. H. Chai,  L. Wang,  L. Zhang,  '\n",
      " 'Q. H. Li,  L. Zhao,  Y.',\n",
      " 'He,  X. L. Gu,  X.',\n",
      " 'B. Ji,  L. Li,  Z. J. Jie,  Q. Li,  X. Y. Li,  H. Z. Lu,  W. H. Zhang,  Y. '\n",
      " 'L. Song,  J. M. Qu,  J. F. Xu, Shanghai Clinical Treatment Experts Group for '\n",
      " 'COVID-19, \\n'\n",
      " 'Association between ages and clinical characteristics and outcomes of '\n",
      " 'coronavirus disease 2019.',\n",
      " 'Eur.',\n",
      " 'Respir.',\n",
      " 'J.',\n",
      " '55, \\n2001112 (2020).',\n",
      " 'doi:10.1183/13993003.01112-2020pmid:32312864OpenUrlAbstract/FREE Full Text↵ '\n",
      " 'J. Westmeier,  K. Paniskaki,  Z. Karaköse,  T. Werner,  K. Sutter,  S. '\n",
      " 'Dolff,  M. Overbeck,  A. Limmer,  J. Liu,  X. Zheng,  T. Brenner,  M. M. '\n",
      " 'Berger,  O. Witzke,  M. Trilling,  M. Lu,  D. Yang,  N. Babel,  T. '\n",
      " 'Westhoff,  U. Dittmer,  G. Zelinskyy, \\n'\n",
      " 'Impaired Cytotoxic CD8+ T Cell Response in Elderly COVID-19 Patients.',\n",
      " 'mBio\\n11, \\ne02243–e20 (2020).',\n",
      " 'pmid:32948688OpenUrlPubMed↵ A. T. Levin,  W. P. Hanage,  N. Owusu-Boaitey,  '\n",
      " 'K. B. Cochran,  S. P. Walsh,  G. Meyerowitz-Katz, \\n'\n",
      " 'Assessing the age specificity of infection fatality rates for COVID-19: '\n",
      " 'Systematic review, meta-analysis, and public policy implications.',\n",
      " 'Eur.',\n",
      " 'J. Epidemiol.',\n",
      " '35, \\n1123–1138 (2020).',\n",
      " 'doi:10.1007/s10654-020-00698-1pmid:33289900OpenUrlCrossRefPubMed↵ H. Salje,  '\n",
      " 'C. Tran Kiem,  N. Lefrancq,  N. Courtejoie,  P. Bosetti,  J. Paireau,  A. '\n",
      " 'Andronico,  N. Hozé,  J. Richet,  C.-L. Dubost,  Y.',\n",
      " 'Le Strat,  J. Lessler,  D. Levy-Bruhl,  A. Fontanet,  L. Opatowski,  P.-Y.',\n",
      " 'Boelle,  S. Cauchemez, \\nEstimating the burden of SARS-CoV-2 in France.',\n",
      " 'Science\\n369, \\n208–211 (2020).',\n",
      " 'doi:10.1126/science.abc3517pmid:32404476OpenUrlAbstract/FREE Full Text↵K.',\n",
      " 'M. Bubar et al., kbubar/vaccine_prioritization: Updated code for published '\n",
      " 'paper.',\n",
      " 'Zenodo (2020).doi:10.5281/zenodo.4308794↵M.',\n",
      " 'Brenan, Willingness to Get COVID-19 Vaccine Ticks Up to 63% in U.S., Online '\n",
      " '(8 December 2020); '\n",
      " 'https://news.gallup.com/poll/327425/willingness-covid-vaccine-ticks.aspx.↵ '\n",
      " 'P. A.',\n",
      " 'Gross,  A. W. Hermogenes,  H. S. Sacks,  J. Lau,  R. A. Levandowski, \\n'\n",
      " 'The efficacy of influenza vaccine in elderly persons.',\n",
      " 'A meta-analysis and review of the literature.',\n",
      " 'Ann.',\n",
      " 'Intern.',\n",
      " 'Med.',\n",
      " '123, \\n518–527 (1995).',\n",
      " 'doi:10.7326/0003-4819-123-7-199510010-00008pmid:7661497OpenUrlCrossRefPubMedWeb '\n",
      " 'of Science J. K. H. Lee,  G. K. L. Lam,  T. Shin,  J. Kim,  A. Krishnan,  D. '\n",
      " 'P. Greenberg,  A. Chit, \\n'\n",
      " 'Efficacy and effectiveness of high-dose versus standard-dose influenza '\n",
      " 'vaccination for older adults: A systematic review and meta-analysis.',\n",
      " 'Expert Rev.',\n",
      " 'Vaccines\\n17, \\n435–443 (2018).',\n",
      " 'doi:10.1080/14760584.2018.1471989pmid:29715054OpenUrlCrossRefPubMed T. M. E. '\n",
      " 'Govaert,  C. T. Thijs,  N. Masurel,  M. J. Sprenger,  G. J. Dinant,  J.',\n",
      " 'A. Knottnerus, \\n'\n",
      " 'The efficacy of influenza vaccination in elderly individuals.',\n",
      " 'A randomized double-blind placebo-controlled trial.',\n",
      " 'JAMA\\n272, \\n1661–1665 (1994).',\n",
      " 'doi:10.1001/jama.1994.03520210045030pmid:7966893OpenUrlCrossRefPubMedWeb of '\n",
      " 'Science↵ J.',\n",
      " 'A. Lewnard,  S. Cobey, \\nImmune History and Influenza Vaccine Effectiveness.',\n",
      " 'Vaccines\\n6, \\n28 (2018).',\n",
      " 'doi:10.3390/vaccines6020028pmid:29883414OpenUrlCrossRefPubMed↵ S. F. Lumley '\n",
      " 'et al., N. Engl.',\n",
      " 'J. Med.',\n",
      " '10.1056/NEJMoa2034545 (2020).↵City of New York, COVID-19 data (2020); '\n",
      " 'www1.nyc.gov/site/doh/covid/covid-19-data-testing.page.↵ K. L. Bajema et '\n",
      " 'al., JAMA Intern.',\n",
      " 'Med.',\n",
      " '10.1001/jamainternmed.2020.7976 (2020).↵H.',\n",
      " 'Ward et al., Declining prevalence of antibody positivity to SARS-CoV-2: a '\n",
      " 'community study of 365,000 adults.',\n",
      " 'medRxiv 20219725 [Preprint] 27 October 2020. '\n",
      " 'https://doi.org/10.1101/2020.10.26.20219725.doi:10.1101/2020.10.26.20219725OpenUrlAbstract/FREE '\n",
      " 'Full Text↵J.',\n",
      " 'M. Dan et al., Immunological memory to SARS-CoV-2 assessed for up to eight '\n",
      " 'months after infection.',\n",
      " 'bioRxiv 383323 [Preprint] 18 December 2020. '\n",
      " 'https://doi.org/10.1101/2020.11.15.383323.doi:10.1101/2020.11.15.383323OpenUrlAbstract/FREE '\n",
      " 'Full Text↵D.',\n",
      " 'B. Larremore et al., Estimating SARS-CoV-2 seroprevalence and '\n",
      " 'epidemiological parameters with uncertainty from serological surveys.',\n",
      " 'medRxiv 20067066 [Preprint] 22 June 2020. '\n",
      " 'https://doi.org/10.1101/2020.04.15.20067066.doi:10.1101/2020.04.15.20067066OpenUrlAbstract/FREE '\n",
      " 'Full Text↵ D. Ellenberger,  R. A. Otten,  B. Li,  M. Aidoo,  I. V. '\n",
      " 'Rodriguez,  C. A. Sariol,  M. Martinez,  M. Monsour,  L. Wyatt,  M. G. '\n",
      " 'Hudgens,  E. Kraiselburd,  B. Moss,  H. Robinson,  T. Folks,  S. Butera, \\n'\n",
      " 'HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection '\n",
      " 'during repeated mucosal SHIV challenges.',\n",
      " 'Virology\\n352, \\n216–225 (2006).',\n",
      " 'doi:10.1016/j.virol.2006.04.005pmid:16725169OpenUrlCrossRefPubMedWeb of '\n",
      " 'Science↵ K. E. Langwig,  A. R. Wargo,  D. R. Jones,  J. R. Viss,  B. J. '\n",
      " 'Rutan,  N. A. Egan,  P. Sá-Guimarães,  M. S. Kim,  G. Kurath,  M. G. M. '\n",
      " 'Gomes,  M. Lipsitch, \\n'\n",
      " 'Vaccine effects on heterogeneity in susceptibility and implications for '\n",
      " 'population health management.',\n",
      " 'mBio\\n8, \\ne00796-17 (2017).',\n",
      " 'doi:10.1128/mBio.00796-17pmid:29162706OpenUrlAbstract/FREE Full Text↵P.',\n",
      " 'Span, “Older adults may be left out of some COVID-19 trials,” The New York '\n",
      " 'Times 19 June 2020; '\n",
      " 'https://www.nytimes.com/2020/06/19/health/vaccine-trials-elderly.html.',\n",
      " 'H. R. Sharpe,  C. Gilbride,  E. Allen,  S. Belij-Rammerstorfer,  C. '\n",
      " 'Bissett,  K. Ewer,  T. Lambe, \\n'\n",
      " 'The early landscape of coronavirus disease 2019 vaccine development in the '\n",
      " 'UK and rest of the world.',\n",
      " 'Immunology\\n160, \\n223–232 (2020).',\n",
      " 'doi:10.1111/imm.13222pmid:32460358OpenUrlCrossRefPubMed↵M.',\n",
      " 'Kornfield, “When will children get a coronavirus vaccine?',\n",
      " 'Not in time for the new school year, experts fear,” The Washington Post 2 '\n",
      " 'December 2020; '\n",
      " 'www.washingtonpost.com/health/2020/12/02/kids-vaccine-delay.↵K.',\n",
      " 'Prem et al., Projecting contact matrices in 177 geographical regions: an '\n",
      " 'update and comparison with empirical data for the COVID-19 era.',\n",
      " 'medRxiv 20159772 [Preprint] (2020); '\n",
      " 'https://doi.org/10.1101/2020.07.22.20159772.doi:10.1101/2020.07.22.20159772OpenUrlAbstract/FREE '\n",
      " 'Full Text↵ C. I. Jarvis,  K. Van Zandvoort,  A. Gimma,  K. Prem,  P. '\n",
      " 'Klepac,  G. J. Rubin,  W. J. Edmunds; CMMID COVID-19 working group, \\n'\n",
      " 'Quantifying the impact of physical distance measures on the transmission of '\n",
      " 'COVID-19 in the UK.',\n",
      " 'BMC Med.',\n",
      " '18, \\n124 (2020).',\n",
      " 'doi:10.1186/s12916-020-01597-8pmid:32375776OpenUrlCrossRefPubMed↵J.',\n",
      " 'A.',\n",
      " 'Backer et al., The impact of physical distancing measures against COVID-19 '\n",
      " 'transmission on contacts and mixing patterns in the Netherlands: repeated '\n",
      " 'cross-sectional surveys in 2016/2017, April 2020 and June 2020. medRxiv '\n",
      " '20101501 [Preprint] 16 October 2020. '\n",
      " 'https://doi.org/10.1101/2020.05.18.20101501.doi:10.1101/2020.05.18.20101501OpenUrlAbstract/FREE '\n",
      " 'Full Text↵S.',\n",
      " 'Ghisolfi et al., “Predicted COVID-19 fatality rates based on age, sex, '\n",
      " 'comorbidities, and health system capacity,” working paper (Center for Global '\n",
      " 'Development, 2020).↵ M. Lipsitch,  N. E. Dean, \\n'\n",
      " 'Understanding COVID-19 vaccine efficacy.',\n",
      " 'Science\\n370, \\n763–765 (2020).',\n",
      " 'doi:10.1126/science.abe5938pmid:33087460OpenUrlAbstract/FREE Full Text↵ L. '\n",
      " 'E. Duijzer,  W. L. van Jaarsveld,  J. Wallinga,  R. Dekker, \\n'\n",
      " 'Dose-Optimal Vaccine Allocation over Multiple Populations.',\n",
      " 'Prod.',\n",
      " 'Oper.',\n",
      " 'Manag.',\n",
      " '27, \\n143–159 (2018).',\n",
      " 'doi:10.1111/poms.12788pmid:32327917OpenUrlCrossRefPubMed↵ T. Takahashi,  M. '\n",
      " 'K. Ellingson,  P. Wong,  B. Israelow,  C. Lucas,  J. Klein,  J. Silva,  T. '\n",
      " 'Mao,  J. E. Oh,  M. Tokuyama,  P. Lu,  A. Venkataraman,  A.',\n",
      " 'Park,  F. Liu,  A. Meir,  J.',\n",
      " 'Sun,  E. Y. Wang,  A. Casanovas-Massana,  A. L. Wyllie,  C. B. F. Vogels,  '\n",
      " 'R. Earnest,  S. Lapidus,  I. M. Ott,  A. J. Moore,  A. Shaw,  J.',\n",
      " 'B. Fournier,  C. D. Odio,  S. Farhadian,  C. Dela Cruz,  N. D. Grubaugh,  W. '\n",
      " 'L. Schulz,  A. M. Ring,  A. I. Ko,  S. B. Omer,  A. Iwasaki; Yale IMPACT '\n",
      " 'Research Team, \\n'\n",
      " 'Sex differences in immune responses that underlie COVID-19 disease outcomes.',\n",
      " 'Nature\\n588, \\n315–320 (2020).',\n",
      " 'doi:10.1038/s41586-020-2700-3pmid:32846427OpenUrlCrossRefPubMed↵ D. '\n",
      " 'Chakravarty,  S. S. Nair,  N. Hammouda,  P. Ratnani,  Y. Gharib,  V. '\n",
      " 'Wagaskar,  N. Mohamed,  D. Lundon,  Z. Dovey,  N. Kyprianou,  A. K. '\n",
      " 'Tewari, \\n'\n",
      " 'Sex differences in SARS-CoV-2 infection rates and the potential link to '\n",
      " 'prostate cancer.',\n",
      " 'Commun.',\n",
      " 'Biol.',\n",
      " '3, \\n374 (2020).',\n",
      " 'doi:10.1038/s42003-020-1088-9pmid:32641750OpenUrlCrossRefPubMed↵ M. Webb '\n",
      " 'Hooper,  A. M. Nápoles,  E. J. Pérez-Stable, \\n'\n",
      " 'COVID-19 and racial/ethnic disparities.',\n",
      " 'JAMA\\n323, \\n2466–2467 (2020).',\n",
      " 'doi:10.1001/jama.2020.8598pmid:32391864OpenUrlCrossRefPubMed↵M.',\n",
      " 'Jenco, “CDC vaccine committee may prioritize health care workers for '\n",
      " 'COVID-19 vaccines,”AAP News 27 August 2020; '\n",
      " 'https://www.aappublications.org/news/2020/08/27/covid19vaccinepriorities082620.↵ '\n",
      " 'J. Cohen, \\n'\n",
      " 'The line starts to form for a coronavirus vaccine.',\n",
      " 'Science\\n369, \\n15–16 (2020).',\n",
      " 'doi:10.1126/science.369.6499.15pmid:32631874OpenUrlAbstract/FREE Full Text↵ '\n",
      " 'S. Mishra,  J. C. Kwong,  A. K. Chan,  S. D. Baral, \\n'\n",
      " 'Understanding heterogeneity to inform the public health response to COVID-19 '\n",
      " 'in Canada.',\n",
      " 'CMAJ\\n192, \\nE684–E685 (2020).',\n",
      " 'doi:10.1503/cmaj.201112pmid:32493741OpenUrlFREE Full Text L. Hawks,  S. '\n",
      " 'Woolhandler,  D. McCormick, \\n'\n",
      " 'COVID-19 in Prisons and Jails in the United States.',\n",
      " 'JAMA Intern.',\n",
      " 'Med.',\n",
      " '180, \\n1041–1042 (2020).',\n",
      " 'doi:10.1001/jamainternmed.2020.1856pmid:32343355OpenUrlCrossRefPubMed H. S. '\n",
      " 'Badr et al., Lancet Infect.',\n",
      " 'Dis.',\n",
      " '10.1016/S1473-3099(20)30861-6 (2020).↵J.',\n",
      " 'Ducharme, “These maps show how drastically COVID-19 risk varies by '\n",
      " 'neighborhood,” Time 22 July 2020; '\n",
      " 'https://time.com/5870041/COVID-19-neighborhood-risk.↵United Nations '\n",
      " 'Department of Economic and Social Affairs Population Division, World '\n",
      " 'population prospects (2019); https://population.un.org/wpp.↵ C. H. '\n",
      " 'GeurtsvanKessel,  N. M. A. Okba,  Z. Igloi,  S. Bogers,  C. W. E. Embregts,  '\n",
      " 'B. M. Laksono,  L. Leijten,  C. Rokx,  B. Rijnders,  J. Rahamat-Langendoen,  '\n",
      " 'J. P. C. van den Akker,  J. J.',\n",
      " 'A. van Kampen,  A.',\n",
      " 'A. van der Eijk,  R. S. van Binnendijk,  B. Haagmans,  M. Koopmans, \\n'\n",
      " 'An evaluation of COVID-19 serological assays informs future diagnostics and '\n",
      " 'exposure assessment.',\n",
      " 'Nat.',\n",
      " 'Commun.',\n",
      " '11, \\n3436 (2020).',\n",
      " 'doi:10.1038/s41467-020-17317-ypmid:32632160OpenUrlCrossRefPubMed↵R Core '\n",
      " 'Team, R: A Language and Environment for Statistical Computing (R Foundation '\n",
      " 'for Statistical Computing, 2019).K.',\n",
      " 'E. Atkinson, An Introduction to Numerical Analysis (Wiley, 1989), chap.',\n",
      " '2, pp.',\n",
      " '56–58, second edn.↵Global Health Observatory, Life tables by country (2016); '\n",
      " 'https://apps.who.int/gho/data/view.main.LT62160?lang=en.Acknowledgments: The '\n",
      " 'authors thank S. Herzog, M. Jit, J. Wallinga, and H. Johnson for their '\n",
      " 'feedback.',\n",
      " 'Funding: K.M.B.',\n",
      " 'was supported in part by the Interdisciplinary Quantitative Biology (IQ '\n",
      " 'Biology) Ph.D. program at the BioFrontiers Institute, University of Colorado '\n",
      " 'Boulder.',\n",
      " 'K.M.B.',\n",
      " 'and D.B.L.',\n",
      " 'were supported in part through the MIDAS Coordination Center (MIDASNI2020-2) '\n",
      " 'by a grant from the National Institute of General Medical Science '\n",
      " '(3U24GM132013-02S2).',\n",
      " 'M.L., S.M.K., and Y.H.G.',\n",
      " 'were supported in part by the Morris-Singer Fund for the Center for '\n",
      " 'Communicable Disease Dynamics at the Harvard T. H. Chan School of Public '\n",
      " 'Health.',\n",
      " 'M.L.',\n",
      " 'and D.B.L.',\n",
      " 'were supported in part by the SeroNet program of the National Cancer '\n",
      " 'Institute (1U01CA261277-01).',\n",
      " 'Author contributions: K.M.B., S.M.K., M.L., S.C., Y.H.G., and D.B.L.',\n",
      " 'conceived of the study.',\n",
      " 'K.M.B.',\n",
      " 'and D.B.L.',\n",
      " 'performed the analyses.',\n",
      " 'K.M.B.',\n",
      " 'and K.R.',\n",
      " 'generated all figures.',\n",
      " 'K.R.',\n",
      " 'created interactive visualization tools.',\n",
      " 'All authors wrote and revised the manuscript.',\n",
      " 'Competing interests: M.L.',\n",
      " 'discloses honoraria from and consulting for Merck, Affinivax, '\n",
      " 'Sanofi-Pasteur, Bristol Myers Squibb, and Antigen Discovery; research '\n",
      " 'funding (institutional) from Pfizer; and unpaid scientific advice to '\n",
      " 'Janssen, Astra-Zeneca, and Covaxx (United Biomedical); M.L.',\n",
      " 'is an honorary faculty member, Wellcome Sanger Institute, and an associate '\n",
      " 'member, Broad Institute.',\n",
      " 'Y.H.G.',\n",
      " 'discloses consulting for Merck and GlaxoSmithKline, and research funding '\n",
      " 'from Pfizer not related to this project or topic.',\n",
      " 'D.B.L.',\n",
      " 'is a member of the scientific advisory board of Darwin BioSciences.',\n",
      " 'Data and materials availability: Reproduction code is open source and '\n",
      " 'provided by the authors (21).',\n",
      " 'This work is licensed under a Creative Commons Attribution 4.0 International '\n",
      " '(CC BY 4.0) license, which permits unrestricted use, distribution, and '\n",
      " 'reproduction in any medium, provided the original work is properly cited.',\n",
      " 'To view a copy of this license, visit '\n",
      " 'https://creativecommons.org/licenses/by/4.0/.',\n",
      " 'This license does not apply to figures/photos/artwork or other content '\n",
      " 'included in the article that is credited to a third party; obtain '\n",
      " 'authorization from the rights holder before using such material.',\n",
      " 'Science\\n'\n",
      " 'Vol 371, Issue 653226 February 2021 \\n'\n",
      " 'Table of Contents \\n'\n",
      " 'Print Table of Contents \\n'\n",
      " 'Advertising (PDF)\\n'\n",
      " 'Classified (PDF)\\n'\n",
      " 'Masthead (PDF)\\n'\n",
      " ' \\n'\n",
      " ' \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '          Article Tools        \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " ' Email\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Thank you for your interest in spreading the word about Science.NOTE: We '\n",
      " 'only request your email address so that the person you are recommending the '\n",
      " 'page to knows that you wanted them to see it, and that it is not junk mail.',\n",
      " 'We do not capture any email address.',\n",
      " 'Your Email\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Your Name\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Send To\\n'\n",
      " '\\n'\n",
      " 'Enter multiple addresses on separate lines or separate them with commas.',\n",
      " 'You are going to email the following\\n'\n",
      " 'Model-informed COVID-19 vaccine prioritization strategies by age and '\n",
      " 'serostatus\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Message Subject\\n'\n",
      " ' (Your Name) has forwarded a page to you from Science\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Message Body\\n'\n",
      " ' (Your Name) thought you would like to see this page from the Science web '\n",
      " 'site.',\n",
      " 'Your Personal Message\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'CAPTCHAThis question is for testing whether or not you are a human visitor '\n",
      " 'and to prevent automated spam submissions.',\n",
      " 'Send Message \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " ' \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " ' Download Powerpoint \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " ' Print \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " ' \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " ' Alerts \\n'\n",
      " '\\n'\n",
      " 'Please log in to add an alert for this article.',\n",
      " 'Log In with your AAAS ID\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Sign In to Email Alerts with your Email Address\\n'\n",
      " 'Email\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Log in\\n'\n",
      " '\\n'\n",
      " ' \\n'\n",
      " '\\n'\n",
      " ' \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " ' Citation tools \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Model-informed COVID-19 vaccine prioritization strategies by age and '\n",
      " 'serostatus\\n'\n",
      " 'By Kate M. Bubar, Kyle Reinholt, Stephen M. Kissler, Marc Lipsitch, Sarah '\n",
      " 'Cobey, Yonatan H. Grad, Daniel B. Larremore\\n'\n",
      " 'Science26 Feb 2021 : 916-921 \\n'\n",
      " '\\n'\n",
      " 'To minimize mortality, vaccinate seronegative persons most at risk of death: '\n",
      " 'those with comorbidities and those 60+ years of age.',\n",
      " 'Supplementary Materials\\n'\n",
      " ' \\n'\n",
      " ' \\n'\n",
      " '\\n'\n",
      " 'Citation Manager Formats\\n'\n",
      " '\\n'\n",
      " 'BibTeX\\n'\n",
      " 'Bookends\\n'\n",
      " 'EasyBib\\n'\n",
      " 'EndNote (tagged)\\n'\n",
      " 'EndNote 8 (xml)\\n'\n",
      " 'Medlars\\n'\n",
      " 'Mendeley\\n'\n",
      " 'Papers\\n'\n",
      " 'RefWorks Tagged\\n'\n",
      " 'Ref Manager\\n'\n",
      " 'RIS\\n'\n",
      " 'Zotero\\n'\n",
      " ' \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " ' \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " ' Share \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Model-informed COVID-19 vaccine prioritization strategies by age and '\n",
      " 'serostatus\\n'\n",
      " 'By Kate M. Bubar, Kyle Reinholt, Stephen M. Kissler, Marc Lipsitch, Sarah '\n",
      " 'Cobey, Yonatan H. Grad, Daniel B. Larremore\\n'\n",
      " 'Science26 Feb 2021 : 916-921 \\n'\n",
      " '\\n'\n",
      " 'To minimize mortality, vaccinate seronegative persons most at risk of death: '\n",
      " 'those with comorbidities and those 60+ years of age.',\n",
      " 'Supplementary Materials\\n'\n",
      " ' \\n'\n",
      " ' \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Share This Article:\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Copy\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '         \\n'\n",
      " '\\n'\n",
      " ' \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '          My saved folders        \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " ' Save to my folders\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Log In with your AAAS ID\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " ' \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Stay Connected to Science\\n'\n",
      " '\\n'\n",
      " 'Facebook\\n'\n",
      " 'Twitter\\n'\n",
      " ' \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '          Related Content        \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '          Similar Articles in:        \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '          Citing Articles in:        \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '          Navigate This Article        \\n'\n",
      " 'ArticleVaccine prioritizationAbstractEvaluation of vaccine prioritization '\n",
      " 'strategiesImpact of transmission rates, age demographics, and contact '\n",
      " 'structureVaccines with imperfect transmission-blocking effectsVariation in '\n",
      " 'vaccine efficacy by ageIncorporation of population seroprevalence and '\n",
      " 'individual serological testingDiscussionSupplementary MaterialsReferences '\n",
      " 'and NotesFigures & DataInfo & MetricseLetters PDF\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " ' \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Read the Latest Issue of Science\\n'\n",
      " '\\n'\n",
      " '5 March 2021\\n'\n",
      " 'Vol 371, Issue 6533\\n'\n",
      " 'Table of Contents\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Feature\\n'\n",
      " 'Nuclear medicine\\n'\n",
      " 'Research Ethics\\n'\n",
      " 'Human embryo research beyond the primitive streak\\n'\n",
      " 'Film\\n'\n",
      " 'Science at Sundance 2021\\n'\n",
      " 'SCI COMMUN\\n'\n",
      " 'News at a glance\\n'\n",
      " 'Hydrology\\n'\n",
      " 'Deforestation, forestation, and water supply\\n'\n",
      " 'Working Life\\n'\n",
      " 'Leadership challenges defused\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '  \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'About UsJournals\\n'\n",
      " 'News from Science\\n'\n",
      " 'Leadership\\n'\n",
      " 'Team Members\\n'\n",
      " 'Work at AAAS\\n'\n",
      " '\\n'\n",
      " 'For AdvertisersAdvertising Kits\\n'\n",
      " 'Awards and Prizes\\n'\n",
      " 'Custom Publishing\\n'\n",
      " 'Webinars\\n'\n",
      " '\\n'\n",
      " 'For AuthorsSubmit\\n'\n",
      " 'Information for Authors\\n'\n",
      " 'Editorial Policies\\n'\n",
      " '\\n'\n",
      " 'For LibrariansManage Your Institutional Subscription\\n'\n",
      " 'Information for Librarians\\n'\n",
      " 'Request a Quote\\n'\n",
      " 'FAQs\\n'\n",
      " '\\n'\n",
      " 'Related SitesAAAS.org\\n'\n",
      " 'EurekAlert!',\n",
      " 'Science in the Classroom\\n'\n",
      " 'Science Magazine Japanese\\n'\n",
      " '\\n'\n",
      " 'HelpAccess and Subscriptions\\n'\n",
      " 'Order a Single Issue\\n'\n",
      " 'Reprints and Permissions\\n'\n",
      " 'Contact Us\\n'\n",
      " 'Accessibility\\n'\n",
      " '\\n'\n",
      " 'Stay Connected Facebook\\n'\n",
      " ' Twitter\\n'\n",
      " ' Instagram\\n'\n",
      " ' YouTube\\n'\n",
      " ' RSS Feeds\\n'\n",
      " ' WeChat\\n'\n",
      " '\\n'\n",
      " ' \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " ' \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '© 2021 American Association for the Advancement of Science.',\n",
      " 'All rights reserved.',\n",
      " 'AAAS is a partner of\\xa0HINARI,\\xa0AGORA, OARE, CHORUS,\\xa0CLOCKSS,\\xa0'\n",
      " 'CrossRef\\xa0and\\xa0COUNTER.',\n",
      " 'Science ISSN 1095-9203.',\n",
      " 'Terms of Service\\nPrivacy Policy\\nContact AAAS\\n\\n\\n \\n\\n\\n<!--//--><!',\n",
      " '[CDATA[//><!--\\n'\n",
      " \"var _prum=[['id', '568d96eaabe53dc70c276890'], ['mark', 'firstbyte',\\n\"\n",
      " '      (new Date()).getTime()]]; (function() {\\n'\n",
      " \"      var s=document.getElementsByTagName('script')[0],\\n\"\n",
      " \"      p=document.createElement('script');\\n\"\n",
      " \"      p.async='async'; \"\n",
      " \"p.src='//rum-static.pingdom.net/prum.min.js';s.parentNode.insertBefore(p,s);})();\\n\"\n",
      " '//--><!',\n",
      " ']]>\\n\\n\\n\\n<!--//--><!',\n",
      " '[CDATA[//><!--\\ndocument.createElement( \"picture\" );\\n//--><!',\n",
      " ']]>\\n\\n\\n\\n\\n\\n\\n\\n<!--//--><!',\n",
      " '[CDATA[//><!--\\n'\n",
      " 'if(typeof window.MathJax === \"undefined\") window.MathJax = { menuSettings: { '\n",
      " 'zoom: \"Click\" } };\\n'\n",
      " '//--><!',\n",
      " ']]>\\n\\n\\n\\n\\n\\n<!--//--><!',\n",
      " '[CDATA[//><!--\\n'\n",
      " '(function(i,s,o,g,r,a,m){i[\"GoogleAnalyticsObject\"]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new '\n",
      " 'Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\"script\",\"//www.google-analytics.com/analytics.js\",\"ga\");ga(\"create\", '\n",
      " '\"UA-189672-10\", {\"cookieDomain\":\"auto\"});ga(\"set\", \"anonymizeIp\", '\n",
      " 'true);ga(\"send\", \"pageview\");\\n'\n",
      " '//--><!',\n",
      " ']]>\\n\\n\\n\\n<!--//--><!',\n",
      " '[CDATA[//><!--\\n'\n",
      " 'var oas_tag = {};\\n'\n",
      " \"oas_tag.query = 'subject=EPIDEMIOLOGY';\\n\"\n",
      " '//--><!',\n",
      " ']]>\\n\\n\\n\\n\\n\\n\\n\\n<!--//--><!',\n",
      " '[CDATA[//><!--\\n'\n",
      " 'jQuery.extend(Drupal.settings,{\"basePath\":\"\\\\/\",\"pathPrefix\":\"\",\"ajaxPageState\":{\"theme\":\"science_jcore\",\"theme_token\":\"lA-TUN_YlTsOCecVIvIxw8x512x8EAH1jbUWrDUV9M8\",\"css\":{\"modules\\\\/system\\\\/system.base.css\":1,\"modules\\\\/system\\\\/system.menus.css\":1,\"modules\\\\/system\\\\/system.messages.css\":1,\"modules\\\\/system\\\\/system.theme.css\":1,\"misc\\\\/ui\\\\/jquery.ui.core.css\":1,\"misc\\\\/ui\\\\/jquery.ui.theme.css\":1,\"misc\\\\/ui\\\\/jquery.ui.button.css\":1,\"misc\\\\/ui\\\\/jquery.ui.resizable.css\":1,\"misc\\\\/ui\\\\/jquery.ui.dialog.css\":1,\"misc\\\\/ui\\\\/jquery.ui.tooltip.css\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/date\\\\/date_api\\\\/date.css\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/date\\\\/date_popup\\\\/themes\\\\/datepicker.1.7.css\":1,\"modules\\\\/field\\\\/theme\\\\/field.css\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/highwire_draw\\\\/css\\\\/highwire-draw.css\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/highwire_folders\\\\/highwire_folders.css\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/highwire_responsive\\\\/css\\\\/highwire-responsive.css\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/highwire_saved_searches\\\\/highwire_saved_searches.css\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/highwire_user\\\\/highwire_user.css\":1,\"sites\\\\/all\\\\/modules\\\\/shared\\\\/jnl_sci_styles\\\\/css\\\\/jnl_sci_styles.css\":1,\"modules\\\\/node\\\\/node.css\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/picture\\\\/picture_wysiwyg.css\":1,\"modules\\\\/search\\\\/search.css\":1,\"modules\\\\/user\\\\/user.css\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/views\\\\/css\\\\/views.css\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/ckeditor\\\\/css\\\\/ckeditor.css\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/colorbox\\\\/styles\\\\/default\\\\/colorbox_style.css\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/ctools\\\\/css\\\\/ctools.css\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/highwire.style.highwire.css\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/css\\\\/nlm-elements.css\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/panels\\\\/css\\\\/panels.css\":1,\"public:\\\\/\\\\/ctools\\\\/css\\\\/263bfdb18936424f0ade19d6bd885f37.css\":1,\"\\\\/\\\\/cdn.jsdelivr.net\\\\/qtip2\\\\/2.2.1\\\\/jquery.qtip.min.css\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/panels_ajax_tab\\\\/css\\\\/panels_ajax_tab.css\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/highwire.style.markup.css\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/panels\\\\/plugins\\\\/layouts\\\\/onecol\\\\/onecol.css\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/forward\\\\/forward.css\":1,\"0\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/plugins\\\\/content_types\\\\/css\\\\/highwire_share_link.css\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/plugins\\\\/content_types\\\\/css\\\\/highwire_copy_permalink.css\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/panels\\\\/plugins\\\\/layouts\\\\/flexible\\\\/flexible.css\":1,\"1\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/ctools\\\\/css\\\\/collapsible-div.css\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/css\\\\/highwire.gtranslate.css\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/highwire_theme_tools\\\\/css\\\\/font-hwicons.css\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/highwire_theme_tools\\\\/css\\\\/font-hwicons-glyphs.css\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/plugins\\\\/content_types\\\\/css\\\\/highwire_corrections.css\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/library\\\\/css\\\\/critical-jcore.css\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/library\\\\/css\\\\/drupal-specific.css\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/css\\\\/global.css\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/css\\\\/temp.css\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/system.theme.css\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/system.base.css\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/system.menus.css\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/system.messages.css\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/field.css\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/date.css\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/datepicker.1.7.css\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/search_api_page.css\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/jquery.ui.theme.min.css\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/highwire_lens.css\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/highwire_issue_archive.css\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/highwire-article-citation-list.css\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/highwire_search.css\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/highwire_search_results_tool.css\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/highwire_user.css\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/highwire_folders.css\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/css\\\\/highwire-forms.css\":1},\"js\":{\"sites\\\\/all\\\\/libraries\\\\/enquire.js\\\\/enquire.min.js\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/picture\\\\/picturefill2\\\\/picturefill.min.js\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/picture\\\\/picture.min.js\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/plugins\\\\/content_types\\\\/js\\\\/highwire_panels_ajax_tab.js\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/plugins\\\\/highwire_markup_process\\\\/js\\\\/highwire_openurl.js\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/plugins\\\\/highwire_markup_process\\\\/js\\\\/highwire_google_scholar_sprinkle.js\":1,\"sites\\\\/all\\\\/libraries\\\\/lazysizes\\\\/lazysizes.min.js\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/plugins\\\\/highwire_markup_process\\\\/js\\\\/highwire_figures.js\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/plugins\\\\/content_types\\\\/js\\\\/highwire_article_trendmd.js\":1,\"sites\\\\/all\\\\/modules\\\\/shared\\\\/jnl_sci_styles\\\\/js\\\\/jnl_sci_cookie_domain.js\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/jquery_update\\\\/replace\\\\/jquery\\\\/1.8\\\\/jquery.min.js\":1,\"misc\\\\/jquery-extend-3.4.0.js\":1,\"misc\\\\/jquery.once.js\":1,\"misc\\\\/drupal.js\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/jquery_update\\\\/replace\\\\/ui\\\\/ui\\\\/minified\\\\/jquery.ui.core.min.js\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/jquery_update\\\\/replace\\\\/ui\\\\/ui\\\\/minified\\\\/jquery.ui.widget.min.js\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/jquery_update\\\\/replace\\\\/ui\\\\/ui\\\\/minified\\\\/jquery.ui.button.min.js\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/jquery_update\\\\/replace\\\\/ui\\\\/ui\\\\/minified\\\\/jquery.ui.mouse.min.js\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/jquery_update\\\\/replace\\\\/ui\\\\/ui\\\\/minified\\\\/jquery.ui.draggable.min.js\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/jquery_update\\\\/replace\\\\/ui\\\\/ui\\\\/minified\\\\/jquery.ui.position.min.js\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/jquery_update\\\\/replace\\\\/ui\\\\/ui\\\\/minified\\\\/jquery.ui.resizable.min.js\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/jquery_update\\\\/replace\\\\/ui\\\\/ui\\\\/minified\\\\/jquery.ui.dialog.min.js\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/jquery_update\\\\/replace\\\\/ui\\\\/ui\\\\/minified\\\\/jquery.ui.tooltip.min.js\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/js\\\\/highwire.equal-heights.js\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/js\\\\/highwire.panels-ajax-tab.js\":1,\"sites\\\\/all\\\\/modules\\\\/shared\\\\/jnl_sci_styles\\\\/js\\\\/jnl_sci_script.js\":1,\"sites\\\\/all\\\\/libraries\\\\/colorbox\\\\/jquery.colorbox-min.js\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/colorbox\\\\/js\\\\/colorbox.js\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/colorbox\\\\/styles\\\\/default\\\\/colorbox_style.js\":1,\"https:\\\\/\\\\/scholar.google.com\\\\/scholar_js\\\\/casa.js\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/highwire_log\\\\/highwire_log.js\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/highwire_user\\\\/js\\\\/highwire_user_meta.js\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/panels\\\\/js\\\\/panels.js\":1,\"\\\\/\\\\/cdn.jsdelivr.net\\\\/qtip2\\\\/2.2.1\\\\/jquery.qtip.min.js\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/js\\\\/highwire.article-citation-author-tooltip.js\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/panels_ajax_tab\\\\/js\\\\/panels_ajax_tab.js\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/plugins\\\\/highwire_markup_process\\\\/js\\\\/highwire_article_reference_popup.js\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/plugins\\\\/highwire_markup_process\\\\/js\\\\/highwire_article_glossary_popup.js\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/plugins\\\\/highwire_markup_process\\\\/js\\\\/highwire_at_symbol.js\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/library\\\\/js\\\\/swfobject.js\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/captcha\\\\/captcha.js\":1,\"misc\\\\/textarea.js\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/recaptcha\\\\/js\\\\/recaptcha.js\":1,\"https:\\\\/\\\\/www.google.com\\\\/recaptcha\\\\/api.js?hl=en\\\\u0026render=explicit\\\\u0026onload=drupalRecaptchaOnload\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/panels_ajax_pane\\\\/panels_ajax_pane.js\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/highwire_citation\\\\/plugins\\\\/content_types\\\\/js\\\\/highwire_citation_export.js\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/plugins\\\\/content_types\\\\/js\\\\/highwire_share_dialog.js\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/plugins\\\\/content_types\\\\/js\\\\/clipboard.min.js\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/plugins\\\\/content_types\\\\/js\\\\/highwire_clipboard.js\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/plugins\\\\/content_types\\\\/js\\\\/minipanel_dialog_link.js\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/ctools\\\\/js\\\\/collapsible-div.js\":1,\"sites\\\\/all\\\\/modules\\\\/shared\\\\/jnl_sci_styles\\\\/js\\\\/jnl_sci_social_icons.js\":1,\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/google_analytics\\\\/googleanalytics.js\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/js\\\\/highwire.gtranslate.js\":1,\"sites\\\\/all\\\\/modules\\\\/shared\\\\/jnl_sci_data_layer\\\\/js\\\\/jnl_sci_user_data.js\":1,\"https:\\\\/\\\\/cdnjs.cloudflare.com\\\\/ajax\\\\/libs\\\\/ally.js\\\\/1.4.1\\\\/ally.min.js\":1,\"\\\\/\\\\/cdn.rawgit.com\\\\/ricmoo\\\\/aes-js\\\\/e27b99df\\\\/index.js\":1,\"\\\\/\\\\/assets.sciencemag.org\\\\/js\\\\/global-header-bundle.js\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/plugins\\\\/content_types\\\\/js\\\\/highwire_article_nav.js\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/library\\\\/js\\\\/fontfaceobserver.js\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/library\\\\/js\\\\/jquery.sticky.js\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/library\\\\/js\\\\/jquery.stickyHeader.js\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/library\\\\/js\\\\/jquery.switchPng.js\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/library\\\\/js\\\\/mediaelement-and-player.min.js\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/library\\\\/js\\\\/respondTable.js\":1,\"sites\\\\/all\\\\/themes\\\\/shared\\\\/science_jcore\\\\/js\\\\/script.js\":1,\"sites\\\\/all\\\\/modules\\\\/highwire\\\\/highwire\\\\/highwire_responsive\\\\/js\\\\/highwire-mediaqueries.js\":1}},\"colorbox\":{\"opacity\":\"0.85\",\"current\":\"{current} '\n",
      " 'of {total}\",\"previous\":\"\\\\u00ab Prev\",\"next\":\"Next '\n",
      " '\\\\u00bb\",\"close\":\"Close\",\"maxWidth\":\"98%\",\"maxHeight\":\"98%\",\"fixed\":true,\"mobiledetect\":true,\"mobiledevicewidth\":\"480px\"},\"highwire\":{\"nid\":\"757409\",\"apath\":\"\\\\/sci\\\\/371\\\\/6532\\\\/916.atom\",\"pisa\":\"sci;371\\\\/6532\\\\/916\",\"markup\":[{\"requested\":\"short-text\",\"variant\":\"abstract\",\"view\":\"abstract\",\"pisa\":\"sci;371\\\\/6532\\\\/916\"},{\"requested\":\"long\",\"variant\":\"full-text\",\"view\":\"full\",\"pisa\":\"sci;371\\\\/6532\\\\/916\"},{\"requested\":\"precis-abstract\",\"variant\":\"precis-abstract\",\"view\":\"precis\",\"pisa\":\"sci;371\\\\/6532\\\\/916\"},{\"requested\":\"precis-abstract\",\"variant\":\"precis-abstract\",\"view\":\"precis\",\"pisa\":\"sci;371\\\\/6532\\\\/916\"},{\"requested\":\"full-text\",\"variant\":\"full-text\",\"view\":\"full\",\"pisa\":\"sci;371\\\\/6532\\\\/916\"}],\"ac\":{\"\\\\/sci\\\\/371\\\\/6532\\\\/916.atom\":{\"access\":{\"full\":true,\"abstract\":true,\"editor_summary\":true},\"pisa_id\":\"\",\"apath\":\"\\\\/sci\\\\/371\\\\/6532\\\\/916.atom\",\"jcode\":\"sci\"},\"sci;371\\\\/6532\\\\/916\":{\"access\":{\"full\":true},\"pisa_id\":\"sci;371\\\\/6532\\\\/916\",\"apath\":\"\",\"jcode\":\"sci\"}},\"processed\":[\"highwire_math\"],\"trendmd\":{\"trendmd-suggestions\":\"{\\\\u0022element\\\\u0022:\\\\u0022#trendmd-suggestions\\\\u0022,\\\\u0022track_id\\\\u0022:\\\\u0022null\\\\u0022}\"},\"modal_window_width\":\"560\",\"share_modal_width\":\"560\",\"share_modal_title\":\"Share '\n",
      " 'this '\n",
      " 'Article\",\"AAASdataLayer\":\"{\\\\u0022page\\\\u0022:{\\\\u0022pageInfo\\\\u0022:{\\\\u0022pageTitle\\\\u0022:\\\\u0022Model-informed '\n",
      " 'COVID-19 vaccine prioritization strategies by age and '\n",
      " 'serostatus\\\\u0022,\\\\u0022pageURL\\\\u0022:\\\\u0022science.sciencemag.org\\\\\\\\\\\\/content\\\\\\\\\\\\/371\\\\\\\\\\\\/6532\\\\\\\\\\\\/916\\\\u0022,\\\\u0022pagePath\\\\u0022:\\\\u0022916\\\\u0022,\\\\u0022pageType\\\\u0022:\\\\u0022journal '\n",
      " 'page\\\\u0022,\\\\u0022issueDate\\\\u0022:\\\\u00222021-02-26\\\\u0022,\\\\u0022pubDate\\\\u0022:\\\\u00222021-02-25 '\n",
      " '10:41:01\\\\u0022,\\\\u0022nlmArticleType\\\\u0022:\\\\u0022research-article\\\\u0022,\\\\u0022DOI\\\\u0022:\\\\u002210.1126\\\\\\\\\\\\/science.abe6959\\\\u0022,\\\\u0022author\\\\u0022:\\\\u0022Kate '\n",
      " 'M. Bubar|Kyle Reinholt|Stephen M. Kissler|Marc Lipsitch|Sarah Cobey|Yonatan '\n",
      " 'H. Grad|Daniel B. '\n",
      " 'Larremore\\\\u0022,\\\\u0022firstRelease\\\\u0022:\\\\u0022no\\\\u0022,\\\\u0022issnOnline\\\\u0022:\\\\u00221095-9203\\\\u0022,\\\\u0022issnPrint\\\\u0022:\\\\u00220036-8075\\\\u0022,\\\\u0022volume\\\\u0022:\\\\u0022371\\\\u0022,\\\\u0022issue\\\\u0022:\\\\u00226532\\\\u0022,\\\\u0022articleType\\\\u0022:\\\\u0022Research '\n",
      " 'Article\\\\u0022,\\\\u0022tabView\\\\u0022:\\\\u0022main_tab\\\\u0022,\\\\u0022viewType\\\\u0022:\\\\u0022full\\\\u0022},\\\\u0022attributes\\\\u0022:{\\\\u0022accessType\\\\u0022:\\\\u0022Free\\\\u0022,\\\\u0022openAccess\\\\u0022:\\\\u0022yes\\\\u0022,\\\\u0022freeAccess\\\\u0022:\\\\u0022yes\\\\u0022,\\\\u0022subject\\\\u0022:\\\\u0022\\\\u0022,\\\\u0022fieldCode\\\\u0022:\\\\u0022EPIDEMIOLOGY\\\\u0022,\\\\u0022OAS_subject\\\\u0022:\\\\u0022subject=EPIDEMIOLOGY;\\\\u0022}},\\\\u0022user\\\\u0022:{\\\\u0022memberID\\\\u0022:\\\\u0022\\\\u0022,\\\\u0022institutionID\\\\u0022:\\\\u0022\\\\u0022,\\\\u0022institution\\\\u0022:\\\\u0022\\\\u0022,\\\\u0022accessMethod\\\\u0022:\\\\u0022guest\\\\u0022,\\\\u0022registeredUser\\\\u0022:\\\\u0022no\\\\u0022,\\\\u0022authenticated\\\\u0022:\\\\u0022no\\\\u0022,\\\\u0022access\\\\u0022:\\\\u0022yes\\\\u0022,\\\\u0022entitled\\\\u0022:\\\\u0022no\\\\u0022}}\"},\"jcarousel\":{\"ajaxPath\":\"\\\\/jcarousel\\\\/ajax\\\\/views\"},\"panels_ajax_pane\":{\"new-26\":\"{\\\\u0022encrypted\\\\u0022:\\\\u0022{\\\\\\\\\\\\u0022encrypted\\\\\\\\\\\\u0022:\\\\\\\\\\\\u0022ZfwNSM\\\\\\\\\\\\\\\\\\\\\\\\\\\\/vTtYg6xBh4UcDHkG7MiR3otR+vLBMqR20JXSeusE3xkXhp7mVeahCtoeUhNCxxVfktkBJjIibah3qFm\\\\\\\\\\\\\\\\\\\\\\\\\\\\/WAOwvATy8BtWA5HnY5rJ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/n\\\\\\\\\\\\\\\\\\\\\\\\\\\\/QZfWVcVrx5yq0b8IgFs3zG+v5tSBr\\\\\\\\\\\\\\\\\\\\\\\\\\\\/OMNuWwK1OA5HA5SBwlz2612SAy9fjOmPWhawjB+CiLzlGOdy7Le96FPaUt4BW9DMkMfZXQZvo\\\\\\\\\\\\\\\\\\\\\\\\\\\\/kLmiBOjrOGePrvSVCkbOw3Bgnix7O700qLRBwZTYepBS5dU7anXXoN\\\\\\\\\\\\\\\\\\\\\\\\\\\\/uFys\\\\\\\\\\\\\\\\\\\\\\\\\\\\/MpW8OqqaoG0edFBsTrC\\\\\\\\\\\\\\\\\\\\\\\\\\\\/wZvypR4R+846fE2JP85g1j6yAiKW5n7cPP1es\\\\\\\\\\\\\\\\\\\\\\\\\\\\/WuSl9GSHBqed9fbR0VL5NR6HIdhNz2NPVR4LKVQWgDUyxnUZKX0+9fvouPh5dGzfT\\\\\\\\\\\\\\\\\\\\\\\\\\\\/lDnsxGI+zpCjMdj2uYLaZgZ3q5z9V+KNftsL4eC9n7QkECj4HD1oPjw424jKE1\\\\\\\\\\\\\\\\\\\\\\\\\\\\/cZw2TtImrO2n97EGPe2tN3rIBJkISIzXMWITHgUmVQTDnx3mRpRtcB42dUp8AZHSQvmKrO11\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Gk6pu6VMicDHy3tP29OmmV149CEhPqZZq8FAvsohq5U6ZLQj1iBsVQnQrbVu1yZDDXanQST131kDag4cs0WV\\\\\\\\\\\\\\\\\\\\\\\\\\\\/xUvIqrVKiu+UVq9un+pEi1hRctZZVpLv\\\\\\\\\\\\\\\\\\\\\\\\\\\\/cnYgScpFeFqxkpIqPEP0oj2TMTk3jwnq94d+79cNMlN\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Krm5NRN6YRvOW2iK7uziKwylb+xSF9eHX8xh8n1DL3AK\\\\\\\\\\\\\\\\\\\\\\\\\\\\/1zNarO4IH1iS8UdsAuttbeioiK85u075E1q3za9OFXTqPH79pXk6\\\\\\\\\\\\\\\\\\\\\\\\\\\\/FOzZyyZEGAQGmNz\\\\\\\\\\\\\\\\\\\\\\\\\\\\/\\\\\\\\\\\\\\\\\\\\\\\\\\\\/+SXIvBpX9OOaD17ybYogMBUnl84IKKiQq36KLJxbWF0gvA6v4phigdxKq0VWoJlVBwWcZQn9pcKi4n\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Ltnzj94rfBrGF7B4A7Qe6IjeYrHVxWoyx9ZjSubYWX066sM9hXr9cbUEljmhoYNcv3WALNbeO3gs\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Du+TivdG3ckxX5QJkefFlbAmrLtIHFIMcfAyseIb8KdhXVFt\\\\\\\\\\\\\\\\\\\\\\\\\\\\/R014cygPUzwA2F3D+a6Uiw9EsU7awYyoQabHetuIZKbs2g\\\\\\\\\\\\\\\\\\\\\\\\\\\\/zwd8G+rOeysKfcmwZ4kFxVDi6Q53GulG4EhQmczqL13fv5CYEHeaod7nb0I0WhxqrxZ2hdBUXKdLwN1\\\\\\\\\\\\\\\\\\\\\\\\\\\\/SPF\\\\\\\\\\\\\\\\\\\\\\\\\\\\/WLt\\\\\\\\\\\\\\\\\\\\\\\\\\\\/3\\\\\\\\\\\\\\\\\\\\\\\\\\\\/cgtYXcBfrBys9Dp9xSNRuGzqSodS1nP17hP1ockR21e6dE2f0IapGKt\\\\\\\\\\\\\\\\\\\\\\\\\\\\/2fSGw3s5\\\\\\\\\\\\\\\\\\\\\\\\\\\\/uI3BLjBilINdPejwHJR6K7MoeiRag9JMM8e4GIb1+do8G7iLkduAts\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ZSCXrfejAysMSTM7+ADC33aNRvMg7I025sc3EcZ+QRBabDHOXNQtW0Z6wJpLCQTLbJTt+bWLMBa3YTgIHh9LuYONrYCEiw3Zqlx0edhM5mg8pjF2HspVeYi5bOQ4MVr2QAyK25PazxImtpA9cAWyymjksM7wYV8QLKdTllUzjQoBSWya+HkmcCHG1EZhjnc+gUsC5LlB3\\\\\\\\\\\\\\\\\\\\\\\\\\\\/MI7PgScCGHlrGw8wzLrmyzmrwo+gkZGULNJ1GzWC4neXBmM7EuD0tAnr31Yj+cK8OnDA8K9Y2Fht275Klg3WE3GedzonHbVUZ5jWnbD18d6Kl\\\\\\\\\\\\\\\\\\\\\\\\\\\\/22i1ocgsvm\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ahYzbqUmdQSlu5ovykfaA+HmX\\\\\\\\\\\\\\\\\\\\\\\\\\\\/IFhU\\\\\\\\\\\\\\\\\\\\\\\\\\\\/2JABrcxx8qcuooLfcQF8YQZxos5dD0V51\\\\\\\\\\\\\\\\\\\\\\\\\\\\/dZ3p7KXBsqX\\\\\\\\\\\\\\\\\\\\\\\\\\\\/qvQLpYpkMKNMddFIr4KYbgDm1PAeTME6pd2gksjCxtGJXm5dQdkQBf+9fmZxkfYMWf6UT\\\\\\\\\\\\\\\\\\\\\\\\\\\\/K8tlDQCEHAnYMcWcXlpLBZFnC61B76\\\\\\\\\\\\\\\\\\\\\\\\\\\\/1PBPVct\\\\\\\\\\\\\\\\\\\\\\\\\\\\/isv56ck6fuv9\\\\\\\\\\\\\\\\\\\\\\\\\\\\/wGZmoDiZ+aj0IO6qXRXNEz2LiIy4D0qXGvmUQiUH0iOzxcH0+qCeVVEHqKq8hDt2du53e\\\\\\\\\\\\\\\\\\\\\\\\\\\\/WXc+C8tKtBwoQ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/wmo7+SYfjtoYSLdgmW4kdpLj6N\\\\\\\\\\\\\\\\\\\\\\\\\\\\/4QFCF912iVyi0t5fnEGzRKQUdaizl9orYjiThfoiN9T7q0TXZB5nw1qwoaR0BX+hg4\\\\\\\\\\\\\\\\\\\\\\\\\\\\/+t7Hgwpulh9oMhqiAfpYQmHkLJgXmGMdui6hy8J1o89j+Vl80K+lZ6kbf4Gdb2r\\\\\\\\\\\\\\\\\\\\\\\\\\\\/D08Hnlb9Foyrtn4AwmcJlxqB8OJLR1OqQHsuOjCTa8Q2F4w17B4xuhyd+X1F72Xw7cLcLdtjB1l4yZGW1hGgW4qNGjv8JqAzHVph8htMSqcOkFy79tbpoQW4QG7pDp5sCoSgdCPjbWPAVb6Oxml+P55dvrBTn\\\\\\\\\\\\\\\\\\\\\\\\\\\\/lSW41DpKzLtce1S37sTKzx6L5irgC0Wm\\\\\\\\\\\\\\\\\\\\\\\\\\\\/knBJMpRIQmAJrE34dK7c0FAcBIEtchu\\\\\\\\\\\\\\\\\\\\\\\\\\\\/G2nEXXUzHShedwnBlyXy1gw2MDwA5MNxeRUNKA64lZcSczFHMdhutZj3GLCigyQbZlOcLMTR6\\\\\\\\\\\\\\\\\\\\\\\\\\\\/mkHxQgGaV8jCEwhZgSGMTpPT6ziCOSH0yKIqGPDwc4dDQTlSc27QGzZXqoOSLWdVhYq+kg8mebERAGvkLJ4HIi1fSmwQl5J8foOa+446tETK296LSZ7qha6kxrj4L2g9l+YdZaawKeqIF2gbz8mDiBs0c1yZzX2zetoJvChK1npBp3oTj8xWQijQdjzjyExAa4wYI2Pk178zox\\\\\\\\\\\\\\\\\\\\\\\\\\\\/+pU6nxcog1ilP3EyVsj7SJ0TTe\\\\\\\\\\\\\\\\\\\\\\\\\\\\/8GfW9J+mYktL0dsPgn0nncJPBO1AHKbM+fMimWxqw4R+9ckQcc+yw3nmN2PTMc1soYf8ydYNwU6y6HeENTqpMigxm8jG6q+zpWFSZAhchDg4GhV+TVdSBjVAWO\\\\\\\\\\\\\\\\\\\\\\\\\\\\/N4AcMNaW7r4vk3S0jpG1llilgE3EkkFvvsVuST9rB6daQXioydF9YqQij4mamhOw1pkhJjxO0jGvOR8FGLxX+6NCpozuwhqy4sMY51Tgjai80GR1mpvKnCnPXWrCuTNo9lLbDKAo0Ns7SHivNJ0H76miSMgnDeoEjT37IX8exzE8nyY5DsxZaYnJuIWHjQVwIu0eheer3LPGe0oV2NkU85oAzvvvrDSWRrvOM\\\\\\\\\\\\\\\\\\\\\\\\\\\\/0pkFuTMKv3AhNDW+JdpP3rAcnKJfc0dO9BkkpBKOq89LyM2lOUzG2AQ4Rj4KVayCL\\\\\\\\\\\\\\\\\\\\\\\\\\\\/GOqsE+vOcSaqwu93ln6kHgb9FLCWp9Wml+r1FW+qRg456Kewed2686EKUJVhjPVrMhGsQgn63qrlyyy6uhvxVG6HCbDRREbODhQcx9bFwMpGfpw7L8X\\\\\\\\\\\\\\\\\\\\\\\\\\\\/blRuzd5zCsp6KQCC\\\\\\\\\\\\\\\\\\\\\\\\\\\\/zTIj90CExowaTHLStEQEw7m0m7KG69w8+hKvgq85rHNhVE3G1A8F0EdtVFQsUv3rQ9TFJNgOGq3bt9j4J8nh5\\\\\\\\\\\\\\\\\\\\\\\\\\\\/HEiER5BfDOVTbP9gr2m\\\\\\\\\\\\\\\\\\\\\\\\\\\\/lVs9X99s6pBLgs0sYdm4\\\\\\\\\\\\\\\\\\\\\\\\\\\\/PL5JYcpT9XiWkP3usy1NDux+ifwl2qsgFsg1re+sg5CObhC8X9c3TAGBdVggGzf2S9oivmGDF4FH6M7ZT2W6HLKtSl3B83IMncgQn\\\\\\\\\\\\\\\\\\\\\\\\\\\\/razeTtp1lGevRMnfdmZ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/LU4uunkni7U\\\\\\\\\\\\\\\\\\\\\\\\\\\\/wzeIirop14Xpjm94315WpREK+82\\\\\\\\\\\\\\\\\\\\\\\\\\\\/tSoDC6G\\\\\\\\\\\\\\\\\\\\\\\\\\\\/COuZah23Q\\\\\\\\\\\\\\\\\\\\\\\\\\\\/yF4BXRrCPhy7CzLhBXh4HyXT4oZspyabAnjHwYfBqbO35ccp3rBTyLGkn7p8zgv3Fhi7\\\\\\\\\\\\\\\\\\\\\\\\\\\\/4tYHo14kMv5TT7u7XMTr7QGZE2awBTgzgVLJlNieBTWkKkn6TINc8OZyK\\\\\\\\\\\\\\\\\\\\\\\\\\\\/N03CY1iRQWs4Boy\\\\\\\\\\\\\\\\\\\\\\\\\\\\/FMHEaFFcGogD0YTReZQftoL\\\\\\\\\\\\\\\\\\\\\\\\\\\\/TQYJKkQjbjZVAeTd5HU8gyO2FkLY5bh310ZW9jjB18GvkzGx52Pu6ejyqk9qicvqoDtiUy7q9FI8H0AeFR0QNDuInLiipjXqJTiGn6M0DZks8DjLTzQic1K7WfYpvUTD2Ptyjpq+w2wKlYxR3C+dm5qhxkx3qW7Ggj+kEi3K9N9MgsUO9p4hWD\\\\\\\\\\\\\\\\\\\\\\\\\\\\/eX5m+LimuLmy8VvKddAl21VuqSpeA0qkvo2xD+yMIrbkPyu25h2q7SmSvFo+3HCNg5zwMVAOIt5yV\\\\\\\\\\\\\\\\\\\\\\\\\\\\/IhUZZciVanNb2pm5R4J1+3Q\\\\\\\\\\\\\\\\\\\\\\\\\\\\/kpaB5ONykP8wanl5BKHtel88+1utdZaETrOFhXyxb7vYpMmBty\\\\\\\\\\\\\\\\\\\\\\\\\\\\/CciAYLzcH\\\\\\\\\\\\\\\\\\\\\\\\\\\\/kcI07ceTMNQKRC477rD31bEkWr9EC7FOXJ4m3WyfgBNJd63apsCxZJAhsilYbvXht8rq2DNiwsD30y1kx5r7Y\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Ps74UW3xuM\\\\\\\\\\\\\\\\\\\\\\\\\\\\/b0PiVLEIaeqKY8CVyahNuBQiV8WNVv5gfIYh4xZlDC7oXbeIvPN2P1FGw1HecyNrpWI6nbqDr3oEzGaDNfHLBhmN84ia2icBuQQ0PoVsCnaLEBj6nxmpBHq\\\\\\\\\\\\\\\\\\\\\\\\\\\\/d3PzT\\\\\\\\\\\\\\\\\\\\\\\\\\\\/TDdD5d\\\\\\\\\\\\\\\\\\\\\\\\\\\\/I+EVkOPxcGaQMUIxZtopjhbfXELjU5ZgFmuED8ZLj33QyzT5wTcUpIqGXCkn002FSh+lfcnknn1ZR7LAoiR4TAqnUmK48jU7jYn9p8HF79vTROt+p8g8IvPkdsTi5znWR32jBMf2MR\\\\\\\\\\\\\\\\\\\\\\\\\\\\/jodpZn3qchtXB7LDAS2uQoEi6QPH38AfFgI7dlNWmSfUWTiVw7lU18oJlBlrpOazDn\\\\\\\\\\\\\\\\\\\\\\\\\\\\/LvYLXT17GLGNTnIC28xYSlevLovXTowvCZl0Yj3LQIzcvJdTN2eWQbzdVM+YvPArgej6cButkV2a7ivL91qD9wzX65bxTXWvgEi6DhzHYJFpRM17kp7SueiiB7OPPqzEBV+7WRA5lHyOq1ZWtncYqcy\\\\\\\\\\\\\\\\\\\\\\\\\\\\/T1v0hviqGJsbLEecCY9yPjI37qSSw4yleT84h4Cwm\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ZIPzMRn5iVy3hmliSIBOFELcSibWQqpiBvRO5cTQm0MpW504OSl+FyjlDOg4BKasEja5NxbBhh195q\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ZbDydTlzs9cQQYX3Qrhm1iTmEJNnxcWYR7Z2YoSvz7NkPgB2GfMtz\\\\\\\\\\\\\\\\\\\\\\\\\\\\/0i2x1xKMvaUCVCNeNBxBM+FRg4WpLCxAq3lD49KYBSStQZUQvmDd9T+N8qTwMWmIVdDjvY+nlMToprvQ3x3eNX2Drps7kxCtnXSG0VtvjL00lvrkEOAoS6HloT+FYw+0DgbLVQEjo1fP5be5Vr6nGgsbXITiKlZlvFmte5WHPBpro35CwY+Hn\\\\\\\\\\\\\\\\\\\\\\\\\\\\/OT8\\\\\\\\\\\\\\\\\\\\\\\\\\\\/q9cLco6D0aTc3CLsedoGYrPdOeCk+LPKa2WnfkD3pWEc65mj73EN\\\\\\\\\\\\\\\\\\\\\\\\\\\\/GU+tDeImsbuCmF2lZVJIdz+a5CsunPff42PNWt9GedEKfn5DhXtcYiubgVuUjwWEtGdAiT1nCWuBjAtQDTmILztvYWf86XFOwWPUrbnj8RfQLn\\\\\\\\\\\\\\\\\\\\\\\\\\\\/SUZnlW+1LnAnF\\\\\\\\\\\\\\\\\\\\\\\\\\\\/SuNDv35q5W4Vj1agSBVVCvMuVO1j36ShZY5oVBbBfi1LzYZWBDr\\\\\\\\\\\\\\\\\\\\\\\\\\\\/CfZ2CCrjszOLVdAKAqFbHilwOetHq3QjM7Bh4j4KhFr6aZlyxWlGgU8V6j8KNlAzhcWWaaB6Bp409gp6JY7h5++X4Lx15VSw6KJ8nSB4SV4XSaHgwqBjvVzYtdQwGWvc9Zjx7w\\\\\\\\\\\\\\\\\\\\\\\\\\\\/4TUdKHDsSz0hN1+7S1Zt6UwK8IWoEUzMRqor4izaKvZKTGspJ9F3dcGdz7CMRTcKq8AHLlnOyl9SHfAFyXOaO1XbMAw0L1tx\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ja5WPbdJzrqHhcpnt32EAChBR9s5y8K8YXF5mi89w+z1yldNG8OuGh2Ap0C1GhzhK9O6rTG+xbbaDB+3iN0LYMVlpuOMPmQ1aJY98gizkc9Bzum8HFn6C4HIWJuzwXem7nt0AR5GRMqMm1EKOcJFss09Bpl302Ghmbh95Dct5xpp6XHZhw0R4oAIJoqEZiXJkqr\\\\\\\\\\\\\\\\\\\\\\\\\\\\/D1iFRKdgNdafMPHFrapyUVTKiQ4hMPTnToo8tv8wO5dytmdny7+G4tm9XMtothc+a+9zshuWNwClg+s3YpnHlxUx+eNCNIru6OdKWCfN0Csg7SUIsZKERK6taghZTSfSXMbfpcSKtYP8Gnafj1TewJvIKZRFb42nit2XDHv5WLu75Ia2n3+r1loMuWDfomDoyABTELCH8g9g3DMkCPmQu9M16CIsCUjxYAdx3i7MtSffSOiPvg14LctpCUVjXHNQ3kaT1lI7VqKYUsZnVUPw4o7Xh9Zvk46+5\\\\\\\\\\\\\\\\\\\\\\\\\\\\/DKe\\\\\\\\\\\\\\\\\\\\\\\\\\\\/T2yvJBLBQROFOiWCrI5K8rjo05IVl3NT1djyGsyOWKsneRV2ZDGEeT\\\\\\\\\\\\\\\\\\\\\\\\\\\\/hx2YzaYomgzA+5B9D1XGgQN1hdZt5KgJfT91cYCov0jG\\\\\\\\\\\\\\\\\\\\\\\\\\\\/jMWFnvizGhm4FU518PhgJf2jWO4O5vnitspAeMjS3hZYcVF4KXgrH7I\\\\\\\\\\\\\\\\\\\\\\\\\\\\/4nLI7JQqkDqxUZfkKMwQqXxkl04b2zbNsI3K8T\\\\\\\\\\\\\\\\\\\\\\\\\\\\/AWgP18XceK5dnIkzSpReYdpcC9huvz5XV2X90uRrJoX3J0J4YsyyH5SeoZSpaKO3\\\\\\\\\\\\\\\\\\\\\\\\\\\\/9Z+EtYDYGRAOBt5PvKfB5OBfewKZRwa+do+BkMU6hRq00aTIXvR2SkV+9l6wxgyq4trogHJpsWzi6gxZFF8ob4bk3qP9CxW+J87wOPEildNBKAeUs6W+xgAaFisdCBq0R+MYfmVdDk2JI1wULSV7xv4hjJtZjYEqHTkEqAge7B87N6JE6qxAXct+IjO10ymEw\\\\\\\\\\\\\\\\\\\\\\\\\\\\/\\\\\\\\\\\\\\\\\\\\\\\\\\\\/DS6JiLj1jSHvuXqAGQ2XmJzzKIypWcaf\\\\\\\\\\\\\\\\\\\\\\\\\\\\/IKu6pqJJUrXpAQBOsb0vS\\\\\\\\\\\\\\\\\\\\\\\\\\\\/QFG516TC6tPHFufhm5p4spj\\\\\\\\\\\\\\\\\\\\\\\\\\\\/GXkGNIVkwO\\\\\\\\\\\\\\\\\\\\\\\\\\\\/p\\\\\\\\\\\\\\\\\\\\\\\\\\\\/nlGak+YcdRlVGlsulsEYCQ4YbqNiMAREXVDtOgVtGEUc2NESbCl3o8K4bfK1tPWiZplKE831CbWkCqOiu83ePvCOOdBN1tKK0DwUcoj9zYrPFQNnN4E1vhfW7FtsMWw0xYvhH2Pi8t5HJC1biXejQYuxd3DnWJ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/0ieiGqg64bnknbo8N\\\\\\\\\\\\\\\\\\\\\\\\\\\\/DiNu9L6g2d6nSOSd6ca8HicDOV5+v\\\\\\\\\\\\\\\\\\\\\\\\\\\\/AxixShmgMm38jTy\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Z\\\\\\\\\\\\\\\\\\\\\\\\\\\\/hA+aKya\\\\\\\\\\\\\\\\\\\\\\\\\\\\/PWG0Cu\\\\\\\\\\\\\\\\\\\\\\\\\\\\/mUy2fqEdWcZb7OfGmGn0dMhS85kwjFupA+b5g9SGHyX1Fy3fHlN4SCSDgBhaR5zGgf4m2xsndWEJJuCWZiDJdh8IUG3cTgOVSCZwQrAfFWLIaTr\\\\\\\\\\\\\\\\\\\\\\\\\\\\/2Q4ikKQW9ROnFx8F4pBz0AxJPKG9sLiE6nf5+8i1Llt2UoTkeibrT0WVqvJmy4wWtCCXbq1yecLxuJL8CFue1XX7Nf0jsHSP7alToOx0K\\\\\\\\\\\\\\\\\\\\\\\\\\\\/UGnatuSsrgd8YIlf0OQire9ot6OpXAcdgMA9RGrEQ2qMJhbWR0Bp9Mp7CbW7tgv1CtpfYgCnMzG8gILl3Jq1xDGy4iaw4lWcgA0WzVj1mRJS5MHM50iMB+pAfRWQrDtxRycMTIYeNxiTyOSEFi690N2Fi2dRNJHmg68g4E7YZ+z0MfMCDJ3sV7qCmEa9N0SyK+TF396Jm\\\\\\\\\\\\\\\\\\\\\\\\\\\\/R3paEsOWe13mjnVLgJ4BX+jfX5SBJN04aBIBpm4R1fReTOT8Yq+UYobZhjm7+FdkwJtHzdIFneQe\\\\\\\\\\\\\\\\\\\\\\\\\\\\/SyizF4yE0yiLim0UG9wiU8v0UJfzqkB1pp2eq\\\\\\\\\\\\\\\\\\\\\\\\\\\\/hOiTAGJDF72GoOGrHOcHqmqEuDNK+f0EAKeudixfmTdxgp8PwzdLoBwDCzLuGhwZQUw+66ZfgNSYIeM2m2disXdOtfHnpeRJiaSP2E1nIDEUmcD8cDuOcK+nRi8VXyo9E\\\\\\\\\\\\\\\\\\\\\\\\\\\\/v5dLRHLw6fNSbQK\\\\\\\\\\\\\\\\\\\\\\\\\\\\/DaeHGtp8oFzGFzR+fz+ppkxNEe9aYQ8mELIlU6w7gmsJ394xl9eMG38xIQWYp2uYCETm\\\\\\\\\\\\\\\\\\\\\\\\\\\\/DSwJyape+JcexMONAdcl\\\\\\\\\\\\\\\\\\\\\\\\\\\\/oQZEcRxWPMBc8dUQmQn6lXg83ZX\\\\\\\\\\\\\\\\\\\\\\\\\\\\/cwiDuHngv5MFqaoEjJTFwAqbQqBLQv19uHkS83mEktE3GxzHeJOliEgBzv0jE1Nd7+cp\\\\\\\\\\\\\\\\\\\\\\\\\\\\/BYWgoyhDPaXjNuAz6mjxGdfU6\\\\\\\\\\\\\\\\\\\\\\\\\\\\/FdsUxRBr9KfIPq8b3j\\\\\\\\\\\\\\\\\\\\\\\\\\\\/r\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Co+JTz8dH2t94F7pKRnO1Ehb3Kb61mAL5DqsWz712SmwZnmOYEvqQjXy1Uj7qbMQ3BN33YZfRbqV0xJA9MnsxMHmXHC1hr9zWQo0MZvoZ5UPh2Zs3bjZ+F8cozTt6QQfsoCLL3o\\\\\\\\\\\\\\\\\\\\\\\\\\\\/iTee6lvr7802cVtHRDKXRibh9w2U8KCLnmJRkbt024r7QGNO2+rMKvS7RE\\\\\\\\\\\\\\\\\\\\\\\\\\\\/nr2qzTQfla7XABZ0ydnvuyVB3x7B+wfd1SX7X2ycqavnufg3tstcEvidf3VFrauDj2lTT7BoIsjXXDwElwTZuLoEmnu6iAqU4+kj5LhI8JqP40rNYO+b1NI0tWAJrI8si75uEuUWdxmPb2wK+lFTbAlqQ6IJOwHnbeL\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ttKPATq+vPAj7BgcC3djXxBeys314K93GqKfFDmF17tU7PkzoiiBaJwy5ADqfodNhxevxsKGEIvZdbi5NYb\\\\\\\\\\\\\\\\\\\\\\\\\\\\/LXNMUYZgt\\\\\\\\\\\\\\\\\\\\\\\\\\\\/VAl46IUG56a74Guj7CmD4Rk8HN5Hkazcu02OCx40nEqeHY0JOF2Sxa2rLhCFrSemFc7RKiruPoRoh9JNEPQaNFQaMKu6W6SMro4YjBUs77+ngLfhqy+pNsSHUoinjCQXKCUqnJ6pWXm+GjD\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ZG99Vhr+CZm3dO8b5aolVD43KoD3d9x4ebcLH0ljCmKVRGRgD2wF4W4eNTefLCISs5jSp9pgVoFBnMqgpuNh3wpSMiGBaKFQVcZjPyRGP+ygoQcUXhd1BvpDrpR6DQRgyklxG9KyHo+6yrl705Dun3bYt3F+GjytYBeWBpXQXPyAyGOIo8jxip7cA0K95YuY9nHukbnItS7OrVCabutCRY6XVLsNw7WmV1ncatMAPAbD+pCvzygAaCf9s+EOcIGsFn1zeQ5Z0S9mVvWCaFBLxX202mUp+ja\\\\\\\\\\\\\\\\\\\\\\\\\\\\/N+55d0wmE6AH7lKNqIyoLKOAgn5yK1lm0t\\\\\\\\\\\\\\\\\\\\\\\\\\\\/620Pj1voTf+RWubVsDopZnwMXcAq3fi7JYeaEAuU04zNwRhzigAS5huyZiU+JyiY6x3Dgdgzrf9HdKIwz\\\\\\\\\\\\\\\\\\\\\\\\\\\\/4S7uO5GyUj5FBsJAkW+\\\\\\\\\\\\\\\\\\\\\\\\\\\\/bd2qzTzdxXMUbb6QfLLkeoVTHpbKMSW47rvCMi77KThKdmW9CR\\\\\\\\\\\\\\\\\\\\\\\\\\\\/b9Cni8GljgpYa2TVUTxNmtHX3aTZrbhxsoD95GM9Y2PJ2W8CNgji7PzOEvgycQX+BrchXQQ7KNpYuIJDjwDtew+5XL6NJToevDi3zPWnuabPm82zn14HA002GzZQXN9VyuTZ8QiNsTi\\\\\\\\\\\\\\\\\\\\\\\\\\\\/0JxWtK4cAGig6a0glywfY\\\\\\\\\\\\\\\\\\\\\\\\\\\\/OJlPbYTOPOC5lcqoSoI0ZdgA+9yfede+Cb7XlV7zdiivahE\\\\\\\\\\\\\\\\\\\\\\\\\\\\/h7GWxZZrZLEFFqv05hTZz2e1xal0yvSXPzARn1xurCAobQ+PtsraY40kWRitcG4noia9YsSOdv9PDc5RU5S5ClJ2eE1HjlMCEt8bWJfNr8UxSUC3V606zJafb75AVh9kNbNy0L7IHTQpuLz8hl0ANqqxmkmGLqAm3Pg9r\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Sx1E1URCw90etv0IsVXfNzUDSCVIS2jyE5x\\\\\\\\\\\\\\\\\\\\\\\\\\\\/kwc+daNP\\\\\\\\\\\\\\\\\\\\\\\\\\\\/IDBv8pbLBsANb0QsrxKIEIkUPLMeGP2roLCVF4pU6mm9rZzUM0JE7IlhHzdx2oW83wJvApnrtDSg2OQm\\\\\\\\\\\\\\\\\\\\\\\\\\\\/m\\\\\\\\\\\\\\\\\\\\\\\\\\\\/AlHvvjiCgI7bo82ComoBrt9wNqg8s3IRRLE+vzdWr8xaEQK12tr8OO2YRr7PrO55K3SDqVW3RAUVHS51oMhb+bAzKKxpQz+kyYUVo2QevAHOoiSJp88vFKkvORvQdGZSD51NNYrB2VybPxE5FX9l4ppUbAI2OaEKr\\\\\\\\\\\\\\\\\\\\\\\\\\\\/mqpu219MZtvXUGXfIEWTm\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Vyg4n2nSRR9knBBpB\\\\\\\\\\\\\\\\\\\\\\\\\\\\/4aexoUypU2uVMF\\\\\\\\\\\\\\\\\\\\\\\\\\\\/YP\\\\\\\\\\\\\\\\\\\\\\\\\\\\/S7hNe3csV2\\\\\\\\\\\\\\\\\\\\\\\\\\\\/3CCpbdlFvO\\\\\\\\\\\\\\\\\\\\\\\\\\\\/hwLRKXhChyvyLWJhHjjFDZegcKPaNnlK+26cg9Whc53lFkvC8Nxqq5E\\\\\\\\\\\\\\\\\\\\\\\\\\\\/am5G5uAJXSTCO3aIa8O3YS6YKmY+QteWaGWGUhHbzoNa9xwjcg3vJqfxazvkGR8Xdf5UXelH36i+pq7gm0ip+v+hCSCzMbIhTu2pSv2fBWtijIrLTvU3ixhOQe4l+GfX1PSLIseWAdjzvh7m4PUvhutym10dfxxLEs6phS9cNsiGLqLr3MuXA0IbE1jdXaxwk78zspFHIhEmTATBiGfuJ2OXABwQjevw46rN1p62MgPnZYKshr0AlXFjA6qK+hFcZ6KkE3kVZUjit+VDxO7AJqwmvCgYs\\\\\\\\\\\\\\\\\\\\\\\\\\\\/t4fyMWgnvY9c3XVqlsrPO\\\\\\\\\\\\\\\\\\\\\\\\\\\\/5sLkJQSqWcl9YHhs2INZqZtYDHnVDboce0OOzLWMdNiV3FVY+\\\\\\\\\\\\\\\\\\\\\\\\\\\\/0FrctQKqJ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/gJZijCKHNpmzqi6rZ+YjmhZcquA0sf4kT+M\\\\\\\\\\\\\\\\\\\\\\\\\\\\/UWKhmptBLatCv2tutHvC6MNdUB2uoGbG455iwEyTraraJAPntF4hTIvRDynLHXVkaeBJXocI4pfxGnDtPwdCtyjNUh6l9bOHjMgPDncAT6Psna0TfQUFHB9YzpLEF8t3hJAzuPpP1tG\\\\\\\\\\\\\\\\\\\\\\\\\\\\/VnJA9OTiyyXiqV76rvfgb21lbRWMzqsAG\\\\\\\\\\\\\\\\\\\\\\\\\\\\/NS7HraaPOSFKBClWphB1Lk8uNhmqO56qVO5U+PO6MF0BptCjsHUEvQfBp9LO0ZtgzIZOdcWxcwRPpBElK52UWSbuj8CA4JAQ9YlydAcFVKUYJeUPPDjEMWRGQf27XXIK3vVai20iHM1\\\\\\\\\\\\\\\\\\\\\\\\\\\\/+JNA6tgVpqBapiTyXig6cCYDBpRd+zfbeDPFk6DXAHHUTGg61AbUYO3+mkPaN2vpNGJ9ZJmALXlWS9ESzMJt8V3jRxF5vCClminy2bXPXk5AAO4tnqQ3vIC4+u7CERbRYD46LRJ53qluQGKOEtpCormFDKMejJP1F4HT5HAkBRutDfimlIKQGs4\\\\\\\\\\\\\\\\\\\\\\\\\\\\/2VzcgaZ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/327jB9hmSPvW7s9QzfphusS3j5\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Ycm0oNKOfitI4DhVSQUHVRFii8oVaksQld2Xw511V8wWNLjEUQ9uK3I4gK\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Kz+vRsz1hsypL2MM+Cx55YfEj2n6oo9mQXgWVTPVrWZSFbZ+jymGN4N+dcgvL00kZLY2pngPBuVm0DNIZ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/fw4zruYWWCN9qt9ymSTh092E0SXuClS8URh\\\\\\\\\\\\\\\\\\\\\\\\\\\\/zy1TSy3C7v9vGLfnYikyI+xm98EuxTacDgPGuwSnHhksPh\\\\\\\\\\\\\\\\\\\\\\\\\\\\/AZzS0rvLsCc5HRxd+MkDMRLT2vrBeCrFyYLlUyZ6jygTCZ79cHwwiNwm7QlJ53jZ8Sr\\\\\\\\\\\\\\\\\\\\\\\\\\\\/TlaN\\\\\\\\\\\\\\\\\\\\\\\\\\\\/CG7c6aXcTqqcXy\\\\\\\\\\\\\\\\\\\\\\\\\\\\/RnmEj+u0MOLzoA9sTrrbfjdL7t8\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Ms3wHpJngOLTGGBFLpwUxSLjI1dWLmIOJs3LmZiIfXa+8TIo1FPya1dq+xfYHdoHosdvbaz8wiy9vGN5q00RFmCIBTR1+0CnM5AU88YteOFiR1bPytso49CyHqWVvGXTvCUZQG9f4JkNAzvK\\\\\\\\\\\\\\\\\\\\\\\\\\\\/+kXa4WlFf0w+oNF2EFC295c2w4mJEs2TniQSWIv1vx95uF67NJs35SUxxdcj1d86O1OOE0IkZ7Dwnqo6z+\\\\\\\\\\\\\\\\\\\\\\\\\\\\/RcBfRC9yhcnsQ4n3QYgmJnSKufDv2AZ37U7TV0kFqX+vjDLNpKjA2DQ+OJ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/xM8XwTYSGxtc+N9qdmt85gQtsFrP5lH\\\\\\\\\\\\\\\\\\\\\\\\\\\\/F0UTe6grnZY1Z1Xh0EIiXdPVrwZ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ricTf4xqDdWQC6lyf4ysvUgF4uriphk1Vn90iQ1\\\\\\\\\\\\\\\\\\\\\\\\\\\\/cK+Ece4123yHU9W35uvS5n5Hn2qnpyhOuFj\\\\\\\\\\\\\\\\\\\\\\\\\\\\/pW3rj2C2g6DedzD7P+6PVsQ8Iq8XS0EISMLoaqJ1vutm3Qu\\\\\\\\\\\\\\\\\\\\\\\\\\\\/u3tkVppPwpNiTnc0TE3pfLlY9inVN2Ch77GfK796ULsB3nSzySRd3O2pjhOL3CemdU81epGwPFFtaYq0UR8yqsQKVw\\\\\\\\\\\\\\\\\\\\\\\\\\\\/4diWBHIs+YiXU0cY0GukmrfgEHvvHhqtqVfFSR2OA+dsoqDeFXYhPu8SyimktqZuy704DmhGyVqjIegdLojifXUngq0IKVHGYk5H\\\\\\\\\\\\\\\\\\\\\\\\\\\\/CGNfxhOWS00qG6sgWrL5OAjpsdpSHpUFRildKE9W9SYJ+Je9feoBFD+fzeGAoiDIzJL6kvo1PoxUgrlLvr8711NOFT\\\\\\\\\\\\\\\\\\\\\\\\\\\\/BVxB0U1Nnj9HGT0GvtKMu+FEOp3HMg1URz6NYVAI3GC7o2ooWk0z6kRS0WJVltsUrp51FbN0sfQOltLgDewJYxV8ZkSmH5Fo5JAmhtMZ37wEjNlXgL5USX72sIAjv\\\\\\\\\\\\\\\\\\\\\\\\\\\\/bop1otUooNmI5eMxDAPLE4O7Hf0JprIZbDZk+TlY\\\\\\\\\\\\\\\\\\\\\\\\\\\\/x+9dAZm0J68KhF3X\\\\\\\\\\\\\\\\\\\\\\\\\\\\/1UMCvlMQq35zGJfdfVcqDcSyUoL6hLfHmOuDc736LyU6hSSlY19+ykFg\\\\\\\\\\\\\\\\\\\\\\\\\\\\/hAjKdKHt4l3FlY3wvyEs7okY3X7XIbaFzAhcPYqVRN00oGYNVeUgLG3x8IQS\\\\\\\\\\\\\\\\\\\\\\\\\\\\/JE2BdKwwB+NVUVfWgwfvIawpylXA3CJVjE\\\\\\\\\\\\\\\\\\\\\\\\\\\\/MXOepDcRSFcPk5XYi+g9qtFydzsvd5WnEtyDTFtOYePftym0NMYewiHShuEw6wbOJTPKKX25rG92ZxchyqCJ4uydv0UMc8qmx5YJpu5EfrFzf0ROFE9LKBC04ecOTmnxhU5eXG+kaEo8\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Mnw\\\\\\\\\\\\\\\\\\\\\\\\\\\\/19GcQB3Shj5VolNP7QL0kEBV0lYvjV9bnT97dCBB9YPlNDpKN6yz\\\\\\\\\\\\\\\\\\\\\\\\\\\\/CkeVMmEDXPAe9iW3TBEBWb\\\\\\\\\\\\\\\\\\\\\\\\\\\\/v5X7BS71vKg+Exdpqcc7MQd9LlDpXm83xNr\\\\\\\\\\\\\\\\\\\\\\\\\\\\/g0eKOHj4ZF0bop\\\\\\\\\\\\\\\\\\\\\\\\\\\\/K4ayoXQ1DtLL6sH5YfoF6FGvsSP7+C9rELmzct31qIxrTphonIruZij9dtyiQjnsSEjqdX5TKdtNoGWtDsOOAv5Vbx6TngZuOTpjgFnIYya\\\\\\\\\\\\\\\\\\\\\\\\\\\\/W70HrAEJWyv7xLev1rPCIosILODETn56haB6iHPJjRdTAfUgGsU\\\\\\\\\\\\\\\\\\\\\\\\\\\\/SKhkAvdpz8gmmr40\\\\\\\\\\\\\\\\\\\\\\\\\\\\/WTkcgIhQTfy3wYt7+Z6FS6+m0dr5H+TK3d\\\\\\\\\\\\\\\\\\\\\\\\\\\\/CN3KY5HBuGELgyU\\\\\\\\\\\\\\\\\\\\\\\\\\\\/CIFKIuE2VvzuvhsOl1wEMPyQDxZ7jVQt3u6GiVeZuZHKvZIqRvJ7Nq7ke\\\\\\\\\\\\\\\\\\\\\\\\\\\\/F\\\\\\\\\\\\\\\\\\\\\\\\\\\\/w5XmtYyQkAEmrU+b6nkopKYrWzNQaD2dQ+hLpyixMO5ME+U8dMZXX\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ol8MfuK304uOzQ7MiMS+E9rcKuogPODDqOLoIXszLwOIPmwCBZ2UUXcgExO+1X3EJ+1OdRZb7GdxGqGXTGBOFOIpiBfFdQa\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Xyr2oEFQs7df+PP9GMZtls+2yPALh6xFvtyC\\\\\\\\\\\\\\\\\\\\\\\\\\\\/r9vDhH4OIm5KKrfeYDzBZdMnJUDZZziikz9n1ruVHMi3RAsB8ybJJruqBa5ed7bH5LD0UnnechfGnVvwrT25OsjSDw8B9OIoUrRvWUbY\\\\\\\\\\\\\\\\\\\\\\\\\\\\/9\\\\\\\\\\\\\\\\\\\\\\\\\\\\/xV1vIqOW0MzAtwHeKOxYn6Vh14QutDLo0PcEuHf2Ozu2lBAIjHZtb++tS3DlVNyABLd0cYBjYMGH44sv5DOM\\\\\\\\\\\\\\\\\\\\\\\\\\\\/DEP5QXrFsQU9lRbIn4qUddfOn1CnKmJoPt+Kb9YGzI+SoyYa60ShNjI27OzShc2pKmdIBLoSFbKcJKHA\\\\\\\\\\\\\\\\\\\\\\\\\\\\/eekjz+fxGIv8Z6k8vo2SbL0mYVj0ZY5uwaebPuDHPk8vKhV6BSf106VmfGmSyO55RYFXEY4U+fdKeCJQiOxIqb+kmaV6c6McY8pbqmY8475oZycGmGI3P7oVLCFOpsfVvA45wwVDoLtUWUHRu3ZH3K0VutMBvXyyqvzBhhBaGaAgquxKOeKseyQCJzrqu3cqERqLMvfxG8hqX0FukXmp6LZdNIaLVDLfyy8hu7UXUOId60Y1joeV2bIh8NVJ5nc9ISd7fCHpOQWHEY7htX3jZOhpuBbdIgFTNKPg8wzOTF+XN1jIxqNQGtqN+vKmw4Bvpv2J8LlbmCN4Axyl0sE\\\\\\\\\\\\\\\\\\\\\\\\\\\\/c8e296L3fS3QYNQ3BSkz9SxMWxA+XtHZsUam0LC2zRuOe0KdugeViINraDEM23q+8rEPu1EVJ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ResiDETu31BB8JGMvt0FRAL+jm3oZsVxSDqa5mBJPBxSA5arTN1y6YBTHIn5lFKLflyY5hEDlrKiQ1aTJrKoF3PeZ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/RjEYdVINK6u4M9MT7wzYh4JocGLBeQ496szpBkAuHxRxj2lJMUZPJfewJScQX6YPk4iN\\\\\\\\\\\\\\\\\\\\\\\\\\\\/J1DEPrbG++t1FL+YMur+WVQFqCSshng\\\\\\\\\\\\\\\\\\\\\\\\\\\\/fNArNP6eLsvftnXjg4g1msbu+l3017Cjc3dLSzHvVG1O7UjgU8R5chjDAay1OpnOo2f3rQFeFhjsffeD5wdR6pbYPcQ9fc3X0DFM20KPOE3MHe6nrrR3w3x0BjgpbaaYJKSecF2j+JCAW6V9GVoiIgEGq\\\\\\\\\\\\\\\\\\\\\\\\\\\\/eSUI3E5REeCKUAZJ64cjqpwywnCly\\\\\\\\\\\\\\\\\\\\\\\\\\\\/N2zG1M5euX9e5jAyDaiQ2LN3m97Qywl7u+eeSZMsEG8R8LHvYyT8162ciyz9ePVJkvCv\\\\\\\\\\\\\\\\\\\\\\\\\\\\/w77Y3HhDp2EtAQHtwD7chWvlpay2NStMvaF\\\\\\\\\\\\\\\\\\\\\\\\\\\\/gV6BDVy7BQv7\\\\\\\\\\\\\\\\\\\\\\\\\\\\/A\\\\\\\\\\\\\\\\\\\\\\\\\\\\/GFdM6\\\\\\\\\\\\\\\\\\\\\\\\\\\\/wb0ekuDk3NYVWPPk2BOnWA\\\\\\\\\\\\\\\\\\\\\\\\\\\\/JmfATa7NBpbfvjC\\\\\\\\\\\\\\\\\\\\\\\\\\\\/+cbWC0qDv\\\\\\\\\\\\\\\\\\\\\\\\\\\\/AZlg3pQqQ2t0ZBIHNLQZ+nYqK1qy7sA1VzAKCy\\\\\\\\\\\\\\\\\\\\\\\\\\\\/uuo5DfWEbbtzgwpWylvKGa2bZ4u0MwONedIVOtyqvD46eb48St\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ve\\\\\\\\\\\\\\\\\\\\\\\\\\\\/+PrqshUNcrQnInYdXWTmML5C\\\\\\\\\\\\\\\\\\\\\\\\\\\\/R4eETtg3t5f475b3mxPu0N6sVyAPzUadX0JcjhA9psroQGJ4dPSSD4JhXumbgdO7GQ9JsY3SJJoZAUUNMpW7sIOgk1FoM8BX0I9IYXfoEcsK3SQsS7vJwqWuQsmhZUsJo2IYY+DDMUuxLCyZF\\\\\\\\\\\\\\\\\\\\\\\\\\\\/nmNBC4sK\\\\\\\\\\\\\\\\\\\\\\\\\\\\/hEMCdB50jIPVkk6oi5tqDFpyMiurA7XJb2gJjLVmtk7T6ufDD0Mr0Mt4Mek2KtKtMMC4glTMufhtowAgOJu3Fsn66mAo2Y6TMlnJ49tvyYqVockER4BJJUq3QHobAJ0RihNTTV\\\\\\\\\\\\\\\\\\\\\\\\\\\\/EV1OMw4pNqB9r\\\\\\\\\\\\\\\\\\\\\\\\\\\\/HGzYUJBK1RmZ5Aa\\\\\\\\\\\\\\\\\\\\\\\\\\\\/3IHOWC1vPOGqB0zXytiqpIH9v4wzkj7DZcLYfRIUpoT2TH1pslEQZdFjL\\\\\\\\\\\\\\\\\\\\\\\\\\\\/9tORByhnYLquBydhGSrSQKnH5ySzdTdsqJ8BeQmHiaS\\\\\\\\\\\\\\\\\\\\\\\\\\\\/B9xhPjo89bjBRCglQR\\\\\\\\\\\\\\\\\\\\\\\\\\\\/XNYpaAcs8IxbRbBorgB7\\\\\\\\\\\\\\\\\\\\\\\\\\\\/wI5OmdmoLJrwX9vh\\\\\\\\\\\\\\\\\\\\\\\\\\\\/IxgVATqXUsQlOJZXUqPnXrfo0rgix4vm5xEDF3pw82vKiyIeYL8NihzhNZ5KuF4Zaue3bApYGRPeb3PByLNzxfapXuMMCpsQRkL8Kaxbg8gt6gKDq0z0tCOtAP8ehVOR5bWRHmKYo8zbgLQA7jN+hwY678QZE0OJZtilVLLRey7zrfxMdno15EPLASpbynLxIgcRIH8cOoo3m7KMJJK6ma1bNAnv2\\\\\\\\\\\\\\\\\\\\\\\\\\\\/UkB9J5YJF\\\\\\\\\\\\\\\\\\\\\\\\\\\\/2Hv1o95jlHW52Vwa90d+rvP41DDRAgG2r9bmnvuSMV3pHSo2YrDPrbZbovnN\\\\\\\\\\\\\\\\\\\\\\\\\\\\/qqH9T8JAg5DUpmlKrIhwV54J9R7aFafiT1z9WXZSvgvAJGc2B3T9gdEe7GWKIylj8cp6c5g08Gmvggabvt+L1ovSZuEcBlK+apVBJav\\\\\\\\\\\\\\\\\\\\\\\\\\\\/5vEMFuJGBAgtVH2exUgB\\\\\\\\\\\\\\\\\\\\\\\\\\\\/0T6NAegJtUCByaxO28TCeMJ0z8gXoqzqvHu3aTEnqrhMkjsimIGJMSgbFRN56YMxDdnNpEGc4X0kahH1YqsjjYJXMtZlOxpUY5vdzYt4voE2FhsaSVe5qaY3Tc8XfQe799Wg\\\\\\\\\\\\\\\\\\\\\\\\\\\\/oRwCzyNJvC44RiMlBd+tUSg\\\\\\\\\\\\\\\\\\\\\\\\\\\\/cw8ruMbsL0MziLnqS1leTxjZnURYXtPvYq6eWHB3chyq5qBegC4cceHoQLqyOr+R+Putwq9TPVyfjF\\\\\\\\\\\\\\\\\\\\\\\\\\\\/BehnCjpVZGJ7aTMMDS2KWylljMFT3xEdpr1IUQ5RUDhNN3gTTtXBF1DiklBbcD2ALTk1ca8ELNXoCBK9VnCdoiTIn5Ms7qOSZMZ33QjJpNJeRgNUhJhfFfvK4SP+zlEnws5JYDbA\\\\\\\\\\\\\\\\\\\\\\\\\\\\/X32H7EYIBmNABvSB\\\\\\\\\\\\\\\\\\\\\\\\\\\\/R5WqDn6\\\\\\\\\\\\\\\\\\\\\\\\\\\\/SQ67osWWA9m\\\\\\\\\\\\\\\\\\\\\\\\\\\\/YiwxwPyhw+6FhfLOWVhKXVUZz996YZpD5Cm44n2lt5Hz0\\\\\\\\\\\\\\\\\\\\\\\\\\\\/wp21I7lV1dDoK0XQuKq+7L4\\\\\\\\\\\\\\\\\\\\\\\\\\\\/+Fd0J8XrmZ3IE8kTs6QA0g2miS1WhxKfTepW2XYiSNbgSf5k8lAkgnRe2ctH5KsVe1BdSOM06mYeeqOlyiXQayRcONze+1WlD7ON92dYiF6BFXODETN8vWRujhZ7ESGLJ6S7DLBj2aBnj7X+aMIIxpFbgoAH8umexu\\\\\\\\\\\\\\\\\\\\\\\\\\\\/gfjLiyw27mDiJuQ460fZ8lQOe\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Svw7ApgVNXhExy7NCMo2hDQSmGSjaAWiOl3B9MKncWWmP8usP26ZZiH8ys9Y1Ev5Ouo\\\\\\\\\\\\\\\\\\\\\\\\\\\\/f+uVqtfO6swCHaI4gjKLOfkgGMCPetPdtUhzGRYoksc4DGlDZghH7hs+SRRJuGAyEVRsxx7vcA7csWgo2vrBkTN4yYmK6Hmjg9lmjSMQL2OM9o96FfmCG37Gj+fNpX3OkskATRT3HPUnvnWzK8dwPKn18e+O1XUnrQKPz3q\\\\\\\\\\\\\\\\\\\\\\\\\\\\/CL64eoT0zpLzCd+lbBJ3YLXKfk6Ggix5Gi\\\\\\\\\\\\\\\\\\\\\\\\\\\\/lKCIy1wb91kjw9AGcyCIvTaTjCVxtQ9vYQPHUQO\\\\\\\\\\\\\\\\\\\\\\\\\\\\/zKOFCcgtdmon\\\\\\\\\\\\\\\\\\\\\\\\\\\\/VO\\\\\\\\\\\\\\\\\\\\\\\\\\\\/KQih2A8ua8wcLdOCy89rw4cldqeVrus\\\\\\\\\\\\\\\\\\\\\\\\\\\\/WuEZG2Ibb\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Sm2AAE8TaM8wa9NYgT4fH4BvqzOm6ADyNltFSxdeXkekG3MxEJhYtPFqznuj5uBMCSH1X+E44UU6U\\\\\\\\\\\\\\\\\\\\\\\\\\\\/WVwAXm\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ZHeFHd9MgIwLZO0JYcxEzjzT7K\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ZR2fjJfcaFaLOf1AJVMfvZ462e1ZKoIaIomueNg+IjhiM+1I\\\\\\\\\\\\\\\\\\\\\\\\\\\\/SjIGzoNHV3CDocrQX29qpLvwBqYYrsMbonYNjL7n+66wV5WoOeAtOblqIEk3IrGDoaj0mBArT\\\\\\\\\\\\\\\\\\\\\\\\\\\\/LV+9B1Hk91+7RVFYygjLuucBZBvBMx3JJkh2N56mEYnwsYRx4OQdKPXj1GLbf7LI1OGPfitPUjt2VNmW1pZYLr4+BySWm0JoyCguwTGEMDLrO8wfvGfzkx8VybEbetWyJSR0wH1Rcig\\\\\\\\\\\\\\\\\\\\\\\\\\\\/US+Va+TAW1ffO0CbJKwZ9YHlo7DTsVxmxbKBAaUDtf\\\\\\\\\\\\\\\\\\\\\\\\\\\\/6Pu0TT0Rd7Pih4hA9K3zv+wdwbH+TWu\\\\\\\\\\\\\\\\\\\\\\\\\\\\/TAS\\\\\\\\\\\\\\\\\\\\\\\\\\\\/9YpyqzOUqs9iHBTla3W4W9xyn9VqEmZKacmO3U6aLQ6eRlZLiV4r\\\\\\\\\\\\\\\\\\\\\\\\\\\\/DH7TrEZ7cASajzUNa0azDNbMAiVdGO8a4\\\\\\\\\\\\\\\\\\\\\\\\\\\\/o9oWV5NW\\\\\\\\\\\\\\\\\\\\\\\\\\\\/pUPy4mc+y5UmXs6tT0EnYY+2r9DPsOzYcu+RvKVz4W9VVW5tj4mHuBXeAwPTffN91IKBxiI3Roc+HCn66JrcmywU7YLg9wuJeq8c4EtUFH20pQxPKnsTa7kHPHkjl5pr86kiTmhWYDXwZ85zePrj8E4tr\\\\\\\\\\\\\\\\\\\\\\\\\\\\/NW+dyjktMSg9LftlfUwLZ2kmyCtcWyUHWdLEfWW5m2b09LrmDNzbuJ6aLfCZVKJlAb1jzhBwKdq4aAgeBu3OOkWgqzfnGZhh3IKpHLhE3\\\\\\\\\\\\\\\\\\\\\\\\\\\\/EH6TxIyzc\\\\\\\\\\\\\\\\\\\\\\\\\\\\/kf7UCnLKtXF4Uxccda9dBXGtomxyJEfvcG8JwcXpH5Tdq0QVGJ69RNMDoTEGipxFLk0hUhMVmTJle\\\\\\\\\\\\\\\\\\\\\\\\\\\\/u3hxs9qSy31gxsasM\\\\\\\\\\\\\\\\\\\\\\\\\\\\/wkWeEpm5ElReSnvthu+J45V\\\\\\\\\\\\\\\\\\\\\\\\\\\\/rbBXSobTaAHlH04oEfDZsbjsoyr4lzuir7C9owiC00I\\\\\\\\\\\\\\\\\\\\\\\\\\\\/g7Y9GcGDjVDfz1xe2AE5A+vvH9vaz+NYl2wITB42t02BbIGBXDyFzhLxHhdnoRxty+YGcmFOo+dTVYM8zG30LoIRTjK9OlMrHcm+AOZuGEr2A9kLQtTNrbCGrALOkteFxkl+t2HijDINZDykm45jCWm2S1SwgG0fVUF+vn9vad9Ci4HuMUH2Fa9j+sLPGL+kAJFUIuwx3x2sFjTC0Ocfiofh6oxSKNiGT9TAzSDB7n3BPRz9dyVwoU8Hl5NjNkvsP31jmySGoyEktrR\\\\\\\\\\\\\\\\\\\\\\\\\\\\/8+rGz1uRlNZdCfr0kaPgLyK8jQLhmmFOT7Of5uFYsV5uiFzSn1WjlOZZJUv9YRgf5\\\\\\\\\\\\\\\\\\\\\\\\\\\\/OIcQFv55XNwu0HK1OtrdqX42haC5m9vqoxZJDW9xG8pPSiAWM1S+7d09+v7ubViT74MGaTOh1QmGyPlRD\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ZaoZILpLkw4VZEk326DM6Y1JPogO1hVlheOrO9lQ1lwpCUdkiYQnhAteO7E9bpGYIRRQ+KfDqf1wJbTVljIte\\\\\\\\\\\\\\\\\\\\\\\\\\\\/FVGc3hu3QJ4K9o\\\\\\\\\\\\\\\\\\\\\\\\\\\\/cFTIdGchwbWESZ6G4x+bdP23zgmP4rAse1tS\\\\\\\\\\\\\\\\\\\\\\\\\\\\/gw13SouKLnH\\\\\\\\\\\\\\\\\\\\\\\\\\\\/bJIA2Yha2QPaV\\\\\\\\\\\\\\\\\\\\\\\\\\\\/W0Na0td5ehP2wscGrJpeYHumNzU0FWRkNs61ur68eckBlNTR39Uf1iQERRDQtpoTpONjZqK\\\\\\\\\\\\\\\\\\\\\\\\\\\\/DxE2TzxiYybQFtplXkIR+9Qicqma4QtqQaNoAICHo5f1ViAJ7KYHvVnQnscS0jmaQugODZD\\\\\\\\\\\\\\\\\\\\\\\\\\\\/jMD3bzqM6LCDFILKYgmI+a9EETXVRb8aWDmfucc2BD0BINl7i3jCYFdFMQ1zHB3SFVHV2qn3zdlydLu3tOWgDeWAs4h59ywz4pAjlCAnPO6HCc2\\\\\\\\\\\\\\\\\\\\\\\\\\\\/+8xcvFeZ0depOYAJSoaK55SOKuYmxcwIuOOaYkbm153cmMnVaI+RO1GBZFD7LYmkhvR5u67f81nuSFKk2Jv2FpUTGeW\\\\\\\\\\\\\\\\\\\\\\\\\\\\/lBnDmTYB6qEXjoFxD4QKeAGCiwbvQcMkk5msHO\\\\\\\\\\\\\\\\\\\\\\\\\\\\/g04j\\\\\\\\\\\\\\\\\\\\\\\\\\\\/xIonJT6VvaeJkehS3bHYiGWUvZdo1FAFavmRacwzMIWQpcwZZ1DFb9uNPJ19IksvATuD36qh+AMde+W9IMQiCTt87EmPRwyMP+4mq7H+12\\\\\\\\\\\\\\\\\\\\\\\\\\\\/3DwhRiw5IWKdfm\\\\\\\\\\\\\\\\\\\\\\\\\\\\/vRG03T9BXVrY3vWfhpSVukD1IzVcTszutUAL98LZtSPrrZkjDaxJ1E+r0g8ToUKApq2XKGGdmMNfQhhFfZnJkJDU69ytHh4cE9QP5jayNZBPBJ8sj0HhJUepfr+MgKkAUcMuRcC0UAlBLKJsIEza8gUUXRIx3PmYkWAvTsXZ0KRbS8PvIEaiudqDSzTLQiS8NlrFSsH7OUI8RmmvcQOuXv1ll0c\\\\\\\\\\\\\\\\\\\\\\\\\\\\/dkAjfIylJVqSiS0lmnCTeCWyAFZBVTybvzlMpAcWO978+ciY\\\\\\\\\\\\\\\\\\\\\\\\\\\\/mv5e9CacW3Jo7hz\\\\\\\\\\\\\\\\\\\\\\\\\\\\/wtzqUMSjGgamrWD+tdN9lImFNrp63rJhlvyWwZpw+SGCWcBxiGpnzNP3QDhgvN4D5HaI5YQz2EGaVFy\\\\\\\\\\\\\\\\\\\\\\\\\\\\/VDR4CUTRVL\\\\\\\\\\\\\\\\\\\\\\\\\\\\/lrVKUMleyksn+VjpLpyC1MHR0KcX6uFM7FpFoPPpxK0vDMCpojLbbDlDZRIcWLqqZsvrVOGvfNsI4zTLxkP8asjmRAcNcvVqyMtCqsBHOE8QEV14btPAPv6cW2vIIsknnj1CFGYixG8BXYeDXGUexjZ8Be7r6jvyT1PhYQ2UwFHvisnRXDlBpG1TVGRuW1hDJFdSGheTRON0HtV6ThA3qK+uNFi5eV1+OsBMSwhQGaFn9r+T8R1aXT9BwfxKV7RYGE\\\\\\\\\\\\\\\\\\\\\\\\\\\\/41EprN2iXvfY8yUL\\\\\\\\\\\\\\\\\\\\\\\\\\\\/\\\\\\\\\\\\\\\\\\\\\\\\\\\\/axlpDchJoh+XKBUY9mr4\\\\\\\\\\\\\\\\\\\\\\\\\\\\/1yKSc4RMbNTGDA19w8y\\\\\\\\\\\\\\\\\\\\\\\\\\\\/\\\\\\\\\\\\\\\\\\\\\\\\\\\\/FwxZ1ES8y5qvfE4sQb2pszKuBDs9Jbrj9ttaF9pCmH6bH4pbssVR8MosQo7K6mDIC9jAc3jot\\\\\\\\\\\\\\\\\\\\\\\\\\\\/8sSWp3TjEZUNyvL\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Nmid6CIQshvA1jzLhrQ7jSk2GWi1VGMWZK8gz9RBTxqviA8uk114+a7yXq5\\\\\\\\\\\\\\\\\\\\\\\\\\\\/P8zEaJG0W9E3zkZGdwPjI5v7zKR2+tOvWh4LtoIwKQWF4dbrqb5ob7py+hvF8jFT741JykV+Jv+SBEGCxXLJe\\\\\\\\\\\\\\\\\\\\\\\\\\\\/RHQXsXyaQ3QammnryT5YIdwEoShH21Slb94XzctZP2zQkBCoDz8hDNJokYl3YxpteZxwvpvHaEi1siy5c+ITYHJRUIqcIKhGy1geePmFkyAeP6Hoh77LiO6W6xWFwy8SXxw\\\\\\\\\\\\\\\\\\\\\\\\\\\\/GiABdtWOSUs2x6BD0zH9MTSFSnCYPsiysoDE1b974YZ9J1CpRszkjIXqX\\\\\\\\\\\\\\\\\\\\\\\\\\\\/XbAL2hqitKMRTIqJVdwr8dIgXOwEsKXTecBKco9u9OGSCeY9PD4mKG\\\\\\\\\\\\\\\\\\\\\\\\\\\\/rmQ0ZAvrFx9qPzRLhF1x5oqBcEaFyQnINd9iEUOjeGu4IgaAXKMB3NUyNQXwT1cYwOx6q7NqxXTo383VMvwkc+NW8gppYUVtCnQnqJAQEOuC100EtNZp4rFWPFH51OIqt4JCOzpV68q12k\\\\\\\\\\\\\\\\\\\\\\\\\\\\/MU8Pl5n5L+9sduBZGGwFINJIQugRNF35bJl0KLtVs5M5hPr5t7zj+4hQbY8F+\\\\\\\\\\\\\\\\\\\\\\\\\\\\/yfU2NU9A3BPGZ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/hBWss+Su+pMIJonGrWuZ+2FEa1pQtnT6IaQhMXKt7y03FONRnJQnkqkM0TGkH91w56KudhfyYvvAPmKD85sfGdgBseyUchUt3h6GCnH9dBZbPJn57ewNP4vzJ8zi6RdFa\\\\\\\\\\\\\\\\\\\\\\\\\\\\/WWXBfp7YwRGFOH5yu8\\\\\\\\\\\\\\\\\\\\\\\\\\\\/DeeCzPHzUAhrO3l5IBdJ0gt5r2pxtmVDq7ewFS7WHBapVaADXMT+MXfeNJd1SySosKv1CTVaKAXDb1Md0+n\\\\\\\\\\\\\\\\\\\\\\\\\\\\/IC8IgfUSbfLuqkwns1rN5NGkU35Rr1wwjbT3n+7RSn9jSE8TBLaO0CYN+kJ0s5FccSDUgpxBsQQW+hPxI82UThNxFG0mk00z8dajI92D\\\\\\\\\\\\\\\\\\\\\\\\\\\\/4V6W91J5mGt+dno2jZFLJFflOq6BceX2FfczqACYqMSCbgxtu3xbe9\\\\\\\\\\\\\\\\\\\\\\\\\\\\/b8w5XPxvb1dlxL93cqdzD0UmfWNTFZcuOph1tATz77mGKUzjrwyoS8miaELKnJSy9M8IWgBul\\\\\\\\\\\\\\\\\\\\\\\\\\\\/cB3GzN8ds7EPAKRSk2v57xMlM0pHzcCEGU2arK4jcwg2djDGgqtcRZa9cFADzlc\\\\\\\\\\\\\\\\\\\\\\\\\\\\/JlYrzZQAveQ5jlx7dC0Fhbm0J+ppxwvKnOnpo+BZ6G7iWxTLreqJt0EVvsG+NXAjbJMn2H3J2ZTrP3FILFLBRXXTZcAVNvBIdiAsPNGhvWg5yPAfoqLFsMbjMJ9cP2D2aY3f7ovX2MIukf\\\\\\\\\\\\\\\\\\\\\\\\\\\\/fPrff4\\\\\\\\\\\\\\\\\\\\\\\\\\\\/1SNZPglghhWahGE5EQhQfpEOxPowSHbOEYUcbauIxRdRl2f2P+4U7g6O9uhQWu3zzc1iZopTrt7tkWJs1n9\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Wx48Exla4dl9aWRKCwKCGHrsO\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Ijt5WFgvdNh8Ng16WrSePUOYgYrHpz0\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ZqUnMSzxHps\\\\\\\\\\\\\\\\\\\\\\\\\\\\/w3VtgEVbDLiszn1dhaeTimz9ANahbGDTmR9SOCTJlTJyyAPQE6JDI90UJGXKNT6XSK1ZGCm\\\\\\\\\\\\\\\\\\\\\\\\\\\\/dUO8fA+bDwE2HdmAw2zTFm8hdPBcBMSe\\\\\\\\\\\\\\\\\\\\\\\\\\\\/lq72icdimchJJgpcv6uRKlULKJC7AQ46dJLu5P61DoFgCcHaYGAZmRs8O2JHN723oKZLKZKAAetOiqByYJZD2SB50J1HKsyfJKyicNqgBHWnJsRYEwqLf80nxfJFDW2PmI8DkCAWa\\\\\\\\\\\\\\\\\\\\\\\\\\\\/DoQAs\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Ak0x+z5KRlG34k3M3ceAiDIV+vs5IEObh8Wdzj1U3HLJrQy7kYepbyJSMNLC6YHMJllasYreDa3TG3SJ20X9Ui\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Ih4eq90u3Kc3bYqERDP\\\\\\\\\\\\\\\\\\\\\\\\\\\\/5iWXUgWucN+lnmIE9eGcxMiUS3vciMz6F2eHnZwBdXXIc8TPPmG7FNmzQuV7vSsviZlv6nl7xLVHvBh7P8nzLMG3HWECV91fTdQeWgPEsghH4pV7OuBNq8XdVQ0ANMdLF7awbB+npP5FywxIp9Y+TH1Sl8R1xLF+zX2HZ0\\\\\\\\\\\\\\\\\\\\\\\\\\\\/\\\\\\\\\\\\\\\\\\\\\\\\\\\\/S4nyhvRWPtvAf0nftAZWOQDEJETrkCnTzSzoIoHkTcD4gv\\\\\\\\\\\\\\\\\\\\\\\\\\\\/PEG+bRPYfla5zAaYzLqjtom9rskBwJV5SUB\\\\\\\\\\\\\\\\\\\\\\\\\\\\/1YtdMp12yq\\\\\\\\\\\\\\\\\\\\\\\\\\\\/FtDXwCrxrLRepQbfhaFMXHDURw6tnTLvX3qu9GBZeF2KrF3xlhRQAtHij0QfmktN0Cffu0j2r\\\\\\\\\\\\\\\\\\\\\\\\\\\\/tdrqElxqXPF3KDuviA7YlttDew76QsAuXs\\\\\\\\\\\\\\\\\\\\\\\\\\\\/soJ0oW9Es6Y2vN6ul9Ww6EkFQhQ3CKzPtlnubLVGIGsmu7nzjjUe2uexxrpTzLUuxs1sRupctKtFqlkgH9Ep\\\\\\\\\\\\\\\\\\\\\\\\\\\\/SfvOLNejVSCqyJi9yUHhpZroVXqsUizzgZIQELV8M9yHJmkLTwOk5yFxmgmJtaeTGj91lWmgIBxE7\\\\\\\\\\\\\\\\\\\\\\\\\\\\/oC67IHrag2gqI+KT0BLea8d56NCUs4xFltJatfN\\\\\\\\\\\\\\\\\\\\\\\\\\\\/tqDoCixeS5n4OrqHBjWMVkEuy\\\\\\\\\\\\\\\\\\\\\\\\\\\\/gJt3Q6vwrqubxQu+DOMCxy4LP2qWL9Vc8YH14ZJms2uGTJ3KZLaYVLV8UKJCdi7+WJfPtk4u44JIopRtbLebvIiFWdPNTgDcfuXHuSqI5y7hTMUuNMkWaCr+r1F+aak9pqA1Hk8cx6buSkzZ2TJfYz1zWA2tapy93CCr5KAM\\\\\\\\\\\\\\\\\\\\\\\\\\\\/WOvaAgEY5uGCrnbWPZfu7J1PbHgTc\\\\\\\\\\\\\\\\\\\\\\\\\\\\/3xSEpAx670J3+PxWPRlRLpvEqE8CQR13fyszmnWVtcvVBcJcyrVzN80+rxybR4z3o\\\\\\\\\\\\\\\\\\\\\\\\\\\\/R3sT9y9pZfRHdELICLl0AeRaNuSI01XaP99wQqK7ncKTu079i0whTMJoM4IE00CynFJHaekJPmifv2xvF16LQDUykjusZFhFj6jIbcJPABVebouVdt36cZMBFI0gP6IMOKXQ5Ali132P\\\\\\\\\\\\\\\\\\\\\\\\\\\\/gHFEGLabYBQoDBy4nO1sxhpCXk\\\\\\\\\\\\\\\\\\\\\\\\\\\\/iQMePuOxqpwDrvGt6w0MzfJJC3l8lkO\\\\\\\\\\\\\\\\\\\\\\\\\\\\/FBOQjneoVaYLnep1pvR4D30GMf74nDt6pRRzzSNElkcw38d3eor5ZphFd70U1YWaePzNmTqNyxeThNVbJo1igClNx5udG4vVCeSy1XHUVzzlUYo\\\\\\\\\\\\\\\\\\\\\\\\\\\\/YDwdG9rbnLXE06Tj+Qe9F5trW1dd9Fy9am5ZYLsOiak5SYWGz8XK8IQpscRZUFMXxAOU8eooPxVstiYkQS0jrhBSGwbNWdFycSfWJVNvsILa2rvZ+vY2ESMHTEgP2bJmdN8coFVek8gRaAeuT6HFpohbkiqrVG\\\\\\\\\\\\\\\\\\\\\\\\\\\\/XQloFf6RC+kh0s+U5keJbYkA1Hn4Z+tkN+SjCgyEVCtDV8Nketw7eLu5HRIQjCVZ4pE8QyZx0ktWoXcVftI4ab94FjRn3fZIU9ZZqv43SLzFjJRQzXLwud1C+UPd5oucbwmiThg4vZf4B\\\\\\\\\\\\\\\\\\\\\\\\\\\\/4MO9hGAIAf8OUlgT1NwtAKj5bcA+fYP1UK6zQ+kCJD7ED1zJQ8RdF0H6XU4Il4JBqfwgH4b8tbiuYvc5PBZy\\\\\\\\\\\\\\\\\\\\\\\\\\\\/PC4W1heju6ixe8oQvsTDQjnMhap9gVVc1\\\\\\\\\\\\\\\\\\\\\\\\\\\\/y0Oz+JFW3UES8jLmFgj1wMw3N8eJ1zpaJvIU\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Nfr1JcHOcqhZUaaNXt7G\\\\\\\\\\\\\\\\\\\\\\\\\\\\/E0\\\\\\\\\\\\\\\\\\\\\\\\\\\\/kGjMzN9hUKgqgjkNRByi+WY7E7vo3ha+cAV0A6WZ6tw2eH4vMWki\\\\\\\\\\\\\\\\\\\\\\\\\\\\/sC58u2ifPr+hZ+5EWootOsZdYyWQxJmYef7Wgnw2Sc83PtB0+8Hmdzy\\\\\\\\\\\\\\\\\\\\\\\\\\\\/\\\\\\\\\\\\\\\\\\\\\\\\\\\\/u5kOOLjBwdVRcYU4AFGg8zNweR8zj+1xaTZBpoezXeCfDQ37Yu3WHhFuwhckRgVU58iG\\\\\\\\\\\\\\\\\\\\\\\\\\\\/tc17pzatYlYPepXYLxKmuITUwHI4gBG4dVPsuDNzAT+wtWxXxEBJMVHmVMDcCKqgXKVoJ9MCnNk4UQhSuB+dPZrJyxMkBZib1GeM9P2y+fpEprheA57Yx\\\\\\\\\\\\\\\\\\\\\\\\\\\\/MFKYKH79L3iEY5NGPCM4yo81U31DnkIvTuG6sOnYORTLCrKiktqhXWYuwFBUtTmyRHPN68ibzw0rOOrIeQOk5hDu\\\\\\\\\\\\\\\\\\\\\\\\\\\\/DHbgqXpbaPHmxNjc4AQrbuc8WbSbGrxdRUwg4qMYTdUpaew2H6IQUpsqCVRrWF91gbz0zJnZ8vsI7Lb3vEVUvyJ7T6UNwX4QQGWEduLnAEF9fMEf\\\\\\\\\\\\\\\\\\\\\\\\\\\\/sKrr9wEf1bpPJA\\\\\\\\\\\\\\\\\\\\\\\\\\\\/33hDFwD8ypcX26L2MOf4bISJWYVickPfefhfT\\\\\\\\\\\\\\\\\\\\\\\\\\\\/VuLF0DMparPeCdjNuXbNTxld5qllOamezvGk2D9r3OE8df4m6FvQzvjj4h+yJ4DQ7dogAb+AZFfsE8HgmQm50x2ySNmwK45BpTCBNEijL3Tm+lX7eWtdzyiUj0JlYIrT6owSb\\\\\\\\\\\\\\\\\\\\\\\\\\\\/0MtxKZTMN3iuCE3Y0\\\\\\\\\\\\\\\\\\\\\\\\\\\\/hv576uB4wlEI3geFz3GOyJuc9GbR79W4QHgqM+2JyDHQxKx7Qz8X2DImz5IA7PntrYaMjJ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/0vdHVZW8o0siWfcKyLU0kkl\\\\\\\\\\\\\\\\\\\\\\\\\\\\/xVUVFlWazo74Lr4w3xh95I7rCvRdKj1Q\\\\\\\\\\\\\\\\\\\\\\\\\\\\/2GMBtzDw4GKHsBDDdQsPASXwqTucBlsKkXZMjtTAf\\\\\\\\\\\\\\\\\\\\\\\\\\\\/HZHMgXdz3l5C8hKwjguUcoIYRjme66TQ+AjaQE5LPFisdPJmqsHP55vVV2s6dusWrysENEFDkYqzrFegoSL3fZdGnrIqFKGPisMuAZK6ARO6ds2nd\\\\\\\\\\\\\\\\\\\\\\\\\\\\/KvQfeAk640FpiPkL7e4362M1Tq8FsGM58tEksmFc64+wiDpe4O7y3UP7auJUiWtsqTKhGhEsIxAOGKz3vbt392Epzwfdou7S4YZcRvFbq1Z17aU7zd2YsJJbYI9TN8M9MaqVObEgVmeeVT0mAzyjVlp2q1Hdg+GwTSEgnmdkD2gP1L7\\\\\\\\\\\\\\\\\\\\\\\\\\\\/7kotZlcsjO9d61mS+ToIcdPgsJFKgLPXhiWKDP8smHqamnC6h+gT5IIJnlkrq7s+iPcvlMw+eCnm1kbVcjGAh8o6q77F7e3iiiAaFglnK6XPUrsQSRRHoRD88orc2onM4tqV6mwBBH183eN7TTPRPQFH6TxEZHg9ZlAx40X78D1NmfBv9tL5lFGv46uDAGljfYOfwW13v9Nq1SJiQD9aKqqlNHi+RsaVbrwJCbkMXx2PGAWkf1LOcH\\\\\\\\\\\\\\\\\\\\\\\\\\\\/n0rwmmI\\\\\\\\\\\\\\\\\\\\\\\\\\\\/h1vkxqt01d4DPlehwty+MwbhssHtnHpLDIEv7CM3vnZxyBrIZr6bL2YVGYr2RTZiszmRqfUFW8R3pJA10pNzDbR3z7opkGn1gMydzqVMYKUmQu5fqM7AFjqOuwWL3FcyoFV6k7Pp0g5f5PNCXGHiAcYIoohQhOBQHoYOt8DY7UoFZJ3ORjjzSWdAjztwbifxTEvbP9fruqgp0EUFDh2DSa4W5Sv8hIjkXIXfO429gJMROPF1T8W2yzJGKNUw1pYluFhcTKYcHkbvzUZRm87qaq9l8fgBDc\\\\\\\\\\\\\\\\\\\\\\\\\\\\/\\\\\\\\\\\\\\\\\\\\\\\\\\\\/nfiwHClrfQF50cxpMNhECyAJgeiXwjukUvV0liInvj+XzysMNlLqLjwZoPnQugFP+d8RT2D+Dy7KGF7+865W2p\\\\\\\\\\\\\\\\\\\\\\\\\\\\/cM188QSc4G2lu1yFXGQIB1OeNeEWFIHjgXFhhm3IFLuuxUXovf36jqdDkxD8EhY5FzZYX3q49QciVF1PDDdp5B7l2bVfYhEMh67DgQbXRhLI0Zizd9kiwSgBGYk8jB5y+eU15XwrOiO+tTZzY+cOWkH3PjbMwx0nGOSLskucyWm1RIh7jj7SZ0YD8IQUkjFCR8X+5Z1Rc\\\\\\\\\\\\\\\\\\\\\\\\\\\\/NU8lw5MEFbbBahcIqdHyW0XwrSzUw5tVEBXnN1XUM5fLtx2RDHI33XG6E9+KxrAOOS8QIzA\\\\\\\\\\\\\\\\\\\\\\\\\\\\/pf0rvb3Vx5ifLgOLYENfnlMKlrb65bdwZnhvwC9jQgDwlD7\\\\\\\\\\\\\\\\\\\\\\\\\\\\/hnBCZS4OzuytPWjKNPTe6g0AQU61Q6OjeofW4A9CuKJYxPUUkhgs\\\\\\\\\\\\\\\\\\\\\\\\\\\\/e1\\\\\\\\\\\\\\\\\\\\\\\\\\\\/FKLl072efvFWO7qvNZl3MxdDmz7fjw1zdulWwDV85ye4GqiAoY6jsl6\\\\\\\\\\\\\\\\\\\\\\\\\\\\/vXtAX2M6wOHgDRujndDeY0wv6\\\\\\\\\\\\\\\\\\\\\\\\\\\\/gb3YYy\\\\\\\\\\\\\\\\\\\\\\\\\\\\/tn6MQDS\\\\\\\\\\\\\\\\\\\\\\\\\\\\/yzU9VkrJmpqR7wpFqhN6DMSSuupmGL7NUfxwYT116IdWTT1b1xg1PkTJ0B9YPd116Pcd17dxIFuooVzYjTxFJSO1bF0pvDaWqvRJ190X66ne8wLFcm3UtVP25z3fGeHXvBAwCiCIKrLY4IbrJpMpUX6E91S7PtQdJbYJcLIEMk5V508dIvnxlhFz4o+RelXGGqQrRvjWW2L\\\\\\\\\\\\\\\\\\\\\\\\\\\\/yN4pbDMNCTU7T4SZfla91RagtPKWc1k7Mmtrwak6aqJh0Vq2mHuwP+IDGvpg++4OxzgwesIB\\\\\\\\\\\\\\\\\\\\\\\\\\\\/43jROExq+YgOdnQipPhdfjIMs3I6Rhp6JmYTmSII8PZPAXfLeCteLu0G7NClDyN35clvLXJFqklxIRMi2uLKHPhor+J7a+cdX+VNJCDUOcLxbY80Fk6lL6CNrZdLEx705tx8szOX3gD5mpvzI2ZgmO6vlLmgfKaaTJJGxyJ8J3opid37IuC976UnZFvs2CphELdg5WQHg48x2lRuM1nQNfOjhEtonZS37Ty6QrD3OlIgHUWIR9NXfqs+8HWrQk5h3CvNROxr9OTxlj4BaikdC7bKzakNCpA10aoSeB1dP+\\\\\\\\\\\\\\\\\\\\\\\\\\\\/J\\\\\\\\\\\\\\\\\\\\\\\\\\\\/k1bU0ia876U4HIj5vYNFbp29x7cnY\\\\\\\\\\\\\\\\\\\\\\\\\\\\/\\\\\\\\\\\\\\\\\\\\\\\\\\\\/D\\\\\\\\\\\\\\\\\\\\\\\\\\\\/6lW7tyOZPDHkHhyaJyL1oQGas44AqIrJtBVNu6WerSHgPbnus90VqMDs16LIIfMTcB6WU+ed\\\\\\\\\\\\\\\\\\\\\\\\\\\\/u\\\\\\\\\\\\\\\\\\\\\\\\\\\\/5FZef3l8ju0df15qgt\\\\\\\\\\\\\\\\\\\\\\\\\\\\/2VGnYFOBit4fhMxc+OW\\\\\\\\\\\\\\\\\\\\\\\\\\\\/tU+ysyH\\\\\\\\\\\\\\\\\\\\\\\\\\\\/1JoQz08saz+alimCZzRnV2rlfULaX8XPns91gObLjjF2Q\\\\\\\\\\\\\\\\\\\\\\\\\\\\/4JaDj8pIgfNTnUVv8nBh0pm3H2\\\\\\\\\\\\\\\\\\\\\\\\\\\\/q5Ir03ajqfP5PRUWWC9NXN9a0Wf5s3T946xRm+b7zwZvx11gIWIaYwkJK58Tdx+vtSyEI1NVDYpLqrk2jh2hlYQ0EHehTt3CA2m7OZyL9L88z6dPXnU7hLhxIsN9lBh8tBBwRuabs1iZHMOzxG2VPaJR5yYtM0N7Fy+oihWo1sWMcFXnwwqGdFOiJwI+P3bExcr5TfFA1Z+1MTOLqic\\\\\\\\\\\\\\\\\\\\\\\\\\\\/sh8dbh+J6f4\\\\\\\\\\\\\\\\\\\\\\\\\\\\/LaXPoym3j74TulJxvX0FcrMTDliGd1TXlgR+h8o6HcTgTB\\\\\\\\\\\\\\\\\\\\\\\\\\\\/BvBXERFuSk7BWqGaJ3fMtcqiGP+IaChW\\\\\\\\\\\\\\\\\\\\\\\\\\\\/S4GrZF96KXCr4tk6jXIU5\\\\\\\\\\\\\\\\\\\\\\\\\\\\/9gSlm75+boozpKn4z4gJvCqr7Q6NGj7xhNVfQhvJM1A6zt1VhPnptbZJBhj6QGsnhD9AvpsIZXN+Ao+ZS362WhcJyuykZcolptws3Y2+daLtywItOnmLRfYEQOf8jXyV6rjtwwizfT1oIZSN9GMKtSCeq0HRZkhQZ9BcSgFSyqGU2b6HAN5GctrDd4vd9pmgAB0e7Hc53+tJJaBP8MqMsJZ6wtSVhdQlCWy7DqiL8pjyQkjW2h6rd1KjkYznZO1CTjOXS9yQKtaCsCZfKvF3D\\\\\\\\\\\\\\\\\\\\\\\\\\\\/sxNCgDET6u9aA9YPq45CPH3XUkNJAO5rZIaJtgtL03VM0S+wchpHIDNqgIC7Z8Af9Z7VHy7tvQnxpJDdGWEcHTFm8K\\\\\\\\\\\\\\\\\\\\\\\\\\\\/YgsDvuyr54ls5FtX\\\\\\\\\\\\\\\\\\\\\\\\\\\\/3TQYIXfH2GApTcQSh+ULPgpb7y9fzNU6vy3vVt+y8+oZ0zw9BYTQqOiaOeMdxqCAMHjqlUdNggjltqXvP00JUHEQFltMkVC33iZISbd+tdPXRjZfTCsIbbePVDGRhNv7QxjGl6YIxyIdfDJbYzu3uWIJ2KWiuToy88BRuHNqdmUwxDjHyc8ZNqUMIfKzC3NwWKcGGCCZdf25xdlN4junkfu2Phn92yhikVALUJWU6yLnuN0BK\\\\\\\\\\\\\\\\\\\\\\\\\\\\/+zfL2\\\\\\\\\\\\\\\\\\\\\\\\\\\\/l7X1UsYl+\\\\\\\\\\\\\\\\\\\\\\\\\\\\/lcQD7gkCrThMtTK5SI7nuPTmV8K9y99\\\\\\\\\\\\\\\\\\\\\\\\\\\\/E+G6odHoTo7CFYYh913NF0jP5plPEPE699NIUfBDWZUfWSTT4Wn8qJjfAyhu+E4SeWIrdtoh6MNo48JnpLEF1Ci5egGVej98fWpYMcygKrF+dtvIUnSyyuaaMq5+k73Y6RUU+HmbSHjapCVKldArB763ABQvIkmqxYtECMFRW7+aZz2QCpD2o3ysEjyIjPDWaTMiJd1iZ8tmvMeckJJDOQd1ZjRvVz625wSB3sKnS7rSNMO53dbkIQiD8kJFOt27dpkkrY2qO8zRZB\\\\\\\\\\\\u0022,\\\\\\\\\\\\u0022iv\\\\\\\\\\\\u0022:\\\\\\\\\\\\u0022CEQYdnAUqeO\\\\\\\\\\\\\\\\\\\\\\\\\\\\/GXfV3ylZkg==\\\\\\\\\\\\u0022,\\\\\\\\\\\\u0022salt\\\\\\\\\\\\u0022:\\\\\\\\\\\\u0022f4d040311b2fd2429a61a615cefc1b83\\\\\\\\\\\\u0022}\\\\u0022,\\\\u0022hmac\\\\u0022:\\\\u00229d75534928752a5ff2e05733230c34cc9d01007cd4efbe33dc9a94f000fb6de6\\\\u0022}\",\"new-28\":\"{\\\\u0022encrypted\\\\u0022:\\\\u0022{\\\\\\\\\\\\u0022encrypted\\\\\\\\\\\\u0022:\\\\\\\\\\\\u0022Sx1nAxu+nG6mAfi6evxd9YKZ6xE0zIjC07lr2EzxvnTr0gt5dzSUqvEpXn6eaVNaIzPncei\\\\\\\\\\\\\\\\\\\\\\\\\\\\/1oumCqYU+4Y9zMtJ6H+MKuNDNFZeEue0STonFZkGICncm7rvk\\\\\\\\\\\\\\\\\\\\\\\\\\\\/bXgSy8KT7fOadeeK7EuuH\\\\\\\\\\\\\\\\\\\\\\\\\\\\/sJpG0txMIQaMiDkyiRfAuFEeyrfKj\\\\\\\\\\\\\\\\\\\\\\\\\\\\/V3JUDCoQjuswTy+ePEQfKwws9G6SW0acEiLNxlmOGTPyz0KBGp9CCvuHTdzNscwRIXfD8uiC9iy5367Ve0OK9XtYnXkFoIXcZuBX7Y9TH1ZfnoZobf4fJFGcxdfkY7riX35+4VvB60MJ6Pe7cc2k6bcqO9CEALpXVHGW+10Xdz1ouq9ywYjdHuD9+3nm3Z6rOme9MOaRMzSV7a65ryZ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/pN3gxPXSU\\\\\\\\\\\\\\\\\\\\\\\\\\\\/pTU539CWeHppmgQypwKUiqnjXHLRNR2h7U9IyylppwSpAUh5gKNiOSdItdRwoG2EwpiAzQzxU5hM0GY901SeDC4MufUnUC6peK5ak8FWqal3H4gvo2zR355qq4zPsWvSOR8yus3YKvjEvQm0UijwM4LFTreq8vNxzH39Dpo0Npev6qu7StEV7QxnNAOvymgm9y0Fe2g55UoVR05ba2O1c5mR7GysX3bP9b7oyiMoArargsQjUwZQk9INHjBXgDLbpuPhtbZSlUTp4ga8b5JUjP55U3Gl1Mi5ZYjLr+qJo4nVeCqDwA\\\\\\\\\\\\\\\\\\\\\\\\\\\\/0rM7QAue2ZryJ+F546B4eoZ5vbiC8dX4XgFwxh+GBf3r8Enex7vhzEEE4MDXugU+mZwY8c9cyahmUeXx7fjIShbxHimQAcasE3Yo3ZNjDogckIdXHLj2LqxsE41wzCG3qqpNAFUBgKSOuV032qhxdBpYfjKZwj4xJ2bYtmwmm5K0TWEw4Jh3jfEUuegkeKItmMHeTRgKjy5KqeqvvsCHbv2aDTKPCTsQwMZ1plG6WgbEhnWVt5lbOx7b97rhfSZvyRtmC3\\\\\\\\\\\\\\\\\\\\\\\\\\\\/uWS7Lm0fND92HFM0k9WvQzMsK+WGv3ijK2sQaW6S\\\\\\\\\\\\\\\\\\\\\\\\\\\\/0P6i65JeCCKrDLYPsTOjEawenNj3ch+ZRA\\\\\\\\\\\\\\\\\\\\\\\\\\\\/iLcvugl6dRCqrbmTQXcK\\\\\\\\\\\\\\\\\\\\\\\\\\\\/rKFTWhMHoiA0I\\\\\\\\\\\\\\\\\\\\\\\\\\\\/QTofYUG7w6TEbdV01Wr1k84BrYCTrUDw13OfyS23043l2D6PF33iOt\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ulH1lyL\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ST0gS6SYQh\\\\\\\\\\\\\\\\\\\\\\\\\\\\/oHzQcHhGBU\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Nuq6Er7EkJOcYMQy9siecNan6UG7e+653a1phbVVspFPTJ9oZF5XMkgbRcFZgSlgNookwvaaSyncxbZvv8Gj4Hmre6s6D37C0\\\\\\\\\\\\\\\\\\\\\\\\\\\\/KuC+86\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ZNV2GU1Tr61s0OTs8ey\\\\\\\\\\\\\\\\\\\\\\\\\\\\/jRNu3fcqksnB56IBBOD1ZaNwaXyzcqfjCV5CHOT95Du+Hw\\\\\\\\\\\\\\\\\\\\\\\\\\\\/r76QEBbE73driQpO7TacsUYzK48I+oG6g9b3jFTiP8aPqXbnpzQ0o\\\\\\\\\\\\\\\\\\\\\\\\\\\\/0X5slfsK9OCY9Tkxx0djdGmuG7NoviFw8HDpo8Ab643NmpoZVjkSz2ZV3Cgz\\\\\\\\\\\\\\\\\\\\\\\\\\\\/EJumx3lmGVGoD6O6ou5IXmwBJVCn9MRTFbGnPeSGl6gvWzgMSEuZQXyH8aJodBq9ywonafhdaQLrSRebQnQWsznEkPBm5pcKlg0KqBer\\\\\\\\\\\\\\\\\\\\\\\\\\\\/TAl6ijqthBPlvZIprYGNchLpkPFVAFuj1lYuCHMCAiNmCkr3h40meic1kIq1lTcvQmdCekgMbkKuL7SkosFSSCa1FEjDfIwle2TBY5fR34NwWP21sAbKjhC3tGICYMSjJ9R4QJMpl45CMKLLta\\\\\\\\\\\\\\\\\\\\\\\\\\\\/tKVOijGqFidmkU\\\\\\\\\\\\\\\\\\\\\\\\\\\\/cfnjBwFcvu08BIDwVGkeMLnAp52pVQkCUEeiUyL9jboakJEaDDtjhfZ1cZ4A829cYMcgjP0lu7nfcKlBTKHDDv+Caj+z1vm1pz1PeJSSMtYt71EK4mBAHTMN2QYVgBDkAuYvii6\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ReAbNjygPPYYGeD0w3lhkopFru3gOutWGLowN5TWUKPQUjpfNmKvYdCG1sMLQtnJjyaFR79sB1p8yx56kgIKjzCGwpNIDicmc9CdJrpvVPrQN12UM4keJl\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Z+aNA9JxzgAkTcb4KGosdEaKf\\\\\\\\\\\\\\\\\\\\\\\\\\\\/otLHMAbxR2Ew1hDFsKL1A+zmr+7VaSoEVJGBDiYQc0RWnXf4ewBxy8nhxjYMcO5LtBrdwVX1i3rUY55Y9Ey7N6kH3D3RtTohAuEtI6jYfTGuJUGQ1TeWeM6p\\\\\\\\\\\\\\\\\\\\\\\\\\\\/0JI4HOEK3su6F8FB1ifpnvC625rGkj\\\\\\\\\\\\\\\\\\\\\\\\\\\\/qOgGdYgM\\\\\\\\\\\\\\\\\\\\\\\\\\\\/F9pm95hRNvSQSweHS\\\\\\\\\\\\\\\\\\\\\\\\\\\\/brGYYL7MaVbjCaCx4uatlXGMGZTgnoKJwx8zJfhldctYq0Ml0nbMibk3398qUYwwcR5TTvOe06VNDz3vQfnWcC\\\\\\\\\\\\\\\\\\\\\\\\\\\\/K8PZreCJbtdfssYiJmQ0Ez6LYR2d3TAJFJ9vdqzo4dW62w4wBzzpWLJL8b1Jqv3Lw9ku3mPMoPbE\\\\\\\\\\\\\\\\\\\\\\\\\\\\/YtBJZy3ghw5P2U1Jc1BKwFbRnbc3F5IXJlcpOkxQztmL90WC7DAYHedT0ow\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Yjoeta3T64v1WLNaLPUBqzH+OTgf5PuA\\\\\\\\\\\\\\\\\\\\\\\\\\\\/AkNv53MR7\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ZCwNL09VgYj9vZ+vHatD4VL5YDTKmPWpwMDe36EvKfXJNWHWdWoqaGpX+Qeg2WWk6wR\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Rld4flT9vmGe67wA52LgcksPe+8z0\\\\\\\\\\\\\\\\\\\\\\\\\\\\/cd7CSnEn38+3seSSpOz\\\\\\\\\\\\\\\\\\\\\\\\\\\\/mOIAyvC6IvPQ62CKdAGd+MMEpeVeCCgV4r7O6SC3fFXFSJIFDIuc6urUkbV88WaWUt7sJejLDPQzjjDRRWIbaAdygjS0Y178ZLBvtXRCbdwKW\\\\\\\\\\\\\\\\\\\\\\\\\\\\/szQJRJi3Xe56trp4qMyeQs01xm71+cbJC+KMMrT59PB\\\\\\\\\\\\\\\\\\\\\\\\\\\\/YrvTEo1\\\\\\\\\\\\\\\\\\\\\\\\\\\\/8Yx903IOXyE0IxYtdL8QTJC\\\\\\\\\\\\\\\\\\\\\\\\\\\\/96ShVbESFwQHwlnLtbUAco2D80K4xMXjP2CgGpKtggkqgAVzoQYOPsiGTEb8FUvn4BGN6B1u9RrVQ3DCN278Cf85GFdZrxh3Iu1RgnqDOd68LSRxqrF4fjEhgEZ97UqaeNWtisU5T6euEo8Pd6o31yCclO4vKlIHiAUIwvABvbZJ7h4whBViKNP8DSfmuySwKL3iUZFiDV+FPfnFor3Nj\\\\\\\\\\\\\\\\\\\\\\\\\\\\/UiJW9\\\\\\\\\\\\\\\\\\\\\\\\\\\\/HkyY3AMhv4IYHquxlYzT7Jx+amgSl\\\\\\\\\\\\\\\\\\\\\\\\\\\\/dlfsye7L9f5P0uCIYoBO0QXbTKkWC8elkQpg8\\\\\\\\\\\\\\\\\\\\\\\\\\\\/pVhn00UoXraGpvtaVZMQObByIZrG8Rk1yTG5IXEeiwkWoad4m\\\\\\\\\\\\\\\\\\\\\\\\\\\\/j4H8YmAxDRifZNAAd88rKPKz3tql+OrU6ktuHQzzb2AxyZ+I7ATAlJRw9LejVGBKRzjZJxHmFrc57JhHymkk6uPFb11\\\\\\\\\\\\\\\\\\\\\\\\\\\\/RyWUizTftq5JB9xYkeosPx+zGfEiMmHTh8\\\\\\\\\\\\\\\\\\\\\\\\\\\\/N2rz\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Mr1\\\\\\\\\\\\\\\\\\\\\\\\\\\\/DYj9wFEHZuk82xmajGY9\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ReapVm+8gjFY5XX0KtMiMYp+nro61ZKnEVG+SswRq6s+85Fwa\\\\\\\\\\\\\\\\\\\\\\\\\\\\/U7tUGuc0Xcl3ZvWAyG3xPlLcSY4PviAjmPCF8Ji4Qf9\\\\\\\\\\\\\\\\\\\\\\\\\\\\/eyUNkaIM9RgjFL14QhR+rDIPoMt2rf1rAr0bCwWMbl10nLjaKolxJ3trExTlvw5SObVH60zALXMKiEqq\\\\\\\\\\\\\\\\\\\\\\\\\\\\/3gbo1FhLnUGI006dVlMeXzzjrBkBJzy+4wxvX3fbce4aRiPdgZZ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/LqEIQTwXG+ayDRpcVXLvSIGiU0Yu3bMBPXTX78OUSQyh2OPBL2P3KvDO7o29vFKvM8OKoA2gQzfMSAYfdT0mtsqR26XWOip0eYUkEPv07wVFvOV58mE666v3cQBgZ96soe4mX1M\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Y8v1En4V847PlXHveSSO8mkDtfDKA+P2asm+H5uKuEDnrhpLxyqDJdOaP08I95NQpV\\\\\\\\\\\\\\\\\\\\\\\\\\\\/o0UBLec0u1RUbnBMw7vAS3yCQZl4poUjpfn+Dz0CYTVVIZxQ0q3jdbwriKYqnP5EH\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Z0ZwyLAuiPYeafRyzfCUsfYcyWor1aET4dIgw5Bvr3v\\\\\\\\\\\\\\\\\\\\\\\\\\\\/IRPlNYsz7f79LsBgzuvqvs+TKH\\\\\\\\\\\\\\\\\\\\\\\\\\\\/BztnmxHFprXT+XPYprD+0aw2z2Z6\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Vow\\\\\\\\\\\\\\\\\\\\\\\\\\\\/9IDNfAlBpILWSjZtreRHd1qwALocPG8gYjOC45pZV7Xp3g5fx\\\\\\\\\\\\\\\\\\\\\\\\\\\\/WjnQTlwfPIfZKo8Ze8QW1HFJDMdIwy19l7tXhlW2a3QG40heI2TBuZiiYiqmHSCwLhyK5VqZPo7Kt\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Qv3wcn7kloaWQkkl4iw1QiKHymhv\\\\\\\\\\\\\\\\\\\\\\\\\\\\/WFiOUyYBrMByQIy3kfjc4vFecOhuFQ9Znb9cWrNnsTuueEw5WLTXA2fyrzc5Gk3r+HXpT9rNe2XcSSIyyTfUXQNZQEpjPehGJszRHXcSx4wSdXCeyPIaVHliPfJxa4gLMgQB7PGtWEPBD4e1R5RS\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ui1mbrgE8bhYvQSEjgHVvQ+XU9pWU430mR39808l\\\\\\\\\\\\\\\\\\\\\\\\\\\\/\\\\\\\\\\\\\\\\\\\\\\\\\\\\/5CpyuAbOkWYdZZZgdTO4BWiWKiLxr6NgGfKoUZLhO+1gL2C7eUqIO5Z4e0o27SdsyHOV9ORZEQBdllopCp91K4+5Ad6i2oRhzxKBd6HmQhstyiy4AlW1DLfhD7p59TUBWWv0M553FAvwuyyxYVDAieE1oIm0TOzY5YxbgIUOrxK74nPcYoAvbdcQFwxtCSsvLtjIYhwenAvHkwNxJ5z2cU+azW10IoXHTOjcEMMCRP9hq2r7OhWygBqtVbfc9bkrF02b2B85gPep7JHZgmYPiXCFwNPNsL6KLtWJI3RIvhmDXXcAD5WnvjerzVlUCgoOWQelH82qHkDbZFptuC8OAEGlJJ6XPQL0bGFkTewwODlGEDI6bx6yg9weKPaG4yJXq3zNpaJKXbxv8pDD+LlQ5Tau9sLLdhNjLF21WLyGNwuUK+GIbSRkobhSsW7yAomfDy9XP\\\\\\\\\\\\\\\\\\\\\\\\\\\\/alj1p59JyWhnNGojdNQm\\\\\\\\\\\\\\\\\\\\\\\\\\\\/NG+6A2guKGibYUX0wxxrLdcWL5X52bY9bTooeDfIY0dI\\\\\\\\\\\\\\\\\\\\\\\\\\\\/iEinpjL4vx0JDEIu3GtOn\\\\\\\\\\\\\\\\\\\\\\\\\\\\/poA4r7tpIKRJtJPFyhZrdbHWV6W+7KkJnonq0wpT7ooCRFm27UJ2brtcj0HhRBUxUbP49TqKv8WZoFIJCqLPltHTHPW\\\\\\\\\\\\\\\\\\\\\\\\\\\\/whmvfT+BnNRxqz8dGqPQq2LBPHL6hndXLmqqSJUDwOdzow+M6w77VBTSSXBuEdtRymV1h5SvBLR2udZvlx1csOIjmBNUzZCTR8+q5C+W96cASVef8YQqWB\\\\\\\\\\\\\\\\\\\\\\\\\\\\/YkhwrvogIyF8wMIVqBZeCPIoZUZ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/TJlSHHay5KsDq7erZk0uaFe38\\\\\\\\\\\\\\\\\\\\\\\\\\\\/LQn+jI0DpT4zKZ2m\\\\\\\\\\\\\\\\\\\\\\\\\\\\/13dRQg\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ltUHoKcFlG\\\\\\\\\\\\\\\\\\\\\\\\\\\\/3vIfthifxe04ozksvTe1mRByzk954yV\\\\\\\\\\\\\\\\\\\\\\\\\\\\/xS3PB4Bk1sjk40qe9K4oPCq+4pGH6w00Nd4MDp0hUMUDSkSFAI0ReleMAKAXmrKE\\\\\\\\\\\\\\\\\\\\\\\\\\\\/I7K5dp1ASerlU65QnSLN2kNZb52iT9V450zWFGUt6uoms\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Mtr8uJrF8YzIohBN04rx5zLv9pPAZxy7fk1bMTWSleOAgsZjspFVHGupqTRVJu7d0xuTA2NUI0nPCGH95xXThOsyrvJTOqtN\\\\\\\\\\\\\\\\\\\\\\\\\\\\/5EsZdIPa9vxQOuw4CpuOkn6AejXYx03tJEE6NcaFJlbhZpDfeCVqC81Q9niyaltI4Vd+pA6qu2\\\\\\\\\\\\\\\\\\\\\\\\\\\\/e\\\\\\\\\\\\\\\\\\\\\\\\\\\\/3dl9BxmhHgbXD5Yr2B6I3eFg6KiVuyF1re+WlZOwprGp4oInuezZ8vE2CLBPHOPZ24NyUhFo90qXgoKvKAOKwlc\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ZobbKlhZjlPHsK\\\\\\\\\\\\\\\\\\\\\\\\\\\\/C1gWGEZq9fhPZTOr4c9OhE2p6yPW5ZQTm9BqqC9rxgQ8KjxP\\\\\\\\\\\\\\\\\\\\\\\\\\\\/wwBRpd+XxQIS5Vd0+XE87oayjhOAvOlwwifhDRUrS\\\\\\\\\\\\\\\\\\\\\\\\\\\\/4BnWtbjApaQ03Kf2+gRFzXg81P+wyNIuDL2lUPRFjvLEpiYvsKtVJiYhS64fTal7twYHl\\\\\\\\\\\\\\\\\\\\\\\\\\\\/LC6d20DbHUEsK4zyggv3G78Vr\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Rqw4vqGvPyWaTeTu7puz\\\\\\\\\\\\\\\\\\\\\\\\\\\\/xTY0BQvBGTMqpdF+Guh\\\\\\\\\\\\\\\\\\\\\\\\\\\\/3Fi26z+426Pg+tvVMgZkn2\\\\\\\\\\\\\\\\\\\\\\\\\\\\/OYAOUgb\\\\\\\\\\\\\\\\\\\\\\\\\\\\/EJ6tP6bLfOX2E4abq45CePwp+Qj+SfeppUMQpLIjIYUKznHPAOuuwwQb9Jf6yeSIwFJqLbOOzQQ19pw5IxmGu2llA2cex3O0kmg3\\\\\\\\\\\\\\\\\\\\\\\\\\\\/yHklCxRQeXT\\\\\\\\\\\\\\\\\\\\\\\\\\\\/0gUAHAKcFWS8avTgAGzXV9ygnklt+0g1x9x5uYbpWutwZaT1zp28Syo93LbPyeWOM8LDcfBYFn+VBy1wjXK9xmbaIBYQJDaclv2E5W1HdwrfAccGpzPsOeApEyG0lz3m1\\\\\\\\\\\\\\\\\\\\\\\\\\\\/DGDiOkk1Q2cE9XU6ANYUxLg4ZuM7lamyU5D20n0RYMM1k1kVS29CjeyY3klkWnc9mV2GqaHQGAoy6stGzcF\\\\\\\\\\\\\\\\\\\\\\\\\\\\/kNKhxbFVNwOEXAInwcku4fvXzqWVRQRlCSwe1eWRepvV1fynl0cYyFSKa2tbzO5WLk+Kwqk8SLTaF89LShcPk+uweyTLX1+T2UkjbUNlflNR1yfNqkKAcEg1oMkNaVqTpEU8qNRLJeE7S6iK\\\\\\\\\\\\\\\\\\\\\\\\\\\\/kTCARLxXMJWyFRQPSJ8hq5izlfKE2WO1LK0BKNRWsqf39kV93Sw5nCwVdZ30ZvtPmjDa1+cDhCbKWaoDJLsOF1ImR\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Hq525gcuMOMhvm4V0k97aSpaIPBZARDLOpUMPhA3LDln+tRIxpc2BHe\\\\\\\\\\\\\\\\\\\\\\\\\\\\/GE0qmzwmJ9hhCuHsorBvUc3OweXpKbFLutHgjXw2VslznSor1f6B4RgS8ONOU0xdkWRuXyxzRk796M5nB9tXA5BKevrytfGPVjj2cIyNVF91UoEo3s2rYTzNwjtAdWKJG5+Yo+NxHkVaXm9rjrQAjRebl8SP15eQWMwtDmrgBfcZaWPAS29AoMGI0ICO1jzt1j1EH6c9LPe5seF9rOZm7lxxE7fly6CYo3I4VEPw\\\\\\\\\\\\\\\\\\\\\\\\\\\\/eM8Wbu9wK2TIE17IaOWpSCWAVRiJHfiHmVBetzZ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/i7I7cd+bYRiWlgVEvEx\\\\\\\\\\\\\\\\\\\\\\\\\\\\/vXI41xH7FFja4wknaTu2C5F6k9c1IY5B0f0PkWmLLa84vStP18hMJYOBf4tMZNX7ssFeLMNhph1SK5ymT4VpI4yyfm\\\\\\\\\\\\\\\\\\\\\\\\\\\\/rbw\\\\\\\\\\\\\\\\\\\\\\\\\\\\/9Nq2fjtzsiLN6GgxB6nPgHND2g7f8DjLSTA+QbfH\\\\\\\\\\\\\\\\\\\\\\\\\\\\/4mL2h0L8jWwljxRAskbskHKC24Z48zZYWdH\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Acjhy47Bui54OzeYjsPUtk0PMDTOxMfEQZEe9fYT0D058oF03FA5oZQ6U5LUpc6t4CMieS7DK4Bnt7iO+\\\\\\\\\\\\\\\\\\\\\\\\\\\\/KpN03YycnWH5F5IanSb8ykENFUr6NEEyvJJMxxy\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ZEz+fsU50TNrUhbsowDVsNXjdebJDzaArBHjYC4VbPACEJqPnfgpCJORA5lHXAycV+NyEZPoEToEswlB4vjVvc8705KLY2Pp7s+Lixesr8LnK+h8F4Nq0R9tOKzHtxLntggjsbBFgcnxUB0O01JMYPPu9d\\\\\\\\\\\\\\\\\\\\\\\\\\\\/deYCbjGNxdeohx7Bg9B5JGX1asWEbEZf3uvXbbEcAhUvV8rRaWWSwgMl236pEAY7T4ykyphslq59JWVKLQZrZqWaEl5dy3EzHqCIozrgMwo+V18a8pGNuzeiLGqIiRLoZb1F82vNPeKgkil0y7kbVAr1c1WopA25bPhbKnJwuYLVtGjWhXGeHMgXvJ4NG1SKaqtQ+AAkAJEtErn73IiK4vpEvERs5jY11bxktoLK1M08mcX9gfDzUrKDnPL07awVI9XM2JvQJsYSc0G2Wt68o5TKVxvZ8mpVM5eYgX337zz72RnUBCsPfaZn1vCzD6heQ1phMbsoVouokZ8dbo84NHi8AtXraLSFynbchKILCxV3RRyqQUQJZC3DYeVTQJMvWPj+gMvfAXM5h\\\\\\\\\\\\\\\\\\\\\\\\\\\\/7\\\\\\\\\\\\\\\\\\\\\\\\\\\\/CKJSIvqrEX4d+k7U11ztLkIuo3OzngueOlqoKK4BCZ0r7dJLUDUsgW\\\\\\\\\\\\\\\\\\\\\\\\\\\\/1IMCjEUzv\\\\\\\\\\\\\\\\\\\\\\\\\\\\/EKHZdmippXn7Ykt5rRm59u76GxngYiXs1rhAAiui6jvszUI9tr++NJscxuoi8j5r+AiJVDab86xs7RX4\\\\\\\\\\\\\\\\\\\\\\\\\\\\/qG8HI7qdRnlfzcI74Qyc5G+qP99huk2vPmZXJ+yGq5fhK5vJSArI7nqEyja1+MFZ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/uhUm2MjHYA471XpJwGyN9qOpAIaimsc6vqY9SV3YttoJaBmTJpwEMq6syIoSMppIALPBZkAULkwFc3omvmsoIE2PyeXgA73GLa029AUPls1vshojOR+FxxEOdzcObBVjkyIpr6iWmZD+yUjpvOHZZPdD9zizaCoxoCrjZeeA0sSCSR8yjwafmTJCp9sQuSsGmwpOPDkUrh4vRbtHruaFfgD\\\\\\\\\\\\\\\\\\\\\\\\\\\\/tZroPx+WB4oH\\\\\\\\\\\\\\\\\\\\\\\\\\\\/k\\\\\\\\\\\\\\\\\\\\\\\\\\\\/dAn4DcJQUg9hq1PvzkfqJxsKrv8NDQ9rVxUBVeWKW\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ObkGt2eAomX1fWZgFT9+4wh17mwe1ctAgDUHePICF9wYAZk88j2yBmKQ3dh+NfF53wTlx5YvcI+zung8K5Six+tHdew2Djt8J0z54ht8vARopxN+5BwIkDPvYAHKxMKL0qiT5jzuhPzrqsGNWA64agJj87dFX1RFc1JtLkYccjeK2G+hYsun8dqr8rOsZsKly3i8CDrMQBBa+vCKrYyQtFDtd0tKNjigyUFQ2yxD30Q0cUCYaF7IckA52pr2o52kZmNbNgEn5TODei8zCMEPeYrp+OhKtsppaCU7RF5fSPG5HtVbYL765lSuUWVizYEzQf+28A2RPY7qO9q3aHA64mgwEQjIjjUfl8u+\\\\\\\\\\\\\\\\\\\\\\\\\\\\/UvREG1JNbffvONFjnVjRcVTK8h0ShDxNFfBgUYv4R9inmhvteF9dLLDM+AJk7dLu8dOfWe6MOP8ABLlgam7xlHxM2FvAB9gHi33Agvlsa8rePTVCOqBogoHS1Y3qU3BjYZBIFub7D2RL3fYI80VTebxSG1FlbBFUz1OJR3Z+L3mj4KspwpxwtZ+QvcCSUvpswShhNB\\\\\\\\\\\\\\\\\\\\\\\\\\\\/lfRjO6QXt1JlhaGCqkpixGRibxQbzhuhqfyM1L4I043UhZwivUh3S9xnb40m+MPJ2q\\\\\\\\\\\\\\\\\\\\\\\\\\\\/7\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ZSaXcqRInSVxu\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Q+SEdiZQ1G3N4xElpKvElPGxoO7xHEE32PnaQotm\\\\\\\\\\\\\\\\\\\\\\\\\\\\/tDGh8Du9f6wHyzSEyTqNRViWsopWIF2R3z1QpbaGBIR9YP6K7\\\\\\\\\\\\\\\\\\\\\\\\\\\\/8lfbeG7occlGtfRu57x7hGHCBmbNPlQTBp+yj7jqWJvAJtomfcCK4YkCbQYs\\\\\\\\\\\\\\\\\\\\\\\\\\\\/TwEGvlHm7AJ7DnjZaUPgVV9JLuLhxwcMY4EOW0DC6cnfw2l7R5q\\\\\\\\\\\\\\\\\\\\\\\\\\\\/LHcCl6Nz8mcZgmYjrQ5ysYvcV42myTcQihOo\\\\\\\\\\\\\\\\\\\\\\\\\\\\/1MLRcYbvaoufKSao\\\\\\\\\\\\\\\\\\\\\\\\\\\\/rmnp2zHxjNxbNh1s0vFK3UU90iMWlVx1OXY9ITYIqgcvtOwdLfOG84FoFLlX0RHuohiYTOoBS2AVPk8etYabr+VKGVBb82sBAp0tv9HW2+nj\\\\\\\\\\\\\\\\\\\\\\\\\\\\/XaYhrVBEm\\\\\\\\\\\\\\\\\\\\\\\\\\\\/De5oAkIhOHbt5+NuKsI956Dfgymn7og4yOvlHInW\\\\\\\\\\\\\\\\\\\\\\\\\\\\/oXSIbJra7ZV\\\\\\\\\\\\\\\\\\\\\\\\\\\\/AQi78MXCeTaS2+c9xecQ41srg92oDEfXg2PPKg38\\\\\\\\\\\\\\\\\\\\\\\\\\\\/lFhV8eqft6IxmWEt9zCCLmYE6RpnAgT07rhRR80gInT3lMYOpWguTykUR8V9pWwCFBzcXMglSpQj6Utcqc\\\\\\\\\\\\\\\\\\\\\\\\\\\\/LqfYznp3bZfNgbZriDVmp32BdOaGScvEHAtUWRKFWiBLdUMUAtvEWHjaW+WHY2nTj4tCdE8hhiahJ0qiJ1fw6TSP8B5+WvCt3DDmOxTLT60xSxmNp1es7vK0mEVVgaXEtJPwy5QptGtbT7qy9MOHD9F8g8U7Qu7+TYCPW1h5ojqfMjolvOPSeWtZM2zNW\\\\\\\\\\\\\\\\\\\\\\\\\\\\/kLF+aVp\\\\\\\\\\\\\\\\\\\\\\\\\\\\/KX6JSUyX8Mc\\\\\\\\\\\\\\\\\\\\\\\\\\\\/HyH4hFOShfXJuA4Ed9+PU2qn2jMzDAlQ9vrc1BXdWTvpNhCXL9UARRbQtaOxEOZkXVu1x8CjF0l3WBdnvJHOn\\\\\\\\\\\\\\\\\\\\\\\\\\\\/WI77uIGkWcHk8jj+O4k4NNOahrtEuBjP9sVP1pMBJGf9Bu\\\\\\\\\\\\\\\\\\\\\\\\\\\\/cURSntO0DhNK1E2P4umEtdfa2jKyj4w6Co6hFlMDxBKCCVidchUD8Bvbk9GZTIOOXuCShX+J4Mz+B+7E9zixa7yw5PRUEMQ7h0yowW6ozcqax0YDjyqtBmrimmOad80vEW0\\\\\\\\\\\\\\\\\\\\\\\\\\\\/H1dcAZE5eBRmgZa8yGVqxbHZyGA3\\\\\\\\\\\\\\\\\\\\\\\\\\\\/1WWw7fvZhICefLaATO0kzNWEso7e1M3bXcs0UW42nx6yuy9g+iKKz6NyRMJ3Ujz5dBR6WJkkiJ7+joz5uFFLIJ1hGkknImtPYWXIDscMkKedkq\\\\\\\\\\\\\\\\\\\\\\\\\\\\/7TYbayWC7z7Q0Zn342eWqK6DbLme1lGDVJM0j8Jzy2qvqNnd4bF6npGtuZouxsXrgoBnXeWj3uPNkhikl+h\\\\\\\\\\\\\\\\\\\\\\\\\\\\/LyXhdLSQXqXnHBYrp0mC6TdwSrHz986Fc8f1IweyMzIKUgjOXTKAXTFXfoBBuLOahHjQBaQ0G8dPclkGF6a6jQmpGv8eQqKn7S9qCu7qnOw6Wfq3FSsJOrjdfFAdpuJ+tZXSzhwRZxr77VNoRYYCZrTZHNbOoZ1LdnrG5Sl+LltTZelhCxRSl0vjRBueNNDutllvR1+maRM3NQysPuRlyXHQ5ZS8Eq25Qwy8DnCl6oEJoC30onuUk9Vti9N6rnVpgGJY5jmxqdS\\\\\\\\\\\\\\\\\\\\\\\\\\\\/99K25q1Kmqnv59W1SdcXpfCOIkkD+mzOGpOEcaE884t6OtK7Zrfr8xW7VTJoX+bP1gGsrCWXM8OjZU7rbLtfa5Acif+LjTZdTjrVfblpSx0U8iX8TPXhUfeoWKNr+j9fJZ86\\\\\\\\\\\\\\\\\\\\\\\\\\\\/8cjK4XfVsR5x9j8QOkq5TX5zolYWHcW9v+7CCK6SWJI35vhQUCrFVYMo1GeGUQUGxGKXixM58WbILJEql8Oa8\\\\\\\\\\\\\\\\\\\\\\\\\\\\/k6ZJ5vinFXCeacmBX2LpcsoqdqL+5hDVtsd+W3tTDwRP1E2Bdobgcf3NseOomYd3vsLvnXAXaZ7N1GUunN0T8OVatijoPmr50XlHh5Nv4LluVrKG8YcTLIUOrFd2USAIEkFR+F1zul931zWCs\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ddQTQqJkFqd6M\\\\\\\\\\\\\\\\\\\\\\\\\\\\/x0K4ecgwMZcdvASWTDlrEYL3Ozd54QLRVt\\\\\\\\\\\\\\\\\\\\\\\\\\\\/qwCrJ9LP6VKPH8rrFQsqLrzpt+3K8xv27H\\\\\\\\\\\\\\\\\\\\\\\\\\\\/TWHav\\\\\\\\\\\\\\\\\\\\\\\\\\\\/4CD9WHkP8lkqWs\\\\\\\\\\\\\\\\\\\\\\\\\\\\/SlSLgjC9SI8nvpiQRFCcNNswOZgRtO9K5b43iC3+zpVaHSJ5FPA5yABt+CWocpYyvmHm587KrLFPa\\\\\\\\\\\\\\\\\\\\\\\\\\\\/rY7NgI\\\\\\\\\\\\\\\\\\\\\\\\\\\\/\\\\\\\\\\\\\\\\\\\\\\\\\\\\/xcPAcI0x6dfAkwp6LfG2lzSLlj6lKtxZZUqnBUPpOFtlVxVAoB966PIB2L0efJRxgZrlamfmtrDJ1fHlKja4OaMBVMSau1uUOuUM8dbZul2MBxD8s9KhogVcQgidNwnKBIvLPzn68gBBo51WvRGjv\\\\\\\\\\\\\\\\\\\\\\\\\\\\/FDvZyiftw32ywHrXiTdQKpGjZvehpbUdxzA03quKOPAa\\\\\\\\\\\\\\\\\\\\\\\\\\\\/lLALC59XykbcDTGPR4\\\\\\\\\\\\\\\\\\\\\\\\\\\\/LrhUp4eND\\\\\\\\\\\\\\\\\\\\\\\\\\\\/skLn\\\\\\\\\\\\\\\\\\\\\\\\\\\\/yYFl1A17TIbsH\\\\\\\\\\\\\\\\\\\\\\\\\\\\/4M2Oqn6VbrBBDrN7L4HmRy7zuTtF\\\\\\\\\\\\\\\\\\\\\\\\\\\\/47VZxbwZfaN7inlLPy4bqZ2ehB3PjanZZUiApDL+OkAvRVLMCwX2ilyLF8AMRb55h7G5EsBNrsL1PfuwhD6KhfFL\\\\\\\\\\\\\\\\\\\\\\\\\\\\/V06r1P30+2pSm4Ed8vD5aQEai2jRmViO+PPUfXNi2p\\\\\\\\\\\\\\\\\\\\\\\\\\\\/C\\\\\\\\\\\\\\\\\\\\\\\\\\\\/6D736r5YI9wzrXKz8kzrRvKLfVAIETNx0gC6wG3uFK4g+nCs0tp1E2t\\\\\\\\\\\\\\\\\\\\\\\\\\\\/YtsiNpttdEfWKCKhBEfyCarGIqQCp\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Gw1VHPUnN+TWlKQL+yw+Uh2K4FkW1GUdKPYYvpbiVN9TFd3\\\\\\\\\\\\\\\\\\\\\\\\\\\\/NzDcZWmrkymaaiZJ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/PGGSDWnbWH0icOBL28564G1wV8gnsjBUvbHaniPfMYYHPu2J2wVzkN3V9dGHeZucUzC8odN2GRx5SwBz6rWaLihOcOQg3g2Jnik5OAEKVUeHlB15KkTXlatdgZHoSPW9uMezXxTdOuJsY3cGGDML43GfNh7pDc5fBM0lFN0zwwU7XvQ3G1WAjA6opjd0G2ODUpfn1QFptTOqlnYh0bg3jlldiGPnxhg5PFbNSzOpEJ03yxP+ALv+agt0P\\\\\\\\\\\\\\\\\\\\\\\\\\\\/7rNkq0O1XAi43o3pp4yiLyp33YQSBAir68I5NvXpwq4FLTZkt+4w0iQveVuXvVYLppZpDIfbXA3mas5ZRVstJzUKUpeGU71BmKXMqwgfYakr20GdjoL\\\\\\\\\\\\\\\\\\\\\\\\\\\\/CFFXJngeLgGPm33HK2phLChQA\\\\\\\\\\\\\\\\\\\\\\\\\\\\/YpEFhCjYyIfC2Vr4h7HVCwk4kdwkFgHz4fsC93Ah+2v9DLzpz5dvHMoYgvedYuSWmIgYQRJT86mvV032xNAETraTDduz24rVUoC\\\\\\\\\\\\\\\\\\\\\\\\\\\\/HrOwOYY1oJpRZN6G59qHAG\\\\\\\\\\\\\\\\\\\\\\\\\\\\/mV7ipIdL0wr6T5R962XA3LHWZcjPDC4IrOYXNd8ICEWN2iiwQ9I3tKsYEcggQPG0bbBBIMMfPjFdIRrDrh5G\\\\\\\\\\\\\\\\\\\\\\\\\\\\/CA05\\\\\\\\\\\\\\\\\\\\\\\\\\\\/cS2mNcT6y6SDkXLAR9wxi10Wko4vW2Icr8zbqc1Mk6yLHR3+x89\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Y+5iUQ3cvb240TY84rjfLJ+OPB9mbPRk\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ICjUFpRBIvnwA6W6d4zE5NoZidFXR26ROQhl0mWbkgiSck2xihtCpMkX1zA358kSWnAwaWVE1jniN4WrFzXijXQIDDhLqbZEFcLxKZKm2Bpyl1yNc0shV1KiAicYVYAm8fwRvovJIv8Q9oI5\\\\\\\\\\\\\\\\\\\\\\\\\\\\/NAI+UOhb78VWZiA\\\\\\\\\\\\\\\\\\\\\\\\\\\\/\\\\\\\\\\\\\\\\\\\\\\\\\\\\/gu0lrBaMx7ktiULbD\\\\\\\\\\\\\\\\\\\\\\\\\\\\/uynEezoV7\\\\\\\\\\\\\\\\\\\\\\\\\\\\/8YQRcuSgaqB9poCPbIcG9UpwgKcVDT0yLlChPva+lFPyjbNi3kGdyQOgzDs2ejheAy3pZ+pJ3leo25VtATl3Ts+ZwZ2OOyLyROjYmiT7p+UKado\\\\\\\\\\\\\\\\\\\\\\\\\\\\/t\\\\\\\\\\\\\\\\\\\\\\\\\\\\/pxqgAGL1eqZaBRAGHug6HdCaE3s7J\\\\\\\\\\\\\\\\\\\\\\\\\\\\/9G+UMosi+BLQ16PhiKBGWveUNE\\\\\\\\\\\\\\\\\\\\\\\\\\\\/qTxT43zy9nv8LmXbDO3xmydjFei+MSsWGXY1CtZKj94jmxVv4jhGFEvP9jyPDSgEypeZlrADqTBNvxIcYJ9dNARvDmHN2l369wDSxKG+Myfnq7WyBSgzs3YR474gDxX28o6R2tJXfge02R9If4OVF0rLBsdpgj5YsbCWKBiM7V3mJiLatLrH+25H\\\\\\\\\\\\\\\\\\\\\\\\\\\\/SiaqgQV0pTNOoe9ZEDLJ+jN3O\\\\\\\\\\\\\\\\\\\\\\\\\\\\/NDeA+5qn5NnwuCtzBea7z6NkHIO+lQrW3ltEEPNJnuYqizQA7OLZuUZw89Fs\\\\\\\\\\\\\\\\\\\\\\\\\\\\/PsPv1xU9PxRM1fRcU\\\\\\\\\\\\\\\\\\\\\\\\\\\\/B9Db8KanuAcAI95pNpFO1JdY3ep42M8kbvIed2\\\\\\\\\\\\\\\\\\\\\\\\\\\\/s5QyFlWF2ftilhcUuY2JNlxlLMZlrDl31MnJk2RhJ0Qkk9dLHfnpqwx6SIWv8I\\\\\\\\\\\\\\\\\\\\\\\\\\\\/F4QcYn1et1YpP7HZpFfY6RyE\\\\\\\\\\\\\\\\\\\\\\\\\\\\/f4q9lTd6bFDkpm\\\\\\\\\\\\\\\\\\\\\\\\\\\\/T3jWl5JnhmWfCBT3jkd\\\\\\\\\\\\\\\\\\\\\\\\\\\\/\\\\\\\\\\\\\\\\\\\\\\\\\\\\/M0mijVF9dp\\\\\\\\\\\\\\\\\\\\\\\\\\\\/0X3lLvJH1PSjYwRAzd3P4lF5K7531WRO9jHtLcS1PAVx51PNC6wHMpankwpMkanwSBGC9u91+rglcmCpVWvXG\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ZBt5NepMLLrqC5R1DsMNZf4nLiO07BjtUZLNLsfK2p16klqln\\\\\\\\\\\\\\\\\\\\\\\\\\\\/0wybkivWWHHcn0fgIfj3nnQmCF3N8REHBitoFmZJ55k\\\\\\\\\\\\\\\\\\\\\\\\\\\\/0gmPauROmgh3tTrJ9tH53du3nGlUMBYMYfF7yivQuc9X+5KzASfUuatejRemBabEFY7ntSnJu0gfRR8zIF3wKRk7e1QaPOZh24eVWAo3++7zNQd\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Ytcndh99PPyMnrs9iylytgTcMv6VUOf1XfKCNw0Mr1PzoWyoqzpZeWd2GG4\\\\\\\\\\\\\\\\\\\\\\\\\\\\/E1Da+fXyvSYZxrrcyNDOPbRhnFex5UgbucTI8L\\\\\\\\\\\\\\\\\\\\\\\\\\\\/w2fT8zyIK4BCuSifr9ypLyqa\\\\\\\\\\\\\\\\\\\\\\\\\\\\/dH51hgPykAU6e5RFBratUK2RBjioMjAyAR8vrEQjzLrADrJ0aCcvJ1HFVe6+\\\\\\\\\\\\\\\\\\\\\\\\\\\\/n1ttVFYMvOIdF893U+HMyRHz2wqVy4TBDfyd\\\\\\\\\\\\\\\\\\\\\\\\\\\\/mqM7LnTZcjxKuVY8QLkZhBnz9ZhZ5T2Bcagdy1BwXaXYjEvXpRBqeDlM9mvWKI8AfqWsoh5evNeXkbCtRg2KjCm+GkVLFW8zUl6Fublcfy5sVonXAijt6PDfTB3OaYO15r7Onmilvx8Fp09hO5L\\\\\\\\\\\\\\\\\\\\\\\\\\\\/+OMLpEdoLjSxK8N5XZu2trIPrzCfgY75xLnJ7QaTFZrpizwqsccY6KrpTNU8DLestTHtBvkx5RgL3QwAKTHF+Pvaq8hn\\\\\\\\\\\\\\\\\\\\\\\\\\\\/X0tWXUyzz4g5uX2QKlPWQZqoV5+VI4+Er0fJGtxbRnfqM0Arb9tCqckxvRFpwOfvWyy6ivCsG3oynNkEWTp3BaFkS5a9drCrLboeLjNsXF1tUPABXw1vjTvPvKSTjzxUxldbLGhJDOonvuCZiFdWL+CDwvvbSMI15VK+XegBfHgtH97iX7xuaj01ghH\\\\\\\\\\\\\\\\\\\\\\\\\\\\/5+AYEb7RGlFwd+kuqbLXkaVhc5D\\\\\\\\\\\\\\\\\\\\\\\\\\\\/iNW\\\\\\\\\\\\\\\\\\\\\\\\\\\\/1T6Fo9mNhhykHUexdPKECwqOIZ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/qsaL722+dNES+RYVJu2RYAAi0V5Q1lKxnK\\\\\\\\\\\\\\\\\\\\\\\\\\\\/DwPXL49MwNPZyIZ9O+X1NxmJGXR1gf8MffPkLYHm\\\\\\\\\\\\\\\\\\\\\\\\\\\\/HtmgjGq+mpPBQVRJ4MQ1k0XkBAG+EKvUuxcvpHnrhrf9SCA5Go6LXgpimAps5M6b8R29zO\\\\\\\\\\\\\\\\\\\\\\\\\\\\/qHMgBJd21zx3blEn1yLMkdus6BDBF2\\\\\\\\\\\\\\\\\\\\\\\\\\\\/zb34AgfcB\\\\\\\\\\\\\\\\\\\\\\\\\\\\/wvnDCH+qNkRmXMu0B+fqrWyiu+ypXuZDmG1LfUKe\\\\\\\\\\\\\\\\\\\\\\\\\\\\/jzrbcTwsXgsP\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Zt5YuJZDzPVE03GTkX2tGuwim+89EXwpLDxaK6OjCa69vnrIZgb9ZTtvW5FGVu5SLLBqsWEZIcrkPEUjn+s0yT+PAwIRoMCqCmkO\\\\\\\\\\\\\\\\\\\\\\\\\\\\/DWqD8tDAXa5xW5w+01+M1s9Dk4llQIs4FjRBz2v6354Hxg1K5daJmplka2sbOIwJ5zS26h\\\\\\\\\\\\\\\\\\\\\\\\\\\\/qVw1QZKUKm9NV9jCvNHq0TPJEl9X1H\\\\\\\\\\\\\\\\\\\\\\\\\\\\/s1PW3c\\\\\\\\\\\\\\\\\\\\\\\\\\\\/NQZKnI5KkVx\\\\\\\\\\\\\\\\\\\\\\\\\\\\/aM4M5TCtLxItbB98Cqy\\\\\\\\\\\\\\\\\\\\\\\\\\\\/a71bcYeBm49R\\\\\\\\\\\\\\\\\\\\\\\\\\\\/BoqYnki\\\\\\\\\\\\\\\\\\\\\\\\\\\\/6m1My0SctOTd8vMUIL0LusX\\\\\\\\\\\\\\\\\\\\\\\\\\\\/EUpbHh5zxPIQf2\\\\\\\\\\\\\\\\\\\\\\\\\\\\/O9jZHLDiwYOXRjRw3Ig\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Wok3V81P2Y1jkHH+C17EqqmA+7TdYa3iPavX3ivrOrzh7B5Yn1Kbbr2GPwEpvFLLGuwz+wbaEGNQYIfdBCn0cUzg7F0Wy2pk4XOiHb3ZbHdxk6rCTpRHpwtwcAmuYM6d8ta7wbWlYswAHKTAi+X9GmTcf0Aci5TKX8P3MrLAaRJw5o7gZ8E9RkSsoDillX\\\\\\\\\\\\\\\\\\\\\\\\\\\\/RvVfLxXaDG7bcw1dsWRz0kixW6loW1ywjIDmYuTi6Y4XAYuvkES+a\\\\\\\\\\\\\\\\\\\\\\\\\\\\/uymffXSTnpK0WyuzSroq+DIFvY\\\\\\\\\\\\\\\\\\\\\\\\\\\\/us95dUmnHgloa4eKn5yLTgCF63TQDQdljbJipXdQxUtxv9utqY5Zo5TqG6UAFE2+Mmqd8Rxe3EWpLOkPOkKefbIBvDyHVlH0xezsbZy1jnE0Q\\\\\\\\\\\\\\\\\\\\\\\\\\\\/WL4t5lJfeUfCON8q7T3IVyLQAga6SkwuJzvxm12zNn7LzcHEvSw\\\\\\\\\\\\\\\\\\\\\\\\\\\\/\\\\\\\\\\\\\\\\\\\\\\\\\\\\/g+NPpCeptdUuuG217P866KlMwo7TPpEkNVe8RUdIMnwen3rTwd08DPCs2JnKGRtzEwe7uClwkqO\\\\\\\\\\\\\\\\\\\\\\\\\\\\/2vvAYVZY\\\\\\\\\\\\\\\\\\\\\\\\\\\\/caBNTU8t8m8g3erO1vn1sjdnBmlozvSz502Z4ncARLBfJDx0Kv6Eto52rD7Jpa6rvMqyNtdAoA8gmynf5qilFHFMss51VW1YkA5YnyXBgryhktDe1kncr0CX8P2brOh68Fkrx+bn959nfhpHoP6zwk6psVoY05k9DlizX5ikoq0c8Yx0DZhfAhq7RZ3L2nBI50vMISzoxjxUDfg6MLcWnWzh9OHzrcEIaTmaXj0p9kvbe8TfCzISFXOn4r1VDMasl4aW93iGQbI154YkbiwSSMW8JGmw5YpWR0cwRL0ugiZOimH0tQSDJeFDuiALX\\\\\\\\\\\\\\\\\\\\\\\\\\\\/EXMESxhwBq4KNP\\\\\\\\\\\\\\\\\\\\\\\\\\\\/DaeSDsIsN8Ffzan72DrFs\\\\\\\\\\\\\\\\\\\\\\\\\\\\/l6gF8xLNkevBZv8yxRI\\\\\\\\\\\\\\\\\\\\\\\\\\\\/vSVMiGRBX+mmVAdCRIAdNwvysbk4OD6iH15nqdfiAJjswOkgHzDHGtH5fubpmnYMDAzyKdrE7Uygq+8tVHRPAP+AR4zmZpRIaAWodIVZGoRIButajwhbP1IPx5Lc391EntsP9qtGOp58Avn0ZA2olxDhfSFMsEAJpsKVqUBmeTv3iphIPJ08UU2dLQmZ7hnlh\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ceH7GK5rAnG1CKwU8iDdzPI+LwmbiBnbQ0Er5hEFO9WHlG1Ik9Y\\\\\\\\\\\\\\\\\\\\\\\\\\\\/s5DKbptCwP2FDcFbhUEYqHIu316QSlcPpwOhv+XhGkrcRzlqU+6+voBXD34ve8wFp8jkXdvC8\\\\\\\\\\\\\\\\\\\\\\\\\\\\/uqfVQHYCVIWt8s7tuyyAjPikAvIkTQrsNHqk73GACS7IDt5olqczuq7GDADHC08r1EoQFLpT0mB2AWGGUYbbcn70qL2HBn9365iLRT47ySgt5Z2e91\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Sn89+bGWbEArpKXiMmmAPo8+VEmMc7Gf3U0uMMJvg+s144JTNk5CPKCiJugHL9JR7Ce3dDRI7E5hY4OuG3P9NFpgazw4fnKI7pmLsaGfift4WrkmNZYdTmqgP7NJ91ruSUpIfl6PohlLKlBtwCuX6JMJOZ2B9O7CsazEjoUIfVxRqtqKBT+4eaJnfrZRErqXlCFKYxTQHVlFKfqR6Qnj83l9rC6EaiDJKEJB4fGyb2PtW7J7j+yJOTZLi9rxC4JZpf5MiE+iCpy4mLtytQDFDhkUhUYQL9Sr0DxtgpBmkxlsFvSHIRLRpiAP\\\\\\\\\\\\\\\\\\\\\\\\\\\\/3qKyCybN4dn3rD9I15NvlPcuTV7tSBhN1MJa\\\\\\\\\\\\\\\\\\\\\\\\\\\\/GrXvxIosbS81Orqu4zg6cLD1AEmYDUZaAdaHK\\\\\\\\\\\\\\\\\\\\\\\\\\\\/XRRMwMcEEhayS0Roqx4NM8ZnyTaEG82LC7Z97wFOAvAYd2Vh37xEjbaA2v1Mn0u094h1XDcHwlfPN0zPe1pEXXdN3qaoZfOwN2ghtAUSpyeOQm4r5+Xyo186lIo4zAjb9BKmyMPGHk7qvrv1UHuIzTXKcY7zMNL2EKQdfwsfI+fBnPfIZ7GfTV9y78qAiiZU20+QlcgQQwvUpBh0D9KzA2OX2fFjIksLskOWDCLxLLwi5bk8pTKIrTd+QNQJoVvzy9zpTUgc3jY6bcWqaeBvn\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ZCXQSOkt4BCOClhIr0eyFY\\\\\\\\\\\\\\\\\\\\\\\\\\\\/XBTbXd81J+nUfCJIAxqHVQYSuWKO6iajQIWwQKTwHag20JB35Gmwk+iRTcpqizgPNcvv5aP5Rqmwl5qIeMoHrG4kgNS81N1w+DXrchaE6p+DdQ+eIF3TfudoZ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/3eJ00p6\\\\\\\\\\\\\\\\\\\\\\\\\\\\/hi0C777aSZjeHbIgWluiV3HNgfviAyFRYgpWSDEOpvZGaEmyn\\\\\\\\\\\\\\\\\\\\\\\\\\\\/gbOUJdOqlde9RO0j7HM6RF1Vpa3IuXsVQTX6ORZ7+dN2Ug3vhGrm8fFokseps+Ru76ZwlzL3Ik3vEt8yz3YmgaUTg7gGO+QTEHPSf54qS0ypvyx50atcLTyoepIuaP3jhbgBuNCwe6bRVewqqKPJ9ML3SHyKPYQRM8Zm82zoF\\\\\\\\\\\\\\\\\\\\\\\\\\\\/dvYn1ubBX1wTrg\\\\\\\\\\\\\\\\\\\\\\\\\\\\/JeCg3t1E+vGWDNReEbn5\\\\\\\\\\\\\\\\\\\\\\\\\\\\/eU6rngF+NCFVGWd\\\\\\\\\\\\\\\\\\\\\\\\\\\\/aWyiU3HGWmrSr2e2Zu2CHDT4MZLMrvlxjAGpH7zMrKRoKsDZii84NVdBUVnFW6j8g9NWppadXzt+3JxW0tk2lCcbnOyIArb7l+vNfMlUW0itNzQ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/gispOBYuiliuh7S1js2s5PMxwHZxyytpekfcgBoFFvIpvCNEax4thTfBK03mq01fAE8Fu8ImZkHeh0woVX58sMOTIPFzv\\\\\\\\\\\\\\\\\\\\\\\\\\\\/74C9LorY+66KGvnO8N90FKjeKW0tW2GxERg3r9riDFQiVBoG9qhd8foW2kgfj4xfDZ8Ll+tQNSMwmuyRN3uF2nUpEfgwBdkQ8+4XDxMUZRquIZmuO\\\\\\\\\\\\\\\\\\\\\\\\\\\\/U4eV4VvceLb3s6NUr6er4sBLFmWvw3msIrOMuq+IjjYRtyu3eJS\\\\\\\\\\\\\\\\\\\\\\\\\\\\/PED3fqGbdpRtWODQjzTsgW3GT1EIhQgGvl9qnnyu1QLY\\\\\\\\\\\\\\\\\\\\\\\\\\\\/7P+o2fHKwcr4crCyi8l24PLfU60TBOgjRFC5BIwggJt21px8Bzdfv4rnSWY1SuLKJaFCgGCP0qGzj4uCNeX54rlFNrpQDPAQKI6gGeHCPywp4nzZfCQ2Suv3c29vPdHcNQPuZ9UGYn4TJuMknmBpRTx0TxEF\\\\\\\\\\\\\\\\\\\\\\\\\\\\/oX1+cVGvy0WLbMYLKFnkqNa6tfpQqkRsfg4\\\\\\\\\\\\\\\\\\\\\\\\\\\\/a9BMeoyfprK\\\\\\\\\\\\\\\\\\\\\\\\\\\\/orjFMCq3OAvGVjXHmpB3jZwq4+JwngKBVEhEvO1ToX2c+NJtidtdjE0dunvLnkmCoPt2wsZS0wyDYJcROeej3YtcUgW5Egb2aT8+Ancme1k6i5nvFa\\\\\\\\\\\\\\\\\\\\\\\\\\\\/xQQvcIoiJ4+7MqAm3uz5nPwmFph4T+waEr5QYRk8RTKHWK0ho97HgGZ2FxZHISHO971zogRUZ7Yko\\\\\\\\\\\\\\\\\\\\\\\\\\\\/f9wnF0QAMvm5ahhsmG3\\\\\\\\\\\\\\\\\\\\\\\\\\\\/KZlNC0parcrtOFwFalu6\\\\\\\\\\\\\\\\\\\\\\\\\\\\/N0H\\\\\\\\\\\\\\\\\\\\\\\\\\\\/FmvzldjE\\\\\\\\\\\\\\\\\\\\\\\\\\\\/hHlrSAfIyesBijQnvAnbgOYleJ3FFV1PRfH+PVbvamGji7+AXVZ14YTLFA9LnEC+SIGTvkusAPqj4v+n5F8AM4aTC2MTfQM18BJSZErUZLRd1rXnzAdqfH2x60leziy2gFoVNLtEyPmc6n7d54i+DXUk0fSYvDJocEZgKsB36rBJ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ZiIqCm2ukhmrbkDK7bTU74idwNubqmOZaYtRf3GPvUcqwOC5CHA4zCCbWeYSO+yyh3obFsnLT+lEK468LM0fhzyBrMb+mSVkPcGSYycvNcJR89hYBILHCeocets1q1w6hVDDlsnvUObnrAtyJvgWAg+ZMP21YTSTUzbDOawnCLdCdmr\\\\\\\\\\\\\\\\\\\\\\\\\\\\/3+TGzUuRf2g7Y1G8+7i85hsrdRm5Mz2yxkiY1wvXB3xjBSsY5QCQ0hnCzkAKUaMYnx\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Da6XwJNgv9HfnH67MG+HIL0oRIOGzLKjOLECZz+Tghm1QLtG3XjEbTxa2hWKFsF9w3RaIORQSfGBAvZKzYABupmRx0iUWWn9WCagim7jzdd2tBTy7uQRaBkkuUyKCyeoCSCymAWSgvnEXPmOz2OMaBaU4jpnWCwdEfy\\\\\\\\\\\\\\\\\\\\\\\\\\\\/uNKzH13KgDt5t0toaougOzJ+NnVXy5+b3HkLPgikvKMHXfD25kzc6eGhQ8LNhO5Hmdyu6zBMJkmGBPAKHxmzldbaF6Y5l+0hofxyx01\\\\\\\\\\\\\\\\\\\\\\\\\\\\/MQsuGmaTJFXzqJ1AwR3dfhe0EaH9ZMS7Btw4MKj8EdwShplPDHSXmBFgBsh7oA\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Ex9zuvPPp3ocHu1Mw\\\\\\\\\\\\\\\\\\\\\\\\\\\\/z25eX5v1bVGwvhU2D9LFHNl4Bs6lIEL\\\\\\\\\\\\\\\\\\\\\\\\\\\\/0QoWJjABwc1vtyX8T7MY1RxNfuZgfZBeaOlWqcElQQSzhnjiPI8i\\\\\\\\\\\\\\\\\\\\\\\\\\\\/y5cr7Bb3yXphPta8EsdxSWcvEKIPjCb+ai829HKhH64\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Ln8broLItD4mMZBPxWArilqcxQJYDlbPCw3JQ7Ov1beqjXyyni35kv6zYXj\\\\\\\\\\\\\\\\\\\\\\\\\\\\/QsUaB7UCdLBurJLZRXOIpsWbZKgZ5ICCm196lBAc6EP2CnkmiRa0iakz9DzZEwHtinx9hArh32wqFWtHgZGISSQHvjaVLnWvvryALuronCG1crRYCeiyCBis4PXyVV6EUTyDf0eGU1zde+j\\\\\\\\\\\\\\\\\\\\\\\\\\\\/7OAHFExPd+Jpje3lm19bNlJ7pwCvMps6QrSh6QScETQVSEnb3H2iGmk3QlPus3slDe5hTw7wi6ub1no1KCa\\\\\\\\\\\\\\\\\\\\\\\\\\\\/2E95Ib9oo01NEbe9QXk52RJPslarxlZMbeLnmHWXfJ5idV4bZpsGWSg0hO8D9Pte6zbIxOkRVn9\\\\\\\\\\\\\\\\\\\\\\\\\\\\/4o\\\\\\\\\\\\\\\\\\\\\\\\\\\\/8nNGg+lrVLInH5MsMPo4gfLyL5d4rHbmiu+qv1dYcMjDW\\\\\\\\\\\\\\\\\\\\\\\\\\\\/UnIbPmjJVNQKSJXqgvSbqCyzYyKclB2KVpOxXVnIPMkMQNpt2k4qHzbfbciKeDC3v7Gjs5LOA6IRrwEOgyWn\\\\\\\\\\\\\\\\\\\\\\\\\\\\/dR3kP0GcZx0ln\\\\\\\\\\\\\\\\\\\\\\\\\\\\/QezTKoDAT4vk56EQOy1lNbtTVY4699yFMyWZemcEPuOk8oGBAJCtJuqayU2kXjj66yjGVA1uJTz6IkCXayyr82B84XSAGhahJ432Vmj1On6q6pRDFuwiCWuoes85YcLFtr7YS6HSZPr1Tlnv9bWTGY3P8VW+SmXKgqgRRaids4Rlo0iSUYl4TegSR1eSLjtY7+g5usrIqgBV+QGFLSyn9BdonnGWtkaiobEeWbaL5tafPvRkaTUfdLAn7N4xecJNS9RCCWS+AVEPaOEQ8LBrujiWt+GO\\\\\\\\\\\\\\\\\\\\\\\\\\\\/47wLNDS7KzQq4DEGJW\\\\\\\\\\\\\\\\\\\\\\\\\\\\/zIb9MH21ZBWe6D0FXp\\\\\\\\\\\\\\\\\\\\\\\\\\\\/epUQik81YXd8kxpcNb0iMUokRgaoXcMpQBgVmlWFuTYytPwayoa1cuYR6MtOLjeAS9y6aWA9k6YTouc+jIP6YtgztKuKG5lMlTi3I0ApTBBWi2L4ffWUWLGxlcwWFMmK0A9pCigmNEwsdPguYXgRoDbORBm8r1bGPmvYZ8O6uJy128ThZnRpqU7Oqf+ZP29SmRPenVGJQQYFO6AM1tQP49UUVmWv8dUjf9bJt6Xtb59fnovssIXN0XMArMmJagoK5hBs215T\\\\\\\\\\\\\\\\\\\\\\\\\\\\/SY2MUQy8ptSMPZ6qcko47lYpp4nvUKZox+Jwd+TmtqJwYrdZRbLHfAAjImUzHhXFKIj78K7j\\\\\\\\\\\\\\\\\\\\\\\\\\\\/0nroy8JuQ5\\\\\\\\\\\\\\\\\\\\\\\\\\\\/P5okBcGC9V79sdN95U2bofRs\\\\\\\\\\\\\\\\\\\\\\\\\\\\/\\\\\\\\\\\\\\\\\\\\\\\\\\\\/anbX51qjKMa4bHDLlhNwrWK7Hztm7L8+Ye080uinNSbbxEGRhMDNbOJ3gbqohw\\\\\\\\\\\\\\\\\\\\\\\\\\\\/V2tP1mzw5W8Nx8iUT+JijH0Vv\\\\\\\\\\\\\\\\\\\\\\\\\\\\/SQlt8pcMu0tdDibyp7jUZ4SJ6OGvSYHvZCrCdMqrrkgz3InjdS2CN2VV84hd7bL\\\\\\\\\\\\\\\\\\\\\\\\\\\\/moxK+gGEn9lqgoSBfTR3BCkmxdRQL1JCXXM5O7GdGb5Ps6esQt4y7Z75hS3rMBxX6n\\\\\\\\\\\\\\\\\\\\\\\\\\\\/\\\\\\\\\\\\\\\\\\\\\\\\\\\\/cZlCV74p83UmonTWMtxbeQ6IvO\\\\\\\\\\\\\\\\\\\\\\\\\\\\/JQBA0bieg8uXrAVAOC20WcksZj3J81hph+V6BKKTWELPmOq771aZ8xEd26w\\\\\\\\\\\\\\\\\\\\\\\\\\\\/kDhRe0fI5108T0Sasb9spKULk85scKb20Sliw5uNOVE100sErtTRXrJnLyJL0CmAWMq6w+mxFMB+KUrC+bJVmsArxhvjy\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ifsK8gh1x3p6b5du6qJrC2M3ckt4uKHraBD8d9Oaw\\\\\\\\\\\\\\\\\\\\\\\\\\\\/rYQAqC4rL+E\\\\\\\\\\\\\\\\\\\\\\\\\\\\/TkzbOQJftO8DUw9TtDpx\\\\\\\\\\\\\\\\\\\\\\\\\\\\/jxfcLa2yrmCTWt34zqw2jF4ZfFzfImvZsB1ItQWvDxV1ruvbjBtIRXS2Viq7QFucQpWPRlJbaqqiywrJC49Y6RyZTVzmbheYMdcajACOSC\\\\\\\\\\\\\\\\\\\\\\\\\\\\/cwl8ZO6DFzKRHXo5uMa5FNB6bVAODSnQzEDvRb7D4ZLplMT18\\\\\\\\\\\\\\\\\\\\\\\\\\\\/kzJg9txqwLpvHHEiES0qHaJyphsAUsVyXPuU1NOqD4r3UHcaGo3n2Y7hWBmmoeAkOF4TBdKpxX9Hhsn4TzrXSHqonBz16ET4qgMQ2HNBnoAaPyUcjvGc9w6V5k+SXZ3l7jpjnk+BR5oCLdTK9+kBtZJMAPDM9dYJxe9Z8gzV5FicM\\\\\\\\\\\\\\\\\\\\\\\\\\\\/OcXGLWnRrvjhbbujYITwKDfbLrOF27j8rnWN3FWA0ymZXnCJXcClUM3Ilyj68yH30RvZGVbxDAA1usrJB4AJEON3KUzHS0ycFKH2BWcghKIHsfR18ujscDcFeaQyrAbEzxmNmBQrv0jVC57S12tzodVbHNrvKCxOM5avWxwxYs7+zupitKBumcxPIMlpIFjZnPfyfMESxOUvkogwvvgEqRu8g\\\\\\\\\\\\\\\\\\\\\\\\\\\\/2fjcWH\\\\\\\\\\\\\\\\\\\\\\\\\\\\/mNLv3eW82yblbO756kKrWVytKW9tjDoQ7DV+JptJMQVW7MfqRCB\\\\\\\\\\\\\\\\\\\\\\\\\\\\/iIY91KBJ8yxvWZxpLyWttC\\\\\\\\\\\\\\\\\\\\\\\\\\\\/thTEbzZefEmV2dp3xMxDg4uwBt6P7nfKStoN0\\\\\\\\\\\\\\\\\\\\\\\\\\\\/3sksZeRTlyQxxoqJ9YpJSMRZZrP4xYDABY2G4FOrEJyuUInQitmdh3RiPlLqXsz4h150TNSJj6CqN3LI52w\\\\\\\\\\\\\\\\\\\\\\\\\\\\/RWCPSuPHMPS+UkmU3gLuAs2EWfUdTPl8bpUSRinVvIGxx9rjcmlwuWArFpO+NiXslp2ktVfXTPsPSO+DRZTrqm1f5K4W4mliGexMZzcLN0FIrHdnT6YxX1ry38Zrg9chKr+daSjo2\\\\\\\\\\\\\\\\\\\\\\\\\\\\/GbZG6uTf9Z1gSSf5QcxEGkrK0nD5FS91TfRGjsoeqsy9qyangxEwTJIp9cWCrr5PkRy++wme5U5dgan7MkVgujDWP5uS\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Z8yhdfpGr1PAhbnUPxzDFpSDZuUrGIR2Edi7y7IZmgpTsgXVTAcCsrYgk2i\\\\\\\\\\\\\\\\\\\\\\\\\\\\/BSVIAVzgMUtB+LeiMiYUY2HYJRzls+7Q8sz6gikgFudJoMAhjLMNxq1OpIPQZ4Jzo6lUWygllwNcQrnWkPCu076TZAV4b6C5aRWt7i9Fx8KzjNCqISZLLlyyKkPVhDX81S59WEFCit5LsuAstX+gl1Heh5fv4nZHMsEP\\\\\\\\\\\\\\\\\\\\\\\\\\\\/TRSRAAZESXL6udd4\\\\\\\\\\\\\\\\\\\\\\\\\\\\/I7ZwHzzwVX3TnB2iIYGi0TczQQvt0X2Qa3Bkf6Oprqgvg1nrWe+VV92FWLGuGhOK9fjBkxBoS1EXniswi\\\\\\\\\\\\\\\\\\\\\\\\\\\\/EHZswXbbsOs7vIN3+0k9wicr0b\\\\\\\\\\\\\\\\\\\\\\\\\\\\/fn0Ezj+GH5\\\\\\\\\\\\\\\\\\\\\\\\\\\\/fd3alWA\\\\\\\\\\\\\\\\\\\\\\\\\\\\/raLxk7x6I2+BfHl24GdbbZcSGtxW0q2QNdTHpbo\\\\\\\\\\\\\\\\\\\\\\\\\\\\/NNXUiVnEWaAeF0VaVpQUInLoxppXEwSX0toLoAiox87bVRFYjyi6PgvveBH3CYnXYLJ2a38paKB3b3ridE0YYnujFzXeU6ExE2Rac\\\\\\\\\\\\\\\\\\\\\\\\\\\\/GM4zhdoEISlSIQBxDYvL2w9F3uACQH9NFRn0ARjf7W+sss9VkrdxnqE2oV\\\\\\\\\\\\\\\\\\\\\\\\\\\\/bbASLDc8J0CbvPHB2DQcqBToKTeRk9zmhWaXiIxmTuuEMyZiJvTAXQDYElL12oCyGeEELaf45CtepWxepk94JUBIULpJkU\\\\\\\\\\\\\\\\\\\\\\\\\\\\/XzukXCnTHWKXutQQoZ9hC50nuzgWBanZEoEkqAq25R5q2W91dCppPxNkh1IcEB8wwcaEPoEro\\\\\\\\\\\\\\\\\\\\\\\\\\\\/HoQyJ8XZBn+kKRjioA1lJ1D6G\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ceDZO3aHDd5laAWCit\\\\\\\\\\\\\\\\\\\\\\\\\\\\/7tfZSOkDYK5Y9fUHge69mb+85KxEzXsxPkzMHm5hPHjr\\\\\\\\\\\\\\\\\\\\\\\\\\\\/8zM+OwwaVjF4s55Ct3Zkv1lWXzIEaFUWByR3bL+9MaThSx0k+rJytFhNG6n6rl\\\\\\\\\\\\\\\\\\\\\\\\\\\\/bhz4nij\\\\\\\\\\\\\\\\\\\\\\\\\\\\/cZL2e5+V8VjBPLm\\\\\\\\\\\\\\\\\\\\\\\\\\\\/2yu5iGqQDMg4UBMC+FRG2x0JtDgdaiiXWrmpoPgN2juaFVuqYXGpABfy\\\\\\\\\\\\\\\\\\\\\\\\\\\\/TTK5cLBUDkVguBtI78\\\\\\\\\\\\\\\\\\\\\\\\\\\\/pH5HmBHn3k8K3gbBYqdzjQAU4hrfVihDO8PN58Zgrn+Snq28MyAm2W6LRfGT0VNB0skpATS9uC8\\\\\\\\\\\\\\\\\\\\\\\\\\\\/yfj8XyJY6VYxK3yYbTWyDaJbpq+PL9QvQoRdakKorHcTytB+MxnSSXoT\\\\\\\\\\\\\\\\\\\\\\\\\\\\/YduXIwUmKrQxPG3XVxBozJNPOqANo1rcxk8EbXXYuJWD+lTxLyL8dsn3r9qkiA3Mb1Fg\\\\\\\\\\\\\\\\\\\\\\\\\\\\/dqIwKVL44y1h9hk7lxCbXxR\\\\\\\\\\\\\\\\\\\\\\\\\\\\/BWDILvicVJ6uogVxFlXNdf6EwF65K3xLXC2IFYQ0e3YR5Ey7S7cxvQlio4JLFnWTzSgBivw5X3jvKr6nz9cTtKRq4u2lIEz7VhowHV21W+QNI8lbSsyNWTHDy1RPMWLFSe3MKW0gpRcT63eW6SSDhPHM0t6JOJT\\\\\\\\\\\\\\\\\\\\\\\\\\\\/v1Aog7HI6LC4VdsQJL9u6l9yqNu2uM86iEkN7qlp9kNNL49AZY4OCxxJebUxJcLjTxjnajcKvLg3QsPdawQpTfd95+Rhiket29KUBUTh\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Id\\\\\\\\\\\\\\\\\\\\\\\\\\\\/wmmzH8prDMXDSGPrn2c8ewznkKscpgkEadlKJoI3odD7h184QyhF54GOVFpA\\\\\\\\\\\\\\\\\\\\\\\\\\\\/0M3u\\\\\\\\\\\\\\\\\\\\\\\\\\\\/9kjsnR+suR9WKfmcFvL1sGMpvgFqKhtvLndFk0hZhEDtlNPGRx4b7dwjrwa8jDc2ptfo0R+5h1CuFszMc8K4XMqnmbSJXyKCX\\\\\\\\\\\\\\\\\\\\\\\\\\\\/RW31pB\\\\\\\\\\\\\\\\\\\\\\\\\\\\/tZ6UI06gcRWPrOmBFB0CjEcbTFiq3HObpMJqs061qoIY\\\\\\\\\\\\\\\\\\\\\\\\\\\\/0ubQzr7Mz5lYMwtCPFIxOyzTOyXVcB9ONWlMnRzuadrQdxiYhR5d5G\\\\\\\\\\\\\\\\\\\\\\\\\\\\/mISW4A50Ylvng14lhv4H4RWgbeWF4kjCtC4qTSuu8Kz8ietc\\\\\\\\\\\\\\\\\\\\\\\\\\\\/7t1\\\\\\\\\\\\\\\\\\\\\\\\\\\\/KHvMfkivj+M2daZVoNcvJ+IeG8VW8ouz3XbbRI10ZH9aa\\\\\\\\\\\\\\\\\\\\\\\\\\\\/zX4wnhEdZPBtTN5V2cGMv7xw0VmswJ2V9VPh2JaCzncROuOgUZiWbjsE1lZ4CcWruj6eINZYoqbVPVjcE98qnNeMPXdfkxp5bQYe0a49Z8cNDFWP1z\\\\\\\\\\\\\\\\\\\\\\\\\\\\/JNoJ8GT2oDMm0a2NbDSBjOYyHYfajsIl3iAuwI4V9wmei\\\\\\\\\\\\\\\\\\\\\\\\\\\\/C9BLsulMqlNi4i03b5fjEzljGFVJnK7YEXOzMeCEq5swhuY6y4OYRzMScnOpoDqIutRc5cOey8Ps\\\\\\\\\\\\\\\\\\\\\\\\\\\\/CUcqAZjotRBuM\\\\\\\\\\\\\\\\\\\\\\\\\\\\/APlN\\\\\\\\\\\\\\\\\\\\\\\\\\\\/oxytDla4qCshv9qy9c28DIQqEL\\\\\\\\\\\\\\\\\\\\\\\\\\\\/UAgLdCv7rVloXez4GNGBr6a\\\\\\\\\\\\\\\\\\\\\\\\\\\\/k02qoFgcNx5Et2bRxxzhOpzV3gA1O4yxIt9xw9IZqzng3P6bOTkbBuoI4VmhnlmVNpcpsL1rCLNKsbe0eBDzGmp1Nh\\\\\\\\\\\\\\\\\\\\\\\\\\\\/gPkkEI4PlVUbZ3r5EWrJySlC9Mj9sxuk2z1ed4yJCRPqavY4UbS4hWbLCUJyk2LDPoWjQCL2olE757UtiUfL226ntHA\\\\\\\\\\\\\\\\\\\\\\\\\\\\/oM+5FKptW7aZOELam6JAMLwb3IXNtRDXlI8Ad\\\\\\\\\\\\\\\\\\\\\\\\\\\\/dWUht01S2DsRVuB1ExGoaySvtA6gD+4u7te5dNDaTIXldtaWpVWcDjz5OUzF\\\\\\\\\\\\\\\\\\\\\\\\\\\\/pgVEVwyuk\\\\\\\\\\\\\\\\\\\\\\\\\\\\/JOFXzS\\\\\\\\\\\\\\\\\\\\\\\\\\\\/CjPMsZnQULh+BBIO\\\\\\\\\\\\\\\\\\\\\\\\\\\\/dsaepQoUkNg2mkZYp5e4uU4ofdYwvRbZDq0t+TY6YsM2UQ8i+rzOWhn7B54sKcxOYVHY47OZZ7fbxWVdxq0NQZy9BvcbstcF2ANTGbGGCN035Ja0yWPLLnGxNVp4aa5O05sg0oqxMG6N5pmePpwWypPbUSZDPvBdxvbaww4QpSKGshTXqPFdqHu+5zyDIvnxfYozhQ4l+W57IcsgQwXt2QtCoJK9VwQQudT7QsV\\\\\\\\\\\\\\\\\\\\\\\\\\\\/4jmQmujzP1m2n4KrkoFO\\\\\\\\\\\\\\\\\\\\\\\\\\\\/kEiZ5J7O9JOhLRmFbIYOJPHqUotrTRprHt6GKJbuwpTcCKkxR2U2NvvjYOuY1PN0sGG\\\\\\\\\\\\\\\\\\\\\\\\\\\\/1f27sPDCdgHR+6e8DtUkU4XL9Z1wx9aIo7WDjo1eN6FjXzoZFGaGkzRvg1e\\\\\\\\\\\\\\\\\\\\\\\\\\\\/d9fvuqemBXgosdgxyPg+g97P0JagDl9F5FSDv048X\\\\\\\\\\\\\\\\\\\\\\\\\\\\/c40ADvC\\\\\\\\\\\\\\\\\\\\\\\\\\\\/VZJTulAkN3ufBLEU8FPqPMJTmZKoleU2zB6aKsfdhhJXND68exOM9aKcdzyn9R754fte+qjuba06Ng2fdVykaDZzbrkgokkEfHU0pKZExBl0z6IDZ05WbUmHSAssRaY5pJLd+ubQ0BDdBm\\\\\\\\\\\\\\\\\\\\\\\\\\\\/1RFwaKYcF6idaUkXeMdcUdqvfh5l+ZIIw3ZfOzZE4k90RbgEXzXi3Zo5LfnXu8D5SKh3OUN4qhtIpJLCRw\\\\\\\\\\\\\\\\\\\\\\\\\\\\/xoU+1YHoxdnPvPT\\\\\\\\\\\\\\\\\\\\\\\\\\\\/2zgyVW9PEtGSQKjDq+PgsfIpqGP7YQ8uwC0+jw85GGLwLw7ETYuB+vut9seDI0\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Ve3RO+nsUaHJLwKFwaF4A5+iiLtPHNUfhO2+N0xou4\\\\\\\\\\\\\\\\\\\\\\\\\\\\/l7HxUNrKVRxwTzALA0SrGtAT\\\\\\\\\\\\\\\\\\\\\\\\\\\\/GqB5xyw2jp85qT4BqSacb2J4D7YBPAAqoxbPr9kahtCbbfGwMJMKwSxlJsDBInakjn++iGirOe1DF9rmd8Dq9UL8WqJUyA\\\\\\\\\\\\\\\\\\\\\\\\\\\\/YtpHvx6wxluwZvF+2KVEhoI+uEtI4wbxn9XvwKxSDHMEoMzodWdzIHP09aUX59UpLj4cCPM1Ps+kYY+rxbIaeh1zUSuSkZWK2SGyRCLoN3L1trgMAElpwqWeb7l9Oqfif37tGzYpiZn1H\\\\\\\\\\\\\\\\\\\\\\\\\\\\/JucMxSeUXV2PPE7DhPyt1BnWEd3inoyeFjAiOFH9vSUOs7M1wPzl67LGwvRxakmc12DT0vQ4nTYVG9LxYvhuMl604Ngn7bEVY0vREvcrfX9rPMeC9rCNSSyF+WFGXeTS2Q2umtwRzPyRwvspw65WgW9PxMHBfjLKqR4Y\\\\\\\\\\\\\\\\\\\\\\\\\\\\/v\\\\\\\\\\\\\\\\\\\\\\\\\\\\/BkumIs7SoeD1zwmF6x0Dp2gp\\\\\\\\\\\\\\\\\\\\\\\\\\\\/vKa3T7+XGfAa3YmV3XFkaRMgB6rLjMSSAbCAgrSA5gNWPnzNnGA8ZSguFOKgd0tEVj5e2dTAyWRtV2U5vySdPQRzKFGq\\\\\\\\\\\\\\\\\\\\\\\\\\\\/RJQVgTdJc8slGTBt6jc96CoBuYfSelLXSx+xCcmHyw\\\\\\\\\\\\\\\\\\\\\\\\\\\\/3wXn1Xr\\\\\\\\\\\\\\\\\\\\\\\\\\\\/fVyl0F10TAP1gggCrphOYggq+2NU5dL8O3KX9uOHThyhphlx2eRTj3BmtFjYdZd9+YJDCobi\\\\\\\\\\\\\\\\\\\\\\\\\\\\/1jSw8wTo\\\\\\\\\\\\\\\\\\\\\\\\\\\\/yS\\\\\\\\\\\\\\\\\\\\\\\\\\\\/gBpHNNe77fLYuHb5Ks8KN67KJcCWzxI9bBhc124R3s8BEf\\\\\\\\\\\\\\\\\\\\\\\\\\\\/sO6ExPdr\\\\\\\\\\\\\\\\\\\\\\\\\\\\/EkntuugnbPQlL\\\\\\\\\\\\\\\\\\\\\\\\\\\\/fZHmZdtskI63\\\\\\\\\\\\\\\\\\\\\\\\\\\\/rBcYhd15njRYcE\\\\\\\\\\\\\\\\\\\\\\\\\\\\/wGz7FLU1oN6f5685NHHh4znvAYAIbIoz3VTLDAZDtTv5xr1ouu7UEG7BYno+ndsHpStzyih+m9N0f8rcOVchag3dg7c+V1JCMnal\\\\\\\\\\\\\\\\\\\\\\\\\\\\/HD1eUBjXD0MynooQe0z4Y3V5jWU8g5gOP9EsqrEArtNyjYBGzhsN1sNmXfFaB7QTc1DsGZPKJWLzCB2sP7eIqzOmcITMK0+Bpqv6FDs+22GdxIhUrMyByl\\\\\\\\\\\\\\\\\\\\\\\\\\\\/tOqT+2Fa927aq0WSQ8xbh3\\\\\\\\\\\\\\\\\\\\\\\\\\\\/DPCk0O2lJDpHudz3kc1E2hOosBYT\\\\\\\\\\\\\\\\\\\\\\\\\\\\/bPotqpQNSvYAO7fWNkcphcxLEWfVKFVO+24g8dIgKgRJERNwEP+mDVPY1+NF6ZGcUAn0YkbXhFsVP\\\\\\\\\\\\\\\\\\\\\\\\\\\\/iJedBdYRF7wv8jrkWTT8cVLmKL1eZC5YBqnZpVTHYj5pOFFDZKxImXY8eJQ13J7DwyELWuG5HMVY2okcsoN6vqyEXNUTmz+1HJGEt3I8u22kykrTtdpwjW5++mFyK0V2cx1gEE4oeRBlIzBiHCCoM2AMt5DYiltwb9Jk5UMyG0ysWxn\\\\\\\\\\\\\\\\\\\\\\\\\\\\/s6543AL4+q4jvSQZPQ+8RmO5ClBcN64MlwVrcw8ZAXJuseWYxPkHKOgIKCOyBICVNk\\\\\\\\\\\\\\\\\\\\\\\\\\\\/TrnC9B4Q9+i0zSTjCmFx0RypLcSpsef4wdKAwsHfGZGiFgmaAqcQOjLVVc5o30eXTDYI3MKVYUX0WPQX8UUkwmFh8esmL9gyLfbLgDnMzjpG1PPnt2KhSCKvuQfSHPkpf9nHXXk2iWdNg4QcIuEdSc0Uy7C5GpoFHyi\\\\\\\\\\\\\\\\\\\\\\\\\\\\/xbt2+YnFX46lwj+aakvOzENLrMyPdHV9l8rG2BrcyEfjnoM0IAF8MPgW+ax4cQF0RKwoPCI2DcF35XFIyBpmSIe1p+CYzIgFrH88GuoLYXcNZJbvSTOXvGbIPGBEQmq7TiWeczlF1sxtzOkM5xEI3NxWDRXkLjnJpLqOVEKA+OTnTcfPjG5DBhOxuT5JJ2ZxGK1zYvFsiluI8MYDB6RbVMZxV1ZjKQ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/PSDCVx4BJ6sztsl6yc2WSsbHxGlQEYVoG18KlGh30\\\\\\\\\\\\\\\\\\\\\\\\\\\\/GFB02UUai7Ww1Px2G5tO4FQNS+m2xpTod5FTntLWpRoL5lapf58pox3rIz2J1uxBvrEPVxBafWWh\\\\\\\\\\\\\\\\\\\\\\\\\\\\/utXHg197UX\\\\\\\\\\\\\\\\\\\\\\\\\\\\/5eh6GwaC52egQoqDGneadgAz9mRNW0K70L4vpCa+g8GGGavcmOttrams8QQOev7xQ++kLXwmdDNGtfG\\\\\\\\\\\\\\\\\\\\\\\\\\\\/GnSUnK2lXjqOp+Og\\\\\\\\\\\\\\\\\\\\\\\\\\\\/BL0S4ppk9tsQH33KVtWD6wTr9QcjbTnSonjtWt1ZutIpDKH12WkRu3k+FKJCKBge3YNQZxQWI5Sx5Dhu9Tl7pYZoc4zgZbbPxDSsIiBbOjkPYK1YqjKCZ7EauLjRwBs7J2xI70m5Q6uJgg8zXSSX\\\\\\\\\\\\u0022,\\\\\\\\\\\\u0022iv\\\\\\\\\\\\u0022:\\\\\\\\\\\\u00229Jm7EKDj6nSzKOXW1esBqA==\\\\\\\\\\\\u0022,\\\\\\\\\\\\u0022salt\\\\\\\\\\\\u0022:\\\\\\\\\\\\u0022f4d040311b2fd2429a61a615cefc1b83\\\\\\\\\\\\u0022}\\\\u0022,\\\\u0022hmac\\\\u0022:\\\\u002295bda9cbf8f4ad75b1e3ea9d659596cd53d18c2bf0c32c7f7c1db1781c05842f\\\\u0022}\",\"new-29\":\"{\\\\u0022encrypted\\\\u0022:\\\\u0022{\\\\\\\\\\\\u0022encrypted\\\\\\\\\\\\u0022:\\\\\\\\\\\\u0022ZBj0KAYuE6UNI2oBHtf6O8MG8Ffh6PWbIICKsQZ59ATx9ygrt8VFl1TGDlWy7M+vfG+hZtiGXLbI0wxXnTv6NhgvYFOOguPuYXy2zi1OOmXRi0BZSJUUlqNxq3IMofIj2Q5JrztTvlrma8cLoyxzxnpTQfkh2KuDGD9GoNmvuYwlqgu7wZWN2m8K29l924ieESxm+YvXytdyFtwTMetAm6nqi3BnWv1yIZxEUJ1rtQHzZdIh\\\\\\\\\\\\\\\\\\\\\\\\\\\\/c3Mum\\\\\\\\\\\\\\\\\\\\\\\\\\\\/6JWxgEAF33p+F\\\\\\\\\\\\\\\\\\\\\\\\\\\\/VYWYWMqm2OHBEmJPoj32fj0PHExfsRWnr\\\\\\\\\\\\\\\\\\\\\\\\\\\\/N5LwjY0rsPG2LPFaavHtdL5D2MuvxU7nnzSbMfDE6L\\\\\\\\\\\\\\\\\\\\\\\\\\\\/9+C3fxWt3BHEqcWhXg5Gp+bXyw8U41GbDwfwlKaIsVya2K5BnOy42tMYX2YPu46Ljx9Wh+PClwRDmWhfloCd7ELTvPk232ZXxW6t94b1rqKdBQPxo96dYtzWDX4sCtQljH15S\\\\\\\\\\\\\\\\\\\\\\\\\\\\/4O9LgPJGVRHYPzBIU1TbPRTBJghQl61XbDqhRI4xNtPxunxZz60WTAurbVPPrTVNAalviVpz4JhVeuwT3+kg5morjln3\\\\\\\\\\\\\\\\\\\\\\\\\\\\/FGGKsFJG2ZWSFPzVUvgcNTQJfDdk42P73Z1okqLQggAITUpEYEftq6SFZ2IBs0HDxKvCb3gQBeTEw3K7eG5\\\\\\\\\\\\\\\\\\\\\\\\\\\\/P3TcRMZRD75CXjWlOVOEY8c1lEeHDgTxxJ7QjjMvm1w6d8l3eXmmAgxEkXpGqbYXny1vXTdrpPmBeX0yiS8314pXwRVlt\\\\\\\\\\\\\\\\\\\\\\\\\\\\/dUt14wmfNeD3b1Lsyfmeix9HlZudOwjoz9hOHq7rGrY14nSPx0UjH+k0cBvXd05VgZYuSGajcCGvGLCmlAVLRtlFWZokNhX1y3yr5DzYe4V2Aq3zhXw9y6RU5krHdFKFt3Huauez0sQvaPSxn4IGpoPyMEj9Xp\\\\\\\\\\\\\\\\\\\\\\\\\\\\/+M1MCZUG552Ob6qIjWh0JYSr+AZcy3NI\\\\\\\\\\\\\\\\\\\\\\\\\\\\/hooLt74wnMEBt4DlcN4jwM93YRDmbVl8qlMAvS4kinG2bOTRzqab\\\\\\\\\\\\\\\\\\\\\\\\\\\\/dKshS6XhS5l0R4yYOC5ysACt8F4jZ6aJf0fuzYq4h3En7fg7jWVD\\\\\\\\\\\\\\\\\\\\\\\\\\\\/S8VsPIgYPVu3A\\\\\\\\\\\\\\\\\\\\\\\\\\\\/8KVp5Xn4WDwzNufGt2VVoGABfDiGRREMf6aL31OUtSP1YWdDwdEcryDUAGSAmlN8GxzgEmideBBa\\\\\\\\\\\\\\\\\\\\\\\\\\\\/AEvuclEzpPo3f+WukyxB3j\\\\\\\\\\\\\\\\\\\\\\\\\\\\/UtxjV\\\\\\\\\\\\\\\\\\\\\\\\\\\\/RQ9ihqIvyoNJwStr8Rs5YMoJN903osCjUqn94zf0O+bVl3JysKhdYi+WYPzobVLa\\\\\\\\\\\\\\\\\\\\\\\\\\\\/BOmy6Uq0qQFsmB08nRkEgV0hRB7ioeygYWide4DIfmwvtif2R9LnJ89pg4m+UpGdudgL6P3g1bW15eaIEglOg5b6\\\\\\\\\\\\\\\\\\\\\\\\\\\\/tR09qyq6cK6ObKutUUkxjLtddp\\\\\\\\\\\\\\\\\\\\\\\\\\\\/EzRzJ2rA4ET3FbW5DxqQdTPO\\\\\\\\\\\\\\\\\\\\\\\\\\\\/eGh669w+ayVGVKzcn6UDC66O+I\\\\\\\\\\\\\\\\\\\\\\\\\\\\/q5UYwfzNUEjs2hcIUSg1z9\\\\\\\\\\\\\\\\\\\\\\\\\\\\/5TvSrX9Pylcm7v8RkCn4x566OfmQFl50e5llQEkK5zCS86HnIrMAqvrf64FgsbwuFpUSAmRT+Zy4zUG\\\\\\\\\\\\\\\\\\\\\\\\\\\\/qkb6S82cFFj93CAeXWbCgW43TUQYNGXO4TV4QNERrfVp\\\\\\\\\\\\\\\\\\\\\\\\\\\\/mbf9xBZpJAWZDBLJhUN7eJoIOqVV0Zzwa82Vwan0SjzUfCUEmRtriEWpqyIeNPYKYJSepl0SGlW6yGKv\\\\\\\\\\\\\\\\\\\\\\\\\\\\/FwDhUonZ3nUBO\\\\\\\\\\\\\\\\\\\\\\\\\\\\/j9KfJ9OOuHJ9usaXmkxnHX7m8dWVd7743WOpeYwi8ZZUAJxd8K2Y5ABnKyKJc9cfc+Fm2iT3YWcIGmIQuYekYmJZN7V+v\\\\\\\\\\\\\\\\\\\\\\\\\\\\/1bpYSzEoJExpqFQ6OqxB67z94gqTbUyEjkxh+gf0INy\\\\\\\\\\\\\\\\\\\\\\\\\\\\/YEGB29xIXf9Fg7TIZPiPWPmlfz3LnSx6A8KUgL9avtCwiBShQL6mfRLTa6Ush2rFsFPGTCUpDQ60e\\\\\\\\\\\\\\\\\\\\\\\\\\\\/1neJf3Hmf0urzEIeFw3IZ51xmqKgLTPiRL90Mjy4pL2FIGTEibIVNjtJ7GwMPHyY6VP6GuHe3m5ervFyfAILwdvmjo4\\\\\\\\\\\\\\\\\\\\\\\\\\\\/WDFPXCn0RQKrIJihkyWiI+9UpHG89Y+B9VclsU8nRk5e\\\\\\\\\\\\\\\\\\\\\\\\\\\\/nYjuSkFFwOYweh2mVvyyQHFXqAWst1Z7XAy3OyedweXT2xDV2eZYLAPF9CWAz5E6uevMWIqwO0ZK2tUG0k5w\\\\\\\\\\\\\\\\\\\\\\\\\\\\/dloOJm\\\\\\\\\\\\\\\\\\\\\\\\\\\\/AQtKpkDctAZHOLGHs\\\\\\\\\\\\\\\\\\\\\\\\\\\\/J27Z4mF28cKiKi5zLlGjVUizqWgYl4EQDjaf5CjNk60XNB1CYUsSPITW6enbb\\\\\\\\\\\\\\\\\\\\\\\\\\\\/q6eIWihzFF7PEqDfiRkgiDJwCJ5gIVce9lj2imDiDMqWbDIH93Ne23QIK7nn8OFud5Jqn2e54S3rdDOde1jJo4xdxeg0f6UtWaok8x\\\\\\\\\\\\\\\\\\\\\\\\\\\\/JI87IG7tZcIjNKKn7YDHfMg57d9yaAoi6APYiFa\\\\\\\\\\\\u0022,\\\\\\\\\\\\u0022iv\\\\\\\\\\\\u0022:\\\\\\\\\\\\u0022V2C24i62cmxvDJKeEMNZtw==\\\\\\\\\\\\u0022,\\\\\\\\\\\\u0022salt\\\\\\\\\\\\u0022:\\\\\\\\\\\\u0022f4d040311b2fd2429a61a615cefc1b83\\\\\\\\\\\\u0022}\\\\u0022,\\\\u0022hmac\\\\u0022:\\\\u00225eceacd216e4eae67e8e71004f9518c3129690b62d7c544cf4192dae39829430\\\\u0022}\",\"new-30\":\"{\\\\u0022encrypted\\\\u0022:\\\\u0022{\\\\\\\\\\\\u0022encrypted\\\\\\\\\\\\u0022:\\\\\\\\\\\\u00227heW\\\\\\\\\\\\\\\\\\\\\\\\\\\\/w7GHf4ittIJju9navTtzeiTNpGrYiC1bCxuG\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Z5xkJafb0inAv1ywG1r+sflDqkK4QunFLUNQ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/rEuEj8q7CaHKvf+TimvPff\\\\\\\\\\\\\\\\\\\\\\\\\\\\/UydH62mpmbPRfRm08G7Rxc+lxYNrPkyh6tnXRAjkhLZ6ZpEjMItknAF0jVlHkigumC7WiNGvBCMb87qe4YSS+5jNDQJR20Q7aEqzIrQMGnBR9DXirMR9ccC0lYEPVMTwcSoG2NjQz4MMlBWaP6yY1uNWNfxFJUJxF9bqY3HOk22Jg\\\\\\\\\\\\\\\\\\\\\\\\\\\\/SrezLj+kIHl2xpk0Tsn6PFF4ML5BcbiJVh8zssqmNBmq9qGTHP2FelI8uOgsqJwl+3mJYSy4uN6SB3CMvTvReP6FSqAOusMxGwRGLhjZP4DUMynM+oG1hOmOu4AQERHhHCzAI\\\\\\\\\\\\\\\\\\\\\\\\\\\\/+eBfQ0qmoEq\\\\\\\\\\\\\\\\\\\\\\\\\\\\/tNZjfPZyx4\\\\\\\\\\\\\\\\\\\\\\\\\\\\/RhvedvUe4CiqpMqGqGMiik1z9tPo1Qwx0k2GiLEcDkaiFtf8QaWoJWy3I+lM1XGqs9zFpLrHSesYoFfiqhdUT9CtswJ+wmZz4M7a14H4Blpn1ag8PFTGpwLGgwBlGqz+smP51BL0QwVYHT+Rcxny83+0nu9+wOPpfbX4\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Loo2eZI3AWj9qe\\\\\\\\\\\\\\\\\\\\\\\\\\\\/izQXq2YmNGPW3Na0IDGHjQGGclyBNvphaGko6rX\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Q5pyu5+lRVKYbnQuwnNbZc9x55Lc7ZKlo0hTwhBOaZiT9N4m5VHP2Bky8a6A15iOpRGHZydxv+352XHiT9b23BoBAjGaUaTEqhZ1WalleyWA\\\\\\\\\\\\\\\\\\\\\\\\\\\\/iO\\\\\\\\\\\\\\\\\\\\\\\\\\\\/gFqJVhhsIPvKOD5WAAn56m2dZvqlyYwDE9QEVcy14y0zUkjsGXV3w5ZtKYG45j6T9tApmeMQu3o4+wo\\\\\\\\\\\\\\\\\\\\\\\\\\\\/yXy\\\\\\\\\\\\\\\\\\\\\\\\\\\\/K9VrIA49Q3eY2u4sz90juEfcfMxnVXCxBHN7sj9O4wCq7H5tUktPmA8FsdsrO5uDd2nZpuBTCW6J6RNWIj0Gj+VnkfytPyT0L\\\\\\\\\\\\\\\\\\\\\\\\\\\\/\\\\\\\\\\\\\\\\\\\\\\\\\\\\/YYHPnEyHAaG6a2AbbSX\\\\\\\\\\\\\\\\\\\\\\\\\\\\/HPxfv5rq5wx28dUOPrSgWp33ZpNKcZ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/T+jiSaPvs4k5sd0pq2DOS6DbPDC0QZeZoQ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Du2rJRXTEuxzpurcbHgNxSoVES9PozNG1JE5P0WD4Wjp2dRzhMZXAXGE1d3hgy9k7QZw7vutPuGdvSfZkfT\\\\\\\\\\\\\\\\\\\\\\\\\\\\/rfACyeY6PKeoERzO2kbtGVa\\\\\\\\\\\\\\\\\\\\\\\\\\\\/4+LauYtt\\\\\\\\\\\\\\\\\\\\\\\\\\\\/IQgD0mHV69lDscuzRiAhva0IMOJUTb32ofD92q+nqBHBH5jdquXosJ8dJ1t7Ts6QVenoYKN71ZLcOoB98mpZ2ZL74jxp6dBKVGJdpb5KrwZK+ctJu59q3WNM0ENO+O+HI+y7jhM2eicc6gKbCOsf9KXhC5R0apa0sUM6yccayzKzt86nLxrplGXwj7xeyMOf8X7sYua7vMCt2rtL1YZ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/JQRvCBw+VFQk\\\\\\\\\\\\\\\\\\\\\\\\\\\\/tvtVN1W372mPtWQQ8rqBlc+p\\\\\\\\\\\\\\\\\\\\\\\\\\\\/WUUDj6Ur6t9wYfGcCsxrU\\\\\\\\\\\\\\\\\\\\\\\\\\\\/b35exa8CIxCGNbGVGBGxLqLytpLhZwv3293Duh034WRgSCo8bTfdckxCNEdS946\\\\\\\\\\\\\\\\\\\\\\\\\\\\/PbjgjIeJceEefDIm6lroxO4mp60SdHqOpdlsjzwnvKi1Tfn6fnnCFpo1wKEj08e3NlW57Amj9dma1\\\\\\\\\\\\\\\\\\\\\\\\\\\\/09saSoolfJ8VGcpRY94hO5wxiUHfauuKZTs6IAlFicxYWJJ7Lt7hQ2T9rvoGUBDAtqtFvq\\\\\\\\\\\\\\\\\\\\\\\\\\\\/afI5vpUMEoK7AoLFhR2ZPALklz9zPBiCt8oR3JsJ9CwBMi\\\\\\\\\\\\\\\\\\\\\\\\\\\\/IrV2AgoOCSDQeySMjbAUY01oOauzUnbfO9YNlA4ERA1o7dI1AyHZBCByfjZyVU8OQN6JEFQPibfJEMF0lpvVOohLcyQGFWzj0SnRO1mgQMcP97K2XQdD72zhqBZcG6RhEda9QuWWgTIGbPuOaDAS72Qq7MaSOg+3gKVmZEGUoeztdQRt+FTsNGWGbxMpaINfPecUACPOaTX3Bsimz26GmaqlAo291tG2eqpPGg4HBZidVeoMl+yRvmh+X7lwerL8u5vkDNSrga+5bXsJOzCkZulisqteqM+P\\\\\\\\\\\\\\\\\\\\\\\\\\\\/44NGXWVeZR0\\\\\\\\\\\\\\\\\\\\\\\\\\\\/GFIxgvaA5t2U\\\\\\\\\\\\\\\\\\\\\\\\\\\\/JjT23F\\\\\\\\\\\\\\\\\\\\\\\\\\\\/nQjBmfsjebS0LSNevv80RZYO2LzdBwHsoKol\\\\\\\\\\\\\\\\\\\\\\\\\\\\/7xbJKLJ6E8SWIyyM\\\\\\\\\\\\\\\\\\\\\\\\\\\\/hbc77pfRjPGLnIdM2Vh69LaGLz1Y158Aj68Xc++swk9QwQm1Jj8E9ulVnWh2GFtZd1s9yGt+RvOvGrnEoPD4+IipbZfcVKEhcpEdyM1PftqjU1aYpIby2oLD15gvKc+zFdyuClZkXajBBWmrQJDUfLouxzAL\\\\\\\\\\\\\\\\\\\\\\\\\\\\/AQOLRAeyUz8J4Kw6hujPW2+ikIDNnqr0LKsEZ9f++qjWzfQFqebJJquiAXVeVXyI1Ze7XpDkO\\\\\\\\\\\\\\\\\\\\\\\\\\\\/Zc3MFL\\\\\\\\\\\\\\\\\\\\\\\\\\\\/kxcQ08ZPLpPU7yejYlGbs6T+19azN0mn7oqILiNiekEDRSnQF13joYQ3Z9GBTrmRqPu97Z\\\\\\\\\\\\\\\\\\\\\\\\\\\\/9Lu8deb3FMzhXQYmPppTjOBkEZW4c7AMTOXjhrPM5RLg=\\\\\\\\\\\\u0022,\\\\\\\\\\\\u0022iv\\\\\\\\\\\\u0022:\\\\\\\\\\\\u0022q08nw4z0IjWoA0mNCGZfBQ==\\\\\\\\\\\\u0022,\\\\\\\\\\\\u0022salt\\\\\\\\\\\\u0022:\\\\\\\\\\\\u0022f4d040311b2fd2429a61a615cefc1b83\\\\\\\\\\\\u0022}\\\\u0022,\\\\u0022hmac\\\\u0022:\\\\u0022dc6ca7faed64eb8c7c7fdce2fa046ff98ceb65564b17c9ac11ab7dcfea18b954\\\\u0022}\",\"new-43\":\"{\\\\u0022encrypted\\\\u0022:\\\\u0022{\\\\\\\\\\\\u0022encrypted\\\\\\\\\\\\u0022:\\\\\\\\\\\\u00221T95gzSX3lduDdgKX1P+CV42ih3nuerfAIBUfJqNpwVuP3AyW3+JzBA7LFGEgeJnphGm+eAGnNOg1r6K5KYpttOBGMx7QozSaSZApykcmwWuI4SgIfNHAdv2IwU3QgEifLJmVPoR6XoOxDsFx0rJWQSnpQFS2TeBjAI1Uq\\\\\\\\\\\\\\\\\\\\\\\\\\\\/RtCLaPJZkGd6EIxZ1Lc+3QhjicZZnQDqRRfkXqo8lriXyqm1KsA\\\\\\\\\\\\\\\\\\\\\\\\\\\\/KpWqQREDrmPe35UhT0X1RavjzidkhsEJPzD4CsIVmDPO1Gnt\\\\\\\\\\\\\\\\\\\\\\\\\\\\/RfC7cvuX+Nx08WewfodXz5khpwD3BIC\\\\\\\\\\\\\\\\\\\\\\\\\\\\/RJiIfqUNfqj1m1Y5UO+zciPvyb4fpTwa71xxbc1b\\\\\\\\\\\\\\\\\\\\\\\\\\\\/MHyXl6t5NsztSuhYyWxCP7GPgw\\\\\\\\\\\\\\\\\\\\\\\\\\\\/kfuke22sDjkdrmvktj5QlENtC+EeUnlvQQyzkWYhZ7HuQFR9HKJ65M7JJjbHq1byQhZeOrc8BGR2fRb3Y2EBSFoYSIXBdSh1l68a05lSt42SbWyF8pknuDMinn1K3zVtvSpF7kw7p7HQov8\\\\\\\\\\\\\\\\\\\\\\\\\\\\/gb6r7JtA8z6mnBDAiJqckkCqM42ETPR3u+aTC\\\\\\\\\\\\\\\\\\\\\\\\\\\\/YPOVNI5mBGGssVq1EyP92GaAd8F8pj49JJVV2n70zDNnAirBVFrWaxpMLlHN+1aMHdiUFzEkly1LV+l15pAUFVzhGgTJNC7wbAe3rLMjQQ28fOJtbSA2Ch4px23Pd5oMvjSOsSlswpNPG\\\\\\\\\\\\\\\\\\\\\\\\\\\\/6HdNjPSVjWE3isYa0JbNqp309J58vw5aXWhxmugI336aXkRaNSA5YVIWhtfPe6BI4dwy1LhFXmkDPTnCDBiR6HslUBDxlsjxvqWeSMyusLL1tBlOSgSb16oaAjDk7MnFA2VurOGoszUIMeIHWBaImPhrXXP+z4SY00XO9xZALkUzYUGeBQ47UYZYdTRyR2PdPJQb5N4aVsiMqfbvzgP9tpYZjQ+vkVvJlryz6YMvfiOKhlP9\\\\\\\\\\\\\\\\\\\\\\\\\\\\/0v8ZlNfwMZuPQTJv0X5MLdoManR92vwKUbheEvnXU2ALqrFVUO8IXKTcWWBAAE3qOFv9klZs3VKNxtazyxS+h\\\\\\\\\\\\\\\\\\\\\\\\\\\\/xSasJMA7kvMPTDBywLRx+ji5fGS3T2W2bRW6fQBY1nOK9EHCcPls\\\\\\\\\\\\\\\\\\\\\\\\\\\\/NpcLTLgO\\\\\\\\\\\\\\\\\\\\\\\\\\\\/NZIdzlLIZP3k+nawx1zhWZTq4iBJ5rlpXKbLw4A1bjckLJ7OkGBfVus0gpkNuQcDpo0rTDhR460GmmH6VBMMos1m5nKr5KaTDD7\\\\\\\\\\\\\\\\\\\\\\\\\\\\/MvqmfA6XGBQC7yHwITaCVkyvJZrJ25y\\\\\\\\\\\\\\\\\\\\\\\\\\\\/SscwW2Iw2uSsIXDaZTIsU0P1OXWEydGucIDo6hqAnMtNOYo5Cr5Ll+iCZHyPwYJ2QitC\\\\\\\\\\\\\\\\\\\\\\\\\\\\/y23q89jaBdC6eljN8ydjzlKbF64KUXE9JLz2G0uOvRN8ue3DMkvKJbZdPKMBFljD1qP+TLxceV5bx2GOXjd2ppDTkP12oJ+M8LNjlHfG9o+VeI4V5FuZh\\\\\\\\\\\\\\\\\\\\\\\\\\\\/060Lp4vMJ1cCOMpJlUE32u2jr+Qwz6n1p\\\\\\\\\\\\\\\\\\\\\\\\\\\\/WI37i\\\\\\\\\\\\\\\\\\\\\\\\\\\\/pwT3h6msGiQWasWv6pRZFEYt4ss2qormoHpD6CDRWM\\\\\\\\\\\\\\\\\\\\\\\\\\\\/SCoAtKyUHzaXk8wTqh6Xt+UPdSf5IIm+f7d70tO+ycG5Lk5Fp+CPhRzC2lIgTZRSQiEz7+XRVsZlfHe1CjGMIlRKqpe40ROikj6UOPuHMtZmWbKcb1\\\\\\\\\\\\\\\\\\\\\\\\\\\\/7AymYu8C5jPRuh7neZ+F0aPW\\\\\\\\\\\\\\\\\\\\\\\\\\\\/TCxM5VlIJcHFPI1KGSHJL0j3RvLZ\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ppBLxXn53NPhGOm36JK1QClNqrv8fDrri84rXB7AIFeUgLfY7i66GNZiwynzQt5b84LRufDT8iReTvTrMNaFHYm2x8N4N\\\\\\\\\\\\\\\\\\\\\\\\\\\\/cgs6sHcrOMSAs2RT73E2RJ8XAS+N91kORIt\\\\\\\\\\\\\\\\\\\\\\\\\\\\/tiysaB9gusJiaauLWOrOSk+KfwZE3bDVaLtLR7E5HW0p1A4b98Xk0Cp+iMCTXUaEkfTcfqaEPtDPNww9e1XM5ne1nO62VEnxr9JLOdFxqnOoj1nCoU27hZt1WILyCxxrYeFBr+xIHSQ1Lg5TmcdAC+V8v+P9B9N6laaEGzk0cHurujzSDTomdvdZ3EEgYtDCAd6Z5WPKqI2w9phb5cvvuC9rGiMHmdMaCCHG+dxpLvRecs064UxXoV7X\\\\\\\\\\\\\\\\\\\\\\\\\\\\/+BFh3BeLfkzlGDxtg9w+avTl1RCjkgYIxLFYeCYRB2KXFObmm2yBZH7Sx9hzpTHvurI4CXvNb9CAedwvmlxRXSYpm6lgbIEVoJ1jZAYTLG00rstxij35R3Ip3MHU\\\\\\\\\\\\\\\\\\\\\\\\\\\\/dUttKSICa0Xbat\\\\\\\\\\\\\\\\\\\\\\\\\\\\/pF72Mpk84RuyQx79+vr614DT5mlOJ60TY94K0sTz1Bmoll7uxA4VmcJasWXimuhfk4DRlb9lJuTp5z+6qarU31APL4r\\\\\\\\\\\\\\\\\\\\\\\\\\\\/zxUZTDj8HwoxlI7EdzIluklLBNIO12c4OuzsomG4M3uMz4Y0uGWDa1R\\\\\\\\\\\\\\\\\\\\\\\\\\\\/VVf9UGaYCrdBWJ+LpfiLLnTesOJqfXvIUXNaSUr1+vEPgeN9GCRlolQidQHvDKxZI0bmn1KI\\\\\\\\\\\\\\\\\\\\\\\\\\\\/ObQ+vyNwcAvsrGZNgZ2khGjYIkPEyaamUnUIrNBZZZrj9CWgYRpEcTHtCXsgQYR8zYKMCcgpVyGrQNy0Z9AILnI2M3HiYgUIBx5XpMEovgnrpdEAygSWGE2457S6Zw==\\\\\\\\\\\\u0022,\\\\\\\\\\\\u0022iv\\\\\\\\\\\\u0022:\\\\\\\\\\\\u0022kEB0EFdRDVqMDH5ETy4i4g==\\\\\\\\\\\\u0022,\\\\\\\\\\\\u0022salt\\\\\\\\\\\\u0022:\\\\\\\\\\\\u0022f4d040311b2fd2429a61a615cefc1b83\\\\\\\\\\\\u0022}\\\\u0022,\\\\u0022hmac\\\\u0022:\\\\u0022e915ebbe8e8cd1019debda8643aa8adeab84eb63c70512416ad6fafaad5917c6\\\\u0022}\"},\"instances\":\"{\\\\u0022highwire_abstract_tooltip\\\\u0022:{\\\\u0022content\\\\u0022:{\\\\u0022text\\\\u0022:\\\\u0022\\\\u0022},\\\\u0022style\\\\u0022:{\\\\u0022tip\\\\u0022:{\\\\u0022width\\\\u0022:20,\\\\u0022height\\\\u0022:20,\\\\u0022border\\\\u0022:1,\\\\u0022offset\\\\u0022:0,\\\\u0022corner\\\\u0022:true},\\\\u0022classes\\\\u0022:\\\\u0022qtip-custom '\n",
      " 'hw-tooltip hw-abstract-tooltip qtip-shadow '\n",
      " 'qtip-rounded\\\\u0022,\\\\u0022classes_custom\\\\u0022:\\\\u0022hw-tooltip '\n",
      " 'hw-abstract-tooltip\\\\u0022},\\\\u0022position\\\\u0022:{\\\\u0022at\\\\u0022:\\\\u0022right '\n",
      " 'center\\\\u0022,\\\\u0022my\\\\u0022:\\\\u0022left '\n",
      " 'center\\\\u0022,\\\\u0022viewport\\\\u0022:true,\\\\u0022adjust\\\\u0022:{\\\\u0022method\\\\u0022:\\\\u0022shift\\\\u0022}},\\\\u0022show\\\\u0022:{\\\\u0022event\\\\u0022:\\\\u0022mouseenter '\n",
      " 'click '\n",
      " '\\\\u0022,\\\\u0022solo\\\\u0022:true},\\\\u0022hide\\\\u0022:{\\\\u0022event\\\\u0022:\\\\u0022mouseleave '\n",
      " '\\\\u0022,\\\\u0022fixed\\\\u0022:1,\\\\u0022delay\\\\u0022:\\\\u0022100\\\\u0022}},\\\\u0022highwire_author_tooltip\\\\u0022:{\\\\u0022content\\\\u0022:{\\\\u0022text\\\\u0022:\\\\u0022\\\\u0022},\\\\u0022style\\\\u0022:{\\\\u0022tip\\\\u0022:{\\\\u0022width\\\\u0022:15,\\\\u0022height\\\\u0022:15,\\\\u0022border\\\\u0022:1,\\\\u0022offset\\\\u0022:0,\\\\u0022corner\\\\u0022:true},\\\\u0022classes\\\\u0022:\\\\u0022qtip-custom '\n",
      " 'hw-tooltip hw-author-tooltip qtip-shadow '\n",
      " 'qtip-rounded\\\\u0022,\\\\u0022classes_custom\\\\u0022:\\\\u0022hw-tooltip '\n",
      " 'hw-author-tooltip\\\\u0022},\\\\u0022position\\\\u0022:{\\\\u0022at\\\\u0022:\\\\u0022top '\n",
      " 'center\\\\u0022,\\\\u0022my\\\\u0022:\\\\u0022bottom '\n",
      " 'center\\\\u0022,\\\\u0022viewport\\\\u0022:true,\\\\u0022adjust\\\\u0022:{\\\\u0022method\\\\u0022:\\\\u0022\\\\u0022}},\\\\u0022show\\\\u0022:{\\\\u0022event\\\\u0022:\\\\u0022mouseenter '\n",
      " '\\\\u0022,\\\\u0022solo\\\\u0022:true},\\\\u0022hide\\\\u0022:{\\\\u0022event\\\\u0022:\\\\u0022mouseleave '\n",
      " '\\\\u0022,\\\\u0022fixed\\\\u0022:1,\\\\u0022delay\\\\u0022:\\\\u0022100\\\\u0022}},\\\\u0022highwire_reflinks_tooltip\\\\u0022:{\\\\u0022content\\\\u0022:{\\\\u0022text\\\\u0022:\\\\u0022\\\\u0022},\\\\u0022style\\\\u0022:{\\\\u0022tip\\\\u0022:{\\\\u0022width\\\\u0022:15,\\\\u0022height\\\\u0022:15,\\\\u0022border\\\\u0022:1,\\\\u0022mimic\\\\u0022:\\\\u0022top '\n",
      " 'center\\\\u0022,\\\\u0022offset\\\\u0022:0,\\\\u0022corner\\\\u0022:true},\\\\u0022classes\\\\u0022:\\\\u0022qtip-custom '\n",
      " 'hw-tooltip hw-ref-link-tooltip qtip-shadow '\n",
      " 'qtip-rounded\\\\u0022,\\\\u0022classes_custom\\\\u0022:\\\\u0022hw-tooltip '\n",
      " 'hw-ref-link-tooltip\\\\u0022},\\\\u0022position\\\\u0022:{\\\\u0022at\\\\u0022:\\\\u0022bottom '\n",
      " 'left\\\\u0022,\\\\u0022my\\\\u0022:\\\\u0022top '\n",
      " 'left\\\\u0022,\\\\u0022viewport\\\\u0022:true,\\\\u0022adjust\\\\u0022:{\\\\u0022method\\\\u0022:\\\\u0022flip\\\\u0022}},\\\\u0022show\\\\u0022:{\\\\u0022event\\\\u0022:\\\\u0022mouseenter '\n",
      " '\\\\u0022,\\\\u0022solo\\\\u0022:true},\\\\u0022hide\\\\u0022:{\\\\u0022event\\\\u0022:\\\\u0022mouseleave '\n",
      " '\\\\u0022,\\\\u0022fixed\\\\u0022:1,\\\\u0022delay\\\\u0022:\\\\u0022100\\\\u0022}}}\",\"qtipDebug\":\"{\\\\u0022leaveElement\\\\u0022:0}\",\"panel_ajax_tab\":{\"path\":\"sites\\\\/all\\\\/modules\\\\/contrib\\\\/panels_ajax_tab\"},\"urlIsAjaxTrusted\":{\"\\\\/content\\\\/371\\\\/6532\\\\/916\":true},\"highwireResponsive\":{\"enquire_enabled\":1,\"breakpoints_configured\":1,\"breakpoints\":{\"zero\":\"(min-width: '\n",
      " '0px)\",\"small\":\"(min-width: 480px)\",\"med\":\"(min-width: '\n",
      " '768px)\",\"med2\":\"(min-width: 900px)\",\"med3\":\"(min-width: '\n",
      " '1025px)\",\"large\":\"(min-width: '\n",
      " '1100px)\"}},\"googleanalytics\":{\"trackOutbound\":1,\"trackMailto\":1,\"trackDownload\":1,\"trackDownloadExtensions\":\"7z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\",\"trackColorbox\":1}});\\n'\n",
      " '//--><!',\n",
      " ']]>\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '/* ForeSee Embed Script v2.01\\n'\n",
      " '\\t// DO NOT MODIFY BELOW THIS LINE '\n",
      " '*****************************************/\\n'\n",
      " '\\t;(function (g) {\\n'\n",
      " '\\t\\tvar d = document, am = d.createElement(\"script\"), h = d.head || '\n",
      " 'd.getElementsByTagName(\"head\")[0], fsr = \"fsReady\",\\n'\n",
      " '\\t\\t\\taex = {\\n'\n",
      " '\\t\\t\\t\\t\"src\": \"https://www.cdc.gov/JScript/foresee/latest/gateway.min.js\",\\n'\n",
      " '\\t\\t\\t\\t\"type\": \"text/javascript\",\\n'\n",
      " '\\t\\t\\t\\t\"async\": \"true\",\\n'\n",
      " '\\t\\t\\t\\t\"data-vendor\": \"fs\",\\n'\n",
      " '\\t\\t\\t\\t\"data-mode\": \"selfhost\",\\n'\n",
      " '\\t\\t\\t\\t\"data-environment\": \"production\",\\n'\n",
      " '\\t\\t\\t\\t\"data-hasssl\": \"true\",\\n'\n",
      " '\\t\\t\\t\\t\"data-client\": \"cdc\",\\n'\n",
      " '\\t\\t\\t\\t\"data-codelocation\": '\n",
      " '\"https://www.cdc.gov/JScript/foresee/latest/foresee_assets/code/19.7.6/\",\\n'\n",
      " '\\t\\t\\t\\t\"data-isselfhosted\": \"true\",\\n'\n",
      " '\\t\\t\\t\\t\"data-product-assets\": '\n",
      " '\"https://www.cdc.gov/JScript/foresee/latest/foresee_assets/product_assets/\",\\n'\n",
      " '\\t\\t\\t\\t\"data-role\": \"gateway\"\\n'\n",
      " '\\t\\t\\t};\\n'\n",
      " '\\t\\tfor (var attr in aex){am.setAttribute(attr, '\n",
      " 'aex[attr]);}h.appendChild(am); g[fsr] || (g[fsr] = function () {var aT = '\n",
      " '\"__\" + fsr + \"_stk__\";g[aT] = g[aT] || [];g[aT].push(arguments);});\\n'\n",
      " '\\t})(window);\\n'\n",
      " '\\t/* DO NOT MODIFY ABOVE THIS LINE '\n",
      " '*****************************************/\\n'\n",
      " '\\n'\n",
      " 'Understanding How COVID-19 Vaccines Work  | CDC\\n'\n",
      " '  \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " ' \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " ' \\n'\n",
      " '\\n'\n",
      " '.theme-cyan nav ul.tp-nav-main '\n",
      " 'li.active.selected>a:first-child{color:#006c80;}\\n'\n",
      " '  \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Skip directly to site content\\n'\n",
      " 'Skip directly to page options\\n'\n",
      " 'Skip directly to A-Z link\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'var axel = Math.random() + \"\";\\n'\n",
      " 'var a = axel * 10000000000000;\\n'\n",
      " \"document.write('<iframe \"\n",
      " 'src=\"https://10322181.fls.doubleclick.net/activityi;src=10322181;type=ptnuh0;cat=2021_0;dc_lat=;dc_rdid=;tag_for_child_directed_treatment=;tfua=;npa=;gdpr=${GDPR};gdpr_consent=${GDPR_CONSENT_755};ord=1;num=\\' '\n",
      " '+ a + \\'?\"',\n",
      " 'width=\"1\" height=\"1\" frameborder=\"0\" style=\"display:none\">\\');\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Self-Checker\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Coronavirus Self-Checker\\n'\n",
      " '\\n'\n",
      " '×\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Centers for Disease Control and Prevention.',\n",
      " 'CDC twenty four seven.',\n",
      " 'Saving Lives, Protecting People\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '       \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '×\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Submit\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'COVID-19\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'COVID-19\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\tCoronavirus Home\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Home\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\tYour Health\\t\\t\\t\\t\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'About COVID-19 \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Symptoms\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Testing\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Variants\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\tVIEW MORE\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Masks \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Your Guide to Masks\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'How to Wear Masks\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Improve Your Masks\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\tVIEW MORE\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Daily Life \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'If You Are Sick\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'People at Increased Risk\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Travel\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\tVIEW MORE\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\tVaccines\\t\\t\\t\\t\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Getting a Vaccine \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Information for Specific Groups \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Before Your Appointment\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'After the Vaccine\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\tVIEW MORE\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'About the Vaccines \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Key Things to Know\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Different Vaccines \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Vaccine Safety\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\tVIEW MORE\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Resources \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Clinical Resources\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Questions & Answers\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Vaccine Rollout Recommendations \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\tVIEW MORE\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\tCases & Data\\t\\t\\t\\t\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'COVID Data Tracker \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Cases in the Last 7 Days\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'County Level Cases\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Vaccinations in the US\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\tVIEW MORE\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Research & Surveillance \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Weekly Summary\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Special Populations Data\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Forecasts\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\tVIEW MORE\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\tWork & School\\t\\t\\t\\t\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Workplaces & Businesses \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Info by Industry\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Questions & Answers\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Disinfecting Your Facility\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\tVIEW MORE\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Schools & Child Care \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'K-12 Operational Strategy\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Prevention in K-12 Schools\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Child Care Programs\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\tVIEW MORE\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Community \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Colleges & Universities\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Parks & Recreational Facilities\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Health Equity\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\tVIEW MORE\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\tHealthcare Workers\\t\\t\\t\\t\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Healthcare Workers \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Clinical Care\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Infection Control\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Exposure in Healthcare Settings\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\tVIEW MORE\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Laboratories \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Resources for Labs\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'CDC Lab Work\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Questions & Answers\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\tVIEW MORE\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\tHealth Depts\\t\\t\\t\\t\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Resources \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Key Resources\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Search Health Dept Resources\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Testing\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\tVIEW MORE\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Community Mitigation \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Community-Related Exposures\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Expanded Screening Testing\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Evaluating Strategies\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\tVIEW MORE\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Contact Tracing \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Resources\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Notification of Exposure\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Principles\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\tVIEW MORE\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\tMore\\t\\t\\t\\t\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " ' \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Science & Research \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Global COVID-19\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'CDC in Action\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Guidance for COVID-19\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Communication Resources\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\tVIEW MORE\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Section Navigation\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'CDC Home\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " ' \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " ' \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Understanding How COVID-19 Vaccines WorkUnderstanding How COVID-19 Vaccines '\n",
      " 'Work \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\t\\t\\tUpdated Jan. 13, 2021\\t\\t\\t\\t\\t\\t\\t\\t\\n'\n",
      " '\\n'\n",
      " 'LanguagesEspañol简体中文Tiếng Việt한국어Other Languages \\n'\n",
      " '\\n'\n",
      " 'Print\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Minus\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Related Pages\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'The Immune System—The Body’s Defense Against Infection\\n'\n",
      " 'To understand how COVID-19 vaccines work, it helps to first look at how our '\n",
      " 'bodies fight illness.',\n",
      " 'When germs, such as the virus that causes COVID-19, invade our bodies, they '\n",
      " 'attack and multiply.',\n",
      " 'This invasion, called an infection, is what causes illness.',\n",
      " 'Our immune system uses several tools to fight infection.',\n",
      " 'Blood contains red cells, which carry oxygen to tissues and organs, and '\n",
      " 'white or immune cells, which fight infection.',\n",
      " 'Different types of white blood cells fight infection in different ways:\\n'\n",
      " '\\n'\n",
      " 'Macrophages\\xa0are white blood cells that swallow up and digest germs and '\n",
      " 'dead or dying cells.',\n",
      " 'The macrophages leave behind parts of the invading germs called antigens.',\n",
      " 'The body identifies antigens as dangerous and stimulates antibodies to '\n",
      " 'attack them.',\n",
      " 'B-lymphocytes\\xa0are defensive white blood cells.',\n",
      " 'They produce antibodies that attack the pieces of the virus left behind by '\n",
      " 'the macrophages.',\n",
      " 'T-lymphocytes\\xa0are another type of defensive white blood cell.',\n",
      " 'They attack cells in the body that have already been infected.',\n",
      " 'The first time a person is infected with the virus that causes COVID-19, it '\n",
      " 'can take several days or weeks for their body to make and use all the '\n",
      " 'germ-fighting tools needed to get over the infection.',\n",
      " 'After the infection, the person’s immune system remembers what it learned '\n",
      " 'about how to protect the body against that disease.',\n",
      " 'The body keeps a few T-lymphocytes, called memory cells, that go into action '\n",
      " 'quickly if the body encounters the same virus again.',\n",
      " 'When the familiar antigens are detected, B-lymphocytes produce antibodies to '\n",
      " 'attack them.',\n",
      " 'Experts are still learning how long these memory cells protect a person '\n",
      " 'against the virus that causes COVID-19.',\n",
      " 'How COVID-19 Vaccines Work\\n'\n",
      " 'COVID-19 vaccines help our bodies develop immunity to the virus that causes '\n",
      " 'COVID-19 without us having to get the illness.',\n",
      " 'Different types of vaccines work in different ways to offer protection, but '\n",
      " 'with all types of vaccines, the body is left with a supply of “memory” '\n",
      " 'T-lymphocytes as well as B-lymphocytes that will remember how to fight that '\n",
      " 'virus in the future.',\n",
      " 'It typically takes a few weeks for the body to produce T-lymphocytes and '\n",
      " 'B-lymphocytes after vaccination.',\n",
      " 'Therefore, it is possible that a person could be infected with the virus '\n",
      " 'that causes COVID-19 just before or just after vaccination and then get sick '\n",
      " 'because the vaccine did not have enough time to provide protection.',\n",
      " 'Sometimes after vaccination, the process of building immunity can cause '\n",
      " 'symptoms, such as fever.',\n",
      " 'These symptoms are normal and are a sign that the body is building immunity.',\n",
      " 'Types of Vaccines\\n'\n",
      " 'Currently, there are three main types of COVID-19 vaccines that are or soon '\n",
      " 'will be undergoing large-scale (Phase 3) clinical trials in the United '\n",
      " 'States.',\n",
      " 'Below is a description of how each type of vaccine prompts our bodies to '\n",
      " 'recognize and protect us from the virus that causes COVID-19.',\n",
      " 'None of these vaccines can give you COVID-19.',\n",
      " 'mRNA vaccines contain material from the virus that causes COVID-19 that '\n",
      " 'gives our cells instructions for how to make a harmless protein that is '\n",
      " 'unique to the virus.',\n",
      " 'After our cells make copies of the protein, they destroy the genetic '\n",
      " 'material from the vaccine.',\n",
      " 'Our bodies recognize that the protein should not be there and build '\n",
      " 'T-lymphocytes and B-lymphocytes that will remember how to fight the virus '\n",
      " 'that causes COVID-19 if we are infected in the future.',\n",
      " 'Protein subunit vaccines include harmless pieces (proteins) of the virus '\n",
      " 'that cause COVID-19 instead of the entire germ.',\n",
      " 'Once vaccinated, our immune system recognizes that the proteins don’t belong '\n",
      " 'in the body and begins making T-lymphocytes and\\xa0antibodies.',\n",
      " 'If we are ever infected in the future, memory cells will recognize and fight '\n",
      " 'the virus.',\n",
      " 'Vector vaccines contain a weakened version of a live virus—a different virus '\n",
      " 'than the one that causes COVID-19—that has genetic material from the virus '\n",
      " 'that causes COVID-19 inserted in it (this is called a viral vector).',\n",
      " 'Once the viral vector is inside our cells, the genetic material gives cells '\n",
      " 'instructions to make a protein that is unique to the virus that causes '\n",
      " 'COVID-19.',\n",
      " 'Using these instructions, our cells make copies of the protein.',\n",
      " 'This prompts our bodies to build T-lymphocytes and B-lymphocytes that will '\n",
      " 'remember how to fight that virus if we are infected in the future.',\n",
      " 'Most COVID-19 Vaccines Require More Than One Shot\\n'\n",
      " 'All but one of the COVID-19 vaccines that are currently in Phase 3 clinical '\n",
      " 'trials in the United States use two shots.',\n",
      " 'The first shot starts building protection.',\n",
      " 'A second shot a few weeks later is needed to get the most protection the '\n",
      " 'vaccine has to offer.',\n",
      " 'One vaccine in Phase 3 clinical trials only needs one shot.',\n",
      " 'The Bottom Line\\n'\n",
      " 'Getting vaccinated is one of many steps you can take to protect yourself and '\n",
      " 'others from COVID-19.',\n",
      " 'Protection from COVID-19 is critically important because for some people, it '\n",
      " 'can cause severe illness or death.',\n",
      " 'Stopping a pandemic requires using all the tools available.',\n",
      " 'Vaccines work with your immune system so your body will be ready to fight '\n",
      " 'the virus if you are exposed.',\n",
      " 'Other steps, like masks and social distancing, help reduce your chance of '\n",
      " 'being exposed to the virus or spreading it to others.',\n",
      " 'Together, COVID-19 vaccination and following CDC’s recommendations to '\n",
      " 'protect yourself and others will offer the best protection from COVID-19.',\n",
      " 'Facebook\\n'\n",
      " 'Twitter\\n'\n",
      " 'LinkedIn\\n'\n",
      " 'Syndicate\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t\\t\\t\\t\\tLast Updated Jan. 13, 2021\\t\\t\\t\\t\\t\\t\\tContent source: \\t'\n",
      " 'National Center for Immunization and Respiratory Diseases (NCIRD), Division '\n",
      " 'of Viral Diseases\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'homeVaccinesKey Things to Knowplus iconFrequently Asked Questions about '\n",
      " 'VaccinationMyths & FactsInformation for Specific Groupsplus iconHealthcare '\n",
      " 'PersonnelLong-term Care Facility ResidentsEssential Workersplus '\n",
      " 'iconWorkplace Vaccination ProgramHow to Get VaccinatedOlder AdultsPeople '\n",
      " 'with DisabilitiesPregnancy or BreastfeedingUnderlying Medical '\n",
      " 'ConditionsPeople with AllergiesVaccine Rollout RecommendationsHow CDC is '\n",
      " 'Making Vaccine RecommendationsWhat to Expect at Your Vaccine Appointmentplus '\n",
      " 'iconAfter Getting the VaccineBenefits of Getting VaccinatedDifferent '\n",
      " 'Vaccinesplus iconHow Vaccines WorkUnderstanding mRNA '\n",
      " 'VaccinesPfizer-BioNTechModernaUnderstanding Viral Vector COVID-19 '\n",
      " \"VaccinesJohnson & Johnson's JanssenEnsuring the Safety of Vaccinesplus \"\n",
      " 'iconV-safeV-safe Print ResourcesAllergic ReactionsSafety of COVID-19 '\n",
      " 'VaccinesVaccine Reporting Systemsplus iconMonitoring Systems for Pregnant '\n",
      " 'PeopleV-safe Pregnancy RegistryEnsuring Vaccines WorkHow Vaccines Get to '\n",
      " 'Youplus iconPercent of Doses AdministeredCommunication Resourcesplus '\n",
      " 'iconToolkitsplus iconFor Essential WorkersFor Community-Based '\n",
      " 'Organizations \\n'\n",
      " '\\n'\n",
      " ' email_03Get Email Updates  To receive email updates about COVID-19, enter '\n",
      " \"your email address:     Email Address       What's this?\",\n",
      " 'Submit       \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '// Print Button (pre 2020 theme)\\r\\n'\n",
      " '( function() {\\r\\n'\n",
      " '  var nTimer = setInterval( function() {\\r\\n'\n",
      " '    if ( window.jQuery && !',\n",
      " \"window.jQuery('html').hasClass('cdc-2020') ) {\\r\\n\"\n",
      " '      clearInterval( nTimer );\\r\\n'\n",
      " \"      var targetNodeForInsertion = jQuery( 'h1#content' );\\r\\n\"\n",
      " '      if ( 0 === targetNodeForInsertion.length ) {\\r\\n'\n",
      " '        return;\\r\\n'\n",
      " '      }\\r\\n'\n",
      " '\\r\\n'\n",
      " \"      if ( targetNodeForInsertion.parent().hasClass( 'syndicate' ) ) {\\r\\n\"\n",
      " '        targetNodeForInsertion = targetNodeForInsertion.parent();\\r\\n'\n",
      " '      }\\r\\n'\n",
      " '\\r\\n'\n",
      " \"      if ( targetNodeForInsertion.next().hasClass( 'dropdown' ) ) {\\r\\n\"\n",
      " '        targetNodeForInsertion.next().append( \\'<button id=\"clickToPrint\" '\n",
      " 'class=\"btn bg-white c-blue b-gray-l3 fs08 ml-2\" aria-label=\"Click to print '\n",
      " 'page\" onclick=\"window.print()\">Print Page</button>\\' );\\r\\n'\n",
      " '      } else {\\r\\n'\n",
      " '        targetNodeForInsertion.after( \\'<div class=\"dropdown p-none\" '\n",
      " 'style=\"margin-top:-5px; margin-bottom:33px;\"><button id=\"clickToPrint\" '\n",
      " 'class=\"btn bg-white c-blue b-gray-l3 fs08\" aria-label=\"Click to print page\" '\n",
      " 'onclick=\"window.print()\">Print Page</button></div>\\' );\\r\\n'\n",
      " '      }\\r\\n'\n",
      " '    }\\r\\n'\n",
      " '  }, 50 );\\r\\n'\n",
      " '})();\\r\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " ' \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'HAVE QUESTIONS?',\n",
      " 'Visit CDC-INFO\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Call 800-232-4636\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Email CDC-INFO\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Open 24/7\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'CDC INFORMATION\\n'\n",
      " '\\n'\n",
      " 'About CDC\\n'\n",
      " 'Jobs\\n'\n",
      " 'Funding\\n'\n",
      " 'Policies\\n'\n",
      " 'File Viewers & Players\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Privacy\\n'\n",
      " 'FOIA\\n'\n",
      " 'No Fear Act\\n'\n",
      " 'OIG\\n'\n",
      " 'Nondiscrimination\\n'\n",
      " 'Accessibility\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'CONNECT WITH CDC\\n'\n",
      " '\\n'\n",
      " 'Facebook\\n'\n",
      " 'Twitter\\n'\n",
      " 'Instagram\\n'\n",
      " 'LinkedIn\\n'\n",
      " 'Snapchat\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Youtube\\n'\n",
      " 'Syndicate\\n'\n",
      " 'CDC TV\\n'\n",
      " 'RSS\\n'\n",
      " 'Email\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'U.S. Department of Health & Human Services\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'USA.gov\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'CDC Website Exit Disclaimer external icon\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'LANGUAGE ASSISTANCE\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Español\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '繁體中文\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Tiếng Việt\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '한국어\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Tagalog\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Русский\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'العربية\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Kreyòl Ayisyen\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Français\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Polski\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Português\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Italiano\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Deutsch\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '日本語\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'فارسی\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'English\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'CONTACT CDC\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Visit CDC-INFO\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Call 800-232-4636\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Email CDC-INFO\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Open 24/7\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'ABOUT CDC\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'About CDC\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Jobs\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Funding\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'POLICIES\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Policies\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'File Viewers & Players\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Privacy\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'FOIA\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'No Fear Act\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'OIG\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Nondiscrimination\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Accessibility\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'CDC Website Exit Disclaimer external icon\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'LANGUAGE ASSISTANCE\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Español\\n'\n",
      " '繁體中文\\n'\n",
      " 'Tiếng Việt\\n'\n",
      " '한국어\\n'\n",
      " 'Tagalog\\n'\n",
      " 'Русский\\n'\n",
      " 'العربية\\n'\n",
      " 'Kreyòl Ayisyen\\n'\n",
      " 'Français\\n'\n",
      " 'Polski\\n'\n",
      " 'Português\\n'\n",
      " 'Italiano\\n'\n",
      " 'Deutsch\\n'\n",
      " '日本語\\n'\n",
      " 'فارسی\\n'\n",
      " 'English\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Facebook\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Twitter\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Instagram\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'LinkedIn\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Snapchat\\n'\n",
      " '\\n'\n",
      " 'Youtube\\n'\n",
      " 'Syndicate\\n'\n",
      " 'CDC TV\\n'\n",
      " 'RSS\\n'\n",
      " 'Email\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'U.S. Department of Health & Human Services\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'USA.gov\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'SAS\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'stats\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t.st0 {\\r\\n'\n",
      " '\\t\\t\\t\\tfill: #FFFFFF;\\r\\n'\n",
      " '\\t\\t\\t}\\r\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t.st1 {\\r\\n'\n",
      " '\\t\\t\\t\\tfill: none;\\r\\n'\n",
      " '\\t\\t\\t\\tstroke: #FFFFFF;\\r\\n'\n",
      " '\\t\\t\\t\\tstroke-width: 2.1206;\\r\\n'\n",
      " '\\t\\t\\t}\\r\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t.st2 {\\r\\n'\n",
      " '\\t\\t\\t\\tfill: #005DA9;\\r\\n'\n",
      " '\\t\\t\\t}\\r\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t.st3 {\\r\\n'\n",
      " '\\t\\t\\t\\tfill: none;\\r\\n'\n",
      " '\\t\\t\\t\\tstroke: #FFFFFF;\\r\\n'\n",
      " '\\t\\t\\t\\tstroke-width: 1.8943;\\r\\n'\n",
      " '\\t\\t\\t}\\r\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t.st4 {\\r\\n'\n",
      " '\\t\\t\\t\\tfill: #607171;\\r\\n'\n",
      " '\\t\\t\\t}\\r\\n'\n",
      " '\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t.st0 {\\r\\n'\n",
      " '\\t\\t\\t\\tfill: #FFFFFF;\\r\\n'\n",
      " '\\t\\t\\t}\\r\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t.st1 {\\r\\n'\n",
      " '\\t\\t\\t\\tfill: none;\\r\\n'\n",
      " '\\t\\t\\t\\tstroke: #FFFFFF;\\r\\n'\n",
      " '\\t\\t\\t\\tstroke-width: 2.1206;\\r\\n'\n",
      " '\\t\\t\\t}\\r\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t.st2 {\\r\\n'\n",
      " '\\t\\t\\t\\tfill: #005DA9;\\r\\n'\n",
      " '\\t\\t\\t}\\r\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t.st3 {\\r\\n'\n",
      " '\\t\\t\\t\\tfill: none;\\r\\n'\n",
      " '\\t\\t\\t\\tstroke: #FFFFFF;\\r\\n'\n",
      " '\\t\\t\\t\\tstroke-width: 1.8943;\\r\\n'\n",
      " '\\t\\t\\t}\\r\\n'\n",
      " '\\r\\n'\n",
      " '\\t\\t\\t.st4 {\\r\\n'\n",
      " '\\t\\t\\t\\tfill: #607171;\\r\\n'\n",
      " '\\t\\t\\t}\\r\\n'\n",
      " '\\t\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '    \\r\\n'\n",
      " '    s.pageName=document.title;\\r\\n'\n",
      " 's.channel=\"Coronavirus\";\\r\\n'\n",
      " 'siteCatalyst.setLevel1(\"ncird\");\\r\\n'\n",
      " 'siteCatalyst.setLevel2(\"coronavirus\");\\r\\n'\n",
      " 'siteCatalyst.setLevel3(\"multi\");\\r\\n'\n",
      " 'siteCatalyst.setLevel4(\"dvd\");\\r\\n'\n",
      " 'siteCatalyst.setLevel5(\"covid-vax\"); <!-- NEW LEVEL as of 12/16/2020 '\n",
      " '-->    \\r\\n'\n",
      " '    \\n'\n",
      " '\\r\\n'\n",
      " '\\twindow.shortTitle = \"Understanding How COVID-19 Vaccines Work\";\\r\\n'\n",
      " '\\twindow.pageOptions = window.pageOptions || {};\\r\\n'\n",
      " '\\twindow.pageOptions.navigation = window.pageOptions.navigation || { '\n",
      " 'fourthLevelCollapsed: false, showFourthLevel: true\\t}; \\t\\t'\n",
      " \"window.pageOptions.navigation.breadcrumbs = { mode: 'auto', showCurrentPage: \"\n",
      " 'false , prefix: [{\"text\":\"CDC\",\"href\":\"https:\\\\/\\\\/www.cdc.gov\\\\/\"}] }; \\r\\n'\n",
      " '\\twindow.CDC.tp4.public.appInit( window.pageOptions );\\r\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Exit Notification/Disclaimer Policy\\n'\n",
      " '\\n'\n",
      " 'Close\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Links with this icon  indicate that you are leaving the CDC website.',\n",
      " 'The Centers for Disease Control and Prevention (CDC) cannot attest to the '\n",
      " 'accuracy of a non-federal website.',\n",
      " 'Linking to a non-federal website does not constitute an endorsement by CDC '\n",
      " 'or any of its employees of the sponsors or the information and products '\n",
      " 'presented on the website.',\n",
      " \"You will be subject to the destination website's privacy policy when you \"\n",
      " 'follow the link.',\n",
      " 'CDC is not responsible for Section 508 compliance (accessibility) on other '\n",
      " 'federal or private website.',\n",
      " \"For more information on CDC's web notification policies, see Website \"\n",
      " 'Disclaimers.',\n",
      " 'Cancel\\n'\n",
      " 'Continue\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Coronavirus (COVID-19) vaccine - NHS\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '{\"@context\": \"http://schema.org\", \"@type\": \"WebPage\", \"about\": {\"@type\": '\n",
      " '\"WebPage\", \"name\": \"Coronavirus (COVID-19) vaccine\"}, \"author\": {\"@type\": '\n",
      " '\"Organization\", \"email\": \"nhswebsite.servicedesk@nhs.net\", \"logo\": '\n",
      " '\"https://www.nhs.uk/nhscwebservices/documents/logo1.jpg\", \"name\": \"NHS '\n",
      " 'website\", \"url\": \"https://www.nhs.uk\"}, \"breadcrumb\": {\"@context\": '\n",
      " '\"http://schema.org\", \"@type\": \"BreadcrumbList\", \"itemListElement\": '\n",
      " '[{\"@type\": \"ListItem\", \"item\": {\"@id\": \"https://www.nhs.uk/conditions/\", '\n",
      " '\"genre\": \"condition\", \"name\": \"Health A to Z\"}, \"position\": 0}, {\"@type\": '\n",
      " '\"ListItem\", \"item\": {\"@id\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/\", \"genre\": \"hub\", '\n",
      " '\"name\": \"Coronavirus (COVID-19)\"}, \"position\": 1}, {\"@type\": \"ListItem\", '\n",
      " '\"item\": {\"@id\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/\", '\n",
      " '\"genre\": \"hub\", \"name\": \"Coronavirus vaccination\"}, \"position\": 2}, '\n",
      " '{\"@type\": \"ListItem\", \"item\": {\"@id\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/\", '\n",
      " '\"genre\": \"guide\", \"name\": \"Coronavirus (COVID-19) vaccine\"}, \"position\": '\n",
      " '3}]}, \"copyrightHolder\": {\"@type\": \"Organization\", \"name\": \"Crown '\n",
      " 'Copyright\"}, \"description\": \"NHS information about coronavirus vaccines, '\n",
      " 'including vaccine safety and who can get the vaccine.',\n",
      " '\", \"genre\": \"guide\", \"hasPart\": [{\"@type\": \"WebPageElement\", \"description\": '\n",
      " '\"The coronavirus (COVID-19) vaccine is safe and effective.',\n",
      " 'It gives you the best protection against coronavirus.',\n",
      " '\", \"name\": \"overview\", \"text\": \"\", \"title\": \"\", \"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/#overview\"}, '\n",
      " '{\"@type\": \"WebPageElement\", \"description\": \"People most at risk from '\n",
      " 'coronavirus (COVID-19) are being offered the COVID-19 vaccine first.',\n",
      " 'It will be offered to more people over time.',\n",
      " '\", \"name\": \"SuitabilityHealthAspect\", \"text\": \"<p>The NHS is currently '\n",
      " 'offering the COVID-19 vaccine to people most at risk from '\n",
      " 'coronavirus.</p><p>In England, the vaccine is being\\\\u00a0offered in some '\n",
      " 'hospitals and pharmacies, at local vaccination centres run by GPs and at '\n",
      " 'larger vaccination centres.',\n",
      " \"More centres are opening all the time.</p><p>It's being given \"\n",
      " 'to:</p><ul><li>people aged 60 and over</li><li>people at <a '\n",
      " 'href=\\\\\"/conditions/coronavirus-covid-19/people-at-higher-risk/whos-at-higher-risk-from-coronavirus/\\\\\">high '\n",
      " 'risk from coronavirus</a> (clinically extremely vulnerable)</li><li>people '\n",
      " 'who live or work in care homes</li><li>health and social care '\n",
      " 'workers</li><li>people with a condition that puts them at higher risk '\n",
      " '(clinically vulnerable)</li><li>people who are a main carer for someone at '\n",
      " 'high risk from coronavirus</li></ul>\", \"title\": \"Who can get the COVID-19 '\n",
      " 'vaccine\", \"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/#suitability\"}, '\n",
      " '{\"@type\": \"WebPageElement\", \"description\": \"The coronavirus (COVID-19) '\n",
      " 'vaccine is given as an injection.',\n",
      " 'There are 2 doses given 3 to 12 weeks apart.',\n",
      " '\", \"name\": \"UsageOrScheduleHealthAspect\", \"text\": \"<p>The COVID-19 vaccine '\n",
      " \"is given as an injection into your upper arm.</p><p>It's given as 2 doses.\",\n",
      " 'You will have the 2nd dose 3 to 12 weeks after having the 1st dose.</p>\", '\n",
      " '\"title\": \"How the COVID-19 vaccine is given\", \"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/#dosage-and-administration\"}, '\n",
      " '{\"@type\": \"WebPageElement\", \"description\": \"If you\\\\u2019re eligible, you '\n",
      " 'can book your coronavirus (COVID-19) vaccination appointments online at '\n",
      " 'www.nhs.uk/covid-vaccination or by calling 119.',\n",
      " '\", \"name\": \"HowOrWhereHealthAspect\", \"text\": \"<p>You can book your '\n",
      " 'vaccination appointments online if any of the following '\n",
      " 'apply:</p><ul><li>you are aged 60 or over</li><li>you are at <a '\n",
      " 'href=\\\\\"/conditions/coronavirus-covid-19/people-at-higher-risk/whos-at-higher-risk-from-coronavirus/\\\\\">high '\n",
      " 'risk from coronavirus</a> (clinically extremely vulnerable)</li><li>you are '\n",
      " 'an eligible frontline health or social care worker</li><li>you have a '\n",
      " 'condition that puts you at higher risk (clinically vulnerable)</li><li>you '\n",
      " 'are a main carer for someone at high risk from coronavirus</li></ul><p>You '\n",
      " 'can book appointments at a larger vaccination centre or a pharmacy that '\n",
      " 'provides COVID-19 vaccinations.</p><p>You do not need to wait to be '\n",
      " 'contacted by the NHS.</p>\", \"title\": \"How to get the COVID-19 vaccine\", '\n",
      " '\"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/#how-to-get-it\"}, '\n",
      " '{\"@type\": \"WebPageElement\", \"description\": \"Millions of people have had the '\n",
      " 'coronavirus (COVID-19) vaccine and reports of serious problems, such as '\n",
      " 'allergic reactions, have been very rare.',\n",
      " '\", \"name\": \"SafetyHealthAspect\", \"text\": \"<p>The vaccines approved for use '\n",
      " 'in the UK have met strict standards of safety, quality and effectiveness set '\n",
      " 'out by the independent Medicines and Healthcare products Regulatory Agency '\n",
      " '(MHRA).</p><p>Any coronavirus vaccine that is approved must go through all '\n",
      " 'the clinical trials and safety checks all other licensed medicines go '\n",
      " 'through.',\n",
      " 'The MHRA follows international standards of safety.</p><p>Other vaccines are '\n",
      " 'being developed.',\n",
      " 'They will only be available on the NHS once they have been thoroughly tested '\n",
      " 'to make sure they are safe and effective.</p><p>So far, millions of people '\n",
      " 'have been given a COVID-19 vaccine and reports of serious side effects, such '\n",
      " 'as allergic reactions, have been very rare.',\n",
      " 'No long-term complications have been reported.</p>\", \"title\": \"How safe is '\n",
      " 'the COVID-19 vaccine?',\n",
      " '\", \"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/#safety\"}, '\n",
      " '{\"@type\": \"WebPageElement\", \"description\": \"Most people who have the '\n",
      " 'coronavirus (COVID-19) vaccine will be protected from the virus.',\n",
      " '2 doses are needed for longer lasting protection.',\n",
      " '\", \"name\": \"BenefitsHealthAspect\", \"text\": \"<p>The 1st dose of the COVID-19 '\n",
      " 'vaccine should give you good protection from coronavirus.',\n",
      " 'But you need to have the 2 doses of the vaccine to give you longer lasting '\n",
      " 'protection.</p><p>There is a chance you might still get or spread '\n",
      " 'coronavirus even if you have the vaccine.</p><p>This means it is important '\n",
      " 'to:</p><ul><li>continue to follow <a '\n",
      " 'href=\\\\\"/conditions/coronavirus-covid-19/social-distancing/what-you-need-to-do/\\\\\">social '\n",
      " 'distancing guidance</a></li><li>if you can, wear something that covers your '\n",
      " \"nose and mouth in places where it's hard to stay away from other \"\n",
      " 'people</li></ul>\", \"title\": \"How effective is the COVID-19 vaccine?',\n",
      " '\", \"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/#effectiveness\"}, '\n",
      " '{\"@type\": \"WebPageElement\", \"description\": \"Some people who have the '\n",
      " 'coronavirus (COVID-19) vaccine have mild side effects for a few days, such '\n",
      " 'as a sore arm or tiredness.',\n",
      " '\", \"name\": \"SideEffectsHealthAspect\", \"text\": \"<p>Most side effects of the '\n",
      " 'COVID-19 vaccine are mild and should not last longer than a week, such '\n",
      " 'as:</p><ul><li>a sore arm where the needle went in</li><li>feeling '\n",
      " 'tired</li><li>a headache</li><li>feeling achy</li><li>feeling or being '\n",
      " 'sick</li></ul><p>You can take painkillers, such as paracetamol, if you need '\n",
      " 'to.</p><p>If you have a high temperature you may have coronavirus or another '\n",
      " 'infection.</p><p>If your symptoms get worse or you are worried, call '\n",
      " '111.</p><h3>Allergic reactions</h3><p>Tell healthcare staff before you are '\n",
      " \"vaccinated if you've ever had a serious allergic reaction.</p><p>You should \"\n",
      " 'not have the COVID-19 vaccine if you have ever had a serious allergic '\n",
      " 'reaction (including anaphylaxis) to:</p><ul><li>a previous dose of the same '\n",
      " 'vaccine</li><li>any of the ingredients in the vaccine</li></ul><p>Serious '\n",
      " 'allergic reactions are rare.',\n",
      " 'If you do have a reaction to the vaccine, it usually happens in minutes.',\n",
      " 'Staff giving the vaccine are trained to deal with allergic reactions and '\n",
      " 'treat them immediately.</p>\", \"title\": \"COVID-19 vaccine side effects\", '\n",
      " '\"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/#side-effects\"}], '\n",
      " '\"lastReviewed\": [\"2021-02-26T08:10:00+00:00\", \"2021-03-12T18:10:00+00:00\"], '\n",
      " '\"license\": \"https://developer.api.nhs.uk/terms\", \"name\": \"Coronavirus '\n",
      " '(COVID-19) vaccine\", \"relatedLink\": [{\"@type\": \"LinkRole\", '\n",
      " '\"linkRelationship\": \"Navigation\", \"name\": \"Coronavirus vaccination\", '\n",
      " '\"position\": 0, \"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/\"}, '\n",
      " '{\"@type\": \"LinkRole\", \"linkRelationship\": \"Navigation\", \"name\": \"Coronavirus '\n",
      " '(COVID-19) vaccine\", \"position\": 1, \"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/\"}, '\n",
      " '{\"@type\": \"LinkRole\", \"linkRelationship\": \"Navigation\", \"name\": \"Who can get '\n",
      " 'the coronavirus (COVID-19) vaccine\", \"position\": 2, \"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/who-can-get-the-vaccine/\"}, '\n",
      " '{\"@type\": \"LinkRole\", \"linkRelationship\": \"Navigation\", \"name\": \"How you '\n",
      " 'will be contacted for your coronavirus (COVID-19) vaccination\", \"position\": '\n",
      " '3, \"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/how-you-will-be-contacted/\"}, '\n",
      " '{\"@type\": \"LinkRole\", \"linkRelationship\": \"Navigation\", \"name\": \"Book or '\n",
      " 'manage your coronavirus vaccination\", \"position\": 4, \"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/book-coronavirus-vaccination/\"}, '\n",
      " '{\"@type\": \"LinkRole\", \"linkRelationship\": \"Navigation\", \"name\": \"What '\n",
      " 'happens at your appointment\", \"position\": 5, \"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/what-happens-at-your-appointment/\"}, '\n",
      " '{\"@type\": \"LinkRole\", \"linkRelationship\": \"Navigation\", \"name\": \"Health '\n",
      " 'conditions and coronavirus (COVID-19) vaccination\", \"position\": 6, \"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/health-conditions/\"}], '\n",
      " '\"schemaVersion\": [\"http://schema.org/version/3.9/\", \"g-20190515\"], \"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/\"}\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'window.digitalData=\\n'\n",
      " '            {\"page\": {\\n'\n",
      " '                \"pageInfo\": {\\n'\n",
      " '                    \"pageName\": '\n",
      " '\"nhs:web:conditions:coronavirus-covid-19:coronavirus-vaccination:coronavirus-vaccine\"\\n'\n",
      " '               },\\n'\n",
      " '                \"category\":\\n'\n",
      " '                    {\\n'\n",
      " '            \"primaryCategory\": \"conditions\",\\n'\n",
      " '            \"subCategory1\":\"coronavirus-covid-19\",\\n'\n",
      " '            \"subCategory2\":\"coronavirus-vaccination\",\\n'\n",
      " '            \"subCategory3\":\"coronavirus-vaccine\"\\n'\n",
      " '            }\\n'\n",
      " '                },\\n'\n",
      " '               };\\n'\n",
      " '            \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '        (function (h, o, t, j, a, r) {\\n'\n",
      " '          h.hj = h.hj || function () {\\n'\n",
      " '            (h.hj.q = h.hj.q || []).push(arguments)\\n'\n",
      " '          };\\n'\n",
      " '          h._hjSettings = {\\n'\n",
      " '            hjid: 681718,\\n'\n",
      " '            hjsv: 6,\\n'\n",
      " '          };\\n'\n",
      " \"          a = o.getElementsByTagName('head')[0];\\n\"\n",
      " \"          r = o.createElement('script');\\n\"\n",
      " '          r.async = 1;\\n'\n",
      " '          r.src = t + h._hjSettings.hjid + j + h._hjSettings.hjsv;\\n'\n",
      " '          a.appendChild(r);\\n'\n",
      " \"        })(window, document, '//static.hotjar.com/c/hotjar-', '.js?sv=');\\n\"\n",
      " '      \\n'\n",
      " '\\n'\n",
      " '      window.NHSUK_SETTINGS = {};\\n'\n",
      " '      window.NHSUK_SETTINGS.BANNER_API_URL = '\n",
      " '\"//www.nhs.uk/externalservices/surveyfeedapi/api/bannerfeed\";\\n'\n",
      " '      window.NHSUK_SETTINGS.BANNER_TEST_API_URL = '\n",
      " '\"//www.nhs.uk/externalservices/surveyfeedapi/api/testfeed\";\\n'\n",
      " '      \\n'\n",
      " '        window.NHSUK_SETTINGS.EMERGENCY_ALERT_DISABLED = true;\\n'\n",
      " '      \\n'\n",
      " '      window.NHSUK_SETTINGS.SUGGESTIONS_TEST_HOST = '\n",
      " '\"//api.nhs.uk/site-search/autocomplete\";\\n'\n",
      " '      window.NHSUK_SETTINGS.SEARCH_TEST_HOST = \"//nhs.uk/search/results\";\\n'\n",
      " '      window.NHSUK_SETTINGS.USER_FEEDBACK_STORE_ENDPOINT = '\n",
      " '\"https://nhsuk-user-feedback-func-prod-uks.azurewebsites.net/\";\\n'\n",
      " '    \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Skip to main content\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Menu\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Search\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Search the NHS website\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Search\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Close search\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Menu\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Close menu\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '        Home\\n'\n",
      " '        \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '    Health A-Z\\n'\n",
      " '    \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '    Live Well\\n'\n",
      " '    \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '    Care and support\\n'\n",
      " '    \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '    Pregnancy\\n'\n",
      " '    \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '    NHS services\\n'\n",
      " '    \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Home\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Health A to Z\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Coronavirus (COVID-19)\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Coronavirus vaccination\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Back to \\n'\n",
      " '            Coronavirus vaccination\\n'\n",
      " '          \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Coronavirus (COVID-19) vaccine\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'The coronavirus (COVID-19) vaccine is safe and effective.',\n",
      " 'It gives you the best protection against coronavirus.',\n",
      " 'Who can get the COVID-19 vaccine\\n'\n",
      " 'The NHS is currently offering the COVID-19 vaccine to people most at risk '\n",
      " 'from coronavirus.In England, the vaccine is being\\xa0offered in some '\n",
      " 'hospitals and pharmacies, at local vaccination centres run by GPs and at '\n",
      " 'larger vaccination centres.',\n",
      " \"More centres are opening all the time.It's being given to:people aged 60 and \"\n",
      " 'overpeople at high risk from coronavirus (clinically extremely '\n",
      " 'vulnerable)people who live or work in care homeshealth and social care '\n",
      " 'workerspeople with a condition that puts them at higher risk (clinically '\n",
      " 'vulnerable)people who are a main carer for someone at high risk from '\n",
      " 'coronavirus\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'The order in which people will be offered the vaccine is based on advice '\n",
      " 'from the Joint Committee on Vaccination and Immunisation (JCVI).Read the '\n",
      " 'latest JCVI advice on priority groups for the COVID-19 vaccination on '\n",
      " 'GOV.UK\\n'\n",
      " '\\n'\n",
      " 'If you are not eligible yet\\n'\n",
      " 'Wait to be contacted.',\n",
      " \"The NHS will let you know when it's your turn to have the vaccine.\",\n",
      " \"It's important not to contact the NHS for a vaccination before then.\",\n",
      " \"Advice if you're of childbearing age, pregnant or breastfeeding\\n\"\n",
      " \"There's no evidence the COVID-19 vaccine is unsafe if you're pregnant.\",\n",
      " 'But more evidence is needed before you can routinely be offered it.The JCVI '\n",
      " 'has updated its advice to recommend you may be able to have the vaccine if '\n",
      " \"you're pregnant and:at high risk of getting coronavirus because of where you \"\n",
      " \"workhave a health condition that means you're at high risk of serious \"\n",
      " \"complications of coronavirusYou can have the COVID-19 vaccine if you're \"\n",
      " 'breastfeeding.Speak to a healthcare professional before you have the '\n",
      " 'vaccination.',\n",
      " 'They will discuss the benefits and risks with you.You do not need to avoid '\n",
      " 'pregnancy after vaccination.',\n",
      " 'The vaccine cannot give you or your baby COVID-19.Read the latest COVID-19 '\n",
      " \"vaccine advice if you're pregnant, may get pregnant or are breastfeeding on \"\n",
      " 'GOV.UKRead the latest Royal College of Obstetricians and Gynaecologists and '\n",
      " 'Royal College of Midwives statement on the COVID-19 vaccine and fertility\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'How the COVID-19 vaccine is given\\n'\n",
      " \"The COVID-19 vaccine is given as an injection into your upper arm.It's given \"\n",
      " 'as 2 doses.',\n",
      " 'You will have the 2nd dose 3 to 12 weeks after having the 1st dose.',\n",
      " 'How to get the COVID-19 vaccine\\n'\n",
      " 'You can book your vaccination appointments online if any of the following '\n",
      " 'apply:you are aged 60 or overyou are at high risk from coronavirus '\n",
      " '(clinically extremely vulnerable)you are an eligible frontline health or '\n",
      " 'social care workeryou have a condition that puts you at higher risk '\n",
      " '(clinically vulnerable)you are a main carer for someone at high risk from '\n",
      " 'coronavirusYou can book appointments at a larger vaccination centre or a '\n",
      " 'pharmacy that provides COVID-19 vaccinations.You do not need to wait to be '\n",
      " 'contacted by the NHS.',\n",
      " 'Book your COVID-19 vaccination appointments\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Information: \\n'\n",
      " 'If you are at moderate risk from coronavirus (clinically vulnerable) the NHS '\n",
      " 'will contact you to arrange your vaccination appointments.',\n",
      " 'How safe is the COVID-19 vaccine?',\n",
      " 'The vaccines approved for use in the UK have met strict standards of safety, '\n",
      " 'quality and effectiveness set out by the independent Medicines and '\n",
      " 'Healthcare products Regulatory Agency (MHRA).Any coronavirus vaccine that is '\n",
      " 'approved must go through all the clinical trials and safety checks all other '\n",
      " 'licensed medicines go through.',\n",
      " 'The MHRA follows international standards of safety.Other vaccines are being '\n",
      " 'developed.',\n",
      " 'They will only be available on the NHS once they have been thoroughly tested '\n",
      " 'to make sure they are safe and effective.So far, millions of people have '\n",
      " 'been given a COVID-19 vaccine and reports of serious side effects, such as '\n",
      " 'allergic reactions, have been very rare.',\n",
      " 'No long-term complications have been reported.',\n",
      " 'To find out more about the vaccines approved in the UK, see:GOV.UK: '\n",
      " 'Pfizer/BioNTech vaccine for COVID-19 approved by MHRAGOV.UK: '\n",
      " 'Oxford/AstraZeneca vaccine for COVID-19 approved by MHRAGOV.UK: Moderna '\n",
      " 'vaccine for COVID-19 approved by MHRA\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'How effective is the COVID-19 vaccine?',\n",
      " 'The 1st dose of the COVID-19 vaccine should give you good protection from '\n",
      " 'coronavirus.',\n",
      " 'But you need to have the 2 doses of the vaccine to give you longer lasting '\n",
      " 'protection.There is a chance you might still get or spread coronavirus even '\n",
      " 'if you have the vaccine.This means it is important to:continue to follow '\n",
      " 'social distancing guidanceif you can, wear something that covers your nose '\n",
      " \"and mouth in places where it's hard to stay away from other people\\n\"\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Information: \\n'\n",
      " 'Read more about why vaccines are safe and important, including how they work '\n",
      " 'and what they contain.',\n",
      " 'COVID-19 vaccine side effects\\n'\n",
      " 'Most side effects of the COVID-19 vaccine are mild and should not last '\n",
      " 'longer than a week, such as:a sore arm where the needle went infeeling '\n",
      " 'tireda headachefeeling achyfeeling or being sickYou can take painkillers, '\n",
      " 'such as paracetamol, if you need to.If you have a high temperature you may '\n",
      " 'have coronavirus or another infection.If your symptoms get worse or you are '\n",
      " 'worried, call 111.Allergic reactionsTell healthcare staff before you are '\n",
      " \"vaccinated if you've ever had a serious allergic reaction.You should not \"\n",
      " 'have the COVID-19 vaccine if you have ever had a serious allergic reaction '\n",
      " '(including anaphylaxis) to:a previous dose of the same vaccineany of the '\n",
      " 'ingredients in the vaccineSerious allergic reactions are rare.',\n",
      " 'If you do have a reaction to the vaccine, it usually happens in minutes.',\n",
      " 'Staff giving the vaccine are trained to deal with allergic reactions and '\n",
      " 'treat them immediately.',\n",
      " 'Information: \\n'\n",
      " 'You can report any suspected side effect using the Coronavirus Yellow Card '\n",
      " 'safety scheme.Visit the Coronavirus Yellow Card to report a vaccine side '\n",
      " 'effect\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'COVID-19 vaccine ingredients\\n'\n",
      " 'The approved COVID-19 vaccines do not contain any animal products or egg.',\n",
      " 'More information\\n'\n",
      " 'Sign up to be contacted for coronavirus vaccine researchGOV.UK: COVID-19 '\n",
      " 'vaccination guide for older adultsGOV.UK: why you have to wait for your '\n",
      " 'COVID-19 vaccineNHS Inform: coronavirus vaccination in ScotlandPublic Health '\n",
      " 'Wales: coronavirus vaccination in WalesPublic Health Agency: coronavirus '\n",
      " 'vaccination in Northern Ireland\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '          More in\\n'\n",
      " '          \\n'\n",
      " '            Coronavirus vaccination\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '                  Coronavirus (COVID-19) vaccine\\n'\n",
      " '                \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '                    Who can get the vaccine\\n'\n",
      " '                  \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '                    How you will be contacted\\n'\n",
      " '                  \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '                    What happens at your appointment\\n'\n",
      " '                  \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '                    Health conditions and coronavirus vaccination\\n'\n",
      " '                  \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '      Page last reviewed: 26 February 2021\\n'\n",
      " '      \\n'\n",
      " '      Next review due: 12 March 2021\\n'\n",
      " '    \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Support links\\n'\n",
      " '\\n'\n",
      " 'NHS sites\\n'\n",
      " 'About us\\n'\n",
      " 'Contact us\\n'\n",
      " 'Profile editor login\\n'\n",
      " 'Site map\\n'\n",
      " 'Accessibility statement\\n'\n",
      " 'Our policies\\n'\n",
      " 'Cookies\\n'\n",
      " '\\n'\n",
      " '© Crown copyright\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'COVID-19 Vaccine Information\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '        // initialize plugins\\r\\n'\n",
      " '\\t\\t$ektron().ready(function(){\\r\\n'\n",
      " \"\\t\\t\\t$ektron('ul#mainNav').superfish();\\r\\n\"\n",
      " '\\t\\t\\t\\t\\t\\t\\r\\n'\n",
      " '            $ektron(\".sort_color_off\").click(function(){        \\r\\n'\n",
      " '                $ektron(\"#srchloading\").show();\\r\\n'\n",
      " '            });            \\r\\n'\n",
      " '\\t\\t});\\r\\n'\n",
      " '    \\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '      /***********************************************\\r\\n'\n",
      " '      * Accordion Content script- (c) Dynamic Drive DHTML code library '\n",
      " '(www.dynamicdrive.com)\\r\\n'\n",
      " '      * Visit http://www.dynamicDrive.com for hundreds of DHTML scripts\\r\\n'\n",
      " '      * This notice must stay intact for legal use\\r\\n'\n",
      " '      ***********************************************/\\r\\n'\n",
      " '    \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '      '\n",
      " \"(function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){\\r\\n\"\n",
      " '      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new '\n",
      " 'Date();a=s.createElement(o),\\r\\n'\n",
      " '      '\n",
      " 'm=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)\\r\\n'\n",
      " '      '\n",
      " \"})(window,document,'script','https://www.google-analytics.com/analytics.js','ga');\\r\\n\"\n",
      " '\\r\\n'\n",
      " \"      ga('create', 'UA-76662241-1', 'auto');\\r\\n\"\n",
      " \"      ga('send', 'pageview');\\r\\n\"\n",
      " '\\r\\n'\n",
      " '    \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '                Note: Javascript is disabled or is not supported by your '\n",
      " 'browser.',\n",
      " 'All \\r\\n            content is viewable but it will not display as intended.',\n",
      " 'Skip to global menu 5\\n'\n",
      " 'Skip to local menu 2\\n'\n",
      " 'Skip to content 3\\n'\n",
      " 'Skip to footer 6\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Advanced\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Topics:\\n'\n",
      " 'A\\n'\n",
      " 'B \\n'\n",
      " 'C \\n'\n",
      " 'D \\n'\n",
      " 'E \\n'\n",
      " 'F \\n'\n",
      " 'G \\n'\n",
      " 'H \\n'\n",
      " 'I \\n'\n",
      " 'J \\n'\n",
      " 'K \\n'\n",
      " 'L \\n'\n",
      " 'M \\n'\n",
      " 'N \\n'\n",
      " 'O \\n'\n",
      " 'P \\n'\n",
      " 'Q \\n'\n",
      " 'R \\n'\n",
      " 'S \\n'\n",
      " 'T \\n'\n",
      " 'U \\n'\n",
      " 'V \\n'\n",
      " 'W \\n'\n",
      " 'X \\n'\n",
      " 'Y \\n'\n",
      " 'Z \\n'\n",
      " 'All \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Mobile | \\n'\n",
      " 'Inicio en español\\n'\n",
      " '\\r\\n'\n",
      " '                            Text Size:\\r\\n'\n",
      " '                        \\r\\n'\n",
      " '                    \\r\\n'\n",
      " '\\n'\n",
      " 'Font Larger\\n'\n",
      " 'Font Smaller\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'HomeCOVID-19About DSHSAdministrative ContactsAdvisory CommitteesContracts '\n",
      " 'and BudgetsCustomer ServiceData and ReportsDoing Business with DSHSExecutive '\n",
      " 'TeamHHS RulemakingHHSC Executive CouncilLegislative InformationOffice '\n",
      " 'ClosuresOrganization ChartPublic Health CampaignsVisitor '\n",
      " 'InformationVolunteer with DSHSNewsNews ReleasesHealth Alerts & '\n",
      " 'AdvisoriesNews UpdatesI am a...CitizenContractorGrant WriterHealth '\n",
      " 'ProfessionalIndividual or FamilyJournalistLicensee or '\n",
      " 'BusinessParent/GuardianPublic ServantResearcherStudentTexas '\n",
      " 'ResidentVolunteerMost PopularCoronavirus Disease 2019Birth CertificatesDeath '\n",
      " 'CertificatesEMS Certification and LicensingFlu SurveillanceJobs at '\n",
      " 'DSHSImmunizationsMarriage/Divorce VerificationOnline LicensesTxEVERAll Most '\n",
      " 'Popular...ResourcesAdvisory CommitteesAudiovisual LibraryDisease '\n",
      " 'ReportingDSHS Research ArticleseGrants SystemForms and PublicationsFunding '\n",
      " 'Information CenterMedical and Research LibraryOpen MeetingsOpen Records '\n",
      " 'RequestsPublic Health RegionsRelated WebsitesRules and RegulationsTexas '\n",
      " 'Health LibraryOnline ServicesBirth CertificatesBusiness/Professional '\n",
      " 'LicensesDeath CertificateseGrants SystemEMS Certification & LicensesFood '\n",
      " 'Handler TrainingForms and PublicationsFunding OpportunitiesJob '\n",
      " 'OpportunitiesMarriage/Divorce VerificationsTexas Immunization '\n",
      " 'RegistryContact Us\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Skip to content 3\\n'\n",
      " '\\r\\n'\n",
      " \"        Ektron.PBSettings = { 'dontClose': false }\\r\\n\"\n",
      " '    \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\r\\n'\n",
      " 'Ektron.ready(function(event, eventName){\\r\\n'\n",
      " '\\r\\n'\n",
      " '                $ektron(\".ux-app-siteApppageBuilder-setSizeTemplate '\n",
      " '.ui-dialog-buttonpane a\").button();\\r\\n'\n",
      " '                $ektron(\".ux-app-siteApppageBuilder-setSizeTemplate '\n",
      " '.framework\").accordion({\\r\\n'\n",
      " '                    heightStyle: \"content\",\\r\\n'\n",
      " '                    activate: function(event, ui){\\r\\n'\n",
      " '                        '\n",
      " '$ektron(ui).closest(\".ui-accordion\").accordion(\"refresh\");\\r\\n'\n",
      " '                    }\\r\\n'\n",
      " '                });\\r\\n'\n",
      " '                '\n",
      " '$ektron(\".ux-app-siteApppageBuilder-setSizeTemplate\").draggable({ handle: '\n",
      " '\"div.ui-dialog-titlebar \", containment: $ektron(\"body\") });\\r\\n'\n",
      " '            \\r\\n'\n",
      " '});\\r\\n'\n",
      " '\\r\\n'\n",
      " '\\r\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'COVID-19 Vaccine HomeFind VaccineHub ProvidersVaccine Availability '\n",
      " 'MapAccessible List of Vaccine ProvidersCOVID-19 Vaccine FAQsInformation for '\n",
      " 'Vaccination ProvidersInformation for ProvidersProvider EnrollmentVaccine '\n",
      " 'ManagementProvider FAQsCOVID-19 Vaccine AllocationsExpert Vaccine Allocation '\n",
      " 'PanelPublic Health Entity ForumsVaccine SafetyCOVID-19 Vaccine Communication '\n",
      " 'Tools\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Home > COVID-19 > Immunizations > COVID-19 Vaccine > \\n'\n",
      " 'COVID-19 Vaccine Information\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '            COVID-19 Vaccine Information\\r\\n'\n",
      " '        \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " 'span.red {\\r\\n'\n",
      " '    background: #AB2328;\\r\\n'\n",
      " '\\tborder-radius: 0.8em;\\r\\n'\n",
      " '\\t-moz-border-radius: 0.8em;\\r\\n'\n",
      " '\\t-webkit-border-radius: 0.8em;\\r\\n'\n",
      " '\\tcolor: #ffffff;\\r\\n'\n",
      " '\\tdisplay: inline-block;\\r\\n'\n",
      " '\\tfont-weight: bold;\\r\\n'\n",
      " '\\tline-height: 1.6em;\\r\\n'\n",
      " '\\tmargin-right: 15px;\\r\\n'\n",
      " '\\ttext-align: center;\\r\\n'\n",
      " '\\twidth: 1.6em;\\r\\n'\n",
      " '\\tfloat: left;\\r\\n'\n",
      " '\\tmargin-bottom: 60%;\\r\\n'\n",
      " '}\\r\\n'\n",
      " 'div.fourThings, div.fourThings p {\\r\\n'\n",
      " '\\toverflow: hidden;\\r\\n'\n",
      " '}\\r\\n'\n",
      " '.asideMenu a, .asideMenu a:visited {\\r\\n'\n",
      " '\\tpadding: .5em .5em!important;\\r\\n'\n",
      " '}\\r\\n'\n",
      " 'small {\\r\\n'\n",
      " '\\tfont-size: 70%;\\r\\n'\n",
      " '}\\r\\n'\n",
      " 'a.ctaButton {\\r\\n'\n",
      " '   margin: .25em 0; \\r\\n'\n",
      " '}\\r\\n'\n",
      " 'div.contentTwoCols {\\r\\n'\n",
      " '    margin-top: .5em;\\r\\n'\n",
      " '}\\r\\n'\n",
      " '\\n'\n",
      " 'en españolFacebookInstagramTwitterYouTube\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'More information\\n'\n",
      " '\\n'\n",
      " 'Texas Vaccination Plan (PDF)\\n'\n",
      " 'Expert Vaccine Allocation Panel\\n'\n",
      " 'Vaccine Allocation Guiding Principles (PDF)\\n'\n",
      " 'Phase 1A: Who Is Eligible for Vaccine Now (PDF)\\n'\n",
      " 'Phase 1B: Who Is Eligible for Vaccine Now (PDF)\\n'\n",
      " 'COVID-19 Vaccine Allocations\\n'\n",
      " 'Vaccine FAQs\\n'\n",
      " 'V-safe Information Sheet (PDF)\\n'\n",
      " 'CDC Vaccine Information\\n'\n",
      " 'FDA Vaccine Information\\n'\n",
      " 'Texas Vaccine Data Dashboard\\n'\n",
      " 'Accessible Vaccine Data (XLS)\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " \"Who's Eligible Now?\",\n",
      " 'Where to Get Vaccinated\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Important to Know TX Vaccine Timeline\\n'\n",
      " '\\n'\n",
      " \"Who's Eligible to Get the Vaccine Now?\",\n",
      " 'School and Child Care Personnel Now Eligible To Be Vaccinated\\n'\n",
      " 'With the federal directive, the following education and child care personnel '\n",
      " 'are now eligible to be vaccinated in Texas:\\n'\n",
      " '\\n'\n",
      " 'Those who work in pre-primary, primary, and secondary schools;\\n'\n",
      " 'Head Start and Early Head Start programs (including teachers, staff, and bus '\n",
      " 'drivers); and\\n'\n",
      " 'Those who work as or for licensed child care providers, including '\n",
      " 'center-based and family care providers.',\n",
      " 'Phase 1A: Front-line healthcare workers and residents at long-term care '\n",
      " 'facilities\\n'\n",
      " 'Phase 1B: People 65+ or people 16+ with a health condition that increases '\n",
      " 'risk of severe COVID‑19 illness, including but not limited to:\\n'\n",
      " '\\n'\n",
      " 'Cancer\\n'\n",
      " 'Chronic kidney disease\\n'\n",
      " 'COPD (chronic obstructive pulmonary disease)\\n'\n",
      " 'Down Syndrome\\n'\n",
      " 'Heart conditions, such as heart failure, coronary artery disease, or '\n",
      " 'cardiomyopathies\\n'\n",
      " 'Organ transplantation\\n'\n",
      " 'Obesity\\n'\n",
      " 'Pregnancy\\n'\n",
      " 'Sickle cell disease\\n'\n",
      " 'Type 2 diabetes\\n'\n",
      " '\\n'\n",
      " 'If you have a medical condition not listed above, you may still qualify for '\n",
      " 'the vaccine.',\n",
      " 'Talk to your provider to confirm.',\n",
      " 'Spring 2021 is the best estimate of when vaccines will be available for the '\n",
      " 'general public.',\n",
      " 'Availability will depend on vaccine supply.',\n",
      " 'Check back here for updates.',\n",
      " 'Where to Get Vaccinated\\n'\n",
      " 'If you’re eligible to get vaccinated now, you can check with a large '\n",
      " 'vaccination hub and/or a local vaccine provider, like a nearby pharmacy or '\n",
      " 'your doctor.',\n",
      " 'Find Vaccine: \\n'\n",
      " 'Large Vaccination Hubs   Vaccine Availability Map   List of All Providers  \\n'\n",
      " 'When searching for a vaccination site, remember:\\n'\n",
      " '\\n'\n",
      " 'Vaccine supply is limited.',\n",
      " 'Not all local providers have vaccine each week and hubs may have long '\n",
      " 'waiting lists.',\n",
      " 'Do not show up at a hub or provider looking for a vaccine.',\n",
      " 'Instead, check the provider’s website.',\n",
      " 'Call only if the website doesn’t answer your questions.',\n",
      " 'Do you know someone who is eligible for a vaccine but doesn’t have internet '\n",
      " 'access?',\n",
      " 'Please let them know they can call 2‑1‑1 for referral to a local vaccine '\n",
      " 'provider.',\n",
      " 'Vaccine supply is still limited in Texas, but more arrives each week.',\n",
      " 'Important to Know\\n'\n",
      " '\\n'\n",
      " 'Two Doses\\n'\n",
      " 'Moderna and Pfizer COVID-19 vaccines both require two doses.',\n",
      " 'It’s best if you get your second dose from the same brand as your first '\n",
      " 'dose.',\n",
      " 'For example, if you got a Moderna first dose, it’s best to get Moderna for '\n",
      " 'your second dose.',\n",
      " 'The timing between your first and second dose depends on which vaccine you '\n",
      " 'received:\\n'\n",
      " '\\n'\n",
      " 'Moderna: 4 to 6 weeks after your first dose\\n'\n",
      " 'Pfizer: 3 to 6 weeks after your first dose\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Side Effects & Allergic Reactions\\n'\n",
      " 'Mild side effects are normal signs your body is building protection, and '\n",
      " 'they usually go away after a few days.',\n",
      " 'The chance of a severe reaction is less than 0.5%.',\n",
      " 'To be safe, your provider will have you wait on-site for 15-30 minutes after '\n",
      " 'your shot.',\n",
      " \"V-safe: Register with CDC's V-safe After Vaccination Health Checker on your \"\n",
      " 'smartphone to report any side effects after getting the COVID-19 vaccine.',\n",
      " 'You’ll also get reminders for your second vaccine dose.',\n",
      " 'Texas Vaccine Rollout Timeline\\n'\n",
      " '\\n'\n",
      " 'Texas continues to receive doses of the Pfizer and Moderna COVID-19 '\n",
      " 'vaccines, and is distributing statewide to hospitals, pharmacies, local '\n",
      " 'health departments, freestanding ERs, and other clinics.',\n",
      " 'Spring 2021 is the best estimate of when vaccine will be available for the '\n",
      " 'general public, but that may change.',\n",
      " 'It depends on vaccine production and how quickly other vaccines become '\n",
      " 'available.',\n",
      " 'Please check this page regularly for updates.',\n",
      " '▲ Top \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " \"    $ektron('table.zebra tr:nth-child(even)')\\r\\n\"\n",
      " \"        .add('table.zebraBorder tr:nth-child(even)')\\r\\n\"\n",
      " \"        .addClass('zebraEven');\\r\\n\"\n",
      " ' \\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\r\\n'\n",
      " '\\t$ektron().ready(function(){\\t\\t\\t\\t\\r\\n'\n",
      " \"\\t\\t $ektron('#navigation').accordion({\\r\\n\"\n",
      " '\\t\\t\\t    active: false,\\r\\n'\n",
      " \"\\t\\t\\t    header: '.head',\\r\\n\"\n",
      " '\\t\\t\\t    navigation: true,\\r\\n'\n",
      " \"\\t\\t\\t    event: 'mouseover',\\r\\n\"\n",
      " '\\t\\t\\t    fillSpace: true,\\r\\n'\n",
      " \"\\t\\t\\t    animated: 'slide'\\r\\n\"\n",
      " '\\t\\t    });\\r\\n'\n",
      " \"\\t\\t    $ektron('.navigation1').accordion({\\r\\n\"\n",
      " '\\t\\t\\t    active: false,\\r\\n'\n",
      " \"\\t\\t\\t    header: '.head',\\r\\n\"\n",
      " '\\t\\t\\t    navigation: true,\\r\\n'\n",
      " \"\\t\\t\\t    event: 'mouseover',\\r\\n\"\n",
      " '\\t\\t\\t    fillSpace: true,\\r\\n'\n",
      " \"\\t\\t\\t    animated: 'slide'\\r\\n\"\n",
      " '\\t\\t    });\\r\\n'\n",
      " '\\t});\\t\\r\\n'\n",
      " '\\t\\n'\n",
      " '\\r\\n'\n",
      " '\\t#navigation ul\\r\\n'\n",
      " '        {\\r\\n'\n",
      " '\\t      height: auto !important;\\t      \\r\\n'\n",
      " '        }\\r\\n'\n",
      " '\\t\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Last updated  March 3, 2021\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " '\\n'\n",
      " 'Contact Us | Visitor Information | Compact with Texans | File Viewing '\n",
      " 'Information | Site Policies | Texas HHS | Jobs at DSHSTexas Homeland '\n",
      " 'Security | Statewide Search | Texas.gov | Texas Veterans Portal | Privacy '\n",
      " 'Practices | Report Fraud, Waste, and Abuse']\n"
     ]
    }
   ],
   "source": [
    "import nltk\n",
    "nltk.download('punkt')\n",
    "from nltk import tokenize\n",
    "\n",
    "sentences = tokenize.sent_tokenize(webContents)\n",
    "\n",
    "# printing sentences to verify\n",
    "import pprint\n",
    "pprint.pprint(sentences)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "Jx8u88VZmZc2"
   },
   "source": [
    "## 2. Cleaning the Data\n",
    "\n",
    "In this part, we will try the best to clean the data. "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "6yNN-XUVUQUG"
   },
   "source": [
    "### 2.1 Cleaning the Data - 1\n",
    "\n",
    "From the above output, we can see variable 'sentences' is a list consisting of many strings with format 'str' (in python). \n",
    "Basically, each string should be represented as a completed sentence. In the output, we can see there many strings are just '\\t', '\\n', ,html tags, or codes. So we will simply delete these strings from sentences.\n",
    "- delete sentences consisting of '\\n'\n",
    "- delete sentences consisting of '\\t'\n",
    "- delete sentences consisting of only one work\n",
    "- delete sentences consisting of html tags\n",
    "- delete sentences consisting of javascript codes\n",
    "\n",
    "Wow! I suddently think of we actually could also use Regular expression! A standard English sentence should be format like this: word + ' ' + word + ' ' + ... + 'word'\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "i8BgroUcbK3B"
   },
   "outputs": [],
   "source": [
    "import re\n",
    "\n",
    "# delete sentences consisting of '\\n', '\\t', html tags, and javascript codes\n",
    "clean_sents = []\n",
    "sent_pattern = r'\\b([a-zA-z]+)(.*)'\n",
    "\n",
    "for sent in sentences:\n",
    "  result = re.match(sent_pattern, sent)\n",
    "  if result:\n",
    "    clean_sents.append(result.group())\n",
    "\n",
    "# pprint.pprint(clean_sents)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "m95ZcENTzSYd"
   },
   "source": [
    "### 2.2 Clean the data - 2\n",
    "After the above step, we stil have some issue left. For instance, some sentences don't have period mark('.'), the full sentence should be the sentence + the sentence in the next line which has a period mark. So we will combine this type of sentence to let it become a full sentence. \n",
    "If in the line doesn't have a period mark, it means the sentence is too long to structured, we don't count it. \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "wGUrmQl807c4",
    "outputId": "c97d3af8-bae0-4a99-faf3-6a90f2a92d12",
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['As of February\\xa02021[update], eleven vaccines are authorized by at least '\n",
      " 'one national regulatory authority for public use: two RNA vaccines (the '\n",
      " 'Pfizer–BioNTech vaccine and the Moderna vaccine), four conventional '\n",
      " 'inactivated vaccines (BBIBP-CorV, Covaxin, CoronaVac, and CoviVac), four '\n",
      " 'viral vector vaccines (Sputnik V, the Oxford–AstraZeneca vaccine, '\n",
      " 'Convidicea, and the Johnson & Johnson vaccine), and one peptide vaccine '\n",
      " '(EpiVacCorona).',\n",
      " 'Moderna targets producing 600 million doses and Convidicea 500 million doses '\n",
      " 'in 2021.',\n",
      " 'Prior to COVID‑19, a vaccine for an infectious disease had never been '\n",
      " 'produced in less than several years—and no vaccine existed for preventing a '\n",
      " 'coronavirus infection in humans.',\n",
      " 'Vaccines against SARS[12] and MERS[13] have been tested in non-human '\n",
      " 'animals.',\n",
      " 'According to studies published in 2005 and 2006, the identification and '\n",
      " 'development of novel vaccines and medicines to treat SARS was a priority for '\n",
      " 'governments and public health agencies around the world at that time.',\n",
      " 'The rapid development and urgency of producing a vaccine for the COVID‑19 '\n",
      " 'pandemic may increase the risks and failure rate of delivering a safe, '\n",
      " 'effective vaccine.',\n",
      " 'It comprises four pillars, each managed by two to three collaborating '\n",
      " 'partners: Vaccines (also called \"COVAX\"), Diagnostics, Therapeutics, and '\n",
      " 'Health Systems Connector.',\n",
      " 'The WHO vaccine coalition will prioritize which vaccines should go into '\n",
      " 'Phase II and III clinical trials, and determine harmonized Phase\\xa0III '\n",
      " 'protocols for all vaccines achieving the pivotal trial stage.',\n",
      " 'Canada announced funding for 96 research vaccine research projects at '\n",
      " 'Canadian companies and universities, with plans to establish a \"vaccine '\n",
      " 'bank\" that could be used if another coronavirus outbreak occurs,[46] and to '\n",
      " 'support clinical trials and develop manufacturing and supply chains for '\n",
      " 'vaccines.',\n",
      " 'It encompassed every phase of development from research to manufacturing.',\n",
      " 'Bahrain and the United Arab Emirates granted emergency marketing '\n",
      " 'authorization for BBIBP-CorV, manufactured by Sinopharm.',\n",
      " 'Messenger RNA contained in the vaccine enters cells and is translated into '\n",
      " 'foreign proteins, which trigger an immune response.',\n",
      " 'An RNA vaccine contains RNA which, when introduced into a tissue, acts as '\n",
      " 'messenger RNA (mRNA) to cause the cells to build the foreign protein and '\n",
      " 'stimulate an adaptive immune response which teaches the body how to identify '\n",
      " 'and destroy the corresponding pathogen or cancer cells.',\n",
      " 'RNA vaccines often, but not always, use nucleoside-modified messenger RNA.',\n",
      " 'The delivery of mRNA is achieved by a coformulation of the molecule into '\n",
      " 'lipid nanoparticles which protect the RNA strands and help their absorption '\n",
      " 'into the cells.',\n",
      " 'Vaccines in clinical trials include the Valneva COVID-19 vaccine.',\n",
      " 'The antigens involved are often protein subunits, but can be any molecule '\n",
      " 'that is a fragment of the pathogen.',\n",
      " 'Six of those have been approved for emergency or full use by at least one '\n",
      " 'WHO-recognized stringent regulatory authorities.',\n",
      " 'RNA vaccines\\xa0\\xa0Pfizer–BioNTech\\xa0\\xa0ModernaOverall efficacy was 70%, '\n",
      " 'ranging from 62% to 90% with different dosing regimens, with a peer-reviewed '\n",
      " 'safety profile.',\n",
      " 'Control group: Placebo.',\n",
      " 'Study design: Parallel.Jan–Mar 2021, Cuba',\n",
      " 'Masking: Open.',\n",
      " 'Control group: Uncontrolled.',\n",
      " 'An efficacy of 50% means that there are half as many cases of infection as '\n",
      " 'in unvaccinated individuals.',\n",
      " 'It is not straightforward to compare the efficacies of the different '\n",
      " 'vaccines because the trials were run with different populations, '\n",
      " 'geographies, and variants of the virus.',\n",
      " 'Vaccine efficacy reflects disease prevention, a poor indicator of '\n",
      " 'transmissibility of SARS‑CoV‑2 since asymptomatic people can be highly '\n",
      " 'infectious.',\n",
      " 'The trial location also affects the reported efficacy because different '\n",
      " 'countries have different prevalences of SARS-CoV-2 variants.',\n",
      " 'Ranges below are 95% confidence intervals.',\n",
      " 'The ultimate goal of the study will be find whether the mix and match method '\n",
      " 'is just as or more effective than the currently used practice.',\n",
      " 'The study will utilize the shot developed by Pfizer and BioNTech with the '\n",
      " 'University of Oxford and AstraZeneca shot, two vaccines which rely on '\n",
      " 'different methods to deliver information to the cells of the recipient.',\n",
      " 'Ugur Sahin has voiced his opposition to the trial in December, stating that '\n",
      " 'a study \"will use up doses that people who need them could profit from, I am '\n",
      " 'not happy about this,\" though Pfizer and AstraZeneca have supported the '\n",
      " 'trials.',\n",
      " 'This is because T-cells target multiple pieces of the virus.',\n",
      " 'Viral vector and mRNA based vaccines are believed to elicit the strongest '\n",
      " 't-cell response.',\n",
      " 'Companies including Emergex, Osivax and eTheRNA are targeting these internal '\n",
      " 'antigens in the hope of creating a \"universal\" SARS-CoV-2 vaccine.',\n",
      " 'They have launched a trial of a new vaccine to tackle the South African '\n",
      " '501.V2 variant (also known as B.1.351).',\n",
      " 'Total dose counts for these countries are not included in the World total.',\n",
      " 'These paragraphs are an excerpt from Deployment of COVID-19 '\n",
      " 'vaccines[edit]You may improve this section, discuss the issue on the talk '\n",
      " 'page, or create a new section, as appropriate.',\n",
      " 'Though high-income nations represent only 14% of the global population, as '\n",
      " 'of 15 November 2020, they had contracted to buy 51% of all pre-sold doses.',\n",
      " 'Some high-income nations bought more doses than would be necessary to '\n",
      " 'vaccinate their entire populations.',\n",
      " 'Just 25 doses have been given in one lowest-income country.',\n",
      " 'Not 25 million; not 25 thousand; just 25.',\n",
      " 'A report by Carnegie Endowment for International Peace cited the current '\n",
      " 'poverty rate in Egypt as around 29.7 percent, which constitutes '\n",
      " 'approximately 30.5 million people, and claimed that about 15 million of the '\n",
      " 'Egyptians would be unable to gain access to the luxury of vaccination.',\n",
      " 'A human rights lawyer, Khaled Ali launched a lawsuit against the government, '\n",
      " 'forcing them to provide vaccination free of cost to all members of the '\n",
      " 'public.',\n",
      " 'Vaccine hesitancyThe poll also showed a positive correlation between '\n",
      " 'education level and willingness to take the vaccine.',\n",
      " 'Journal of Biomedical Science.',\n",
      " 'PMC\\xa07749790.',\n",
      " 'PMID\\xa033341119.',\n",
      " 'BusinessWorld.',\n",
      " 'Retrieved 24 February 2021.',\n",
      " 'Vaccine Centre, London School of Hygiene and Tropical Medicine.',\n",
      " 'Retrieved 18 January 2021.',\n",
      " 'The Guardian.',\n",
      " 'ISSN\\xa00261-3077.',\n",
      " 'Retrieved 26 December 2020.',\n",
      " 'Our World in Data.',\n",
      " 'Retrieved 7 February 2021.',\n",
      " 'Pharmaceutical Processing World.',\n",
      " 'Retrieved 1 March 2021.',\n",
      " 'ca.sports.yahoo.com.',\n",
      " 'Retrieved 1 March 2021.',\n",
      " 'Nature.',\n",
      " 'doi:10.1038/d41586-020-03370-6.',\n",
      " 'PMID\\xa033257891.',\n",
      " 'S2CID\\xa0227246811.',\n",
      " 'Retrieved 11 December 2020.',\n",
      " 'BMJ.',\n",
      " 'doi:10.1136/bmj.m4750.',\n",
      " 'ISSN\\xa01756-1833.',\n",
      " 'PMC\\xa07735431.',\n",
      " 'PMID\\xa033323376.',\n",
      " 'The Gates Notes.',\n",
      " 'Archived from the original on 14 May 2020.',\n",
      " 'Retrieved 2 May 2020.',\n",
      " 'Avian Pathology.',\n",
      " 'doi:10.1080/03079450310001621198.',\n",
      " 'PMC\\xa07154303.',\n",
      " 'PMID\\xa014676007.',\n",
      " 'Lancet.',\n",
      " 'doi:10.1016/S0140-6736(03)14962-8.',\n",
      " 'PMC\\xa07112457.',\n",
      " 'PMID\\xa014667748.',\n",
      " 'Vaccine.',\n",
      " 'doi:10.1016/j.vaccine.2014.08.058.',\n",
      " 'PMC\\xa07115510.',\n",
      " 'PMID\\xa025192975.',\n",
      " 'The Journal of Infectious Diseases.',\n",
      " 'doi:10.1086/427242.',\n",
      " 'PMC\\xa07110081.',\n",
      " 'PMID\\xa015655773.',\n",
      " 'Journal of Virological Methods.',\n",
      " 'doi:10.1016/j.jviromet.2005.03.021.',\n",
      " 'PMC\\xa07112802.',\n",
      " 'PMID\\xa015885812.',\n",
      " 'The Journal of Infectious Diseases.',\n",
      " 'doi:10.1086/500143.',\n",
      " 'PMC\\xa07109703.',\n",
      " 'PMID\\xa016453264.',\n",
      " 'Future Virology.',\n",
      " 'doi:10.2217/fvl.12.126.',\n",
      " 'PMC\\xa07079997.',\n",
      " 'PMID\\xa032201503.',\n",
      " 'National Health Service.',\n",
      " 'Archived from the original on 9 March 2020.',\n",
      " 'Retrieved 31 January 2020.',\n",
      " 'Frontiers of Medicine.',\n",
      " 'doi:10.1007/s11684-016-0430-6.',\n",
      " 'PMC\\xa07089261.',\n",
      " 'PMID\\xa026791756.',\n",
      " 'Nature.',\n",
      " 'Bibcode:2012Natur.490...20B.',\n",
      " 'doi:10.1038/490020a.',\n",
      " 'PMID\\xa023038444.',\n",
      " 'The Lancet.',\n",
      " 'Infectious Diseases.',\n",
      " 'doi:10.1016/S1473-3099(19)30266-X.',\n",
      " 'PMC\\xa07185789.',\n",
      " 'PMID\\xa031351922.',\n",
      " 'Frontiers in Microbiology.',\n",
      " 'PMC\\xa06688523.',\n",
      " 'PMID\\xa031428074.',\n",
      " 'The New York Times.',\n",
      " 'ISSN\\xa00362-4331.',\n",
      " 'Archived from the original on 11 May 2020.',\n",
      " 'Retrieved 2 May 2020.',\n",
      " 'The Lancet.',\n",
      " 'Infectious Diseases.',\n",
      " 'doi:10.1016/S1473-3099(20)30123-7.',\n",
      " 'ISSN\\xa01474-4457.',\n",
      " 'PMC\\xa07158580.',\n",
      " 'PMID\\xa032197097.',\n",
      " 'Reuters.',\n",
      " 'Archived from the original on 15 May 2020.',\n",
      " 'Retrieved 2 May 2020.',\n",
      " 'South China Morning Post.',\n",
      " 'Archived from the original on 26 January 2020.',\n",
      " 'Retrieved 28 January 2020.',\n",
      " 'The New York Times.',\n",
      " 'ISSN\\xa00362-4331.',\n",
      " 'Archived from the original on 4 May 2020.',\n",
      " 'Retrieved 4 May 2020.',\n",
      " 'Nature Reviews Drug Discovery.',\n",
      " 'doi:10.1038/d41573-020-00151-8.',\n",
      " 'ISSN\\xa01474-1776.',\n",
      " 'PMID\\xa032887942.',\n",
      " 'S2CID\\xa0221503034.',\n",
      " 'Nature Reviews Drug Discovery.',\n",
      " 'doi:10.1038/d41573-020-00073-5.',\n",
      " 'ISSN\\xa01474-1776.',\n",
      " 'PMID\\xa032273591.',\n",
      " 'Cell Host and Microbe.',\n",
      " 'doi:10.1016/j.chom.2020.04.021.',\n",
      " 'PMC\\xa07219397.',\n",
      " 'PMID\\xa032407708.',\n",
      " 'Science.',\n",
      " 'Bibcode:2020Sci...367.1405T.',\n",
      " 'doi:10.1126/science.abb8492.',\n",
      " 'PMID\\xa032205459.',\n",
      " 'National Post.',\n",
      " 'Archived from the original on 1 November 2020.',\n",
      " 'Retrieved 3 May 2020.',\n",
      " 'It could put a generation of researchers at risk\".',\n",
      " 'Stat.',\n",
      " 'Archived from the original on 6 May 2020.',\n",
      " 'Retrieved 4 May 2020.',\n",
      " 'vaccines.gov.',\n",
      " 'US Department of Health and Human Services.',\n",
      " 'Archived from the original on 22 April 2020.',\n",
      " 'Retrieved 13 April 2020.',\n",
      " 'U.S. Food and Drug Administration (FDA).',\n",
      " 'Archived from the original on 22 February 2020.',\n",
      " 'Retrieved 12 April 2020.',\n",
      " 'Science.',\n",
      " 'Bibcode:2020Sci...368.1295C.',\n",
      " 'doi:10.1126/science.368.6497.1295.',\n",
      " 'PMID\\xa032554572.',\n",
      " 'Human Vaccines and Immunotherapeutics.',\n",
      " 'doi:10.4161/hv.24657.',\n",
      " 'ISSN\\xa02164-554X.',\n",
      " 'PMC\\xa03906279.',\n",
      " 'PMID\\xa023584253.',\n",
      " 'CNN.',\n",
      " 'Archived from the original on 21 June 2020.',\n",
      " 'Retrieved 21 June 2020.',\n",
      " 'European Medicines Agency.',\n",
      " 'Archived from the original on 24 September 2020.',\n",
      " 'Retrieved 21 August 2020.',\n",
      " 'BioPharma-Reporter.com, William Reed Business Media Ltd. Retrieved 25 '\n",
      " 'November 2020.',\n",
      " 'Global News.',\n",
      " 'Retrieved 25 November 2020.',\n",
      " 'World Health Organization (WHO).',\n",
      " 'World Health Organization (WHO).',\n",
      " 'Retrieved 16 December 2020.',\n",
      " 'World Health Organization (WHO).',\n",
      " 'Archived from the original on 30 April 2020.',\n",
      " 'Retrieved 2 May 2020.',\n",
      " 'It is vital that we evaluate as many vaccines as possible as we cannot '\n",
      " 'predict how many will turn out to be viable.',\n",
      " 'To increase the chances of success (given the high level of attrition during '\n",
      " 'vaccine development), we must test all candidate vaccines until they fail.',\n",
      " 'The results for the efficacy of each vaccine are expected within three to '\n",
      " 'six months and this evidence, combined with data on safety, will inform '\n",
      " 'decisions about whether it can be used on a wider scale.',\n",
      " 'Global News.',\n",
      " 'Archived from the original on 9 April 2020.',\n",
      " 'Retrieved 24 March 2020.',\n",
      " 'Government of Canada.',\n",
      " 'Archived from the original on 13 May 2020.',\n",
      " 'Retrieved 4 May 2020.',\n",
      " 'Nikkei Asian Review.',\n",
      " 'Archived from the original on 10 May 2020.',\n",
      " 'Retrieved 3 May 2020.',\n",
      " 'Pharmafield.',\n",
      " 'Archived from the original on 17 June 2020.',\n",
      " 'Retrieved 3 May 2020.',\n",
      " 'CNN.',\n",
      " 'Archived from the original on 13 May 2020.',\n",
      " 'Retrieved 2 May 2020.',\n",
      " 'Science.',\n",
      " 'Bibcode:2020Sci...368..692C.',\n",
      " 'doi:10.1126/science.368.6492.692.',\n",
      " 'ISSN\\xa00036-8075.',\n",
      " 'PMID\\xa032409451.',\n",
      " 'Bloomberg.',\n",
      " 'Archived from the original on 21 May 2020.',\n",
      " 'Retrieved 15 May 2020.CS1 maint: uses authors parameter (link)',\n",
      " 'World Health Organization.',\n",
      " 'Archived from the original on 29 April 2020.',\n",
      " 'Retrieved 2 May 2020.',\n",
      " 'Nature Reviews Drug Discovery.',\n",
      " 'doi:10.1038/d41573-020-00073-5.',\n",
      " 'ISSN\\xa01474-1776.',\n",
      " 'PMID\\xa032273591.',\n",
      " 'The New England Journal of Medicine.',\n",
      " 'doi:10.1056/nejmp2003762.',\n",
      " 'PMID\\xa032109012.',\n",
      " 'The New England Journal of Medicine.',\n",
      " 'doi:10.1056/nejme2002387.',\n",
      " 'PMC\\xa07121221.',\n",
      " 'PMID\\xa032109011.',\n",
      " 'Nature Reviews Drug Discovery.',\n",
      " 'doi:10.1038/d41573-020-00151-8.',\n",
      " 'ISSN\\xa01474-1776.',\n",
      " 'PMID\\xa032887942.',\n",
      " 'S2CID\\xa0221503034.',\n",
      " 'Harvard Business Review.',\n",
      " 'ISSN\\xa00017-8012.',\n",
      " 'Archived from the original on 9 June 2020.',\n",
      " 'Retrieved 9 June 2020.',\n",
      " 'CBC Radio.',\n",
      " 'Archived from the original on 13 May 2020.',\n",
      " 'Retrieved 8 June 2020.',\n",
      " 'Stat.',\n",
      " 'Archived from the original on 12 June 2020.',\n",
      " 'Retrieved 8 June 2020.',\n",
      " 'Business Insider.',\n",
      " 'Retrieved 11 November 2020.',\n",
      " 'World Health Organization.',\n",
      " 'Archived from the original on 30 April 2020.',\n",
      " 'Retrieved 2 May 2020.',\n",
      " 'It is vital that we evaluate as many vaccines as possible as we cannot '\n",
      " 'predict how many will turn out to be viable.',\n",
      " 'To increase the chances of success (given the high level of attrition during '\n",
      " 'vaccine development), we must test all candidate vaccines until they fail.',\n",
      " 'The results for the efficacy of each vaccine are expected within three to '\n",
      " 'six months and this evidence, combined with data on safety, will inform '\n",
      " 'decisions about whether it can be used on a wider scale.',\n",
      " 'Lancet.',\n",
      " 'doi:10.1016/S0140-6736(20)30763-7.',\n",
      " 'PMC\\xa07271264.',\n",
      " 'PMID\\xa032243778.',\n",
      " 'CEPI estimates that developing up to three vaccines in the next 12–18 months '\n",
      " 'will require an investment of at least US$2\\xa0billion.',\n",
      " 'This estimate includes Phase\\xa01 clinical trials of eight vaccine '\n",
      " 'candidates, progression of up to six candidates through Phase\\xa02 and\\xa03 '\n",
      " 'trials, completion of regulatory and quality requirements for at least three '\n",
      " 'vaccines, and enhancing global manufacturing capacity for three vaccines.',\n",
      " 'South China Morning Post.',\n",
      " 'Archived from the original on 26 September 2020.',\n",
      " 'Retrieved 26 September 2020.',\n",
      " 'The New York Times.',\n",
      " 'ISSN\\xa00362-4331.',\n",
      " 'Archived from the original on 27 September 2020.',\n",
      " 'Retrieved 28 September 2020.',\n",
      " 'Pfizer (Press release).',\n",
      " 'Retrieved 20 November 2020.',\n",
      " 'Time.',\n",
      " 'Retrieved 20 November 2020.',\n",
      " 'Medicines & Healthcare products Regulatory Agency (MHRA).',\n",
      " 'Retrieved 13 December 2020.',\n",
      " 'Medicines and Healthcare products Regulatory Agency (MHRA).',\n",
      " 'Retrieved 19 December 2020.',\n",
      " 'Medicines and Healthcare Products Regulatory Agency, Government of the UK.',\n",
      " 'Retrieved 2 December 2020.',\n",
      " 'The New York Times.',\n",
      " 'Retrieved 2 December 2020.',\n",
      " 'BBC.',\n",
      " 'Retrieved 2 December 2020.',\n",
      " 'European Commission.',\n",
      " 'Retrieved 21 December 2020.',\n",
      " 'Bahrain News Agency.',\n",
      " 'Retrieved 9 December 2020.',\n",
      " 'Gulf News.',\n",
      " 'Retrieved 9 December 2020.',\n",
      " 'Clears Pfizer Vaccine, and Millions of Doses Will Be Shipped Right Away\".',\n",
      " 'The New York Times.',\n",
      " 'Retrieved 12 December 2020.',\n",
      " 'U.S. Food and Drug Administration (FDA) (Press release).',\n",
      " 'Retrieved 18 December 2020.',\n",
      " 'MMWR.',\n",
      " 'Morbidity and Mortality Weekly Report.',\n",
      " 'doi:10.15585/mmwr.mm695152e1.',\n",
      " 'PMID\\xa033382675.',\n",
      " 'S2CID\\xa0229945697.',\n",
      " 'CNBC.',\n",
      " 'Retrieved 19 December 2020.',\n",
      " 'Nature Reviews Drug Discovery.',\n",
      " 'doi:10.1038/d41573-020-00151-8.',\n",
      " 'ISSN\\xa01474-1776.',\n",
      " 'PMID\\xa032887942.',\n",
      " 'S2CID\\xa0221503034.',\n",
      " 'Nature.',\n",
      " 'Bibcode:2020Natur.586..516K.',\n",
      " 'doi:10.1038/s41586-020-2798-3.',\n",
      " 'PMID\\xa032967006.',\n",
      " 'S2CID\\xa0221887746.',\n",
      " 'Advanced Drug Delivery Reviews.',\n",
      " 'doi:10.1016/j.addr.2020.12.008.',\n",
      " 'PMC\\xa07744276.',\n",
      " 'PMID\\xa033340620.',\n",
      " 'Mol Ther.',\n",
      " 'doi:10.1016/j.ymthe.2019.02.012.',\n",
      " 'PMC\\xa06453548.',\n",
      " 'PMID\\xa030846391.',\n",
      " 'Nano Today.',\n",
      " 'Centers for Disease Control and Prevention (CDC).',\n",
      " 'Retrieved 18 February 2021.',\n",
      " 'European Commission - European Commission.',\n",
      " 'Retrieved 19 February 2021.',\n",
      " 'Health Canada, Government of Canada.',\n",
      " 'Retrieved 9 December 2020.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'United States National Library of Medicine.',\n",
      " 'NCT04368728.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 14 July 2020.',\n",
      " 'EU Clinical Trials Register.',\n",
      " 'European Union.',\n",
      " 'EudraCT 2020-001038-36.',\n",
      " 'Archived from the original on 22 April 2020.',\n",
      " 'Retrieved 22 April 2020.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'United States National Library of Medicine.',\n",
      " 'NCT04470427.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 27 July 2020.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 27 July 2020.',\n",
      " 'European Medicines Agency (EMA) (Press release).',\n",
      " 'Retrieved 12 February 2021.',\n",
      " 'GAVI.',\n",
      " 'Retrieved 26 January 2021.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'United States National Library of Medicine.',\n",
      " 'NCT04400838.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 14 July 2020.',\n",
      " 'EU Clinical Trials Register.',\n",
      " 'European Union.',\n",
      " 'EudraCT 2020-001228-32.',\n",
      " 'Archived from the original on 5 October 2020.',\n",
      " 'Retrieved 3 August 2020.',\n",
      " 'ISRCTN.',\n",
      " 'doi:10.1186/ISRCTN89951424.',\n",
      " 'ISRCTN89951424.',\n",
      " 'The New York Times.',\n",
      " 'Retrieved 27 January 2021.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'Archived from the original on 16 September 2020.',\n",
      " 'Retrieved 23 August 2020.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'US National Library of Medicine.',\n",
      " 'Archived from the original on 26 September 2020.',\n",
      " 'The Washington Post.',\n",
      " 'Fortune.',\n",
      " 'Retrieved 28 February 2021.',\n",
      " 'Immunology and Cell Biology.',\n",
      " 'doi:10.1111/j.0818-9641.2004.01272.x.',\n",
      " 'ISSN\\xa00818-9641.',\n",
      " 'PMID\\xa015479434.',\n",
      " 'S2CID\\xa0154670.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'United States National Library of Medicine.',\n",
      " 'NCT04383574.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 14 July 2020.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'United States National Library of Medicine.',\n",
      " 'NCT04456595.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 3 August 2020.',\n",
      " 'Bio Farma (10 August 2020).',\n",
      " 'Registri Penyakit Indonesia.',\n",
      " 'Retrieved 15 August 2020.',\n",
      " 'Chinese Clinical Trial Registry.',\n",
      " 'Retrieved 15 August 2020.',\n",
      " 'Precision Vaccinations.',\n",
      " 'Retrieved 11 January 2021.',\n",
      " 'clinicaltrials.gov.',\n",
      " 'U.S. National Library of Medicine.',\n",
      " 'Retrieved 11 January 2021.',\n",
      " 'WHO Vaccine Safety Basics.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'United States National Library of Medicine.',\n",
      " 'NCT04368988.',\n",
      " 'Retrieved 16 November 2020.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'United States National Library of Medicine.',\n",
      " 'NCT04368988.',\n",
      " 'Archived from the original on 14 July 2020.',\n",
      " 'Retrieved 14 July 2020.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'United States National Library of Medicine.',\n",
      " 'NCT04495933.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 4 August 2020.',\n",
      " 'precisionvaccinations.com.',\n",
      " 'Retrieved 11 December 2020.',\n",
      " 'ctri.nic.in.',\n",
      " 'Clinical Trials Registry India.',\n",
      " 'CTRI/2020/07/026352.',\n",
      " 'Archived from the original on 22 November 2020.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'United States National Library of Medicine.',\n",
      " 'NCT04336410.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 14 July 2020.',\n",
      " 'International Vaccine Institute.',\n",
      " 'Retrieved 23 April 2020.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'United States National Library of Medicine.',\n",
      " 'NCT04463472.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 14 July 2020.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'United States National Library of Medicine.',\n",
      " 'NCT04445389.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 14 July 2020.',\n",
      " 'Reuters.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 25 June 2020.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'United States National Library of Medicine.',\n",
      " 'NCT04299724.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 14 July 2020.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'United States National Library of Medicine.',\n",
      " 'NCT04276896.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 14 July 2020.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'United States National Library of Medicine.',\n",
      " 'NCT04608305.',\n",
      " 'The Washington Post.',\n",
      " 'ISSN\\xa00190-8286.',\n",
      " 'Retrieved 31 December 2020.',\n",
      " 'World Health Organization (WHO).',\n",
      " 'Archived from the original on 30 April 2020.',\n",
      " 'Retrieved 1 May 2020.',\n",
      " 'Centers for Disease Control and Prevention, National Center for Immunization '\n",
      " 'and Respiratory Diseases, US Department of Health and Human Services.',\n",
      " 'Archived from the original on 7 May 2020.',\n",
      " 'Retrieved 6 May 2020.',\n",
      " 'Centers for Disease Control and Prevention, Center for Surveillance, '\n",
      " 'Epidemiology, and Laboratory Services, US Department of Health and Human '\n",
      " 'Services.',\n",
      " 'Archived from the original on 6 April 2020.',\n",
      " 'Retrieved 6 May 2020.',\n",
      " 'BMC Medicine.',\n",
      " 'PMC\\xa05830330.',\n",
      " 'PMID\\xa029490655.',\n",
      " 'U.S. Food and Drug Administration (FDA).',\n",
      " 'Archived from the original on 13 December 2019.',\n",
      " 'Retrieved 3 April 2020.',\n",
      " 'World Health Organization (WHO).',\n",
      " 'Archived (PDF) from the original on 12 May 2020.',\n",
      " 'Retrieved 9 May 2020.',\n",
      " 'Pfizer.',\n",
      " 'New England Journal of Medicine.',\n",
      " 'doi:10.1056/NEJMoa2034577.',\n",
      " 'PMC\\xa07745181.',\n",
      " 'PMID\\xa033301246.',\n",
      " 'U.S. Food and Drug Administration (FDA) (Report).',\n",
      " 'Retrieved 11 December 2020.',\n",
      " 'This article incorporates text from this source, which is in the public '\n",
      " 'domain.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 18 November 2020.',\n",
      " 'What Does That Mean?You might assume that 95 out of every 100 people '\n",
      " 'vaccinated will be protected from Covid-19.',\n",
      " 'But that\\'s not how the math works\".',\n",
      " 'The New York Times.',\n",
      " 'Retrieved 21 November 2020.',\n",
      " 'Seenews.',\n",
      " 'www.govern.ad.',\n",
      " 'Retrieved 19 February 2021.',\n",
      " 'La Nación (in Spanish).',\n",
      " 'Retrieved 23 December 2020.',\n",
      " 'www.government.aw.',\n",
      " 'Retrieved 19 February 2021.',\n",
      " 'Al Jazeera.',\n",
      " 'Retrieved 5 December 2020.',\n",
      " 'Health Canada, Government of Canada.',\n",
      " 'Retrieved 9 December 2020.',\n",
      " 'Trinidad and Tobago Newsday.',\n",
      " 'Retrieved 24 February 2021.',\n",
      " 'The Straits Times.',\n",
      " 'Retrieved 17 December 2020.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 6 January 2021.',\n",
      " 'The Tico Times.',\n",
      " 'Retrieved 16 December 2020.',\n",
      " 'Retrieved 17 December 2020.',\n",
      " 'news.gov.hk.',\n",
      " 'Retrieved 15 February 2021.',\n",
      " 'MSN.',\n",
      " 'Retrieved 27 December 2020.',\n",
      " 'The Jerusalem Post.',\n",
      " 'Retrieved 28 December 2020.',\n",
      " 'France 24.',\n",
      " 'Retrieved 15 December 2020.',\n",
      " 'Arab News.',\n",
      " 'Retrieved 15 December 2020.',\n",
      " 'covid19.trackvaccines.org.',\n",
      " 'Retrieved 19 February 2021.',\n",
      " 'Bloomberg.',\n",
      " 'Retrieved 12 December 2020.',\n",
      " 'The Economic Times.',\n",
      " 'Retrieved 14 January 2021.',\n",
      " 'en.gouv.mc.',\n",
      " 'Retrieved 19 February 2021.',\n",
      " 'Ministry of Health.',\n",
      " 'Retrieved 6 February 2021.',\n",
      " 'RadioFreeEurope/RadioLiberty.',\n",
      " 'Retrieved 19 February 2021.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 16 December 2020.',\n",
      " 'Yahoo!Finance.',\n",
      " 'Retrieved 16 December 2020.',\n",
      " 'CNN Philippines.',\n",
      " 'Retrieved 14 January 2021.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 24 December 2020.',\n",
      " 'Government of Saint Vincent and the Grenadines.',\n",
      " 'Retrieved 12 February 2021.',\n",
      " 'AP NEWS.',\n",
      " 'Retrieved 15 December 2020.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 28 February 2021.',\n",
      " 'Swiss Agency for Therapeutic Products (Swissmedic).',\n",
      " 'Retrieved 19 December 2020.',\n",
      " 'Retrieved 31 January 2021.',\n",
      " 'Emirates Woman.',\n",
      " 'Retrieved 28 December 2020.',\n",
      " 'Medicines and Healthcare Products Regulatory Agency, Government of the UK.',\n",
      " 'Retrieved 2 December 2020.',\n",
      " 'Medicines & Healthcare products Regulatory Agency (MHRA).',\n",
      " 'Retrieved 13 December 2020.',\n",
      " 'Medicines & Healthcare products Regulatory Agency (MHRA).',\n",
      " 'Retrieved 13 December 2020.',\n",
      " 'ISSN\\xa02071-5358.',\n",
      " 'United States Department of the Interior (DOI).',\n",
      " 'Retrieved 13 January 2021.',\n",
      " 'This article incorporates text from this source, which is in the public '\n",
      " 'domain.',\n",
      " 'Hawaii Public Radio.',\n",
      " 'Retrieved 13 January 2021.',\n",
      " 'U.S. Food and Drug Administration (FDA).',\n",
      " 'Retrieved 11 December 2020.',\n",
      " 'This article incorporates text from this source, which is in the public '\n",
      " 'domain.',\n",
      " 'Pfizer.',\n",
      " 'National Catholic Reporter.',\n",
      " 'Retrieved 9 February 2021.',\n",
      " 'vatican.va (Press release).',\n",
      " 'Retrieved 9 February 2021.',\n",
      " 'World Health Organization (WHO).',\n",
      " 'World Health Organization (WHO) (Press release).',\n",
      " 'Retrieved 6 January 2021.',\n",
      " 'Therapeutic Goods Administration.',\n",
      " 'Retrieved 25 January 2021.',\n",
      " 'Therapeutic Goods Administration (TGA).',\n",
      " 'Retrieved 25 January 2021.',\n",
      " 'G1.',\n",
      " 'Retrieved 23 February 2021.',\n",
      " 'European Medicines Agency (EMA).',\n",
      " 'Retrieved 23 December 2020.',\n",
      " 'European Commission.',\n",
      " 'Retrieved 21 December 2020.',\n",
      " 'Union Register of medicinal products.',\n",
      " 'Retrieved 8 January 2021.',\n",
      " 'Lægemiddelstyrelsen (in Danish).',\n",
      " 'Retrieved 26 December 2020.',\n",
      " 'Lyfjastofnun (in Icelandic).',\n",
      " 'Retrieved 26 December 2020.',\n",
      " 'Nikkei Asia.',\n",
      " 'Retrieved 14 February 2021.',\n",
      " 'Malay Mail.',\n",
      " 'Retrieved 8 January 2021.',\n",
      " 'Statens legemiddelverk (in Norwegian Bokmål).',\n",
      " 'Retrieved 26 December 2020.',\n",
      " 'Al Arabiya English.',\n",
      " 'Retrieved 10 December 2020.',\n",
      " 'The New York Times.',\n",
      " 'Retrieved 12 December 2020.',\n",
      " 'BalkanInsight.',\n",
      " 'Retrieved 26 December 2020.',\n",
      " 'Serbian government website.',\n",
      " 'Retrieved 26 December 2020.',\n",
      " 'Arirang News.',\n",
      " 'Retrieved 28 February 2021.',\n",
      " 'Yonhap News Agency.',\n",
      " 'Retrieved 5 March 2021.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'Archived from the original on 12 September 2020.',\n",
      " 'Retrieved 11 September 2020.',\n",
      " 'The Lancet.',\n",
      " 'doi:10.1016/S0140-6736(21)00234-8.',\n",
      " 'ISSN\\xa00140-6736.',\n",
      " 'PMC\\xa07852454.',\n",
      " 'PMID\\xa033545094.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'Health Ministry of the Russian Federation.',\n",
      " 'Retrieved 18 January 2021.',\n",
      " 'Hindustan Times.',\n",
      " 'The Indian Express.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'Health Ministry of the Russian Federation.',\n",
      " 'Retrieved 18 January 2021.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'Health Ministry of the Russian Federation.',\n",
      " 'Retrieved 18 January 2021.',\n",
      " 'Clinical Trials Arena.',\n",
      " 'Algeria Press service.',\n",
      " 'Gamaleya Center.',\n",
      " 'Retrieved 1 January 2021.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 1 February 2021.',\n",
      " 'Retrieved 19 February 2021 – via www.reuters.com.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 22 December 2020.',\n",
      " 'www.minsalud.gob.bo.',\n",
      " 'Retrieved 1 January 2021.',\n",
      " 'Gulf News.',\n",
      " 'Retrieved 24 February 2021.',\n",
      " 'Gamaleya Center.',\n",
      " 'Retrieved 17 February 2021.',\n",
      " 'Reuters.',\n",
      " 'Reuters.',\n",
      " 'africa news.',\n",
      " 'Xinhuanet.com.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 19 February 2021.',\n",
      " 'www.thestar.com.my.',\n",
      " 'Retrieved 19 February 2021.',\n",
      " 'Reuters.',\n",
      " 'The Jakarta Post.',\n",
      " 'Urdu Point.',\n",
      " 'Reuters.',\n",
      " 'TASS.',\n",
      " 'Retrieved 19 February 2021.',\n",
      " 'wsoctv.',\n",
      " 'Dawn.',\n",
      " 'RFID.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 15 January 2021.',\n",
      " 'Tass.',\n",
      " 'Retrieved 8 February 2021.',\n",
      " 'The Lancet.',\n",
      " 'Respiratory Medicine.',\n",
      " 'doi:10.1016/S2213-2600(20)30402-1.',\n",
      " 'PMC\\xa07837053.',\n",
      " 'PMID\\xa032896274.',\n",
      " 'Unioneonline.',\n",
      " 'N1 (in Serbian).',\n",
      " 'rdif.ru.',\n",
      " 'Retrieved 1 March 2021.',\n",
      " 'Gamaleya Center.',\n",
      " 'Retrieved 30 January 2021.',\n",
      " 'Khaleej Times.',\n",
      " 'Retrieved 21 January 2021.',\n",
      " 'India Blooms.',\n",
      " 'Reuters.',\n",
      " 'VnExpress.',\n",
      " 'Retrieved 26 February 2021.',\n",
      " 'Reuters.',\n",
      " 'The Moscow Times.',\n",
      " 'Gamaleya Center (Press release).',\n",
      " 'Roya.',\n",
      " 'Orient.',\n",
      " \"Agence France-Presse (Barron's).\",\n",
      " 'The Economic Times.',\n",
      " 'Retrieved 15 June 2020.',\n",
      " 'The Financial Express.',\n",
      " 'São Paulo: CNN.',\n",
      " 'Archived from the original on 3 August 2020.',\n",
      " 'Retrieved 3 August 2020.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'United States National Library of Medicine.',\n",
      " 'NCT04383574.',\n",
      " 'Archived from the original on 23 August 2020.',\n",
      " 'Retrieved 26 August 2020.',\n",
      " 'Lancet.',\n",
      " 'doi:10.1016/S0140-6736(20)32661-1.',\n",
      " 'PMC\\xa07723445.',\n",
      " 'PMID\\xa033306989.',\n",
      " 'Jenner Institute.',\n",
      " 'Archived from the original on 9 September 2020.',\n",
      " 'Retrieved 26 August 2020.',\n",
      " 'mint.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 24 February 2021.',\n",
      " 'www.aljazeera.com.',\n",
      " 'Retrieved 24 February 2021.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 30 December 2020.',\n",
      " 'Saudigazette.',\n",
      " 'Retrieved 30 January 2021.',\n",
      " 'thedailystar.net.',\n",
      " 'Retrieved 6 January 2021.',\n",
      " 'aa.com.tr.',\n",
      " 'Retrieved 6 January 2021.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 17 January 2021.',\n",
      " 'Agencia EFE (in Spanish).',\n",
      " 'Reuters.',\n",
      " 'Retrieved 30 January 2021.',\n",
      " 'Gulf News.',\n",
      " 'Retrieved 24 February 2021.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 19 February 2021.',\n",
      " 'www.paho.org.',\n",
      " 'Retrieved 19 February 2021.',\n",
      " 'The New York Times.',\n",
      " 'Retrieved 3 January 2021.',\n",
      " 'Big News Network.com.',\n",
      " 'Retrieved 30 January 2021.',\n",
      " 'www.xinhuanet.com.',\n",
      " 'Retrieved 19 February 2021.',\n",
      " 'Africanews.',\n",
      " 'Retrieved 24 February 2021.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 14 January 2021.',\n",
      " 'Xinhua News.',\n",
      " 'Reuters.',\n",
      " 'BBC News Pidgin.',\n",
      " 'Retrieved 24 February 2021.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 28 January 2021.',\n",
      " 'gulfnews.com.',\n",
      " 'Retrieved 19 January 2021.',\n",
      " 'AP NEWS.',\n",
      " 'Retrieved 22 January 2021.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 28 February 2021.',\n",
      " 'Pattaya Mail.',\n",
      " 'Medicines and Healthcare products Regulatory Agency (MHRA).',\n",
      " 'Retrieved 4 January 2021.',\n",
      " 'Department of Health and Social Care.',\n",
      " 'Retrieved 30 December 2020.',\n",
      " 'Medicines and Healthcare products Regulatory Agency (MHRA).',\n",
      " 'Retrieved 4 January 2021.',\n",
      " 'CNA.',\n",
      " 'Retrieved 5 February 2021.',\n",
      " 'World Health Organization (WHO).',\n",
      " 'Retrieved 27 February 2021.',\n",
      " 'Forbes.',\n",
      " 'Retrieved 16 February 2021.',\n",
      " 'ABC News.',\n",
      " 'Retrieved 16 February 2021.',\n",
      " 'Therapeutic Goods Administration (TGA).',\n",
      " 'Retrieved 16 February 2021.',\n",
      " 'Health Canada.',\n",
      " 'Retrieved 26 February 2021.',\n",
      " 'European Medicines Agency (EMA).',\n",
      " 'Retrieved 29 January 2021.',\n",
      " 'European Medicines Agency (EMA) (Press release).',\n",
      " 'Retrieved 29 January 2021.',\n",
      " 'European Commission (Press release).',\n",
      " 'Retrieved 29 January 2021.',\n",
      " 'Yonhap News Agency.',\n",
      " 'Retrieved 10 February 2021.',\n",
      " 'UPI.',\n",
      " 'Retrieved 10 February 2021.',\n",
      " 'The New York Times.',\n",
      " 'Retrieved 30 December 2020.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'Archived from the original on 14 September 2020.',\n",
      " 'Retrieved 15 September 2020.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'Retrieved 28 September 2020.',\n",
      " 'chictr.org.cn.',\n",
      " 'Chinese Clinical Trial Register (ChiCTR).',\n",
      " 'Retrieved 15 December 2020.',\n",
      " 'MSN.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 3 November 2020.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 23 February 2021.',\n",
      " 'www.thestar.com.my.',\n",
      " 'Retrieved 28 February 2021.',\n",
      " 'Khmer Times.',\n",
      " 'Retrieved 4 February 2021.',\n",
      " 'xinhuanet.com.',\n",
      " 'National Post.',\n",
      " 'Financial Tribune.',\n",
      " 'Retrieved 23 February 2021.',\n",
      " 'Roya News.',\n",
      " 'Retrieved 9 January 2021.',\n",
      " 'Daily Star.',\n",
      " 'Retrieved 2 March 2021.',\n",
      " 'IAG.',\n",
      " 'Retrieved 24 February 2021.',\n",
      " 'en.yabiladi.com.',\n",
      " 'Kathmandu Post.',\n",
      " 'Retrieved 19 February 2021.',\n",
      " 'Reuters.',\n",
      " 'Reuters.',\n",
      " 'Africanews.',\n",
      " 'Retrieved 23 February 2021.',\n",
      " 'RadioFreeEurope/RadioLiberty.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 2 March 2021.',\n",
      " 'The Star.',\n",
      " 'Retrieved 20 February 2021.',\n",
      " 'Arabian Business Industries.',\n",
      " 'The Washington Post.',\n",
      " 'www.statehouse.gov.sc.',\n",
      " 'Retrieved 5 February 2021.',\n",
      " 'The New York Times.',\n",
      " 'Retrieved 12 December 2020.',\n",
      " 'The National.',\n",
      " 'Retrieved 24 November 2020.',\n",
      " 'ABC News.',\n",
      " 'Associated Press.',\n",
      " 'Retrieved 28 December 2020.',\n",
      " 'The Straits Times.',\n",
      " 'Retrieved 11 January 2021.',\n",
      " 'Bloomberg.',\n",
      " 'Retrieved 12 January 2021.',\n",
      " 'Archived from the original on 29 October 2020.',\n",
      " 'Retrieved 29 October 2020.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 29 October 2020.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'Archived from the original on 20 October 2020.',\n",
      " 'Retrieved 22 October 2020.',\n",
      " 'Anadolu Agency.',\n",
      " 'Retrieved 7 February 2021.',\n",
      " 'noticias.uol.com.br (in Portuguese).',\n",
      " 'Retrieved 6 January 2021.',\n",
      " 'Cambodianess.',\n",
      " 'Retrieved 12 February 2021.',\n",
      " 'France 24.',\n",
      " 'Retrieved 30 January 2021.',\n",
      " 'Anadolu Agency.',\n",
      " 'Retrieved 7 February 2021.',\n",
      " 'National Post.',\n",
      " 'Retrieved 26 February 2021.',\n",
      " 'news.gov.hk.',\n",
      " 'Retrieved 19 February 2021.',\n",
      " 'Tempo.',\n",
      " 'Retrieved 11 January 2021.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 7 February 2021.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 11 February 2021.',\n",
      " 'Reuters.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 23 February 2021.',\n",
      " 'Anadolu.',\n",
      " 'Retrieved 11 January 2021.',\n",
      " 'National Institutes of Health (NIH).',\n",
      " 'New England Journal of Medicine.',\n",
      " 'doi:10.1056/NEJMoa2035389.',\n",
      " 'PMC\\xa07787219.',\n",
      " 'PMID\\xa033378609.',\n",
      " 'Health Canada, Government of Canada.',\n",
      " 'Retrieved 23 December 2020.',\n",
      " 'modernatx.com.',\n",
      " 'Retrieved 4 January 2021.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 3 February 2021.',\n",
      " 'Swiss Agency for Therapeutic Products (Swissmedic).',\n",
      " 'Retrieved 12 January 2020.',\n",
      " 'Medicines and Healthcare products Regulatory Agency (MHRA).',\n",
      " 'Retrieved 8 January 2021.',\n",
      " 'Medicines and Healthcare products Regulatory Agency (MHRA).',\n",
      " 'Retrieved 9 January 2021.',\n",
      " 'U.S. Food and Drug Administration (FDA) (Press release).',\n",
      " 'Retrieved 18 December 2020.',\n",
      " 'MMWR.',\n",
      " 'Morbidity and Mortality Weekly Report.',\n",
      " 'doi:10.15585/mmwr.mm695152e1.',\n",
      " 'PMID\\xa033382675.',\n",
      " 'S2CID\\xa0229945697.',\n",
      " 'VnExpress.',\n",
      " 'Retrieved 26 February 2021.',\n",
      " 'European Medicines Agency (EMA).',\n",
      " 'Retrieved 20 January 2021.',\n",
      " 'European Commission (Press release).',\n",
      " 'Retrieved 6 January 2021.',\n",
      " 'European Medicines Agency.',\n",
      " 'Retrieved 6 January 2021.',\n",
      " 'Union Register of medicinal products.',\n",
      " 'Retrieved 14 January 2021.',\n",
      " 'Lægemiddelstyrelsen (in Danish).',\n",
      " 'Retrieved 7 January 2021.',\n",
      " 'Lyfjastofnun (in Icelandic).',\n",
      " 'Retrieved 7 January 2021.',\n",
      " 'Statens legemiddelverk (in Norwegian Bokmål).',\n",
      " 'Retrieved 7 January 2021.',\n",
      " 'Johnson & Johnson.',\n",
      " 'Retrieved 29 January 2021.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 25 February 2021.',\n",
      " 'ABC News.',\n",
      " 'Retrieved 25 February 2021.',\n",
      " 'BBC News Online.',\n",
      " 'Retrieved 19 February 2021.',\n",
      " 'U.S. Food and Drug Administration (FDA) (Press release).',\n",
      " 'Retrieved 27 February 2021.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 8 February 2021.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'United States National Library of Medicine.',\n",
      " 'NCT04540419.',\n",
      " 'Retrieved 17 November 2020.',\n",
      " 'La Tercera.',\n",
      " 'Retrieved 15 December 2020.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 4 November 2020.',\n",
      " 'South China Morning Post.',\n",
      " 'Retrieved 4 November 2020.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 4 November 2020.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'Archived from the original on 18 September 2020.',\n",
      " 'Retrieved 17 September 2020.',\n",
      " 'Nikkei Asia.',\n",
      " 'Retrieved 24 December 2020.',\n",
      " 'Bloomberg L.P. Retrieved 24 December 2020.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 12 February 2021.',\n",
      " 'Oreanda News.',\n",
      " 'Rospotrebnadzor (in Russian).',\n",
      " 'The Pharma Letter.',\n",
      " 'Turkmenistan Today.',\n",
      " 'EN24.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'NCT04641481.',\n",
      " 'Retrieved 26 November 2020.',\n",
      " 'NDTV.com.',\n",
      " 'Retrieved 3 January 2021.',\n",
      " 'Business Standard India.',\n",
      " 'Government of Russia.',\n",
      " 'Retrieved 20 February 2021.',\n",
      " 'Reuters.',\n",
      " 'Milken Institute.',\n",
      " 'Retrieved 11 December 2020.',\n",
      " 'Lay summary.',\n",
      " 'World Health Organization (WHO).',\n",
      " 'Retrieved 11 December 2020.',\n",
      " 'Science.',\n",
      " 'Bibcode:2020Sci...370..649W.',\n",
      " 'doi:10.1126/science.370.6517.649.',\n",
      " 'PMID\\xa033154120.',\n",
      " 'Science.',\n",
      " 'doi:10.1126/science.abg3441.',\n",
      " 'Archived from the original on 22 November 2020.',\n",
      " 'Retrieved 24 July 2020.',\n",
      " 'ACS Nano.',\n",
      " 'doi:10.1021/acsnano.0c07197.',\n",
      " 'PMC\\xa07553041.',\n",
      " 'PMID\\xa033034449.',\n",
      " 'ACS Applied Nano Materials.',\n",
      " 'doi:10.1021/acsanm.0c01978.',\n",
      " 'PMC\\xa07482545.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'Retrieved 22 November 2020.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'Retrieved 30 December 2020.',\n",
      " 'The New England Journal of Medicine.',\n",
      " 'doi:10.1056/NEJMoa2026920.',\n",
      " 'PMC\\xa07494251.',\n",
      " 'PMID\\xa032877576.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 24 February 2021.',\n",
      " 'euronews.',\n",
      " 'Retrieved 24 February 2021.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'South China Morning Post.',\n",
      " 'Retrieved 26 December 2020.',\n",
      " 'New Straits Times.',\n",
      " 'Retrieved 28 December 2020.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'United States National Library of Medicine.',\n",
      " 'NCT04466085.',\n",
      " 'Archived from the original on 28 July 2020.',\n",
      " 'Retrieved 26 August 2020.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 2 March 2021.',\n",
      " 'CureVac.',\n",
      " 'Retrieved 21 December 2020.',\n",
      " 'EU Clinical Trials Register.',\n",
      " 'Retrieved 19 December 2020.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'NCT04449276.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 14 July 2020.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'NCT04515147.',\n",
      " 'Archived from the original on 23 August 2020.',\n",
      " 'Retrieved 28 August 2020.',\n",
      " 'The Astana Times.',\n",
      " 'Retrieved 2 March 2021.',\n",
      " 'clinicaltrials.gov.',\n",
      " 'clinicaltrials.gov.',\n",
      " 'The Hindu.',\n",
      " 'The Economic Times.',\n",
      " 'Retrieved 16 December 2020.',\n",
      " 'Press Information Bureau.',\n",
      " 'European Journal of Pharmacology.',\n",
      " 'ISSN\\xa01879-0712.',\n",
      " 'PMC\\xa07685956.',\n",
      " 'PMID\\xa033245898.',\n",
      " 'PMLive.',\n",
      " 'Retrieved 16 November 2020.',\n",
      " 'National Post.',\n",
      " 'Reuters.',\n",
      " 'Archived from the original on 1 November 2020.',\n",
      " 'Retrieved 14 July 2020.',\n",
      " 'Clinical Trials.',\n",
      " 'Retrieved 26 November 2020.',\n",
      " 'Times of Israel.',\n",
      " 'Retrieved 1 January 2021.',\n",
      " 'Registro Público Cubano de Ensayos Clínicos.',\n",
      " 'Retrieved 22 January 2021.',\n",
      " 'Registro Público Cubano de Ensayos Clínicos.',\n",
      " 'Retrieved 22 January 2021.',\n",
      " 'Viet Nam News.',\n",
      " 'WHO.',\n",
      " 'Voice of Vietnam.',\n",
      " 'VnExpress.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'United States National Library of Medicine.',\n",
      " 'NCT04412538.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 14 July 2020.',\n",
      " 'AnGes, Inc. Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 1 August 2020.',\n",
      " 'UK BioIndustry Association.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 23 August 2020.',\n",
      " 'clinicaltrials.gov.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 23 August 2020.',\n",
      " 'Shenzhen Genoimmune Medical Institute.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 1 August 2020.',\n",
      " 'ISRCTN.',\n",
      " 'doi:10.1186/ISRCTN17072692.',\n",
      " 'ISRCTN17072692.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'United States National Library of Medicine.',\n",
      " 'NCT04528641.',\n",
      " 'ReiThera Srl.',\n",
      " 'Yahoo!Finance.',\n",
      " 'Retrieved 12 January 2021.',\n",
      " 'ANSA.',\n",
      " 'Retrieved 1 August 2020.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'United States National Library of Medicine.',\n",
      " 'NCT04405908.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 14 July 2020.',\n",
      " 'Clinical Trials Arena.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 25 June 2020.',\n",
      " 'Clover Biopharmaceuticals.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 1 August 2020.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'United States National Library of Medicine.',\n",
      " 'NCT04453852.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 14 July 2020.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 1 August 2020.',\n",
      " 'Chinese Clinical Trial Register.',\n",
      " 'ChiCTR2000034112.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 6 July 2020.',\n",
      " 'Walvax Biotechnology.',\n",
      " 'Archived from the original on 11 October 2020.',\n",
      " 'Retrieved 1 August 2020.',\n",
      " 'Press Information Bureau.',\n",
      " 'Retrieved 13 January 2021.',\n",
      " 'Gennova Biopharmaceuticals Limited.',\n",
      " 'Retrieved 13 January 2021.',\n",
      " 'The Indian Express.',\n",
      " 'thedailystar.net.',\n",
      " 'The Daily Star.',\n",
      " 'arabnews.com.',\n",
      " 'Arab News.',\n",
      " 'bdnews24.com.',\n",
      " 'Bdnews24.com.',\n",
      " 'newagebd.net.',\n",
      " 'New Age.',\n",
      " 'ctri.nic.in.',\n",
      " 'Clinical Trials Registry India.',\n",
      " 'CTRI/2020/11/029032.',\n",
      " 'Archived from the original on 12 November 2020.',\n",
      " 'Baylor College of Medicine.',\n",
      " 'Mint.',\n",
      " 'CBC.',\n",
      " 'globalnews.ca.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'Retrieved 26 January 2021.',\n",
      " 'ClinicalTrials.gov.',\n",
      " 'Retrieved 26 January 2021.',\n",
      " 'Merck (Press release).',\n",
      " 'Retrieved 25 January 2021.',\n",
      " 'U.S. Food and Drug Administration.',\n",
      " 'Retrieved 1 January 2021.',\n",
      " 'Stat.',\n",
      " 'Retrieved 28 February 2021.',\n",
      " 'Immunity.',\n",
      " 'doi:10.1016/j.immuni.2020.04.012.',\n",
      " 'PMC\\xa07236739.',\n",
      " 'PMID\\xa032433946.',\n",
      " 'What does that mean?\".',\n",
      " 'NBC News.',\n",
      " 'Retrieved 8 January 2021.',\n",
      " 'www.raps.org.',\n",
      " 'Retrieved 8 January 2021.',\n",
      " 'DailyMed.',\n",
      " 'U.S. National Institutes of Health.',\n",
      " 'Retrieved 20 December 2020.',\n",
      " 'DailyMed.',\n",
      " 'U.S. National Institutes of Health.',\n",
      " 'Retrieved 14 December 2020.',\n",
      " 'The Lancet.',\n",
      " 'doi:10.1016/S0140-6736(21)00234-8.',\n",
      " 'ISSN\\xa00140-6736.',\n",
      " 'PMC\\xa07852454.',\n",
      " 'PMID\\xa033545094.',\n",
      " 'Science.',\n",
      " 'doi:10.1126/science.abg8101.',\n",
      " 'ir.novavax.com.',\n",
      " 'Retrieved 3 March 2021.',\n",
      " 'The New York Times.',\n",
      " 'Retrieved 30 December 2020.',\n",
      " 'Sinopharm.',\n",
      " 'Archived from the original on 9 February 2021.',\n",
      " 'Retrieved 3 March 2021.',\n",
      " 'Reuters.',\n",
      " 'Retrieved December 25, 2020.',\n",
      " 'Bloomberg.',\n",
      " 'Retrieved 7 January 2021.',\n",
      " 'Stat.',\n",
      " 'Retrieved 29 January 2021.',\n",
      " 'Janssen Global Services.',\n",
      " 'Retrieved 2 March 2021.',\n",
      " 'mint.',\n",
      " 'The Wall Street Journal.',\n",
      " 'ISSN\\xa00099-9660.',\n",
      " 'Retrieved 4 February 2021.',\n",
      " 'bioRxiv\\xa0: The Preprint Server for Biology.',\n",
      " 'doi:10.1101/2021.01.27.427998.',\n",
      " 'PMC\\xa07852264.',\n",
      " 'PMID\\xa033532771 – via medRxiv.',\n",
      " 'bioRxiv: 2020.12.08.416750. doi:10.1101/2020.12.08.416750.',\n",
      " 'The Scientist Magazine.',\n",
      " 'Retrieved 25 January 2021.',\n",
      " 'Labiotech.eu.',\n",
      " 'Retrieved 25 January 2021.',\n",
      " 'www.nature.com.',\n",
      " 'Retrieved 15 February 2021.',\n",
      " 'Nature.',\n",
      " 'doi:10.1038/d41586-021-00241-6.',\n",
      " 'besedina.moscow.',\n",
      " 'Retrieved 22 February 2021.',\n",
      " 'www.ema.europa.eu.',\n",
      " 'Retrieved 22 February 2021.',\n",
      " 'kremlin.ru.',\n",
      " 'Retrieved 22 February 2021.',\n",
      " 'The New York Times.',\n",
      " 'Retrieved 29 January 2021.',\n",
      " 'RNZ.',\n",
      " 'Retrieved 30 January 2021.',\n",
      " 'Science: eabg6105.',\n",
      " 'doi:10.1126/science.abg6105.',\n",
      " 'ISSN\\xa00036-8075.',\n",
      " 'PMID\\xa033514629.',\n",
      " 'Science: eabg6105.',\n",
      " 'doi:10.1126/science.abg6105.',\n",
      " 'ISSN\\xa00036-8075.',\n",
      " 'PMID\\xa033514629.',\n",
      " 'bioRxiv: 2021.01.26.426986. doi:10.1101/2021.01.26.426986.',\n",
      " 'Financial Times.',\n",
      " 'Retrieved 30 January 2021.',\n",
      " 'New England Journal of Medicine.',\n",
      " 'doi:10.1056/nejmc2102017.',\n",
      " 'Retrieved 25 February 2021.',\n",
      " 'Johnson & Johnson.',\n",
      " 'Retrieved 29 January 2021.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 8 February 2021.',\n",
      " 'BBC News.',\n",
      " 'Retrieved 8 February 2021.',\n",
      " 'The Washington Post.',\n",
      " 'London.',\n",
      " 'Retrieved 8 February 2021.',\n",
      " 'South Africa will suspend use of the coronavirus vaccine being developed by '\n",
      " 'Oxford University and AstraZeneca after researchers found it provided '\n",
      " '\"minimal protection\" against mild to moderate coronavirus infections caused '\n",
      " 'by the new variant first detected in that country.',\n",
      " 'BBC News Online.',\n",
      " 'Retrieved 12 February 2021.',\n",
      " 'Human Vaccines and Immunotherapeutics.',\n",
      " 'doi:10.1080/21645515.2017.1415684.',\n",
      " 'ISSN\\xa02164-5515.',\n",
      " 'PMC\\xa05861793.',\n",
      " 'PMID\\xa029232151.',\n",
      " 'AAPS PharmSciTech.',\n",
      " 'ISSN\\xa01530-9932.',\n",
      " 'PMC\\xa07405756.',\n",
      " 'PMID\\xa032761294.',\n",
      " 'Our World in Data\\xa0\\xa0Sourced from individual health agencies.',\n",
      " 'Centers for Disease Control and Prevention.',\n",
      " 'Our World in Data.',\n",
      " 'World Health Organization.',\n",
      " 'Archived from the original on 30 April 2020.',\n",
      " 'Retrieved 2 May 2020.',\n",
      " 'It is vital that we evaluate as many vaccines as possible as we cannot '\n",
      " 'predict how many will turn out to be viable.',\n",
      " 'To increase the chances of success (given the high level of attrition during '\n",
      " 'vaccine development), we must test all candidate vaccines until they fail.',\n",
      " 'The results for the efficacy of each vaccine are expected within three to '\n",
      " 'six months and this evidence, combined with data on safety, will inform '\n",
      " 'decisions about whether it can be used on a wider scale.',\n",
      " 'The Gates Notes.',\n",
      " 'Archived from the original on 14 May 2020.',\n",
      " 'Retrieved 2 May 2020.',\n",
      " 'The New England Journal of Medicine.',\n",
      " 'doi:10.1056/nejmp2003762.',\n",
      " 'PMID\\xa032109012.',\n",
      " 'Harvard Business Review.',\n",
      " 'ISSN\\xa00017-8012.',\n",
      " 'Archived from the original on 9 June 2020.',\n",
      " 'Retrieved 9 June 2020.',\n",
      " 'Reuters.',\n",
      " 'Archived from the original on 15 May 2020.',\n",
      " 'Retrieved 2 May 2020.',\n",
      " 'Latest news on UK trials\".',\n",
      " 'The Telegraph.',\n",
      " 'ISSN\\xa00307-1235.',\n",
      " 'Archived from the original on 4 May 2020.',\n",
      " 'Retrieved 3 May 2020.',\n",
      " 'Nature Reviews Drug Discovery.',\n",
      " 'doi:10.1038/d41573-020-00073-5.',\n",
      " 'ISSN\\xa01474-1776.',\n",
      " 'PMID\\xa032273591.',\n",
      " 'Nature Reviews Drug Discovery.',\n",
      " 'doi:10.1038/d41573-020-00151-8.',\n",
      " 'ISSN\\xa01474-1776.',\n",
      " 'PMID\\xa032887942.',\n",
      " 'S2CID\\xa0221503034.',\n",
      " 'Lancet.',\n",
      " 'doi:10.1016/S0140-6736(20)30763-7.',\n",
      " 'PMC\\xa07271264.',\n",
      " 'PMID\\xa032243778.',\n",
      " 'CEPI estimates that developing up to three vaccines in the next 12–18 months '\n",
      " 'will require an investment of at least US$2\\xa0billion.',\n",
      " 'This estimate includes Phase\\xa01 clinical trials of eight vaccine '\n",
      " 'candidates, progression of up to six candidates through Phase\\xa02 and\\xa03 '\n",
      " 'trials, completion of regulatory and quality requirements for at least three '\n",
      " 'vaccines, and enhancing global manufacturing capacity for three vaccines.',\n",
      " 'World Health Organization.',\n",
      " 'Archived (PDF) from the original on 12 May 2020.',\n",
      " 'Retrieved 9 May 2020.',\n",
      " 'GAVI.',\n",
      " 'Archived from the original on 25 September 2020.',\n",
      " 'Retrieved 28 August 2020.',\n",
      " 'World Health Organization.',\n",
      " 'Archived (PDF) from the original on 15 May 2020.',\n",
      " 'Retrieved 10 May 2020.',\n",
      " 'Archived from the original on 25 April 2020.',\n",
      " 'Retrieved 22 April 2020.',\n",
      " 'European Commission.',\n",
      " 'Question: What is the difference in liability between EU Conditional '\n",
      " 'Marketing Authorisation vs Emergency Use Authorisations?.',\n",
      " 'Retrieved 29 December 2020.',\n",
      " 'European Parliament.',\n",
      " 'Ms. Gallina stressed negotiations with companies had been difficult but '\n",
      " 'underlined that those companies developing and manufacturing COVID-19 '\n",
      " 'vaccines would indeed be liable according to current laws and if something '\n",
      " 'goes wrong they could be taken to court.',\n",
      " 'This also goes for compensation for hidden defects.',\n",
      " 'Retrieved 29 December 2020.',\n",
      " 'BMJ.',\n",
      " 'doi:10.1136/bmj.m4750.',\n",
      " 'ISSN\\xa01756-1833.',\n",
      " 'PMC\\xa07735431.',\n",
      " 'PMID\\xa033323376.',\n",
      " 'www.who.int.',\n",
      " 'Retrieved 25 January 2021.',\n",
      " 'ABC News.',\n",
      " 'Retrieved 13 December 2020.',\n",
      " 'Reuters.',\n",
      " 'Retrieved 9 December 2020.',\n",
      " 'The Guardian.',\n",
      " 'Retrieved 17 February 2021.',\n",
      " 'The New York Times.',\n",
      " 'Retrieved 17 February 2021.',\n",
      " 'Bloomberg.',\n",
      " 'Retrieved 17 February 2021.',\n",
      " 'Carnegie Endowment for International Peace.',\n",
      " 'Retrieved 25 February 2021.',\n",
      " 'American Medical Association.',\n",
      " 'Retrieved 4 March 2021.',\n",
      " 'CNN.',\n",
      " 'Retrieved 4 March 2021.',\n",
      " 'World Health Organization (WHO).',\n",
      " 'Archived from the original on 11 November 2019.',\n",
      " 'Retrieved 26 May 2020.',\n",
      " 'EClinicalMedicine, the Lancet.',\n",
      " 'ISSN\\xa02589-5370.',\n",
      " 'PMC\\xa07423333.',\n",
      " 'PMID\\xa032838242.',\n",
      " 'National Geographic.',\n",
      " 'Retrieved 12 December 2020.',\n",
      " 'The Guardian.',\n",
      " 'Retrieved 26 December 2020.',\n",
      " 'The Guardian.',\n",
      " 'Retrieved 26 December 2020.',\n",
      " 'The Guardian.',\n",
      " 'Retrieved 26 December 2020.',\n",
      " 'Further readingFront Pharmacol.',\n",
      " 'PMC\\xa07317023.',\n",
      " 'PMID\\xa032636754.',\n",
      " 'Development and Licensure of Vaccines to Prevent COVID-19: Guidance for '\n",
      " 'Industry (Report).',\n",
      " 'U.S. Food and Drug Administration.',\n",
      " 'June 2020.',\n",
      " 'Ramsay M, ed.',\n",
      " 'Immunisation against infectious disease.',\n",
      " 'Public Health England.',\n",
      " 'Levine, Hallie (23 September 2020).',\n",
      " 'Johnson & Johnson.',\n",
      " 'Zimmer C, Sheikh K, Weiland N (20 May 2020).',\n",
      " 'The New York Times.',\n",
      " 'Vaccine protocolsModerna.',\n",
      " 'Pfizer.',\n",
      " 'AstraZeneca.',\n",
      " 'Janssen Vaccines & Prevention.',\n",
      " 'Janssen Vaccines & Prevention.',\n",
      " 'External linksWorld Health Organization (WHO).',\n",
      " 'COVID‑19 Vaccine Tracker.',\n",
      " 'Regulatory FocusStat.',\n",
      " 'European Medicines Agency.',\n",
      " 'U.S. Food and Drug Administration.',\n",
      " 'The New York Times.',\n",
      " 'M.I.T.',\n",
      " 'Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a '\n",
      " 'non-profit organization.',\n",
      " 'Privacy policyloadCSS.',\n",
      " 'loadCSS rel=preload polyfill.',\n",
      " 'CSS rel=preload polyfill.',\n",
      " 'Depends on loadCSS function.',\n",
      " 'See allHide authors and affiliationsBubar et al.',\n",
      " \"modeled across countries how uncertainty about a vaccine's characteristics \"\n",
      " 'affects prioritization strategies for reducing deaths and transmission (see '\n",
      " 'the Perspective by Fitzpatrick and Galvani).',\n",
      " 'In the model, vaccine efficacy and its ability to reduce disease and/or '\n",
      " 'block transmission was accounted for in relation to age-related variations '\n",
      " 'in susceptibility, fatality rates, and immune decline.',\n",
      " 'In almost all circumstances, reducing fatalities required distributing the '\n",
      " 'vaccine to those who are most at risk of death, usually persons over 60 '\n",
      " 'years of age and those with comorbidities.',\n",
      " 'If a vaccine is leaky or poorly efficacious in older adults, then priority '\n",
      " 'could be given to younger age groups.',\n",
      " 'To increase the available doses, further priority should be given to '\n",
      " 'seronegative individuals.Science, this issue p. 916; see also p. '\n",
      " '890AbstractLimited initial supply of severe acute respiratory syndrome '\n",
      " 'coronavirus 2 (SARS-CoV-2) vaccine raises the question of how to prioritize '\n",
      " 'available doses.',\n",
      " 'We used a mathematical model to compare five age-stratified prioritization '\n",
      " 'strategies.',\n",
      " 'A highly effective transmission-blocking vaccine prioritized to adults ages '\n",
      " '20 to 49 years minimized cumulative incidence, but mortality and years of '\n",
      " 'life lost were minimized in most scenarios when the vaccine was prioritized '\n",
      " 'to adults greater than 60 years old.',\n",
      " 'Use of individual-level serological tests to redirect doses to seronegative '\n",
      " 'individuals improved the marginal impact of each dose while potentially '\n",
      " 'reducing existing inequities in COVID-19 impact.',\n",
      " 'Although maximum impact prioritization strategies were broadly consistent '\n",
      " 'across countries, transmission rates, vaccination rollout speeds, and '\n",
      " 'estimates of naturally acquired immunity, this framework can be used to '\n",
      " 'compare impacts of prioritization strategies across contexts.Severe acute '\n",
      " 'respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a public health '\n",
      " 'and economic crisis worldwide.',\n",
      " 'As of January 2021, there have been more than 85 million cases and 1.8 '\n",
      " 'million deaths reported (1).',\n",
      " 'To combat this crisis, a variety of nonpharmaceutical interventions have '\n",
      " 'been implemented, including shelter-in-place orders, limited travel, and '\n",
      " 'remote schooling.',\n",
      " 'Although these efforts are essential to slowing transmission in the short '\n",
      " 'term, long-term solutions—such as vaccines that protect from SARS-CoV-2 '\n",
      " 'infection—remain urgently needed.',\n",
      " 'The benefits of an effective vaccine for individuals and their communities '\n",
      " 'have resulted in widespread demand, so it is critical that decision-making '\n",
      " 'on vaccine distribution is well motivated, particularly in the initial '\n",
      " 'phases when vaccine availability is limited (2).We used a model-informed '\n",
      " 'approach to quantify the impact of COVID-19 vaccine prioritization '\n",
      " 'strategies on cumulative incidence, mortality, and years of life lost.',\n",
      " 'Our approach explicitly addresses variation in three areas that can '\n",
      " 'influence the outcome of vaccine distribution decisions.',\n",
      " 'First, we considered variation in the performance of the vaccine, including '\n",
      " 'its overall efficacy, a hypothetical decrease in efficacy by age, and the '\n",
      " 'vaccine’s ability to block transmission.',\n",
      " 'Second, we considered variation in both susceptibility to infection and the '\n",
      " 'infection fatality rate by age.',\n",
      " 'Third, we considered variation in the population and policy—including the '\n",
      " 'age distribution, age-stratified contact rates, and initial fraction of '\n",
      " 'seropositive individuals by age—and the speed and timing of the vaccine’s '\n",
      " 'rollout relative to transmission.',\n",
      " 'Although the earliest doses of vaccines will be given to front-line health '\n",
      " 'care workers under plans such as those from the COVAX initiative and the '\n",
      " 'U.S. National Academies of Sciences, Engineering, and Medicine (NASEM) '\n",
      " 'recommendations (3), our work is focused on informing the prioritization of '\n",
      " 'the doses that follow.',\n",
      " 'On the basis of regulatory approvals and initial vaccine rollout speeds of '\n",
      " 'early 2021, our investigation focuses generally on scenarios with a '\n",
      " 'partially mitigated pandemic [reproduction number (R) between 1.1 and 2.0], '\n",
      " 'vaccines with protective efficacy of 90%, and rollout speeds of 0.2% of the '\n",
      " 'population per day.There are two main approaches to vaccine prioritization: '\n",
      " '(i) directly vaccinate those at highest risk for severe outcomes and (ii) '\n",
      " 'protect them indirectly by vaccinating those who do the most transmitting.',\n",
      " 'Model-based investigations of the trade-offs between these strategies for '\n",
      " 'influenza vaccination have led to recommendations that children be '\n",
      " 'vaccinated because of their critical role in transmission (4, 5) and have '\n",
      " 'shown that direct protection is superior when reproduction numbers are high '\n",
      " 'but indirect protection is superior when transmission is low (6).',\n",
      " 'Similar modeling for COVID-19 vaccination has found that the optimal balance '\n",
      " 'between direct and indirect protection depends on both vaccine efficacy and '\n",
      " 'supply, recommending direct vaccination of older adults for low-efficacy '\n",
      " 'vaccines and for high-efficacy but supply-limited vaccines (7).',\n",
      " 'Rather than comparing prioritization strategies, others have compared '\n",
      " 'hypothetical vaccines, showing that even those with lower efficacy for '\n",
      " 'direct protection may be more valuable if they also provide better indirect '\n",
      " 'protection by blocking transmission (8).',\n",
      " 'Prioritization of transmission-blocking vaccines can also be dynamically '\n",
      " 'updated on the basis of the current state of the epidemic, shifting '\n",
      " 'prioritization to avoid decreasing marginal returns (9).',\n",
      " 'These efforts to prioritize and optimize doses complement other work showing '\n",
      " 'that under different vaccine efficacy and durability of immunity, the '\n",
      " 'economic and health benefits of COVID-19 vaccines will be large in the short '\n",
      " 'and medium terms (10).',\n",
      " 'The problem of vaccine prioritization also parallels the more general '\n",
      " 'problem of optimal resource allocation to reduce transmission, such as with '\n",
      " 'masks (11).Evaluation of vaccine prioritization strategiesWe evaluated the '\n",
      " 'impact of vaccine prioritization strategies using an age-stratified SEIR '\n",
      " 'model (susceptible, exposed, infectious, recovered) because age has been '\n",
      " 'shown to be an important correlate of susceptibility (12–14), seroprevalence '\n",
      " '(12, 15), severity (16–18), and mortality (19, 20).',\n",
      " 'This model includes an age-dependent contact matrix, susceptibility to '\n",
      " 'infection, and infection fatality rate (IFR), allowing us to estimate '\n",
      " 'cumulative incidence of SARS-CoV-2 infections, mortality due to infection, '\n",
      " 'and years of life lost (YLL) (supplementary materials, materials and '\n",
      " 'methods) by means of forward simulations of 1 year of disease dynamics.',\n",
      " 'Cumulative incidence, mortality, and YLL were then used as outcomes by which '\n",
      " 'to compare vaccine prioritization strategies.',\n",
      " 'These comparisons may be explored by using accompanying open-source and '\n",
      " 'interactive calculation tools that accompany this study (21).We first '\n",
      " 'examined the impact of five vaccine prioritization strategies for a '\n",
      " 'hypothetical infection- and transmission-blocking vaccine of varying '\n",
      " 'efficacy.',\n",
      " 'The strategies prioritized vaccines to (i) children and teenagers, (ii) '\n",
      " 'adults between ages 20 and 49 years, (iii) adults 20 years or older, (iv) '\n",
      " 'adults 60 years or older, and (v) all individuals (Fig.',\n",
      " 'In all strategies, once the prioritized population was vaccinated, vaccines '\n",
      " 'were allocated irrespective of age—that is, in proportion to their numbers '\n",
      " 'in the population.',\n",
      " 'To incorporate vaccine hesitancy, at most 70% of any age group was eligible '\n",
      " 'to be vaccinated (22).',\n",
      " 'Download high-res imageSquares and diamonds show how the outputs from single '\n",
      " 'simulations [(F) and (G)] correspond to points in summary curves (H).',\n",
      " 'Gray shading indicates the period during which vaccine is being rolled out '\n",
      " 'at 0.2% of total population per day.',\n",
      " 'Black dots indicate break points at which prioritized demographic groups '\n",
      " 'have been 70% vaccinated, after which vaccines are distributed without '\n",
      " 'prioritization.',\n",
      " 'These simulations assume contact patterns and demographics of the United '\n",
      " 'States (38, 53) and an all-or-nothing, transmission-blocking vaccine with '\n",
      " '90% vaccine efficacy and R0 = 1.5 (scenario 2) and R0 = 1.15 (scenario 1).',\n",
      " 'We measured reductions in cumulative incidence, mortality, and YLL achieved '\n",
      " 'by each strategy, varying the vaccine supply between 1 and 50% of the total '\n",
      " 'population, under two scenarios.',\n",
      " 'In scenario 1, vaccines were administered to 0.2% of the population per day '\n",
      " 'until supply was exhausted, with basic reproduction number (R0) = 1.15, '\n",
      " 'representing highly mitigated spread during vaccine rollout.',\n",
      " 'In scenario 2, vaccines were administered to 0.2% of the population per day '\n",
      " 'until supply was exhausted, but with R0 = 1.5, representing substantial '\n",
      " 'viral growth during vaccine rollout (example model outputs are provided in '\n",
      " 'Fig.',\n",
      " 'Results for additional scenarios in which vaccines were administered before '\n",
      " 'transmission began are described in the supplementary materials, '\n",
      " 'supplementary text, corresponding to countries without ongoing community '\n",
      " 'spread such as South Korea and New Zealand.',\n",
      " 'We considered two ways in which vaccine efficacy (ve) could be below 100%: '\n",
      " 'an all-or-nothing vaccine, in which the vaccine provides perfect protection '\n",
      " 'to a fraction ve of individuals who receive it, or as a leaky vaccine, in '\n",
      " 'which all vaccinated individuals have reduced probability ve of infection '\n",
      " 'after vaccination (supplementary materials, materials and methods).Of the '\n",
      " 'five strategies, direct vaccination of adults older than 60 years of age '\n",
      " '(60+) always reduced mortality and YLL more than the alternative strategies '\n",
      " 'when transmission was high [R0 = 1.5, scenario 2, 90% efficacy (Fig.',\n",
      " 'S5)].',\n",
      " 'For lower transmission (R0 = 1.15, scenario 1), vaccination of adults aged '\n",
      " '20 to 49 years reduced mortality and YLL more than the alternative '\n",
      " 'strategies, but differences between prioritization of adults aged 20 to 49 '\n",
      " 'years, 20+ years, and 60+ years were small for vaccine supplies above 25% '\n",
      " '(Fig.',\n",
      " 'S5).',\n",
      " 'Prioritizing adults aged 20 to 49 years minimized cumulative incidence in '\n",
      " 'both scenarios for all vaccine efficacies (Fig.',\n",
      " 'S5).',\n",
      " 'Prioritizing adults aged 20 to 49 years also minimized cumulative incidence '\n",
      " 'in both scenarios under alternative rollout speeds (0.05 to 1% vaccinated '\n",
      " 'per day) (fig.',\n",
      " 'S6).',\n",
      " 'When rollout speeds were at least 0.3% per day and vaccine supply covered at '\n",
      " 'least 25% of the population, the mortality-minimizing strategy shifted from '\n",
      " 'prioritization of ages 20 to 49 years to adults aged 20+ or 60+ years for '\n",
      " 'scenario 1; when rollout speeds were at least 0.75% per day and covered at '\n",
      " 'least 24% of the population, the mortality-minimizing strategy shifted from '\n",
      " 'prioritization of adults aged 60+ years to adults aged 20+ or 20 to 49 years '\n",
      " 'for scenario 2 (fig.',\n",
      " 'S6).',\n",
      " 'Findings for mortality and YLL were only slightly changed by modeling '\n",
      " 'vaccine efficacy as all or nothing (fig.',\n",
      " 'S5) or leaky (fig.',\n",
      " 'S7).Impact of transmission rates, age demographics, and contact structureTo '\n",
      " 'evaluate the impact of transmission rates on the strategy that most reduced '\n",
      " 'mortality, we varied the basic reproductive number R0 from 1.1 to 2.0 when '\n",
      " 'considering a hypothetical infection- and transmission-blocking vaccine with '\n",
      " '90% vaccine efficacy.',\n",
      " 'We found that prioritizing adults aged 60+ years remained the best way to '\n",
      " 'reduce mortality and YLL for R0 ≥ 1.3, but prioritizing adults aged 20 to 49 '\n",
      " 'years was superior for R0 ≤ 1.2 (Fig.',\n",
      " 'S8).',\n",
      " 'Prioritizing adults aged 20 to 49 years minimized infections for all values '\n",
      " 'of R0 investigated (fig.',\n",
      " 'S8).To evaluate the impact of transmission rates on the strategy that most '\n",
      " 'reduced mortality, we varied the basic reproductive number R0 from 1.1 to '\n",
      " '2.0 when considering a hypothetical infection- and transmission-blocking '\n",
      " 'vaccine with 90% vaccine efficacy.',\n",
      " 'We found that prioritizing adults aged 60+ years remained the best way to '\n",
      " 'reduce mortality and YLL for R0 ≥ 1.3, but prioritizing adults aged 20 to 49 '\n",
      " 'years was superior for R0 ≤ 1.2 (Fig.',\n",
      " 'S8).',\n",
      " 'Prioritizing adults aged 20 to 49 years minimized infections for all values '\n",
      " 'of R0 investigated (fig.',\n",
      " 'S8).To evaluate the impact of transmission rates on the strategy that most '\n",
      " 'reduced mortality, we varied the basic reproductive number R0 from 1.1 to '\n",
      " '2.0 when considering a hypothetical infection- and transmission-blocking '\n",
      " 'vaccine with 90% vaccine efficacy.',\n",
      " 'We found that prioritizing adults aged 60+ years remained the best way to '\n",
      " 'reduce mortality and YLL for R0 ≥ 1.3, but prioritizing adults aged 20 to 49 '\n",
      " 'years was superior for R0 ≤ 1.2 (Fig.',\n",
      " 'S8).',\n",
      " 'Prioritizing adults aged 20 to 49 years minimized infections for all values '\n",
      " 'of R0 investigated (fig.',\n",
      " 'S8).',\n",
      " 'Download high-res imageTo determine whether our findings were robust across '\n",
      " 'countries, we analyzed the ranking of prioritization strategies for '\n",
      " 'populations with the age distributions and modeled contact structures of the '\n",
      " 'United States, Belgium, Brazil, China, India, Poland, South Africa, and '\n",
      " 'Spain.',\n",
      " 'Across these countries, direct vaccination of adults aged 60+ years '\n",
      " 'minimized mortality for all levels of vaccine supply when transmission was '\n",
      " 'high (R0 = 1.5, scenario 2) (Fig.',\n",
      " 'Decreasing rollout speed from 0.2% to 0.1% per day caused prioritization of '\n",
      " 'adults aged 60+ years to be favored in additional scenarios (Fig.',\n",
      " 'Across countries, vaccination of adults aged 20 to 49 years nearly always '\n",
      " 'minimized infections, and vaccination of adults aged 60+ years nearly always '\n",
      " 'minimized YLL for scenario 2, but no clear ranking of strategies emerged '\n",
      " 'consistently to minimize YLL in scenario 1 (fig.',\n",
      " 'S9).Vaccines with imperfect transmission-blocking effectsWe also considered '\n",
      " 'whether the rankings of prioritization strategies to minimize mortality '\n",
      " 'would change if a vaccine were to block COVID-19 symptoms and mortality with '\n",
      " '90% efficacy but with variable impact on SARS-CoV-2 infection and '\n",
      " 'transmission.',\n",
      " 'We found that direct vaccination of adults aged 60+ years minimized '\n",
      " 'mortality for all vaccine supplies and transmission-blocking effects under '\n",
      " 'scenario 2 and for all vaccine supplies when up to 50% of transmission was '\n",
      " 'blocked in scenario 1 (supplementary text and fig.',\n",
      " 'S10).Variation in vaccine efficacy by ageCOVID-19 vaccines may not be '\n",
      " 'equally effective across age groups in preventing infection or disease, a '\n",
      " 'phenomenon known to affect influenza vaccines (23–26).',\n",
      " 'To understand the impact of age-dependent COVID-19 vaccine efficacy, we '\n",
      " 'incorporated a hypothetical linear decrease from a baseline efficacy of 90% '\n",
      " 'for those younger than 60 years to 50% in those 80 years and older (Fig.',\n",
      " 'As expected, this diminished the benefits of any prioritization strategy '\n",
      " 'that included older adults.',\n",
      " 'For example, strategies that prioritize adults aged 20 to 49 years were '\n",
      " 'unaffected by decreased efficacy among adults aged 60+ years, whereas '\n",
      " 'strategies prioritizing adults aged 60+ years were markedly diminished (Fig.',\n",
      " 'Despite these effects, prioritization of adults aged 60+ years remained '\n",
      " 'superior to the alternative strategies to minimize mortality in scenario 2.',\n",
      " 'Download high-res imageBlack dots indicate break points at which prioritized '\n",
      " 'demographic groups have been 70% vaccinated, after which vaccines are '\n",
      " 'distributed without prioritization.',\n",
      " 'Shown are contact patterns and demographics of the United States (38, 53); '\n",
      " 'all-or-nothing and transmission-blocking vaccine.',\n",
      " 'To test whether more substantial age-dependent vaccine effects would change '\n",
      " 'which strategy minimized mortality in scenario 2, we varied the onset age of '\n",
      " 'age-dependent decreases in efficacy, the extent to which it decreased, and '\n",
      " 'the baseline efficacy from which it decreased.',\n",
      " 'We found that as long as the age at which efficacy began to decrease was 70 '\n",
      " 'years or older and vaccine efficacy among adults aged 80+ years was at least '\n",
      " '25%, prioritizing adults aged 60+ years remained superior in the majority of '\n",
      " 'parameter combinations.',\n",
      " 'This finding was robust to whether the vaccine was modeled as leaky versus '\n",
      " 'all or nothing, but we observed considerable variation from country to '\n",
      " 'country (fig.',\n",
      " 'S11).Incorporation of population seroprevalence and individual serological '\n",
      " 'testingBecause of early indications that naturally acquired antibodies '\n",
      " 'correlate with protection from reinfection (27), seroprevalence will affect '\n",
      " 'vaccine prioritization in two ways.',\n",
      " 'First, depending on the magnitude and age distribution of seroprevalence at '\n",
      " 'the time of vaccine distribution, the ranking of strategies could change.',\n",
      " 'Second, distributing vaccines to seropositive individuals would reduce the '\n",
      " 'marginal benefit of vaccination per dose.To investigate the impact of '\n",
      " 'vaccinating midepidemic while using serology to target the vaccine to '\n",
      " 'seronegative individuals, we included age-stratified seroprevalence '\n",
      " 'estimates in our model by moving the data-specified proportion of '\n",
      " 'seropositive individuals from susceptible to recovered status.',\n",
      " 'We then simulated two approaches to vaccine distribution.',\n",
      " 'In the first, vaccines were distributed according to the five prioritization '\n",
      " 'strategies introduced above, regardless of any individual’s serostatus.',\n",
      " 'In the second, vaccines were distributed with a serological test, so that '\n",
      " 'individuals with a positive serological test would not be vaccinated, '\n",
      " 'allowing their dose to be given to someone else in their age group.We '\n",
      " 'included age-stratified seroprevalence estimates from New York City [August '\n",
      " '2020; overall seroprevalence 26.9% (28)] and demographics and age-contact '\n",
      " 'structure from the United States in evaluations of the previous five '\n",
      " 'prioritization strategies.',\n",
      " 'For this analysis, we focused on scenario 2 (0.2% rollout per day, R0 = 1.5 '\n",
      " 'inclusive of seropositives) and found that the ranking of strategies to '\n",
      " 'minimize incidence, mortality, and YLL remained unchanged: Prioritizing '\n",
      " 'adults aged 60+ years most reduced mortality, and prioritizing adults aged '\n",
      " '20 to 49 years most reduced incidence, regardless of whether vaccination was '\n",
      " 'limited to seronegative individuals (Fig.',\n",
      " 'These rankings were unchanged when we used lower or higher age-stratified '\n",
      " 'seroprevalence estimates to test the consistency of results [Connecticut, '\n",
      " 'July 2020, overall seroprevalence 3.4% (29) and synthetic, overall '\n",
      " 'seroprevalence 39.5%] (figs.',\n",
      " 'S12 and S13).',\n",
      " 'Despite lowered sensitivity to detect past exposure due to seroreversion '\n",
      " '(30, 31), preferentially vaccinating seronegative individuals yielded large '\n",
      " 'additional reductions in cumulative incidence and mortality in locations '\n",
      " 'with higher seroprevalence (Fig.',\n",
      " 'S13) and modest reductions in locations with low seroprevalence (fig.',\n",
      " 'S12).',\n",
      " 'These results remained unchanged when statistical uncertainty, because of '\n",
      " 'sample size and imperfect test sensitivity and specificity, was incorporated '\n",
      " 'into the model (32).',\n",
      " 'Download high-res imagePlots show reductions for scenario 2 (0.2% rollout '\n",
      " 'per day, R0 = 1.5) when vaccines are given to all individuals (solid lines) '\n",
      " 'or to only seronegatives (dashed lines), inclusive of 96% serotest '\n",
      " 'sensitivity, 99% specificity (54), and approximately 3 months of '\n",
      " 'seroreversion (supplementary materials, materials and methods) (29).',\n",
      " 'Shown are U.S. contact patterns and demographics (38, 53), all-or-nothing '\n",
      " 'and transmission-blocking vaccine with 90% vaccine efficacy.',\n",
      " 'Lower and higher seroprevalence examples are provided in figs.',\n",
      " 'S12 and S13, respectively.',\n",
      " 'DiscussionThis study demonstrated the use of an age-stratified modeling '\n",
      " 'approach to evaluate and compare vaccine prioritization strategies for '\n",
      " 'SARS-CoV-2.',\n",
      " 'After accounting for country-specific age structure, age-contact structure, '\n",
      " 'infection fatality rates, and seroprevalence, as well as the age-varying '\n",
      " 'efficacy of a hypothetical vaccine, we found that across countries, those '\n",
      " 'aged 60 years and older should be prioritized to minimize deaths, assuming a '\n",
      " 'return to high contact rates and prepandemic behavior during or after '\n",
      " 'vaccine rollout.',\n",
      " 'This recommendation is robust because of the dramatic differences in IFR by '\n",
      " 'age.',\n",
      " 'Our model identified three general regimes in which prioritizing adults aged '\n",
      " '20 to 49 years would provide greater mortality benefits than would '\n",
      " 'prioritizing older adults.',\n",
      " 'One such regime was in the presence of substantial transmission-mitigating '\n",
      " 'interventions (R0 = 1.15) and a vaccine with 80% or higher '\n",
      " 'transmission-blocking effects.',\n",
      " 'A second regime was characterized by substantial transmission-mitigating '\n",
      " 'interventions (R0 = 1.15) and either rollout speeds of at most 0.2% per day '\n",
      " 'or vaccine supplies of at most 25% of the population.',\n",
      " 'The third regime was characterized by vaccines with very low efficacy in '\n",
      " 'older adults, very high efficacy in younger adults, and declines in efficacy '\n",
      " 'starting at age 59 or 69 years.',\n",
      " 'The advantage of prioritizing all adults or adults aged 20 to 49 versus 60+ '\n",
      " 'years was small under these conditions.',\n",
      " 'Thus, we conclude that for mortality reduction, prioritization of older '\n",
      " 'adults is a robust strategy that will be optimal or close to optimal to '\n",
      " 'minimize mortality for virtually all plausible vaccine characteristics.By '\n",
      " 'contrast, the ranking of infection-minimizing strategies for midepidemic '\n",
      " 'vaccination led to consistent recommendations to prioritize adults aged 20 '\n",
      " 'to 49 years across efficacy values and countries.',\n",
      " 'For pretransmission vaccination, prioritization shifted toward children and '\n",
      " 'teenagers for leaky vaccine efficacies 50% and below, which is in line with '\n",
      " 'prior work (7), as well as for vaccines with weak transmission-blocking '\n",
      " 'properties.',\n",
      " 'Because a vaccine is likely to have properties of both leaky and '\n",
      " 'all-or-nothing models, empirical data on vaccine performance could help '\n",
      " 'resolve this difference in model recommendations, although data are '\n",
      " 'difficult to obtain in practice [for example, (33, 34)].It is not yet clear '\n",
      " 'whether the first generation of COVID-19 vaccines will be approved '\n",
      " 'everywhere for the elderly or those under 18 years of age (35–37).',\n",
      " 'Although our conclusions assumed that the vaccine would be approved for all '\n",
      " 'age groups, the evaluation approaches introduced here can be tailored to '\n",
      " 'evaluate a subset of approaches restricted to those within the age groups '\n",
      " 'for which a vaccine is licensed, by using open-source tools such as those '\n",
      " 'that accompany this study.',\n",
      " 'Furthermore, although we considered three possible goals of '\n",
      " 'vaccination—minimizing cumulative incidence, mortality, or YLL—our framework '\n",
      " 'can be adapted to consider goals such as minimizing hospitalizations, '\n",
      " 'intensive care unit occupancy (7), or economic costs (10).We demonstrated '\n",
      " 'that there is value in pairing individual-level serological tests with '\n",
      " 'vaccination, even when accounting for the uncertainties in seroprevalence '\n",
      " 'estimates (32) and seroreversion (30).',\n",
      " 'The marginal gain in effective vaccine supply, relative to no serological '\n",
      " 'testing, must be weighed against the challenges of serological testing '\n",
      " 'before vaccination.',\n",
      " 'Serostatus itself is an imperfect indicator of protection, and the '\n",
      " 'relationship of prior infection, serostatus, and protection may change over '\n",
      " 'time (10, 27, 30, 31).',\n",
      " 'Delays in serological test results would impair vaccine distribution, but '\n",
      " 'partial seronegative-targeting effects might be realized if those with past '\n",
      " 'polymerase chain reaction (PCR)–confirmed infections voluntarily '\n",
      " 'deprioritized their own vaccinations.The best-performing strategies depend '\n",
      " 'on assumptions about the extent of a population’s interactions.',\n",
      " 'We used prepandemic contact matrices (38), reflecting the goal of a return '\n",
      " 'to prepandemic routines once a vaccine is available, but more recent '\n",
      " 'estimates of age-stratified contact rates could be valuable in modeling '\n",
      " 'midpandemic scenarios (39, 40).',\n",
      " 'Whether prepandemic or midpandemic contact estimates are representative of '\n",
      " 'contact patterns during vaccine rollout remains unknown and may vary on the '\n",
      " 'basis of numerous social, political, and other factors.',\n",
      " 'The scenarios modeled here did not incorporate explicit nonpharmaceutical '\n",
      " 'interventions, which might persist if vaccination coverage is incomplete, '\n",
      " 'but are implicitly represented in scenario 1 (R0 = 1.15).Our study relies on '\n",
      " 'estimates of other epidemiological parameters.',\n",
      " 'In local contexts, these include age-structured seroprevalence and IFR, '\n",
      " 'which vary by population (19, 20, 41).',\n",
      " 'Globally, key parameters include the degree to which antibodies protect '\n",
      " 'against reinfection or severity of disease and relative infectiousness by '\n",
      " 'age.',\n",
      " 'From vaccine trials, we also need evidence of efficacy in groups vulnerable '\n",
      " 'to severe outcomes, including the elderly.',\n",
      " 'Additionally, it will be critical to measure whether a vaccine that protects '\n",
      " 'against symptomatic disease also blocks infection and transmission of '\n",
      " 'SARS-CoV-2 (42).The role of children during this pandemic has been unclear.',\n",
      " 'Under our assumptions about susceptibility by age, children are not the '\n",
      " 'major drivers of transmission in communities, which is consistent with '\n",
      " 'emerging evidence (12).',\n",
      " 'Thus, our results differ from the optimal distribution for influenza '\n",
      " 'vaccines, which prioritize school-age children and adults aged 30 to 39 '\n",
      " 'years (5).',\n",
      " 'However, the relative susceptibility and infectiousness of SARS-CoV-2 by age '\n",
      " 'remain uncertain.',\n",
      " 'Although it is unlikely that susceptibility to infection conditional on '\n",
      " 'exposure is constant across age groups (12), we ran our model to test the '\n",
      " 'sensitivity of this parameter.',\n",
      " 'Under the scenario of constant susceptibility by age, vaccinating those '\n",
      " 'under 20 years of age has a greater impact on reducing cumulative cases than '\n",
      " 'vaccinating those aged 20 to 49 years (figs.',\n",
      " 'S14 and 15).Our study is subject to a number of limitations.',\n",
      " 'First, our evaluation strategy focuses on a single country at a time, rather '\n",
      " 'than on between-population allocation (43).',\n",
      " 'Second, we only consider variation in disease severity by age.',\n",
      " 'However, other factors correlate with disease outcomes, such as treatment '\n",
      " 'and health care access and comorbidities, which may correlate with factors '\n",
      " 'such as rural versus urban location, socioeconomic status, sex (44, 45), and '\n",
      " 'race and ethnicity (46), which are not accounted for in this study.',\n",
      " 'Inclusion of these factors in a model would be possible, but only with '\n",
      " 'statistically sound measurements of their stratified infection risk, contact '\n",
      " 'rates, and disease outcomes.',\n",
      " 'Even in the case of age stratification, contact surveys have typically not '\n",
      " 'surveyed those 80 years and older, yet it is this population that suffers '\n",
      " 'dramatically more severe COVID-19 disease and higher infection fatality '\n",
      " 'rates.',\n",
      " 'We extrapolated contact matrices to those older than 80, but direct '\n",
      " 'measurements would be superior.',\n",
      " 'Last, our study focused on guiding strategy rather than providing more '\n",
      " 'detailed forecasting or estimates (10).',\n",
      " 'As such, we have not made detailed parameter fits to time series of cases or '\n",
      " 'deaths but rather have used epidemiologic models to identify robust '\n",
      " 'strategies across a range of transmission scenarios.Our study also considers '\n",
      " 'variation in disease risk only by age, through age-structured contact '\n",
      " 'matrices and age-specific susceptibility, whereas many discussions around '\n",
      " 'COVID-19 vaccine distribution have thus far focused on prioritizing health '\n",
      " 'care or essential workers (47, 48).',\n",
      " 'Contact rates, and thus infection potential, vary greatly not only by '\n",
      " 'occupation and age but also by living arrangement (such as congregate '\n",
      " 'settings or dormitories), neighborhood and mobility (49–52), and whether the '\n",
      " 'population has a coordinated and fundamentally effective policy to control '\n",
      " 'the virus.',\n",
      " 'With a better understanding of population structure during the pandemic, and '\n",
      " 'risk factors of COVID-19, these limitations could be addressed.',\n",
      " 'Meanwhile, the robust findings in favor of prioritizing those age groups '\n",
      " 'with the highest IFR to minimize mortality could potentially be extended to '\n",
      " 'prioritize those with comorbidities that predispose them to a high IFR '\n",
      " 'because the strategy of prioritizing the older age groups depends on direct '\n",
      " 'rather than indirect protection.Vaccine prioritization is not solely a '\n",
      " 'question of science but a question of ethics as well.',\n",
      " 'Hallmarks of the COVID-19 pandemic, as with other global diseases, are '\n",
      " 'inequalities and disparities.',\n",
      " 'Although these modeling efforts focus on age and minimizing incidence and '\n",
      " 'death within a simply structured population, other considerations are '\n",
      " 'crucial, from equity in allocation between countries to disparities in '\n",
      " 'access to health care, including vaccination, that vary by neighborhood.',\n",
      " 'Thus, the model’s simplistic representation of vulnerability (age) should be '\n",
      " 'augmented by better information on the correlates of infection risk and '\n",
      " 'severity.',\n",
      " 'Fair vaccine prioritization should avoid further harming disadvantaged '\n",
      " 'populations.',\n",
      " 'We suggest that after distribution, pairing serological testing with '\n",
      " 'vaccination in the hardest-hit populations is one possible equitable way to '\n",
      " 'extend the benefits of vaccination in settings where vaccination might '\n",
      " 'otherwise not be deemed cost effective.Supplementary '\n",
      " 'Materialsscience.sciencemag.org/content/371/6532/916/suppl/DC1Materials and '\n",
      " 'MethodsSupplementary TextFigs.',\n",
      " 'S1 to S15Tables S1 and S2References (55–57)MDAR Reproducibility '\n",
      " 'Checklisthttps://creativecommons.org/licenses/by/4.0/This is an open-access '\n",
      " 'article distributed under the terms of the Creative Commons Attribution '\n",
      " 'license, which permits unrestricted use, distribution, and reproduction in '\n",
      " 'any medium, provided the original work is properly cited.References and '\n",
      " 'Notes↵Johns Hopkins University Coronavirus Research Center, COVID-19 '\n",
      " 'Dashboard by the Center for Systems Science and Engineering at Johns Hopkins '\n",
      " 'University (2020); https://coronavirus.jhu.edu/map.html.↵ R. Khamsi, ',\n",
      " 'Naturedoi:10.1038/d41586-020-01063-8pmid:32273621OpenUrlCrossRefPubMed↵National '\n",
      " 'Academies of Sciences, Engineering, and Medicine, Framework for Equitable '\n",
      " 'Allocation of COVID-19 Vaccine (National Academies Press, 2020); '\n",
      " 'https://doi.org/10.17226/25917.doi:10.17226/25917↵ D. Weycker,  J. '\n",
      " 'Edelsberg,  M. E. Halloran,  I. M. Longini Jr..,  A. Nizam,  V. Ciuryla,  G. '\n",
      " 'Oster, ',\n",
      " 'Vaccinedoi:10.1016/j.vaccine.2004.08.044pmid:15652671OpenUrlCrossRefPubMedWeb '\n",
      " 'of Science↵ J. Medlock,  A. P. Galvani, ',\n",
      " 'Sciencedoi:10.1126/science.1175570pmid:19696313OpenUrlAbstract/FREE Full '\n",
      " 'Text↵ S. Bansal,  B. Pourbohloul,  L. A. Meyers, ',\n",
      " 'PLOS Med.',\n",
      " 'doi:10.1371/journal.pmed.0030387pmid:17020406OpenUrlCrossRefPubMed↵L.',\n",
      " 'Matrajt, J. Eaton, T. Leung, E. R. Brown, Vaccine optimization for COVID-19: '\n",
      " 'who to vaccinate first?',\n",
      " 'medRxiv 20175257 [Preprint].',\n",
      " 'E. Gallagher et al., Considering indirect benefits is critical when '\n",
      " 'evaluating SARS-CoV-2 vaccine candidates.',\n",
      " 'medRxiv 20170456 [Preprint].',\n",
      " 'H. Buckner, G. Chowell, M. R. Springborn, Dynamic prioritization of COVID-19 '\n",
      " 'vaccines when social distancing is limited for essential workers.',\n",
      " 'medRxiv 20199174 [Preprint] 6 October 2020. '\n",
      " 'https://doi.org/10.1101/2020.09.22.20199174.doi:10.1101/2020.09.22.20199174OpenUrlAbstract/FREE '\n",
      " 'Full Text↵F.',\n",
      " 'Sandmann et al., The potential health and economic value of SARS-CoV-2 '\n",
      " 'vaccination alongside physical distancing in the UK: transmission '\n",
      " 'model-based future scenario analysis and economic evaluation.',\n",
      " 'medRxiv 20200857 [Preprint] 25 September 2020. '\n",
      " 'https://doi.org/10.1101/2020.09.24.20200857.doi:10.1101/2020.09.24.20200857OpenUrlAbstract/FREE '\n",
      " 'Full Text↵ C. J. Worby,  H.-H. Chang, ',\n",
      " 'Nat.',\n",
      " 'Commun.',\n",
      " 'doi:10.1038/s41467-020-17922-xpmid:32792562OpenUrlCrossRefPubMed↵ E. '\n",
      " 'Goldstein,  M. Lipsitch,  M. Cevik, ',\n",
      " 'J. Infect.',\n",
      " 'Dis.',\n",
      " 'doi:10.1093/infdis/jiaa691pmid:33119738OpenUrlCrossRefPubMed N. G. Davies,  '\n",
      " 'P. Klepac,  Y. Liu,  K. Prem,  M. Jit,  R. M. Eggo; CMMID COVID-19 working '\n",
      " 'group, ',\n",
      " 'Nat.',\n",
      " 'Med.',\n",
      " 'doi:10.1038/s41591-020-0962-9pmid:32546824OpenUrlCrossRefPubMed↵ J. Zhang,  '\n",
      " 'M. Litvinova,  Y. Liang,  Y. Wang,  W. Wang,  S. Zhao,  Q. Wu,  S. Merler,  '\n",
      " 'C. Viboud,  A. Vespignani,  M. Ajelli,  H. Yu, ',\n",
      " 'Sciencedoi:10.1126/science.abb8001pmid:32350060OpenUrlAbstract/FREE Full '\n",
      " 'Text↵S.',\n",
      " 'Herzog et al., Seroprevalence of IgG antibodies against SARS coronavirus 2 '\n",
      " 'in Belgium – a serial prospective cross-sectional nationwide study of '\n",
      " 'residual samples.',\n",
      " 'medRxiv 20125179 [Preprint] (2020).',\n",
      " 'https://doi.org/10.1101/2020.06.08.20125179.doi:10.1101/2020.06.08.20125179OpenUrlAbstract/FREE '\n",
      " 'Full Text↵ A. L. Mueller,  M. S. McNamara,  D. A. Sinclair, ',\n",
      " 'Aging (Albany NY)doi:10.18632/aging.103344pmid:32470948OpenUrlCrossRefPubMed '\n",
      " 'Y. Liu,  B. Mao,  S. Liang,  J. W. Yang,  H. W. Lu,  Y. H. Chai,  L. Wang,  '\n",
      " 'L. Zhang,  Q. H. Li,  L. Zhao,  Y.',\n",
      " 'He,  X. L. Gu,  X.',\n",
      " 'B. Ji,  L. Li,  Z. J. Jie,  Q. Li,  X. Y. Li,  H. Z. Lu,  W. H. Zhang,  Y. '\n",
      " 'L. Song,  J. M. Qu,  J. F. Xu, Shanghai Clinical Treatment Experts Group for '\n",
      " 'COVID-19, ',\n",
      " 'Eur.',\n",
      " 'Respir.',\n",
      " 'J.',\n",
      " 'doi:10.1183/13993003.01112-2020pmid:32312864OpenUrlAbstract/FREE Full Text↵ '\n",
      " 'J. Westmeier,  K. Paniskaki,  Z. Karaköse,  T. Werner,  K. Sutter,  S. '\n",
      " 'Dolff,  M. Overbeck,  A. Limmer,  J. Liu,  X. Zheng,  T. Brenner,  M. M. '\n",
      " 'Berger,  O. Witzke,  M. Trilling,  M. Lu,  D. Yang,  N. Babel,  T. '\n",
      " 'Westhoff,  U. Dittmer,  G. Zelinskyy, ',\n",
      " 'mBiopmid:32948688OpenUrlPubMed↵ A. T. Levin,  W. P. Hanage,  N. '\n",
      " 'Owusu-Boaitey,  K. B. Cochran,  S. P. Walsh,  G. Meyerowitz-Katz, ',\n",
      " 'Eur.',\n",
      " 'J. Epidemiol.',\n",
      " 'doi:10.1007/s10654-020-00698-1pmid:33289900OpenUrlCrossRefPubMed↵ H. Salje,  '\n",
      " 'C. Tran Kiem,  N. Lefrancq,  N. Courtejoie,  P. Bosetti,  J. Paireau,  A. '\n",
      " 'Andronico,  N. Hozé,  J. Richet,  C.-L. Dubost,  Y.',\n",
      " 'Le Strat,  J. Lessler,  D. Levy-Bruhl,  A. Fontanet,  L. Opatowski,  P.-Y.',\n",
      " 'Boelle,  S. Cauchemez, ',\n",
      " 'Sciencedoi:10.1126/science.abc3517pmid:32404476OpenUrlAbstract/FREE Full '\n",
      " 'Text↵K.',\n",
      " 'M. Bubar et al., kbubar/vaccine_prioritization: Updated code for published '\n",
      " 'paper.',\n",
      " 'Zenodo (2020).doi:10.5281/zenodo.4308794↵M.',\n",
      " 'Brenan, Willingness to Get COVID-19 Vaccine Ticks Up to 63% in U.S., Online '\n",
      " '(8 December 2020); '\n",
      " 'https://news.gallup.com/poll/327425/willingness-covid-vaccine-ticks.aspx.↵ '\n",
      " 'P. A.',\n",
      " 'Gross,  A. W. Hermogenes,  H. S. Sacks,  J. Lau,  R. A. Levandowski, ',\n",
      " 'A meta-analysis and review of the literature.',\n",
      " 'Ann.',\n",
      " 'Intern.',\n",
      " 'Med.',\n",
      " 'doi:10.7326/0003-4819-123-7-199510010-00008pmid:7661497OpenUrlCrossRefPubMedWeb '\n",
      " 'of Science J. K. H. Lee,  G. K. L. Lam,  T. Shin,  J. Kim,  A. Krishnan,  D. '\n",
      " 'P. Greenberg,  A. Chit, ',\n",
      " 'Expert Rev.',\n",
      " 'Vaccinesdoi:10.1080/14760584.2018.1471989pmid:29715054OpenUrlCrossRefPubMed '\n",
      " 'T. M. E. Govaert,  C. T. Thijs,  N. Masurel,  M. J. Sprenger,  G. J. '\n",
      " 'Dinant,  J.',\n",
      " 'A. Knottnerus, ',\n",
      " 'A randomized double-blind placebo-controlled trial.',\n",
      " 'JAMAdoi:10.1001/jama.1994.03520210045030pmid:7966893OpenUrlCrossRefPubMedWeb '\n",
      " 'of Science↵ J.',\n",
      " 'A. Lewnard,  S. Cobey, ',\n",
      " 'Vaccinesdoi:10.3390/vaccines6020028pmid:29883414OpenUrlCrossRefPubMed↵ S. F. '\n",
      " 'Lumley et al., N. Engl.',\n",
      " 'J. Med.',\n",
      " 'Med.',\n",
      " 'Ward et al., Declining prevalence of antibody positivity to SARS-CoV-2: a '\n",
      " 'community study of 365,000 adults.',\n",
      " 'medRxiv 20219725 [Preprint] 27 October 2020. '\n",
      " 'https://doi.org/10.1101/2020.10.26.20219725.doi:10.1101/2020.10.26.20219725OpenUrlAbstract/FREE '\n",
      " 'Full Text↵J.',\n",
      " 'M. Dan et al., Immunological memory to SARS-CoV-2 assessed for up to eight '\n",
      " 'months after infection.',\n",
      " 'bioRxiv 383323 [Preprint] 18 December 2020. '\n",
      " 'https://doi.org/10.1101/2020.11.15.383323.doi:10.1101/2020.11.15.383323OpenUrlAbstract/FREE '\n",
      " 'Full Text↵D.',\n",
      " 'B. Larremore et al., Estimating SARS-CoV-2 seroprevalence and '\n",
      " 'epidemiological parameters with uncertainty from serological surveys.',\n",
      " 'medRxiv 20067066 [Preprint] 22 June 2020. '\n",
      " 'https://doi.org/10.1101/2020.04.15.20067066.doi:10.1101/2020.04.15.20067066OpenUrlAbstract/FREE '\n",
      " 'Full Text↵ D. Ellenberger,  R. A. Otten,  B. Li,  M. Aidoo,  I. V. '\n",
      " 'Rodriguez,  C. A. Sariol,  M. Martinez,  M. Monsour,  L. Wyatt,  M. G. '\n",
      " 'Hudgens,  E. Kraiselburd,  B. Moss,  H. Robinson,  T. Folks,  S. Butera, ',\n",
      " 'Virologydoi:10.1016/j.virol.2006.04.005pmid:16725169OpenUrlCrossRefPubMedWeb '\n",
      " 'of Science↵ K. E. Langwig,  A. R. Wargo,  D. R. Jones,  J. R. Viss,  B. J. '\n",
      " 'Rutan,  N. A. Egan,  P. Sá-Guimarães,  M. S. Kim,  G. Kurath,  M. G. M. '\n",
      " 'Gomes,  M. Lipsitch, ',\n",
      " 'mBiodoi:10.1128/mBio.00796-17pmid:29162706OpenUrlAbstract/FREE Full Text↵P.',\n",
      " 'Span, “Older adults may be left out of some COVID-19 trials,” The New York '\n",
      " 'Times 19 June 2020; '\n",
      " 'https://www.nytimes.com/2020/06/19/health/vaccine-trials-elderly.html.',\n",
      " 'H. R. Sharpe,  C. Gilbride,  E. Allen,  S. Belij-Rammerstorfer,  C. '\n",
      " 'Bissett,  K. Ewer,  T. Lambe, ',\n",
      " 'Immunologydoi:10.1111/imm.13222pmid:32460358OpenUrlCrossRefPubMed↵M.',\n",
      " 'Kornfield, “When will children get a coronavirus vaccine?Not in time for the '\n",
      " 'new school year, experts fear,” The Washington Post 2 December 2020; '\n",
      " 'www.washingtonpost.com/health/2020/12/02/kids-vaccine-delay.↵K.',\n",
      " 'Prem et al., Projecting contact matrices in 177 geographical regions: an '\n",
      " 'update and comparison with empirical data for the COVID-19 era.',\n",
      " 'medRxiv 20159772 [Preprint] (2020); '\n",
      " 'https://doi.org/10.1101/2020.07.22.20159772.doi:10.1101/2020.07.22.20159772OpenUrlAbstract/FREE '\n",
      " 'Full Text↵ C. I. Jarvis,  K. Van Zandvoort,  A. Gimma,  K. Prem,  P. '\n",
      " 'Klepac,  G. J. Rubin,  W. J. Edmunds; CMMID COVID-19 working group, ',\n",
      " 'BMC Med.',\n",
      " 'doi:10.1186/s12916-020-01597-8pmid:32375776OpenUrlCrossRefPubMed↵J.',\n",
      " 'A.',\n",
      " 'Backer et al., The impact of physical distancing measures against COVID-19 '\n",
      " 'transmission on contacts and mixing patterns in the Netherlands: repeated '\n",
      " 'cross-sectional surveys in 2016/2017, April 2020 and June 2020. medRxiv '\n",
      " '20101501 [Preprint] 16 October 2020. '\n",
      " 'https://doi.org/10.1101/2020.05.18.20101501.doi:10.1101/2020.05.18.20101501OpenUrlAbstract/FREE '\n",
      " 'Full Text↵S.',\n",
      " 'Ghisolfi et al., “Predicted COVID-19 fatality rates based on age, sex, '\n",
      " 'comorbidities, and health system capacity,” working paper (Center for Global '\n",
      " 'Development, 2020).↵ M. Lipsitch,  N. E. Dean, ',\n",
      " 'Sciencedoi:10.1126/science.abe5938pmid:33087460OpenUrlAbstract/FREE Full '\n",
      " 'Text↵ L. E. Duijzer,  W. L. van Jaarsveld,  J. Wallinga,  R. Dekker, ',\n",
      " 'Prod.',\n",
      " 'Oper.',\n",
      " 'Manag.',\n",
      " 'doi:10.1111/poms.12788pmid:32327917OpenUrlCrossRefPubMed↵ T. Takahashi,  M. '\n",
      " 'K. Ellingson,  P. Wong,  B. Israelow,  C. Lucas,  J. Klein,  J. Silva,  T. '\n",
      " 'Mao,  J. E. Oh,  M. Tokuyama,  P. Lu,  A. Venkataraman,  A.',\n",
      " 'Park,  F. Liu,  A. Meir,  J.',\n",
      " 'Sun,  E. Y. Wang,  A. Casanovas-Massana,  A. L. Wyllie,  C. B. F. Vogels,  '\n",
      " 'R. Earnest,  S. Lapidus,  I. M. Ott,  A. J. Moore,  A. Shaw,  J.',\n",
      " 'B. Fournier,  C. D. Odio,  S. Farhadian,  C. Dela Cruz,  N. D. Grubaugh,  W. '\n",
      " 'L. Schulz,  A. M. Ring,  A. I. Ko,  S. B. Omer,  A. Iwasaki; Yale IMPACT '\n",
      " 'Research Team, ',\n",
      " 'Naturedoi:10.1038/s41586-020-2700-3pmid:32846427OpenUrlCrossRefPubMed↵ D. '\n",
      " 'Chakravarty,  S. S. Nair,  N. Hammouda,  P. Ratnani,  Y. Gharib,  V. '\n",
      " 'Wagaskar,  N. Mohamed,  D. Lundon,  Z. Dovey,  N. Kyprianou,  A. K. Tewari, ',\n",
      " 'Commun.',\n",
      " 'Biol.',\n",
      " 'doi:10.1038/s42003-020-1088-9pmid:32641750OpenUrlCrossRefPubMed↵ M. Webb '\n",
      " 'Hooper,  A. M. Nápoles,  E. J. Pérez-Stable, ',\n",
      " 'JAMAdoi:10.1001/jama.2020.8598pmid:32391864OpenUrlCrossRefPubMed↵M.',\n",
      " 'Jenco, “CDC vaccine committee may prioritize health care workers for '\n",
      " 'COVID-19 vaccines,”AAP News 27 August 2020; '\n",
      " 'https://www.aappublications.org/news/2020/08/27/covid19vaccinepriorities082620.↵ '\n",
      " 'J. Cohen, ',\n",
      " 'Sciencedoi:10.1126/science.369.6499.15pmid:32631874OpenUrlAbstract/FREE Full '\n",
      " 'Text↵ S. Mishra,  J. C. Kwong,  A. K. Chan,  S. D. Baral, ',\n",
      " 'CMAJdoi:10.1503/cmaj.201112pmid:32493741OpenUrlFREE Full Text L. Hawks,  S. '\n",
      " 'Woolhandler,  D. McCormick, ',\n",
      " 'JAMA Intern.',\n",
      " 'Med.',\n",
      " 'doi:10.1001/jamainternmed.2020.1856pmid:32343355OpenUrlCrossRefPubMed H. S. '\n",
      " 'Badr et al., Lancet Infect.',\n",
      " 'Dis.',\n",
      " 'Ducharme, “These maps show how drastically COVID-19 risk varies by '\n",
      " 'neighborhood,” Time 22 July 2020; '\n",
      " 'https://time.com/5870041/COVID-19-neighborhood-risk.↵United Nations '\n",
      " 'Department of Economic and Social Affairs Population Division, World '\n",
      " 'population prospects (2019); https://population.un.org/wpp.↵ C. H. '\n",
      " 'GeurtsvanKessel,  N. M. A. Okba,  Z. Igloi,  S. Bogers,  C. W. E. Embregts,  '\n",
      " 'B. M. Laksono,  L. Leijten,  C. Rokx,  B. Rijnders,  J. Rahamat-Langendoen,  '\n",
      " 'J. P. C. van den Akker,  J. J.',\n",
      " 'A. van Kampen,  A.',\n",
      " 'A. van der Eijk,  R. S. van Binnendijk,  B. Haagmans,  M. Koopmans, ',\n",
      " 'Nat.',\n",
      " 'Commun.',\n",
      " 'doi:10.1038/s41467-020-17317-ypmid:32632160OpenUrlCrossRefPubMed↵R Core '\n",
      " 'Team, R: A Language and Environment for Statistical Computing (R Foundation '\n",
      " 'for Statistical Computing, 2019).K.',\n",
      " 'E. Atkinson, An Introduction to Numerical Analysis (Wiley, 1989), chap.',\n",
      " 'Funding: K.M.B.',\n",
      " 'was supported in part by the Interdisciplinary Quantitative Biology (IQ '\n",
      " 'Biology) Ph.D. program at the BioFrontiers Institute, University of Colorado '\n",
      " 'Boulder.',\n",
      " 'K.M.B.',\n",
      " 'and D.B.L.',\n",
      " 'were supported in part through the MIDAS Coordination Center (MIDASNI2020-2) '\n",
      " 'by a grant from the National Institute of General Medical Science '\n",
      " '(3U24GM132013-02S2).',\n",
      " 'M.L., S.M.K., and Y.H.G.',\n",
      " 'were supported in part by the Morris-Singer Fund for the Center for '\n",
      " 'Communicable Disease Dynamics at the Harvard T. H. Chan School of Public '\n",
      " 'Health.',\n",
      " 'M.L.',\n",
      " 'and D.B.L.',\n",
      " 'were supported in part by the SeroNet program of the National Cancer '\n",
      " 'Institute (1U01CA261277-01).',\n",
      " 'Author contributions: K.M.B., S.M.K., M.L., S.C., Y.H.G., and D.B.L.',\n",
      " 'conceived of the study.',\n",
      " 'K.M.B.',\n",
      " 'and D.B.L.',\n",
      " 'performed the analyses.',\n",
      " 'K.M.B.',\n",
      " 'and K.R.',\n",
      " 'generated all figures.',\n",
      " 'K.R.',\n",
      " 'created interactive visualization tools.',\n",
      " 'All authors wrote and revised the manuscript.',\n",
      " 'Competing interests: M.L.',\n",
      " 'discloses honoraria from and consulting for Merck, Affinivax, '\n",
      " 'Sanofi-Pasteur, Bristol Myers Squibb, and Antigen Discovery; research '\n",
      " 'funding (institutional) from Pfizer; and unpaid scientific advice to '\n",
      " 'Janssen, Astra-Zeneca, and Covaxx (United Biomedical); M.L.',\n",
      " 'is an honorary faculty member, Wellcome Sanger Institute, and an associate '\n",
      " 'member, Broad Institute.',\n",
      " 'Y.H.G.',\n",
      " 'discloses consulting for Merck and GlaxoSmithKline, and research funding '\n",
      " 'from Pfizer not related to this project or topic.',\n",
      " 'D.B.L.',\n",
      " 'is a member of the scientific advisory board of Darwin BioSciences.',\n",
      " 'Data and materials availability: Reproduction code is open source and '\n",
      " 'provided by the authors (21).',\n",
      " 'This work is licensed under a Creative Commons Attribution 4.0 International '\n",
      " '(CC BY 4.0) license, which permits unrestricted use, distribution, and '\n",
      " 'reproduction in any medium, provided the original work is properly cited.',\n",
      " 'To view a copy of this license, visit '\n",
      " 'https://creativecommons.org/licenses/by/4.0/.',\n",
      " 'This license does not apply to figures/photos/artwork or other content '\n",
      " 'included in the article that is credited to a third party; obtain '\n",
      " 'authorization from the rights holder before using such material.',\n",
      " 'ScienceWe do not capture any email address.',\n",
      " 'AAAS is a partner of\\xa0HINARI,\\xa0AGORA, OARE, CHORUS,\\xa0CLOCKSS,\\xa0'\n",
      " 'CrossRef\\xa0and\\xa0COUNTER.',\n",
      " 'Science ISSN 1095-9203.',\n",
      " 'Saving Lives, Protecting PeopleWhen germs, such as the virus that causes '\n",
      " 'COVID-19, invade our bodies, they attack and multiply.',\n",
      " 'This invasion, called an infection, is what causes illness.',\n",
      " 'Our immune system uses several tools to fight infection.',\n",
      " 'Blood contains red cells, which carry oxygen to tissues and organs, and '\n",
      " 'white or immune cells, which fight infection.',\n",
      " 'Different types of white blood cells fight infection in different ways:The '\n",
      " 'macrophages leave behind parts of the invading germs called antigens.',\n",
      " 'The body identifies antigens as dangerous and stimulates antibodies to '\n",
      " 'attack them.',\n",
      " 'B-lymphocytes\\xa0are defensive white blood cells.',\n",
      " 'They produce antibodies that attack the pieces of the virus left behind by '\n",
      " 'the macrophages.',\n",
      " 'T-lymphocytes\\xa0are another type of defensive white blood cell.',\n",
      " 'They attack cells in the body that have already been infected.',\n",
      " 'The first time a person is infected with the virus that causes COVID-19, it '\n",
      " 'can take several days or weeks for their body to make and use all the '\n",
      " 'germ-fighting tools needed to get over the infection.',\n",
      " 'After the infection, the person’s immune system remembers what it learned '\n",
      " 'about how to protect the body against that disease.',\n",
      " 'The body keeps a few T-lymphocytes, called memory cells, that go into action '\n",
      " 'quickly if the body encounters the same virus again.',\n",
      " 'When the familiar antigens are detected, B-lymphocytes produce antibodies to '\n",
      " 'attack them.',\n",
      " 'Experts are still learning how long these memory cells protect a person '\n",
      " 'against the virus that causes COVID-19.',\n",
      " 'How COVID-19 Vaccines WorkDifferent types of vaccines work in different ways '\n",
      " 'to offer protection, but with all types of vaccines, the body is left with a '\n",
      " 'supply of “memory” T-lymphocytes as well as B-lymphocytes that will remember '\n",
      " 'how to fight that virus in the future.',\n",
      " 'It typically takes a few weeks for the body to produce T-lymphocytes and '\n",
      " 'B-lymphocytes after vaccination.',\n",
      " 'Therefore, it is possible that a person could be infected with the virus '\n",
      " 'that causes COVID-19 just before or just after vaccination and then get sick '\n",
      " 'because the vaccine did not have enough time to provide protection.',\n",
      " 'Sometimes after vaccination, the process of building immunity can cause '\n",
      " 'symptoms, such as fever.',\n",
      " 'These symptoms are normal and are a sign that the body is building immunity.',\n",
      " 'Types of VaccinesBelow is a description of how each type of vaccine prompts '\n",
      " 'our bodies to recognize and protect us from the virus that causes COVID-19.',\n",
      " 'None of these vaccines can give you COVID-19.',\n",
      " 'mRNA vaccines contain material from the virus that causes COVID-19 that '\n",
      " 'gives our cells instructions for how to make a harmless protein that is '\n",
      " 'unique to the virus.',\n",
      " 'After our cells make copies of the protein, they destroy the genetic '\n",
      " 'material from the vaccine.',\n",
      " 'Our bodies recognize that the protein should not be there and build '\n",
      " 'T-lymphocytes and B-lymphocytes that will remember how to fight the virus '\n",
      " 'that causes COVID-19 if we are infected in the future.',\n",
      " 'Protein subunit vaccines include harmless pieces (proteins) of the virus '\n",
      " 'that cause COVID-19 instead of the entire germ.',\n",
      " 'Once vaccinated, our immune system recognizes that the proteins don’t belong '\n",
      " 'in the body and begins making T-lymphocytes and\\xa0antibodies.',\n",
      " 'If we are ever infected in the future, memory cells will recognize and fight '\n",
      " 'the virus.',\n",
      " 'Vector vaccines contain a weakened version of a live virus—a different virus '\n",
      " 'than the one that causes COVID-19—that has genetic material from the virus '\n",
      " 'that causes COVID-19 inserted in it (this is called a viral vector).',\n",
      " 'Once the viral vector is inside our cells, the genetic material gives cells '\n",
      " 'instructions to make a protein that is unique to the virus that causes '\n",
      " 'COVID-19.',\n",
      " 'Using these instructions, our cells make copies of the protein.',\n",
      " 'This prompts our bodies to build T-lymphocytes and B-lymphocytes that will '\n",
      " 'remember how to fight that virus if we are infected in the future.',\n",
      " 'Most COVID-19 Vaccines Require More Than One ShotThe first shot starts '\n",
      " 'building protection.',\n",
      " 'A second shot a few weeks later is needed to get the most protection the '\n",
      " 'vaccine has to offer.',\n",
      " 'One vaccine in Phase 3 clinical trials only needs one shot.',\n",
      " 'The Bottom LineProtection from COVID-19 is critically important because for '\n",
      " 'some people, it can cause severe illness or death.',\n",
      " 'Stopping a pandemic requires using all the tools available.',\n",
      " 'Vaccines work with your immune system so your body will be ready to fight '\n",
      " 'the virus if you are exposed.',\n",
      " 'Other steps, like masks and social distancing, help reduce your chance of '\n",
      " 'being exposed to the virus or spreading it to others.',\n",
      " 'Together, COVID-19 vaccination and following CDC’s recommendations to '\n",
      " 'protect yourself and others will offer the best protection from COVID-19.',\n",
      " 'Visit CDC-INFOThe Centers for Disease Control and Prevention (CDC) cannot '\n",
      " 'attest to the accuracy of a non-federal website.',\n",
      " 'Linking to a non-federal website does not constitute an endorsement by CDC '\n",
      " 'or any of its employees of the sponsors or the information and products '\n",
      " 'presented on the website.',\n",
      " \"You will be subject to the destination website's privacy policy when you \"\n",
      " 'follow the link.',\n",
      " 'CDC is not responsible for Section 508 compliance (accessibility) on other '\n",
      " 'federal or private website.',\n",
      " \"For more information on CDC's web notification policies, see Website \"\n",
      " 'Disclaimers.',\n",
      " 'CancelIt gives you the best protection against coronavirus.',\n",
      " 'It will be offered to more people over time.',\n",
      " \"More centres are opening all the time.</p><p>It's being given \"\n",
      " 'to:</p><ul><li>people aged 60 and over</li><li>people at <a '\n",
      " 'href=\\\\\"/conditions/coronavirus-covid-19/people-at-higher-risk/whos-at-higher-risk-from-coronavirus/\\\\\">high '\n",
      " 'risk from coronavirus</a> (clinically extremely vulnerable)</li><li>people '\n",
      " 'who live or work in care homes</li><li>health and social care '\n",
      " 'workers</li><li>people with a condition that puts them at higher risk '\n",
      " '(clinically vulnerable)</li><li>people who are a main carer for someone at '\n",
      " 'high risk from coronavirus</li></ul>\", \"title\": \"Who can get the COVID-19 '\n",
      " 'vaccine\", \"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/#suitability\"}, '\n",
      " '{\"@type\": \"WebPageElement\", \"description\": \"The coronavirus (COVID-19) '\n",
      " 'vaccine is given as an injection.',\n",
      " 'There are 2 doses given 3 to 12 weeks apart.',\n",
      " 'You will have the 2nd dose 3 to 12 weeks after having the 1st dose.</p>\", '\n",
      " '\"title\": \"How the COVID-19 vaccine is given\", \"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/#dosage-and-administration\"}, '\n",
      " '{\"@type\": \"WebPageElement\", \"description\": \"If you\\\\u2019re eligible, you '\n",
      " 'can book your coronavirus (COVID-19) vaccination appointments online at '\n",
      " 'www.nhs.uk/covid-vaccination or by calling 119.',\n",
      " 'The MHRA follows international standards of safety.</p><p>Other vaccines are '\n",
      " 'being developed.',\n",
      " 'They will only be available on the NHS once they have been thoroughly tested '\n",
      " 'to make sure they are safe and effective.</p><p>So far, millions of people '\n",
      " 'have been given a COVID-19 vaccine and reports of serious side effects, such '\n",
      " 'as allergic reactions, have been very rare.',\n",
      " 'No long-term complications have been reported.</p>\", \"title\": \"How safe is '\n",
      " 'the COVID-19 vaccine?',\n",
      " 'But you need to have the 2 doses of the vaccine to give you longer lasting '\n",
      " 'protection.</p><p>There is a chance you might still get or spread '\n",
      " 'coronavirus even if you have the vaccine.</p><p>This means it is important '\n",
      " 'to:</p><ul><li>continue to follow <a '\n",
      " 'href=\\\\\"/conditions/coronavirus-covid-19/social-distancing/what-you-need-to-do/\\\\\">social '\n",
      " 'distancing guidance</a></li><li>if you can, wear something that covers your '\n",
      " \"nose and mouth in places where it's hard to stay away from other \"\n",
      " 'people</li></ul>\", \"title\": \"How effective is the COVID-19 vaccine?',\n",
      " 'If you do have a reaction to the vaccine, it usually happens in minutes.',\n",
      " 'Staff giving the vaccine are trained to deal with allergic reactions and '\n",
      " 'treat them immediately.</p>\", \"title\": \"COVID-19 vaccine side effects\", '\n",
      " '\"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/#side-effects\"}], '\n",
      " '\"lastReviewed\": [\"2021-02-26T08:10:00+00:00\", \"2021-03-12T18:10:00+00:00\"], '\n",
      " '\"license\": \"https://developer.api.nhs.uk/terms\", \"name\": \"Coronavirus '\n",
      " '(COVID-19) vaccine\", \"relatedLink\": [{\"@type\": \"LinkRole\", '\n",
      " '\"linkRelationship\": \"Navigation\", \"name\": \"Coronavirus vaccination\", '\n",
      " '\"position\": 0, \"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/\"}, '\n",
      " '{\"@type\": \"LinkRole\", \"linkRelationship\": \"Navigation\", \"name\": \"Coronavirus '\n",
      " '(COVID-19) vaccine\", \"position\": 1, \"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/\"}, '\n",
      " '{\"@type\": \"LinkRole\", \"linkRelationship\": \"Navigation\", \"name\": \"Who can get '\n",
      " 'the coronavirus (COVID-19) vaccine\", \"position\": 2, \"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/who-can-get-the-vaccine/\"}, '\n",
      " '{\"@type\": \"LinkRole\", \"linkRelationship\": \"Navigation\", \"name\": \"How you '\n",
      " 'will be contacted for your coronavirus (COVID-19) vaccination\", \"position\": '\n",
      " '3, \"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/how-you-will-be-contacted/\"}, '\n",
      " '{\"@type\": \"LinkRole\", \"linkRelationship\": \"Navigation\", \"name\": \"Book or '\n",
      " 'manage your coronavirus vaccination\", \"position\": 4, \"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/book-coronavirus-vaccination/\"}, '\n",
      " '{\"@type\": \"LinkRole\", \"linkRelationship\": \"Navigation\", \"name\": \"What '\n",
      " 'happens at your appointment\", \"position\": 5, \"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/what-happens-at-your-appointment/\"}, '\n",
      " '{\"@type\": \"LinkRole\", \"linkRelationship\": \"Navigation\", \"name\": \"Health '\n",
      " 'conditions and coronavirus (COVID-19) vaccination\", \"position\": 6, \"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/health-conditions/\"}], '\n",
      " '\"schemaVersion\": [\"http://schema.org/version/3.9/\", \"g-20190515\"], \"url\": '\n",
      " '\"https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/\"}',\n",
      " 'It gives you the best protection against coronavirus.',\n",
      " \"Who can get the COVID-19 vaccineMore centres are opening all the time.It's \"\n",
      " 'being given to:people aged 60 and overpeople at high risk from coronavirus '\n",
      " '(clinically extremely vulnerable)people who live or work in care homeshealth '\n",
      " 'and social care workerspeople with a condition that puts them at higher risk '\n",
      " '(clinically vulnerable)people who are a main carer for someone at high risk '\n",
      " 'from coronavirus',\n",
      " \"The NHS will let you know when it's your turn to have the vaccine.\",\n",
      " \"It's important not to contact the NHS for a vaccination before then.\",\n",
      " \"Advice if you're of childbearing age, pregnant or breastfeedingBut more \"\n",
      " 'evidence is needed before you can routinely be offered it.The JCVI has '\n",
      " 'updated its advice to recommend you may be able to have the vaccine if '\n",
      " \"you're pregnant and:at high risk of getting coronavirus because of where you \"\n",
      " \"workhave a health condition that means you're at high risk of serious \"\n",
      " \"complications of coronavirusYou can have the COVID-19 vaccine if you're \"\n",
      " 'breastfeeding.Speak to a healthcare professional before you have the '\n",
      " 'vaccination.',\n",
      " 'They will discuss the benefits and risks with you.You do not need to avoid '\n",
      " 'pregnancy after vaccination.',\n",
      " 'The vaccine cannot give you or your baby COVID-19.Read the latest COVID-19 '\n",
      " \"vaccine advice if you're pregnant, may get pregnant or are breastfeeding on \"\n",
      " 'GOV.UKRead the latest Royal College of Obstetricians and Gynaecologists and '\n",
      " 'Royal College of Midwives statement on the COVID-19 vaccine and fertility',\n",
      " 'You will have the 2nd dose 3 to 12 weeks after having the 1st dose.',\n",
      " 'The MHRA follows international standards of safety.Other vaccines are being '\n",
      " 'developed.',\n",
      " 'They will only be available on the NHS once they have been thoroughly tested '\n",
      " 'to make sure they are safe and effective.So far, millions of people have '\n",
      " 'been given a COVID-19 vaccine and reports of serious side effects, such as '\n",
      " 'allergic reactions, have been very rare.',\n",
      " 'No long-term complications have been reported.',\n",
      " 'To find out more about the vaccines approved in the UK, see:GOV.UK: '\n",
      " 'Pfizer/BioNTech vaccine for COVID-19 approved by MHRAGOV.UK: '\n",
      " 'Oxford/AstraZeneca vaccine for COVID-19 approved by MHRAGOV.UK: Moderna '\n",
      " 'vaccine for COVID-19 approved by MHRA',\n",
      " 'The 1st dose of the COVID-19 vaccine should give you good protection from '\n",
      " 'coronavirus.',\n",
      " 'But you need to have the 2 doses of the vaccine to give you longer lasting '\n",
      " 'protection.There is a chance you might still get or spread coronavirus even '\n",
      " 'if you have the vaccine.This means it is important to:continue to follow '\n",
      " 'social distancing guidanceif you can, wear something that covers your nose '\n",
      " \"and mouth in places where it's hard to stay away from other people\",\n",
      " 'COVID-19 vaccine side effectsIf you do have a reaction to the vaccine, it '\n",
      " 'usually happens in minutes.',\n",
      " 'Staff giving the vaccine are trained to deal with allergic reactions and '\n",
      " 'treat them immediately.',\n",
      " 'Spring 2021 is the best estimate of when vaccines will be available for the '\n",
      " 'general public.',\n",
      " 'Availability will depend on vaccine supply.',\n",
      " 'Check back here for updates.',\n",
      " 'Do not show up at a hub or provider looking for a vaccine.',\n",
      " 'Instead, check the provider’s website.',\n",
      " 'Call only if the website doesn’t answer your questions.',\n",
      " 'Do you know someone who is eligible for a vaccine but doesn’t have internet '\n",
      " 'access?Please let them know they can call 2‑1‑1 for referral to a local '\n",
      " 'vaccine provider.',\n",
      " 'Vaccine supply is still limited in Texas, but more arrives each week.',\n",
      " 'Important to KnowIt’s best if you get your second dose from the same brand '\n",
      " 'as your first dose.',\n",
      " 'For example, if you got a Moderna first dose, it’s best to get Moderna for '\n",
      " 'your second dose.',\n",
      " 'The timing between your first and second dose depends on which vaccine you '\n",
      " 'received:The chance of a severe reaction is less than 0.5%.',\n",
      " 'To be safe, your provider will have you wait on-site for 15-30 minutes after '\n",
      " 'your shot.',\n",
      " \"V-safe: Register with CDC's V-safe After Vaccination Health Checker on your \"\n",
      " 'smartphone to report any side effects after getting the COVID-19 vaccine.',\n",
      " 'You’ll also get reminders for your second vaccine dose.',\n",
      " 'Texas Vaccine Rollout TimelineSpring 2021 is the best estimate of when '\n",
      " 'vaccine will be available for the general public, but that may change.',\n",
      " 'It depends on vaccine production and how quickly other vaccines become '\n",
      " 'available.']\n"
     ]
    }
   ],
   "source": [
    "i = 0\n",
    "clean_sents_2 = []\n",
    "while i < len(clean_sents)-1:\n",
    "  if '.' in clean_sents[i]:\n",
    "    clean_sents_2.append(clean_sents[i])\n",
    "    i += 1\n",
    "  elif '.' in clean_sents[i+1]:\n",
    "    clean_sents_2.append(clean_sents[i]+clean_sents[i+1])\n",
    "    i += 2\n",
    "  else:\n",
    "    j = i + 2\n",
    "    while j < len(clean_sents)-1:\n",
    "      if '.' in clean_sents[j]:\n",
    "        i = j+1\n",
    "        break\n",
    "      j += 1\n",
    "pprint.pprint(clean_sents_2)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "PNk3G1cxhbEL"
   },
   "source": [
    "### 2.3 Clean the data - 3\n",
    "\n",
    "We will only keep the sentences that the length greater than 65. \n",
    "We will delete the sentences which are url."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "ry525OLlhulq",
    "outputId": "f711a938-7557-44ac-b367-dea7ae84223b",
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['As of February\\xa02021[update], eleven vaccines are authorized by at least '\n",
      " 'one national regulatory authority for public use: two RNA vaccines (the '\n",
      " 'Pfizer–BioNTech vaccine and the Moderna vaccine), four conventional '\n",
      " 'inactivated vaccines (BBIBP-CorV, Covaxin, CoronaVac, and CoviVac), four '\n",
      " 'viral vector vaccines (Sputnik V, the Oxford–AstraZeneca vaccine, '\n",
      " 'Convidicea, and the Johnson & Johnson vaccine), and one peptide vaccine '\n",
      " '(EpiVacCorona).',\n",
      " 'Moderna targets producing 600 million doses and Convidicea 500 million doses '\n",
      " 'in 2021.',\n",
      " 'Prior to COVID‑19, a vaccine for an infectious disease had never been '\n",
      " 'produced in less than several years—and no vaccine existed for preventing a '\n",
      " 'coronavirus infection in humans.',\n",
      " 'Vaccines against SARS[12] and MERS[13] have been tested in non-human '\n",
      " 'animals.',\n",
      " 'According to studies published in 2005 and 2006, the identification and '\n",
      " 'development of novel vaccines and medicines to treat SARS was a priority for '\n",
      " 'governments and public health agencies around the world at that time.',\n",
      " 'The rapid development and urgency of producing a vaccine for the COVID‑19 '\n",
      " 'pandemic may increase the risks and failure rate of delivering a safe, '\n",
      " 'effective vaccine.',\n",
      " 'It comprises four pillars, each managed by two to three collaborating '\n",
      " 'partners: Vaccines (also called \"COVAX\"), Diagnostics, Therapeutics, and '\n",
      " 'Health Systems Connector.',\n",
      " 'The WHO vaccine coalition will prioritize which vaccines should go into '\n",
      " 'Phase II and III clinical trials, and determine harmonized Phase\\xa0III '\n",
      " 'protocols for all vaccines achieving the pivotal trial stage.',\n",
      " 'Canada announced funding for 96 research vaccine research projects at '\n",
      " 'Canadian companies and universities, with plans to establish a \"vaccine '\n",
      " 'bank\" that could be used if another coronavirus outbreak occurs,[46] and to '\n",
      " 'support clinical trials and develop manufacturing and supply chains for '\n",
      " 'vaccines.',\n",
      " 'It encompassed every phase of development from research to manufacturing.',\n",
      " 'Bahrain and the United Arab Emirates granted emergency marketing '\n",
      " 'authorization for BBIBP-CorV, manufactured by Sinopharm.',\n",
      " 'Messenger RNA contained in the vaccine enters cells and is translated into '\n",
      " 'foreign proteins, which trigger an immune response.',\n",
      " 'An RNA vaccine contains RNA which, when introduced into a tissue, acts as '\n",
      " 'messenger RNA (mRNA) to cause the cells to build the foreign protein and '\n",
      " 'stimulate an adaptive immune response which teaches the body how to identify '\n",
      " 'and destroy the corresponding pathogen or cancer cells.',\n",
      " 'RNA vaccines often, but not always, use nucleoside-modified messenger RNA.',\n",
      " 'The delivery of mRNA is achieved by a coformulation of the molecule into '\n",
      " 'lipid nanoparticles which protect the RNA strands and help their absorption '\n",
      " 'into the cells.',\n",
      " 'Vaccines in clinical trials include the Valneva COVID-19 vaccine.',\n",
      " 'The antigens involved are often protein subunits, but can be any molecule '\n",
      " 'that is a fragment of the pathogen.',\n",
      " 'Six of those have been approved for emergency or full use by at least one '\n",
      " 'WHO-recognized stringent regulatory authorities.',\n",
      " 'RNA vaccines\\xa0\\xa0Pfizer–BioNTech\\xa0\\xa0ModernaOverall efficacy was 70%, '\n",
      " 'ranging from 62% to 90% with different dosing regimens, with a peer-reviewed '\n",
      " 'safety profile.',\n",
      " 'An efficacy of 50% means that there are half as many cases of infection as '\n",
      " 'in unvaccinated individuals.',\n",
      " 'It is not straightforward to compare the efficacies of the different '\n",
      " 'vaccines because the trials were run with different populations, '\n",
      " 'geographies, and variants of the virus.',\n",
      " 'Vaccine efficacy reflects disease prevention, a poor indicator of '\n",
      " 'transmissibility of SARS‑CoV‑2 since asymptomatic people can be highly '\n",
      " 'infectious.',\n",
      " 'The trial location also affects the reported efficacy because different '\n",
      " 'countries have different prevalences of SARS-CoV-2 variants.',\n",
      " 'The ultimate goal of the study will be find whether the mix and match method '\n",
      " 'is just as or more effective than the currently used practice.',\n",
      " 'The study will utilize the shot developed by Pfizer and BioNTech with the '\n",
      " 'University of Oxford and AstraZeneca shot, two vaccines which rely on '\n",
      " 'different methods to deliver information to the cells of the recipient.',\n",
      " 'Ugur Sahin has voiced his opposition to the trial in December, stating that '\n",
      " 'a study \"will use up doses that people who need them could profit from, I am '\n",
      " 'not happy about this,\" though Pfizer and AstraZeneca have supported the '\n",
      " 'trials.',\n",
      " 'This is because T-cells target multiple pieces of the virus.',\n",
      " 'Viral vector and mRNA based vaccines are believed to elicit the strongest '\n",
      " 't-cell response.',\n",
      " 'Companies including Emergex, Osivax and eTheRNA are targeting these internal '\n",
      " 'antigens in the hope of creating a \"universal\" SARS-CoV-2 vaccine.',\n",
      " 'They have launched a trial of a new vaccine to tackle the South African '\n",
      " '501.V2 variant (also known as B.1.351).',\n",
      " 'Total dose counts for these countries are not included in the World total.',\n",
      " 'These paragraphs are an excerpt from Deployment of COVID-19 '\n",
      " 'vaccines[edit]You may improve this section, discuss the issue on the talk '\n",
      " 'page, or create a new section, as appropriate.',\n",
      " 'Though high-income nations represent only 14% of the global population, as '\n",
      " 'of 15 November 2020, they had contracted to buy 51% of all pre-sold doses.',\n",
      " 'Some high-income nations bought more doses than would be necessary to '\n",
      " 'vaccinate their entire populations.',\n",
      " 'Just 25 doses have been given in one lowest-income country.',\n",
      " 'A report by Carnegie Endowment for International Peace cited the current '\n",
      " 'poverty rate in Egypt as around 29.7 percent, which constitutes '\n",
      " 'approximately 30.5 million people, and claimed that about 15 million of the '\n",
      " 'Egyptians would be unable to gain access to the luxury of vaccination.',\n",
      " 'A human rights lawyer, Khaled Ali launched a lawsuit against the government, '\n",
      " 'forcing them to provide vaccination free of cost to all members of the '\n",
      " 'public.',\n",
      " 'Vaccine hesitancyThe poll also showed a positive correlation between '\n",
      " 'education level and willingness to take the vaccine.',\n",
      " 'Vaccine Centre, London School of Hygiene and Tropical Medicine.',\n",
      " 'BioPharma-Reporter.com, William Reed Business Media Ltd. Retrieved 25 '\n",
      " 'November 2020.',\n",
      " 'It is vital that we evaluate as many vaccines as possible as we cannot '\n",
      " 'predict how many will turn out to be viable.',\n",
      " 'To increase the chances of success (given the high level of attrition during '\n",
      " 'vaccine development), we must test all candidate vaccines until they fail.',\n",
      " 'The results for the efficacy of each vaccine are expected within three to '\n",
      " 'six months and this evidence, combined with data on safety, will inform '\n",
      " 'decisions about whether it can be used on a wider scale.',\n",
      " 'Retrieved 15 May 2020.CS1 maint: uses authors parameter (link)',\n",
      " 'It is vital that we evaluate as many vaccines as possible as we cannot '\n",
      " 'predict how many will turn out to be viable.',\n",
      " 'To increase the chances of success (given the high level of attrition during '\n",
      " 'vaccine development), we must test all candidate vaccines until they fail.',\n",
      " 'The results for the efficacy of each vaccine are expected within three to '\n",
      " 'six months and this evidence, combined with data on safety, will inform '\n",
      " 'decisions about whether it can be used on a wider scale.',\n",
      " 'CEPI estimates that developing up to three vaccines in the next 12–18 months '\n",
      " 'will require an investment of at least US$2\\xa0billion.',\n",
      " 'This estimate includes Phase\\xa01 clinical trials of eight vaccine '\n",
      " 'candidates, progression of up to six candidates through Phase\\xa02 and\\xa03 '\n",
      " 'trials, completion of regulatory and quality requirements for at least three '\n",
      " 'vaccines, and enhancing global manufacturing capacity for three vaccines.',\n",
      " 'Medicines & Healthcare products Regulatory Agency (MHRA).',\n",
      " 'Medicines and Healthcare products Regulatory Agency (MHRA).',\n",
      " 'Medicines and Healthcare Products Regulatory Agency, Government of the UK.',\n",
      " 'Clears Pfizer Vaccine, and Millions of Doses Will Be Shipped Right Away\".',\n",
      " 'U.S. Food and Drug Administration (FDA) (Press release).',\n",
      " 'Centers for Disease Control and Prevention, National Center for Immunization '\n",
      " 'and Respiratory Diseases, US Department of Health and Human Services.',\n",
      " 'Centers for Disease Control and Prevention, Center for Surveillance, '\n",
      " 'Epidemiology, and Laboratory Services, US Department of Health and Human '\n",
      " 'Services.',\n",
      " 'This article incorporates text from this source, which is in the public '\n",
      " 'domain.',\n",
      " 'What Does That Mean?You might assume that 95 out of every 100 people '\n",
      " 'vaccinated will be protected from Covid-19.',\n",
      " 'Swiss Agency for Therapeutic Products (Swissmedic).',\n",
      " 'Medicines and Healthcare Products Regulatory Agency, Government of the UK.',\n",
      " 'Medicines & Healthcare products Regulatory Agency (MHRA).',\n",
      " 'Medicines & Healthcare products Regulatory Agency (MHRA).',\n",
      " 'This article incorporates text from this source, which is in the public '\n",
      " 'domain.',\n",
      " 'This article incorporates text from this source, which is in the public '\n",
      " 'domain.',\n",
      " 'Medicines and Healthcare products Regulatory Agency (MHRA).',\n",
      " 'Medicines and Healthcare products Regulatory Agency (MHRA).',\n",
      " 'Swiss Agency for Therapeutic Products (Swissmedic).',\n",
      " 'Medicines and Healthcare products Regulatory Agency (MHRA).',\n",
      " 'Medicines and Healthcare products Regulatory Agency (MHRA).',\n",
      " 'U.S. Food and Drug Administration (FDA) (Press release).',\n",
      " 'U.S. Food and Drug Administration (FDA) (Press release).',\n",
      " 'AnGes, Inc. Archived from the original on 11 October 2020.',\n",
      " 'bioRxiv: 2020.12.08.416750. doi:10.1101/2020.12.08.416750.',\n",
      " 'bioRxiv: 2021.01.26.426986. doi:10.1101/2021.01.26.426986.',\n",
      " 'South Africa will suspend use of the coronavirus vaccine being developed by '\n",
      " 'Oxford University and AstraZeneca after researchers found it provided '\n",
      " '\"minimal protection\" against mild to moderate coronavirus infections caused '\n",
      " 'by the new variant first detected in that country.',\n",
      " 'Our World in Data\\xa0\\xa0Sourced from individual health agencies.',\n",
      " 'It is vital that we evaluate as many vaccines as possible as we cannot '\n",
      " 'predict how many will turn out to be viable.',\n",
      " 'To increase the chances of success (given the high level of attrition during '\n",
      " 'vaccine development), we must test all candidate vaccines until they fail.',\n",
      " 'The results for the efficacy of each vaccine are expected within three to '\n",
      " 'six months and this evidence, combined with data on safety, will inform '\n",
      " 'decisions about whether it can be used on a wider scale.',\n",
      " 'CEPI estimates that developing up to three vaccines in the next 12–18 months '\n",
      " 'will require an investment of at least US$2\\xa0billion.',\n",
      " 'This estimate includes Phase\\xa01 clinical trials of eight vaccine '\n",
      " 'candidates, progression of up to six candidates through Phase\\xa02 and\\xa03 '\n",
      " 'trials, completion of regulatory and quality requirements for at least three '\n",
      " 'vaccines, and enhancing global manufacturing capacity for three vaccines.',\n",
      " 'Question: What is the difference in liability between EU Conditional '\n",
      " 'Marketing Authorisation vs Emergency Use Authorisations?.',\n",
      " 'Ms. Gallina stressed negotiations with companies had been difficult but '\n",
      " 'underlined that those companies developing and manufacturing COVID-19 '\n",
      " 'vaccines would indeed be liable according to current laws and if something '\n",
      " 'goes wrong they could be taken to court.',\n",
      " 'This also goes for compensation for hidden defects.',\n",
      " 'Development and Licensure of Vaccines to Prevent COVID-19: Guidance for '\n",
      " 'Industry (Report).',\n",
      " 'Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a '\n",
      " 'non-profit organization.',\n",
      " \"modeled across countries how uncertainty about a vaccine's characteristics \"\n",
      " 'affects prioritization strategies for reducing deaths and transmission (see '\n",
      " 'the Perspective by Fitzpatrick and Galvani).',\n",
      " 'In the model, vaccine efficacy and its ability to reduce disease and/or '\n",
      " 'block transmission was accounted for in relation to age-related variations '\n",
      " 'in susceptibility, fatality rates, and immune decline.',\n",
      " 'In almost all circumstances, reducing fatalities required distributing the '\n",
      " 'vaccine to those who are most at risk of death, usually persons over 60 '\n",
      " 'years of age and those with comorbidities.',\n",
      " 'If a vaccine is leaky or poorly efficacious in older adults, then priority '\n",
      " 'could be given to younger age groups.',\n",
      " 'To increase the available doses, further priority should be given to '\n",
      " 'seronegative individuals.Science, this issue p. 916; see also p. '\n",
      " '890AbstractLimited initial supply of severe acute respiratory syndrome '\n",
      " 'coronavirus 2 (SARS-CoV-2) vaccine raises the question of how to prioritize '\n",
      " 'available doses.',\n",
      " 'We used a mathematical model to compare five age-stratified prioritization '\n",
      " 'strategies.',\n",
      " 'A highly effective transmission-blocking vaccine prioritized to adults ages '\n",
      " '20 to 49 years minimized cumulative incidence, but mortality and years of '\n",
      " 'life lost were minimized in most scenarios when the vaccine was prioritized '\n",
      " 'to adults greater than 60 years old.',\n",
      " 'Use of individual-level serological tests to redirect doses to seronegative '\n",
      " 'individuals improved the marginal impact of each dose while potentially '\n",
      " 'reducing existing inequities in COVID-19 impact.',\n",
      " 'Although maximum impact prioritization strategies were broadly consistent '\n",
      " 'across countries, transmission rates, vaccination rollout speeds, and '\n",
      " 'estimates of naturally acquired immunity, this framework can be used to '\n",
      " 'compare impacts of prioritization strategies across contexts.Severe acute '\n",
      " 'respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a public health '\n",
      " 'and economic crisis worldwide.',\n",
      " 'As of January 2021, there have been more than 85 million cases and 1.8 '\n",
      " 'million deaths reported (1).',\n",
      " 'To combat this crisis, a variety of nonpharmaceutical interventions have '\n",
      " 'been implemented, including shelter-in-place orders, limited travel, and '\n",
      " 'remote schooling.',\n",
      " 'Although these efforts are essential to slowing transmission in the short '\n",
      " 'term, long-term solutions—such as vaccines that protect from SARS-CoV-2 '\n",
      " 'infection—remain urgently needed.',\n",
      " 'The benefits of an effective vaccine for individuals and their communities '\n",
      " 'have resulted in widespread demand, so it is critical that decision-making '\n",
      " 'on vaccine distribution is well motivated, particularly in the initial '\n",
      " 'phases when vaccine availability is limited (2).We used a model-informed '\n",
      " 'approach to quantify the impact of COVID-19 vaccine prioritization '\n",
      " 'strategies on cumulative incidence, mortality, and years of life lost.',\n",
      " 'Our approach explicitly addresses variation in three areas that can '\n",
      " 'influence the outcome of vaccine distribution decisions.',\n",
      " 'First, we considered variation in the performance of the vaccine, including '\n",
      " 'its overall efficacy, a hypothetical decrease in efficacy by age, and the '\n",
      " 'vaccine’s ability to block transmission.',\n",
      " 'Second, we considered variation in both susceptibility to infection and the '\n",
      " 'infection fatality rate by age.',\n",
      " 'Third, we considered variation in the population and policy—including the '\n",
      " 'age distribution, age-stratified contact rates, and initial fraction of '\n",
      " 'seropositive individuals by age—and the speed and timing of the vaccine’s '\n",
      " 'rollout relative to transmission.',\n",
      " 'Although the earliest doses of vaccines will be given to front-line health '\n",
      " 'care workers under plans such as those from the COVAX initiative and the '\n",
      " 'U.S. National Academies of Sciences, Engineering, and Medicine (NASEM) '\n",
      " 'recommendations (3), our work is focused on informing the prioritization of '\n",
      " 'the doses that follow.',\n",
      " 'On the basis of regulatory approvals and initial vaccine rollout speeds of '\n",
      " 'early 2021, our investigation focuses generally on scenarios with a '\n",
      " 'partially mitigated pandemic [reproduction number (R) between 1.1 and 2.0], '\n",
      " 'vaccines with protective efficacy of 90%, and rollout speeds of 0.2% of the '\n",
      " 'population per day.There are two main approaches to vaccine prioritization: '\n",
      " '(i) directly vaccinate those at highest risk for severe outcomes and (ii) '\n",
      " 'protect them indirectly by vaccinating those who do the most transmitting.',\n",
      " 'Model-based investigations of the trade-offs between these strategies for '\n",
      " 'influenza vaccination have led to recommendations that children be '\n",
      " 'vaccinated because of their critical role in transmission (4, 5) and have '\n",
      " 'shown that direct protection is superior when reproduction numbers are high '\n",
      " 'but indirect protection is superior when transmission is low (6).',\n",
      " 'Similar modeling for COVID-19 vaccination has found that the optimal balance '\n",
      " 'between direct and indirect protection depends on both vaccine efficacy and '\n",
      " 'supply, recommending direct vaccination of older adults for low-efficacy '\n",
      " 'vaccines and for high-efficacy but supply-limited vaccines (7).',\n",
      " 'Rather than comparing prioritization strategies, others have compared '\n",
      " 'hypothetical vaccines, showing that even those with lower efficacy for '\n",
      " 'direct protection may be more valuable if they also provide better indirect '\n",
      " 'protection by blocking transmission (8).',\n",
      " 'Prioritization of transmission-blocking vaccines can also be dynamically '\n",
      " 'updated on the basis of the current state of the epidemic, shifting '\n",
      " 'prioritization to avoid decreasing marginal returns (9).',\n",
      " 'These efforts to prioritize and optimize doses complement other work showing '\n",
      " 'that under different vaccine efficacy and durability of immunity, the '\n",
      " 'economic and health benefits of COVID-19 vaccines will be large in the short '\n",
      " 'and medium terms (10).',\n",
      " 'The problem of vaccine prioritization also parallels the more general '\n",
      " 'problem of optimal resource allocation to reduce transmission, such as with '\n",
      " 'masks (11).Evaluation of vaccine prioritization strategiesWe evaluated the '\n",
      " 'impact of vaccine prioritization strategies using an age-stratified SEIR '\n",
      " 'model (susceptible, exposed, infectious, recovered) because age has been '\n",
      " 'shown to be an important correlate of susceptibility (12–14), seroprevalence '\n",
      " '(12, 15), severity (16–18), and mortality (19, 20).',\n",
      " 'This model includes an age-dependent contact matrix, susceptibility to '\n",
      " 'infection, and infection fatality rate (IFR), allowing us to estimate '\n",
      " 'cumulative incidence of SARS-CoV-2 infections, mortality due to infection, '\n",
      " 'and years of life lost (YLL) (supplementary materials, materials and '\n",
      " 'methods) by means of forward simulations of 1 year of disease dynamics.',\n",
      " 'Cumulative incidence, mortality, and YLL were then used as outcomes by which '\n",
      " 'to compare vaccine prioritization strategies.',\n",
      " 'These comparisons may be explored by using accompanying open-source and '\n",
      " 'interactive calculation tools that accompany this study (21).We first '\n",
      " 'examined the impact of five vaccine prioritization strategies for a '\n",
      " 'hypothetical infection- and transmission-blocking vaccine of varying '\n",
      " 'efficacy.',\n",
      " 'The strategies prioritized vaccines to (i) children and teenagers, (ii) '\n",
      " 'adults between ages 20 and 49 years, (iii) adults 20 years or older, (iv) '\n",
      " 'adults 60 years or older, and (v) all individuals (Fig.',\n",
      " 'In all strategies, once the prioritized population was vaccinated, vaccines '\n",
      " 'were allocated irrespective of age—that is, in proportion to their numbers '\n",
      " 'in the population.',\n",
      " 'To incorporate vaccine hesitancy, at most 70% of any age group was eligible '\n",
      " 'to be vaccinated (22).',\n",
      " 'Download high-res imageSquares and diamonds show how the outputs from single '\n",
      " 'simulations [(F) and (G)] correspond to points in summary curves (H).',\n",
      " 'Gray shading indicates the period during which vaccine is being rolled out '\n",
      " 'at 0.2% of total population per day.',\n",
      " 'Black dots indicate break points at which prioritized demographic groups '\n",
      " 'have been 70% vaccinated, after which vaccines are distributed without '\n",
      " 'prioritization.',\n",
      " 'These simulations assume contact patterns and demographics of the United '\n",
      " 'States (38, 53) and an all-or-nothing, transmission-blocking vaccine with '\n",
      " '90% vaccine efficacy and R0 = 1.5 (scenario 2) and R0 = 1.15 (scenario 1).',\n",
      " 'We measured reductions in cumulative incidence, mortality, and YLL achieved '\n",
      " 'by each strategy, varying the vaccine supply between 1 and 50% of the total '\n",
      " 'population, under two scenarios.',\n",
      " 'In scenario 1, vaccines were administered to 0.2% of the population per day '\n",
      " 'until supply was exhausted, with basic reproduction number (R0) = 1.15, '\n",
      " 'representing highly mitigated spread during vaccine rollout.',\n",
      " 'In scenario 2, vaccines were administered to 0.2% of the population per day '\n",
      " 'until supply was exhausted, but with R0 = 1.5, representing substantial '\n",
      " 'viral growth during vaccine rollout (example model outputs are provided in '\n",
      " 'Fig.',\n",
      " 'Results for additional scenarios in which vaccines were administered before '\n",
      " 'transmission began are described in the supplementary materials, '\n",
      " 'supplementary text, corresponding to countries without ongoing community '\n",
      " 'spread such as South Korea and New Zealand.',\n",
      " 'We considered two ways in which vaccine efficacy (ve) could be below 100%: '\n",
      " 'an all-or-nothing vaccine, in which the vaccine provides perfect protection '\n",
      " 'to a fraction ve of individuals who receive it, or as a leaky vaccine, in '\n",
      " 'which all vaccinated individuals have reduced probability ve of infection '\n",
      " 'after vaccination (supplementary materials, materials and methods).Of the '\n",
      " 'five strategies, direct vaccination of adults older than 60 years of age '\n",
      " '(60+) always reduced mortality and YLL more than the alternative strategies '\n",
      " 'when transmission was high [R0 = 1.5, scenario 2, 90% efficacy (Fig.',\n",
      " 'For lower transmission (R0 = 1.15, scenario 1), vaccination of adults aged '\n",
      " '20 to 49 years reduced mortality and YLL more than the alternative '\n",
      " 'strategies, but differences between prioritization of adults aged 20 to 49 '\n",
      " 'years, 20+ years, and 60+ years were small for vaccine supplies above 25% '\n",
      " '(Fig.',\n",
      " 'Prioritizing adults aged 20 to 49 years minimized cumulative incidence in '\n",
      " 'both scenarios for all vaccine efficacies (Fig.',\n",
      " 'Prioritizing adults aged 20 to 49 years also minimized cumulative incidence '\n",
      " 'in both scenarios under alternative rollout speeds (0.05 to 1% vaccinated '\n",
      " 'per day) (fig.',\n",
      " 'When rollout speeds were at least 0.3% per day and vaccine supply covered at '\n",
      " 'least 25% of the population, the mortality-minimizing strategy shifted from '\n",
      " 'prioritization of ages 20 to 49 years to adults aged 20+ or 60+ years for '\n",
      " 'scenario 1; when rollout speeds were at least 0.75% per day and covered at '\n",
      " 'least 24% of the population, the mortality-minimizing strategy shifted from '\n",
      " 'prioritization of adults aged 60+ years to adults aged 20+ or 20 to 49 years '\n",
      " 'for scenario 2 (fig.',\n",
      " 'Findings for mortality and YLL were only slightly changed by modeling '\n",
      " 'vaccine efficacy as all or nothing (fig.',\n",
      " 'S7).Impact of transmission rates, age demographics, and contact structureTo '\n",
      " 'evaluate the impact of transmission rates on the strategy that most reduced '\n",
      " 'mortality, we varied the basic reproductive number R0 from 1.1 to 2.0 when '\n",
      " 'considering a hypothetical infection- and transmission-blocking vaccine with '\n",
      " '90% vaccine efficacy.',\n",
      " 'We found that prioritizing adults aged 60+ years remained the best way to '\n",
      " 'reduce mortality and YLL for R0 ≥ 1.3, but prioritizing adults aged 20 to 49 '\n",
      " 'years was superior for R0 ≤ 1.2 (Fig.',\n",
      " 'Prioritizing adults aged 20 to 49 years minimized infections for all values '\n",
      " 'of R0 investigated (fig.',\n",
      " 'S8).To evaluate the impact of transmission rates on the strategy that most '\n",
      " 'reduced mortality, we varied the basic reproductive number R0 from 1.1 to '\n",
      " '2.0 when considering a hypothetical infection- and transmission-blocking '\n",
      " 'vaccine with 90% vaccine efficacy.',\n",
      " 'We found that prioritizing adults aged 60+ years remained the best way to '\n",
      " 'reduce mortality and YLL for R0 ≥ 1.3, but prioritizing adults aged 20 to 49 '\n",
      " 'years was superior for R0 ≤ 1.2 (Fig.',\n",
      " 'Prioritizing adults aged 20 to 49 years minimized infections for all values '\n",
      " 'of R0 investigated (fig.',\n",
      " 'S8).To evaluate the impact of transmission rates on the strategy that most '\n",
      " 'reduced mortality, we varied the basic reproductive number R0 from 1.1 to '\n",
      " '2.0 when considering a hypothetical infection- and transmission-blocking '\n",
      " 'vaccine with 90% vaccine efficacy.',\n",
      " 'We found that prioritizing adults aged 60+ years remained the best way to '\n",
      " 'reduce mortality and YLL for R0 ≥ 1.3, but prioritizing adults aged 20 to 49 '\n",
      " 'years was superior for R0 ≤ 1.2 (Fig.',\n",
      " 'Prioritizing adults aged 20 to 49 years minimized infections for all values '\n",
      " 'of R0 investigated (fig.',\n",
      " 'Download high-res imageTo determine whether our findings were robust across '\n",
      " 'countries, we analyzed the ranking of prioritization strategies for '\n",
      " 'populations with the age distributions and modeled contact structures of the '\n",
      " 'United States, Belgium, Brazil, China, India, Poland, South Africa, and '\n",
      " 'Spain.',\n",
      " 'Across these countries, direct vaccination of adults aged 60+ years '\n",
      " 'minimized mortality for all levels of vaccine supply when transmission was '\n",
      " 'high (R0 = 1.5, scenario 2) (Fig.',\n",
      " 'Decreasing rollout speed from 0.2% to 0.1% per day caused prioritization of '\n",
      " 'adults aged 60+ years to be favored in additional scenarios (Fig.',\n",
      " 'Across countries, vaccination of adults aged 20 to 49 years nearly always '\n",
      " 'minimized infections, and vaccination of adults aged 60+ years nearly always '\n",
      " 'minimized YLL for scenario 2, but no clear ranking of strategies emerged '\n",
      " 'consistently to minimize YLL in scenario 1 (fig.',\n",
      " 'S9).Vaccines with imperfect transmission-blocking effectsWe also considered '\n",
      " 'whether the rankings of prioritization strategies to minimize mortality '\n",
      " 'would change if a vaccine were to block COVID-19 symptoms and mortality with '\n",
      " '90% efficacy but with variable impact on SARS-CoV-2 infection and '\n",
      " 'transmission.',\n",
      " 'We found that direct vaccination of adults aged 60+ years minimized '\n",
      " 'mortality for all vaccine supplies and transmission-blocking effects under '\n",
      " 'scenario 2 and for all vaccine supplies when up to 50% of transmission was '\n",
      " 'blocked in scenario 1 (supplementary text and fig.',\n",
      " 'S10).Variation in vaccine efficacy by ageCOVID-19 vaccines may not be '\n",
      " 'equally effective across age groups in preventing infection or disease, a '\n",
      " 'phenomenon known to affect influenza vaccines (23–26).',\n",
      " 'To understand the impact of age-dependent COVID-19 vaccine efficacy, we '\n",
      " 'incorporated a hypothetical linear decrease from a baseline efficacy of 90% '\n",
      " 'for those younger than 60 years to 50% in those 80 years and older (Fig.',\n",
      " 'As expected, this diminished the benefits of any prioritization strategy '\n",
      " 'that included older adults.',\n",
      " 'For example, strategies that prioritize adults aged 20 to 49 years were '\n",
      " 'unaffected by decreased efficacy among adults aged 60+ years, whereas '\n",
      " 'strategies prioritizing adults aged 60+ years were markedly diminished (Fig.',\n",
      " 'Despite these effects, prioritization of adults aged 60+ years remained '\n",
      " 'superior to the alternative strategies to minimize mortality in scenario 2.',\n",
      " 'Download high-res imageBlack dots indicate break points at which prioritized '\n",
      " 'demographic groups have been 70% vaccinated, after which vaccines are '\n",
      " 'distributed without prioritization.',\n",
      " 'Shown are contact patterns and demographics of the United States (38, 53); '\n",
      " 'all-or-nothing and transmission-blocking vaccine.',\n",
      " 'To test whether more substantial age-dependent vaccine effects would change '\n",
      " 'which strategy minimized mortality in scenario 2, we varied the onset age of '\n",
      " 'age-dependent decreases in efficacy, the extent to which it decreased, and '\n",
      " 'the baseline efficacy from which it decreased.',\n",
      " 'We found that as long as the age at which efficacy began to decrease was 70 '\n",
      " 'years or older and vaccine efficacy among adults aged 80+ years was at least '\n",
      " '25%, prioritizing adults aged 60+ years remained superior in the majority of '\n",
      " 'parameter combinations.',\n",
      " 'This finding was robust to whether the vaccine was modeled as leaky versus '\n",
      " 'all or nothing, but we observed considerable variation from country to '\n",
      " 'country (fig.',\n",
      " 'S11).Incorporation of population seroprevalence and individual serological '\n",
      " 'testingBecause of early indications that naturally acquired antibodies '\n",
      " 'correlate with protection from reinfection (27), seroprevalence will affect '\n",
      " 'vaccine prioritization in two ways.',\n",
      " 'First, depending on the magnitude and age distribution of seroprevalence at '\n",
      " 'the time of vaccine distribution, the ranking of strategies could change.',\n",
      " 'Second, distributing vaccines to seropositive individuals would reduce the '\n",
      " 'marginal benefit of vaccination per dose.To investigate the impact of '\n",
      " 'vaccinating midepidemic while using serology to target the vaccine to '\n",
      " 'seronegative individuals, we included age-stratified seroprevalence '\n",
      " 'estimates in our model by moving the data-specified proportion of '\n",
      " 'seropositive individuals from susceptible to recovered status.',\n",
      " 'We then simulated two approaches to vaccine distribution.',\n",
      " 'In the first, vaccines were distributed according to the five prioritization '\n",
      " 'strategies introduced above, regardless of any individual’s serostatus.',\n",
      " 'In the second, vaccines were distributed with a serological test, so that '\n",
      " 'individuals with a positive serological test would not be vaccinated, '\n",
      " 'allowing their dose to be given to someone else in their age group.We '\n",
      " 'included age-stratified seroprevalence estimates from New York City [August '\n",
      " '2020; overall seroprevalence 26.9% (28)] and demographics and age-contact '\n",
      " 'structure from the United States in evaluations of the previous five '\n",
      " 'prioritization strategies.',\n",
      " 'For this analysis, we focused on scenario 2 (0.2% rollout per day, R0 = 1.5 '\n",
      " 'inclusive of seropositives) and found that the ranking of strategies to '\n",
      " 'minimize incidence, mortality, and YLL remained unchanged: Prioritizing '\n",
      " 'adults aged 60+ years most reduced mortality, and prioritizing adults aged '\n",
      " '20 to 49 years most reduced incidence, regardless of whether vaccination was '\n",
      " 'limited to seronegative individuals (Fig.',\n",
      " 'These rankings were unchanged when we used lower or higher age-stratified '\n",
      " 'seroprevalence estimates to test the consistency of results [Connecticut, '\n",
      " 'July 2020, overall seroprevalence 3.4% (29) and synthetic, overall '\n",
      " 'seroprevalence 39.5%] (figs.',\n",
      " 'Despite lowered sensitivity to detect past exposure due to seroreversion '\n",
      " '(30, 31), preferentially vaccinating seronegative individuals yielded large '\n",
      " 'additional reductions in cumulative incidence and mortality in locations '\n",
      " 'with higher seroprevalence (Fig.',\n",
      " 'S13) and modest reductions in locations with low seroprevalence (fig.',\n",
      " 'These results remained unchanged when statistical uncertainty, because of '\n",
      " 'sample size and imperfect test sensitivity and specificity, was incorporated '\n",
      " 'into the model (32).',\n",
      " 'Download high-res imagePlots show reductions for scenario 2 (0.2% rollout '\n",
      " 'per day, R0 = 1.5) when vaccines are given to all individuals (solid lines) '\n",
      " 'or to only seronegatives (dashed lines), inclusive of 96% serotest '\n",
      " 'sensitivity, 99% specificity (54), and approximately 3 months of '\n",
      " 'seroreversion (supplementary materials, materials and methods) (29).',\n",
      " 'Shown are U.S. contact patterns and demographics (38, 53), all-or-nothing '\n",
      " 'and transmission-blocking vaccine with 90% vaccine efficacy.',\n",
      " 'Lower and higher seroprevalence examples are provided in figs.',\n",
      " 'DiscussionThis study demonstrated the use of an age-stratified modeling '\n",
      " 'approach to evaluate and compare vaccine prioritization strategies for '\n",
      " 'SARS-CoV-2.',\n",
      " 'After accounting for country-specific age structure, age-contact structure, '\n",
      " 'infection fatality rates, and seroprevalence, as well as the age-varying '\n",
      " 'efficacy of a hypothetical vaccine, we found that across countries, those '\n",
      " 'aged 60 years and older should be prioritized to minimize deaths, assuming a '\n",
      " 'return to high contact rates and prepandemic behavior during or after '\n",
      " 'vaccine rollout.',\n",
      " 'This recommendation is robust because of the dramatic differences in IFR by '\n",
      " 'age.',\n",
      " 'Our model identified three general regimes in which prioritizing adults aged '\n",
      " '20 to 49 years would provide greater mortality benefits than would '\n",
      " 'prioritizing older adults.',\n",
      " 'One such regime was in the presence of substantial transmission-mitigating '\n",
      " 'interventions (R0 = 1.15) and a vaccine with 80% or higher '\n",
      " 'transmission-blocking effects.',\n",
      " 'A second regime was characterized by substantial transmission-mitigating '\n",
      " 'interventions (R0 = 1.15) and either rollout speeds of at most 0.2% per day '\n",
      " 'or vaccine supplies of at most 25% of the population.',\n",
      " 'The third regime was characterized by vaccines with very low efficacy in '\n",
      " 'older adults, very high efficacy in younger adults, and declines in efficacy '\n",
      " 'starting at age 59 or 69 years.',\n",
      " 'The advantage of prioritizing all adults or adults aged 20 to 49 versus 60+ '\n",
      " 'years was small under these conditions.',\n",
      " 'Thus, we conclude that for mortality reduction, prioritization of older '\n",
      " 'adults is a robust strategy that will be optimal or close to optimal to '\n",
      " 'minimize mortality for virtually all plausible vaccine characteristics.By '\n",
      " 'contrast, the ranking of infection-minimizing strategies for midepidemic '\n",
      " 'vaccination led to consistent recommendations to prioritize adults aged 20 '\n",
      " 'to 49 years across efficacy values and countries.',\n",
      " 'For pretransmission vaccination, prioritization shifted toward children and '\n",
      " 'teenagers for leaky vaccine efficacies 50% and below, which is in line with '\n",
      " 'prior work (7), as well as for vaccines with weak transmission-blocking '\n",
      " 'properties.',\n",
      " 'Because a vaccine is likely to have properties of both leaky and '\n",
      " 'all-or-nothing models, empirical data on vaccine performance could help '\n",
      " 'resolve this difference in model recommendations, although data are '\n",
      " 'difficult to obtain in practice [for example, (33, 34)].It is not yet clear '\n",
      " 'whether the first generation of COVID-19 vaccines will be approved '\n",
      " 'everywhere for the elderly or those under 18 years of age (35–37).',\n",
      " 'Although our conclusions assumed that the vaccine would be approved for all '\n",
      " 'age groups, the evaluation approaches introduced here can be tailored to '\n",
      " 'evaluate a subset of approaches restricted to those within the age groups '\n",
      " 'for which a vaccine is licensed, by using open-source tools such as those '\n",
      " 'that accompany this study.',\n",
      " 'Furthermore, although we considered three possible goals of '\n",
      " 'vaccination—minimizing cumulative incidence, mortality, or YLL—our framework '\n",
      " 'can be adapted to consider goals such as minimizing hospitalizations, '\n",
      " 'intensive care unit occupancy (7), or economic costs (10).We demonstrated '\n",
      " 'that there is value in pairing individual-level serological tests with '\n",
      " 'vaccination, even when accounting for the uncertainties in seroprevalence '\n",
      " 'estimates (32) and seroreversion (30).',\n",
      " 'The marginal gain in effective vaccine supply, relative to no serological '\n",
      " 'testing, must be weighed against the challenges of serological testing '\n",
      " 'before vaccination.',\n",
      " 'Serostatus itself is an imperfect indicator of protection, and the '\n",
      " 'relationship of prior infection, serostatus, and protection may change over '\n",
      " 'time (10, 27, 30, 31).',\n",
      " 'Delays in serological test results would impair vaccine distribution, but '\n",
      " 'partial seronegative-targeting effects might be realized if those with past '\n",
      " 'polymerase chain reaction (PCR)–confirmed infections voluntarily '\n",
      " 'deprioritized their own vaccinations.The best-performing strategies depend '\n",
      " 'on assumptions about the extent of a population’s interactions.',\n",
      " 'We used prepandemic contact matrices (38), reflecting the goal of a return '\n",
      " 'to prepandemic routines once a vaccine is available, but more recent '\n",
      " 'estimates of age-stratified contact rates could be valuable in modeling '\n",
      " 'midpandemic scenarios (39, 40).',\n",
      " 'Whether prepandemic or midpandemic contact estimates are representative of '\n",
      " 'contact patterns during vaccine rollout remains unknown and may vary on the '\n",
      " 'basis of numerous social, political, and other factors.',\n",
      " 'The scenarios modeled here did not incorporate explicit nonpharmaceutical '\n",
      " 'interventions, which might persist if vaccination coverage is incomplete, '\n",
      " 'but are implicitly represented in scenario 1 (R0 = 1.15).Our study relies on '\n",
      " 'estimates of other epidemiological parameters.',\n",
      " 'In local contexts, these include age-structured seroprevalence and IFR, '\n",
      " 'which vary by population (19, 20, 41).',\n",
      " 'Globally, key parameters include the degree to which antibodies protect '\n",
      " 'against reinfection or severity of disease and relative infectiousness by '\n",
      " 'age.',\n",
      " 'From vaccine trials, we also need evidence of efficacy in groups vulnerable '\n",
      " 'to severe outcomes, including the elderly.',\n",
      " 'Additionally, it will be critical to measure whether a vaccine that protects '\n",
      " 'against symptomatic disease also blocks infection and transmission of '\n",
      " 'SARS-CoV-2 (42).The role of children during this pandemic has been unclear.',\n",
      " 'Under our assumptions about susceptibility by age, children are not the '\n",
      " 'major drivers of transmission in communities, which is consistent with '\n",
      " 'emerging evidence (12).',\n",
      " 'Thus, our results differ from the optimal distribution for influenza '\n",
      " 'vaccines, which prioritize school-age children and adults aged 30 to 39 '\n",
      " 'years (5).',\n",
      " 'However, the relative susceptibility and infectiousness of SARS-CoV-2 by age '\n",
      " 'remain uncertain.',\n",
      " 'Although it is unlikely that susceptibility to infection conditional on '\n",
      " 'exposure is constant across age groups (12), we ran our model to test the '\n",
      " 'sensitivity of this parameter.',\n",
      " 'Under the scenario of constant susceptibility by age, vaccinating those '\n",
      " 'under 20 years of age has a greater impact on reducing cumulative cases than '\n",
      " 'vaccinating those aged 20 to 49 years (figs.',\n",
      " 'S14 and 15).Our study is subject to a number of limitations.',\n",
      " 'First, our evaluation strategy focuses on a single country at a time, rather '\n",
      " 'than on between-population allocation (43).',\n",
      " 'Second, we only consider variation in disease severity by age.',\n",
      " 'However, other factors correlate with disease outcomes, such as treatment '\n",
      " 'and health care access and comorbidities, which may correlate with factors '\n",
      " 'such as rural versus urban location, socioeconomic status, sex (44, 45), and '\n",
      " 'race and ethnicity (46), which are not accounted for in this study.',\n",
      " 'Inclusion of these factors in a model would be possible, but only with '\n",
      " 'statistically sound measurements of their stratified infection risk, contact '\n",
      " 'rates, and disease outcomes.',\n",
      " 'Even in the case of age stratification, contact surveys have typically not '\n",
      " 'surveyed those 80 years and older, yet it is this population that suffers '\n",
      " 'dramatically more severe COVID-19 disease and higher infection fatality '\n",
      " 'rates.',\n",
      " 'We extrapolated contact matrices to those older than 80, but direct '\n",
      " 'measurements would be superior.',\n",
      " 'Last, our study focused on guiding strategy rather than providing more '\n",
      " 'detailed forecasting or estimates (10).',\n",
      " 'As such, we have not made detailed parameter fits to time series of cases or '\n",
      " 'deaths but rather have used epidemiologic models to identify robust '\n",
      " 'strategies across a range of transmission scenarios.Our study also considers '\n",
      " 'variation in disease risk only by age, through age-structured contact '\n",
      " 'matrices and age-specific susceptibility, whereas many discussions around '\n",
      " 'COVID-19 vaccine distribution have thus far focused on prioritizing health '\n",
      " 'care or essential workers (47, 48).',\n",
      " 'Contact rates, and thus infection potential, vary greatly not only by '\n",
      " 'occupation and age but also by living arrangement (such as congregate '\n",
      " 'settings or dormitories), neighborhood and mobility (49–52), and whether the '\n",
      " 'population has a coordinated and fundamentally effective policy to control '\n",
      " 'the virus.',\n",
      " 'With a better understanding of population structure during the pandemic, and '\n",
      " 'risk factors of COVID-19, these limitations could be addressed.',\n",
      " 'Meanwhile, the robust findings in favor of prioritizing those age groups '\n",
      " 'with the highest IFR to minimize mortality could potentially be extended to '\n",
      " 'prioritize those with comorbidities that predispose them to a high IFR '\n",
      " 'because the strategy of prioritizing the older age groups depends on direct '\n",
      " 'rather than indirect protection.Vaccine prioritization is not solely a '\n",
      " 'question of science but a question of ethics as well.',\n",
      " 'Hallmarks of the COVID-19 pandemic, as with other global diseases, are '\n",
      " 'inequalities and disparities.',\n",
      " 'Although these modeling efforts focus on age and minimizing incidence and '\n",
      " 'death within a simply structured population, other considerations are '\n",
      " 'crucial, from equity in allocation between countries to disparities in '\n",
      " 'access to health care, including vaccination, that vary by neighborhood.',\n",
      " 'Thus, the model’s simplistic representation of vulnerability (age) should be '\n",
      " 'augmented by better information on the correlates of infection risk and '\n",
      " 'severity.',\n",
      " 'Fair vaccine prioritization should avoid further harming disadvantaged '\n",
      " 'populations.',\n",
      " 'We suggest that after distribution, pairing serological testing with '\n",
      " 'vaccination in the hardest-hit populations is one possible equitable way to '\n",
      " 'extend the benefits of vaccination in settings where vaccination might '\n",
      " 'otherwise not be deemed cost effective.Supplementary '\n",
      " 'Materialsscience.sciencemag.org/content/371/6532/916/suppl/DC1Materials and '\n",
      " 'MethodsSupplementary TextFigs.',\n",
      " 'Vaccinedoi:10.1016/j.vaccine.2004.08.044pmid:15652671OpenUrlCrossRefPubMedWeb '\n",
      " 'of Science↵ J. Medlock,  A. P. Galvani, ',\n",
      " 'Sciencedoi:10.1126/science.1175570pmid:19696313OpenUrlAbstract/FREE Full '\n",
      " 'Text↵ S. Bansal,  B. Pourbohloul,  L. A. Meyers, ',\n",
      " 'doi:10.1371/journal.pmed.0030387pmid:17020406OpenUrlCrossRefPubMed↵L.',\n",
      " 'Matrajt, J. Eaton, T. Leung, E. R. Brown, Vaccine optimization for COVID-19: '\n",
      " 'who to vaccinate first?',\n",
      " 'E. Gallagher et al., Considering indirect benefits is critical when '\n",
      " 'evaluating SARS-CoV-2 vaccine candidates.',\n",
      " 'H. Buckner, G. Chowell, M. R. Springborn, Dynamic prioritization of COVID-19 '\n",
      " 'vaccines when social distancing is limited for essential workers.',\n",
      " 'Sandmann et al., The potential health and economic value of SARS-CoV-2 '\n",
      " 'vaccination alongside physical distancing in the UK: transmission '\n",
      " 'model-based future scenario analysis and economic evaluation.',\n",
      " 'doi:10.1038/s41467-020-17922-xpmid:32792562OpenUrlCrossRefPubMed↵ E. '\n",
      " 'Goldstein,  M. Lipsitch,  M. Cevik, ',\n",
      " 'doi:10.1093/infdis/jiaa691pmid:33119738OpenUrlCrossRefPubMed N. G. Davies,  '\n",
      " 'P. Klepac,  Y. Liu,  K. Prem,  M. Jit,  R. M. Eggo; CMMID COVID-19 working '\n",
      " 'group, ',\n",
      " 'doi:10.1038/s41591-020-0962-9pmid:32546824OpenUrlCrossRefPubMed↵ J. Zhang,  '\n",
      " 'M. Litvinova,  Y. Liang,  Y. Wang,  W. Wang,  S. Zhao,  Q. Wu,  S. Merler,  '\n",
      " 'C. Viboud,  A. Vespignani,  M. Ajelli,  H. Yu, ',\n",
      " 'Sciencedoi:10.1126/science.abb8001pmid:32350060OpenUrlAbstract/FREE Full '\n",
      " 'Text↵S.',\n",
      " 'Herzog et al., Seroprevalence of IgG antibodies against SARS coronavirus 2 '\n",
      " 'in Belgium – a serial prospective cross-sectional nationwide study of '\n",
      " 'residual samples.',\n",
      " 'Aging (Albany NY)doi:10.18632/aging.103344pmid:32470948OpenUrlCrossRefPubMed '\n",
      " 'Y. Liu,  B. Mao,  S. Liang,  J. W. Yang,  H. W. Lu,  Y. H. Chai,  L. Wang,  '\n",
      " 'L. Zhang,  Q. H. Li,  L. Zhao,  Y.',\n",
      " 'B. Ji,  L. Li,  Z. J. Jie,  Q. Li,  X. Y. Li,  H. Z. Lu,  W. H. Zhang,  Y. '\n",
      " 'L. Song,  J. M. Qu,  J. F. Xu, Shanghai Clinical Treatment Experts Group for '\n",
      " 'COVID-19, ',\n",
      " 'doi:10.1183/13993003.01112-2020pmid:32312864OpenUrlAbstract/FREE Full Text↵ '\n",
      " 'J. Westmeier,  K. Paniskaki,  Z. Karaköse,  T. Werner,  K. Sutter,  S. '\n",
      " 'Dolff,  M. Overbeck,  A. Limmer,  J. Liu,  X. Zheng,  T. Brenner,  M. M. '\n",
      " 'Berger,  O. Witzke,  M. Trilling,  M. Lu,  D. Yang,  N. Babel,  T. '\n",
      " 'Westhoff,  U. Dittmer,  G. Zelinskyy, ',\n",
      " 'mBiopmid:32948688OpenUrlPubMed↵ A. T. Levin,  W. P. Hanage,  N. '\n",
      " 'Owusu-Boaitey,  K. B. Cochran,  S. P. Walsh,  G. Meyerowitz-Katz, ',\n",
      " 'doi:10.1007/s10654-020-00698-1pmid:33289900OpenUrlCrossRefPubMed↵ H. Salje,  '\n",
      " 'C. Tran Kiem,  N. Lefrancq,  N. Courtejoie,  P. Bosetti,  J. Paireau,  A. '\n",
      " 'Andronico,  N. Hozé,  J. Richet,  C.-L. Dubost,  Y.',\n",
      " 'Le Strat,  J. Lessler,  D. Levy-Bruhl,  A. Fontanet,  L. Opatowski,  P.-Y.',\n",
      " 'Sciencedoi:10.1126/science.abc3517pmid:32404476OpenUrlAbstract/FREE Full '\n",
      " 'Text↵K.',\n",
      " 'M. Bubar et al., kbubar/vaccine_prioritization: Updated code for published '\n",
      " 'paper.',\n",
      " 'Gross,  A. W. Hermogenes,  H. S. Sacks,  J. Lau,  R. A. Levandowski, ',\n",
      " 'doi:10.7326/0003-4819-123-7-199510010-00008pmid:7661497OpenUrlCrossRefPubMedWeb '\n",
      " 'of Science J. K. H. Lee,  G. K. L. Lam,  T. Shin,  J. Kim,  A. Krishnan,  D. '\n",
      " 'P. Greenberg,  A. Chit, ',\n",
      " 'Vaccinesdoi:10.1080/14760584.2018.1471989pmid:29715054OpenUrlCrossRefPubMed '\n",
      " 'T. M. E. Govaert,  C. T. Thijs,  N. Masurel,  M. J. Sprenger,  G. J. '\n",
      " 'Dinant,  J.',\n",
      " 'A randomized double-blind placebo-controlled trial.',\n",
      " 'JAMAdoi:10.1001/jama.1994.03520210045030pmid:7966893OpenUrlCrossRefPubMedWeb '\n",
      " 'of Science↵ J.',\n",
      " 'Vaccinesdoi:10.3390/vaccines6020028pmid:29883414OpenUrlCrossRefPubMed↵ S. F. '\n",
      " 'Lumley et al., N. Engl.',\n",
      " 'Ward et al., Declining prevalence of antibody positivity to SARS-CoV-2: a '\n",
      " 'community study of 365,000 adults.',\n",
      " 'M. Dan et al., Immunological memory to SARS-CoV-2 assessed for up to eight '\n",
      " 'months after infection.',\n",
      " 'B. Larremore et al., Estimating SARS-CoV-2 seroprevalence and '\n",
      " 'epidemiological parameters with uncertainty from serological surveys.',\n",
      " 'Virologydoi:10.1016/j.virol.2006.04.005pmid:16725169OpenUrlCrossRefPubMedWeb '\n",
      " 'of Science↵ K. E. Langwig,  A. R. Wargo,  D. R. Jones,  J. R. Viss,  B. J. '\n",
      " 'Rutan,  N. A. Egan,  P. Sá-Guimarães,  M. S. Kim,  G. Kurath,  M. G. M. '\n",
      " 'Gomes,  M. Lipsitch, ',\n",
      " 'mBiodoi:10.1128/mBio.00796-17pmid:29162706OpenUrlAbstract/FREE Full Text↵P.',\n",
      " 'H. R. Sharpe,  C. Gilbride,  E. Allen,  S. Belij-Rammerstorfer,  C. '\n",
      " 'Bissett,  K. Ewer,  T. Lambe, ',\n",
      " 'Immunologydoi:10.1111/imm.13222pmid:32460358OpenUrlCrossRefPubMed↵M.',\n",
      " 'Kornfield, “When will children get a coronavirus vaccine?Not in time for the '\n",
      " 'new school year, experts fear,” The Washington Post 2 December 2020; '\n",
      " 'www.washingtonpost.com/health/2020/12/02/kids-vaccine-delay.↵K.',\n",
      " 'Prem et al., Projecting contact matrices in 177 geographical regions: an '\n",
      " 'update and comparison with empirical data for the COVID-19 era.',\n",
      " 'doi:10.1186/s12916-020-01597-8pmid:32375776OpenUrlCrossRefPubMed↵J.',\n",
      " 'Ghisolfi et al., “Predicted COVID-19 fatality rates based on age, sex, '\n",
      " 'comorbidities, and health system capacity,” working paper (Center for Global '\n",
      " 'Development, 2020).↵ M. Lipsitch,  N. E. Dean, ',\n",
      " 'Sciencedoi:10.1126/science.abe5938pmid:33087460OpenUrlAbstract/FREE Full '\n",
      " 'Text↵ L. E. Duijzer,  W. L. van Jaarsveld,  J. Wallinga,  R. Dekker, ',\n",
      " 'doi:10.1111/poms.12788pmid:32327917OpenUrlCrossRefPubMed↵ T. Takahashi,  M. '\n",
      " 'K. Ellingson,  P. Wong,  B. Israelow,  C. Lucas,  J. Klein,  J. Silva,  T. '\n",
      " 'Mao,  J. E. Oh,  M. Tokuyama,  P. Lu,  A. Venkataraman,  A.',\n",
      " 'Sun,  E. Y. Wang,  A. Casanovas-Massana,  A. L. Wyllie,  C. B. F. Vogels,  '\n",
      " 'R. Earnest,  S. Lapidus,  I. M. Ott,  A. J. Moore,  A. Shaw,  J.',\n",
      " 'B. Fournier,  C. D. Odio,  S. Farhadian,  C. Dela Cruz,  N. D. Grubaugh,  W. '\n",
      " 'L. Schulz,  A. M. Ring,  A. I. Ko,  S. B. Omer,  A. Iwasaki; Yale IMPACT '\n",
      " 'Research Team, ',\n",
      " 'Naturedoi:10.1038/s41586-020-2700-3pmid:32846427OpenUrlCrossRefPubMed↵ D. '\n",
      " 'Chakravarty,  S. S. Nair,  N. Hammouda,  P. Ratnani,  Y. Gharib,  V. '\n",
      " 'Wagaskar,  N. Mohamed,  D. Lundon,  Z. Dovey,  N. Kyprianou,  A. K. Tewari, ',\n",
      " 'doi:10.1038/s42003-020-1088-9pmid:32641750OpenUrlCrossRefPubMed↵ M. Webb '\n",
      " 'Hooper,  A. M. Nápoles,  E. J. Pérez-Stable, ',\n",
      " 'JAMAdoi:10.1001/jama.2020.8598pmid:32391864OpenUrlCrossRefPubMed↵M.',\n",
      " 'Sciencedoi:10.1126/science.369.6499.15pmid:32631874OpenUrlAbstract/FREE Full '\n",
      " 'Text↵ S. Mishra,  J. C. Kwong,  A. K. Chan,  S. D. Baral, ',\n",
      " 'CMAJdoi:10.1503/cmaj.201112pmid:32493741OpenUrlFREE Full Text L. Hawks,  S. '\n",
      " 'Woolhandler,  D. McCormick, ',\n",
      " 'doi:10.1001/jamainternmed.2020.1856pmid:32343355OpenUrlCrossRefPubMed H. S. '\n",
      " 'Badr et al., Lancet Infect.',\n",
      " 'A. van der Eijk,  R. S. van Binnendijk,  B. Haagmans,  M. Koopmans, ',\n",
      " 'doi:10.1038/s41467-020-17317-ypmid:32632160OpenUrlCrossRefPubMed↵R Core '\n",
      " 'Team, R: A Language and Environment for Statistical Computing (R Foundation '\n",
      " 'for Statistical Computing, 2019).K.',\n",
      " 'E. Atkinson, An Introduction to Numerical Analysis (Wiley, 1989), chap.',\n",
      " 'was supported in part by the Interdisciplinary Quantitative Biology (IQ '\n",
      " 'Biology) Ph.D. program at the BioFrontiers Institute, University of Colorado '\n",
      " 'Boulder.',\n",
      " 'were supported in part through the MIDAS Coordination Center (MIDASNI2020-2) '\n",
      " 'by a grant from the National Institute of General Medical Science '\n",
      " '(3U24GM132013-02S2).',\n",
      " 'were supported in part by the Morris-Singer Fund for the Center for '\n",
      " 'Communicable Disease Dynamics at the Harvard T. H. Chan School of Public '\n",
      " 'Health.',\n",
      " 'were supported in part by the SeroNet program of the National Cancer '\n",
      " 'Institute (1U01CA261277-01).',\n",
      " 'Author contributions: K.M.B., S.M.K., M.L., S.C., Y.H.G., and D.B.L.',\n",
      " 'discloses honoraria from and consulting for Merck, Affinivax, '\n",
      " 'Sanofi-Pasteur, Bristol Myers Squibb, and Antigen Discovery; research '\n",
      " 'funding (institutional) from Pfizer; and unpaid scientific advice to '\n",
      " 'Janssen, Astra-Zeneca, and Covaxx (United Biomedical); M.L.',\n",
      " 'is an honorary faculty member, Wellcome Sanger Institute, and an associate '\n",
      " 'member, Broad Institute.',\n",
      " 'discloses consulting for Merck and GlaxoSmithKline, and research funding '\n",
      " 'from Pfizer not related to this project or topic.',\n",
      " 'is a member of the scientific advisory board of Darwin BioSciences.',\n",
      " 'Data and materials availability: Reproduction code is open source and '\n",
      " 'provided by the authors (21).',\n",
      " 'This work is licensed under a Creative Commons Attribution 4.0 International '\n",
      " '(CC BY 4.0) license, which permits unrestricted use, distribution, and '\n",
      " 'reproduction in any medium, provided the original work is properly cited.',\n",
      " 'This license does not apply to figures/photos/artwork or other content '\n",
      " 'included in the article that is credited to a third party; obtain '\n",
      " 'authorization from the rights holder before using such material.',\n",
      " 'AAAS is a partner of\\xa0HINARI,\\xa0AGORA, OARE, CHORUS,\\xa0CLOCKSS,\\xa0'\n",
      " 'CrossRef\\xa0and\\xa0COUNTER.',\n",
      " 'Saving Lives, Protecting PeopleWhen germs, such as the virus that causes '\n",
      " 'COVID-19, invade our bodies, they attack and multiply.',\n",
      " 'This invasion, called an infection, is what causes illness.',\n",
      " 'Our immune system uses several tools to fight infection.',\n",
      " 'Blood contains red cells, which carry oxygen to tissues and organs, and '\n",
      " 'white or immune cells, which fight infection.',\n",
      " 'Different types of white blood cells fight infection in different ways:The '\n",
      " 'macrophages leave behind parts of the invading germs called antigens.',\n",
      " 'The body identifies antigens as dangerous and stimulates antibodies to '\n",
      " 'attack them.',\n",
      " 'They produce antibodies that attack the pieces of the virus left behind by '\n",
      " 'the macrophages.',\n",
      " 'T-lymphocytes\\xa0are another type of defensive white blood cell.',\n",
      " 'They attack cells in the body that have already been infected.',\n",
      " 'The first time a person is infected with the virus that causes COVID-19, it '\n",
      " 'can take several days or weeks for their body to make and use all the '\n",
      " 'germ-fighting tools needed to get over the infection.',\n",
      " 'After the infection, the person’s immune system remembers what it learned '\n",
      " 'about how to protect the body against that disease.',\n",
      " 'The body keeps a few T-lymphocytes, called memory cells, that go into action '\n",
      " 'quickly if the body encounters the same virus again.',\n",
      " 'When the familiar antigens are detected, B-lymphocytes produce antibodies to '\n",
      " 'attack them.',\n",
      " 'Experts are still learning how long these memory cells protect a person '\n",
      " 'against the virus that causes COVID-19.',\n",
      " 'How COVID-19 Vaccines WorkDifferent types of vaccines work in different ways '\n",
      " 'to offer protection, but with all types of vaccines, the body is left with a '\n",
      " 'supply of “memory” T-lymphocytes as well as B-lymphocytes that will remember '\n",
      " 'how to fight that virus in the future.',\n",
      " 'It typically takes a few weeks for the body to produce T-lymphocytes and '\n",
      " 'B-lymphocytes after vaccination.',\n",
      " 'Therefore, it is possible that a person could be infected with the virus '\n",
      " 'that causes COVID-19 just before or just after vaccination and then get sick '\n",
      " 'because the vaccine did not have enough time to provide protection.',\n",
      " 'Sometimes after vaccination, the process of building immunity can cause '\n",
      " 'symptoms, such as fever.',\n",
      " 'These symptoms are normal and are a sign that the body is building immunity.',\n",
      " 'Types of VaccinesBelow is a description of how each type of vaccine prompts '\n",
      " 'our bodies to recognize and protect us from the virus that causes COVID-19.',\n",
      " 'mRNA vaccines contain material from the virus that causes COVID-19 that '\n",
      " 'gives our cells instructions for how to make a harmless protein that is '\n",
      " 'unique to the virus.',\n",
      " 'After our cells make copies of the protein, they destroy the genetic '\n",
      " 'material from the vaccine.',\n",
      " 'Our bodies recognize that the protein should not be there and build '\n",
      " 'T-lymphocytes and B-lymphocytes that will remember how to fight the virus '\n",
      " 'that causes COVID-19 if we are infected in the future.',\n",
      " 'Protein subunit vaccines include harmless pieces (proteins) of the virus '\n",
      " 'that cause COVID-19 instead of the entire germ.',\n",
      " 'Once vaccinated, our immune system recognizes that the proteins don’t belong '\n",
      " 'in the body and begins making T-lymphocytes and\\xa0antibodies.',\n",
      " 'If we are ever infected in the future, memory cells will recognize and fight '\n",
      " 'the virus.',\n",
      " 'Vector vaccines contain a weakened version of a live virus—a different virus '\n",
      " 'than the one that causes COVID-19—that has genetic material from the virus '\n",
      " 'that causes COVID-19 inserted in it (this is called a viral vector).',\n",
      " 'Once the viral vector is inside our cells, the genetic material gives cells '\n",
      " 'instructions to make a protein that is unique to the virus that causes '\n",
      " 'COVID-19.',\n",
      " 'Using these instructions, our cells make copies of the protein.',\n",
      " 'This prompts our bodies to build T-lymphocytes and B-lymphocytes that will '\n",
      " 'remember how to fight that virus if we are infected in the future.',\n",
      " 'Most COVID-19 Vaccines Require More Than One ShotThe first shot starts '\n",
      " 'building protection.',\n",
      " 'A second shot a few weeks later is needed to get the most protection the '\n",
      " 'vaccine has to offer.',\n",
      " 'One vaccine in Phase 3 clinical trials only needs one shot.',\n",
      " 'The Bottom LineProtection from COVID-19 is critically important because for '\n",
      " 'some people, it can cause severe illness or death.',\n",
      " 'Stopping a pandemic requires using all the tools available.',\n",
      " 'Vaccines work with your immune system so your body will be ready to fight '\n",
      " 'the virus if you are exposed.',\n",
      " 'Other steps, like masks and social distancing, help reduce your chance of '\n",
      " 'being exposed to the virus or spreading it to others.',\n",
      " 'Together, COVID-19 vaccination and following CDC’s recommendations to '\n",
      " 'protect yourself and others will offer the best protection from COVID-19.',\n",
      " 'Visit CDC-INFOThe Centers for Disease Control and Prevention (CDC) cannot '\n",
      " 'attest to the accuracy of a non-federal website.',\n",
      " 'Linking to a non-federal website does not constitute an endorsement by CDC '\n",
      " 'or any of its employees of the sponsors or the information and products '\n",
      " 'presented on the website.',\n",
      " \"You will be subject to the destination website's privacy policy when you \"\n",
      " 'follow the link.',\n",
      " 'CDC is not responsible for Section 508 compliance (accessibility) on other '\n",
      " 'federal or private website.',\n",
      " \"For more information on CDC's web notification policies, see Website \"\n",
      " 'Disclaimers.',\n",
      " 'CancelIt gives you the best protection against coronavirus.',\n",
      " 'The MHRA follows international standards of safety.</p><p>Other vaccines are '\n",
      " 'being developed.',\n",
      " 'They will only be available on the NHS once they have been thoroughly tested '\n",
      " 'to make sure they are safe and effective.</p><p>So far, millions of people '\n",
      " 'have been given a COVID-19 vaccine and reports of serious side effects, such '\n",
      " 'as allergic reactions, have been very rare.',\n",
      " 'No long-term complications have been reported.</p>\", \"title\": \"How safe is '\n",
      " 'the COVID-19 vaccine?',\n",
      " 'But you need to have the 2 doses of the vaccine to give you longer lasting '\n",
      " 'protection.</p><p>There is a chance you might still get or spread '\n",
      " 'coronavirus even if you have the vaccine.</p><p>This means it is important '\n",
      " 'to:</p><ul><li>continue to follow <a '\n",
      " 'href=\\\\\"/conditions/coronavirus-covid-19/social-distancing/what-you-need-to-do/\\\\\">social '\n",
      " 'distancing guidance</a></li><li>if you can, wear something that covers your '\n",
      " \"nose and mouth in places where it's hard to stay away from other \"\n",
      " 'people</li></ul>\", \"title\": \"How effective is the COVID-19 vaccine?',\n",
      " 'If you do have a reaction to the vaccine, it usually happens in minutes.',\n",
      " 'It gives you the best protection against coronavirus.',\n",
      " \"Who can get the COVID-19 vaccineMore centres are opening all the time.It's \"\n",
      " 'being given to:people aged 60 and overpeople at high risk from coronavirus '\n",
      " '(clinically extremely vulnerable)people who live or work in care homeshealth '\n",
      " 'and social care workerspeople with a condition that puts them at higher risk '\n",
      " '(clinically vulnerable)people who are a main carer for someone at high risk '\n",
      " 'from coronavirus',\n",
      " \"The NHS will let you know when it's your turn to have the vaccine.\",\n",
      " \"It's important not to contact the NHS for a vaccination before then.\",\n",
      " \"Advice if you're of childbearing age, pregnant or breastfeedingBut more \"\n",
      " 'evidence is needed before you can routinely be offered it.The JCVI has '\n",
      " 'updated its advice to recommend you may be able to have the vaccine if '\n",
      " \"you're pregnant and:at high risk of getting coronavirus because of where you \"\n",
      " \"workhave a health condition that means you're at high risk of serious \"\n",
      " \"complications of coronavirusYou can have the COVID-19 vaccine if you're \"\n",
      " 'breastfeeding.Speak to a healthcare professional before you have the '\n",
      " 'vaccination.',\n",
      " 'They will discuss the benefits and risks with you.You do not need to avoid '\n",
      " 'pregnancy after vaccination.',\n",
      " 'The vaccine cannot give you or your baby COVID-19.Read the latest COVID-19 '\n",
      " \"vaccine advice if you're pregnant, may get pregnant or are breastfeeding on \"\n",
      " 'GOV.UKRead the latest Royal College of Obstetricians and Gynaecologists and '\n",
      " 'Royal College of Midwives statement on the COVID-19 vaccine and fertility',\n",
      " 'You will have the 2nd dose 3 to 12 weeks after having the 1st dose.',\n",
      " 'The MHRA follows international standards of safety.Other vaccines are being '\n",
      " 'developed.',\n",
      " 'They will only be available on the NHS once they have been thoroughly tested '\n",
      " 'to make sure they are safe and effective.So far, millions of people have '\n",
      " 'been given a COVID-19 vaccine and reports of serious side effects, such as '\n",
      " 'allergic reactions, have been very rare.',\n",
      " 'To find out more about the vaccines approved in the UK, see:GOV.UK: '\n",
      " 'Pfizer/BioNTech vaccine for COVID-19 approved by MHRAGOV.UK: '\n",
      " 'Oxford/AstraZeneca vaccine for COVID-19 approved by MHRAGOV.UK: Moderna '\n",
      " 'vaccine for COVID-19 approved by MHRA',\n",
      " 'The 1st dose of the COVID-19 vaccine should give you good protection from '\n",
      " 'coronavirus.',\n",
      " 'But you need to have the 2 doses of the vaccine to give you longer lasting '\n",
      " 'protection.There is a chance you might still get or spread coronavirus even '\n",
      " 'if you have the vaccine.This means it is important to:continue to follow '\n",
      " 'social distancing guidanceif you can, wear something that covers your nose '\n",
      " \"and mouth in places where it's hard to stay away from other people\",\n",
      " 'COVID-19 vaccine side effectsIf you do have a reaction to the vaccine, it '\n",
      " 'usually happens in minutes.',\n",
      " 'Staff giving the vaccine are trained to deal with allergic reactions and '\n",
      " 'treat them immediately.',\n",
      " 'Spring 2021 is the best estimate of when vaccines will be available for the '\n",
      " 'general public.',\n",
      " 'Do not show up at a hub or provider looking for a vaccine.',\n",
      " 'Call only if the website doesn’t answer your questions.',\n",
      " 'Do you know someone who is eligible for a vaccine but doesn’t have internet '\n",
      " 'access?Please let them know they can call 2‑1‑1 for referral to a local '\n",
      " 'vaccine provider.',\n",
      " 'Vaccine supply is still limited in Texas, but more arrives each week.',\n",
      " 'Important to KnowIt’s best if you get your second dose from the same brand '\n",
      " 'as your first dose.',\n",
      " 'For example, if you got a Moderna first dose, it’s best to get Moderna for '\n",
      " 'your second dose.',\n",
      " 'The timing between your first and second dose depends on which vaccine you '\n",
      " 'received:The chance of a severe reaction is less than 0.5%.',\n",
      " 'To be safe, your provider will have you wait on-site for 15-30 minutes after '\n",
      " 'your shot.',\n",
      " \"V-safe: Register with CDC's V-safe After Vaccination Health Checker on your \"\n",
      " 'smartphone to report any side effects after getting the COVID-19 vaccine.',\n",
      " 'You’ll also get reminders for your second vaccine dose.',\n",
      " 'Texas Vaccine Rollout TimelineSpring 2021 is the best estimate of when '\n",
      " 'vaccine will be available for the general public, but that may change.',\n",
      " 'It depends on vaccine production and how quickly other vaccines become '\n",
      " 'available.']\n"
     ]
    }
   ],
   "source": [
    "clean_sents_3 = []\n",
    "for sent in clean_sents_2:\n",
    "  if len(sent) > 50 and 'http' not in sent:\n",
    "    clean_sents_3.append(sent)\n",
    "\n",
    "pprint.pprint(clean_sents_3)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "e2HTgIq5cpn-"
   },
   "source": [
    "### 2.4 Clean the data - 4\n",
    "\n",
    "Until now, the left sentences only contains some cites of the authors, press sections. \n",
    "From here we will save the data into .csv file, then we will delete the useless sentences without meaning manually. Then we will name a new .csv file with 'data_new.csv'. The sentences in this file are almost clean. "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "Z-EMaCE-dn1x"
   },
   "outputs": [],
   "source": [
    "import csv\n",
    "\n",
    "with open('data.csv', 'w', encoding='utf-8') as f:\n",
    "  writer = csv.writer(f)\n",
    "  writer.writerow(['sentence'])\n",
    "  for row in clean_sents_3:\n",
    "    writer.writerow([str(row)])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "lkfa8vRHl4F_"
   },
   "source": [
    "## 3. Extract sentece to triples\n",
    "\n",
    "From this part, we will load the contents from 'data_new.csv', the extrace the sentence to triples, with format of (subject, predict, object) \\\\\n",
    "We will use the toolkit, NLPTriples."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "0DhVOyO3z1dS",
    "outputId": "ce991d4d-33bc-4206-eb73-d1af20921186",
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Collecting nlptriples\n",
      "  Downloading https://files.pythonhosted.org/packages/b1/a2/082bbc73670781aca2393786fa900ae36d803de1be68e060184bc08d0c34/NLPTriples-0.1.7-py3-none-any.whl\n",
      "Collecting tensorflow==1.15.2\n",
      "\u001b[?25l  Downloading https://files.pythonhosted.org/packages/5b/81/84fb7a323f9723f81edfc796d89e89aa95a9446ed7353c144195b3a3a3ba/tensorflow-1.15.2-cp37-cp37m-manylinux2010_x86_64.whl (110.5MB)\n",
      "\u001b[K     |████████████████████████████████| 110.5MB 47kB/s \n",
      "\u001b[?25hRequirement already satisfied: spacy<3.0.0,>=2.2.4 in /usr/local/lib/python3.7/dist-packages (from nlptriples) (2.2.4)\n",
      "Requirement already satisfied: cython<0.30.0,>=0.29.16 in /usr/local/lib/python3.7/dist-packages (from nlptriples) (0.29.22)\n",
      "Requirement already satisfied: numpy<2.0.0,>=1.18.2 in /usr/local/lib/python3.7/dist-packages (from nlptriples) (1.19.5)\n",
      "Collecting benepar[cpu]<0.2.0,>=0.1.2\n",
      "\u001b[?25l  Downloading https://files.pythonhosted.org/packages/72/63/dcd46b4bea9430ac6b4df8415016afa6cd724444edf75de0c94f145672a5/benepar-0.1.3.tar.gz (68kB)\n",
      "\u001b[K     |████████████████████████████████| 71kB 6.6MB/s \n",
      "\u001b[?25hRequirement already satisfied: google-pasta>=0.1.6 in /usr/local/lib/python3.7/dist-packages (from tensorflow==1.15.2->nlptriples) (0.2.0)\n",
      "Requirement already satisfied: protobuf>=3.6.1 in /usr/local/lib/python3.7/dist-packages (from tensorflow==1.15.2->nlptriples) (3.12.4)\n",
      "Requirement already satisfied: opt-einsum>=2.3.2 in /usr/local/lib/python3.7/dist-packages (from tensorflow==1.15.2->nlptriples) (3.3.0)\n",
      "Collecting tensorboard<1.16.0,>=1.15.0\n",
      "\u001b[?25l  Downloading https://files.pythonhosted.org/packages/1e/e9/d3d747a97f7188f48aa5eda486907f3b345cd409f0a0850468ba867db246/tensorboard-1.15.0-py3-none-any.whl (3.8MB)\n",
      "\u001b[K     |████████████████████████████████| 3.8MB 37.6MB/s \n",
      "\u001b[?25hRequirement already satisfied: keras-preprocessing>=1.0.5 in /usr/local/lib/python3.7/dist-packages (from tensorflow==1.15.2->nlptriples) (1.1.2)\n",
      "Requirement already satisfied: grpcio>=1.8.6 in /usr/local/lib/python3.7/dist-packages (from tensorflow==1.15.2->nlptriples) (1.32.0)\n",
      "Collecting tensorflow-estimator==1.15.1\n",
      "\u001b[?25l  Downloading https://files.pythonhosted.org/packages/de/62/2ee9cd74c9fa2fa450877847ba560b260f5d0fb70ee0595203082dafcc9d/tensorflow_estimator-1.15.1-py2.py3-none-any.whl (503kB)\n",
      "\u001b[K     |████████████████████████████████| 512kB 41.4MB/s \n",
      "\u001b[?25hRequirement already satisfied: wrapt>=1.11.1 in /usr/local/lib/python3.7/dist-packages (from tensorflow==1.15.2->nlptriples) (1.12.1)\n",
      "Requirement already satisfied: six>=1.10.0 in /usr/local/lib/python3.7/dist-packages (from tensorflow==1.15.2->nlptriples) (1.15.0)\n",
      "Collecting gast==0.2.2\n",
      "  Downloading https://files.pythonhosted.org/packages/4e/35/11749bf99b2d4e3cceb4d55ca22590b0d7c2c62b9de38ac4a4a7f4687421/gast-0.2.2.tar.gz\n",
      "Collecting keras-applications>=1.0.8\n",
      "\u001b[?25l  Downloading https://files.pythonhosted.org/packages/71/e3/19762fdfc62877ae9102edf6342d71b28fbfd9dea3d2f96a882ce099b03f/Keras_Applications-1.0.8-py3-none-any.whl (50kB)\n",
      "\u001b[K     |████████████████████████████████| 51kB 5.8MB/s \n",
      "\u001b[?25hRequirement already satisfied: astor>=0.6.0 in /usr/local/lib/python3.7/dist-packages (from tensorflow==1.15.2->nlptriples) (0.8.1)\n",
      "Requirement already satisfied: termcolor>=1.1.0 in /usr/local/lib/python3.7/dist-packages (from tensorflow==1.15.2->nlptriples) (1.1.0)\n",
      "Requirement already satisfied: wheel>=0.26; python_version >= \"3\" in /usr/local/lib/python3.7/dist-packages (from tensorflow==1.15.2->nlptriples) (0.36.2)\n",
      "Requirement already satisfied: absl-py>=0.7.0 in /usr/local/lib/python3.7/dist-packages (from tensorflow==1.15.2->nlptriples) (0.10.0)\n",
      "Requirement already satisfied: setuptools in /usr/local/lib/python3.7/dist-packages (from spacy<3.0.0,>=2.2.4->nlptriples) (54.0.0)\n",
      "Requirement already satisfied: wasabi<1.1.0,>=0.4.0 in /usr/local/lib/python3.7/dist-packages (from spacy<3.0.0,>=2.2.4->nlptriples) (0.8.2)\n",
      "Requirement already satisfied: tqdm<5.0.0,>=4.38.0 in /usr/local/lib/python3.7/dist-packages (from spacy<3.0.0,>=2.2.4->nlptriples) (4.41.1)\n",
      "Requirement already satisfied: plac<1.2.0,>=0.9.6 in /usr/local/lib/python3.7/dist-packages (from spacy<3.0.0,>=2.2.4->nlptriples) (1.1.3)\n",
      "Requirement already satisfied: srsly<1.1.0,>=1.0.2 in /usr/local/lib/python3.7/dist-packages (from spacy<3.0.0,>=2.2.4->nlptriples) (1.0.5)\n",
      "Requirement already satisfied: thinc==7.4.0 in /usr/local/lib/python3.7/dist-packages (from spacy<3.0.0,>=2.2.4->nlptriples) (7.4.0)\n",
      "Requirement already satisfied: cymem<2.1.0,>=2.0.2 in /usr/local/lib/python3.7/dist-packages (from spacy<3.0.0,>=2.2.4->nlptriples) (2.0.5)\n",
      "Requirement already satisfied: catalogue<1.1.0,>=0.0.7 in /usr/local/lib/python3.7/dist-packages (from spacy<3.0.0,>=2.2.4->nlptriples) (1.0.0)\n",
      "Requirement already satisfied: requests<3.0.0,>=2.13.0 in /usr/local/lib/python3.7/dist-packages (from spacy<3.0.0,>=2.2.4->nlptriples) (2.23.0)\n",
      "Requirement already satisfied: murmurhash<1.1.0,>=0.28.0 in /usr/local/lib/python3.7/dist-packages (from spacy<3.0.0,>=2.2.4->nlptriples) (1.0.5)\n",
      "Requirement already satisfied: blis<0.5.0,>=0.4.0 in /usr/local/lib/python3.7/dist-packages (from spacy<3.0.0,>=2.2.4->nlptriples) (0.4.1)\n",
      "Requirement already satisfied: preshed<3.1.0,>=3.0.2 in /usr/local/lib/python3.7/dist-packages (from spacy<3.0.0,>=2.2.4->nlptriples) (3.0.5)\n",
      "Requirement already satisfied: nltk>=3.2 in /usr/local/lib/python3.7/dist-packages (from benepar[cpu]<0.2.0,>=0.1.2->nlptriples) (3.2.5)\n",
      "Requirement already satisfied: markdown>=2.6.8 in /usr/local/lib/python3.7/dist-packages (from tensorboard<1.16.0,>=1.15.0->tensorflow==1.15.2->nlptriples) (3.3.4)\n",
      "Requirement already satisfied: werkzeug>=0.11.15 in /usr/local/lib/python3.7/dist-packages (from tensorboard<1.16.0,>=1.15.0->tensorflow==1.15.2->nlptriples) (1.0.1)\n",
      "Requirement already satisfied: h5py in /usr/local/lib/python3.7/dist-packages (from keras-applications>=1.0.8->tensorflow==1.15.2->nlptriples) (2.10.0)\n",
      "Requirement already satisfied: importlib-metadata>=0.20; python_version < \"3.8\" in /usr/local/lib/python3.7/dist-packages (from catalogue<1.1.0,>=0.0.7->spacy<3.0.0,>=2.2.4->nlptriples) (3.7.0)\n",
      "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.7/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.0.0,>=2.2.4->nlptriples) (2020.12.5)\n",
      "Requirement already satisfied: urllib3!=1.25.0,!=1.25.1,<1.26,>=1.21.1 in /usr/local/lib/python3.7/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.0.0,>=2.2.4->nlptriples) (1.24.3)\n",
      "Requirement already satisfied: chardet<4,>=3.0.2 in /usr/local/lib/python3.7/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.0.0,>=2.2.4->nlptriples) (3.0.4)\n",
      "Requirement already satisfied: idna<3,>=2.5 in /usr/local/lib/python3.7/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.0.0,>=2.2.4->nlptriples) (2.10)\n",
      "Requirement already satisfied: zipp>=0.5 in /usr/local/lib/python3.7/dist-packages (from importlib-metadata>=0.20; python_version < \"3.8\"->catalogue<1.1.0,>=0.0.7->spacy<3.0.0,>=2.2.4->nlptriples) (3.4.0)\n",
      "Requirement already satisfied: typing-extensions>=3.6.4; python_version < \"3.8\" in /usr/local/lib/python3.7/dist-packages (from importlib-metadata>=0.20; python_version < \"3.8\"->catalogue<1.1.0,>=0.0.7->spacy<3.0.0,>=2.2.4->nlptriples) (3.7.4.3)\n",
      "Building wheels for collected packages: benepar, gast\n",
      "  Building wheel for benepar (setup.py) ... \u001b[?25l\u001b[?25hdone\n",
      "  Created wheel for benepar: filename=benepar-0.1.3-cp37-cp37m-linux_x86_64.whl size=104432 sha256=50726b5b8bdb1b95d31e702efa4185b34f156d3358952960000c6f7cc24542fc\n",
      "  Stored in directory: /root/.cache/pip/wheels/31/1d/e6/7aa04452c51e7d9ee78d876cb65a66d95f4993b54730d9e2cd\n",
      "  Building wheel for gast (setup.py) ... \u001b[?25l\u001b[?25hdone\n",
      "  Created wheel for gast: filename=gast-0.2.2-cp37-none-any.whl size=7540 sha256=163ff1ec1ff6742401a3052c809ae5897384590d926bace6c84d169c78a90a7e\n",
      "  Stored in directory: /root/.cache/pip/wheels/5c/2e/7e/a1d4d4fcebe6c381f378ce7743a3ced3699feb89bcfbdadadd\n",
      "Successfully built benepar gast\n",
      "\u001b[31mERROR: tensorflow-probability 0.12.1 has requirement gast>=0.3.2, but you'll have gast 0.2.2 which is incompatible.\u001b[0m\n",
      "Installing collected packages: tensorboard, tensorflow-estimator, gast, keras-applications, tensorflow, benepar, nlptriples\n",
      "  Found existing installation: tensorboard 2.4.1\n",
      "    Uninstalling tensorboard-2.4.1:\n",
      "      Successfully uninstalled tensorboard-2.4.1\n",
      "  Found existing installation: tensorflow-estimator 2.4.0\n",
      "    Uninstalling tensorflow-estimator-2.4.0:\n",
      "      Successfully uninstalled tensorflow-estimator-2.4.0\n",
      "  Found existing installation: gast 0.3.3\n",
      "    Uninstalling gast-0.3.3:\n",
      "      Successfully uninstalled gast-0.3.3\n",
      "  Found existing installation: tensorflow 2.4.1\n",
      "    Uninstalling tensorflow-2.4.1:\n",
      "      Successfully uninstalled tensorflow-2.4.1\n",
      "Successfully installed benepar-0.1.3 gast-0.2.2 keras-applications-1.0.8 nlptriples-0.1.7 tensorboard-1.15.0 tensorflow-1.15.2 tensorflow-estimator-1.15.1\n"
     ]
    }
   ],
   "source": [
    "# install NLPTriples\n",
    "!pip3 install nlptriples"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "TBZ6NoUX0iQe",
    "outputId": "5b6c212a-6bd1-4b8b-d1c5-699dce0e0cdc"
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(282, 1)"
      ]
     },
     "execution_count": 10,
     "metadata": {
      "tags": []
     },
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "\n",
    "candidate_sentences = pd.read_csv('data_new++.csv')\n",
    "candidate_sentences.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "W8nvdklW04Dk",
    "outputId": "1a092708-d890-49f2-a939-476a8eaa80a0"
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "89     The problem of vaccine prioritization also par...\n",
       "278    V-safe  Register with CDC is V-safe After Vacc...\n",
       "62     This also goes for compensation for hidden def...\n",
       "30     Total dose counts for these countries are not ...\n",
       "190    Although these modeling efforts focus on age a...\n",
       "Name: sentence, dtype: object"
      ]
     },
     "execution_count": 11,
     "metadata": {
      "tags": []
     },
     "output_type": "execute_result"
    }
   ],
   "source": [
    "candidate_sentences['sentence'].sample(5)\n",
    "\n",
    "sample_candidate = candidate_sentences['sentence'].sample(5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 180,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "5C47zdwNqywS",
    "outputId": "1415f1fc-5038-458f-b2c8-22694ca1dda9",
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  1%|          | 2/282 [00:12<29:13,  6.26s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  1%|          | 3/282 [00:18<28:52,  6.21s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  7%|▋         | 19/282 [01:52<25:57,  5.92s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  7%|▋         | 20/282 [01:58<25:27,  5.83s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 12%|█▏        | 35/282 [03:26<23:48,  5.78s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 15%|█▍        | 41/282 [04:01<23:34,  5.87s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 16%|█▌        | 44/282 [04:19<23:19,  5.88s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 16%|█▌        | 45/282 [04:25<23:24,  5.92s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 17%|█▋        | 47/282 [04:37<22:57,  5.86s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 17%|█▋        | 48/282 [04:43<23:01,  5.90s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 17%|█▋        | 49/282 [04:49<23:04,  5.94s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 18%|█▊        | 52/282 [05:07<22:41,  5.92s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 19%|█▉        | 53/282 [05:12<22:15,  5.83s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 21%|██        | 58/282 [05:42<22:27,  6.02s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 21%|██        | 59/282 [05:48<22:04,  5.94s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 22%|██▏       | 61/282 [06:00<22:20,  6.07s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 30%|██▉       | 84/282 [08:19<20:32,  6.23s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 36%|███▌      | 102/282 [10:09<18:13,  6.08s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 38%|███▊      | 106/282 [10:35<19:02,  6.49s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 38%|███▊      | 107/282 [10:40<18:10,  6.23s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 38%|███▊      | 108/282 [10:46<17:53,  6.17s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 39%|███▉      | 111/282 [11:05<17:36,  6.18s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 40%|████      | 113/282 [11:17<17:11,  6.11s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 41%|████      | 116/282 [11:35<16:40,  6.03s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 42%|████▏     | 119/282 [11:54<16:22,  6.03s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 43%|████▎     | 120/282 [12:00<16:23,  6.07s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 43%|████▎     | 121/282 [12:06<16:29,  6.15s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 43%|████▎     | 122/282 [12:12<16:08,  6.05s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 44%|████▎     | 123/282 [12:18<16:18,  6.16s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 44%|████▍     | 124/282 [12:25<16:29,  6.26s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 46%|████▌     | 129/282 [12:55<15:32,  6.09s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 46%|████▌     | 130/282 [13:01<15:24,  6.08s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 48%|████▊     | 135/282 [13:31<14:42,  6.01s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 50%|█████     | 141/282 [14:07<14:14,  6.06s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 51%|█████▏    | 145/282 [14:33<14:15,  6.25s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 52%|█████▏    | 147/282 [14:45<13:55,  6.19s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 56%|█████▌    | 157/282 [15:44<12:31,  6.01s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 56%|█████▌    | 158/282 [15:50<12:21,  5.98s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 61%|██████    | 172/282 [17:15<11:02,  6.03s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 62%|██████▏   | 174/282 [17:27<10:40,  5.93s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 63%|██████▎   | 178/282 [17:51<10:17,  5.93s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 71%|███████   | 199/282 [19:56<08:11,  5.93s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 76%|███████▌  | 215/282 [21:29<06:27,  5.79s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 90%|█████████ | 254/282 [25:19<02:43,  5.85s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 95%|█████████▌| 268/282 [26:44<01:25,  6.08s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 99%|█████████▊| 278/282 [27:42<00:23,  5.78s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 99%|█████████▉| 280/282 [27:54<00:11,  5.90s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "this sentence couldn't be extracted.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 282/282 [28:06<00:00,  5.98s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "235\n",
      "235\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "from nlptriples import triples, setup\n",
    "import networkx as nx\n",
    "import matplotlib.pyplot as plt\n",
    "from tqdm import tqdm\n",
    "import csv\n",
    "%matplotlib inline\n",
    "\n",
    "# f = open('extracted_sentence.csv', 'w', encoding='utf-8')\n",
    "# f_wirter = csv.writer(f)\n",
    "# f_wirter.writerow(['extracted sentences'])\n",
    "triple_list = []\n",
    "sent_list = []\n",
    "for i in tqdm(candidate_sentences['sentence']):\n",
    "  sent = i\n",
    "  rdf = triples.RDF_triple()\n",
    "  try:\n",
    "    triple = rdf.extract(sent)\n",
    "    triple_list.append(triple)\n",
    "    sent_list.append(sent)\n",
    "  except Exception as err:\n",
    "    print(\"this sentence couldn't be extracted.\")\n",
    "    continue\n",
    "print(len(triple_list))\n",
    "print(len(sent_list))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "pW8r1b698pvC"
   },
   "source": [
    "I will save the triple list into a csv file in case of I lose the data when I reload next time. "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 187,
   "metadata": {
    "id": "wJWmJuVP88Ow"
   },
   "outputs": [],
   "source": [
    "with open('triple_list.csv', 'w', encoding='utf-8') as t_list:\n",
    "  list_writer = csv.writer(t_list)\n",
    "  list_writer.writerow(['triples'])\n",
    "  for i in triple_list:\n",
    "    list_writer.writerow([str(i)])\n",
    "with open('sent_list.csv', 'w', encoding='utf-8') as s_list:\n",
    "  list_writer = csv.writer(s_list)\n",
    "  list_writer.writerow(['sentence'])\n",
    "  for i in sent_list:\n",
    "    list_writer.writerow([str(i)])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "bUM4PP_hHOk0"
   },
   "source": [
    "## 4. Visualize the Knowledge Graph\n",
    "\n",
    "Now we have the triple_list, which is consisting of a list of triples with the format of [subject, predicate, object], so we can visualize them. "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "thCWCmugJb0T"
   },
   "source": [
    "### 4.1 Define the knowledge graph\n",
    "\n",
    "In this step, I am going to save all the triples into a pandas.DataFrame object so that it's more convenient to use the data. "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 195,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "1rrJ4lz6IKSt",
    "outputId": "d645b6a1-2875-472f-e3bf-dfbeb1db7b67"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "         subject      predicate     object\n",
      "0       February            are           \n",
      "1       Vaccines         tested           \n",
      "2        studies      published           \n",
      "3    development      producing    vaccine\n",
      "4             It  collaborating           \n",
      "..           ...            ...        ...\n",
      "230      example            got    Moderna\n",
      "231       timing       received     chance\n",
      "232          CDC        getting           \n",
      "233        Texas             be  available\n",
      "234           It         become  available\n",
      "\n",
      "[235 rows x 3 columns]\n"
     ]
    }
   ],
   "source": [
    "# extract subject\n",
    "subs = [i[0] for i in triple_list]\n",
    "\n",
    "# extract predicate\n",
    "pres = [i[1] for i in triple_list]\n",
    "\n",
    "# extract object\n",
    "objs = [i[2] for i in triple_list]\n",
    "\n",
    "# sentence object\n",
    "# sents = [i for i in sent_list]\n",
    "\n",
    "# Use pandas.DataFrame type objec to save triples\n",
    "kg_table = pd.DataFrame({'subject':subs, 'predicate': pres, 'object': objs, 'sentence':sent_list})\n",
    "kg_df = pd.DataFrame({'subject':subs, 'predicate': pres, 'object': objs})\n",
    "# Check the knowledge graph\n",
    "print(kg_df)\n",
    "# Represent the structured triples with sentences. \n",
    "print(kg_table)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "_7PwTRcRKSZ6"
   },
   "source": [
    "### 4.2 Visualize the Knowledge Graph - 1\n",
    "\n",
    "I will create a visuable graph to check how is the roughly knowledge graph looks like"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/",
     "height": 794
    },
    "id": "c9ZA2EpAKjVh",
    "outputId": "e6f6dee3-d2f5-4ff7-c3a8-bc0970d53b12"
   },
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1152x1152 with 1 Axes>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# rendering a image from the dataframe I have already created in last step\n",
    "\n",
    "Gp = nx.from_pandas_edgelist(kg_df, \"subject\", \"object\", edge_attr=True,\n",
    "                             create_using=nx.MultiDiGraph)\n",
    "\n",
    "# rendering the image\n",
    "plt.figure(figsize=(16,16))\n",
    "pos = nx.spring_layout(Gp)\n",
    "nx.draw(Gp, with_labels=True, node_color='skyblue', edge_cmap=plt.cm.Blues, pos=pos)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "i36YT703LvCK"
   },
   "source": [
    "Obviously, there are many subjects and objects in the graph, it's not that clear to tell the relations between two entities (subject and object). The topic of this experiment is 'COVID-19 vaccine' so I will check the entity which includes the contents of 'vaccine' or 'COVID-19 vaccine'. "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "ZjexIqkiMX6l",
    "outputId": "bf700e3c-1c62-485a-9be7-8fb5dd81c65f",
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "We               12\n",
      "It               10\n",
      "vaccine           9\n",
      "They              6\n",
      "we                6\n",
      "you               5\n",
      "model             4\n",
      "Vaccine           3\n",
      "This              3\n",
      "Vaccines          3\n",
      "impact            3\n",
      "chances           3\n",
      "vaccines          3\n",
      "regime            3\n",
      "strategies        3\n",
      "CDC               2\n",
      "types             2\n",
      "estimate          2\n",
      "immune system     2\n",
      "doses             2\n",
      "dtype: int64\n",
      "\n",
      "                  70\n",
      "vaccine           11\n",
      "protection         6\n",
      "adults             5\n",
      "available          4\n",
      "virus              4\n",
      "population         3\n",
      "viable             3\n",
      "transmission       3\n",
      "doses              3\n",
      "vaccines           3\n",
      "prioritization     3\n",
      "vaccination        3\n",
      "chances            3\n",
      "mortality          2\n",
      "scenario           2\n",
      "study              2\n",
      "future             2\n",
      "immunity           2\n",
      "populations        2\n",
      "dtype: int64\n"
     ]
    }
   ],
   "source": [
    "# Checking how many times vaccine related words appear in the triples\n",
    "print(pd.Series(subs).value_counts()[:20])\n",
    "print()\n",
    "print(pd.Series(objs).value_counts()[:20])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "X9TJzKXEOog3"
   },
   "source": [
    "From the above result, for subject position, we can tell the word 'vaccine' appeared 9 times, 'Vaccine' appeared 3 times, 'Vaccines' appeared 3 times, 'vaccines' appeared 3 times. \\\\\n",
    "For object position, 'vaccine' appeared 11 times, 'vaccines' appeared 3 times, 'vaccination' appeared 3 times. \\\\\n",
    "We will take these datas out of the orginal dataframe and create a new dataframe which is only include vaccine. "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "0DM7ZiH0QBn7",
    "outputId": "b11b97e9-aa23-4582-c449-5809db49ac34"
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(35, 3)"
      ]
     },
     "execution_count": 51,
     "metadata": {
      "tags": []
     },
     "output_type": "execute_result"
    }
   ],
   "source": [
    "kg_v1 = kg_df.loc[kg_df['subject']=='vaccine'] # subject is 'vaccine'\n",
    "kg_v2 = kg_df.loc[kg_df['subject']=='Vaccine']  # subject is 'Vaccine'\n",
    "kg_v3 = kg_df.loc[kg_df['subject']=='Vaccines'] # subject is 'Vaccines'\n",
    "kg_v4 = kg_df.loc[kg_df['subject']=='vaccines'] # subject is 'vaccinea'\n",
    "\n",
    "kg_v5 = kg_df.loc[kg_df['object']=='vaccine'] # object is 'vaccine'\n",
    "kg_v6 = kg_df.loc[kg_df['object']=='vaccines']  # object is 'vaccines'\n",
    "kg_v7 = kg_df.loc[kg_df['object']=='vaccination'] # object is 'vaccination'\n",
    "\n",
    "kg_list = [kg_v1, kg_v2, kg_v3, kg_v4, kg_v5, kg_v6, kg_v7]\n",
    "\n",
    "# kg_new is the new graph only contains vaccine\n",
    "kg_new = pd.DataFrame(columns=['subject', 'predicate', 'object'])\n",
    "\n",
    "for i in kg_list:\n",
    "  kg_new = kg_new.append(i)\n",
    "\n",
    "kg_new = kg_new.sort_index() # sort graph contents with index\n",
    "kg_new.shape"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "RHtyIv8nmQau"
   },
   "source": [
    "### 4.3 Visualize Knowledge Graph - 2\n",
    "After above step we have 35 triples which are related with COVID-19 vaccine. We will visualize the graph again."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/",
     "height": 1000
    },
    "id": "lxpw3QohnkV2",
    "outputId": "bc143245-78d3-47e5-b5cc-dea7528ca31e"
   },
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1152x1152 with 1 Axes>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "Gp_v = nx.from_pandas_edgelist(kg_new, \"subject\", \"object\", edge_attr=True,\n",
    "                             create_using=nx.MultiDiGraph)\n",
    "\n",
    "# rendering the image\n",
    "plt.figure(figsize=(16,16))\n",
    "pos = nx.spring_layout(Gp_v)\n",
    "nx.draw(Gp_v, with_labels=True, node_color='red', edge_cmap=plt.cm.Blues, pos=pos)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "-qovlE05oCJT"
   },
   "source": [
    "This graph is much more clearer than the first one.  \\\\\n",
    "In the graph, we can easily see the relations between each node. Some nodes are empty without contents, which means we can create blank nodes when we do the serilization of knowledge graph. Although some triples are still ambiguous, I think it's relative good sample to do the next step. "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "SxlF53quoKSE"
   },
   "source": [
    "## 5. Serilization\n",
    "\n",
    "This I am going to map the vacabulary of an entity in a known ontology, if the vacabulary couldn't map in the known ontology, I will assign a new URI to the entity. \\\n",
    "After mapping, I will serialize the graph with the format of N-Triples and Turtle. "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "A-fEcmNttu1P"
   },
   "source": [
    "\n",
    "### 5.1 Mapping vacabularies"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Here I will check how many triples are in the variable 'kg_new'."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/",
     "height": 1000
    },
    "id": "6mMkgjcnuGFc",
    "outputId": "0309bf3c-78f9-43a4-d9ea-945c164b515d",
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>subject</th>\n",
       "      <th>predicate</th>\n",
       "      <th>object</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Vaccines</td>\n",
       "      <td>tested</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>development</td>\n",
       "      <td>producing</td>\n",
       "      <td>vaccine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>vaccine</td>\n",
       "      <td>go</td>\n",
       "      <td>Phase</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Messenger</td>\n",
       "      <td>contained</td>\n",
       "      <td>vaccine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Vaccines</td>\n",
       "      <td>include</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Vaccine</td>\n",
       "      <td>be</td>\n",
       "      <td>infectious</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>rights</td>\n",
       "      <td>provide</td>\n",
       "      <td>vaccination</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>Vaccine</td>\n",
       "      <td>take</td>\n",
       "      <td>vaccine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>Vaccine</td>\n",
       "      <td>take</td>\n",
       "      <td>vaccine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>52</th>\n",
       "      <td>vaccine</td>\n",
       "      <td>is</td>\n",
       "      <td>leaky</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>68</th>\n",
       "      <td>modeling</td>\n",
       "      <td>recommending</td>\n",
       "      <td>vaccination</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>74</th>\n",
       "      <td>incidence</td>\n",
       "      <td>compare</td>\n",
       "      <td>vaccine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>76</th>\n",
       "      <td>strategies</td>\n",
       "      <td>prioritized</td>\n",
       "      <td>vaccines</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>78</th>\n",
       "      <td>vaccine</td>\n",
       "      <td>vaccinated</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>83</th>\n",
       "      <td>We</td>\n",
       "      <td>varying</td>\n",
       "      <td>vaccine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>104</th>\n",
       "      <td>vaccines</td>\n",
       "      <td>distributing</td>\n",
       "      <td>vaccines</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>104</th>\n",
       "      <td>vaccines</td>\n",
       "      <td>distributing</td>\n",
       "      <td>vaccines</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>106</th>\n",
       "      <td>vaccines</td>\n",
       "      <td>is</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>113</th>\n",
       "      <td>DiscussionThis</td>\n",
       "      <td>evaluate</td>\n",
       "      <td>vaccine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>114</th>\n",
       "      <td>vaccine</td>\n",
       "      <td>accounting</td>\n",
       "      <td>vaccine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>114</th>\n",
       "      <td>vaccine</td>\n",
       "      <td>accounting</td>\n",
       "      <td>vaccine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>119</th>\n",
       "      <td>regime</td>\n",
       "      <td>characterized</td>\n",
       "      <td>vaccines</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>121</th>\n",
       "      <td>vaccine</td>\n",
       "      <td>have</td>\n",
       "      <td>properties</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>126</th>\n",
       "      <td>Delays</td>\n",
       "      <td>impair</td>\n",
       "      <td>vaccine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>132</th>\n",
       "      <td>vaccine</td>\n",
       "      <td>including</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>151</th>\n",
       "      <td>vaccine</td>\n",
       "      <td>harming</td>\n",
       "      <td>populations</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>174</th>\n",
       "      <td>It</td>\n",
       "      <td>produce</td>\n",
       "      <td>vaccination</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>191</th>\n",
       "      <td>vaccine</td>\n",
       "      <td>needs</td>\n",
       "      <td>shot</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>194</th>\n",
       "      <td>Vaccines</td>\n",
       "      <td>fight</td>\n",
       "      <td>virus</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>212</th>\n",
       "      <td>NHS</td>\n",
       "      <td>have</td>\n",
       "      <td>vaccine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>216</th>\n",
       "      <td>vaccine</td>\n",
       "      <td>get</td>\n",
       "      <td>pregnant</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>220</th>\n",
       "      <td>vaccines</td>\n",
       "      <td>approved</td>\n",
       "      <td>UK</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>223</th>\n",
       "      <td>Staff</td>\n",
       "      <td>giving</td>\n",
       "      <td>vaccine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>225</th>\n",
       "      <td>hub</td>\n",
       "      <td>looking</td>\n",
       "      <td>vaccine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>228</th>\n",
       "      <td>Vaccine</td>\n",
       "      <td>limited</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "            subject      predicate       object\n",
       "1          Vaccines         tested             \n",
       "3       development      producing      vaccine\n",
       "5           vaccine             go        Phase\n",
       "9         Messenger      contained      vaccine\n",
       "13         Vaccines        include             \n",
       "17          Vaccine             be   infectious\n",
       "31           rights        provide  vaccination\n",
       "32          Vaccine           take      vaccine\n",
       "32          Vaccine           take      vaccine\n",
       "52          vaccine             is        leaky\n",
       "68         modeling   recommending  vaccination\n",
       "74        incidence        compare      vaccine\n",
       "76       strategies    prioritized     vaccines\n",
       "78          vaccine     vaccinated             \n",
       "83               We        varying      vaccine\n",
       "104        vaccines   distributing     vaccines\n",
       "104        vaccines   distributing     vaccines\n",
       "106        vaccines             is             \n",
       "113  DiscussionThis       evaluate      vaccine\n",
       "114         vaccine     accounting      vaccine\n",
       "114         vaccine     accounting      vaccine\n",
       "119          regime  characterized     vaccines\n",
       "121         vaccine           have   properties\n",
       "126          Delays         impair      vaccine\n",
       "132         vaccine      including             \n",
       "151         vaccine        harming  populations\n",
       "174              It        produce  vaccination\n",
       "191         vaccine          needs         shot\n",
       "194        Vaccines          fight        virus\n",
       "212             NHS           have      vaccine\n",
       "216         vaccine            get     pregnant\n",
       "220        vaccines       approved           UK\n",
       "223           Staff         giving      vaccine\n",
       "225             hub        looking      vaccine\n",
       "228         Vaccine        limited             "
      ]
     },
     "execution_count": 52,
     "metadata": {
      "tags": []
     },
     "output_type": "execute_result"
    }
   ],
   "source": [
    "kg_new"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "xdkFFRgE9GQA"
   },
   "source": [
    "I will manually check if the vocabularies above are existing in the known ontology, DBPedia. \\\n",
    "On subject position like vaccine, vaccines means COVID-19 vaccine (in the previous program 'COVID-19' get lost). \\\n",
    "Vaccine, Vaccines on subject position also means vaccine \\\n",
    "On object position, I assume all the words like vaccine, vaccines means COVID-19 vaccine ( It might not be corrected but I currently don't have a good idea to optimize it.) \n",
    "\n",
    "In a triple, firstly, I will check if the subject, predicate, and object already have been mapped to dbpedia. If yes, I will manually add the URL on them. Secondly, I will choose a subject or object (usually object) as a new subject of an additional triple, the predicate of this additional triple is a label based on my own namespace, the subject is the contents where the first triple come from. \n",
    "\n",
    "I will use rdflib module to do above procedure."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "collapsed": true,
    "id": "UYUaKnCXuU1L",
    "outputId": "66a52d40-28d8-4e12-fbfc-cb5cf1ebd24c"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Collecting rdflib\n",
      "\u001b[?25l  Downloading https://files.pythonhosted.org/packages/d0/6b/6454aa1db753c0f8bc265a5bd5c10b5721a4bb24160fb4faf758cf6be8a1/rdflib-5.0.0-py3-none-any.whl (231kB)\n",
      "\r",
      "\u001b[K     |█▍                              | 10kB 12.1MB/s eta 0:00:01\r",
      "\u001b[K     |██▉                             | 20kB 11.1MB/s eta 0:00:01\r",
      "\u001b[K     |████▎                           | 30kB 8.7MB/s eta 0:00:01\r",
      "\u001b[K     |█████▊                          | 40kB 7.8MB/s eta 0:00:01\r",
      "\u001b[K     |███████                         | 51kB 4.4MB/s eta 0:00:01\r",
      "\u001b[K     |████████▌                       | 61kB 5.0MB/s eta 0:00:01\r",
      "\u001b[K     |██████████                      | 71kB 5.1MB/s eta 0:00:01\r",
      "\u001b[K     |███████████▍                    | 81kB 5.3MB/s eta 0:00:01\r",
      "\u001b[K     |████████████▊                   | 92kB 5.4MB/s eta 0:00:01\r",
      "\u001b[K     |██████████████▏                 | 102kB 5.8MB/s eta 0:00:01\r",
      "\u001b[K     |███████████████▋                | 112kB 5.8MB/s eta 0:00:01\r",
      "\u001b[K     |█████████████████               | 122kB 5.8MB/s eta 0:00:01\r",
      "\u001b[K     |██████████████████▍             | 133kB 5.8MB/s eta 0:00:01\r",
      "\u001b[K     |███████████████████▉            | 143kB 5.8MB/s eta 0:00:01\r",
      "\u001b[K     |█████████████████████▎          | 153kB 5.8MB/s eta 0:00:01\r",
      "\u001b[K     |██████████████████████▊         | 163kB 5.8MB/s eta 0:00:01\r",
      "\u001b[K     |████████████████████████        | 174kB 5.8MB/s eta 0:00:01\r",
      "\u001b[K     |█████████████████████████▌      | 184kB 5.8MB/s eta 0:00:01\r",
      "\u001b[K     |███████████████████████████     | 194kB 5.8MB/s eta 0:00:01\r",
      "\u001b[K     |████████████████████████████▍   | 204kB 5.8MB/s eta 0:00:01\r",
      "\u001b[K     |█████████████████████████████▉  | 215kB 5.8MB/s eta 0:00:01\r",
      "\u001b[K     |███████████████████████████████▏| 225kB 5.8MB/s eta 0:00:01\r",
      "\u001b[K     |████████████████████████████████| 235kB 5.8MB/s \n",
      "\u001b[?25hRequirement already satisfied: six in /usr/local/lib/python3.7/dist-packages (from rdflib) (1.15.0)\n",
      "Requirement already satisfied: pyparsing in /usr/local/lib/python3.7/dist-packages (from rdflib) (2.4.7)\n",
      "Collecting isodate\n",
      "\u001b[?25l  Downloading https://files.pythonhosted.org/packages/9b/9f/b36f7774ff5ea8e428fdcfc4bb332c39ee5b9362ddd3d40d9516a55221b2/isodate-0.6.0-py2.py3-none-any.whl (45kB)\n",
      "\u001b[K     |████████████████████████████████| 51kB 4.2MB/s \n",
      "\u001b[?25hInstalling collected packages: isodate, rdflib\n",
      "Successfully installed isodate-0.6.0 rdflib-5.0.0\n"
     ]
    }
   ],
   "source": [
    "# install reflib\n",
    "!pip install rdflib"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 188,
   "metadata": {
    "id": "2nY6uZMIo3mF"
   },
   "outputs": [],
   "source": [
    "# create function to find the original sentences where triples matched with\n",
    "def find_sent(triple, sentences):\n",
    "  sub, pre, obj = triple\n",
    "  for i in sentences:\n",
    "    if sub in i and pre in i and obj in i:\n",
    "      sent = i\n",
    "  return sent"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 189,
   "metadata": {
    "id": "FfdWsFD6uZ5f"
   },
   "outputs": [],
   "source": [
    "from rdflib import URIRef, BNode, Literal\n",
    "from rdflib import Graph\n",
    "from rdflib import Namespace\n",
    "from rdflib.namespace import CSVW, DC, DCAT, DCTERMS, DOAP, FOAF, ODRL2, ORG, OWL, \\\n",
    "                           PROF, PROV, RDF, RDFS, SDO, SH, SKOS, SOSA, SSN, TIME, \\\n",
    "                           VOID, XMLNS, XSD\n",
    "\n",
    "# define the namespace\n",
    "dbr = Namespace('http://www.dbpedia.org/resource/')\n",
    "exp = Namespace('http://www.exp.org/')\n",
    "expa = Namespace('http://www.exp.org/Action/')\n",
    "expn = Namespace('http://www.exp.org/Noun/')\n",
    "OWL.Thing\n",
    "\n",
    "# create graph\n",
    "g = Graph()\n",
    "g.bind('owl', OWL)\n",
    "g.bind('foaf', FOAF)\n",
    "\n",
    "OWL.Type\n",
    "OWL.Thing\n",
    "exp.label\n",
    "\n",
    "# based on index 1\n",
    "# subject operation\n",
    "Vaccine = dbr.COVID_19_vaccine\n",
    "vaccine_label = Literal('COVID_19_vaccine')\n",
    "g.add((Vaccine, OWL.Type, OWL.Thing)) # map on OWL\n",
    "g.add((Vaccine, RDFS.label, vaccine_label)) # map on RDFS\n",
    "\n",
    "# predicate operation\n",
    "tested = expa.tested\n",
    "tested_label = Literal('tested')\n",
    "g.add((tested, exp.label, tested_label)) # map on my own namespace\n",
    "\n",
    "# subject operation\n",
    "sentence = find_sent(('Vaccine', 'tested', ''), candidate_sentences['sentence']) # find the sentences where the first triple extracted from\n",
    "process = expn.process # object, also the subject of the additional triple\n",
    "from_news = exp.label\n",
    "news = Literal(sentence)\n",
    "\n",
    "g.add((Vaccine, tested, process)) # first triple\n",
    "g.add((process, from_news, news)) # additional triple\n",
    "\n",
    "# index 3\n",
    "development = URIRef('http://dbpedia.org/resource/COVID-19_vaccine_development')\n",
    "producing = expa.producing\n",
    "vaccine = Literal('vaccine@en')\n",
    "vaccine_label = Literal('vaccine_development@en')\n",
    "g.add((development, OWL.Type, OWL.Thing))\n",
    "g.add((development, producing, vaccine))\n",
    "g.add((development, exp.label, vaccine_label))\n",
    "\n",
    "# # index 5\n",
    "vaccine = dbr.COVID_19_vaccine\n",
    "go = expa.go\n",
    "Phase = expn.Phase\n",
    "label = Literal('vaccine_phase@en')\n",
    "g.add((vaccine, go, Phase))\n",
    "g.add((vaccine, OWL.Type, OWL.Thing))\n",
    "g.add((vaccine, exp.label, label))\n",
    "\n",
    "# index 9\n",
    "Messager = exp.Messager\n",
    "contained = expa.contained\n",
    "g.add((Messager, contained, vaccine))\n",
    "\n",
    "# index 13\n",
    "Vaccines = dbr.COVID_19_vaccine\n",
    "include = expa.include\n",
    "composition = BNode()\n",
    "g.add((Vaccines, include, composition))\n",
    "\n",
    "# index 17\n",
    "be = expa.be\n",
    "infectious = expa.infectious\n",
    "g.add((vaccine, be, infectious))\n",
    "\n",
    "# index 31\n",
    "rights = expn.rights\n",
    "provide = expa.provide\n",
    "vaccination = exp.vaccination\n",
    "g.add((rights, provide, vaccination))\n",
    "\n",
    "# index 32\n",
    "take = expa.take\n",
    "g.add((Vaccine, take, vaccine))\n",
    "\n",
    "# index 52\n",
    "leaky = Literal('leaky@en')\n",
    "g.add((vaccine, be, leaky))\n",
    "\n",
    "# index 68\n",
    "modeling = expn.modeling\n",
    "recommending = expa.recommending\n",
    "g.add((modeling, recommending, vaccination))\n",
    "\n",
    "# index 74\n",
    "incidence = expn.incidence\n",
    "compare = expa.compare\n",
    "g.add((incidence, compare, vaccination))\n",
    "\n",
    "# index 76\n",
    "strategy = exp.strategy\n",
    "prioritized = expa.prioritized\n",
    "g.add((strategy, prioritized, vaccine))\n",
    "\n",
    "# index 78\n",
    "vaccinated = expa.vaccinated\n",
    "target = BNode()\n",
    "g.add((vaccine, vaccinated, target))\n",
    "\n",
    "# index 83\n",
    "We = exp.people\n",
    "varying = expa.very\n",
    "g.add((We, varying, vaccine))\n",
    "\n",
    "# index 104\n",
    "distribting = expa.distribution\n",
    "obj_people = BNode()\n",
    "g.add((vaccine, distribting, obj_people))\n",
    "\n",
    "# index 106\n",
    "g.add((vaccine, OWL.Type, OWL.Thing))\n",
    "\n",
    "# index 113\n",
    "Discussion = expn.discussion\n",
    "evaluate = expa.evaluate\n",
    "g.add((Discussion, evaluate, vaccine))\n",
    "\n",
    "# index 114\n",
    "accounting = expa.accounting\n",
    "g.add((vaccine, accounting, vaccine))\n",
    "\n",
    "# index 119\n",
    "regime = expn.regime\n",
    "characterized = expa.characterized\n",
    "g.add((regime, characterized, vaccine))\n",
    "\n",
    "# index 121\n",
    "have = expa.features\n",
    "properties = BNode()\n",
    "g.add((vaccine, have, properties))\n",
    "\n",
    "# index 126, 151\n",
    "harm = expa.side_affect\n",
    "populations = expn.populations\n",
    "g.add((vaccine, harm, populations))\n",
    "\n",
    "# index 174\n",
    "it = exp.companies\n",
    "produce = expa.produce\n",
    "g.add((it, produce, vaccine))\n",
    "\n",
    "# index 191\n",
    "need = expa.need\n",
    "shot = expa.shot\n",
    "g.add((vaccine, need, shot))\n",
    "\n",
    "# index 194\n",
    "virus = dbr.virus\n",
    "fight = expa.function\n",
    "g.add((vaccine, fight, virus))\n",
    "\n",
    "# index 212\n",
    "NHS = dbr.nhs\n",
    "have = expa.who_has\n",
    "g.add((NHS, OWL.Type, OWL.Thing))\n",
    "g.add((NHS, have, vaccine))\n",
    "\n",
    "# index 216\n",
    "get = expa.not_suit\n",
    "pregnant = expn.pregnant_woman\n",
    "g.add((vaccine, get, pregnant))\n",
    "\n",
    "# index 220\n",
    "approved = expa.approved\n",
    "UK = dbr.uk\n",
    "g.add((UK, approved, vaccine))\n",
    "g.add((UK, OWL.Type, OWL.Thing))\n",
    "\n",
    "# index 223\n",
    "staff = expn.people\n",
    "giving = expa.get_vaccine\n",
    "g.add((staff, giving, vaccine))\n",
    "\n",
    "# index 225\n",
    "hub = expn.hub\n",
    "looking = expa.looking_for\n",
    "g.add((hub, looking, vaccine))\n",
    "\n",
    "# index 228\n",
    "limited = expa.bad_affects\n",
    "bad_affects = BNode()\n",
    "g.add((vaccine, limited, bad_affects))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "xLwqoDWq6d05"
   },
   "source": [
    "### 5.2 Serialization\n",
    "\n",
    "After all the triples have been added into the graph, serialize the graph with N-Triple an Turtle format, save the output into a .nl file."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "f3rehHWk6-6h",
    "outputId": "63117393-897a-4095-baac-47a39d4df88b",
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "b'@prefix ns1: <http://www.exp.org/Action/> .\\n@prefix ns2: <http://www.exp.org/> .\\n@prefix owl: <http://www.w3.org/2002/07/owl#> .\\n\\n<http://dbpedia.org/resource/COVID-19_vaccine_development> ns1:producing \"vaccine@en\" ;\\n    ns2:label \"vaccine_development@en\" ;\\n    owl:Type owl:Thing .\\n\\n<http://www.dbpedia.org/resource/nhs> ns1:who_has <http://www.dbpedia.org/resource/COVID_19_vaccine> ;\\n    owl:Type owl:Thing .\\n\\n<http://www.dbpedia.org/resource/uk> ns1:approved <http://www.dbpedia.org/resource/COVID_19_vaccine> ;\\n    owl:Type owl:Thing .\\n\\nns2:Messager ns1:contained <http://www.dbpedia.org/resource/COVID_19_vaccine> .\\n\\n<http://www.exp.org/Noun/discussion> ns1:evaluate <http://www.dbpedia.org/resource/COVID_19_vaccine> .\\n\\n<http://www.exp.org/Noun/hub> ns1:looking_for <http://www.dbpedia.org/resource/COVID_19_vaccine> .\\n\\n<http://www.exp.org/Noun/incidence> ns1:compare ns2:vaccination .\\n\\n<http://www.exp.org/Noun/modeling> ns1:recommending ns2:vaccination .\\n\\n<http://www.exp.org/Noun/people> ns1:get_vaccine <http://www.dbpedia.org/resource/COVID_19_vaccine> .\\n\\n<http://www.exp.org/Noun/regime> ns1:characterized <http://www.dbpedia.org/resource/COVID_19_vaccine> .\\n\\n<http://www.exp.org/Noun/rights> ns1:provide ns2:vaccination .\\n\\nns2:companies ns1:produce <http://www.dbpedia.org/resource/COVID_19_vaccine> .\\n\\nns2:people ns1:very <http://www.dbpedia.org/resource/COVID_19_vaccine> .\\n\\nns2:strategy ns1:prioritized <http://www.dbpedia.org/resource/COVID_19_vaccine> .\\n\\n<http://www.dbpedia.org/resource/COVID_19_vaccine> ns1:Action [ ] ;\\n    ns1:accounting <http://www.dbpedia.org/resource/COVID_19_vaccine> ;\\n    ns1:bad_affects [ ] ;\\n    ns1:be ns1:infectious,\\n        \"leaky@en\" ;\\n    ns1:distribution [ ] ;\\n    ns1:features [ ] ;\\n    ns1:function <http://www.dbpedia.org/resource/virus> ;\\n    ns1:go <http://www.exp.org/Noun/Phase> ;\\n    ns1:include [ ] ;\\n    ns1:need ns1:shot ;\\n    ns1:not_suit <http://www.exp.org/Noun/pregnant_woman> ;\\n    ns1:side_affect <http://www.exp.org/Noun/populations> ;\\n    ns1:take <http://www.dbpedia.org/resource/COVID_19_vaccine> ;\\n    ns1:vaccinated [ ] ;\\n    ns2:label \"vaccine_phase@en\",\\n        \"vaccine_tested@en\" ;\\n    owl:Type owl:Thing .\\n\\n'\n",
      "\n",
      "b'<http://www.dbpedia.org/resource/COVID_19_vaccine> <http://www.exp.org/Action/include> _:Nb615b898b15248799842786cd5a57c2c .\\n<http://www.exp.org/Noun/hub> <http://www.exp.org/Action/looking_for> <http://www.dbpedia.org/resource/COVID_19_vaccine> .\\n<http://www.dbpedia.org/resource/COVID_19_vaccine> <http://www.exp.org/Action/features> _:N201bc753a8e2438cb06c7bfd44f8e6c5 .\\n<http://www.dbpedia.org/resource/COVID_19_vaccine> <http://www.exp.org/Action/Action> _:Nf63193983a194a37a15e54e2bc8741b7 .\\n<http://www.dbpedia.org/resource/COVID_19_vaccine> <http://www.exp.org/Action/vaccinated> _:Nf72892c8be7848889efea4adbf5bedbd .\\n<http://www.dbpedia.org/resource/uk> <http://www.w3.org/2002/07/owl#Type> <http://www.w3.org/2002/07/owl#Thing> .\\n<http://www.dbpedia.org/resource/nhs> <http://www.w3.org/2002/07/owl#Type> <http://www.w3.org/2002/07/owl#Thing> .\\n<http://www.exp.org/Noun/incidence> <http://www.exp.org/Action/compare> <http://www.exp.org/vaccination> .\\n<http://www.dbpedia.org/resource/COVID_19_vaccine> <http://www.exp.org/Action/not_suit> <http://www.exp.org/Noun/pregnant_woman> .\\n<http://www.dbpedia.org/resource/COVID_19_vaccine> <http://www.exp.org/label> \"vaccine_phase@en\" .\\n<http://www.dbpedia.org/resource/COVID_19_vaccine> <http://www.exp.org/Action/be> \"leaky@en\" .\\n<http://www.dbpedia.org/resource/COVID_19_vaccine> <http://www.exp.org/Action/take> <http://www.dbpedia.org/resource/COVID_19_vaccine> .\\n<http://www.dbpedia.org/resource/COVID_19_vaccine> <http://www.exp.org/label> \"vaccine_tested@en\" .\\n<http://www.exp.org/strategy> <http://www.exp.org/Action/prioritized> <http://www.dbpedia.org/resource/COVID_19_vaccine> .\\n<http://dbpedia.org/resource/COVID-19_vaccine_development> <http://www.exp.org/label> \"vaccine_development@en\" .\\n<http://www.dbpedia.org/resource/COVID_19_vaccine> <http://www.exp.org/Action/bad_affects> _:N1a3d38fb3d3b4218affb01c226d33dfa .\\n<http://www.dbpedia.org/resource/COVID_19_vaccine> <http://www.exp.org/Action/need> <http://www.exp.org/Action/shot> .\\n<http://www.exp.org/companies> <http://www.exp.org/Action/produce> <http://www.dbpedia.org/resource/COVID_19_vaccine> .\\n<http://www.exp.org/Noun/regime> <http://www.exp.org/Action/characterized> <http://www.dbpedia.org/resource/COVID_19_vaccine> .\\n<http://www.exp.org/Noun/modeling> <http://www.exp.org/Action/recommending> <http://www.exp.org/vaccination> .\\n<http://www.dbpedia.org/resource/COVID_19_vaccine> <http://www.exp.org/Action/side_affect> <http://www.exp.org/Noun/populations> .\\n<http://www.exp.org/Messager> <http://www.exp.org/Action/contained> <http://www.dbpedia.org/resource/COVID_19_vaccine> .\\n<http://www.dbpedia.org/resource/COVID_19_vaccine> <http://www.exp.org/Action/distribution> _:N1f9acb7c99b04b8a8b228d2cef071902 .\\n<http://www.exp.org/Noun/people> <http://www.exp.org/Action/get_vaccine> <http://www.dbpedia.org/resource/COVID_19_vaccine> .\\n<http://www.dbpedia.org/resource/nhs> <http://www.exp.org/Action/who_has> <http://www.dbpedia.org/resource/COVID_19_vaccine> .\\n<http://www.exp.org/people> <http://www.exp.org/Action/very> <http://www.dbpedia.org/resource/COVID_19_vaccine> .\\n<http://dbpedia.org/resource/COVID-19_vaccine_development> <http://www.w3.org/2002/07/owl#Type> <http://www.w3.org/2002/07/owl#Thing> .\\n<http://www.dbpedia.org/resource/COVID_19_vaccine> <http://www.exp.org/Action/be> <http://www.exp.org/Action/infectious> .\\n<http://www.dbpedia.org/resource/COVID_19_vaccine> <http://www.exp.org/Action/accounting> <http://www.dbpedia.org/resource/COVID_19_vaccine> .\\n<http://www.dbpedia.org/resource/COVID_19_vaccine> <http://www.exp.org/Action/go> <http://www.exp.org/Noun/Phase> .\\n<http://www.dbpedia.org/resource/COVID_19_vaccine> <http://www.exp.org/Action/function> <http://www.dbpedia.org/resource/virus> .\\n<http://www.exp.org/Noun/rights> <http://www.exp.org/Action/provide> <http://www.exp.org/vaccination> .\\n<http://www.exp.org/Noun/discussion> <http://www.exp.org/Action/evaluate> <http://www.dbpedia.org/resource/COVID_19_vaccine> .\\n<http://www.dbpedia.org/resource/uk> <http://www.exp.org/Action/approved> <http://www.dbpedia.org/resource/COVID_19_vaccine> .\\n<http://www.dbpedia.org/resource/COVID_19_vaccine> <http://www.w3.org/2002/07/owl#Type> <http://www.w3.org/2002/07/owl#Thing> .\\n<http://dbpedia.org/resource/COVID-19_vaccine_development> <http://www.exp.org/Action/producing> \"vaccine@en\" .\\n\\n'\n"
     ]
    }
   ],
   "source": [
    "print(g.serialize(format='turtle', encoding='utf-8'))\n",
    "print()\n",
    "print(g.serialize(format='ntriples', encoding='utf-8'))\n",
    "\n",
    "g.serialize(destination='serializationTurtle.nt', format='turtle', encoding='utf-8')\n",
    "g.serialize(destination='serializationNTriples.nt', format='ntriples', encoding='utf-8')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "p4GBH8FTbRaD"
   },
   "source": [
    "## 6. Query and Answer Questions"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "lL4il4da_UuN"
   },
   "source": [
    "### 6.1 Query with SPARQL\n",
    "\n",
    "Let's check if RDF can be queried by SQARQL. "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 192,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "pfBWtYQ5_-m7",
    "outputId": "631f7edd-d82e-4847-ab61-9d9c5d9c58a2"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "(rdflib.term.URIRef('http://www.dbpedia.org/resource/nhs'),)\n"
     ]
    }
   ],
   "source": [
    "dbr = Namespace('http://www.dbpedia.org/resource/')\n",
    "exp = Namespace('http://www.exp.org/')\n",
    "expa = Namespace('http://www.exp.org/Action/')\n",
    "expn = Namespace('http://www.exp.org/Noun/')\n",
    "\n",
    "g_1 = rdflib.Graph()\n",
    "g.bind(\"expa\", expa)\n",
    "g.bind(\"dbr\", dbr)\n",
    "g.bind(\"exp\", exp)\n",
    "\n",
    "# parse the .rdf file\n",
    "g.parse('serializationNTriples.nt', format='nt')\n",
    "\n",
    "\n",
    "\n",
    "# create a query, searching answer for question: 'who has COVID-19 vaccine' --index 212\n",
    "qres = g.query(\n",
    "    \"\"\"SELECT DISTINCT ?s\n",
    "    WHERE{\n",
    "      ?s expa:who_has dbr:COVID_19_vaccine\n",
    "    }\"\"\"\n",
    ")\n",
    "for row in qres:\n",
    "  print(row)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 193,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "rJ-TIg2JfJ7V",
    "outputId": "ce30f4f1-a0c5-4eab-d18c-f6d11d840275"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "(rdflib.term.URIRef('http://www.dbpedia.org/resource/COVID_19_vaccine'), rdflib.term.URIRef('http://www.exp.org/Action/tested'), rdflib.term.Literal('Vaccines against SARS[12] and MERS[13] have been tested in non-human animals'))\n"
     ]
    }
   ],
   "source": [
    "# more question, 'Is the vaccine tested?' index 1\n",
    "question = \"select ?v ?t ?c \\\n",
    "where{?v rdfs:label 'COVID_19_vaccine'. ?t exp:label 'tested'. ?v ?t ?o. ?o exp:label ?c }\"\n",
    "qres = g.query(question)\n",
    "for row in qres:\n",
    "  print(row)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "HJVhS6GSDN2V"
   },
   "source": [
    "More examples"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 157,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "TP2KzZQgDtqt",
    "outputId": "aa2b8fa4-4624-42cb-d809-bc937cae59f3"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "(rdflib.term.URIRef('http://www.dbpedia.org/resource/uk'),)\n"
     ]
    }
   ],
   "source": [
    "# create a query, searching answer for question: 'which country approved the vaccine?'\n",
    "from rdflib.namespace import RDFS\n",
    "\n",
    "g.bind('rdfs', RDFS)\n",
    "g.bind('exp', exp)\n",
    "g.bind('expa', expa)\n",
    "\n",
    "qres = g.query(\n",
    "    \"\"\"SELECT ?country\n",
    "    WHERE{\n",
    "      ?country expa:approved dbr:COVID_19_vaccine.\n",
    "    }\"\"\"\n",
    ")\n",
    "for row in qres:\n",
    "  print(row)\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 7. Conlusion\n",
    "\n",
    "Above is the almost procedures of the project. However, I do realize that my solution isn't ideal enough. \n",
    "\n",
    "Firstly, I didn't notice that I have to represent the extracted triples with resources and sentences. After I did all the process I try to make up it but I only fix the representing of sentence. As the due is approaching I don't have enough time to fix it. I will only write my idea to fix this problem as fellowing:\n",
    "\n",
    "1. Using dictionary to store the web page content when collecting the web page content from internet. The format of dictionary is: {'resource_1':'webContent_1', 'resource_2':'webContent_2', .....}\n",
    "2. When saving the sentences into the .csv file, add an additional column name 'resource'. Assign each sentence a resource\n",
    "3. Extract triples from sentences, if the sentences extracted, save the triple, sentence, resource to a new .csv file.\n",
    "3. Make a dataframe with pandas model, with a columns of subject, predicate, object, sentence, resource. \n",
    "4. Representing the structured data. \n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Secondly, I think the process of extracting sentences into triples is a hard part, the quality of the knowledge graph is depending on the quality of triples. However, due to my limited code skill and perception of NLP I couldn't make it better. \n",
    "\n",
    "Thirdly, in the question-answering part, I have some clues on how to make it better but I didn't implement them into my program. The following is my idea. \n",
    "\n",
    "1. In the real system, we need a reasoning engine. When the user type question with a human linguistic format sentence into the system, the reasoning engine can extract the core information (Here we need NLP technology). For example, in a sentence with different tenses, thesaurus but the same meaning, the engine can recognize it and extract the same core information. \n",
    "2. The system will map the core information into the established knowledge graph, the system representing the knowledge with semantics format to the user ( instead of URL in my program). \n",
    "3. Moreover, a more advanced reasoning engine could deduce the answer according to the existing knowledge graph ( This may use the knowledge of machine learning but I haven't learnt that ). "
   ]
  }
 ],
 "metadata": {
  "colab": {
   "collapsed_sections": [],
   "name": "RDFGraphAssignment.ipynb",
   "provenance": [],
   "toc_visible": true
  },
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 1
}
